Heteroaryl pyridone and aza-pyridone compounds

ABSTRACT

Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X 1 , X 2 , and X 3  are N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

CROSS REFERENCE TO RELATED APPLICATIONS

This divisional application of U.S. Ser. No. 13/667,133, filed 2 Nov.2012, under 37 CFR §1.53(b), and also claims the benefit under 35 USC§119(e) of U.S. Provisional Application Ser. No. 61/555,393 filed on 3Nov. 2011, which is incorporated by reference in entirety.

FIELD OF THE INVENTION

The invention relates generally to compounds for treating disordersmediated by Bruton's Tyrosine Kinase (Btk) including inflammation,immunological, and cancer, and more specifically to compounds whichinhibit Btk activity. The invention also relates to methods of using thecompounds for in vitro, in situ, and in vivo diagnosis or treatment ofmammalian cells, or associated pathological conditions.

BACKGROUND OF THE INVENTION

Protein kinases, the largest family of human enzymes, encompass wellover 500 proteins. Bruton's Tyrosine Kinase (Btk) is a member of the Tecfamily of tyrosine kinases, and is a regulator of early B-celldevelopment as well as mature B-cell activation, signaling, andsurvival.

B-cell signaling through the B-cell receptor (BCR) can lead to a widerange of biological outputs, which in turn depend on the developmentalstage of the B-cell. The magnitude and duration of BCR signals must beprecisely regulated. Aberrant BCR-mediated signaling can causedisregulated B-cell activation and/or the formation of pathogenicauto-antibodies leading to multiple autoimmune and/or inflammatorydiseases. Mutation of Btk in humans results in X-linkedagammaglobulinaemia (XLA). This disease is associated with the impairedmaturation of B-cells, diminished immunoglobulin production, compromisedT-cell-independent immune responses and marked attenuation of thesustained calcium sign upon BCR stimulation. Evidence for the role ofBtk in allergic disorders and/or autoimmune disease and/or inflammatorydisease has been established in Btk-deficient mouse models. For example,in standard murine preclinical models of systemic lupus erythematosus(SLE), Btk deficiency has been shown to result in a marked ameliorationof disease progression. Moreover, Btk deficient mice can also beresistant to developing collagen-induced arthritis and can be lesssusceptible to Staphylococcus-induced arthritis. A large body ofevidence supports the role of B-cells and the humoral immune system inthe pathogenesis of autoimmune and/or inflammatory diseases.Protein-based therapeutics (such as Rituxan) developed to depleteB-cells, represent an approach to the treatment of a number ofautoimmune and/or inflammatory diseases. Because of Btk's role in B-cellactivation, inhibitors of Btk can be useful as inhibitors of B-cellmediated pathogenic activity (such as autoantibody production). Btk isalso expressed in osteoclasts, mast cells and monocytes and has beenshown to be important for the function of these cells. For example, Btkdeficiency in mice is associated with impaired IgE-mediated mast cellactivation (marked diminution of TNF-alpha and other inflammatorycytokine release), and Btk deficiency in humans is associated withgreatly reduced TNF-alpha production by activated monocytes.

Thus, inhibition of Btk activity can be useful for the treatment ofallergic disorders and/or autoimmune and/or inflammatory diseases suchas: SLE, rheumatoid arthritis, multiple vasculitides, idiopathicthrombocytopenic purpura (ITP), myasthenia gravis, allergic rhinitis,and asthma (Di Paolo et al (2011) Nature Chem. Biol. 7(1):41-50; Liu etal (2011) Jour. of Pharm. and Exper. Ther. 338(1):154-163). In addition,Btk has been reported to play a role in apoptosis; thus, inhibition ofBtk activity can be useful for cancer, as well as the treatment ofB-cell lymphoma, leukemia, and other hematological malignancies.Moreover, given the role of Btk in osteoclast function, the inhibitionof Btk activity can be useful for the treatment of bone disorders suchas osteoporosis. Specific Btk inhibitors have been reported (Liu (2011)Drug Metab. and Disposition 39(10):1840-1849; U.S. Pat. No. 7,884,108,WO 2010/056875; U.S. Pat. No. 7,405,295; U.S. Pat. No. 7,393,848; WO2006/053121; U.S. Pat. No. 7,947,835; US 2008/0139557; U.S. Pat. No.7,838,523; US 2008/0125417; US 2011/0118233; PCT/US2011/050034“PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF”,filed 31 Aug. 2011; PCT/US2011/050013 “PYRIDAZINONES, METHOD OF MAKING,AND METHOD OF USE THEREOF”, filed 31 Aug. 2011; U.S. Ser. No. 13/102,720“PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE”, filed 6 May2011).

SUMMARY OF THE INVENTION

The invention relates generally to Formula I, heteroaryl pyridone andaza-pyridone compounds with Bruton's Tyrosine Kinase (Btk) modulatingactivity.

Formula I compounds have the structures:

including stereoisomers, tautomers, or pharmaceutically acceptable saltsthereof. The various substituents are defined herein below.

One aspect of the invention is a pharmaceutical composition comprised ofa Formula I compound and a pharmaceutically acceptable carrier, glidant,diluent, or excipient. The pharmaceutical composition may furthercomprise a second therapeutic agent.

Another aspect of the invention is a process for making a pharmaceuticalcomposition which comprises combining a Formula I compound with apharmaceutically acceptable carrier.

The invention includes a method of treating a disease or disorder whichmethod comprises administering a therapeutically effective amount of aFormula I compound to a patient with a disease or disorder selected fromimmune disorders, cancer, cardiovascular disease, viral infection,inflammation, metabolism/endocrine function disorders and neurologicaldisorders, and mediated by Bruton's tyrosine kinase.

The invention includes a kit for treating a condition mediated byBruton's tyrosine kinase, comprising: a) a first pharmaceuticalcomposition comprising a Formula I compound; and b) instructions foruse.

The invention includes a Formula I compound for use as a medicament, andfor use in treating a disease or disorder selected from immunedisorders, cancer, cardiovascular disease, viral infection,inflammation, metabolism/endocrine function disorders and neurologicaldisorders, and mediated by Bruton's tyrosine kinase.

The invention includes use of a Formula I compound in the manufacture ofa medicament for the treatment of immune disorders, cancer,cardiovascular disease, viral infection, inflammation,metabolism/endocrine function disorders and neurological disorders, andwhere the medicament mediates Bruton's tyrosine kinase.

The invention includes methods of making a Formula I compound.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the preparation of2-(4-(hydroxymethyl)-5-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one101 starting with2,2,2-Trichloro-1-(4,5,6,7-tetrahydro-1H-indol-2-yl)ethanone 101a.

FIG. 2 shows the preparation of2-(4-(Hydroxymethyl)-5-(1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one102 starting with1-Methyl-3-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyridin-2-one102a

FIG. 3 shows the preparation of2-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one103 starting with 2-Bromo-4-chloronicotinaldehyde 103a

FIG. 4 shows the preparation of2-(3-(Hydroxymethyl)-2-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-4-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one104 starting with 4-Bromo-2-chloronicotinaldehyde 104a

FIG. 5 shows the preparation of4-Hydroxymethyl-3-[1-methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-5-{6-oxo-8-thia-5-azatricyclo-[7.4.0.0^(2,7)]trideca-1(9),2(7)-dien-5-yl}pyridine105 starting withN-Methoxy-N-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide105a

FIG. 6 shows the preparation of4-Hydroxymethyl-3-[1-methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-5-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-4-carbaldehyde 106 starting with3,3-Dimethylcyclopentanone 106a

FIG. 7 shows the preparation of10-[4-[1-Methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-4-(hydroxymethyl)pyridin-3-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one107 starting with (E)-Ethyl3-(2-Chloro-4,4-dimethylcyclopent-1-enyl)acrylate 107a

FIG. 8 shows the preparation of2-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one108 starting with4-Chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a.

FIG. 9 shows the preparation of2-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-4,4-dimethyl-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-9-one109 starting with4-Chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde109a.

FIG. 10 shows the preparation of2-(3-(Hydroxymethyl)-4-(1-methyl-5-(6-(4-methylpiperazin-1-yl)pyridine-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one110 starting with1-Methyl-3-(6-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one110a

FIG. 11 shows the preparation of2-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one111 starting with (6-Aminopyridin-3-yl)(morpholino)methanone 111a

FIG. 12 shows the preparation of2-(4-(Hydroxymethyl)-5-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1(2H)-one112 starting with Methyl 5,6,7,8-Tetrahydroindolizine-2-carboxylate 112a

FIG. 13 shows the preparation of2-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one113 starting with (3-Nitro-1H-pyrazol-5-yl)methanol 113a

FIG. 14 shows the preparation of(R)-2-(4-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one114 starting with(R)-5-bromo-3-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-1-methylpyrazin-2(1H)-one114a

FIG. 15 shows the preparation of2-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one115 starting with5-Bromo-1-methyl-3-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2(1H)-one 115a

FIG. 16 shows the preparation of4-Hydroxymethyl-3-[1-methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-5-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine116 starting with3-Bromo-5-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-4-carbaldehyde116a

FIG. 17 shows the preparation of2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(methylsulfonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydro-pyrazino[1,2-a]indol-1(2H)-one117 starting with 5-(Methylthio)-2-nitropyridine 117a

FIG. 18 shows the preparation of2-(4-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one118 starting with tert-Butyl5-Amino-3-cyclopropyl-1H-pyrazole-1-carboxylate 118a

FIG. 19 shows the preparation of(S)-2-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one119 starting with(5)-(4-(1-Methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 119a

FIG. 20 shows the preparation of2-(4-(5-(5-(4-(2-Hydroxy-2-methylpropyl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one120 starting with5-Bromo-3-(5-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one120a

FIG. 21 shows the preparation of2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridine-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1(2H)-one121 starting with4-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde121a

FIG. 22 shows the preparation of2-(4-(5-(5-((2S,5R)-2,5-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one122 starting with (2R,5S)-tert-Butyl2,5-Dimethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 122a

FIG. 23 shows the preparation of2-(4-(5-(5-(4-(2-Hydroxyethyl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydro-pyrazino[1,2-a]indol-1(2H)-one123 starting with (2-Bromoethoxy)(tert-butyl)dimethylsilane 123a

FIG. 24 shows the preparation of3-Hydroxymethyl-4-[1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridine-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine124 starting with4-Chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a

FIG. 25 shows the preparation of7,7-difluoro-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one, usefulfor the preparation of 140, starting from ethyl1H-pyrrole-2-carboxylate.

FIG. 26 shows the preparation of 5-(oxetan-3-yl)-1H-pyrazol-3-amine,useful for the preparation of 266, starting from 3-nitro-1H-pyrazole.

DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

Reference will now be made in detail to certain embodiments of theinvention, examples of which are illustrated in the accompanyingstructures and formulas. While the invention will be described inconjunction with the enumerated embodiments, it will be understood thatthey are not intended to limit the invention to those embodiments. Onthe contrary, the invention is intended to cover all alternatives,modifications, and equivalents which may be included within the scope ofthe present invention as defined by the claims. One skilled in the artwill recognize many methods and materials similar or equivalent to thosedescribed herein, which could be used in the practice of the presentinvention. The present invention is in no way limited to the methods andmaterials described. In the event that one or more of the incorporatedliterature, patents, and similar materials differs from or contradictsthis application, including but not limited to defined terms, termusage, described techniques, or the like, this application controls.Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the invention, suitable methods and materials aredescribed below. All publications, patent applications, patents, andother references mentioned herein are incorporated by reference in theirentirety. The nomenclature used in this Application is based on IUPACsystematic nomenclature, unless indicated otherwise.

DEFINITIONS

When indicating the number of substituents, the term “one or more”refers to the range from one substituent to the highest possible numberof substitution, i.e. replacement of one hydrogen up to replacement ofall hydrogens by substituents. The term “substituent” denotes an atom ora group of atoms replacing a hydrogen atom on the parent molecule. Theterm “substituted” denotes that a specified group bears one or moresubstituents. Where any group may carry multiple substituents and avariety of possible substituents is provided, the substituents areindependently selected and need not to be the same. The term“unsubstituted” means that the specified group bears no substituents.The term “optionally substituted” means that the specified group isunsubstituted or substituted by one or more substituents, independentlychosen from the group of possible substituents. When indicating thenumber of substituents, the term “one or more” means from onesubstituent to the highest possible number of substitution, i.e.replacement of one hydrogen up to replacement of all hydrogens bysubstituents.

The term “alkyl” as used herein refers to a saturated linear orbranched-chain monovalent hydrocarbon radical of one to twelve carbonatoms (C₁-C₁₂), wherein the alkyl radical may be optionally substitutedindependently with one or more substituents described below. In anotherembodiment, an alkyl radical is one to eight carbon atoms (C₁-C₈), orone to six carbon atoms (C₁-C₆). Examples of alkyl groups include, butare not limited to, methyl (Me, —CH₃), ethyl (Et, —CH₂CH₃), 1-propyl(n-Pr, n-propyl, —CH₂CH₂CH₃), 2-propyl (i-Pr, i-propyl, —CH(CH₃)₂),1-butyl (n-Bu, n-butyl, —CH₂CH₂CH₂CH₃), 2-methyl-1-propyl (i-Bu,i-butyl, —CH₂CH(CH₃)₂), 2-butyl (s-Bu, s-butyl, —CH(CH₃)CH₂CH₃),2-methyl-2-propyl (t-Bu, t-butyl, —C(CH₃)₃), 1-pentyl (n-pentyl,—CH₂CH₂CH₂CH₂CH₃), 2-pentyl (—CH(CH₃)CH₂CH₂CH₃), 3-pentyl(—CH(CH₂CH₃)₂), 2-methyl-2-butyl (—C(CH₃)₂CH₂CH₃), 3-methyl-2-butyl(—CH(CH₃)CH(CH₃)₂), 3-methyl-1-butyl (—CH₂CH₂CH(CH₃)₂), 2-methyl-1-butyl(—CH₂CH(CH₃)CH₂CH₃), 1-hexyl (—CH₂CH₂CH₂CH₂CH₂CH₃), 2-hexyl(—CH(CH₃)CH₂CH₂CH₂CH₃), 3-hexyl (—CH(CH₂CH₃)(CH₂CH₂CH₃)),2-methyl-2-pentyl (—C(CH₃)₂CH₂CH₂CH₃), 3-methyl-2-pentyl(—CH(CH₃)CH(CH₃)CH₂CH₃), 4-methyl-2-pentyl (—CH(CH₃)CH₂CH(CH₃)₂),3-methyl-3-pentyl (—C(CH₃)(CH₂CH₃)₂), 2-methyl-3-pentyl(—CH(CH₂CH₃)CH(CH₃)₂), 2,3-dimethyl-2-butyl (—C(CH₃)₂CH(CH₃)₂),3,3-dimethyl-2-butyl (—CH(CH₃)C(CH₃)₃, 1-heptyl, 1-octyl, and the like.

The term “alkylene” as used herein refers to a saturated linear orbranched-chain divalent hydrocarbon radical of one to twelve carbonatoms (C₁-C₁₂), wherein the alkylene radical may be optionallysubstituted independently with one or more substituents described below.In another embodiment, an alkylene radical is one to eight carbon atoms(C₁-C₈), or one to six carbon atoms (C₁-C₆). Examples of alkylene groupsinclude, but are not limited to, methylene (—CH₂—), ethylene (—CH₂CH₂—),propylene (—CH₂CH₂CH₂—), and the like.

The term “alkenyl” refers to linear or branched-chain monovalenthydrocarbon radical of two to eight carbon atoms (C₂-C₈) with at leastone site of unsaturation, i.e., a carbon-carbon, sp² double bond,wherein the alkenyl radical may be optionally substituted independentlywith one or more substituents described herein, and includes radicalshaving “cis” and “trans” orientations, or alternatively, “E” and “Z”orientations. Examples include, but are not limited to, ethylenyl orvinyl (—CH═CH₂), allyl (—CH₂CH═CH₂), and the like.

The term “alkenylene” refers to linear or branched-chain divalenthydrocarbon radical of two to eight carbon atoms (C₂-C₈) with at leastone site of unsaturation, i.e., a carbon-carbon, sp² double bond,wherein the alkenylene radical may be optionally substituted substitutedindependently with one or more substituents described herein, andincludes radicals having “cis” and “trans” orientations, oralternatively, “E” and “Z” orientations. Examples include, but are notlimited to, ethylenylene or vinylene (—CH═CH—), allyl (—CH₂CH═CH—), andthe like.

The term “alkynyl” refers to a linear or branched monovalent hydrocarbonradical of two to eight carbon atoms (C₂-C₈) with at least one site ofunsaturation, i.e., a carbon-carbon, sp triple bond, wherein the alkynylradical may be optionally substituted independently with one or moresubstituents described herein. Examples include, but are not limited to,ethynyl (—C═CH), propynyl (propargyl, —CH₂C═CH), and the like.

The term “alkynylene” refers to a linear or branched divalenthydrocarbon radical of two to eight carbon atoms (C₂-C₈) with at leastone site of unsaturation, i.e., a carbon-carbon, sp triple bond, whereinthe alkynylene radical may be optionally substituted independently withone or more substituents described herein. Examples include, but are notlimited to, ethynylene (—C≡C—), propynylene (propargylene, —CH₂C≡C—),and the like.

The terms “carbocycle”, “carbocyclyl”, “carbocyclic ring” and“cycloalkyl” refer to a monovalent non-aromatic, saturated or partiallyunsaturated ring having 3 to 12 carbon atoms (C₃-C₁₂) as a monocyclicring or 7 to 12 carbon atoms as a bicyclic ring. Bicyclic carbocycleshaving 7 to 12 atoms can be arranged, for example, as a bicyclo [4,5],[5,5], [5,6] or [6,6] system, and bicyclic carbocycles having 9 or 10ring atoms can be arranged as a bicyclo [5,6] or [6,6] system, or asbridged systems such as bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane andbicyclo[3.2.2]nonane. Spiro moieties are also included within the scopeof this definition. Examples of monocyclic carbocycles include, but arenot limited to, cyclopropyl, cyclobutyl, cyclopentyl,1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl,1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl,cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl,cycloundecyl, cyclododecyl, and the like. Carbocyclyl groups areoptionally substituted independently with one or more substituentsdescribed herein.

“Aryl” means a monovalent aromatic hydrocarbon radical of 6-20 carbonatoms (C₆-C₂₀) derived by the removal of one hydrogen atom from a singlecarbon atom of a parent aromatic ring system. Some aryl groups arerepresented in the exemplary structures as “Ar”. Aryl includes bicyclicradicals comprising an aromatic ring fused to a saturated, partiallyunsaturated ring, or aromatic carbocyclic ring. Typical aryl groupsinclude, but are not limited to, radicals derived from benzene (phenyl),substituted benzenes, naphthalene, anthracene, biphenyl, indenyl,indanyl, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthyl, and thelike. Aryl groups are optionally substituted independently with one ormore substituents described herein.

“Arylene” means a divalent aromatic hydrocarbon radical of 6-20 carbonatoms (C₆-C₂₀) derived by the removal of two hydrogen atom from a twocarbon atoms of a parent aromatic ring system. Some arylene groups arerepresented in the exemplary structures as “Ar”. Arylene includesbicyclic radicals comprising an aromatic ring fused to a saturated,partially unsaturated ring, or aromatic carbocyclic ring. Typicalarylene groups include, but are not limited to, radicals derived frombenzene (phenylene), substituted benzenes, naphthalene, anthracene,biphenylene, indenylene, indanylene, 1,2-dihydronaphthalene,1,2,3,4-tetrahydronaphthyl, and the like. Arylene groups are optionallysubstituted with one or more substituents described herein.

The terms “heterocycle,” “heterocyclyl” and “heterocyclic ring” are usedinterchangeably herein and refer to a saturated or a partiallyunsaturated (i.e., having one or more double and/or triple bonds withinthe ring) carbocyclic radical of 3 to about 20 ring atoms in which atleast one ring atom is a heteroatom selected from nitrogen, oxygen,phosphorus and sulfur, the remaining ring atoms being C, where one ormore ring atoms is optionally substituted independently with one or moresubstituents described below. A heterocycle may be a monocycle having 3to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selectedfrom N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9carbon atoms and 1 to 6 heteroatoms selected from N, O, P, and S), forexample: a bicyclo [4,5], [5,5], [5,6], or [6,6] system. Heterocyclesare described in Paquette, Leo A.; “Principles of Modern HeterocyclicChemistry” (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3,4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds, A series ofMonographs” (John Wiley & Sons, New York, 1950 to present), inparticular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960)82:5566. “Heterocyclyl” also includes radicals where heterocycleradicals are fused with a saturated, partially unsaturated ring, oraromatic carbocyclic or heterocyclic ring. Examples of heterocyclicrings include, but are not limited to, morpholin-4-yl, piperidin-1-yl,piperazinyl, piperazin-4-yl-2-one, piperazin-4-yl-3-one,pyrrolidin-1-yl, thiomorpholin-4-yl, S-dioxothiomorpholin-4-yl,azocan-1-yl, azetidin-1-yl, octahydropyrido[1,2-a]pyrazin-2-yl,[1,4]diazepan-1-yl, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl,tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl,tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino,thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl,thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl,thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl,4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl,dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl,pyrazolidinylimidazolinyl, imidazolidinyl, 3-azabicyco[3.1.0]hexanyl,3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indolylquinolizinyl and N-pyridyl ureas. Spiro moieties are also includedwithin the scope of this definition. Examples of a heterocyclic groupwherein 2 ring atoms are substituted with oxo (═O) moieties arepyrimidinonyl and 1,1-dioxo-thiomorpholinyl. The heterocycle groupsherein are optionally substituted independently with one or moresubstituents described herein.

The term “heteroaryl” refers to a monovalent aromatic radical of 5-, 6-,or 7-membered rings, and includes fused ring systems (at least one ofwhich is aromatic) of 5-20 atoms, containing one or more heteroatomsindependently selected from nitrogen, oxygen, and sulfur. Examples ofheteroaryl groups are pyridinyl (including, for example,2-hydroxypyridinyl), imidazolyl, imidazopyridinyl, pyrimidinyl(including, for example, 4-hydroxypyrimidinyl), pyrazolyl, triazolyl,pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl,oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl,isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl,benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl,pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl,triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl,benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl,quinoxalinyl, naphthyridinyl, and furopyridinyl. Heteroaryl groups areoptionally substituted independently with one or more substituentsdescribed herein.

The heterocycle or heteroaryl groups may be carbon (carbon-linked), ornitrogen (nitrogen-linked) bonded where such is possible. By way ofexample and not limitation, carbon bonded heterocycles or heteroarylsare bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5,or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan,tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole,position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4,or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of anaziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6,7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of anisoquinoline.

By way of example and not limitation, nitrogen bonded heterocycles orheteroaryls are bonded at position 1 of an aziridine, azetidine,pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole,imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline,2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline,1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of amorpholine, and position 9 of a carbazole, or β-carboline.

The terms “treat” and “treatment” refer to therapeutic treatment,wherein the object is to slow down (lessen) an undesired physiologicalchange or disorder, such as the development or spread of arthritis orcancer. For purposes of this invention, beneficial or desired clinicalresults include, but are not limited to, alleviation of symptoms,diminishment of extent of disease, stabilized (i.e., not worsening)state of disease, delay or slowing of disease progression, ameliorationor palliation of the disease state, and remission (whether partial ortotal), whether detectable or undetectable. “Treatment” can also meanprolonging survival as compared to expected survival if not receivingtreatment. Those in need of treatment include those with the conditionor disorder.

The phrase “therapeutically effective amount” means an amount of acompound of the present invention that (i) treats the particulardisease, condition, or disorder, (ii) attenuates, ameliorates, oreliminates one or more symptoms of the particular disease, condition, ordisorder, or (iii) prevents or delays the onset of one or more symptomsof the particular disease, condition, or disorder described herein. Inthe case of cancer, the therapeutically effective amount of the drug mayreduce the number of cancer cells; reduce the tumor size; inhibit (i.e.,slow to some extent and preferably stop) cancer cell infiltration intoperipheral organs; inhibit (i.e., slow to some extent and preferablystop) tumor metastasis; inhibit, to some extent, tumor growth; and/orrelieve to some extent one or more of the symptoms associated with thecancer. To the extent the drug may prevent growth and/or kill existingcancer cells, it may be cytostatic and/or cytotoxic. For cancer therapy,efficacy can be measured, for example, by assessing the time to diseaseprogression (TTP) and/or determining the response rate (RR).

“Inflammatory disorder” as used herein can refer to any disease,disorder, or syndrome in which an excessive or unregulated inflammatoryresponse leads to excessive inflammatory symptoms, host tissue damage,or loss of tissue function. “Inflammatory disorder” also refers to apathological state mediated by influx of leukocytes and/or neutrophilchemotaxis.

“Inflammation” as used herein refers to a localized, protective responseelicited by injury or destruction of tissues, which serves to destroy,dilute, or wall off (sequester) both the injurious agent and the injuredtissue. Inflammation is notably associated with influx of leukocytesand/or neutrophil chemotaxis. Inflammation can result from infectionwith pathogenic organisms and viruses and from noninfectious means suchas trauma or reperfusion following myocardial infarction or stroke,immune response to foreign antigen, and autoimmune responses.Accordingly, inflammatory disorders amenable to treatment with Formula Icompounds encompass disorders associated with reactions of the specificdefense system as well as with reactions of the nonspecific defensesystem.

“Specific defense system” refers to the component of the immune systemthat reacts to the presence of specific antigens. Examples ofinflammation resulting from a response of the specific defense systeminclude the classical response to foreign antigens, autoimmune diseases,and delayed type hypersensitivity response mediated by T-cells. Chronicinflammatory diseases, the rejection of solid transplanted tissue andorgans, e.g., kidney and bone marrow transplants, and graft versus hostdisease (GVHD), are further examples of inflammatory reactions of thespecific defense system.

The term “nonspecific defense system” as used herein refers toinflammatory disorders that are mediated by leukocytes that areincapable of immunological memory (e.g., granulocytes, and macrophages).Examples of inflammation that result, at least in part, from a reactionof the nonspecific defense system include inflammation associated withconditions such as adult (acute) respiratory distress syndrome (ARDS) ormultiple organ injury syndromes; reperfusion injury; acuteglomerulonephritis; reactive arthritis; dermatoses with acuteinflammatory components; acute purulent meningitis or other centralnervous system inflammatory disorders such as stroke; thermal injury;inflammatory bowel disease; granulocyte transfusion associatedsyndromes; and cytokine-induced toxicity.

“Autoimmune disease” as used herein refers to any group of disorders inwhich tissue injury is associated with humoral or cell-mediatedresponses to the body's own constituents.

“Allergic disease” as used herein refers to any symptoms, tissue damage,or loss of tissue function resulting from allergy. “Arthritic disease”as used herein refers to any disease that is characterized byinflammatory lesions of the joints attributable to a variety ofetiologies. “Dermatitis” as used herein refers to any of a large familyof diseases of the skin that are characterized by inflammation of theskin attributable to a variety of etiologies. “Transplant rejection” asused herein refers to any immune reaction directed against graftedtissue, such as organs or cells (e.g., bone marrow), characterized by aloss of function of the grafted and surrounding tissues, pain, swelling,leukocytosis, and thrombocytopenia. The therapeutic methods of thepresent invention include methods for the treatment of disordersassociated with inflammatory cell activation.

“Inflammatory cell activation” refers to the induction by a stimulus(including, but not limited to, cytokines, antigens or auto-antibodies)of a proliferative cellular response, the production of solublemediators (including but not limited to cytokines, oxygen radicals,enzymes, prostanoids, or vasoactive amines), or cell surface expressionof new or increased numbers of mediators (including, but not limited to,major histocompatability antigens or cell adhesion molecules) ininflammatory cells (including but not limited to monocytes, macrophages,T lymphocytes, B lymphocytes, granulocytes (i.e., polymorphonuclearleukocytes such as neutrophils, basophils, and eosinophils), mast cells,dendritic cells, Langerhans cells, and endothelial cells). It will beappreciated by persons skilled in the art that the activation of one ora combination of these phenotypes in these cells can contribute to theinitiation, perpetuation, or exacerbation of an inflammatory disorder.

The term “NSAID” is an acronym for “non-steroidal anti-inflammatorydrug” and is a therapeutic agent with analgesic, antipyretic (loweringan elevated body temperature and relieving pain without impairingconsciousness) and, in higher doses, with anti-inflammatory effects(reducing inflammation). The term “non-steroidal” is used to distinguishthese drugs from steroids, which (among a broad range of other effects)have a similar eicosanoid-depressing, anti-inflammatory action. Asanalgesics, NSAIDs are unusual in that they are non-narcotic. NSAIDsinclude aspirin, ibuprofen, and naproxen. NSAIDs are usually indicatedfor the treatment of acute or chronic conditions where pain andinflammation are present. NSAIDs are generally indicated for thesymptomatic relief of the following conditions: rheumatoid arthritis,osteoarthritis, inflammatory arthropathies (e.g. ankylosing spondylitis,psoriatic arthritis, Reiter's syndrome, acute gout, dysmenorrhoea,metastatic bone pain, headache and migraine, postoperative pain,mild-to-moderate pain due to inflammation and tissue injury, pyrexia,ileus, and renal colic. Most NSAIDs act as non-selective inhibitors ofthe enzyme cyclooxygenase, inhibiting both the cyclooxygenase-1 (COX-1)and cyclooxygenase-2 (COX-2) isoenzymes. Cyclooxygenase catalyzes theformation of prostaglandins and thromboxane from arachidonic acid(itself derived from the cellular phospholipid bilayer by phospholipaseA₂). Prostaglandins act (among other things) as messenger molecules inthe process of inflammation. COX-2 inhibitors include celecoxib,etoricoxib, lumiracoxib, parecoxib, rofecoxib, rofecoxib, andvaldecoxib.

The terms “cancer” refers to or describe the physiological condition inmammals that is typically characterized by unregulated cell growth. A“tumor” comprises one or more cancerous cells. Examples of cancerinclude, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma,and leukemia or lymphoid malignancies. More particular examples of suchcancers include squamous cell cancer (e.g., epithelial squamous cellcancer), lung cancer including small-cell lung cancer, non-small celllung cancer (“NSCLC”), adenocarcinoma of the lung and squamous carcinomaof the lung, cancer of the peritoneum, hepatocellular cancer, gastric orstomach cancer including gastrointestinal cancer, pancreatic cancer,glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladdercancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectalcancer, endometrial or uterine carcinoma, salivary gland carcinoma,kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer,hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head andneck cancer.

“Hematological malignancies” (British spelling “Haematological”malignancies) are the types of cancer that affect blood, bone marrow,and lymph nodes. As the three are intimately connected through theimmune system, a disease affecting one of the three will often affectthe others as well: although lymphoma is a disease of the lymph nodes,it often spreads to the bone marrow, affecting the blood. Hematologicalmalignancies are malignant neoplasms (“cancer”), and they are generallytreated by specialists in hematology and/or oncology. In some centers“Hematology/oncology” is a single subspecialty of internal medicinewhile in others they are considered separate divisions (there are alsosurgical and radiation oncologists). Not all hematological disorders aremalignant (“cancerous”); these other blood conditions may also bemanaged by a hematologist. Hematological malignancies may derive fromeither of the two major blood cell lineages: myeloid and lymphoid celllines. The myeloid cell line normally produces granulocytes,erythrocytes, thrombocytes, macrophages and mast cells; the lymphoidcell line produces B, T, NK and plasma cells. Lymphomas, lymphocyticleukemias, and myeloma are from the lymphoid line, while acute andchronic myelogenous leukemia, myelodysplastic syndromes andmyeloproliferative diseases are myeloid in origin. Leukemias includeAcute lymphoblastic leukemia (ALL), Acute myelogenous leukemia (AML),Chronic lymphocytic leukemia (CLL), Chronic myelogenous leukemia (CML),Acute monocytic leukemia (AMOL) and small lymphocytic lymphoma (SLL).Lymphomas include Hodgkin's lymphomas (all four subtypes) andNon-Hodgkin's lymphomas (all subtypes).

A “chemotherapeutic agent” is a chemical compound useful in thetreatment of cancer, regardless of mechanism of action. Classes ofchemotherapeutic agents include, but are not limited to: alkylatingagents, antimetabolites, spindle poison plant alkaloids,cytotoxic/antitumor antibiotics, topoisomerase inhibitors, antibodies,photosensitizers, and kinase inhibitors. Chemotherapeutic agents includecompounds used in “targeted therapy” and conventional chemotherapy.Examples of chemotherapeutic agents include: erlotinib (TARCEVA®,Genentech/OSI Pharm.), docetaxel (TAXOTERE®, Sanofi-Aventis), 5-FU(fluorouracil, 5-fluorouracil, CAS No. 51-21-8), gemcitabine (GEMZAR®,Lilly), PD-0325901 (CAS No. 391210-10-9, Pfizer), cisplatin(cis-diamine, dichloroplatinum(II), CAS No. 15663-27-1), carboplatin(CAS No. 41575-94-4), paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology,Princeton, N.J.), trastuzumab (HERCEPTIN®, Genentech), temozolomide(4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide, CAS No. 85622-93-1, TEMODAR®, TEMODAL®,Schering Plough), tamoxifen((Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine,NOLVADEX®, ISTUBAL®, VALODEX®), and doxorubicin (ADRIAMYCIN®), Akti-1/2,HPPD, and rapamycin.

More examples of chemotherapeutic agents include: oxaliplatin(ELOXATIN®, Sanofi), bortezomib (VELCADE®, Millennium Pharm.), sutent(SUNITINIB®, SU11248, Pfizer), letrozole (FEMARA®, Novartis), imatinibmesylate (GLEEVEC®, Novartis), XL-518 (Mek inhibitor, Exelixis, WO2007/044515), ARRY-886 (Mek inhibitor, AZD6244, Array BioPharma, AstraZeneca), SF-1126 (PI3K inhibitor, Semafore Pharmaceuticals), BEZ-235(PI3K inhibitor, Novartis), XL-147 (PI3K inhibitor, Exelixis), PTK787/ZK222584 (Novartis), fulvestrant (FASLODEX®, AstraZeneca), leucovorin(folinic acid), rapamycin (sirolimus, RAPAMUNEO, Wyeth), lapatinib(TYKERB®, GSK572016, Glaxo Smith Kline), lonafarnib (SARASAR™, SCH66336, Schering Plough), sorafenib (NEXAVAR®, BAY43-9006, Bayer Labs),gefitinib (IRESSA®, AstraZeneca), irinotecan (CAMPTOSAR®, CPT-11,Pfizer), tipifarnib (ZARNESTRA™, Johnson & Johnson), ABRAXANE™(Cremophor-free), albumin-engineered nanoparticle formulations ofpaclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.),vandetanib (rINN, ZD6474, ZACTIMA®, AstraZeneca), chloranmbucil, AG1478,AG1571 (SU 5271; Sugen), temsirolimus (TORISEL®, Wyeth), pazopanib(GlaxoSmithKline), canfosfamide (TELCYTA®, Telik), thiotepa andcyclosphosphamide (CYTOXAN®, NEOSAR®); alkyl sulfonates such asbusulfan, improsulfan and piposulfan; aziridines such as benzodopa,carboquone, meturedopa, and uredopa; ethylenimines and methylamelaminesincluding altretamine, triethylenemelamine, triethylenephosphoramide,triethylenethiophosphoramide and trimethylomelamine; acetogenins(especially bullatacin and bullatacinone); a camptothecin (including thesynthetic analog topotecan); bryostatin; callystatin; CC-1065 (includingits adozelesin, carzelesin and bizelesin synthetic analogs);cryptophycins (particularly cryptophycin 1 and cryptophycin 8);dolastatin; duocarmycin (including the synthetic analogs, KW-2189 andCB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin;nitrogen mustards such as chlorambucil, chlornaphazine,chlorophosphamide, estramustine, ifosfamide, mechlorethamine,mechlorethamine oxide hydrochloride, melphalan, novembichin,phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureassuch as carmustine, chlorozotocin, fotemustine, lomustine, nimustine,and ranimnustine; antibiotics such as the enediyne antibiotics (e.g.,calicheamicin, calicheamicin gamma1I, calicheamicin omegall (Angew Chem.Intl. Ed. Engl. (1994) 33:183-186); dynemicin, dynemicin A;bisphosphonates, such as clodronate; an esperamicin; as well asneocarzinostatin chromophore and related chromoprotein enediyneantibiotic chromophores), aclacinomysins, actinomycin, authramycin,azaserine, bleomycins, cactinomycin, carabicin, caminomycin,carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin,6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin,cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin anddeoxydoxorubicin), epirubicin, esorubicin, idarubicin, nemorubicin,marcellomycin, mitomycins such as mitomycin C, mycophenolic acid,nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin,quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexateand 5-fluorouracil (5-FU); folic acid analogs such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine;androgens such as calusterone, dromostanolone propionate, epitiostanol,mepitiostane, testolactone; anti-adrenals such as aminoglutethimide,mitotane, trilostane; folic acid replenisher such as frolinic acid;aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil;amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine;diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid;gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids suchas maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol;nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharidecomplex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;sizofuran; spirogermanium; tenuazonic acid; triaziquone;2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin,verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (“Ara-C”); cyclophosphamide; thiotepa; 6-thioguanine;mercaptopurine; methotrexate; platinum analogs such as cisplatin andcarboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitoxantrone;vincristine; vinorelbine (NAVELBINE0); novantrone; teniposide;edatrexate; daunomycin; aminopterin; capecitabine (XELODA®, Roche);ibandronate; CPT-11; topoisomerase inhibitor RFS 2000;difluoromethylornithine (DMFO); retinoids such as retinoic acid; andpharmaceutically acceptable salts, acids and derivatives of any of theabove.

Also included in the definition of “chemotherapeutic agent” are: (i)anti-hormonal agents that act to regulate or inhibit hormone action ontumors such as anti-estrogens and selective estrogen receptor modulators(SERMs), including, for example, tamoxifen (including NOLVADEX®;tamoxifen citrate), raloxifene, droloxifene, 4-hydroxytamoxifen,trioxifene, keoxifene, LY117018, onapristone, and FARESTON® (toremifinecitrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase,which regulates estrogen production in the adrenal glands, such as, forexample, 4(5)-imidazoles, aminoglutethimide, MEGASE® (megestrolacetate), AROMASIN® (exemestane; Pfizer), formestanie, fadrozole,RIVISOR® (vorozole), FEMARA® (letrozole; Novartis), and ARIMIDEX®(anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide,nilutamide, bicalutamide, leuprolide, and goserelin; as well astroxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) proteinkinase inhibitors such as MEK inhibitors (WO 2007/044515); (v) lipidkinase inhibitors; (vi) antisense oligonucleotides, particularly thosewhich inhibit expression of genes in signaling pathways implicated inaberrant cell proliferation, for example, PKC-alpha, Raf and H-Ras, suchas oblimersen (GENASENSE®, Genta Inc.); (vii) ribozymes such as VEGFexpression inhibitors (e.g., ANGIOZYME®) and HER2 expression inhibitors;(viii) vaccines such as gene therapy vaccines, for example, ALLOVECTIN®,LEUVECTIN®, and VAXID®; PROLEUKIN® rIL-2; topoisomerase 1 inhibitorssuch as LURTOTECAN®; ABARELIX®rmRH; (ix) anti-angiogenic agents such asbevacizumab (AVASTIN®, Genentech); and pharmaceutically acceptablesalts, acids and derivatives of any of the above.

Also included in the definition of “chemotherapeutic agent” aretherapeutic antibodies such as alemtuzumab (Campath), bevacizumab(AVASTIN®, Genentech); cetuximab (ERBITUX®, Imclone); panitumumab(VECTIBIX®, Amgen), rituximab (RITUXAN®, Genentech/Biogen Idec),pertuzumab (OMNITARGT™, 2C4, Genentech), trastuzumab (HERCEPTIN®,Genentech), tositumomab (Bexxar, Corixia), and the antibody drugconjugate, gemtuzumab ozogamicin (MYLOTARG®, Wyeth).

Humanized monoclonal antibodies with therapeutic potential aschemotherapeutic agents in combination with the Btk inhibitors of theinvention include: alemtuzumab, apolizumab, aselizumab, atlizumab,bapineuzumab, bevacizumab, bivatuzumab mertansine, cantuzumabmertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab,daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab,fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab,labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab,motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab,ocrelizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab,pectuzumab, pertuzumab, pexelizumab, ralivizumab, ranibizumab,reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab,sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan,tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab,trastuzumab, tucotuzumab celmoleukin, tucusituzumab, umavizumab,urtoxazumab, and visilizumab.

A “metabolite” is a product produced through metabolism in the body of aspecified compound or salt thereof. Metabolites of a compound may beidentified using routine techniques known in the art and theiractivities determined using tests such as those described herein. Suchproducts may result for example from the oxidation, reduction,hydrolysis, amidation, deamidation, esterification, deesterification,enzymatic cleavage, and the like, of the administered compound.Accordingly, the invention includes metabolites of compounds of theinvention, including compounds produced by a process comprisingcontacting a Formula I compound of this invention with a mammal for aperiod of time sufficient to yield a metabolic product thereof.

The term “package insert” is used to refer to instructions customarilyincluded in commercial packages of therapeutic products, that containinformation about the indications, usage, dosage, administration,contraindications and/or warnings concerning the use of such therapeuticproducts.

The term “chiral” refers to molecules which have the property ofnon-superimposability of the mirror image partner, while the term“achiral” refers to molecules which are superimposable on their mirrorimage partner.

The term “stereoisomers” refers to compounds which have identicalchemical constitution, but differ with regard to the arrangement of theatoms or groups in space.

“Diastereomer” refers to a stereoisomer with two or more centers ofchirality and whose molecules are not mirror images of one another.Diastereomers have different physical properties, e.g. melting points,boiling points, spectral properties, and reactivities. Mixtures ofdiastereomers may separate under high resolution analytical proceduressuch as electrophoresis and chromatography.

“Enantiomers” refer to two stereoisomers of a compound which arenon-superimposable mirror images of one another.

Stereochemical definitions and conventions used herein generally followS. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984)McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S.,“Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., NewYork, 1994. The compounds of the invention may contain asymmetric orchiral centers, and therefore exist in different stereoisomeric forms.It is intended that all stereoisomeric forms of the compounds of theinvention, including but not limited to, diastereomers, enantiomers andatropisomers, as well as mixtures thereof such as racemic mixtures, formpart of the present invention. Many organic compounds exist in opticallyactive forms, i.e., they have the ability to rotate the plane ofplane-polarized light. In describing an optically active compound, theprefixes D and L, or R and S, are used to denote the absoluteconfiguration of the molecule about its chiral center(s). The prefixes dand l or (+) and (−) are employed to designate the sign of rotation ofplane-polarized light by the compound, with (−) or l meaning that thecompound is levorotatory. A compound prefixed with (+) or d isdextrorotatory. For a given chemical structure, these stereoisomers areidentical except that they are mirror images of one another. A specificstereoisomer may also be referred to as an enantiomer, and a mixture ofsuch isomers is often called an enantiomeric mixture. A 50:50 mixture ofenantiomers is referred to as a racemic mixture or a racemate, which mayoccur where there has been no stereoselection or stereospecificity in achemical reaction or process. The terms “racemic mixture” and “racemate”refer to an equimolar mixture of two enantiomeric species, devoid ofoptical activity. Enantiomers may be separated from a racemic mixture bya chiral separation method, such as supercritical fluid chromatography(SFC). Assignment of configuration at chiral centers in separatedenantiomers may be tentative, and depicted in Table 1 structures forillustrative purposes, while stereochemical determination awaits, suchas x-ray crystallographic data.

The term “tautomer” or “tautomeric form” refers to structural isomers ofdifferent energies which are interconvertible via a low energy barrier.For example, proton tautomers (also known as prototropic tautomers)include interconversions via migration of a proton, such as keto-enoland imine-enamine isomerizations. Valence tautomers includeinterconversions by reorganization of some of the bonding electrons.

The term “pharmaceutically acceptable salts” denotes salts which are notbiologically or otherwise undesirable. Pharmaceutically acceptable saltsinclude both acid and base addition salts. The phrase “pharmaceuticallyacceptable” indicates that the substance or composition must becompatible chemically and/or toxicologically, with the other ingredientscomprising a formulation, and/or the mammal being treated therewith.

The term “pharmaceutically acceptable acid addition salt” denotes thosepharmaceutically acceptable salts formed with inorganic acids such ashydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,carbonic acid, phosphoric acid, and organic acids selected fromaliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic,carboxylic, and sulfonic classes of organic acids such as formic acid,acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid,pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid,succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid,ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamicacid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonicacid “mesylate”, ethanesulfonic acid, p-toluenesulfonic acid, andsalicyclic acid.

The term “pharmaceutically acceptable base addition salt” denotes thosepharmaceutically acceptable salts formed with an organic or inorganicbase. Examples of acceptable inorganic bases include sodium, potassium,ammonium, calcium, magnesium, iron, zinc, copper, manganese, andaluminum salts. Salts derived from pharmaceutically acceptable organicnontoxic bases includes salts of primary, secondary, and tertiaryamines, substituted amines including naturally occurring substitutedamines, cyclic amines and basic ion exchange resins, such asisopropylamine, trimethylamine, diethylamine, triethylamine,tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine,dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine,hydrabamine, choline, betaine, ethylenediamine, glucosamine,methylglucamine, theobromine, purines, piperazine, piperidine,N-ethylpiperidine, and polyamine resins

A “solvate” refers to an association or complex of one or more solventmolecules and a compound of the invention. Examples of solvents thatform solvates include, but are not limited to, water, isopropanol,ethanol, methanol, DMSO, ethylacetate, acetic acid, and ethanolamine.

The term “EC₅₀” is the half maximal effective concentration” and denotesthe plasma concentration of a particular compound required for obtaining50% of the maximum of a particular effect in vivo.

The term “Ki” is the inhibition constant and denotes the absolutebinding affinity of a particular inhibitor to a receptor. It is measuredusing competition binding assays and is equal to the concentration wherethe particular inhibitor would occupy 50% of the receptors if nocompeting ligand (e.g. a radioligand) was present. Ki values can beconverted logarithmically to pKi values (−log Ki), in which highervalues indicate exponentially greater potency.

The term “IC₅₀” is the half maximal inhibitory concentration and denotesthe concentration of a particular compound required for obtaining 50%inhibition of a biological process in vitro. IC₅₀ values can beconverted logarithmically to pIC₅₀ values (−log IC₅₀), in which highervalues indicate exponentially greater potency. The IC₅₀ value is not anabsolute value but depends on experimental conditions e.g.concentrations employed, and can be converted to an absolute inhibitionconstant (Ki) using the Cheng-Prusoff equation (Biochem. Pharmacol.(1973) 22:3099). Other percent inhibition parameters, such as IC₇₀,IC₉₀, etc., may be calculated.

The terms “compound of this invention,” and “compounds of the presentinvention” and “compounds of Formula I” include compounds of Formulas Iand stereoisomers, geometric isomers, tautomers, solvates, metabolites,and pharmaceutically acceptable salts and prodrugs thereof.

Any formula or structure given herein, including Formula I compounds, isalso intended to represent hydrates, solvates, and polymorphs of suchcompounds, and mixtures thereof.

Any formula or structure given herein, including Formula I compounds, isalso intended to represent unlabeled forms as well as isotopicallylabeled forms of the compounds. Isotopically labeled compounds havestructures depicted by the formulas given herein except that one or moreatoms are replaced by an atom having a selected atomic mass or massnumber. Examples of isotopes that can be incorporated into compounds ofthe invention include isotopes of hydrogen, carbon, nitrogen, oxygen,phosphorous, fluorine, and chlorine, such as, but not limited to 2H(deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18F, 31P, 32P, 35S,36Cl, and 125I. Various isotopically labeled compounds of the presentinvention, for example those into which radioactive isotopes such as 3H,13C, and 14C are incorporated. Such isotopically labelled compounds maybe useful in metabolic studies, reaction kinetic studies, detection orimaging techniques, such as positron emission tomography (PET) orsingle-photon emission computed tomography (SPECT) including drug orsubstrate tissue distribution assays, or in radioactive treatment ofpatients. Deuterium labelled or substituted therapeutic compounds of theinvention may have improved DMPK (drug metabolism and pharmacokinetics)properties, relating to distribution, metabolism, and excretion (ADME).Substitution with heavier isotopes such as deuterium may afford certaintherapeutic advantages resulting from greater metabolic stability, forexample increased in vivo half-life or reduced dosage requirements. An18F labeled compound may be useful for PET or SPECT studies.Isotopically labeled compounds of this invention and prodrugs thereofcan generally be prepared by carrying out the procedures disclosed inthe schemes or in the examples and preparations described below bysubstituting a readily available isotopically labeled reagent for anon-isotopically labeled reagent. Further, substitution with heavierisotopes, particularly deuterium (i.e., 2H or D) may afford certaintherapeutic advantages resulting from greater metabolic stability, forexample increased in vivo half-life or reduced dosage requirements or animprovement in therapeutic index. It is understood that deuterium inthis context is regarded as a substituent in the compound of the formula(I). The concentration of such a heavier isotope, specificallydeuterium, may be defined by an isotopic enrichment factor. In thecompounds of this invention any atom not specifically designated as aparticular isotope is meant to represent any stable isotope of thatatom. Unless otherwise stated, when a position is designatedspecifically as “H” or “hydrogen”, the position is understood to havehydrogen at its natural abundance isotopic composition. Accordingly, inthe compounds of this invention any atom specifically designated as adeuterium (D) is meant to represent deuterium.

Heteroaryl Pyridone and Aza-Pyridone Compounds

The present invention provides heteroaryl pyridone and aza-pyridonecompounds of Formula I, including Formulas Ia-Ii, and pharmaceuticalformulations thereof, which are potentially useful in the treatment ofdiseases, conditions and/or disorders modulated by Btk kinase:

including stereoisomers, tautomers, or pharmaceutically acceptable saltsthereof, wherein:

X¹ is CR¹ or N;

X² is CR² or N;

X³ is CR³ or N;

where one or two of X¹, X², and X³ are N;

R¹, R² and R³ are independently selected from H, F, Cl, —NH₂, —NHCH₃,—N(CH₃)₂, —OH, —OCH₃, —OCH₂CH₃, —OCH₂CH₂OH, and C₁-C₃ alkyl;

R⁴ is selected from H, F, Cl, CN, —CH₂OH, —CH(CH₃)OH, —C(CH₃)₂OH,—CH(CF₃)OH, —CHF, —CHF, —CH₂CHF₂, —CF₃, —C(O)NH₂, —C(O)NHCH₃,—C(O)N(CH₃)₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHC(O)CH₃, —OH, —OCH₃, —OCH₂CH₃,—OCH₂CH₂OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl,imidazolyl, pyrazolyl, 3-hydroxy-oxetan-3-yl, oxetan-3-yl, andazetidin-1-yl;

R⁵ is optionally substituted C₆-C₂₀ aryl, C₃-C₁₂ carbocyclyl, C₂-C₂₀heterocyclyl, C₁-C₂₀ heteroaryl, —(C₆-C₂₀ aryl)-(C₂-C₂₀ heterocyclyl),—(C₁-C₂₀ heteroaryl)-(C₂-C₂₀ heterocyclyl), —(C₁-C₂₀ heteroaryl)-(C₂-C₂₀heterocyclyl)-(C₂-C₂₀ heterocyclyl), —(C₁-C₂₀ heteroaryl)-(C₂-C₂₀heterocyclyl)-(C₁-C₆ alkyl), —(C₁-C₂₀ heteroaryl)-(C₁-C₆ alkyl),—(C₂-C₂₀ heterocyclyl)-(C₁-C₆ alkyl), —(C₂-C₂₀ heterocyclyl)-(C₃-C₁₂carbocyclyl), —(C₁-C₂₀ heteroaryl)-(C₃-C₁₂ carbocyclyl), or —(C₁-C₂₀heteroaryl)-C(═O)—(C₂-C₂₀ heterocyclyl);

R⁶ is H, F, —CH₃, —CH₂CH₃, —CH₂CH₂OH, —NH₂, or —OH;

R⁷ is selected from the structures:

where the wavy line indicates the site of attachment; and

Y¹ and Y² are independently selected from CH and N, where Y¹ and Y² arenot each N;

where alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with one or more groups independently selectedfrom F, Cl, Br, I, —CN, —CH₃, —CH₂CH₃, —CH(CH₃)₂, —CH₂CH(CH₃)₂, —CH₂OH,—CH₂OCH₃, —CH₂CH₂OH, —C(CH₃)₂OH, —CH(OH)CH(CH₃)₂, —C(CH₃)₂CH₂OH,—CH₂CH₂SO₂CH₃, —CH₂OP(O)(OH)₂, —CH₂F, —CHF₂, —CF₃, —CH₂CF₃, —CH₂CHF₂,—CH(CH₃)CN, —C(CH₃)₂CN, —CH₂CN, —CO₂H, —COCH₃, —CO₂CH₃, —CO₂C(CH₃)₃,—COCH(OH)CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —C(CH₃)₂CONH₂, —NH₂, —NHCH₃,—N(CH₃)₂, —NHCOCH₃, —N(CH₃)COCH₃, —NHS(O)₂CH₃, —N(CH₃)C(CH₃)₂CONH₂,—N(CH₃)CH₂CH₂S(O)₂CH₃, —NO₂, ═O, —OH, —OCH₃, —OCH₂CH₃, —OCH₂CH₂OCH₃,—OCH₂CH₂OH, —OCH₂CH₂N(CH₃)₂, —OP(O)(OH)₂, —S(O)₂N(CH₃)₂, —SCH₃,—S(O)₂CH₃, —S(O)₃H, cyclopropyl, oxetanyl, azetidinyl,1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino,azetidin-1-ylmethyl, and morpholino.

Exemplary embodiments of Formula I compounds include compounds ofFormulas Ia-c:

Exemplary embodiments of Formula I compounds also include compounds ofFormulas Id-i:

Exemplary embodiments of Formula I compounds include wherein X¹ is N, X¹is N, X¹ is N, X¹ and X³ are N, X¹ and X² are N, or X² and X³ are N, asshown in Formulas Ic-Ii.

Exemplary embodiments of Formula I compounds include wherein R⁵ isoptionally substituted C₁-C₂₀ heteroaryl selected from pyrazolyl,pyridinyl, pyrimidinyl,5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl,5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl,6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl, and1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-yl.

Exemplary embodiments of Formula I compounds include wherein R⁵ is—(C₁-C₂₀ heteroaryl)-(C₂-C₂₀ heterocyclyl) where heteroaryl isoptionally substituted pyridinyl and heterocyclyl is optionallysubstituted piperazinyl.

Exemplary embodiments of Formula I compounds include wherein R⁵ isphenyl, optionally substituted with one or more groups selected from F,Cl, —CH₃, —S(O)₂CH₃, cyclopropyl, azetidinyl, oxetanyl, and morpholino.

Exemplary embodiments of Formula I compounds include wherein R⁵ isselected from the structures:

where the wavy line indicates the site of attachment.

Exemplary embodiments of Formula I compounds include wherein R⁵ is:

where R⁸ is selected from H, —CH₃, —CH₂OCH₃, —CH₂CH₃, —CH(CH₃)₂,—CH₂CH₂OH, —CH₂CH₂OCH₃, —CH₂F, —CHF₂, —CF₃, —CH₂CF₃, —CH₂CHF₂,—CH(CH₃)CN, —C(CH₃)₂CN, —CH₂CN, —C(O)CH₃, —C(O)CH₂CH₃, —C(O)CH(CH₃)₂,—NH₂, —NHCH₃, —N(CH₃)₂, —OH, —OCH₃, —OCH₂CH₃, —OCH₂CH₂OH, cyclopropyl,and oxetanyl.

Exemplary embodiments of Formula I compounds include wherein R⁶ is CH₃.Exemplary embodiments of Formula I compounds include wherein Y¹ is CHand Y² is N, Y¹ is N and Y² is CH, Y¹ and Y² are each CH, or Y¹ and Y²are each CH and R⁶ is CH₃.

Exemplary embodiments of Formula I compounds include the compounds inTables 1 and 2.

The Formula I compounds of the invention may contain asymmetric orchiral centers, and therefore exist in different stereoisomeric forms.It is intended that all stereoisomeric forms of the compounds of theinvention, including but not limited to, diastereomers, enantiomers andatropisomers, as well as mixtures thereof such as racemic mixtures, formpart of the present invention.

In addition, the present invention embraces all diastereomers, includingcis-trans (geometric) and conformational isomers. For example, if aFormula I compound incorporates a double bond or a fused ring, the cis-and trans-forms, as well as mixtures thereof, are embraced within thescope of the invention.

In the structures shown herein, where the stereochemistry of anyparticular chiral atom is not specified, then all stereoisomers arecontemplated and included as the compounds of the invention. Wherestereochemistry is specified by a solid wedge or dashed linerepresenting a particular configuration, then that stereoisomer is sospecified and defined.

The compounds of the present invention may exist in unsolvated as wellas solvated forms with pharmaceutically acceptable solvents such aswater, ethanol, and the like, and it is intended that the inventionembrace both solvated and unsolvated forms.

The compounds of the present invention may also exist in differenttautomeric forms, and all such forms are embraced within the scope ofthe invention. The term “tautomer” or “tautomeric form” refers tostructural isomers of different energies which are interconvertible viaa low energy barrier. For example, proton tautomers (also known asprototropic tautomers) include interconversions via migration of aproton, such as keto-enol and imine-enamine isomerizations. Valencetautomers include interconversions by reorganization of some of thebonding electrons.

Biological Evaluation

The relative efficacies of Formula I compounds as inhibitors of anenzyme activity (or other biological activity) can be established bydetermining the concentrations at which each compound inhibits theactivity to a predefined extent and then comparing the results.Typically, the preferred determination is the concentration thatinhibits 50% of the activity in a biochemical assay, i.e., the 50%inhibitory concentration or “IC₅₀”. Determination of IC₅₀ values can beaccomplished using conventional techniques known in the art. In general,an IC₅₀ can be determined by measuring the activity of a given enzyme inthe presence of a range of concentrations of the inhibitor under study.The experimentally obtained values of enzyme activity then are plottedagainst the inhibitor concentrations used. The concentration of theinhibitor that shows 50% enzyme activity (as compared to the activity inthe absence of any inhibitor) is taken as the IC₅₀ value. Analogously,other inhibitory concentrations can be defined through appropriatedeterminations of activity. For example, in some settings it can bedesirable to establish a 90% inhibitory concentration, i.e., IC₉₀, etc.

Formula I compounds were tested by a standard biochemical Btk KinaseAssay (Example 901).

A general procedure for a standard cellular Btk Kinase Assay that can beused to test Formula I compounds is a Ramos Cell Btk Assay (Example902).

A standard cellular B-cell proliferation assay can be used to testFormula I compounds with B-cells purified from spleen of Balb/c mice(Example 903).

A standard T cell proliferation assay can be used to test Formula Icompounds with T-cells purified from spleen of Balb/c mice (Example904).

A CD86 Inhibition assay can be conducted on Formula I compounds for theinhibition of B cell activity using total mouse splenocytes purifiedfrom spleens of 8-16 week old Balb/c mice (Example 905).

A B-ALL Cell Survival Assay can be conducted on Formula I compounds tomeasure the number of viable B-ALL cells in culture (Example 906).

A CD69 Whole Blood Assay can be conducted on Formula I compounds todetermine the ability of compounds to inhibit the production of CD69 byB lymphocytes in human whole blood activated by crosslinking surface IgMwith goat F(ab′)2 anti-human IgM (Example 907). CD69 is a type II C-typelectin involved in lymphocyte migration and cytokine secretion. CD69expression represents one of the earliest available indicators ofleukocyte activation and its rapid induction occurs throughtranscriptional activation (Vazquez et al (2009) Jour. of ImmunologyPublished Oct. 19, 2009, doi:10.4049/jimmunol.0900839).Concentration-dependent inhibition of antigen receptor stimulation byselective Btk inhibitors induces cell surface expression of thelymphocyte activation marker CD69 (Honigberg et al (2010) Proc. Natl.Acad. Sci. 107(29):13075-13080). Thus, CD69 inhibition by selective Btkinhibitors may be correlated with therapeutic efficacy of certain B-celldisorders. The CD69 Hu Blood FACS IC70 values are displayed forexemplary Formula I compounds in Tables 1 and 2.

The cytotoxic or cytostatic activity of Formula I exemplary compoundscan be measured by: establishing a proliferating mammalian tumor cellline in a cell culture medium, adding a Formula I compound, culturingthe cells for a period from about 6 hours to about 5 days; and measuringcell viability (Example 908). Cell-based in vitro assays are used tomeasure viability, i.e. proliferation (IC₅₀), cytotoxicity (EC₅₀), andinduction of apoptosis (caspase activation) and may be useful inpredicting clinical efficacy against hematological malignancies andsolid tumors.

The in vitro potency of the combinations of Formula I compounds withchemotherapeutic agents can be measured by the cell proliferation assayof Example 908; the CellTiter-Glo® Luminescent Cell Viability Assay,commercially available from Promega Corp., Madison, Wis. Thishomogeneous assay method is based on the recombinant expression ofColeoptera luciferase (U.S. Pat. No. 5,583,024; U.S. Pat. No. 5,674,713;U.S. Pat. No. 5,700,670) and determines the number of viable cells inculture based on quantitation of the ATP present, an indicator ofmetabolically active cells (Crouch et al (1993) J. Immunol. Meth.160:81-88; U.S. Pat. No. 6,602,677). The CellTiter-Glo® Assay wasconducted in 96 or 384 well format, making it amenable to automatedhigh-throughput screening (HTS) (Cree et al (1995) AntiCancer Drugs6:398-404). The homogeneous assay procedure involves adding the singlereagent (CellTiter-Glo® Reagent) directly to cells cultured inserum-supplemented medium. Cell washing, removal of medium and multiplepipetting steps are not required. The system detects as few as 15cells/well in a 384-well format in 10 minutes after adding reagent andmixing.

The homogeneous “add-mix-measure” format results in cell lysis andgeneration of a luminescent signal proportional to the amount of ATPpresent. The amount of ATP is directly proportional to the number ofcells present in culture. The CellTiterGlo® Assay generates a“glow-type” luminescent signal, produced by the luciferase reaction,which has a half-life generally greater than five hours, depending oncell type and medium used. Viable cells are reflected in relativeluminescence units (RLU). The substrate, Beetle Luciferin, isoxidatively decarboxylated by recombinant firefly luciferase withconcomitant conversion of ATP to AMP and generation of photons. Theextended half-life eliminates the need to use reagent injectors andprovides flexibility for continuous or batch mode processing of multipleplates. This cell proliferation assay can be used with various multiwellformats, e.g. 96 or 384 well format. Data can be recorded by luminometeror CCD camera imaging device. The luminescence output is presented asrelative light units (RLU), measured over time.

The anti-proliferative efficacy of Formula I exemplary compounds andcombinations with chemotherapeutic agents are measured by theCellTiter-Glo® Assay (Example 908) against certain hematological tumorcell lines. EC₅₀ values are established for the tested compounds andcombinations.

Exemplary Formula I compounds in Tables 1 and 2 were made,characterized, and tested for inhibition of Btk according to the methodsof this invention, and have the following structures and correspondingnames (ChemDraw Ultra, Version 9.0.1, and ChemBioDraw, Version 11.0,CambridgeSoft Corp., Cambridge Mass.). Where more than one name isassociated with a Formula I compound or intermediate, the chemicalstructure shall define the compound.

TABLE 1 CD69 Hu Blood FACS Mol IC70 No. Structure IUPAC_Name Weight (μM)101

2-{4-Hydroxymethyl-1′- methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 636.74 0.132 102

2-{4-Hydroxymethyl-1′- methyl-5′-[5-(4-methyl-piperazin-1-yl)-pyridin-2- ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 594.71 0.132 103

2-(3-(Hydroxymethyl)-4-(1- methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2- ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2- yl)-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol-1(2H)-one 636.74 0.0776 104

2-(3-(Hydroxymethyl)-2-(1- methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2- ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-4- yl)-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol-1(2H)-one 636.74 0.793 105

2-{4-Hydroxymethyl-1′- methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}- 3,4,5,6,7,8-hexahydro-2H- benzo[4,5]thieno[2,3-c]pyridin-1-one 653.79 0.0654 106

6-{4-Hydroxymethyl-1′- methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}-2,2- dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza- cyclopenta[a]inden-7-one 667.82 0.0576 107

2-{4-Hydroxymethyl-1′- methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}-7,7- dimethyl-3,4,7,8 4etrahydro- 2H,6H-cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 650.77 0.0216 108

2-{3′-Hydroxymethyl-1- methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-7,7- dimethyl-3,4,7,8-tetrahydro- 2H,6H-cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 650.77 0.0319 109

6-{3′-Hydroxymethyl-1- methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-2,2- dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza- cyclopenta[a]inden-7-one 667.82 0.0501 110

2-{3′-Hydroxymethyl-1- methyl-5-[6-(4-methyl- piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro- [3,4′]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H- pyrazino[1,2-a]indol-1-one 594.71 2.7 111

2-{3′-Hydroxymethyl-1- methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]- 6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 609.68 0.131 112

2-{4-Hydroxymethyl-1′- methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}- 2,3,5,6,7,8-hexahydro-4H-2,4b-diaza-fluoren-1-one 636.74 0.492 113

2-[3′-Hydroxymethyl-1- methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5- a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl- 2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 554.64 0.0625 114

2-(4-{6-[4-((R)-1,4-Dimethyl- 3-oxo-piperazin-2-yl)-phenylamino]-4-methyl-5- oxo-4,5-dihydro-pyrazin-2-yl}-3-hydroxymethyl-pyridin- 2-yl)-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 622.72 0.0802 115

2-[3′-Hydroxymethyl-1- methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-6-oxo-1,6- dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H- pyrazino[1,2-a]indol-1-one 499.56 0.286116

3-{4-Hydroxymethyl-1′- methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}-6,7,8,9- tetrahydro-3H- benzo[4,5]thieno[2,3-d]pyridazin-4-one 652.77 0.377 117

2-[3′-Hydroxymethyl-5-(5- methanesulfonyl-pyridin-2-ylamino)-1-methyl-6-oxo-1,6- dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H- pyrazino[1,2-a]indol-1-one 574.65 0.396118

2-[5-(5-Cyclopropyl-1H- pyrazol-3-ylamino)-3′- hydroxymethyl-1-methyl-6-oxo-1,6-dihydro- [3,4′]bipyridinyl-2′-yl]- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 525.60 0.608 119

2-{3′-Hydroxymethyl-1- methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)- pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′- yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 650.77 0.0356 120

2-(3′-Hydroxymethyl-5-{5-[4- (2-hydroxy-2-methyl-propyl)-piperazin-1-yl]-pyridin-2- ylamino}-1-methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′- yl)-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 652.79 0.283 121

2-{3′-Hydroxymethyl-1- methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one 634.73 0.0323 122

2-{5-[5-((2S,5R)-2,5- Dimethyl-4-oxetan-3-yl- piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1- methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 664.80 0.0127 123

2-(5-{5-[4-(2-Hydroxy-ethyl)- piperazin-1-yl]-pyridin-2-ylamino}-3′-hydroxymethyl-1- mcthyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl)- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 624.73 0.0331 124

3-{3′-Hydroxymethyl-1- methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 6,7,8,9-tetrahydro-3H- benzo[4,5]thieno[2,3-d]pyridazin-4-one 652.77 0.0362 125

2-[3′-Hydroxymethyl-1- methyl-5-(5-oxetan-3-yl- 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2- ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 596.68 0.0873 126

2-{4-Hydroxymethyl-1′- methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}-6,7,8,9- tetrahydro-2H-pyrazino[1,2-a]indol-1-one 634.73 0.138 127

2-[3′-Hydroxymethyl-1- methyl-6-oxo-5-(5-piperazin-1-yl-pyridin-2-ylamino)-1,6- dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H- pyrazino[1,2-a]indol-1-one 580.68 0.141128

2-[5-(5-Cyclopropyl-4,5,6,7- tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-3′- hydroxymethyl-1-methyl-6- oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 580.68 0.0918 129

2-[5-(6,7-Dihydro-4H- pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-3′-hydroxymethyl-1- mcthyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 541.60 0.0917 130

2-{3′-Hydroxymethyl-1- methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)- pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′- yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H- cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 664.800.012 131

2-{5-[5-((S)-2-Ethyl-4-oxetan- 3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1- methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 664.80 0.0155 132

2-{4-[5-(6,7-Dihydro-4H- pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methyl-6-oxo-1,6- dihydro-pyridazin-3-yl]-3-hydroxymethyl-pyridin-2-yl}- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 542.59 0.263 133

2-{3-Hydroxymethyl-4-[1- methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5- a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-pyridazin-3-yl]- pyridin-2-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2- a]indol-1-one 555.63 0.227 134

10-Fluoro-2-{3′- hydroxymethyl-1-methyl-5-[5-(4-oxetan-3-yl-piperazin-1- yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl- 2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 654.73 0.0944 135

10-Fluoro-2-[3′- hydroxymethyl-1-methyl-5-(5- methyl-4,5,6,7-tctrahydro-pyrazolo[1,5-a]pyrazin-2- ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 572.63 0.107 136

10-Fluoro-2-{3′- hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl- piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro- [3,4′]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H- pyrazino[1,2-a]indol-1-one 668.76 0.030 137

2-{3′-Hydroxymethyl-1- methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)- pyridm-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′- yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 650.77 0.0646 138

2-[4-Hydroxymethyl-1′- methyl-5′-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5- a]pyrazin-2-ylamino)-6-oxo-1′,6′-dihydro-[3,3′]bipyridinyl- 5-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 554.64 0.353 139

2-{3′-Hydroxymethyl-1- methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 2,3,5,6,7,8-hexahydro-4H-2,4b-diaza-fluoren-1-one 636.74 0.326 140

7,7-Difluoro-2-{3′- hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl- piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro- [3,4′]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H- pyrazino[1,2-a]indol-1-one 686.75 0.308 141

2-[3′-Hydroxymethyl-1- methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5- a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl- 2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H- cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 568.670.0266 142

2-[3′-Hydroxymethyl-1- methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro- [3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H- pyrazino[1,2-a]indol-1-one 497.55 2.1 143

6-[3′-Hydroxymethyl-1- methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro- [3,4′]bipyridinyl-2′-yl]-2,2-dimethyl-2,3,5,6-tetrahydro- 1H,4H-8-thia-6-aza-cyclopenta[a]inden-7-one 528.63 0.0309 144

2-[3′-Hydroxymethyl-1- methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro- [3,4′]bipyridinyl-2-yl]-7,7-dimethyl-3,4,7,8-tetrahydro- 2H,6H- cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one 511.58 0.106 145

6-{3′-Hydroxymethyl-1- methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)- pyridm-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′- yl}-2,2-dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6- aza-cyclopenta[a]inden-7-one 681.85 0.0147146

10-Fluoro-2-[3′- hydroxymethyl-1-methyl-6- oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro-[3,4′]bipyridinyl- 2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 515.54 0.0856 147

2-[3′-Hydroxymethyl-1- methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5- a]pyrazin-2-ylamino)- 6-oxo-1,6-dihydro-[3,4′]bipyridinyl- 2′-yl]-2,3,5,6,7,8-hexahydro-4H-2,4b-diaza-fluoren-1-one 554.64 0.32 148

2-{3′-(3-Hydroxy-oxetan-3- yl)-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl- piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro- [3,4′]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H- pyrazino[1,2-a]indol-1-one 692.81 5 149

2-{3′-Hydroxymethyl-1- methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)- pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′- yl}-2,3,5,6,7,8-hexahydro-4H-2,4b-diaza-fluoren-1-one 650.77 0.0454 150

2-[4-Hydroxymethyl-1′- methyl-5′-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5- a]pyrazin-2-ylamino)-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl- 5-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H- cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 568.670.0316 151

2-{3′-Hydroxymethyl-1- methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)- pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′- yl}-6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one 648.75 0.0455 152

2-{3′-Hydroxymethyl-1- methyl-5-[5-((1S,5R)-3- oxetan-3-yl-3,8-diaza-bicyclo[3.2.1]oct-8-yl)- pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′- yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 662.78 0.188 153

2-{3′-Hydroxymethyl-1- methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)- pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′- yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H- cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 664.800.0238 154

3-{3′-Hydroxymethyl-1- methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)- pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′- yl}-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3- d]pyridazin-4-one 666.79 0.0374 155

2-{5-[5-((2S,5R)-2,5- Dimethyl-4-oxetan-3-yl- piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1- methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 2,3,5,6,7,8-hexahydro-4H-2,4b-diaza-fluoren-1-one 664.80 0.0454 156

2-{5-[5-((2S,5R)-2,5- Dimethyl-4-oxetan-3-yl- piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1- methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-10- fluoro-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 682.79 0.0145 157

2-{5′-[5-((2S,5R)-2,5- Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-4-hydroxymethyl-1′-methyl-6′-oxo-1′,6′-dihydro- [3,3′]bipyridinyl-5-yl}-3,4,6,7,8,9-hexahydro-2H- pyrazino[1,2-a]indol-1-one 664.80 0.0298 158

2-{5-[5-((2S,5R)-2,5- Dimethyl-4-oxetan-3-yl- piperazin-1-yl)-pyridin-2-ylaminol-3′-hydroxymethyl-1- methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-7,7- dimethyl-3,4,7,8-tetrahydro- 2H,6H-cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 678.82 0.020 159

3-{5-[5-((2S,5R)-2,5- Dimethyl-4-oxetan-3-yl- piperazin-1-yl)-pyridin-2-ylamino]-3-hydroxymethyl-1- mcthyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 6,7,8,9-tetrahydro-3H- benzo[4,5]thieno[2,3-d]pyridazin-4-one 680.82 0.082 160

2-{5-[5-((2S,5R)-2,5- Dimcthyl-4-oxetan-3-yl- piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1- methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one 662.78 0.0547 161

2-{5-[5-((S)-2-Ethyl-4-oxetan- 3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1- methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 2,3,5,6,7,8-hexahydro-4H-2,4b-diaza-fluoren-1-one 664.80 0.064 162

2-[3′-Hydroxymethyl-1- methyl-6-oxo-5-(pyrazin-2- ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2-yl]- 3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 497.55 0.434 163

2-[3′-Hydroxymethyl-1- methyl-5-(5-oxetan-3-yl- 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2- ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7- dimethyl-3,4,7,8-tetrahydro- 2H,6H-cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 610.71 0.0228 164

2-{5-[5-((S)-2-Ethyl-4-oxetan- 3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1- mcthyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-7,7- dimethyl-3,4,7,8 -tetrahydro- 2H,6H-cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 678.82 0.029 165

2-{5-[5-((S)-2-Ethyl-4-oxetan- 3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1- methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one 662.78 0.0417 166

10-Fluoro-2-[3′- hydroxymethyl-1-methyl-5-(5- oxetan-3-yl-4,5,6,7-tetrahydro-pyrazolo[1,5- a]pyrazin-2-ylammo)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl- 2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one 614.67 0.155 167

2-(3-(hydroxymethyl)-4-(1- methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3- yl)pyridin-2-yl)-3,4,6,7,8,9- hexahydro-6,9-methanopyrazino[1,2-a]indol- 1(2H)-one 566.65 0.119 168

2-[5-(6,7-Dihydro-4H- pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-3′-hydroxymethyl-1- methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7- dimethyl-3,4,7,8-tetrahydro- 2H,6H-cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 555.63 0.0635 169

2-{3′-Hydroxymethyl-1- methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 3,4,5,6,7,8-hexahydro-2H-benzo[4,5]thieno[2,3- c]pyridin-1-one 653.79 0.206 170

2-(3-(hydroxymethyl)-4-(1- methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3- yl)pyridin-2-yl)-3,4,6,7,8,9- hexahydro-6,9-methanopyrazino[1,2-a]indol- 1(2H)-one 556.65 0.335 171

(1S,11R)-6-[3- (Hydroxymethyl)-4-[1- methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1- yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3- yl]pyridin-2-yl]-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)] tetradeca-2(10),8-dien-7-one662.78 0.036 172

2-(4-(5-(1,2,4-triazin-3- ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3- (hydroxymethyl)pyridin-2-yl)- 3,4,6,7,8,9-hexahydropyrazino[1,2- a]indol-1(2H)-one 498.54 5 173

2-[5-(2,6-Dimethyl-pyrimidin- 4-ylamino)-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro- [3,4′]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro- 2H,6H- cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one 539.63 1 174

(1R,11S)-6-[3- (Hydroxymethyl)-4-[1- methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1- yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3- yl]pyridin-2-yl]-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)] tetradeca-2(10),8-dien-7-one662.78 0.101 175

3-{5-[5-((S)-2-Ethyl-4-oxetan- 3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1- methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}- 6,7,8,9-tetrahydro-3H- benzo[4,5]thieno[2,3-d]pyridazin-4-one 680.82 0.0466 176

(S)-2-(3-(hydroxymcthyl)-4- (1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1- yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3- yl)pyridin-2-yl)-6,7,8,9- tetrahydropyrazino[1,2-a]indol-1(2H)-one 648.75 0.0375 177

2-(4-(5-(5-ethyl-4,5,6,7- tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1- methyl-6-oxo-1,6- dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)- 3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol-1(2H)-one 568.67 0.107 178

3-[3′-Hydroxymethyl-1- methyl-6-oxo-5-(pyridin-2- ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-6,7,8,9- tetrahydro-3H- benzo[4,5]thieno[2,3-d]pyridazin-4-one 512.58 1.1 179

2-[3′-Hydroxymethyl-1- methyl-5-(2-methyl- pyrimidin-4-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl- 2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H- cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 525.600.209 180

2-[3′-Hydroxymethyl-1- methyl-5-(6-methyl- pyrimidin-4-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl- 2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H- cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 525.600.245 181

3-[3′-Hydroxymethyl-1- methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5- a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl- 2′-yl]-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3- d]pyridazin-4-one 570.67 0.144 182

3-[3′-Hydroxymethyl-1- methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro- [3,4′]bipyridinyl-2′-yl]-6,7,8,9- tetrahydro-3H-benzo[4,5]thieno[2,3- d]pyridazin-4-one 513.57 0.813 183

10-fluoro-2-(3- (hydroxymethyl)-4-(1-methyl-6-oxo-5-(pyridin-2-ylamino)- 1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9- hexahydropyrazino[1,2- a]indol-1(2H)-one514.55 0.906 184

6-[3′-Hydroxymethyl-1- methyl-6-oxo-5-(pyrazin-2- ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-2,2- dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza- cyclopenta[a]inden-7-one 528.63 0.601 185

2-{3-Hydroxymethyl-4-[6- (imidazo[1,2-a]pyridin-7-ylamino)-4-methyl-5-oxo-4,5- dihydro-pyrazin-2-yl]-pyridin-2-yl}-7,7-dimethyl-3,4,7,8- tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 550.61 1.3 186

10-fluoro-2-(3- (hydroxymethyl)-4-(4-methyl-5-oxo-6-(pyridin-3-ylamino)- 4,5-dihydropyrazin-2-yl)pyridin-2-yl)-3,4,6,7,8,9- hexahydropyrazino[1,2- a]indol-1(2H)-one515.54 1.6 187

2-(4-(5-(5-(2,2-dimethyl-4- (oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1- methyl-6-oxo-1,6- dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)- 3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol-1(2H)-one 664.80 0.0451 188

2-[3′-Hydroxymethyl-1- methyl-6-oxo-5-(pyrazin-2- ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7- dimethyl-3,4,7,8-tetrahydro- 2H,6H-cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 511.57 0.601 189

2-(3-(hydroxymethyl)-4-(1- methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2- ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2- yl)-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol-1(2H)-one 637.73 0.652

TABLE 2 CD69 Hu Blood FACS No. Structure IUPAC Name (IC70) 190

2-[4-[5-[[5-[2,2-dimethyl-4- (oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-1-methyl-6-oxo- 3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one 0.0704 191

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-3-pyridyl]-2-pyiidyl]-6,7,8,9- tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one 0.0435 192

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,8,9,10- tetrahydropyridazino[4,5-a]indolizin-4-one 1.1 193

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9- tetrahydropyridazino[4,5- b]indolizin-1-one0.0995 194

3-[3-(hydroxymethyl)-4-[1- methyl-6-oxo-5-(pyrazin-2-ylamino)-3-pyridyl]-2-pyridyl]- 6,7,8,9- tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one 1.2 195

2-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9- tetrahydropyrazino[1,2-a]indol- 1-one 0.101196

3-[4-[5-[(2- cyclopropylpyrimidin-4- yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.325 197

2-[3-(hydroxymethyl)-4-[4- methyl-6-[[6-[4-(oxetan-3-yl)piperazin-1-yl]-3- pyridyl]amino]-5-oxo-pyrazin-2-yl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one 2.3 198

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,8,9,10- tetrahydropyridazino[4,5-a]indolizin-4-one 6 199

3-[3-(hydroxymethyl)-4-[5- (imidazo[1,2-a]pyrimidin-7-ylamino)-1-methyl-6-oxo-3- pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.934 200

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[1-(oxetan-3 -yl)-3,6-dihydro-2H-pyridin-4-yl]-2- pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one0.636 201

3-[3-(hydroxymethyl)-4-[6- (imidazo[1,2-a]pyridin-6-ylamino)-4-methyl-5-oxo- pyrazin-2-yl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 3.3 202

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,8,9,10- tetrahydropyridazino[4,5-a]indolizin-4-one 7.3 203

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-6,7-dihydro-4H-thiazolo[5,4- c]pyridin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0605 204

2-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9- tetrahydropyridazino[4,5- b]indolizin-1-one0.436 205

2-[3-(hydroxymethyl)-4-[1- methyl-6-oxo-5-(4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazin-2-ylamino)-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one 0.114 206

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(1-methylazetidin-3-yl)oxy-2-pyridyl]amino]-6- oxo-3-pyridyl]-2-pyridyl]- 3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol- 1-one 0.15 207

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(1-methylazetidin-3-yl)oxy-2-pyridyl]amino]-6- oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.0414 208

2-[4-[5-[(5-ethyl-6,7-dihydro- 4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3- pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9- hexahydropyrido[3,4- b]indolizin-1-one 0.58 209

2-[4-[5-[(5-acetyl-6,7-dihydro- 4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3- pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one 0.116 210

2-(7,7-dimethyl-4-oxo-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-3-pyridyl]pyridine-3-carboxamide 0.914 211

2-(7,7-dimethyl-4-oxo-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-N-methyl- 4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin- 1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]pyridine-3-carboxamide 2.1 212

3-[4-[5-[(5-acetyl-6,7-dihydro- 4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3- pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 0.0152 213

10-fluoro-2-[3-(hydroxymethyl)- 4-[1-methyl-5-[(2-methylpyrimidin-4-yl)amino]-6- oxo-3-pyridyl]-2-pyridyl]- 3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol- 1-one 0.62 214

3-[4-[5-(6,7-dihydro-4H- pyrano[4,3-d]thiazol-2-ylamino)-1-methyl-6-oxo-3- pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 0.124 215

3-[4-(hydroxymethyl)-5-[1- methyl-5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-3-pyridyl]-3- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.457 216

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-6,7-dihydro-4H-thiazolo[5,4- c]pyridin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9- tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one 0.357 217

2-[3-(hydroxymethyl)-4-[5-(1H- imidazo[4,5-b]pyridin-5-ylamino)-1-methyl-6-oxo-3- pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol- 1-one 2.9 218

3-[4-[5-[(1,5-dimethylpyrazol-3- yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0741 219

3-[4-[6-(3-aminoanilino)-4- methyl-5-oxo-pyrazin-2-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.204 220

5-[2-(3,4,6,7,8,9-hexahydro-1H- pyrazino[1,2-a]indol-2-yl)-3-(hydroxymethyl)-4-pyridyl]-1- methyl-3-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]pyridin-2-one 1.6 221

3-[4-[5-[(6-amino-2- pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.121 222

3-[3-(hydroxymethyl)-4-[5-[(2- methylpyrimidin-4-yl)amino]-6-oxo-1H-pyridin-3-yl]-2-pyridyl]- 7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.178 223

10-fluoro-2-[3-(hydroxymethyl)- 4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-thiazolo[5,4- c]pyridin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one0.43 224

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl- 1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 0.0307 225

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-pyridazin-3- yl]-2-pyridyl]-7,7-dimethyl- 1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.766 226

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6- oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 0.117 227

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6- oxo-pyridazin-3-yl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one 0.73 228

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1- yl]pyrazin-2-yl] amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one0.369 229

3-[4-[5-[(2-ethylpyrimidin-4- yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.583 230

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1- yl]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9- tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one 0.179 231

10-fluoro-2-[3-(hydroxymethyl)- 4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin- 1-yl]-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]- 3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol-1-one 0.0624 232

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(1-methyl-4-piperidyl)-2-pyridyl]amino]-6- oxo-3-pyridyl]-2-pyridyl]- 3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol- 1-one 0.0518 233

3-[3-(hydroxymethyl)-4-[1- methyl-6-oxo-5-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin- 2-ylamino)-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 0.0657 234

2-[4-[5-[(5-acetyl-6,7-dihydro- 4H-thiazolo[5,4-c]pyridin-2-yl)amino]-1-methyl-6-oxo-3- pyridyl]-3-(hydroxymethyl)-2-pyridyl]-10-fluoro-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one0.183 235

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1- yl]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.112 236

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(1-methyl-4-piperidyl)-2-pyridyl]amino]-6- oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.0336 237

10-fluoro-2-[3-(hydroxymethyl)- 4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin- 1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrido[3,4- b]indolizin-1-one0.0461 238

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-5,6,7,8- tetrahydro-1H-pyrrolo[3,4-b]indolizin-3-one 5 239

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(1-methylazetidin-3-yl)-2-pyridyl]amino]-6-oxo-3- pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol- 1-one 0.153 240

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(1-methylazetidin-3-yl)-2-pyridyl]amino]-6-oxo-3- pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.0229 241

10-fluoro-2-[3-(hydroxymethyl)- 4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrido[3,4- b]indolizin-1-one0.19 242

2-[4-[5-[(1,5-dimethylpyrazol-3- yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-3,4,6,7,8,9- hexahydropyrido[3,4-b]indolizin-1-one 1.2 243

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[1-[1-(oxetan-3-yl)-4-piperidyl]imidazol-4-yl]amino]- 6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one 2.8 244

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(1-methylazetidin-3-yl)-2-pyridyl]amino]-6-oxo-3- pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4- b]indolizin-1-one 0.138 245

2-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9- tetrahydropyrido[3,4- b]indolizin-1-one0.065 246

2-[4-[5-[(1,5-dimethylpyrazol-3- yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-6,7,8,9- tetrahydropyrido[3,4-b]indolizin-1-one 1.7 247

3-[4-[5-[(5-acetyl-6,7-dihydro- 4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3- pyridyl]-3-(hydroxymethyl)-2-pyridyl]-6,7,8,9- tetrahydrobenzothiopheno[2,3- d]pyridazin-4-one 0.145248

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(3R)-3-methylmorpholine-4-carbonyl]- 2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0703 249

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(3R)-3-methylmorpholine-4-carbonyl]- 2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0177 250

2-[4-[5-[(5,6-dimethyl-6,7- dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl- 6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]- 3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol-1-one 0.171 251 252

3-[4-[5-[(1-ethyl-5-methyl- pyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3- (hydroxymethyl)-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.252 253

3-[3-(hydroxymethyl)-4-[5-[[5- [(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-1H-pyridazin-3-yl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0164 254

3-[4-[5-[(5-acetyl-6,7-dihydro- 4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3- pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one 0.0373 255

2-[4-[5-[(5-acetyl-6,7-dihydro- 4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3- pyridyl]-3-(hydroxymethyl)-2-pyridyl]-10-fluoro-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one0.094 256

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(3S)-3-methylmorpholine-4-carbonyl]- 2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.08 257

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(3S)-3-methylmorpholine-4-carbonyl]- 2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0216 258

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6- oxo-pyridazin-3-yl]-2-pyridyl]- 6,7,8,9-tetrahydrobenzothiopheno[2,3- d]pyridazin-4-one 0.646 259

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6- oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one 0.301 260

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-1H-pyrazol-3-yl)amino]-6-oxo-3- pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0606 261

2-[4-[5-[(1,5-dimethylpyrazol-3- yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-10-fluoro-3,4,6,7,8,9-hexahydropyrido[3,4- b]indolizin-1-one 2.9 262

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyloxazol-2-yl)amino]-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.577 263

10-fluoro-2-[3-(hydroxymethyl)- 4-[1-methyl-6-oxo-5-(pyrimidin-4-ylamino)pyridazin-3-yl]-2- pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol- 1-one 2.2 264

3-[3-(hydroxymethyl)-4-[5-[[2- (1-hydroxy-1-methyl-ethyl)pyrimidin-4-yl]amino]-1- methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 0.653 265

3-[3-(hydroxymethyl)-4-[1- methyl-6-oxo-5-[(5-propanoyl-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazin-2-yl)amino]-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0091 266

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(oxetan-3-yl)-1H-pyrazol-3-yl]amino]-6-oxo-3- pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0293 267

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]-6-oxo-3- pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.225 268

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(1-methylimidazol-4-yl)amino]-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.212 269

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6- oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.0251 270

2-[3-(hydroxymethyl)-4-[1- methyl-5-[(7-methyl-6,8-dihydro-5H-[1,2,4]triazolo[1,5- a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol- 1-one5.9 271

3-[3-(hydroxymethyl)-4-[5-[[5- [(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-1H-pyridin-3-yl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0245 272

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[1-(oxetan-3-yl)azetidin-3-yl]-2- pyridyl]amino]-6-oxo-3- pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.034 273

3-[3-(hydroxymethyl)-4-[1- methyl-6-oxo-5-(2-pyridylamino)-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.299 274

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methylpyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.466 275

3-[4-[5-[(5-fluoro-2- pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.423 276

6-[[5-[2-(7,7-dimethyl-4-oxo- 1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-3- (hydroxymethyl)-4-pyridyl]-1- methyl-2-oxo-3-pyridyl]amino]pyridine-3- carbonitrile 0.358 277

3-[3-(hydroxymethyl)-4-[5-[(5- methoxy-2-pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.339 278

3-[4-[5-[(5-cyclopropyl-2- pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 3.2 279

3-[3-(hydroxymethyl)-4-[1- methyl-6-oxo-5-[[5- (trifluoromethyl)-2-pyridyl]amino]-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 2.1 280

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[1-methyl-5-(morpholine-4-carbonyl)pyrazol- 3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 0.0141 281

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-2-pyridyl)amino]-6-oxo-3- pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.718 282

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2- pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-6,8- dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one 0.0174 283

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.143 284

10-fluoro-2-[3-(hydroxymethyl)- 4-[1-methyl-5-[[5-(oxetan-3-yl)-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9- hexahydropyrido[3,4- b]indolizin-1-one0.131 285

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[1-(oxetan-3-yl)imidazol-4-yl]amino]-6-oxo- 3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.175 286

3-[3-(hydroxymethyl)-4-[5- (isoxazol-3-ylamino)-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.167 287

2-[4-[5-[(4,5-dimethyl-6,7- dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl- 6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]- 3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol-1-one 0.127 288

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1, 3-d]pyridazin-4-one 0.229 289

3-[3-(hydroxymethyl)-4-[1- methyl-6-oxo-5-(1H-pyrazol-3-ylamino)-3-pyridyl]-2-pyridyl]- 7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.214 290

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(1-methylpyrazol-3-yl)amino]-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.113 291

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-3-pyridyl]-2- pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3- d]pyridazin-4-one 0.843 292

3-[4-[5-[(1,5-dimethylpyrazol-3- yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1, 3-d]pyridazin-4-one 0.118 293

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(1-methyltriazol-4-yl)amino]-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0691 294

3-[4-[5-[(5-tert-butylisoxazol-3- yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.276 295

3-[4-[5-[(5-ethylisoxazol-3- yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4] pyrrolo [3,5-b]pyrazin-4-one 0.134 296

3-[3-(hydroxymethyl)-4-[5-[[5- (2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2- yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0193 297

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazin-2-yl)amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.14 298

5-[[5-[2-(7,7-dimethyl-4-oxo- 1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-3- (hydroxymethyl)-4-pyridyl]-1- methyl-2-oxo-3-pyridyl]amino]pyrazine-2- carbonitrile 0.869 299

3-[3-(hydroxymethyl)-4-[1- methyl-6-oxo-5-[(5-phenylisoxazol-3-yl)amino]-3- pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 2.1 300

(R)-2-(3′-(hydroxymethyl)-5-((5- (1-methoxypropan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydro-[3,4′- bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H- cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one0.024 301

3-[3-(hydroxymethyl)-4-[1- methyl-6-oxo-5-[[6-(trifluoromethyl)pyridazin-3- yl]amino]-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 1.3 302

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[1-methyl-5- [[methyl(oxetan-3-yl)amino]methyl]pyrazol-3- yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 0.0228 303

(S)-2-(3′-(hydroxymethyl)-5-((5- (1-methoxypropan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydro-[3,4′- bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H- cyclopenta[4,5]pyrrolo[1,2- ajpyrazin-1-one0.0179 304

3-[3-(hydroxymethyl)-4-[5-[[5- (2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2- yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-6,8- dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one 0.04 305

3-[3-(hydroxymethyl)-4-[5-[[5- (2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2- yl]amino]-1-methyl-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0832 306

3-[3-(hydroxymethyl)-4-[5-[(6- methoxypyridazin-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.602 307

3-[4-[6-[(1,3-dimethylindazol-5- yl)amino]-4-methyl-5-oxo-pyrazin-2-yl]-3- (hydroxymethyl)-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 308

3-[3-(hydroxymethyl)-4-[5-[[5- (2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2- yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno [1,3-c]pyridin-4-one 0.0546 309

3-[3-(hydroxymethyl)-4-[5-[[5- (3-methoxypropyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2- yl] amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0398 310

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methylisothiazol-3-yl)amino]-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.119 311

3-[4-[5-[(5-cyclopropylisoxazol- 3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.158 312

3-[3-(hydroxymethyl)-4-[1- methyl-5-[[5-methyl-1-(oxetan-3-yl)pyrazol-3-yl]amino]-6-oxo- 3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tctrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one5.6 313

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-6-oxo-4,7-dihydropyrazolo[1,5-a]pyrazin- 2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tctrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 0.0191 314

3-[4-[5-[[5-(3-hydroxyazetidin- 1-yl)-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-3- (hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.0446 315

3-[3-(hydroxymcthyl)-4-[1- methyl-5-[[1-methyl-5-(pyrrolidine-1-carbonyl)pyrazol- 3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 0.015 316

3-[3-(hydroxymethyl)-4-[5-[[5- (methoxymethyl)-1-methyl-pyrazol-3-yl]amino]-1-methyl-6- oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.0202 317

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(5-methyl-6-oxo-4,7-dihydropyrazolo[1,5-a]pyrazin- 2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one 0.0586 318

(R)-2-(5-((4,5-dimcthyl-4,5,6,7- tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-3′- (hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4′-bipyridin]- 2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H- cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 0.108 319

(S)-2-(5-((4,5-dimethyl-4,5,6,7- tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-3′- (hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4′-bipyridin]- 2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H- cyclopenta[4,5]pyrrolo[1,2- a]pyrazin-1-one 0.0167 320

3-[4-[5-[[5-[(3S,5R)-3,5- dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1- methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0468 321

3-[4-[5-[[5-[(3S,5R)-3,5- dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1- methyl-6-oxo-pyridazin-3-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.112 322

2-[4-[5-[[5-[(3S,5R)-3,5- dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1- methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]- 3,4,6,7,8,9- hexahydropyrazino[1,2-a]indol-1-one 0.0796 323

3-[3-(hydroxymethyl)-4-[5-[[5- (3-methoxyazetidin-1-yl)-2-pyridyl]amino]-1-methyl-6-oxo- 3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.279 324

3-[4-[5-[[5-[(3S,5S)-3,5- dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1- methyl-6-oxo-pyridazin-3-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0858 325

3-[4-[5-[(1,3- dimethylpyrazolo[3,4-c]pyridin-5-yl)amino]-1-methyl-6-oxo-3- pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 1.4 326

3-[4-[5-[(2,3- dimethylpyrazolo[3,4-c]pyridin-5-yl)amino]-1-methyl-6-oxo-3- pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 1.4 327

3-[3-(hydroxymethyl)-4-[5-[[5- (2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2- yl]amino]-1,2-dimethyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 2.2 328

3-[4-(hydroxymethyl)-5-[5-[[5- (2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2- yl]amino]-1-methyl-6-oxo-3-pyridyl]-3-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0124 329

3-[3-(hydroxymethyl)-2-[5-[[5- (2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2- yl]amino]-1-methyl-6-oxo-3-pyridyl]-4-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.11 330

3-[4-[5-[(6,6-dimethyl-4,7- dihydropyrazolo[5,1-c][1,4]oxazin-2-yl)amino]-1- methyl-6-oxo-pyridazin-3-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno [1,3-c]pyridin-4-one 0.235 331

3-[3-(hydroxymethyl)-4-[4- methyl-6-[(3-methylisothiazol-5-yl)amino]-5-oxo-pyrazin-2-yl]- 2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 332

3-[4-[5-[(5-ethyl-1,3,4- thiadiazol-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3- (hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.0919 333

3-[3-(hydroxymethyl)-4-[1- methyl-5-[(1-methyltriazol-4-yl)amino]-6-oxo-3-pyridyl]-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno [1,3-c]pyridin-4-one 0.209 334

3-[4-[5-[(5-cyclopropyl-1,3,4- thiadiazol-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3- (hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.193 335

3-[4-[5-[(6,6-dimethyl-4,7- dihydropyrazolo[5,1-c][1,4]oxazin-2-yl)amino]-1- methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7- dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1, 3-d]pyridazin-4-one 0.0528 336

2-[3-(hydroxymethyl)-4-[5-[[5- (methoxymethyl)-1-methyl-pyrazol-3-yl]amino]-1-methyl-6- oxo-3-pyridyl]-2-pyridyl]- 3,4,6,7,8,9-hexahydropyrido[3,4- b]indolizin-1-one 0.33 337

3-[4-[5-[(1,2-dimethylimidazol- 4- yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2- pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.613 338

3-[2-[[5-[2-(7,7-dimethyl-4-oxo- 1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-3-yl)-3-(hydroxymethyl)-4-pyridyl]-1- methyl-2-oxo-3-pyridyl]amino]-6,7-dihydro-4H-pyrazolo[1,5- a]pyrazin-5-yl]propanenitrile 0.0178 339

3-[3-(hydroxymethyl)-4-[5-[[5- [4-(2-methoxyethyl)piperazin-1-yl]-2-pyridyl]amino]-1-methyl- 6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8- tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one0.0535 340

3-[3-(hydroxymethyl)-4-[5-[[5- [(2S)-4-(2-methoxyethyl)-2-methyl-piperazin-1-yl]-2- pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7- dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo [3,5-b]pyrazin-4-one 0.0207

Administration of Formula I Compounds

The compounds of the invention may be administered by any routeappropriate to the condition to be treated. Suitable routes includeoral, parenteral (including subcutaneous, intramuscular, intravenous,intraarterial, intradermal, intrathecal and epidural), transdermal,rectal, nasal, topical (including buccal and sublingual), vaginal,intraperitoneal, intrapulmonary and intranasal. For localimmunosuppressive treatment, the compounds may be administered byintralesional administration, including perfusing or otherwisecontacting the graft with the inhibitor before transplantation. It willbe appreciated that the preferred route may vary with for example thecondition of the recipient. Where the compound is administered orally,it may be formulated as a pill, capsule, tablet, etc. with apharmaceutically acceptable carrier or excipient. Where the compound isadministered parenterally, it may be formulated with a pharmaceuticallyacceptable parenteral vehicle and in a unit dosage injectable form, asdetailed below.

A dose to treat human patients may range from about 10 mg to about 1000mg of Formula I compound. A typical dose may be about 100 mg to about300 mg of the compound. A dose may be administered once a day (QID),twice per day (BID), or more frequently, depending on thepharmacokinetic and pharmacodynamic properties, including absorption,distribution, metabolism, and excretion of the particular compound. Inaddition, toxicity factors may influence the dosage and administrationregimen. When administered orally, the pill, capsule, or tablet may beingested daily or less frequently for a specified period of time. Theregimen may be repeated for a number of cycles of therapy.

Methods of Treatment with Formula I Compounds

Formula I compounds of the present invention are useful for treating ahuman or animal patient suffering from a disease or disorder arisingfrom abnormal cell growth, function or behavior associated with Btkkinase such as an immune disorder, cardiovascular disease, viralinfection, inflammation, a metabolism/endocrine disorder or aneurological disorder, may thus be treated by a method comprising theadministration thereto of a compound of the present invention as definedabove. A human or animal patient suffering from cancer may also betreated by a method comprising the administration thereto of a compoundof the present invention as defined above. The condition of the patientmay thereby be improved or ameliorated.

Formula I compounds may be useful for in vitro, in situ, and in vivodiagnosis or treatment of mammalian cells, organisms, or associatedpathological conditions, such as systemic and local inflammation,immune-inflammatory diseases such as rheumatoid arthritis, immunesuppression, organ transplant rejection, allergies, ulcerative colitis,Crohn's disease, dermatitis, asthma, systemic lupus erythematosus,Sjögren's Syndrome, multiple sclerosis, scleroderma/systemic sclerosis,idiopathic thrombocytopenic purpura (ITP), anti-neutrophil cytoplasmicantibodies (ANCA) vasculitis, chronic obstructive pulmonary disease(COPD), psoriasis, and for general joint protective effects.

Methods of the invention also include treating such diseases asarthritic diseases, such as rheumatoid arthritis, monoarticulararthritis, osteoarthritis, gouty arthritis, spondylitis; Behcet disease;sepsis, septic shock, endotoxic shock, gram negative sepsis, grampositive sepsis, and toxic shock syndrome; multiple organ injurysyndrome secondary to septicemia, trauma, or hemorrhage; ophthalmicdisorders such as allergic conjunctivitis, vernal conjunctivitis,uveitis, and thyroid-associated ophthalmopathy; eosinophilic granuloma;pulmonary or respiratory disorders such as asthma, chronic bronchitis,allergic rhinitis, ARDS, chronic pulmonary inflammatory disease (e.g.,chronic obstructive pulmonary disease), silicosis, pulmonarysarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia,bronchiectasis, and pulmonary oxygen toxicity; reperfusion injury of themyocardium, brain, or extremities; fibrosis such as cystic fibrosis;keloid formation or scar tissue formation; atherosclerosis; autoimmunediseases, such as systemic lupus erythematosus (SLE), autoimmunethyroiditis, multiple sclerosis, some forms of diabetes, and Reynaud'ssyndrome; and transplant rejection disorders such as GVHD and allograftrejection; chronic glomerulonephritis; inflammatory bowel diseases suchas chronic inflammatory bowel disease (CIBD), Crohn's disease,ulcerative colitis, and necrotizing enterocolitis; inflammatorydermatoses such as contact dermatitis, atopic dermatitis, psoriasis, orurticaria; fever and myalgias due to infection; central or peripheralnervous system inflammatory disorders such as meningitis, encephalitis,and brain or spinal cord injury due to minor trauma; Sjogren's syndrome;diseases involving leukocyte diapedesis; alcoholic hepatitis; bacterialpneumonia; antigen-antibody complex mediated diseases; hypovolemicshock; Type I diabetes mellitus; acute and delayed hypersensitivity;disease states due to leukocyte dyscrasia and metastasis; thermalinjury; granulocyte transfusion-associated syndromes; andcytokine-induced toxicity.

Methods of the invention also include treating cancer selected frombreast, ovary, cervix, prostate, testis, genitourinary tract, esophagus,larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma,lung, epidermoid carcinoma, large cell carcinoma, non-small cell lungcarcinoma (NSCLC), small cell carcinoma, lung adenocarcinoma, bone,colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma,undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma,sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidneycarcinoma, pancreatic, myeloid disorders, lymphoma, hairy cells, buccalcavity, naso-pharyngeal, pharynx, lip, tongue, mouth, small intestine,colon-rectum, large intestine, rectum, brain and central nervous system,Hodgkin's, leukemia, bronchus, thyroid, liver and intrahepatic bileduct, hepatocellular, gastric, glioma/glioblastoma, endometrial,melanoma, kidney and renal pelvis, urinary bladder, uterine corpus,uterine cervix, multiple myeloma, acute myelogenous leukemia, chronicmyelogenous leukemia, lymphocytic leukemia, chronic lymphoid leukemia(CLL), myeloid leukemia, oral cavity and pharynx, non-Hodgkin lymphoma,melanoma, and villous colon adenoma.

The methods of the invention can have utility in treating subjects whoare or can be subject to reperfusion injury, i.e., injury resulting fromsituations in which a tissue or organ experiences a period of ischemiafollowed by reperfusion. The term “ischemia” refers to localized tissueanemia due to obstruction of the inflow of arterial blood. Transientischemia followed by reperfusion characteristically results inneutrophil activation and transmigration through the endothelium of theblood vessels in the affected area. Accumulation of activatedneutrophils in turn results in generation of reactive oxygenmetabolites, which damage components of the involved tissue or organ.This phenomenon of “reperfusion injury” is commonly associated withconditions such as vascular stroke (including global and focalischemia), hemorrhagic shock, myocardial ischemia or infarction, organtransplantation, and cerebral vasospasm. To illustrate, reperfusioninjury occurs at the termination of cardiac bypass procedures or duringcardiac arrest when the heart, once prevented from receiving blood,begins to reperfuse. It is expected that inhibition of Btk activity mayresult in reduced amounts of reperfusion injury in such situations.

Pharmaceutical Formulations

In order to use a compound of this invention for the therapeutictreatment of mammals including humans, it is normally formulated inaccordance with standard pharmaceutical practice as a pharmaceuticalcomposition. According to this aspect of the invention there is provideda pharmaceutical composition comprising a compound of this invention inassociation with a pharmaceutically acceptable diluent or carrier.

A typical formulation is prepared by mixing a compound of the presentinvention and a carrier, diluent or excipient. Suitable carriers,diluents and excipients are well known to those skilled in the art andinclude materials such as carbohydrates, waxes, water soluble and/orswellable polymers, hydrophilic or hydrophobic materials, gelatin, oils,solvents, water and the like. The particular carrier, diluent orexcipient used will depend upon the means and purpose for which thecompound of the present invention is being applied. Solvents aregenerally selected based on solvents recognized by persons skilled inthe art as safe (GRAS) to be administered to a mammal. In general, safesolvents are non-toxic aqueous solvents such as water and othernon-toxic solvents that are soluble or miscible in water. Suitableaqueous solvents include water, ethanol, propylene glycol, polyethyleneglycols (e.g., PEG 400, PEG 300), etc. and mixtures thereof. Theformulations may also include one or more buffers, stabilizing agents,surfactants, wetting agents, lubricating agents, emulsifiers, suspendingagents, preservatives, antioxidants, opaquing agents, glidants,processing aids, colorants, sweeteners, perfuming agents, flavoringagents and other known additives to provide an elegant presentation ofthe drug (i.e., a compound of the present invention or pharmaceuticalcomposition thereof) or aid in the manufacturing of the pharmaceuticalproduct (i.e., medicament).

The formulations may be prepared using conventional dissolution andmixing procedures. For example, the bulk drug substance (i.e., compoundof the present invention or stabilized form of the compound (e.g.,complex with a cyclodextrin derivative or other known complexationagent) is dissolved in a suitable solvent in the presence of one or moreof the excipients described above. The compound of the present inventionis typically formulated into pharmaceutical dosage forms to provide aneasily controllable dosage of the drug and to enable patient compliancewith the prescribed regimen.

The pharmaceutical composition (or formulation) for application may bepackaged in a variety of ways depending upon the method used foradministering the drug. Generally, an article for distribution includesa container having deposited therein the pharmaceutical formulation inan appropriate form. Suitable containers are well known to those skilledin the art and include materials such as bottles (plastic and glass),sachets, ampoules, plastic bags, metal cylinders, and the like. Thecontainer may also include a tamper-proof assemblage to preventindiscreet access to the contents of the package. In addition, thecontainer has deposited thereon a label that describes the contents ofthe container. The label may also include appropriate warnings.

Pharmaceutical formulations of the compounds of the present inventionmay be prepared for various routes and types of administration. Forexample, a compound of Formula I having the desired degree of purity mayoptionally be mixed with pharmaceutically acceptable diluents, carriers,excipients or stabilizers (Remington's Pharmaceutical Sciences (1980)16th edition, Osol, A. Ed.), in the form of a lyophilized formulation,milled powder, or an aqueous solution. Formulation may be conducted bymixing at ambient temperature at the appropriate pH, and at the desireddegree of purity, with physiologically acceptable carriers, i.e.,carriers that are non-toxic to recipients at the dosages andconcentrations employed. The pH of the formulation depends mainly on theparticular use and the concentration of compound, but may range fromabout 3 to about 8. Formulation in an acetate buffer at pH 5 is asuitable embodiment.

The compound ordinarily can be stored as a solid composition, alyophilized formulation or as an aqueous solution.

The pharmaceutical compositions of the invention will be formulated,dosed and administered in a fashion, i.e., amounts, concentrations,schedules, course, vehicles and route of administration, consistent withgood medical practice. Factors for consideration in this context includethe particular disorder being treated, the particular mammal beingtreated, the clinical condition of the individual patient, the cause ofthe disorder, the site of delivery of the agent, the method ofadministration, the scheduling of administration, and other factorsknown to medical practitioners. The “therapeutically effective amount”of the compound to be administered will be governed by suchconsiderations, and is the minimum amount necessary to ameliorate, ortreat the hyperproliferative disorder.

As a general proposition, the initial pharmaceutically effective amountof the inhibitor administered parenterally per dose will be in the rangeof about 0.01-100 mg/kg, namely about 0.1 to 20 mg/kg of patient bodyweight per day, with the typical initial range of compound used being0.3 to 15 mg/kg/day.

Acceptable diluents, carriers, excipients and stabilizers are nontoxicto recipients at the dosages and concentrations employed, and includebuffers such as phosphate, citrate and other organic acids; antioxidantsincluding ascorbic acid and methionine; preservatives (such asoctadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;benzalkonium chloride, benzethonium chloride; phenol, butyl or benzylalcohol; alkyl parabens such as methyl or propyl paraben; catechol;resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecularweight (less than about 10 residues) polypeptides; proteins, such asserum albumin, gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone; amino acids such as glycine, glutamine,asparagine, histidine, arginine, or lysine; monosaccharides,disaccharides and other carbohydrates including glucose, mannose, ordextrins; chelating agents such as EDTA; sugars such as sucrose,mannitol, trehalose or sorbitol; salt-forming counter-ions such assodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionicsurfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG). Theactive pharmaceutical ingredients may also be entrapped in microcapsulesprepared, for example, by coacervation techniques or by interfacialpolymerization, for example, hydroxymethylcellulose orgelatin-microcapsules and poly-(methylmethacylate) microcapsules,respectively, in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nano-particles andnanocapsules) or in macroemulsions. Such techniques are disclosed inRemington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

Sustained-release preparations of compounds of Formula I may beprepared. Suitable examples of sustained-release preparations includesemipermeable matrices of solid hydrophobic polymers containing acompound of Formula I, which matrices are in the form of shapedarticles, e.g., films, or microcapsules. Examples of sustained-releasematrices include polyesters, hydrogels (for example,poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactides(U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid andgamma-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate,degradable lactic acid-glycolic acid copolymers such as the LUPRONDEPOT™ (injectable microspheres composed of lactic acid-glycolic acidcopolymer and leuprolide acetate) and poly-D-(−)-3-hydroxybutyric acid.

The formulations include those suitable for the administration routesdetailed herein. The formulations may conveniently be presented in unitdosage form and may be prepared by any of the methods well known in theart of pharmacy. Techniques and formulations generally are found inRemington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.).Such methods include the step of bringing into association the activeingredient with the carrier which constitutes one or more accessoryingredients. In general the formulations are prepared by uniformly andintimately bringing into association the active ingredient with liquidcarriers or finely divided solid carriers or both, and then, ifnecessary, shaping the product.

Formulations of a compound of Formula I suitable for oral administrationmay be prepared as discrete units such as pills, capsules, cachets ortablets each containing a predetermined amount of a compound of FormulaI. Compressed tablets may be prepared by compressing in a suitablemachine the active ingredient in a free-flowing form such as a powder orgranules, optionally mixed with a binder, lubricant, inert diluent,preservative, surface active or dispersing agent. Molded tablets may bemade by molding in a suitable machine a mixture of the powdered activeingredient moistened with an inert liquid diluent. The tablets mayoptionally be coated or scored and optionally are formulated so as toprovide slow or controlled release of the active ingredient therefrom.Tablets, troches, lozenges, aqueous or oil suspensions, dispersiblepowders or granules, emulsions, hard or soft capsules, e.g., gelatincapsules, syrups or elixirs may be prepared for oral use. Formulationsof compounds of Formula I intended for oral use may be preparedaccording to any method known to the art for the manufacture ofpharmaceutical compositions and such compositions may contain one ormore agents including sweetening agents, flavoring agents, coloringagents and preserving agents, in order to provide a palatablepreparation. Tablets containing the active ingredient in admixture withnon-toxic pharmaceutically acceptable excipient which are suitable formanufacture of tablets are acceptable. These excipients may be, forexample, inert diluents, such as calcium or sodium carbonate, lactose,calcium or sodium phosphate; granulating and disintegrating agents, suchas maize starch, or alginic acid; binding agents, such as starch,gelatin or acacia; and lubricating agents, such as magnesium stearate,stearic acid or talc. Tablets may be uncoated or may be coated by knowntechniques including microencapsulation to delay disintegration andadsorption in the gastrointestinal tract and thereby provide a sustainedaction over a longer period. For example, a time delay material such asglyceryl monostearate or glyceryl distearate alone or with a wax may beemployed.

For treatment of the eye or other external tissues, e.g., mouth andskin, the formulations are preferably applied as a topical ointment orcream containing the active ingredient(s) in an amount of, for example,0.075 to 20% w/w. When formulated in an ointment, the active ingredientsmay be employed with either a paraffinic or a water-miscible ointmentbase. Alternatively, the active ingredients may be formulated in a creamwith an oil-in-water cream base. If desired, the aqueous phase of thecream base may include a polyhydric alcohol, i.e., an alcohol having twoor more hydroxyl groups such as propylene glycol, butane 1,3-diol,mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400)and mixtures thereof. The topical formulations may desirably include acompound which enhances absorption or penetration of the activeingredient through the skin or other affected areas. Examples of suchdermal penetration enhancers include dimethyl sulfoxide and relatedanalogs. The oily phase of the emulsions of this invention may beconstituted from known ingredients in a known manner. While the phasemay comprise merely an emulsifier, it desirably comprises a mixture ofat least one emulsifier with a fat or an oil or with both a fat and anoil. Preferably, a hydrophilic emulsifier is included together with alipophilic emulsifier which acts as a stabilizer. It is also preferredto include both an oil and a fat. Together, the emulsifier(s) with orwithout stabilizer(s) make up the so-called emulsifying wax, and the waxtogether with the oil and fat make up the so-called emulsifying ointmentbase which forms the oily dispersed phase of the cream formulations.Emulsifiers and emulsion stabilizers suitable for use in the formulationof the invention include Tween® 60, Span® 80, cetostearyl alcohol,benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodiumlauryl sulfate.

Aqueous suspensions of Formula I compounds contain the active materialsin admixture with excipients suitable for the manufacture of aqueoussuspensions. Such excipients include a suspending agent, such as sodiumcarboxymethylcellulose, croscarmellose, povidone, methylcellulose,hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone,gum tragacanth and gum acacia, and dispersing or wetting agents such asa naturally occurring phosphatide (e.g., lecithin), a condensationproduct of an alkylene oxide with a fatty acid (e.g., polyoxyethylenestearate), a condensation product of ethylene oxide with a long chainaliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensationproduct of ethylene oxide with a partial ester derived from a fatty acidand a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). Theaqueous suspension may also contain one or more preservatives such asethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one ormore flavoring agents and one or more sweetening agents, such as sucroseor saccharin.

The pharmaceutical compositions of compounds of Formula I may be in theform of a sterile injectable preparation, such as a sterile injectableaqueous or oleaginous suspension. This suspension may be formulatedaccording to the known art using those suitable dispersing or wettingagents and suspending agents which have been mentioned above. Thesterile injectable preparation may also be a sterile injectable solutionor suspension in a non-toxic parenterally acceptable diluent or solvent,such as a solution in 1,3-butanediol or prepared as a lyophilizedpowder. Among the acceptable vehicles and solvents that may be employedare water, Ringer's solution and isotonic sodium chloride solution. Inaddition, sterile fixed oils may conventionally be employed as a solventor suspending medium. For this purpose any bland fixed oil may beemployed including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid may likewise be used in the preparation ofinjectables.

The amount of active ingredient that may be combined with the carriermaterial to produce a single dosage form will vary depending upon thehost treated and the particular mode of administration. For example, atime-release formulation intended for oral administration to humans maycontain approximately 1 to 1000 mg of active material compounded with anappropriate and convenient amount of carrier material which may varyfrom about 5 to about 95% of the total compositions (weight:weight). Thepharmaceutical composition can be prepared to provide easily measurableamounts for administration. For example, an aqueous solution intendedfor intravenous infusion may contain from about 3 to 500 μg of theactive ingredient per milliliter of solution in order that infusion of asuitable volume at a rate of about 30 mL/hr can occur.

Formulations suitable for parenteral administration include aqueous andnon-aqueous sterile injection solutions which may contain anti-oxidants,buffers, bacteriostats and solutes which render the formulation isotonicwith the blood of the intended recipient; and aqueous and non-aqueoussterile suspensions which may include suspending agents and thickeningagents.

Formulations suitable for topical administration to the eye also includeeye drops wherein the active ingredient is dissolved or suspended in asuitable carrier, especially an aqueous solvent for the activeingredient. The active ingredient is preferably present in suchformulations in a concentration of about 0.5 to 20% w/w, for exampleabout 0.5 to 10% w/w, for example about 1.5% w/w.

Formulations suitable for topical administration in the mouth includelozenges comprising the active ingredient in a flavored basis, usuallysucrose and acacia or tragacanth; pastilles comprising the activeingredient in an inert basis such as gelatin and glycerin, or sucroseand acacia; and mouthwashes comprising the active ingredient in asuitable liquid carrier.

Formulations for rectal administration may be presented as a suppositorywith a suitable base comprising for example cocoa butter or asalicylate.

Formulations suitable for intrapulmonary or nasal administration have aparticle size for example in the range of 0.1 to 500 microns (includingparticle sizes in a range between 0.1 and 500 microns in incrementsmicrons such as 0.5, 1, 30 microns, 35 microns, etc.), which isadministered by rapid inhalation through the nasal passage or byinhalation through the mouth so as to reach the alveolar sacs. Suitableformulations include aqueous or oily solutions of the active ingredient.Formulations suitable for aerosol or dry powder administration may beprepared according to conventional methods and may be delivered withother therapeutic agents such as compounds heretofore used in thetreatment or prophylaxis disorders as described below.

Formulations suitable for vaginal administration may be presented aspessaries, tampons, creams, gels, pastes, foams or spray formulationscontaining in addition to the active ingredient such carriers as areknown in the art to be appropriate.

The formulations may be packaged in unit-dose or multi-dose containers,for example sealed ampoules and vials, and may be stored in afreeze-dried (lyophilized) condition requiring only the addition of thesterile liquid carrier, for example water, for injection immediatelyprior to use. Extemporaneous injection solutions and suspensions areprepared from sterile powders, granules and tablets of the kindpreviously described. Preferred unit dosage formulations are thosecontaining a daily dose or unit daily sub-dose, as herein above recited,or an appropriate fraction thereof, of the active ingredient.

The invention further provides veterinary compositions comprising atleast one active ingredient as above defined together with a veterinarycarrier therefore. Veterinary carriers are materials useful for thepurpose of administering the composition and may be solid, liquid orgaseous materials which are otherwise inert or acceptable in theveterinary art and are compatible with the active ingredient. Theseveterinary compositions may be administered parenterally, orally or byany other desired route.

Combination Therapy

The compounds of Formula I may be employed alone or in combination withother therapeutic agents for the treatment of a disease or disorderdescribed herein, such as inflammation or a hyperproliferative disorder(e.g., cancer). In certain embodiments, a compound of Formula I iscombined in a pharmaceutical combination formulation, or dosing regimenas combination therapy, with an additional, second therapeutic compoundthat has anti-inflammatory or anti-hyperproliferative properties or thatis useful for treating an inflammation, immune-response disorder, orhyperproliferative disorder (e.g., cancer). The additional therapeuticmay be an anti-inflammatory agent, an immunomodulatory agent,chemotherapeutic agent, an apoptosis-enhancer, a neurotropic factor, anagent for treating cardiovascular disease, an agent for treating liverdisease, an anti-viral agent, an agent for treating blood disorders, anagent for treating diabetes, and an agent for treating immunodeficiencydisorders. The second therapeutic agent may be an NSAIDanti-inflammatory agent. The second therapeutic agent may be achemotherapeutic agent. The second compound of the pharmaceuticalcombination formulation or dosing regimen preferably has complementaryactivities to the compound of Formula I such that they do not adverselyaffect each other. Such compounds are suitably present in combination inamounts that are effective for the purpose intended. In one embodiment,a composition of this invention comprises a compound of Formula I, or astereoisomer, tautomer, solvate, metabolite, or pharmaceuticallyacceptable salt or prodrug thereof, in combination with a therapeuticagent such as an NSAID.

The combination therapy may be administered as a simultaneous orsequential regimen. When administered sequentially, the combination maybe administered in two or more administrations. The combinedadministration includes coadministration, using separate formulations ora single pharmaceutical formulation, and consecutive administration ineither order, wherein preferably there is a time period while both (orall) active agents simultaneously exert their biological activities.

Suitable dosages for any of the above coadministered agents are thosepresently used and may be lowered due to the combined action (synergy)of the newly identified agent and other therapeutic agents ortreatments.

The combination therapy may provide “synergy” and prove “synergistic”,i.e., the effect achieved when the active ingredients used together isgreater than the sum of the effects that results from using thecompounds separately. A synergistic effect may be attained when theactive ingredients are: (1) co-formulated and administered or deliveredsimultaneously in a combined, unit dosage formulation; (2) delivered byalternation or in parallel as separate formulations; or (3) by someother regimen. When delivered in alternation therapy, a synergisticeffect may be attained when the compounds are administered or deliveredsequentially, e.g., by different injections in separate syringes,separate pills or capsules, or separate infusions. In general, duringalternation therapy, an effective dosage of each active ingredient isadministered sequentially, i.e., serially, whereas in combinationtherapy, effective dosages of two or more active ingredients areadministered together.

In a particular embodiment of therapy, a compound of Formula I, or astereoisomer, tautomer, solvate, metabolite, or pharmaceuticallyacceptable salt or prodrug thereof, may be combined with othertherapeutic, hormonal or antibody agents such as those described herein,as well as combined with surgical therapy and radiotherapy. Combinationtherapies according to the present invention thus comprise theadministration of at least one compound of Formula I, or a stereoisomer,tautomer, solvate, metabolite, or pharmaceutically acceptable salt orprodrug thereof, and the use of at least one other cancer treatmentmethod. The amounts of the compound(s) of Formula I and the otherpharmaceutically active therapeutic agent(s) and the relative timings ofadministration will be selected in order to achieve the desired combinedtherapeutic effect.

Metabolites of Compounds of Formula I

Also falling within the scope of this invention are the in vivometabolic products of Formula I described herein. Such products mayresult for example from the oxidation, reduction, hydrolysis, amidation,deamidation, esterification, deesterification, enzymatic cleavage, andthe like, of the administered compound. Accordingly, the inventionincludes metabolites of compounds of Formula I, including compoundsproduced by a process comprising contacting a compound of this inventionwith a mammal for a period of time sufficient to yield a metabolicproduct thereof.

Metabolite products typically are identified by preparing aradiolabelled (e.g., ¹⁴C or ³H) isotope of a compound of the invention,administering it parenterally in a detectable dose (e.g., greater thanabout 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, orto man, allowing sufficient time for metabolism to occur (typicallyabout 30 seconds to 30 hours) and isolating its conversion products fromthe urine, blood or other biological samples. These products are easilyisolated since they are labeled (others are isolated by the use ofantibodies capable of binding epitopes surviving in the metabolite). Themetabolite structures are determined in conventional fashion, e.g., byMS, LC/MS or NMR analysis. In general, analysis of metabolites is donein the same way as conventional drug metabolism studies well known tothose skilled in the art. The metabolite products, so long as they arenot otherwise found in vivo, are useful in diagnostic assays fortherapeutic dosing of the compounds of the invention.

Articles of Manufacture

In another embodiment of the invention, an article of manufacture, or“kit”, containing materials useful for the treatment of the diseases anddisorders described above is provided. In one embodiment, the kitcomprises a container comprising a compound of Formula I, or astereoisomer, tautomer, solvate, metabolite, or pharmaceuticallyacceptable salt or prodrug thereof. The kit may further comprise a labelor package insert on or associated with the container. The term “packageinsert” is used to refer to instructions customarily included incommercial packages of therapeutic products, that contain informationabout the indications, usage, dosage, administration, contraindicationsand/or warnings concerning the use of such therapeutic products.Suitable containers include, for example, bottles, vials, syringes,blister pack, etc. The container may be formed from a variety ofmaterials such as glass or plastic. The container may hold a compound ofFormula I or a formulation thereof which is effective for treating thecondition and may have a sterile access port (for example, the containermay be an intravenous solution bag or a vial having a stopper pierceableby a hypodermic injection needle). At least one active agent in thecomposition is a compound of Formula I. The label or package insertindicates that the composition is used for treating the condition ofchoice, such as cancer. In addition, the label or package insert mayindicate that the patient to be treated is one having a disorder such asa hyperproliferative disorder, neurodegeneration, cardiac hypertrophy,pain, migraine or a neurotraumatic disease or event. In one embodiment,the label or package inserts indicates that the composition comprising acompound of Formula I can be used to treat a disorder resulting fromabnormal cell growth. The label or package insert may also indicate thatthe composition can be used to treat other disorders. Alternatively, oradditionally, the article of manufacture may further comprise a secondcontainer comprising a pharmaceutically acceptable buffer, such asbacteriostatic water for injection (BWFI), phosphate-buffered saline,Ringer's solution and dextrose solution. It may further include othermaterials desirable from a commercial and user standpoint, includingother buffers, diluents, filters, needles, and syringes.

The kit may further comprise directions for the administration of thecompound of Formula I and, if present, the second pharmaceuticalformulation. For example, if the kit comprises a first compositioncomprising a compound of Formula I and a second pharmaceuticalformulation, the kit may further comprise directions for thesimultaneous, sequential or separate administration of the first andsecond pharmaceutical compositions to a patient in need thereof.

In another embodiment, the kits are suitable for the delivery of solidoral forms of a compound of Formula I, such as tablets or capsules. Sucha kit preferably includes a number of unit dosages. Such kits caninclude a card having the dosages oriented in the order of theirintended use. An example of such a kit is a “blister pack”. Blisterpacks are well known in the packaging industry and are widely used forpackaging pharmaceutical unit dosage forms. If desired, a memory aid canbe provided, for example in the form of numbers, letters, or othermarkings or with a calendar insert, designating the days in thetreatment schedule in which the dosages can be administered.

According to one embodiment, a kit may comprise (a) a first containerwith a compound of Formula I contained therein; and optionally (b) asecond container with a second pharmaceutical formulation containedtherein, wherein the second pharmaceutical formulation comprises asecond compound with anti-hyperproliferative activity. Alternatively, oradditionally, the kit may further comprise a third container comprisinga pharmaceutically-acceptable buffer, such as bacteriostatic water forinjection (BWFI), phosphate-buffered saline, Ringer's solution anddextrose solution. It may further include other materials desirable froma commercial and user standpoint, including other buffers, diluents,filters, needles, and syringes.

In certain other embodiments wherein the kit comprises a composition ofFormula I and a second therapeutic agent, the kit may comprise acontainer for containing the separate compositions such as a dividedbottle or a divided foil packet, however, the separate compositions mayalso be contained within a single, undivided container. Typically, thekit comprises directions for the administration of the separatecomponents. The kit form is particularly advantageous when the separatecomponents are preferably administered in different dosage forms (e.g.,oral and parenteral), are administered at different dosage intervals, orwhen titration of the individual components of the combination isdesired by the prescribing physician.

Preparation of Formula I Compounds

Compounds of Formula I may be synthesized by synthetic routes thatinclude processes analogous to those well-known in the chemical arts,particularly in light of the description contained herein, and those forother heterocycles described in: Comprehensive Heterocyclic ChemistryII, Editors Katritzky and Rees, Elsevier, 1997, e.g. Volume 3; LiebigsAnnalen der Chemie, (9):1910-16, (1985); Helvetica Chimica Acta,41:1052-60, (1958); Arzneimittel-Forschung, 40(12):1328-31, (1990), eachof which are expressly incorporated by reference. Starting materials aregenerally available from commercial sources such as Aldrich Chemicals(Milwaukee, Wis.) or are readily prepared using methods well known tothose skilled in the art (e.g., prepared by methods generally describedin Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v.1-23, Wiley, N.Y. (1967-2006 ed.), or Beilsteins Handbuch derorganischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, includingsupplements (also available via the Beilstein online database).

Synthetic chemistry transformations and protecting group methodologies(protection and deprotection) useful in synthesizing Formula I compoundsand necessary reagents and intermediates are known in the art andinclude, for example, those described in R. Larock, ComprehensiveOrganic Transformations, VCH Publishers (1989); T. W. Greene and P. G.M. Wuts, Protective Groups in Organic Synthesis, 3^(rd) Ed., John Wileyand Sons (1999); and L. Paquette, ed., Encyclopedia of Reagents forOrganic Synthesis, John Wiley and Sons (1995) and subsequent editionsthereof.

Compounds of Formula I may be prepared singly or as compound librariescomprising at least 2, for example 5 to 1,000 compounds, or 10 to 100compounds. Libraries of compounds of Formula I may be prepared by acombinatorial ‘split and mix’ approach or by multiple parallel synthesesusing either solution phase or solid phase chemistry, by proceduresknown to those skilled in the art. Thus according to a further aspect ofthe invention there is provided a compound library comprising at least 2compounds, or pharmaceutically acceptable salts thereof.

The Figures and Examples provide exemplary methods for preparing FormulaI compounds. Those skilled in the art will appreciate that othersynthetic routes may be used to synthesize the Formula I compounds.Although specific starting materials and reagents are depicted anddiscussed in the Figures and Examples, other starting materials andreagents can be easily substituted to provide a variety of derivativesand/or reaction conditions. In addition, many of the exemplary compoundsprepared by the described methods can be further modified in light ofthis disclosure using conventional chemistry well known to those skilledin the art.

In preparing compounds of Formulas I, protection of remote functionality(e.g., primary or secondary amine) of intermediates may be necessary.The need for such protection will vary depending on the nature of theremote functionality and the conditions of the preparation methods.Suitable amino-protecting groups include acetyl, trifluoroacetyl,t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and9-fluorenylmethyleneoxycarbonyl (Fmoc). The need for such protection isreadily determined by one skilled in the art. For a general descriptionof protecting groups and their use, see T. W. Greene, Protective Groupsin Organic Synthesis, John Wiley & Sons, New York, 1991.

Experimental procedures, intermediates and reagents useful for usefulfor the preparation of Formula I compounds may be found in U.S. Ser. No.13/102,720, “PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE”,filed 6 May 2011, which is incorporated by reference in its entirety.

FIGS. 1-24 describe the synthesis of exemplary embodiments of Formula Icompounds 101-124, more fully described in Examples 101-124, and may beuseful for the preparation of other Formula I compounds.

General Preparative Procedures

General Procedure: Suzuki Coupling

The Suzuki-type coupling reaction is useful to form carbon-carbon bondsto attach the rings of Formula I compounds and intermediates such as A-3(Suzuki (1991) Pure Appl. Chem. 63:419-422; Miyaura and Suzuki (1979)Chem. Reviews 95(7):2457-2483; Suzuki (1999) J. Organometal. Chem.576:147-168). Suzuki coupling is a palladium mediated cross couplingreaction of a heteroarylhalide, such as B-2 or B-4, with a boronic acidsuch as A-1 or A-2. For example, B-2 may be combined with about 1.5equivalents of4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane), anddissolved in about 3 equivalents of sodium carbonate as a 1 molarsolution in water and an equal volume of acetonitrile. A catalyticamount, or more, of a low valent palladium reagent, such asbis(triphenylphosphine)palladium(II) dichloride, is added. In some casespotassium acetate is used in place of sodium carbonate to adjust the pHof the aqueous layer. The reaction is then heated to about 140-150° C.under pressure in a microwave reactor (Biotage AB, Uppsala, Sweden) for10 to 30 minutes. The contents are extracted with ethyl acetate, oranother organic solvent. After evaporation of the organic layer theboron ester A-1 may be purified on silica or by reverse phase HPLC.Substituents are as defined, or protected forms or precursors thereof.Likewise, bromide intermediate B-4 can be boronylated to give A-2.

Suzuki coupling of B-2 and A-2, or of A-1 and B-4, gives Formula Icompound or intermediate A-3. Boronic ester (or acid) (1.5 eq) A-1 orA-2, and a palladium catalyst such asbis(triphenylphosphine)palladium(II) chloride (0.05 eq) is added to amixture of halo intermediate (1 eq) B-2 or B-4 in acetonitrile and 1 Mof sodium carbonate aqueous solution (equal volume as acetonitrile). Thereaction mixture is heated to about 150° C. in a microwave for about 15min. LC/MS indicates when the reaction is complete. Water is added tothe mixture, and the precipitated product is filtered and purified byHPLC to yield the product A-3. Substituents R^(1′), R^(2′), R^(4′) maybe R¹, R², R⁴ as defined, or protected forms or precursors thereof.

A variety of palladium catalysts can be used during the Suzuki couplingstep. Various low valent, Pd(II) and Pd(0) catalysts may be used in theSuzuki coupling reaction, including PdCl2(PPh₃)₂, Pd(t-Bu)₃, PdCl₂ dppfCH₂Cl₂, Pd(PPh₃)₄, Pd(OAc)/PPh₃, Cl₂Pd[(Pet₃)]₂, Pd(DIPHOS)₂,Cl₂Pd(Bipy), [PdCl(Ph₂PCH₂PPh₂)]₂, Cl₂Pd[P(o-tol)₃]₂,Pd₂(dba)₃/P(o-tol)₃, Pd₂(dba)/P(furyl)₃, Cl₂Pd[P(furyl)₃]₂,Cl₂Pd(PMePh₂)₂, Cl₂Pd[P(4-F-Ph)₃]₂, Cl₂Pd[P(C₆F₆)₃]₂,Cl₂Pd[P(2-COOH-Ph)(Ph)₂]₂, Cl₂Pd[P(4-COOH-Ph)(Ph)₂]₂, and encapsulatedcatalysts Pd EnCat™ 30, Pd EnCat™ TPP30, and Pd(II)EnCat™ BINAP30 (US2004/0254066).

General Procedure: Buchwald Reaction

The Buchwald reaction is useful to aminate 6-bromo intermediates B-1(Wolf and Buchwald (2004) Org. Synth Coll. Vol. 10:423; Paul et al(1994) Jour. Amer. Chem. Soc. 116:5969-5970). To a solution of halointermediate B-1 in DMF is added the appropriate amine R⁵—NH₂ (200 mol%), Cs₂CO₃ (50 mol %), Pd₂(dba)₃ (5 mol %), and4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos, CAS Reg. No.161265-03-8, 10 mol %). The reaction is heated to about 110° C. underpressure in a microwave reactor (Biotage AB, Uppsala, Sweden) for about30 min. The resulting solution is concentrated in vacuo to give B-2.Other palladium catalysts and phosphine ligands may be useful.

N-Heteroaryl amide intermediates B-4 can also be prepared under Buchwaldconditions with cyclic amide intermediates (R⁷) such as3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 101e and heteroaryldibromides B-3.

Methods of Separation

In the methods of preparing Formula I compounds, it may be advantageousto separate reaction products from one another and/or from startingmaterials. The desired products of each step or series of steps isseparated and/or purified to the desired degree of homogeneity by thetechniques common in the art. Typically such separations involvemultiphase extraction, crystallization from a solvent or solventmixture, distillation, sublimation, or chromatography. Chromatographycan involve any number of methods including, for example: reverse-phaseand normal phase; size exclusion; ion exchange; high, medium and lowpressure liquid chromatography methods and apparatus; small scaleanalytical; simulated moving bed (SMB) and preparative thin or thicklayer chromatography, as well as techniques of small scale thin layerand flash chromatography.

Another class of separation methods involves treatment of a mixture witha reagent selected to bind to or render otherwise separable a desiredproduct, unreacted starting material, reaction by product, or the like.Such reagents include adsorbents or absorbents such as activated carbon,molecular sieves, ion exchange media, or the like. Alternatively, thereagents can be acids in the case of a basic material, bases in the caseof an acidic material, binding reagents such as antibodies, bindingproteins, selective chelators such as crown ethers, liquid/liquid ionextraction reagents (LIX), or the like. Selection of appropriate methodsof separation depends on the nature of the materials involved, such as,boiling point and molecular weight in distillation and sublimation,presence or absence of polar functional groups in chromatography,stability of materials in acidic and basic media in multiphaseextraction, and the like.

Diastereomeric mixtures can be separated into their individualdiastereomers on the basis of their physical chemical differences bymethods well known to those skilled in the art, such as bychromatography and/or fractional crystallization. Enantiomers can beseparated by converting the enantiomeric mixture into a diastereomericmixture by reaction with an appropriate optically active compound (e.g.,chiral auxiliary such as a chiral alcohol or Mosher's acid chloride),separating the diastereomers and converting (e.g., hydrolyzing) theindividual diastereoisomers to the corresponding pure enantiomers. Also,some of the compounds of the present invention may be atropisomers(e.g., substituted biaryls) and are considered as part of thisinvention. Enantiomers can also be separated by use of a chiral HPLCcolumn.

A single stereoisomer, e.g., an enantiomer, substantially free of itsstereoisomer may be obtained by resolution of the racemic mixture usinga method such as formation of diastereomers using optically activeresolving agents (Eliel, E. and Wilen, S. “Stereochemistry of OrganicCompounds,” John Wiley & Sons, Inc., New York, 1994; Lochmuller, C. H.,(1975) J. Chromatogr., 113(3):283-302). Racemic mixtures of chiralcompounds of the invention can be separated and isolated by any suitablemethod, including: (1) formation of ionic, diastereomeric salts withchiral compounds and separation by fractional crystallization or othermethods, (2) formation of diastereomeric compounds with chiralderivatizing reagents, separation of the diastereomers, and conversionto the pure stereoisomers, and (3) separation of the substantially pureor enriched stereoisomers directly under chiral conditions. See: “DrugStereochemistry, Analytical Methods and Pharmacology,” Irving W. Wainer,Ed., Marcel Dekker, Inc., New York (1993).

Under method (1), diastereomeric salts can be formed by reaction ofenantiomerically pure chiral bases such as brucine, quinine, ephedrine,strychnine, α-methyl-β-phenylethylamine (amphetamine), and the like withasymmetric compounds bearing acidic functionality, such as carboxylicacid and sulfonic acid. The diastereomeric salts may be induced toseparate by fractional crystallization or ionic chromatography. Forseparation of the optical isomers of amino compounds, addition of chiralcarboxylic or sulfonic acids, such as camphorsulfonic acid, tartaricacid, mandelic acid, or lactic acid can result in formation of thediastereomeric salts.

Alternatively, by method (2), the substrate to be resolved is reactedwith one enantiomer of a chiral compound to form a diastereomeric pair(E. and Wilen, S. “Stereochemistry of Organic Compounds”, John Wiley &Sons, Inc., 1994, p. 322). Diastereomeric compounds can be formed byreacting asymmetric compounds with enantiomerically pure chiralderivatizing reagents, such as menthyl derivatives, followed byseparation of the diastereomers and hydrolysis to yield the pure orenriched enantiomer. A method of determining optical purity involvesmaking chiral esters, such as a menthyl ester, e.g., (−) menthylchloroformate in the presence of base, or Mosher ester,α-methoxy-α-(trifluoromethyl)phenyl acetate (Jacob III. J. Org. Chem.(1982) 47:4165), of the racemic mixture, and analyzing the ¹H NMRspectrum for the presence of the two atropisomeric enantiomers ordiastereomers. Stable diastereomers of atropisomeric compounds can beseparated and isolated by normal- and reverse-phase chromatographyfollowing methods for separation of atropisomeric naphthyl-isoquinolines(WO 96/15111). By method (3), a racemic mixture of two enantiomers canbe separated by chromatography using a chiral stationary phase (“ChiralLiquid Chromatography” (1989) W. J. Lough, Ed., Chapman and Hall, NewYork; Okamoto, J. Chromatogr., (1990) 513:375-378). Enriched or purifiedenantiomers can be distinguished by methods used to distinguish otherchiral molecules with asymmetric carbon atoms, such as optical rotationand circular dichroism.

EXAMPLES Example 101a2,2,2-Trichloro-1-(4,5,6,7-tetrahydro-1H-indol-2-yl)ethanone 101a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer, condenser and nitrogen inlet was purged with nitrogen andcharged with 4,5,6,7-tetrahydro-1H-indole (3.00 g, 24.8 mmol),trichloroacetyl chloride (13.5 g, 74.4 mmol) and 1,2-dichloroethane (50mL). The solution was stirred at 85° C. for 2 h. After that time, thereaction mixture was concentrated under reduced pressure to afford a100% yield (6.50 g) of2,2,2-trichloro-1-(4,5,6,7-tetrahydro-1H-indol-2-yl)ethanone 101a as ablack semi-solid: ¹H NMR (500 MHz, DMSO-d₆) δ 11.94 (s, 1H), 7.05 (s,1H), 2.62 (t, 2H, J=6.0 Hz), 2.47 (t, 2H, J=6.0 Hz), 1.80 (m, 2H), 1.65(m, 2H); MS (ESI+) m/z 266.0 (M+H)

Example 101b Ethyl 4,5,6,7-Tetrahydro-1H-indole-2-carboxylate 101b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and nitrogen inlet was purged with nitrogen and charged with101a (6.50 g, 24.8 mmol), sodium ethoxide (17.0 mg, 0.25 mmol) andethanol (40 mL). The solution was stirred at room temperature for 1 h.After that time, the reaction mixture was concentrated under reducedpressure. The residue was purified by column chromatography to afford a100% yield (4.80 g) of ethyl 4,5,6,7-tetrahydro-1H-indole-2-carboxylate101b as a brown solid: mp 70-72° C.; ¹H NMR (300 MHz, CDCl₃) δ 9.08 (s,1H), 6.75 (s, 1H), 4.25 (q, 2H, J=7.2 Hz), 2.65 (t, 2H, J=6.0 Hz), 2.56(t, 2H, J=6.0 Hz), 1.85 (m, 4H), 1.28 (t, 3H, J=7.2 Hz); MS (ESI+) m/z194.1 (M+H)

Example 101c Ethyl1-(Cyanomethyl)-4,5,6,7-tetrahydro-1H-indole-2-carboxylate 101C

A 125-mL single-neck round-bottomed flask equipped with a magneticstirrer and nitrogen inlet was purged with nitrogen and charged with101b (5.76 g, 29.8 mmol) and DMF (50 mL). The solution was cooled to 0°C. using an ice bath. NaH (60% dispersion in mineral oil, 1.43 g, 35.8mmol) was added. The resulting mixture was stirred at room temperaturefor 1 h. After that time, bromoacetonitrile (1.43 g, 35.8 mmol) wasadded. The mixture was stirred at room temperature for 14 h. After thattime, the reaction mixture was concentrated under reduced pressure andthe residue was partitioned between ethyl acetate (150 mL) and water(450 mL). The organic layer was separated, and the aqueous layer wasextracted with ethyl acetate (3×150 mL). The combined organic layerswere washed with brine, dried over sodium sulfate and concentrated underreduced pressure. The residue was purified by column chromatography toafford a 55% yield (3.80 g) of ethyl1-(cyanomethyl)-4,5,6,7-tetrahydro-1H-indole-2-carboxylate 101c as ayellow semi-solid: ¹H NMR (300 MHz, CDCl₃) δ 6.66 (s, 1H), 5.29 (s, 2H),4.28 (q, 2H, J=7.2 Hz), 2.62 (t, 2H, J=6.3 Hz), 2.49 (t, 2H, J=6.3 Hz),1.92 (m, 2H), 1.75 (m, 2H), 1.33 (t, 3H, J=7.2 Hz); MS (ESI+) m/z 233.1(M+H)

Example 101d Ethyl1-(2-Aminoethyl)-4,5,6,7-tetrahydro-1H-indole-2-carboxylate 101d

A 200-mL Parr reactor bottle was purged with nitrogen and charged with10% palladium on carbon (50% wet, 1.28 g dry weight), 101c (3.00 g, 12.9mmol), 12% hydrochloric acid (6.5 mL, 25 mmol), ethyl acetate (60 mL)and ethanol (40 mL). The bottle was attached to a Parr hydrogenator,evacuated, charged with hydrogen gas to a pressure of 50 psi and shakenfor 6 h. After this time, the hydrogen was evacuated, and nitrogen wascharged into the bottle. diatomaceous earth filter agent (CELITE®,Imerys Minerals California, Inc.) CELITE® 521 (4.0 g) was added, and themixture was filtered through a pad of CELITE® 521. The filter cake waswashed with ethanol (2×20 mL), and the combined filtrates wereconcentrated to dryness under reduced pressure. The residue waspartitioned between ethyl acetate (150 mL) and 10% aqueous potassiumcarbonate (100 mL). The organic layer was separated, and the aqueouslayer was extracted with ethyl acetate (3×75 mL). The combined organiclayers were dried over sodium sulfate and concentrated under reducedpressure. The residue was triturated with ethanol (5 mL) to afford a 71%yield (1.71 g) of ethyl1-(2-aminoethyl)-4,5,6,7-tetrahydro-1H-indole-2-carboxylate 101d as awhite solid: mp 102-104° C.; ¹H NMR (500 MHz, DMSO-d₆) δ 6.61 (s, 1H),6.22 (br, 2H), 4.15 (m, 4H), 2.77 (m, 2H), 2.59 (t, 2H, J=6.5 Hz), 2.42(t, 2H, J=6.5 Hz), 1.70 (m, 2H), 1.62 (m, 2H), 1.23 (t, 3H, J=7.0 Hz);MS (APCI+) m/z 237.2 (M+H)

Example 101e 3,4,6,7,8,9-Hexahydropyrazino[1,2-a]indol-1(2H)-one 101e

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and nitrogen inlet was purged with nitrogen and charged with101d (1.80 g, 7.63 mmol), sodium ethoxide (1.55 g, 22.8 mmol) andethanol (50 mL). The mixture was stirred at 55° C. for 5 h. After thattime, the reaction mixture was concentrated under reduced pressure andthe residue was partitioned between ethyl acetate (200 mL) and water(100 mL). The organic layer was separated, and the aqueous layer wasextracted with ethyl acetate (2×100 mL). The combined organic layerswere washed with brine, dried over sodium sulfate and concentrated underreduced pressure. The residue was purified by column chromatography toafford a 42% yield (605 mg) of3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 101e as a whitesolid: mp 207-209° C.; ¹H NMR (500 MHz, DMSO-d₆) δ 7.41 (s, 1H), 6.36(s, 1H), 3.84 (t, 2H, J=6.0 Hz), 3.42 (m, 2H), 2.51 (t, 2H, J=6.0 Hz),2.42 (t, 2H, J=6.0 Hz), 1.76 (m, 2H), 1.65 (m, 2H); (APCI+) m/z 191.3(M+H)

Example 101f3-Bromo-5-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)isonicotinaldehyde101f

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 101e (300 mg, 1.57mmol), 3,5-dibromoisonicotinaldehyde (2) (517 mg, 1.96 mmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XantPhos, 120 mg, 0.2mmol), tris(dibenzylideneacetone)dipalladium(0) (180 mg, 0.2 mmol),Cs₂CO₃ (650 mg, 2 mmol), and 1,4-dioxane (8 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 6 h. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by flash column chromatography eluting with DCM/MeOH (from 40:1to 20:1) to afford 101f as a pale yellow solid (350 mg, 40%). MS: [M+H]⁺374.

Example 101g tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-carboxylate101g

Into a solution of 5-bromo-2-nitropyridine (30 g, 148 mmol) in DMSO (1L) were added K₂CO₃ (40 g, 296 mmol) and tert-butylpiperazine-1-carboxylate (28 g, 148 mmol). The mixture was stirred at65° C. overnight. After cooling down, it was poured into water (2 L).The solid precipitated was collected and dried under vacuum. It was thenfurther purified by flash column eluting with 20:1 petroleum ether/ethylacetate and then with methylene chloride to give 101g as a yellow solid(17 g, 37%). MS: [M+H]⁺ 309.

Example 101h tert-Butyl 4-(6-Aminopyridin-3-yl)piperazine-1-carboxylate101h

A 500-mL bottle was purged with nitrogen and charged with tert-butyl4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 101g (3.1 g, 10 mmol),10% palladium on carbon (50% wet, 1.0 g) and ethanol (100 mL). It wasevacuated, charged with hydrogen gas, and stirred for 16 h at roomtemperature. The hydrogen was then evacuated and nitrogen was chargedinto the bottle. The catalyst was removed by filtration through a pad ofCELITE® and the filtrate concentrated under reduced pressure to afford101h (2.7 g, 97%). MS: [M+H]⁺ 279

Example 101i tert-Butyl4-(6-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridine-3-yl)piperazine-1-carboxylate101i

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (50 mL), 101h(1.3 g, 4.7 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (1.24 g, 4.7mmol), and cesium carbonate (3.8 g, 12 mmol). After bubbling nitrogenthrough the resulting mixture for 30 minutes, XantPhos (272 mg, 0.47mmol) and tris(dibenzylideneacetone)dipalladium(0) (430 mg, 0.47 mmol)were added, and the reaction mixture was heated at reflux for 3 h. Afterthis time the reaction was cooled to room temperature, partitionedbetween ethyl acetate (100 mL) and water (100 mL), and filtered. Theaqueous layer was separated and extracted with ethyl acetate (50 mL×2).The organic layers were combined, washed with brine (50 mL), and driedover sodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified on flash column eluting with 50:1 methylene chloride/methanolto afford 101i (1.3 g, 59%). MS: [M+H]⁺ 464.

Example 101j5-Bromo-1-methyl-3-(5-(piperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one101j

A mixture of 101i (3.6 g, 7.8 mmol) and 4.0 M HCl/dioxane (10 mL) wasstirred for 5 h at room temperature. It was then concentrated at reducedpressure. The residue was basified with aqueous 1.0M NaOH and extractedwith methylene chloride. The combined organic layers were washed withwater and concentrated under reduced pressure to give 101j (2.46 g,87%). MS: [M+H]⁺ 364.

Example 101k5-Bromo-1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one101k

A mixture of 101j (2.75 g, 7.5 mmol), oxetan-3-one (1.6 g, 22.7 mmol),NaBH₃CN (4.75 g, 22.5 mmol), and zinc chloride (3 g, 22.7 mmol) inmethanol (125 mL) was stirred for hours at 50° C. The mixture was addedto water and extracted with methylene chloride for three times. Theorganic layers were concentrated under reduced pressure. The residue waspurified by column chromatography eluting with 25:1 methylenechloride/methanol to give 101k (1.92 g, 61%). MS: [M+H]⁺ 420. ¹H NMR(500 MHz, DMSO) δ 8.58 (d, J=2.5, 1H), 8.55 (s, 1H), 7.94 (d, J=3, 1H),7.54 (d, J=2.5, 1H), 7.39 (dd, J=3, 1H), 7.25 (d, J=4, 1H), 4.56 (t,J=6.5, 2H), 4.46 (t, J=6.5, 2H), 3.50 (s, 3H), 3.43 (m, 1H), 3.01 (m,4H), 2.40 (m, 4H).

Example 101l1-Methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101l

A 500-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 101k (10.5 g, 25 mmol),Pin₂B₂ (15.6 g, 2.5 eq., 62 mmol), Pd₂(dba)₃ (1.14 g, 0.05 eq., 1.25mmol), X-phos (1.16 g, 0.1 eq., 2.5 mmol), AcOK (7.35 g, 3 eq., 75 mmol)and dioxane (150 mL). After three cycles of vacuum/argon flush, themixture was heated to 65° C. for 14 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was washed by PE/EA=3/1 (80 mL) toafford 101l as a yellow solid (10.5 g, 94%). MS: [M+H]⁺ 468.

Example 101m3-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-5-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)isonicotinaldehyde101m

A sealed tube was charged with 101f (200 mg, 0.53 mmol), 101l (250 mg,0.53 mmol), PdCl₂(dppf) (42 mg, 0.05 mmol), K₃PO₄ (210 mg, 1.0 mmol),and NaOAc (85 mg, 1.0 mmol) in acetonitrile/H₂O (8 mL/1 mL). After threecycles of vacuum/argon flush, the mixture was heated at 100° C. in asealed tube for 4 h. It was then filtered and the filtrate wasevaporated in vacuo. The residue was purified on reverse phaseCombi-flash eluting with 20:1 DCM/MeOH to afford 101m (135 mg, 40%).LCMS: [M+H]⁺ 635.

Example 1012-(4-(hydroxymethyl)-5-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one101

A mixture of 101m (135 mg, 0.21 mmol) and NaBH4 (20 mg, 0.5 mmol) inMeOH (5 mL) was stirred at 0° C. for 0.5 h. The mixture was quenchedwith water and the residue was extracted with EtOAc (5 mL×2). Thecombined EtOAc extract was concentrated under reduced pressure and theresidue was purified with reverse-phase prep-HPLC to afford 101 (55 mg,40%). LCMS: [M+H]⁺ 637. ¹H NMR (500 MHz, DMSO) δ 8.58 (s, 1H), 8.55 (s,1H), 8.49 (s, 1H), 8.41 (s, 1H), 7.86 (d, J=3.0, 1H), 7.38-7.37 (m, 2H),7.25-7.23 (m, 1H), 6.54 (s, 1H), 5.16 (t, J=3.0, 1H), 4.56-4.40 (m, 6H),4.19-4.12 (m, 3H), 3.95 (t, J=3.0, 1H), 3.60 (s, 3H), 3.43-3.41 (m, 1H),3.06 (s, 4H), 2.57-2.61 (m, 2H), 2.45-2.48 (m, 6H), 1.78-1.80 (m, 2H),1.69-1.70 (m, 2H)

Example 102a1-Methyl-3-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyridin-2-one102a

A 1-L single-neck round-bottomed flask equipped with a magnetic stirrerand thermoregulator was purged with nitrogen and charged with5-bromo-1-methyl-3-[5-(4-methylpiperazin-1-yl)-pyridin-2-ylamino]-1H-pyridin-2-oneprepared according to US 2009/0318448, (10.0 g, 0.027 mol),bis(pinacolato)diboron (8.06 g, 0.032 mol), potassium acetate (10.4 g,0.11 mol) and 1,4-dioxane (200 mL). After a stream of nitrogen waspassed through the resulting suspension for 30 min., Pd(dppf)Cl₂CH₂Cl₂(582 mg, 0.795 mmol) was added. The resulting reaction mixture wasstirred at reflux for 3 h. Then, it was cooled to room temperature,partitioned between water (400 mL) and ethyl acetate (600 mL) andfiltered through a pad of CELITE®. The organic phase was extracted,dried over sodium sulfate, filtered and concentrated. The residue wastriturated with a mixture of diethyl ether (50 mL) and hexanes (250 mL),and the suspension was filtered. The filter cake was dried under vacuumat room temperature to afford a 27% yield (3.04 g) of1-methyl-3-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyridin-2-one102a as a brown solid.

Example 102b3-(1-Methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-5-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)isonicotinaldehyde102b

A sealed tube was charged with3-bromo-5-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)isonicotinaldehyde101f (200 mg, 0.53 mmol),1-methyl-3-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2(1H)-one102a (225 mg, 0.53 mmol), PdCl₂(dppf) (42 mg, 0.05 mmol), K₃PO₄ (210 mg,1 mmol), and NaOAc (85 mg, 1 mmol) in acetonitrile/H2O (8 mL/1 mL).After three cycles of vacuum/argon flush, the mixture was heated at 100°C. for 4 h. It was then filtered and the filtrate was evaporated invacuo. The residue was purified on flash column eluting with 20:1DCM/MeOH to afford 102b (135 mg, 43%). LCMS: [M+H]⁺ 593.

Example 1022-(4-(Hydroxymethyl)-5-(1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one102

A mixture of3-(1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-5-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)isonicotinaldehyde102b (135 mg, 0.22 mmol) and NaBH4 (20 mg, 0.5 mmol) in MeOH (5 mL) wasstirred at 0° C. for 0.5 h. The mixture was quenched with water and theresidue was extracted with EtOAc (5 mL×2). The combined EtOAc extractwas concentrated under reduced pressure and the residue was purifiedwith reverse-phase prep-HPLC to afford 102 (18 mg, 20%). LCMS: [M+H]⁺595. ¹H NMR (500 MHz, DMSO) δ 8.59 (s, 1H), 8.55 (s, 1H), 8.49 (s, 1H),8.45 (s, 1H), 7.87 (s, 1H), 7.37-7.38 (m, 2H), 7.23-7.25 (m, 1H), 6.54(s, 1H), 5.16 (t, J=3.0, 1H), 4.40 (s, 2H), 4.14-4.18 (m, 3H), 3.93-3.95(m, 1H), 3.60 (s, 3H), 3.09 (s, 4H), 2.60-2.61 (m, 6H), 2.48-2.34 (m,5H), 1.78-1.79 (m, 2H), 1.69-1.70 (m, 2H)

Example 103a 2-Bromo-4-chloronicotinaldehyde 103a

To a solution of 2-bromo-4-chloropyridine (1.6 g, 8.0 mmol) in anhydroustetrahydrofuran (40 mL) cooled at −70° C. was added the solution oflithium diisopropyl-amide (5.0 mL, 10.0 mmol, 2.0 M) over a period of 5minutes and stirred at −70° C. for another 1 h. Anhydrous DMF (1.3 g)was introduced over a period of 3 minutes and the mixture was stirredfor another 30 minutes. It was then quenched with saturated NH₄Cl (30mL) and extracted with ethyl acetate (20 mL×3). The combined organiclayer was dried over anhydrous Mg₂SO₄, filtered, and evaporated underreduced pressure. The residue was purified by silica-gel columnchromatography eluting with petroleum ether/ethyl acetate (20:1) toafford 103a as a yellow solid (900 mg, 48%). ¹H NMR (500 MHz, DMSO) δ10.21 (s, 1H), 8.52 (d, J=5.5 Hz, 1H), 7.79 (d, J=5.0 Hz, 1H).

Example 103b4-Chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde103b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 103a (800 mg, 3.5 mmol),3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 101e (665 mg, 3.5mmol), tris(dibenzylideneacetone)dipalladium(0) (320 mg, 0.35 mmol),XantPhos (400 mg, 0.7 mmol), Cs₂CO₃ (2.3 g, 7.0 mmol), and 1,4-dioxane(20 mL). After three cycles of vacuum/argon flush, the mixture washeated at 90° C. for 5 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by silica-gel column chromatographyeluting with dichloromethane/methanol (80:1) to afford 103b as a yellowsolid (1.2 g, 50%). MS: [M+H]⁺ 330.

Example 103c4-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde103c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 103b (600 mg, 1.0 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxa-borolan-2-yl)pyridin-2(1H)-one101 l (468 mg, 1.0 mmol), Pd(dppf)Cl₂ (81 mg, 0.1 mmol), K₃PO₄.3H₂O (678mg, 3.0 mmol), and tetrahydrofuran (20 mL). After three cycles ofvacuum/argon flush, the mixture was heated at reflux for 4 h. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting withdichloromethane/methanol (40:1) to afford 103c as yellow solid (510 mg,73%). MS: [M+H]⁺ 635.

Example 1032-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one103

To the solution of 103c (500 mg, 0.8 mmol) in methanol (50 mL) was addedsodium borohydride (91 mg, 2.4 mmol) at 0° C. and stirred for another 30minutes. Then the reaction mixture was quenched with water (3 mL) andconcentrated. The residue was purified with reverse-phase prep-HPLC toafford 103 (224 mg, 45%). LCMS: [M+H]⁺ 637. ¹H NMR (500 MHz, DMSO) δ8.61 (d, J=3.0, 1H), 8.48 (d, J=6.0, 1H), 7.92 (d, J=3.5, 1H), 7.81 (d,J=3.0, 1H), 7.78 (s, 1H), 7.38 (d, J=6.0, 1H), 7.24-7.27 (m, 1H), 6.88(s, 1H), 6.81 (d, J=11.5, 1H), 5.01-5.04, (m, 1H), 4.60-4.71 (m, 5H),4.32-4.49 (m, 2H), 3.83-4.15 (m, 3H), 3.70 (s, 3H), 3.53-3.59 (m, 1H),3.13-3.16 (m, 4H), 2.55-2.61 (m, 4H), 2.49-2.52 (m, 4H), 1.78-1.90 (m,4H)

Example 104a 4-Bromo-2-chloronicotinaldehyde 104a

To a solution of 4-bromo-2-chloropyridine (12.0 g, 60.0 mmol) inanhydrous tetrahydrofuran (300 mL) cooled at −70° C. was added thesolution of lithium diisopropylamide (30.0 mL, 60.0 mmol, 2.0 M) over aperiod of 30 minutes and stirred for another at −70° C. 2 h. AnhydrousDMF (12.0 g) was introduced over a period of 10 minutes and stirred foranother 30 minutes. It was then quenched with saturated NaHCO₃ (200 mL),extracted with ethyl acetate (100 mL×3). The combined organic layer wasdried over anhydrous Mg₂SO₄, filtered, and evaporated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with petroleum ether/ethyl acetate (20:1) to afford 104a as ayellow solid (4.0 g, 29%). ¹H NMR (500 MHz, DMSO) δ 10.23 (s, 1H), 8.44(d, J=5.5 Hz, 1H), 7.94 (d, J=5.5 Hz, 1H).

Example 104b2-Chloro-4-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde104b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 104a (1.1 g, 5.0 mmol),3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 101e (477 mg, 2.5mmol), tris(dibenzylideneacetone)dipalladium(0) (230 mg, 0.25 mmol),XantPhos (430 mg, 0.75 mmol), Cs₂CO₃ (1.6 g, 5.0 mmol), and 1,4-dioxane(50 mL). After three cycles of vacuum/argon flush, the mixture washeated at 65° C. for 2 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by silica-gel column chromatographyeluting with dichloromethane/methanol (40:1) to afford 104b as a yellowsolid (1.1 g, 80%). MS: [M+H]⁺ 330.

Example 104c2-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-4-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde104c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 104b (658 mg, 1.0 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxa-borolan-2-yl)pyridin-2(1H)-one101 l (622 mg, 2.0 mmol), Pd (dppf) Cl₂ (65 mg, 0.08 mmol), K₃PO₄.3H₂O(361 mg, 1.6 mmol), and tetrahydrofuran (40 mL). After three cycles ofvacuum/argon flush, the mixture was heated at reflux for 4 h. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting withdichloromethane/methanol (40:1) to afford 104c as a yellow solid (400mg, 63%). MS: [M+H]⁺ 635.

Example 1042-(3-(Hydroxymethyl)-2-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-4-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one104

To the solution of 104c (360 mg, 0.6 mmol) in methanol (50 mL) was addedsodium borohydride (70 mg, 1.8 mmol) at 0° C. and stirred for another 30minutes. Then the reaction mixture was quenched with water (2 mL) andconcentrated. The residue was purified with reverse-phase prep-HPLC toafford 104 (63 mg, 16%) as an off-white solid. LCMS: [M+H]⁺0 637. ¹H NMR(500 MHz, DMSO) δ 8.70 (d, J=3.0, 1H), 8.65 (d, J=5.5, 1H), 8.34 (s,1H), 7.85 (d, J=3.0, 1H), 7.60 (d, J=2.5, 1H), 7.36-7.37 (m, 2H),7.22-7.23 (m, 1H), 6.56 (s, 1H), 5.12 (t, J=5.5, 1H), 4.55-4.56 (m, 2H),4.43-4.45 (m, 4H), 4.14-4.16 (m, 3H), 3.93-3.95 (m, 1H), 3.60 (s, 3H),3.43-3.44 (m, 1H), 3.05-3.08 (m, 4H), 2.61-2.63 (m, 2H), 2.46-2.47 (m,2H), 2.36-2.39 (m, 4H), 1.68-1.78 (m, 4H).

Example 105aN-Methoxy-N-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide105a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer was purged with nitrogen, charged with4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxylic acid (3.00 g, 16.5mmol), methylene chloride (80 mL), and DMF (60 mg, 0.825 mmol) andcooled to 0° C. To the resulting solution, oxalyl chloride (2.31 g, 18.2mmol) was added dropwise. After this addition was complete, the reactionwas warmed to room temperature and stirred for 2 h. After this time, thereaction was concentrated to dryness under reduced pressure. Theresulting white solid was dissolved in methylene chloride (80 mL) andthe solution cooled to 0° C. Triethylamine (5.00 g, 49.5 mmol) andN,O-dimethylhydroxylamine (1.61 g, 16.5 mmol) were then added. After theaddition was complete, the cooling bath was removed, and the reactionmixture was stirred at room temperature for 16 h. After this time, thereaction mixture was partitioned between water (100 mL) and ethylacetate (200 mL). The layers were separated, and the aqueous phase wasextracted with ethyl acetate (100 mL). The combined organic extractswere washed with water (100 mL), followed by brine (100 mL) and driedover sodium sulfate. The drying agent was removed by filtration, and thesolvent was evaporated under reduced pressure. The resulting residue waspurified by flash chromatography to afford an 88% yield of 105a (3.29gm) as a white solid: mp 36-37° C.; ¹H NMR (500 MHz, CDCl₃) δ 7.79 (s,1H), 3.76 (s, 3H), 3.34 (s, 3H), 2.78 (t, 2H, J=6.0 Hz), 2.62 (t, 2H,J=6.0 Hz), 1.82 (m, 4H); MS (APCI+) m/z 226.3 (M+H)

Example 105b3-Chloro-1-(4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)propan-1-one 105b

A 100-mL single-necked round-bottomed flask equipped with a magneticstirrer was purged with nitrogen and charged with 105a (2.70 g, 12.0mmol) and anhydrous THF (45 mL), and the solution was cooled to −10° C.with acetone/ice bath. A 1.0 M solution of vinylmagnesium bromide in THF(13.2 mL, 13.2 mmol) was added dropwise, and the resulting reactionmixture was stirred at 0° C. for 4 h. After this time, the reactionmixture was partitioned between ethyl acetate (100 mL) and 2 M aqueoushydrochloric acid (40 mL). The layers were separated, and the aqueousphase was extracted with ethyl acetate (40 mL). The combined organicextracts were washed with water (100 mL), followed by brine (100 mL),dried over sodium sulfate, filtered and concentrated under reducedpressure. The resulting residue was dissolved in methylene chloride (30mL), and a 2 M solution of hydrogen chloride in diethyl ether (15 mL)was added. After stirring at room temperature for 1 h, the solvents wereremoved under reduced pressure. Purification of the resulting residue bycolumn chromatography afforded a 29% yield (804 mg) of 105b as anoff-white solid: mp 57-58° C.; ¹H NMR (500 MHz, CDCl₃) δ 7.41 (s, 1H),3.89 (t, 2H, J=7.0 Hz), 3.30 (t, 2H, J=7.0 Hz), 2.81 (t, 2H, J=6.0 Hz),2.64 (t, 2H, J=6.0 Hz), 1.83 (m, 4H); MS (ECI+) m/z 229.1 (M+H)

Example 105c5,6,7,8-Tetrahydro-1H-benzo[b]cyclopenta[d]thiophen-3(2H)-one 105c

A 50-mL single-necked round-bottomed flask equipped with a magneticstirrer was charged with 105b (800 mg, 3.51 mmol) and 98% sulfuric acid(8 mL). After stirring at 95° C. for 16 h, the reaction mixture waspoured into ice (50 g), and the resulting suspension was extracted withethyl acetate (3×50 mL). The organic extracts were combined, dried oversodium sulfate, filtered and concentrated under reduced pressure. Theresulting residue was purified by flash chromatography to afford 105c in47% yield (320 mg) as an off-white solid: mp 75-76° C.; ¹H NMR (500 MHz,CDCl₃) δ 2.89 (m, 2H), 2.87-2.83 (m, 4H), 2.56 (t, 2H, J=6.5 Hz), 1.84(m, 4H)

Example 105d5,6,7,8-Tetrahydro-1H-benzo[b]cyclopenta[d]thiophen-3(2H)-one oxime 105d

A 100-mL single-neck round-bottomed flask equipped with a mechanicalstirrer and nitrogen inlet was charged with hydroxylamine hydrochloride(573 mg, 8.25 mmol) and methanol (10 mL). The mixture was cooled to 0°C. using an ice bath. Sodium acetate (677 mg, 8.25 mmol) was added. Themixture was stirred at 0° C. for 30 min. After this time, 105c (319 mg,1.65 mmol) was added, and the reaction was stirred at room temperaturefor 16 h. After this time, the mixture was concentrated, and theresulting residue was triturated with water (10 mL). The resulting solidwas collected and dried in a vacuum oven at 45° C. to afford an 84%yield (287 mg) of 105d as an off-white solid: mp 173-174° C.; ¹H NMR(500 MHz, DMSO-d₆) δ 10.38 (s, 1H), 2.97 (m, 2H), 2.77-2.73 (m, 4H),2.47 (m, 2H), 1.75 (m, 4H); MS (APCI+) m/z 208.3 (M+H)

Example 105e 3,4,5,6,7,8-Hexahydrobenzothieno[2,3-c]pyridin-1(2H)-one105e

A 50-mL single-neck round-bottomed flask equipped with a refluxcondenser, magnetic stirrer and nitrogen inlet was charged with 105d(285 mg, 1.38 mmol) and polyphosphoric acid (15 g). After stirring at80° C. for 16 h, the reaction mixture was cooled to room temperature,and water (30 mL) was added. The resulting mixture was stirred for 30min and filtered. The filter cake was washed with water (20 mL) anddried in a vacuum oven at 45° C. to afford a 75% yield (215 mg) of 105eas an off-white solid: mp 203° C. dec; ¹H NMR (500 MHz, CDCl₃) δ 5.62(s, 1H), 3.59 (t, 2H, J=7.0 Hz), 2.81 (t, 2H, J=6.0 Hz), 2.72 (t, 2H,J=7.0 Hz), 2.48 (t, 2H, J=6.0 Hz), 1.84 (m, 4H). MS (APCI+) m/z 208.3(M+H)

Example 105f3-Bromo-5-{6-oxo-8-thia-5-azatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7)-dien-5-yl}pyridine-4-carbaldehyde105f

To a 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (15 mL),3,5-dibromoisonicotin-aldehyde (400 mg, 1.5 mmol),8-thia-5-azatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7)-dien-6-one 105e(146 mg, 0.76 mmol), and cesium carbonate (176 mg, 1.5 mmol). Xantphos(40 mg, 0.08 mmol) and Pd₂(dba)₃ (70 mg, 0.08 mmol) were added, and thereaction mixture was heated at 100° C. for 5 h. After this time thereaction was cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the residue was purified onflash column eluting with DCM:MeOH (20:1) to afford 105f (200 mg, 70%).MS: [M+H]⁺ 377.

Example 105g3-[1-Methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-5-{6-oxo-8-thia-5-azatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7)-dien-5-yl}pyridine-4-carbaldehyde105g

A sealed tube was charged with 105f (200 mg, 0.53 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101l (240 mg, 0.51 mmol), PdCl₂(dppf) (42 mg, 0.05 mmol), K₃PO₄ (230 mg,1 mmol), and NaOAc (80 mg, 1 mmol) in CH₃CN (5 mL) and H₂O (1.5 mL). Thesystem was evacuated and refilled with N₂. The reaction mixture washeated at 100° C. for 2 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by flash column chromatography elutingwith 10:1 of DCM/MeOH to afford 105g in 40% yield (138 mg) as a paleyellow solid. MS: [M+H]⁺ 638.

Example 1054-Hydroxymethyl-3-[1-methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-5-{6-oxo-8-thia-5-azatricyclo-[7.4.0.0^(2,7)]trideca-1(9),2(7)-dien-5-yl}pyridine105

To a solution of3-[1-methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-5-{6-oxo-8-thia-5-azatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7)-dien-5-yl}pyridine-4-carbaldehyde105g (130 mg, 0.20 mmol) in methanol (5 mL) at 0° C. was added sodiumborohydride (22 mg, 0.6 mmol) and stirred for 30 minutes. Then thereaction mixture was quenched with water (1.0 mL) and concentrated. Theresidue was purified by reverse-phase prep-HPLC to afford 105 (90 mg,65%). LCMS: [M+H]:654. ¹H NMR (500 MHz, DMSO) δ 8.58 (d, J=2.0, 1H),8.56 (s, 1H), 8.49 (s, 1H), 8.41 (s, 1H), 7.86 (s, 1H), 7.36 (m, 2H),7.24-7.22 (m, 1H), 5.14 (t, J=3.0, 1H), 4.56-4.42 (m, 6H), 4.08-3.90 (m,2H), 3.60 (s, 3H), 3.43 (d, J=3.5, 1H), 3.07 (s, 4H), 2.89-2.79 (m, 4H),2.55-2.53 (m, 2H), 2.39-2.37 (m, 4H), 1.80-1.81 (m, 4H)

Example 106a 3,3-Dimethylcyclopentanone 106a

A 1-L three-neck round-bottomed flask equipped with a magnetic stirrer,addition funnel and nitrogen inlet was purged with nitrogen and chargedwith ether (200 mL) and copper (I) iodide (54.46 g, 0.286 mol). Themixture was cooled to 0° C., methyllithium (1.6 M in ether, 357.5 mL,0.572 mol) was added dropwise to the reaction mixture over 1.5 h andstirred at 0° C. for additional 2 h. After this time a solution of3-methylcyclo-pent-2-enone (25 g, 0.260 mol) in ether (150 mL) was addeddropwise over 1.5 h. The reaction mixture was then stirred at 0° C. for2 h and poured into sodium sulfate deca-hydrate (300 g). The resultingmixture was stirred for 30 min. After this time the mixture was filteredand washed with ether (1000 mL). The filtrate was concentrated anddistilled under reduced pressure to afford a 70% yield (20.5 g) of3,3-dimethylcyclo-pentanone 106a as a colorless liquid: by 50-55° C. (at10 mmHg); ¹H NMR (300 MHz, CDCl₃) δ 2.31 (t, 2H, J=7.8 Hz), 2.05 (s,2H), 1.79 (t, 2H, J=7.8 Hz); MS (ESI+) m/z 113.3 (M+H)

Example 106b Ethyl5,5-Dimethyl-5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxylate 106b

A 500-mL three-neck round-bottomed flask equipped with a magneticstirrer, reflux condenser, addition funnel and nitrogen inlet was purgedwith nitrogen and charged with DMF (9.49 g, 0.100 mol) and methylenechloride (100 mL). The reaction mixture was cooled to 0° C. andphosphorus oxychloride (14.1 g, 0.920 mol) was added dropwise to thereaction over 30 min. Once this addition was complete, the reaction waswarmed to room temperature and stirred for 1 h. After this time asolution of 106a (11.2 g, 0.100 mol) in methylene chloride (100 mL) wasadded dropwise over 1 h. The reaction was then stirred at reflux for 18h. The reaction mixture was cooled to room temperature and poured into amixture of crushed ice (400 mL) and sodium acetate (100 g, 1.22 mol).The resulting mixture was stirred for 45 min. After this time theaqueous layer was separated and extracted with methylene chloride (2×500mL). The combined organic layers were then washed with water (2×200 mL),followed by brine (200 mL) and dried over sodium sulfate. The dryingagent was then removed by filtration, and the filtrate was concentratedto afford crude product 2-chloro-4,4-dimethylcyclopent-1-enecarbaldehydewhich was placed in a 500-mL three-neck round bottomed flask equippedwith a mechanical stirrer, reflux condenser and nitrogen inlet.Methylene chloride (200 mL), ethyl 2-mercaptoacetate (11.0 g, 0.092 mol)and triethylamine (30 g, 0.207 mol) were then added. The reactionmixture was then stirred at reflux for 6 h. After this time the reactionwas cooled to room temperature and concentrated to a thick orangeresidue. Ethanol (200 mL) and triethylamine (30.0 g, 0.207 mol) wereadded and the reaction was heated at reflux for 12 h. The reaction wasthen cooled to room temperature and concentrated under reduced pressureand the resulting residue was diluted with ether (600 mL). The resultingmixture was washed with 1 M hydrochloric acid (150 mL), brine (100 mL),dried over sodium sulfate, filtered and concentrated under reducedpressure. The resulting residue was purified by flash chromatography toafford 106b in 34% yield (7.70 g) as a colorless liquid: ¹H NMR (300MHz, CDCl₃) δ 7.48 (s, 1H), 4.33 (q, 2H, J=7.2 Hz), 2.72 (s, 2H), 2.56(s, 2H), 1.38 (t, 3H, J=1.8 Hz), 1.17 (s, 6H); MS (ESI+) m/z 225.1

Example 106c5,5-Dimethyl-5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxylic acid106c

In a 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser, 106b (4.00 g, 17.8 mmol) was dissolved inethanol (50 mL). THF (50 mL), water (50 mL) and lithium hydroxide (854mg, 35.6 mmol) were added, and the mixture was stirred at 60° C. for 4h. After this time the reaction was cooled to room temperature andacidified with 2M hydrochloric acid to pH 1.5, and then extracted withethyl acetate (2×200 mL). The organic layers were combined, washed withwater (2×100 mL), followed by brine (100 ml) and dried over sodiumsulfate. The drying agent was then separated by filtration. Afterevaporating the resulting filtrate, 106c was obtained in 91% yield (3.2g) as a white solid: mp 170-172° C.; ¹H NMR (300 MHz, CDCl₃) δ 12.77 (s,1H), 7.46 (s, 1H), 2.71 (s, 2H), 2.53 (s, 2H), 1.20 (s, 6H); MS (ESI−)m/z 195.0

Example 106d5,5-Dimethyl-5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxylic acid106d

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer, reflux condenser and a bubbler placed on the condenser wascharged with 106c (2.30 g, 11.6 mmol), toluene (25 mL), thionyl chloride(4.09 g, 34.9 mmol) and DMF (1 drop). The mixture was heated at refluxfor 1 h and then evaporated under reduced pressure on a rotaryevaporator at 45° C. The resulting acid chloride was diluted withmethylene chloride (20 mL).

In a separate 250-mL three-neck round-bottomed flask equipped with amagnetic stirrer N,O-dimethylhydroxylamine hydrochloride (2.26 g, 23.2mmol) and N,N-diisopropylethylamine (2.97 g, 23.0 mmol) were dissolvedin anhydrous methylene chloride (20 mL) under nitrogen, and the solutionwas cooled to 0° C. in an ice/water bath. The solution of the acidchloride was added, and the reaction mixture was stirred at roomtemperature for 18 h. The reaction mixture was extracted with water (100mL), 10% aqueous citric acid (50 mL) and a 1:1 mixture of saturatedaqueous sodium bicarbonate and water (100 mL). The organic layer wasdried over sodium sulfate and evaporated under reduced pressure on arotary evaporator to afford a 93% yield (2.60 g) of 106d as a lightyellow solid: ¹H NMR (300 MHz, CDCl₃) δ 7.66 (s, 1H), 3.77 (s, 3H), 3.35(s, 3H), 2.74 (s, 2H), 2.58 (s, 2H), 1.23 (s, 6H)

Example 106e3-Chloro-1-(5,5-dimethyl-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)propan-1-one106e

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was purged with nitrogen and charged with 106d (2.41 g, 10.0mmol) and anhydrous THF (20 mL). The solution was cooled to −70° C., and1 M vinylmagnesium bromide in THF (11 mL, 11.0 mmol) was added with thereaction temperature maintained below −60° C. The reaction mixture wasstirred at −13 to −7° C. for 2 h and then warmed to room temperatureover 30 min. The reaction was again cooled to −70° C., and a 2 Msolution of hydrogen chloride in ether (22.5 ml, 45 mmol) was added. Thereaction was then stored in a freezer at −10° C. overnight. After thistime the mixture was evaporated under reduced pressure on a rotaryevaporator, and the resulting residue partitioned between water (100 mL)and ether (100 mL). The ether extract was dried over sodium sulfate andevaporated under reduced pressure on a rotary evaporator to afford crude106e (2.86 g, 118%) as a brown oil with approximately 75% purity (byNMR): ¹H NMR (300 MHz, CDCl₃) δ 7.45 (s, 1H), 3.89 (t, 2H, J=6.9 Hz),3.30 (t, 2H, J=6.9 Hz), 2.75 (s, 2H), 2.59 (s, 2H), 1.24 (s, 6H)

Example 106f6,6-Dimethyl-1,2,6,7-tetrahydrodicyclopenta[b,d]thiophen-3(5H)-one 106f

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with crude 106e (2.86 g, 10.0 mmol presumingquantitative yield) and 98% sulfuric acid. The reaction mixture washeated in a 90° C. oil bath overnight. The reaction mixture was placedinto an ice/acetone bath, and a cold (5° C.) solution of dipotassiumhydrogen phosphate (105 g, 0.603 mol) in water (300 mL) was added in oneportion. The resulting mixture was shaken with ethyl acetate (300 mL)and filtered. The filter cake was washed with ethyl acetate (100 mL).The ethyl acetate layer of the filtrate was separated, dried over sodiumsulfate and evaporated under reduced pressure on a rotary evaporator.the resulting residue was purified by flash column chromatography(silica, 80:20 hexanes/ethyl acetate) to afford 106f in 37% yield overtwo steps (683 mg) as an amorphous brown solid: mp 60-62° C.; ¹H NMR(500 MHz, CDCl₃) δ 2.92-2.87 (m, 4H), 2.79 (s, 2H), 2.53 (s, 2H), 1.26(s, 6H); LCMS (ESI+) m/z 207.0 (M+H)

Example 106g6,6-Dimethyl-1,2,6,7-tetrahydrodicyclopenta[b,d]thiophen-3(5H)-one 106g

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and nitrogen inlet was charged with hydroxylamine hydrochloride(688 mg, 9.90 mmol), sodium acetate (812 mg, 9.90 mmol) and methanol (10mL), and the mixture at room temperature for 30 min. After this time, asolution of 106f (680 mg, 3.30 mmol) was added dropwise at roomtemperature, and the reaction was stirred at room temperature for 14 hunder nitrogen atmosphere. Since the reaction was not complete,hydroxylamine hydrochloride (1.15 g, 16.5 mmol) and sodium acetate (1.35g, 16.5 mmol) were added, and the stirring was continued at roomtemperature for 58 h. After this time, the mixture was diluted withmethylene chloride (150 mL) and water (100 mL), and the layers wereseparated. The organic layer was washed with brine (50 mL) and driedover sodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated to afford crude 106g in quantitative yield(730 mg) as a yellow semi-solid which was used in the next step withoutpurification: mp 122-124° C.; ¹H NMR for major isomer (500 MHz, CDCl₃) δ3.13-3.11 (m, 2H), 2.85-2.83 (m, 2H), 2.77 (s, 2H), 2.49 (s, 2H), 1.24(s, 6H); MS (ESI+) m/z 222.0 (M+H)

Example 106h6,6-Dimethyl-3,4,6,7-tetrahydro-5H-cyclopenta[4,5]thieno[2,3-c]pyridine-1(2H)-one106h

A 100-mL three-neck round-bottomed flask equipped with a refluxcondenser, mechanical stirrer and nitrogen inlet was charged with 106g(700 mg, 3.16 mmol) and polyphosphoric acid (25 g). The reaction mixturewas stirred at 80° C. for 13 h under nitrogen atmosphere. After thistime, the mixture was cooled to 0° C. and water (50 mL) was addeddropwise carefully maintaining the internal temperature between 10-45°C. The mixture was diluted with 90:10 methylene chloride/methanol (100mL) and the layers were separated. The aqueous layer was extracted with90:10 methylene chloride/methanol (50 mL), and the combined organiclayers were washed with saturated aqueous sodium bicarbonate (50 mL),brine (150 mL) and dried over sodium sulfate. The drying agent wasremoved by filtration. The filtrate was concentrated under reducedpressure, and the resulting residue was purified by flash columnchromatography (silica, 95:5 methylene chloride/methanol) to afford6,6-dimethyl-3,4,6,7-tetrahydro-5H-cyclopenta[4,5]thieno[2,3-c]pyridine-1(2H)-one106h in 90% yield (630 mg) as an amorphous off-white solid: mp 205-207°C.; ¹H NMR (500 MHz, CDCl₃) δ 5.51 (s, 1H), 3.60-3.56 (m, 2H), 2.76-2.73(m, 4H), 2.49 (s, 2H), 1.26 (s, 6H); MS (ESI+) m/z 222.0 (M+H)

Example 106i3-Bromo-5-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-4-carbaldehyde 106i

To a 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (15 mL),3,5-dibromoisonicotin-aldehyde (400 mg, 1.5 mmol),4,4-dimethyl-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-9-one(106h) (170 mg, 0.76 mmol), and cesium carbonate (176 mg, 1.5 mmol).Xantphos (40 mg, 0.08 mmol) and Pd₂(dba)₃ (70 mg, 0.08 mmol) were added,and the reaction mixture was heated at 100° C. for 5 h. After this timethe reaction was cooled to room temperature and filtered. The filtratewas concentrated under reduced pressure and the residue was purified onflash column eluting with DCM:MeOH (20:1) to afford 106i (200 mg, 65%).MS: [M+H]⁺ 405.

Example 106j3-[1-Methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-5-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-4-carbaldehyde 106j

A sealed tube was charged with 106i (200 mg, 0.50 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101 l (240 mg, 0.51 mmol), PdCl₂(dppf) (42 mg, 0.05 mmol), K₃PO₄ (230mg, 1 mmol), and NaOAc (80 mg, 1 mmol) in CH₃CN (5 mL) and H₂O (1.5 mL).The system was evacuated and refilled with N₂. The reaction mixture washeated at 100° C. for 2 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by flash column chromatography elutingwith 10:1 DCM/MeOH to afford 106j (130 mg, 40%) as a pale yellow solid.MS: [M+H] 666.

Example 1064-Hydroxymethyl-3-[1-methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-5-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-4-carbaldehyde 106

To a solution of 106j (130 mg, 0.20 mmol) in methanol (5 mL) at 0° C.was added sodium borohydride (22 mg, 0.6 mmol) and stirred for 30minutes. Then the reaction mixture was quenched with water (1.0 mL) andconcentrated. The residue was purified by reverse-phase prep-HPLC toafford 106 (60 mg, 45%) as a yellow solid. LCMS: [M+H] 668. ¹H NMR (500MHz, DMSO) δ 8.58 (d, J=2.0, 1H), 8.56 (s, 1H), 8.49 (s, 1H), 8.41 (s,1H), 7.87 (d, J=2.5, 1H), 7.38-7.36 (m, 2H), 7.24-7.22 (m, 1H), 5.15 (t,J=5.0, 1H), 4.56-4.42 (m, 6H), 4.08-4.04 (m, 2H), 3.60 (s, 3H),3.43-3.42 (m, 1H), 3.07-2.94 (m, 6H), 2.55-2.53 (m, 4H), 2.39-2.38 (m,4H), 1.23 (s, 6H)

Example 107a (E)-Ethyl 3-(2-Chloro-4,4-dimethyl cyclopent-1-enyl)acrylate 107a

The following two procedures were adapted from Organic Preparations andProcedures Int., 29(4):471-498. A 500-mL single neck round bottomedflask equipped with a magnetic stirrer and nitrogen inlet was chargedwith 2-chloro-4,4-dimethylcyclopent-1-enecarbaldehyde (38 g, 240 mmol)in benzene (240 mL). To the solution was added ethoxycarbonylmethylenetriphenylphosphorane (84 g, 240 mmol). The mixture was stirred for 14 h.After that time, the solvent was evaporated and the residue wastriturated with hexanes (2 L) to extract the product away from the PPh₃by-products. The organic layer was dried over sodium sulfate andconcentrated in vacuo. The residue was purified by column chromatographyusing a 100% hexane—1:1 hexane/ethyl acetate gradient to afford a 37%yield (20 g) of (E)-ethyl3-(2-chloro-4,4-dimethylcyclopent-1-enyl)acrylate 107a.

Example 107b Ethyl5,5-Dimethyl-1,4,5,6-tetrahydrocyclopenta[b]pyrrole-2-carboxylate 107b

A 250-mL single neck round bottomed flask equipped with a magneticstirrer and nitrogen inlet was charged with 107a (17 g, 74 mmol) in DMSO(100 mL). To the solution was added sodium azide (9.6 g, 150 mmol). Themixture was then heated to 75° C. and stirred for 8 h. After cooling tort (room temperature), H₂O (100 mL) and CH₂Cl₂ (200 mL) were added andthe organic layer was separated. The aqueous layer was extracted withCH₂Cl₂ (50 mL). The combined organic layers were washed with brine,dried over sodium sulfate and concentrated in vacuo. The residue waspurified by column chromatography using a 100% hexane—1:1 hexane/ethylacetate gradient to afford a 37% yield (5.7 g) of 107b.

Example 107c Ethyl1-(Cyanomethyl)-5,5-dimethyl-1,4,5,6-tetrahydrocyclo-penta[b]pyrrole-2-carboxylate107c

A 250-mL single neck round bottomed flask equipped with a magneticstirrer and nitrogen inlet was charged with 107b (6.2 g, 30 mmol) in DMF(57 mL). To the solution was added NaH (80% dispersion in mineral oil,1.26 g, 42.1 mmol). The resulting mixture was stirred at rt for 90 min.After that time, bromoacetonitrile (2.94 mL, 42 mmol) was added. Themixture was stirred for 14 h. After that time, water (100 mL) and ethylacetate (200 mL) were added and the organic layer was separated. Theaqueous layer was extracted with ethyl acetate (2×50 mL). The combinedorganic layers were washed with brine, dried over sodium sulfate andconcentrated in vacuo. The residue was purified by column chromatographyto afford a 95% yield (7 g) of 107c.

Example 107d Ethyl1-(2-Aminoethyl)-5,5-dimethyl-1,4,5,6-tetrahydrocyclo-penta[b]pyrrole-2-carboxylatehydrochloride 107d

A 500-mL Parr reactor bottle was purged with nitrogen and charged with10% palladium on carbon (50% wet, 2.0 g dry weight), 107c (4.5 g, 18mmol), 12% hydrochloric acid (9.2 mL, 37 mmol), ethyl acetate (80 mL)and ethanol (52 mL). The bottle was attached to a Parr hydrogenator,evacuated, charged with hydrogen gas to a pressure of 50 psi and shakenfor 6 h. After this time, the hydrogen was evacuated, and nitrogen wascharged into the bottle. CELITE® 521 (10.0 g) was added, and the mixturewas filtered through a pad of CELITE® 521. The filter cake was washedwith ethanol (2×50 mL), and the combined filtrates were concentrated todryness under reduced pressure. The crude residue ethyl1-(2-aminoethyl)-5,5-dimethyl-1,4,5,6-tetrahydrocyclopenta[b]pyrrole-2-carboxylatehydrochloride 107d was carried onto the next step without furtherpurification.

Example 107e4,4-Dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one107e

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and nitrogen inlet was purged with nitrogen and charged withcrude1-(2-aminoethyl)-5,5-dimethyl-1,4,5,6-tetrahydrocyclopenta[b]pyrrole-2-carboxylatehydrochloride 107d (˜18 mmol), sodium ethoxide (6.2 g, 92 mmol) andethanol (120 mL). The mixture was stirred at 55° C. over night. Afterthat time, the reaction mixture was concentrated under reduced pressureand the residue was partitioned between ethyl acetate (200 mL) and water(100 mL). The solution was filtered. The solid was washed with ethylacetate (15 mL) to give 850 mg of desired product 107e. The organiclayer was separated, and the aqueous layer was extracted with ethylacetate (2×100 mL). The combined organic layers were dried over sodiumsulfate and concentrated under reduced pressure to near dryness. Thesolution was filtered and the solid (1.44 g) was washed with ethylacetate (15 mL). The combined solids were dried under vacuum a afford61% yield (2.3 g) of 107e.

Example 107f3-Bromo-5-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-4-carbaldehyde107f

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (15 mL),3,5-dibromoisonicotinaldehyde (400 mg, 1.5 mmol), 107e (155 mg, 0.76mmol), and cesium carbonate (176 mg, 1.5 mmol). Xantphos (40 mg, 0.08mmol) and Pd₂(dba)₃ (70 mg, 0.08 mmol) were added, and the reactionmixture was heated at 100° C. for 5 h. After this time the reaction wascooled to room temperature and filtered. The filtrate was concentratedunder reduced pressure. The residue was purified on flash column elutingwith DCM:MeOH (20:1) to afford 107f (200 mg, 70%). MS: [M+H]⁺ 388.

Example 107g5-[1-Methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-3-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]-dodeca-2(6),7-dien-10-yl}pyridine-4-carbaldehyde107g

A sealed tube was charged with 107f (200 mg, 0.51 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101 l (240 mg, 0.51 mmol), PdCl₂(dppf) (42 mg, 0.05 mmol), K₃PO₄ (230mg, 1 mmol), and NaOAc (80 mg, 1 mmol) in CH₃CN (5 mL) and H₂O (1.5 mL).The system was evacuated and refilled with N₂. The reaction mixture washeated at 100° C. for 2 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by flash column chromatography elutingwith 10:1 of DCM/MeOH to afford 107g in 35% yield (120 mg) as a brownsolid. MS: [M+H] 649.

Example 10710-[4-[1-Methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-4-(hydroxymethyl)pyridin-3-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one107

To a solution of 107g (120 mg, 0.18 mmol) in methanol (5 mL) at 0° C.was added sodium borohydride (22 mg, 0.6 mmol) and the mixture wasstirred for 30 minutes. Then the reaction mixture was quenched withwater (1.0 mL) and concentrated. The residue was purified byreverse-phase prep-HPLC to afford 107 (72 mg, 60%). LCMS: [M+H]:651. ¹HNMR (500 MHz, CDCl₃) δ 8.65 (s, 1H), 8.59 (s, 1H), 8.49 (s, 1H), 7.86(d, J=1.5, 1H), 7.36 (m, 2H), 7.22 (d, J=2.4, 2H), 6.52 (s, 1H), 5.16(t, J=3.0, 1H), 4.56-4.44 (m, 6H), 4.21-4.12 (m, 3H), 3.92 (m, 1H), 3.60(s, 3H), 3.43-3.42 (m, 1H), 3.06 (s, 4H), 2.57-2.38 (m, 8H), 1.21 (s,6H)

Example 108a4-Chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with2-bromo-4-chloronicotinaldehyde 103a (3.0 g, 13.6 mmol),4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one107e (1.84 g, 9.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (826mg, 0.9 mmol), XantPhos (1.04 mg, 1.8 mmol), Cs₂CO₃ (5.8 g, 18.0 mmol),and 1,4-dioxane (40 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 5 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was recrystallized from ethyl acetateto afford 108a as a yellow solid (730 mg, purity: 99%; yield: 31.7%).MS: [M+H] 344.0.

Example 108b4-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]-dodeca-2(6),7-dien-10-yl}nicotinaldehyde108b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diaza-tricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (350 mg, 1.02 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101l (476 mg, 1.02 mmol), Pd(dppf)Cl₂ (83 mg, 0.10 mmol), K₃PO₄ (526 mg,3.06 mmol), and tetrahydrofuran (20 mL). After three cycles ofvacuum/argon flush, the mixture was heated at reflux for 4 h. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting withdichloromethane/methanol (40:1) to afford 108b as white solid (400 mg,61%). MS: [M+H]⁺ 649.4.

Example 1082-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one108

To a solution of4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo-[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}nicotinaldehyde108b (400 mg, 0.62 mmol) in methanol (30 mL) at 0° C. was added sodiumborohydride (70 mg, 1.86 mmol) and stirred for 30 minutes. Then thereaction mixture was quenched with water (1.0 mL) and concentrated. Theresidue was purified by reverse-phase prep-HPLC to afford 108 (170 mg,42%). LCMS: [M+H]⁺ 651.4. ¹H NMR (500 MHz, CDCl₃) δ 8.63 (d, J=2.0, 1H),8.48 (d, J=5.0, 1H), 7.92 (d, J=2.5, 1H), 7.82 (d, J=2.5, 1H), 7.78 (s,1H), 7.36 (d, J=5.0, 1H), 7.27-7.25 (m, 1H), 6.84 (s, 1H), 6.81 (d,J=9.5, 1H), 5.05 (t, J=6.5, 1H), 4.72-4.64 (m, 5H), 4.51-4.48 (m, 1H),4.34-4.32 (m, 1H), 4.15 (d, J=4.5, 2H), 3.87-3.84 (m, 1H), 3.71 (s, 3H),3.59-3.54 (m, 1H), 3.16-3.14 (m, 4H), 2.58-2.50 (m, 8H), 1.27 (s, 6H)

Example 109a4-Chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde109a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with2-bromo-4-chloronicotinaldehyde 103a (660 mg, 3.0 mmol),4,4-dimethyl-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-9-one106h (665 mg, 3.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (270mg, 0.3 mmol), XantPhos (340 mg, 0.6 mmol), Cs₂CO₃ (2.0 g, 6.0 mmol),and 1,4-dioxane (20 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 5 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with dichloromethane to afford 109a as yellowsolid (105 mg, 14%). MS: [M+H]⁺ 361.

Example 109b4-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]-dodeca-1(8),2(6)-dien-10-yl}nicotinaldehyde109b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 109a (75 mg, 0.2 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101 l (94 mg, 0.2 mmol), Pd(dppf)Cl₂ (17 mg, 0.02 mmol), K₃PO₄.3H₂O (140mg, 0.6 mmol), and tetrahydrofuran (10 mL). After three cycles ofvacuum/argon flush, the mixture was heated at reflux for 4 h. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting withdichloromethane/methanol (40:1) to 109b as yellow solid (60 mg, 47%).MS: [M+H]⁺ 666.

Example 1092-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-4,4-dimethyl-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-9-one109

To a solution of 109b (60 mg, 0.1 mmol) in methanol (5 mL) at 0° C. wasadded sodium borohydride (11 mg, 0.3 mmol) and the mixture was stirredfor 30 minutes. Then the reaction mixture was quenched with water (0.3mL) and concentrated. The residue was purified with reverse-phaseprep-HPLC to afford 109 (14 mg, 24%) as a brown solid. LCMS: [M+H]⁺ 668.¹H NMR (500 MHz, DMSO) δ 8.60 (d, J=2.5, 1H), 8.48 (d, J=5.0, 1H), 8.42(s, 1H), 7.85 (d, J=3.0, 1H), 7.44 (d, J=2.0, 1H), 7.34-7.38 (m, 2H),7.23 (d, J=9.0, 1H), 4.94 (t, J=5.0, 1H), 4.55 (t, J=7.0, 2H), 4.39-4.46(m, 4H), 4.14-4.19 (m, 1H), 3.79-3.83 (m, 1H), 3.59 (s, 3H), 3.42-3.44(m, 1H), 3.00-3.07 (m, 5H), 2.85-2.90 (m, 1H), 2.76 (s, 2H), 2.52-2.59(m, 2H), 2.36-2.39 (m, 4H), 1.21 (d, J=6.5, 6H)

Example 110a1-Methyl-3-(6-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one110a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a condenser was charged with5-bromo-1-methyl-3-(6-(4-methylpiperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one(0.45 g, 1.08 mmol), (PinB)₂ (1.37 g, 5.4 mmol), Pd₂(dba)₃ (49 mg, 0.054mmol), X-Phos (52 mg 0.11 mmol), KOAc (318 mg, 3.24 mmol), 1,4-dioxane20 mL). After three cycles of vacuum/argon flush, the reaction mixturewas heated at 60° C. for 15 h. It was then cooled to room temperatureand filtered. The filtrate was concentrated under reduced pressure toafford crude 110a, which was used directly in the next reaction. MS:[M+H]⁺ 426.

Example 110b4-(1-Methyl-5-(6-(4-methylpiperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde110b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino-[1,2-a]indol-2(1H)-yl)nicotinaldehyde103b (377 mg, 1.15 mmol), 110a (320 mg, 0.78 mmol), Pd(dppf)Cl₂ (130 mg,0.16 mmol), K₃PO₄.3H₂O (52.9 mg, 0.23 mmol), and tetrahydrofuran (20mL). After three cycles of vacuum/argon flush, the mixture was heated atreflux overnight, cooled to room temperature and filtered. The filtratewas concentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting withdichloromethane/methanol (40:1) to afford 110b as yellow solid (351 mg,76%). MS: [M+H]⁺ 593.

Example 1102-(3-(Hydroxymethyl)-4-(1-methyl-5-(6-(4-methylpiperazin-1-yl)pyridine-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one110

To the solution of 110b (60 mg, 0.1 mmol) in methanol (50 mL) was addedsodium borohydride (11.5 mg, 0.3 mmol) at 0° C. and the mixture wasstirred for another 30 minutes. Then the reaction mixture was quenchedwith water (3 mL) and concentrated. The residue was purified withreverse-phase prep-HPLC to afford 110 (26.2 mg, 49%). LCMS: [M+H]⁺ 595.¹H NMR (500 MHz, CDCl₃) δ 8.69 (d, J=1.5, 1H), 8.46 (d, J=5.0, 1H), 7.97(s, 1H), 7.80 (s, 1H), 7.41-7.37 (m, 1H), 7.34 (d, J=1.5, 1H), 6.89 (s,1H), 6.22 (d, J=8.0, 1H), 6.15 (d, J=8.5, 1H), 5.10 (t, J=6.5, 1H),4.66-4.64 (m, 1H), 4.51-4.30 (m, 2H), 4.15-4.12 (m, 2H), 3.93-3.89 (m,1H), 3.71 (s, 3H), 3.58-3.48 (m, 4H), 2.61-2.56 (m, 7H), 2.47-2.39 (m,3H), 1.91-1.87 (m, 2H), 1.79-1.78 (d, J=5.0, 3H)

Example 111a (6-Aminopyridin-3-yl)(morpholino)methanone 111a

To a solution of morpholine (9.00 g, 103 mmol) in EtOH (400 mL) wasadded EDCI (10.0 g, 52.2 mmol), HOBt (7.00 g 51.8 mmol), and6-aminonicotinic acid (6.00 g, 43.4 mmol). After stirring for 18 h, theresulting suspension was filtered. The solid was triturated with amixture of MeOH (100 mL) and methylene chloride (100 mL) to afford 111aas a white solid (2.7 g, 30%). LCMS: (M+H)⁺ 208

Example 111b5-Bromo-1-methyl-3-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)pyridine-2(1H)-one111b

Following the procedure described for synthesis of 101i, intermediate111a and 3,5-dibromo-1-methylpyridin-2(1H)-one were reacted to give 111bin 21% yield. LCMS: (M+H)⁺ 394. ¹H NMR (500 MHz, MeOD) δ 8.84 (d, J=2.5,1H), 8.42 (d, J=2, 1H), 7.72 (m, 1H), 7.42 (d, J=2, 1H), 7.11 (d, J=8.5,1H), 3.72 (m, 8H), 3.63 (s, 3H).

Example 111c1-Methyl-3-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one111c

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a condenser was charged with 111b (1.0 g, 0.25 mmol), X-phos(120 mg, 0.025 mmol), Pd₂(dba)₃ (110 g, 0.0125 mmol), KOAc (750 mg, 0.75mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (3.2g, 1.25 mmol) and 1,4-dioxane (50 mL). After three cycles ofvacuum/argon flush, the reaction mixture was heated at 100° C. for 15 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by flash column chromatography eluting with 5:1 petroleumether/ethyl acetate to afford 111c as a yellow solid (700 mg, 63%). MS:[M+H]⁺ 441.

Example 111d4-(1-Methyl-5-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde111d

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a condenser was charged with 111c (450 mg, 1.26 mmol),4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde103b (413 mg, 1.26 mmol), Pd(dppf)Cl₂ (102 mg, 0.126 mmol), K₃PO₄.3H₂O(85 mg, 0.352 mmol), and THF (10 mL). After three cycles of vacuum/argonflush, the reaction mixture was heated at 100° C. for 15 h. It was thencooled to room temperature and filtered. The filtrate was concentratedunder reduced pressure and the resulting residue was purified by flashcolumn chromatography eluting with 7:1 petroleum ether/ethyl acetate toafford 111d as a yellow solid (700 mg, 63%). MS: [M+H]⁺ 608.

Example 1112-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one111

A mixture of 111d (60 mg, 0.05 mmol), NaBH₄ (6.4 mg, 0.1 mmol) and MeOH(5 mL) was stirred at 0° C. for 30 mins. The mixture was evaporated invacuo and the residue was extracted with EtOAc (10 mL×2). The combinedEtOAc extract was concentrated under reduced pressure and the residuewas purified with reverse-phase prep-HPLC to give 111 (27 mg, 44%).LCMS: [M+H]⁺ 610. ¹H NMR (500 MHz, DMSO) δ 9.00 (s, 1H), 8.78 (d, J=2.0,1H), 8.49 (d, J=5, 1H), 8.26 (d, J=2.0, 1H), 7.65-7.67 (m, 2H), 7.60 (d,J=2.5, 1H), 6.58 (s, 1H), 4.96 (t, J=5, 1H), 4.40-4.46 (m, 2H),4.11-4.24 (m, 3H), 3.86-3.88 (m, 1H), 3.56-3.62 (m, 8H), 3.50 (s, 4H),2.62-2.63 (m, 2H), 2.46-2.47 (m, 2H), 1.67-1.80 (m, 4H)

Example 112a Methyl 5,6,7,8-Tetrahydroindolizine-2-carboxylate 112a

A 500-mL round-bottomed flask equipped with a magnetic stirrer andnitrogen inlet was purged with nitrogen and charged with5,6,7,8-tetrahydroindolizine-2-carboxylic acid (30.4 g, 184 mmol), DMF(1.00 g, 13.6 mmol) and methylene chloride (300 mL). The solution wascooled to 0° C. using an ice bath. Oxalyl chloride (28.0 g, 221 mmol)was added dropwise, and the reaction mixture was warmed to roomtemperature over 30 min and stirred for 5 h. After this time, theresulting solution was concentrated to afford a brown solid. This solidwas dissolved in anhydrous methanol (400 mL), and the solution wascooled to 0° C. Triethylamine (57 g, 552 mmol) was added to the reactionmixture, and it was stirred for a further 2 h at room temperature. Afterthis time, the reaction mixture was concentrated to dryness underreduced pressure. The residue was diluted with methylene chloride (300mL) and washed with water (200 mL) and saturated aqueous sodiumbicarbonate (200 mL). The organic layer was dried over sodium sulfate,filtered and concentrated under reduced pressure. The resulting residuewas titrated with hexane (200 mL) to afford 112a in 58% yield (19.1 g)as a white solid: mp 72-74° C.; ¹H NMR (300 MHz, DMSO-d₆) δ 7.13 (s,1H), 6.23 (s, 1H), 3.93 (t, 2H, J=6.0 Hz), 3.77 (s, 3H), 2.75 (t, 2H,J=6.0 Hz), 1.93 (m, 2H), 1.80 (m, 2H); (APCI+) m/z 180.1 (M+H)

Example 112b Methyl3-(Cyanomethyl)-5,6,7,8-tetrahydroindolizine-2-carboxylate 112b

A 500-mL three-neck round-bottomed flask equipped with an additionfunnel, thermometer and charged with 112a (6.70 g, 37.4 mmol),Iodoacetonitrile (12.5 g, 74.9 mmol), iron (II) sulfate heptahydrate(5.20 g, 18.7 mmol) and dimethyl sulfoxide (250 mL). Hydrogen peroxide(35%, 18.2 g, 187 mmol) was added dropwise to the mixture in 1 h througha syringe pump at room temperature using a water bath. Iron (II) sulfateheptahydrate (2 to 3 equivalent) was added to the reaction mixture inportions to keep the temperature between 25° C. to 35° C., until thecolor of the reaction mixture is deep red. If TLC shows the reaction notcompleted, then more hydrogen peroxide (2-3 equivalent) and more iron(II) sulfate heptahydrate (1-2 equivalent) are added in the same manneruntil the reaction is completed. After that time, the reaction mixturewas partitioned between saturated sodium bicarbonate solution (200 mL)and ethyl acetate (400 mL). The organic layer was separated, and theaqueous layer was extracted with ethyl acetate (2×100 mL). The combinedorganic layers were washed with saturated Sodium thiosulfate solution(50 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by column chromatography to afford a78% yield (6.40 g) of 112b as a yellow oil: ¹H NMR (500 MHz, CDCl₃) δ6.23 (s, 1H), 4.23 (s, 2H), 3.94 (t, 2H, J=6.5 Hz), 3.81 (s, 3H), 2.74(t, 2H, J=6.5 Hz), 2.00 (m, 2H), 1.83 (m, 2H); (APCI+) m/z 219.3 (M+H)

Example 112c Methyl3-(2-Aminoethyl)-5,6,7,8-tetrahydroindolizine-2-carboxylate HydrogenChloride Salt 112c

Methyl 3-(Cyanomethyl)-5,6,7,8-tetrahydroindolizine-2-carboxylate 112bwas hydrogenated with platinum oxide catalyst under 50 psi of hydrogenin ethanol and ethyl acetate in the presence of hydrogen chlorideovernight at room temperature to give 112c (380 mg, 1.74 mmol) which wasused directly in the next step.

Example 112d 3,4,6,7,8,9-Hexahydropyrido[3,4-b]indolizin-1(2H)-one 112d

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and nitrogen inlet was purged with nitrogen and charged withmethyl 3-(2-aminoethyl)-5,6,7,8-tetrahydroindolizine-2-carboxylatehydrogen chloride salt 112c (prepared above, estimated 1.74 mmol,presuming quantitative yield), sodium ethoxide (354 mg, 5.22 mmol) andethanol (20 mL). The mixture was stirred at 55° C. for 5 h. After thattime, the reaction mixture was concentrated under reduced pressure andthe residue was partitioned between ethyl acetate (200 mL) and water(100 mL). The organic layer was separated, and the aqueous layer wasextracted with ethyl acetate (2×100 mL). The combined organic layerswere washed with brine, dried over sodium sulfate and concentrated underreduced pressure. The residue was purified by column chromatography toafford a 67% yield (220 mg) of 112d as a white solid: mp 195-197° C.; ¹HNMR (500 MHz, DMSO-d₆) δ 6.76 (s, 1H), 5.89 (s, 1H), 3.78 (t, 2H, J=6.5Hz), 3.35 (m, 2H), 2.66 (m, 4H), 1.87 (m, 2H), 1.72 (m, 2H); (APCI+) m/z191.3 (M+H)

Example 112e3-Bromo-5-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)isonicotinaldehyde112e

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (15 mL),3,5-dibromoisonicotinaldehyde (400 mg, 1.5 mmol), 112d (142 mg, 0.76mmol) and cesium carbonate (176 mg, 1.5 mmol). Xantphos (40 mg, 0.08mmol) and Pd₂(dba)₃ (70 mg, 0.08 mmol) were added, and the reactionmixture was heated at 100° C. for 5 h. After this time the reaction wascooled to room temperature and filtered. The filtrate was concentratedunder reduced pressure and the residue was purified on flash columneluting with DCM:MeOH (20:1) to afford 112e (200 mg, 70%). MS: [M+H]

Example 112f3-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-5-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)isonicotinaldehyde112f

A sealed tube was charged with 112e (200 mg, 0.53 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2(1H)-one101 l (240 mg, 0.51 mmol), PdCl₂(dppf) (42 mg, 0.05 mmol), K₃PO₄ (230mg, 1 mmol), and NaOAc (80 mg, 1 mmol) in CH₃CN (5 mL) and H₂O (1.5 mL).The system was evacuated and refilled with N₂. The reaction mixture washeated at 100° C. for 2 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by flash column chromatography elutingwith 10:1 of DCM/MeOH to afford 112f (138 mg, 40%) as a pale yellowsolid. MS: [M+H] 635.

Example 1122-(4-(Hydroxymethyl)-5-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1(2H)-one112

A mixture of 112f (130 mg, 0.20 mmol) and NaBH4 (20 mg, 0.5 mmol) inMeOH (5 mL) was stirred at 0° C. for 0.5 h. The mixture was quenchedwith water and extracted with EtOAc (5 mL×2). The combined EtOAc extractwas concentrated under reduced pressure and the residue was purifiedwith reverse-phase prep-HPLC to afford 112 (48 mg, 34%). LCMS:[M+H]:637. ¹H NMR (500 MHz, DMSO) δ 8.58 (s, 1H), 8.48 (s, 1H), 8.45 (s,1H), 8.39 (s, 1H), 7.86 (d, J=2.4, 1H), 7.37-7.36 (m, 2H), 7.23-7.21 (m,1H), 6.02 (s, 1H), 5.02 (s, 1H), 4.54 (t, J=6.5, 2H), 4.45 (t, J=5.5,2H), 4.36-4.35 (m, 2H), 4.00-3.79 (m, 4H), 3.59 (s, 3H), 3.43-3.41 (m,1H), 3.07-2.96 (m, 6H), 2.70 (t, J=6.0, 2H), 2.39-2.38 (m, 4H),1.92-1.90 (m, 2H), 1.75-1.73 (m, 2H).

Example 113a (3-Nitro-1H-pyrazol-5-yl)methanol 113a

A 3-L three-neck round-bottomed flask equipped with a mechanicalstirrer, addition funnel and nitrogen inlet was purged with nitrogen andcharged with 3-nitropyrazole-5-carboxylic acid (28.0 g, 178 mmol) andTHF (420 mL) and cooled to −5° C. using an ice/acetone bath. Borane-THFcomplex solution (1.0 M, 535 mL, 535 mmol) was added at a rate thatmaintained the internal reaction temperature below 5° C. After theaddition was complete the cooling bath was removed and the reaction wasstirred at room temperature for 18 h. After this time the reaction wascooled to −5° C. using an ice/acetone bath, water (70 mL) and 4Nhydrochloric acid (70 mL) was added and the reaction was stirred atreflux for 1 h in order to destroy the borane complex with pyrazole. Thereaction was cooled to room temperature and concentrated under reducedpressure to a volume of approximately 30 mL. Ethyl acetate (175 mL) wasadded and the mixture stirred for 15 min. The aqueous layer wasseparated and extracted with ethyl acetate (4×200 mL). The combinedorganic layers were washed with saturated aqueous sodium bicarbonate(2×50 mL), brine (50 mL) and dried over sodium sulfate, the drying agentwas removed by filtration, and the filtrate concentrated under reducedpressure to afford (3-nitro-1H-pyrazol-5-yl)methanol 113a in a 94% yield(24.0 g) as a light yellow solid: ¹H NMR (300 MHz, DMSO-d₆) δ 13.90 (brs, 1H), 6.87 (s, 1H), 5.58 (t, 1H, J=5.4 Hz), 4.53 (d, 2H, J=5.1 Hz); MS(ESI+) m/z 144.0 (M+H)

Example 113b (1-(2-Bromoethyl)-3-nitro-1H-pyrazol-5-yl)methanol 113b

A 1-L three-necked round-bottomed flask equipped with a mechanicalstirrer and thermoregulator was purged with nitrogen and charged with113a (25.0 g, 175 mmol), DMF (250 mL), and cesium carbonate (70.0 g, 215mmol) was heated at 104° C. for 5 min. The reaction mixture was thencooled to 0° C. using an ice/acetone bath and dibromoethane (329 g, 1.75mol) was added portionwise (no exotherm). The reaction was stirred at 0°C. for 1 then at room temperature for 4 h. After this time a solution ofKH₂PO4 (40 g) in water (400 mL) was added slowly. The reaction mixturestirred at room temperature for 30 min. Ethyl acetate (450 mL) was addedand the aqueous layer was separated and extracted with ethyl acetate(2×100 mL). The combined organic layers were washed with water (200 mL),brine (200 mL), dried over sodium sulfate, and the drying agent wasremoved by filtration. The filtrate was concentrated under reducedpressure to afford an 86% yield (37.5 g) of crude 113b as an orange oil:¹H NMR (300 MHz, CDCl₃) δ 6.85 (s, 1H), 4.82 (d, 2H, J=5.4 Hz), 4.66 (t,2H, J=6.3 Hz), 3.83 (t, 2H, J=6.3 Hz); MS (ESI+) m/z 249.9 (M+H).

Example 113c 1-(2-Bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole 113c

A 500-mL three-necked round-bottomed flask equipped with a magneticstirrer, nitrogen inlet and reflux condenser was purged with nitrogenand charged with 113b (37.0 g, 148 mmol) and chloroform (160 mL). Thereaction was cooled to −5° C. using an ice/acetone bath and phosphoroustribromide (40.0 g, 148 mmol) was added portionwise. The cooling bathwas removed and the reaction stirred at reflux for 2 h. After this time,the reaction was cooled to −5° C. and saturated aqueous sodiumbicarbonate (250 mL) was added until a pH of 8.5 was reached. Themixture was extracted with ethyl acetate (3×150 mL) and the combinedorganic layers were washed with saturated aqueous sodium carbonate (2×50mL), brine (75 mL), dried over sodium sulfate and the drying agent wasremoved by filtration. The filtrate was concentrated under reducedpressure to afford a yellow residue that was dissolved with gentleheating in methylene chloride (60 mL). Hexanes (approximately 20 mL) wasadded and the solution became cloudy. The mixture was heated until asolid precipitate formed, methylene chloride (9 mL) was added and thesolution became clear. The solution was left to cool to room temperatureand after 4 h the resulting crystals were collected by vacuumfiltration. The filter cake was washed with a ice cold 1:2 mixture ofmethylene chloride:hexanes (2×20 mL) to afford1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole (19.7 g). Thecombined filtrates were evaporated and the procedure was performed againto afford an additional 9.70 g of1-(2-bromoethyl)-5-(bromo-methyl)-3-nitro-1H-pyrazole. The solids werecombined and dried under high vacuum for 18 h to afford a 57% yield(26.0 g) of 1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole 113c aswhite crystals: mp 95-97° C.; ¹H NMR (300 MHz, CDCl₃) δ 6.93 (s, 1H),4.63 (t, 2H, J=6.0 Hz), 4.54 (s, 2H), 3.86 (t, 2H, J=6.0 Hz).

Example 113d 5-Methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine113d

A 1-L single-neck round-bottomed flask equipped with a magnetic stirrerand nitrogen inlet was charged with THF (350 mL), 113c (10.0 g, 32.2mmol), 2M methylamine solution in THF (113 mL, 225 mmol) and stirred atroom temperature for 72 h. After this time the reaction was concentratedto dryness under reduced pressure, and the resulting solid was stirredwith a mixture of ethyl acetate (75 mL) and 10% aqueous potassiumcarbonate (75 mL). The aqueous layer was separated and extracted withethyl acetate (2×75 mL). The combined organic extracts were washed with10% aqueous potassium carbonate (75 mL), followed by brine (50 mL) anddried over sodium sulfate. The drying agent was removed by filtration,and the filtrate concentrated under reduced pressure to afford 113d in97% yield (5.70 g) as a yellow solid: ¹H NMR (300 MHz, CDCl₃) δ 6.62 (s,1H), 4.28 (t, 2H, J=5.4 Hz), 3.67 (s, 2H), 2.95 (t, 2H, J=5.4 Hz), 2.52(s, 3H); MS (ESI+) m/z 183.0 (M+H)

Example 113e 5-Methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine113e

A 500-mL Parr reactor bottle was purged with nitrogen and charged with10% palladium on carbon (50% wet, 800 mg dry weight) and a solution of113d (4.00 g, 2.20 mmol) in ethanol (160 mL). The bottle was attached toParr hydrogenator, evacuated, charged with hydrogen gas to a pressure of45 psi and shaken for 2 h. After this time, the hydrogen was evacuated,and nitrogen was charged into the bottle. CELITE® 521 (1.0 g) was added,and the mixture was filtered through a pad of CELITE® 521. The filtercake was washed with ethanol (2×75 mL), and the combined filtrates wereconcentrated to dryness under reduced pressure to afford a 99% yield of113e (3.31 g) as an orange solid: ¹H NMR (300 MHz, CDCl₃) δ 5.34 (s,1H), 3.98 (t, 2H, J=5.4 Hz), 3.52 (s, 3H), 2.84 (t, 2H, J=5.7 Hz), 2.45(s, 3H); MS (ESI+) m/z 153.1 (M+H)

Example 113f5-Bromo-1-methyl-3-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridin-2(1H)-one113f

A sealed tube equipped with a magnetic stirrer was charged with 113e(1.02 g, 6.7 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (2.15 g, 8.1mmol), Pd₂(dba)₃ (610 mg, 0.67 mmol),2,2-bis(diphenylphosphino)-1,1-binaphthyl (775 mg, 1.34 mmol), cesiumcarbonate (4.37 g, 13.6 mmol), and 1,4-dioxane (30 mL). After threecycles of vacuum/argon flush, the mixture was heated at 110° C. for 2 h.It was then filtered and the filtrate was evaporated in vacuo. Theresidue was purified by silica gel column chromatography eluting withdichloromethane/methanol (15:1, V/V) to afford 113f (380 mg, 14%) as awhite solid. LCMS: [M+H]⁺ 338

Example 113g2-(4-chloro-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one113g

To a solution of4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde103b (1.0 g, 3.0 mmol) in methanol (50 mL) was added sodium borohydride(380 mg, 9.0 mmol) at 10° C. and the mixture was stirred for another 30minutes. Then the reaction mixture was quenched with water (1 mL) andconcentrated. The residue was dissolved in dichloromethane (50 mL) andwashed with water (10 mL). The organic phase was dried over anhydrousNa₂SO₄, filtered, and evaporated under reduced pressure to afford 113gas a yellow solid (900 mg, 90%). MS: [M+H]⁺ 332.

Example 113h(4-Chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridine-3-yl)methylacetate 113h

To a mixture of 113g (900 mg, 2.7 mol) and triethylamine (900 mg, 9.0mol) in dichloromethane (5 mL) was added dropwise acetyl chloride (600mg, 6.0 mol) while stirring at room temperature and stirred for another1 h. The reaction mixture was concentrated and purified by silica-gelcolumn chromatography eluting with dichloromethane to afford 113h aswhite solid (950 mg, 94%). MS: [M+H]⁺ 374.

Example 113i(2-(1-Oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 113i

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 113h (950 mg, 2.5 mmol),Pin₂B₂ (1.6 g, 2.0 eq., 5 mmol), Pd₂(dba)₃ (230 mg, 0.1 eq., 0.25 mmol),X-phos (232 mg, 0.2 eq., 0.5 mmol), AcOK (735 mg, 3 eq., 7.5 mmol) anddioxane (20 mL). After three cycles of vacuum/argon flush, the mixturewas heated to 65° C. for 14 h. It was then cooled to room temperatureand filtered. The filtrate was concentrated under reduced pressure andthe resulting residue was washed by PE/EA=3/1 (10 mL) to afford 113i asyellow solid (950 mg, 87%). MS: [M+H] 383.

Example 113j(4-(1-Methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 113j

A sealed tube equipped with a magnetic stirrer was charged with 113f(190 mg, 0.56 mmol), 113i (215 mg, 0.56 mmol), Pd (dppf)Cl₂ (47 mg,0.056 mmol), 1.0 M NaOAc (93 mg, 1.12 mmol, 2.0 equiv), 1.0 M K₃PO₄ (240mg, 1.12 mmol, 2.0 equiv), and acetonitrile (3 mL). After three cyclesof vacuum/argon flush, the mixture was heated at 110° C. for 2 h. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified by silica gel column chromatography eluting withdichloromethane/methanol (10:1, V/V) to afford 113j (300 mg, 94%) as abrown solid. LCMS: [M+H] 597

Example 1132-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one113

A mixture of 113j (300 mg, 0.50 mmol) and LiOH.H₂O (120 mg, 2.50 mmol)in ^(i)PrOH/THF (1:1, 3 mL) and H₂O (1 mL) was stirred at 30° C. for 2h. The mixture was evaporated in vacuo and the residue was extractedwith EtOAc (10 mL×2). The combined EtOAc extract was concentrated underreduced pressure and the residue was purified with reverse-phaseprep-HPLC to afford 113 (91 mg, 32%) as a white solid. LCMS: [M+H] 555.¹H NMR (500 MHz, CDCl₃) δ 8.47 (d, J=5.0, 1H), 7.95 (d, J=5.0, 1H), 7.72(d, J=2.0, 1H), 7.42 (s, 1H), 7.35 (d, J=5.0, 1H), 6.89 (s, 1H), 5.69(s, 1H), 5.01-5.02 (m, 1H), 4.61-4.62 (m, 1H), 4.48-4.49 (m, 1H),4.32-4.33 (m, 1H), 4.15-4.07 (m, 4H), 3.86-3.87 (m, 1H), 3.69 (s, 3H),3.60-3.59 (m, 2H), 2.88 (t, J=6.0, 2H), 2.61-2.56 (m, 4H), 2.47 (s, 3H),1.89-1.90 (m, 2H), 1.78-1.79 (m, 2H)

Example 114a(R)-5-bromo-3-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-1-methylpyrazin-2(1H)-one114a

A sealed tube equipped with a magnetic stirrer was charged with(R)-3-(4-aminophenyl)-1,4-dimethylpiperazin-2-one (1.08 g, 5 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (1.47 g, 5.5 mmol),diisopropylethylamine (1.94 g, 15 mmol), and ^(i)PrOH (20 mL). Afterthree cycles of vacuum/argon flush, the mixture was heated at 110° C.overnight. After cooling down to room temperature, water (20 mL) wasadded to, and the mixture was extracted with ethyl acetate (50 mL×2).The organic layer was separated, combined, dried over anhydrous sodiumsulfate, and concentrated. The resulting residue was purified by silicagel column chromatography eluting with dichloromethane/methanol (10:1,UV) to afford 114a (1.8 g, 90%) as a red solid. LCMS: [M+H]⁺ 406

Example 114b(R)-(4-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 114b

A sealed tube equipped with a magnetic stirrer was charged with 114a(228 mg, 0.56 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (215 mg, 0.56 mmol), Pd (dppf)Cl₂ (47 mg, 0.056 mmol), 1.0 MNaOAc (93 mg, 1.12 mmol, 2.0 equiv), 1.0 M K₃PO₄ (240 mg, 1.12 mmol, 2.0equiv), and acetonitrile (3 mL). After three cycles of vacuum/argonflush, the mixture was heated at 110° C. for 2 h. It was then filteredand the filtrate was evaporated in vacuo. The residue was purified bysilica gel column chromatography eluting with dichloromethane/methanol(10:1, V/V) to 114b (360 mg, 96%) as a brown solid. LCMS: [M+H] 665.

Example 114(R)-2-(4-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one114

A mixture of 114b (360 mg, 0.54 mmol) and LiOH.H₂O (138 mg, 2.76 mmol)in ^(i)PrOH/THF (1:1, 3 mL) and H₂O (1 mL) was stirred at 30° C. for 2h. The mixture was evaporated in vacuo and the residue was extractedwith EtOAc (10 mL×2). The combined EtOAc extract was concentrated underreduced pressure and the residue was purified with reverse-phaseprep-HPLC to afford 114 (72 mg, 21%) as a white solid. LCMS: [M+H] 623.¹H NMR (500 MHz, CDCl₃) δ 8.53 (d, J=4.5, 1H), 8.31 (s, 1H), 8.10 (s,1H), 7.83-7.78 (m, 3H), 7.36 (d, J=8.0, 2H), 6.89 (s, 1H), 5.12-5.14 (m,1H), 4.68-4.70 (m, 1H), 4.49-4.53 (m, 1H), 4.38-4.43 (m, 1H), 4.15-4.06(m, 2H), 3.89-3.90 (m, 1H), 3.72-3.73 (m, 2H), 3.65 (s, 3H), 3.21-3.22(m, 1H), 3.01-3.03 (m, 4H), 2.71-2.56 (m, 5H), 2.20 (s, 3H), 1.90-1.92(m, 2H), 1.79-1.80 (m, 2H)

Example 115a5-Bromo-1-methyl-3-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2(1H)-one 115a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (15 mL),5-methyl-1H-pyrazol-3-amine (1 g, 10 mmol) (1),3,5-dibromo-1-methylpyridin-2(1H)-one (4 g, 15 mmol) (2), and cesiumcarbonate (6.4 g, 20 mmol). Xantphos (400 mg, 0.8 mmol) and Pd₂(dba)₃(700 mg, 0.8 mmol) were added, and the reaction mixture was heated at100° C. for 5 h. After this time the reaction was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the residue was purified on flash column eluting withDCM:MeOH (20:1) to afford 115a (1.0 g, 35%). MS: [M+H] 283.

Example 115b4-(1-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde115b

A sealed tube was charged with 115a (280 mg, 1 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (420 mg, 1.1 mmol), PdCl₂(dppf) (41 mg, 0.056 mmol), K₃PO₄(100 mg), and NaOAc (50 mg) in CH₃CN (10 mL) and H₂O (3 mL). The systemwas evacuated and refilled with N₂. The reaction mixture was heated at100° C. for 2 h. It was then cooled to room temperature and filtered.The filtrate was concentrated under reduced pressure and the resultingresidue was purified by flash column chromatography eluting with 10:1 ofDCM/MeOH to afford 115b in 35% yield (190 mg) as a pale yellow solid.MS: [M+H] 542.

Example 1152-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one115

A 100-mL single-neck round-bottomed flask was charged with 115b (190 mg,0.35 mol) in THF/iPA/H₂O (5 mL/5 mL/2 mL) and LiOH (85 mg, 3.5 mmol)while stirring. This mixture was stirred at 50° C. for 0.5 h. Then 20 mLH₂O was added and the mixture was extracted with EA (30 mL×3). Thecombined organic layer was dried over Na₂SO₄ and concentrated to give ayellow solid, which was further purified by reverse-phase prep-HPLC toafford 115 as a white solid (48 mg, 30% yield). LCMS: [M+H] 500. ¹H NMR(500 MHz, CDCl₃) δ 8.44 (d, J=6.0, 1H), 7.95 (s, 1H), 7.69 (s, 1H), 7.44(s, 1H), 7.30 (d, J=6.0, 2H), 6.87 (s, 1H), 5.74 (s, 1H), 4.59-3.86 (m,7H), 3.69 (s, 3H), 2.57-2.56 (m, 4H), 2.25 (s, 3H) 1.88-1.77 (m, 4H)

Example 116a3-Bromo-5-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-4-carbaldehyde116a

To a 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (15 mL),3,5-dibromoisonicotinaldehyde (200 mg, 0.76 mmol),8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-6-one191d (160 mg, 0.76 mmol), and cesium carbonate (176 mg, 1.5 mmol).Cuprous iodide CuI (100 mg, 0.76 mmol) and4,7-dimethoxy-1,10-phenanthroline (127 mg, 0.52 mmol) were added, andthe reaction mixture was heated at 100° C. for 5 h. After this time thereaction was cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the residue was purified onflash column eluting with EtOAC/PE (1:2) to afford 116a (80 mg, 30%).MS: [M+H] 390.

Example 116b3-[1-Methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-4-carbaldehyde116b

A sealed tube was charged with 116a (80 mg, 0.20 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101 l (96 mg, 0.20 mmol), PdCl₂(dppf) (18 mg, 0.02 mmol), K₃PO₄ (30 mg),and NaOAc (20 mg) in CH₃CN (5 mL) and H₂O (1 mL). The system wasevacuated and refilled with N₂. The reaction mixture was heated at 100°C. for 2 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by flash column chromatography eluting with 10:1 ofDCM/MeOH to afford 116b in 35% yield (46 mg). MS: [M+H] 651.

Example 1164-Hydroxymethyl-3-[1-methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-5-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine116

To a solution of 116b (46 mg, 0.07 mmol) at 0° C. in methanol (4 mL) wasadded sodium borohydride (20 mg, 0.7 mmol) and stirred for 30 minutes.Then the reaction mixture was quenched with water (1.0 mL) andconcentrated. The residue was purified by reverse-phase prep-HPLC toafford 116 (12 mg, 28%) as a yellow solid. LCMS: [M+H]⁺ 653. ¹H NMR (500MHz, DMSO) δ 8.60 (s, 1H), 8.59 (s, 1H), 8.56 (d, J=2.0, 1H), 8.50 (s,1H), 8.44 (s, 1H), 7.87 (d, J=3.0, 1H), 7.38-7.36 (m, 2H), 7.24-7.22 (m,1H), 4.90 (m, 1H), 4.56-4.53 (m, 2H), 4.46-4.44 (m, 4H), 3.59 (s, 3H),3.44-3.42 (m, 1H), 3.06 (t, J=4.5, 4H), 2.94-2.93 (m, 2H), 2.85-2.84 (m,2H), 2.38 (t, J=4.0, 4H), 1.89-1.84 (m, 4H)

Example 117a 5-(Methylthio)-2-nitropyridine 117a

To a mixture of 5-chloro-2-nitropyridine (3 g, 18 mmol) in MeOH (20 mL),sodium methanethiolate (1.4 g, 20 mmol) was added at 0° C. and themixture stirred at 20° C. for 2 hours. The resulting suspension wasfiltered and washed with water, and dried in vacuum to afford crude 117aas a yellow solid (2 g, 66%) without purification for next step. MS:[M+H]⁺ 171.

Example 117b 5-(Methylsulfonyl)-2-nitropyridine 117b

To a mixture of 117a (260 mg, 0.5 mmol) in acetic acid (15 mL) was addedH₂O₂ (aq. 30%) (7.5 mL) and the reaction mixture was stirred overnightat 25° C. The reaction solution was poured into water and extracted withEtOAC and concentrated to a pale yellow liquid, purified by silica gelwith (EtOAC/PE:1:3) to give 117b (2 g, 86%). MS: [M+H]⁺ 203.

Example 117c 5-(Methylsulfonyl)pyridin-2-amine 117c

A mixture of 117b (2 g, 10 mmol), MeOH (10 mL), Pd/C (120 mg) inmethanol (8 mL) was stirred fat 25° C. under H₂ (50 Psi) overnight. ThePd/C was removed by filtration and the filtrate was concentrated underreduced pressure to give 117c (1.7 g, 98%). MS: [M+H]⁺ 173.

Example 117d5-Bromo-1-methyl-3-(5-(methylsulfonyl)pyridin-2-ylamino)pyridin-2(1H)-one117d

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (15 mL), 117c(1.7 g, 10 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (5.2 g, 20 mmol)and cesium carbonate (6.4 g, 20 mmol). Xantphos (300 mg, 0.8 mmol) andPd₂(dba)₃ (500 mg, 0.8 mmol) were added, and the reaction mixture washeated at 100° C. for 5 h (hours). After this time the reaction wascooled to room temperature. The mixture was removed by filtration andthe filtrate was concentrated under reduced pressure. The residue waspurified on flash column eluting with DCM:MeOH (20:1) to afford 117d (1g, 30%). MS: [M+H] 358.

Example 117e(4-(1-Methyl-5-(5-(methylsulfonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridine-3-yl)methylacetate 117e

A sealed tube was charged with 117d (100 mg, 0.28 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (115 mg, 0.3 mmol), PdCl₂(dppf) (25 mg, 0.03 mmol), K₃PO₄ (126mg, 0.6 mmol), and NaOAc (60 mg, 0.6 mmol) in MeCN (8 mL) and H₂O (1mL). The system was evacuated and refilled with N₂. The reaction mixturewas heated at 100° C. for 2 h. It was then cooled to room temperatureand filtered. The filtrate was concentrated under reduced pressure andthe resulting residue was purified by silica gel flash column elutingwith DCM:MeOH (20:1) to afford 117e (100 mg, 40%). MS: [M+H]⁺ 617.

Example 1172-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(methylsulfonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydro-pyrazino[1,2-a]indol-1(2H)-one117

A 100-mL single-neck round-bottomed flask compound was charged with 117e(100 mg, 0.2 mol) in THF/iPA/H₂O (5 mL/5 mL/2 mL) and LiOH (50 mg, 2mmol) while stirring. This mixture was stirred at 50° C. for 0.5 h. Then20 mL H₂O was added and the mixture was extracted with EA (30 mL×3). Thecombined organic layer was dried over Na₂SO₄ and concentrated to give ayellow solid, which was further purified by reverse-phase prep-HPLC toafford 117 as a white solid (72 mg, 90% yield). MS: [M+H]⁺ 575. ¹H NMR(500 MHz, CDCl3) δ 9.39 (s, 1H), 8.84 (d, J=2.0, 1H), 8.60 (d, J=2.5,1H), 8.50 (d, J=2.5, 1H), 7.98 (dd, J=2.5, 4.0, 1H), 7.69 (d, J=2.4,1H), 7.49-7.47 (d, J=9.0, 1H), 7.38-7.37 (m, 1H), 6.58 (s, 1H), 4.99 (t,J=4.5, 1H), 4.47-4.39 (m, 2H), 4.26-4.11 (m, 3H), 3.88-3.86 (m, 1H),3.62 (s, 3H), 3.19 (s, 3H), 2.66-2.54 (m, 2H), 2.48-2.46 (m, 2H),1.79-1.66 (m, 4H)

Example 118a tert-Butyl 5-Amino-3-cyclopropyl-1H-pyrazole-1-carboxylate118a

To a mixture of 3-cyclopropyl-1H-pyrazol-5-amine (0.25 g, 2 mmol) andK₂CO₃ (0.828 g, 6 mmol) in THF (5 mL) was added (Boc)₂O (0.436 g, 2mmol) in THF (5 mL). The reaction mixture was stirred at roomtemperature for 15 h. It was then filtered and concentrated. The residuewas purified by flash column eluting with 6:1 petroleum ether/ethylacetate to afford 118a as a white solid (240 mg, 54%). LCMS: (M-Boc)⁺124.

Example 118b5-Bromo-3-(3-cyclopropyl-1H-pyrazol-5-ylamino)-1-methylpyridin-2(1H)-one118b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (15 mL), 118a(455 mg, 1.95 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (0.40 g, 1.5mmol), and cesium carbonate (1.22 g, 3.75 mmol). After bubbling nitrogenthrough the resulting mixture for 30 minutes, XantPhos (87 mg, 0.15mmol) and tris(dibenzylideneacetone)dipalladium(0) (70 mg, 0.075 mmol)were added, and the reaction mixture was heated at reflux for 15 h.After this time the reaction was cooled to room temperature, partitionedbetween ethyl acetate (30 mL) and water (30 mL). The aqueous layer wasseparated and extracted with ethyl acetate (50 mL×2). The organic layerswere combined, washed with brine (50 mL) and dried over sodium sulfate.The drying agent was removed by filtration and the filtrate wasconcentrated under reduced pressure. The residue was purified on flashcolumn eluting with 50:1 DCM/MeOH to afford 118b as a yellow solid (320mg, 50%). LCMS: (M+H)⁺ 309. ¹H NMR (500 MHz, DMSO) δ 11.85 (s, 1H), 8.23(s, 1H), 8.02 (d, J=2.5, 1H), 7.35 (d, J=2.5, 1H), 5.77 (d, J=2, 1H),3.46 (s, 3H), 1.83 (m, 1H), 0.90 (m, 2H), 0.64 (m, 2H)

Example 118c(4-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridine-3-yl)methylacetate 118c

A sealed tube equipped with a magnetic stirrer was charged with 118b(310 mg, 1 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridine-4-ylboronicacid 113i (385 mg, 1 mmol), Pd(dppf)Cl₂ (80 mg, 0.1 mmol), K₃PO₄ (424mg, 2 mmol), NaOAc (165 mg, 2 mmol), CH₃CN (15 mL), and water (1 mL).After three cycles of vacuum/argon flush, the mixture was heated at 110°C. for 3 h. It was evaporated in vacuo. The residue was purified bysilica gel column chromatography eluting with dichloromethane/methanol(50:1, V/V) to afford 118c (400 mg, 68%) as a yellow solid. LCMS: [M+H]⁺569

Example 1182-(4-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one118

A mixture of 118c (350 mg, 0.62 mmol) and LiOH.H₂O (260 mg, 6.2 mmol) in^(i)PrOH/THF (1:1, 3 mL) and H₂O (1 mL) was stirred at 30° C. for 1 h.The mixture was evaporated in vacuo and the residue was extracted withEtOAc (10 mL×2). The combined EtOAc extract was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 118 (200 mg, 54%) as a white solid. LCMS: [M+H] 526. ¹H NMR(500 MHz, DMSO) δ 11.83 (s, 1H), 8.48 (d, J=5, 1H), 8.05 (d, J=2, 1H),8.03 (s, 1H), 7.38 (d, J=2, 1H), 7.31 (d, J=5, 1H), 6.58 (s, 1H), 5.81(d, J=2, 1H), 4.95 (t, J=5, 1H), 4.49-4.51 (m, 1H), 4.38-4.40 (m, 1H),4.19-4.21 (m, 3H), 3.85-3.87 (m, 1H), 3.58 (s, 3H), 2.61-2.62 (m, 1H),2.56-2.57 (m, 1H), 2.48-2.49 (m, 2H), 1.81-1.82 (m, 3H), 1.70-1.71 (m,2H), 0.88-0.89 (m, 2H), 0.63-0.64 (m, 2H)

Example 119a(S)-(4-(1-Methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 119a

Following the procedures as described for 118c,(2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 113i (250 mg) and(S)-5-bromo-1-methyl-3-(3-methyl-5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one130e (233 mg) were reacted to give 119a as a yellow solid (230 mg, 62%).LCMS: [M+H] 693

Example 119(S)-2-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one119

Following the procedures as described for 118, acetate hydrolysis of119a with LiOH.H₂O in ^(i)PrOH/THF (1:1) and H₂O, gave 119 as a whitesolid (184 mg, 85%). LCMS: [M+H]⁺ 651. ¹H NMR (500 MHz, CDCl₃) δ 8.65(d, J=2.5, 1H), 8.50 (d, J=5.0, 1H), 7.99 (s, 1H), 7.87 (s, 1H), 7.84(d, J=2.0, 1H), 7.35 (d, J=5.0, 1H), 7.33 (d, J=7.0, 1H), 6.90 (s, 1H),6.83 (d, J=9.0, 1H), 5.04-5.06 (m, 1H), 4.62-4.73 (m, 5H), 4.51 (s, 1H),4.32 (s, 1H), 4.16 (s, 1H), 4.11 (s, 1H), 3.89 (s, 1H), 3.72 (s, 3H),3.57 (t, J=6.0, 1H), 3.48 (s, 1H), 3.07-3.12 (m, 2H), 2.53-2.63 (m, 7H),2.24 (m, 1H), 1.88-1.93 (m, 2H), 1.80 (s, 2H), 0.99 (d, J=6.5, 3H).

Example 120a5-Bromo-3-(5-(4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one120a

A sealed tube equipped with a magnetic stirrer was charged with5-bromo-1-methyl-3-(5-(piperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one101j (500 mg, 1.37 mmol), 2,2-dimethyloxirane (990 mg, 13.7 mmol),Cs₂CO₃ (1.3 g, 4.11 mmol), and CH₃CN (15 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 110° C. for 15 h. It wasthen filtered and the filtrate was evaporated in vacuum. Crude 120a thusobtained was used in the next step without further purification (460 mg,77%). LCMS: [M+H]⁺ 437.

Example 120b(4-(5-(5-(4-(2-Hydroxy-2-methylpropyl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 120b

Following the procedures as described for preparation of 118c, reactionof 120a (435 mg, 1.0 mmol) and3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (383 mg, 1 mmol) gave 120b (437 mg, 63%). LCMS: [M+H]⁺ 696.

Example 1202-(4-(5-(5-(4-(2-Hydroxy-2-methylpropyl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one120

Following the procedures as described for the preparation of 118,acetate hydrolysis of 120b (70 mg, 0.1 mmol) with LiOH.H₂O in^(i)PrOH/THF (1:1) and H₂O, gave 120 (27 mg, 42%) as a gray solid. LCMS:[M+H] 653. ¹H NMR (500 MHz, DMSO-d6) δ 8.61 (d, J=3, 1H), 8.50 (d, J=5,1H), 8.41 (s, 1H), 7.83 (d, J=3, 1H), 7.46 (d, J=2, 1H), 7.36 (m, 2H),7.24 (d, J=9, 1H), 6.58 (s, 1H), 4.95 (m, 1H), 4.44 (m, 2H), 4.24 (m,2H), 4.13 (m, 2H), 3.87-3.88 (m, 1H), 3.60 (s, 3H), 3.03-3.05 (m, 4H),2.64-2.66 (m, 5H), 2.61-2.63 (m, 1H), 2.49-2.51 (m, 2H), 2.24 (s, 2H),1.70-1.71 (m, 4H), 1.10 (s, 6H).

Example 121a4-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde121a

A flask was charged with4-chloro-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde103b (88 mg, 0.27 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101 l (125 mg, 0.27 mmol), PdCl₂(dppf) (18 mg, 0.02 mmol), K₃PO₄ (30mg), in THF (5 mL) and H₂O (1 mL). The system was evacuated and refilledwith N₂. The reaction mixture was refluxed for 4 h, and then cooled toroom temperature. It was then filtered and the filtrate was concentratedunder reduced pressure. The resulting residue was purified by flashcolumn chromatography eluting with 10:1 of DCM/MeOH to afford 121a (90mg, 56%) as a yellow solid. MS: [M+H] 633.

Example 1212-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridine-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1(2H)-one121

At 0° C., to a suspension of 121a (76 mg, 0.12 mmol) in methanol (4 mL)was added sodium borohydride (20 mg, 0.7 mmol) and stirred for 30minutes. Then the reaction mixture was quenched with water (1.0 mL) andconcentrated. The residue was purified by reverse-phase prep-HPLC toafford 121 (56 mg, 74%). LCMS: [M+H] 635. ¹H NMR (500 MHz, DMSO) δ 8.66(d, J=2.0, 1H), 8.57 (d, J=5.0, 1H), 7.93 (d, J=3.0, 1H), 7.85 (d,J=2.5, 1H), 7.80 (s, 1H), 7.50 (d, J=5.0, 1H), 7.24-7.27 (m, 1H), 7.06(s, 1H), 6.97 (d, J=6.0, 1H), 6.81 (d, J=8.0, 1H), 6.67 (d, J=6.0, 1H),5.08 (d, J=11.5, 1H), 4.67-4.72 (m, 4H), 4.51 (d, J=12.0, 1H), 4.35 (t,J=12.0, 1H), 3.72 (s, 3H), 3.57-3.59 (m, 1H), 3.16-3.17 (m, 4H),2.70-2.74 (m, 4H), 2.52-2.53 (m, 4H), 1.94-1.95 (m, 2H), 1.84-1.86 (m,2H).

Example 122a (2R,5S)-tert-Butyl2,5-Dimethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 122a

Following the procedures as described for compound 101g,(2R,5S)-tert-butyl-2,5-dimethylpiperazine-1-carboxylate (1.5 g, 6.0mmol), and 5-bromo-2-nitropyridine (1212 mg, 6.0 mmol) were reacted togive 122a as a yellow solid (1500 mg, 75%). LCMS: [M+H]⁺ 337

Example 122b (2R,5S)-tert-Butyl4-(6-Aminopyridin-3-yl)-2,5-dimethylpiperazine-1-carboxylate 122b

Following the procedures as described for compound 101h, reaction of122a (1.5 g, 4.46 mmol) afforded 122b as a yellow solid (1130 mg, 83%).LCMS: [M+H]⁺ 307

Example 122c (2R,5S)-tert Butyl4-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridin-3-yl)-2,5-dimethylpiperazine-1-carboxylate122c

Following the procedures as described for compound 101i, reaction of122b (766 mg, 2.50 mmol) and 3,5-dibromo-1-methylpyridin-2(1H)-one (668mg, 2.50 mmol) afforded 122c as a yellow solid (978 mg, 79%). LCMS:[M+H]⁺ 492

Example 122d (2R,5S)-tert-Butyl4-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridin-3-yl)-2,5-dimethylpiperazine-1-carboxylate122d

Following the procedures as described for compound 101j, reaction of122c (978 mg, 1.99 mmol) gave 122d as a yellow solid (700 mg, 90%).LCMS: [M+H]⁺ 392

Example 122e5-Bromo-3-(5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one122e

Following the procedures as described for compound 101k, reaction of122d (700 mg, 1.79 mmol), afforded 122e as a yellow solid (723 mg, 91%).LCMS: [M+H]⁺ 448

Example 122f(4-(5-(5-((2S,5R)-2,5-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 122f

Following the procedures as described for compound 113j, reaction of122e (723 mg, 1.62 mmol) and3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (613 mg, 1.62 mmol) afforded 122f as a yellow solid (464 mg,41%). LCMS: [M+H]⁺ 707

Example 1222-(4-(5-(5-((2S,5R)-2,5-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one122

Following the procedures as described for compound 113, hydrolysis of122f (464 mg, 0.66 mmol) with lithium hydroxide afforded 122 as a whitesolid (83 mg, 20%). LCMS: [M+H]⁺ 665. ¹H NMR (500 MHz, CDCl₃) δ 8.69 (d,J=2.5, 1H), 8.51 (d, J=5.0, 1H), 8.03 (d, J=2.5, 1H), 7.88 (s, 1H), 7.86(d, J=2.5, 1H), 7.38 (d, J=5.0, 2H), 6.90 (s, 1H), 6.82 (d, J=9.0, 1H),5.07 (s, 1H), 4.77-4.72 (m, 2H), 4.68-4.61 (m, 3H), 4.52 (s, 1H), 4.33(s, 1H), 4.17-4.11 (m, 2H), 3.88 (s, 1H), 3.76 (s, 1H), 3.73 (s, 3H),3.19 (s, 1H), 2.93-2.90 (m, 1H), 2.73 (s, 2H), 2.63-2.57 (m, 4H), 2.48(s, 1H), 1.99-1.90 (m, 3H), 1.80 (s, 2H), 0.91 (t, J=5.5, 6H)

Example 123a (2-Bromoethoxy)(tert-butyl)dimethylsilane 123a

To a solution of 2-bromoethanol (5.0 g, 40.3 mmol) in DCM (20 mL) wasadded tert-butyldimethylsilyl chloride (9.1 g, 60.5 mmol) followed bythe additions of triethylamine (8.14 g, 80.6 mmol) and4-dimethylaminopyridine (49.2 mg, 0.4 mmol). The mixture was stirred atroom temperature for 15 h and concentrated in vacuo. The residue waspartitioned between 1N HCl and ethyl acetate. The aqueous portion wasextracted with ethyl acetate. The combined organic portion was washedwith brine, dried over sodium sulfate, filtered and concentrated invacuo to afford yellow oil, which was purified by column chromatographyeluting with PE:EA (50:1) to afford 123a as colorless oil (6.0 g,62.4%). LCMS: (M+H)⁺ 241.

Example 123b5-Bromo-3-(5-(4-(2-(tert-butyldimethylsilyloxy)ethyl)piperazin-1-yl)pyridine-2-ylamino)-1-methylpyridin-2(1H)-one123b

To a suspension of 123a (231 mg, 0.96 mmol) in MeCN (40 mL) at 70° C.was added5-bromo-1-methyl-3-(5-(piperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one101j (350 mg, 0.96 mmol). The reaction mixture was stirred for 3 days.It was then filtered and the filtrate was concentrated under reducedpressure. The resulting residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (30:1) to afford123b as yellow solid (452 mg, 90%). MS: [M+H]⁺ 524.7.

Example 123c5-Bromo-3-(5-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one123c

To a suspension of 123b (300 mg, 0.57 mmol) at room temperature in MeOH(20 mL) was added L(−)-camphorsulfonic acid (199 mg, 0.86 mmol). Thereaction mixture was stirred overnight. Water (20 mL) was added and themixture was extracted with ethyl acetate (50 mL×2). The combined organiclayer was dried over anhydrous sodium sulfate and concentrated to afford123c (325 mg, 95%) as a yellow solid. MS: [M+H]⁺ 408.7.

Example 123d (4-(5-(5-(4-(2-Hydroxyethyl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 123d

A sealed tube was charged with 123c (200 mg, 0.49 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid (113i) (188 mg, 0.49 mmol), Pd(dppf)Cl₂ (40 mg, 0.049 mmol), K₃PO₄(208 mg, 0.98 mmol), NaOAc (133 mg, 0.98 mmol), H₂O (3 mL), and MeCN (50mL). The mixture was heated at 110° for 3 h. The solvent was evaporatedin vacuo and the residue was purified by silica gel chromatographyeluting with 30:1 DCM/MeOH to 123d (187 mg, 57%). MS: [M+H]⁺ 667.7.

Example 1232-(4-(5-(5-(4-(2-Hydroxyethyl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydro-pyrazino[1,2-a]indol-1(2H)-one123

A mixture of 123d (187 mg, 0.28 mmol) and LiOH (235 mg, 5.6 mmol) iniPrOH/THF (1:1, 3.5 mL) and H₂O (0.5 mL) was stirred at 35° C. for 0.5h. It was then evaporated in vacuo and the residue was extracted withEtOAc (5 mL×2). The combined EtOAc extract was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 123 (40 mg, 31%) as a yellow solid. MS: [M+H]⁺ 625.4. ¹H NMR(500 MHz, CDCl₃) δ 8.63 (d, J=2.5, 1H), 8.49 (d, J=5.0, 1H), 7.92 (d,J=2.5, 1H), 7.82 (d, J=2.0, 1H), 7.78 (s, 1H), 7.36 (d, J=5.5, 1H),7.27-7.25 (m, 1H), 6.89 (s, 1H), 6.81 (d, J=9.5, 1H), 5.04-5.02 (m, 1H),4.62 (d, J=10, 1H), 4.50-4.47 (m, 1H), 4.34-4.29 (m, 1H), 4.12-4.09 (m,2H), 3.89-3.85 (m, 1H), 3.71-3.67 (m, 5H), 3.15-3.12 (m, 4H), 2.74-2.54(m, 10H), 1.92-1.87 (m, 2H), 1.79-1.78 (m, 3H)

Example 124a4-Chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a

To a suspension of 2-bromo-4-chloronicotinaldehyde 103a (641 mg, 2.9mmol) and8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-6-one191d (400 mg, 1.94 mmol) in dioxane (20 mL) was added K₂CO₃ (536 mg,3.88 mmol), CuI (369 mg, 1.94 mmol), and4,7-dimethoxy-1,10-phenanthroline (471 mg, 1.96 mmol). After bubblingnitrogen through the resulting solution for 30 min, the mixture wasstirred at 80° C. for 16 h. It was allowed to cool to room temperatureand added into H₂O (100 mL). The aqueous layer was separated andextracted with ethyl acetate (2×200 mL). The combined organic layer waswashed with brine (100 mL) and dried over sodium sulfate. The dryingagent was removed by filtration and the filtrate was concentrated underreduced pressure. The residue was purified on flash column eluting withPE:EA (5:1) to afford 124a (230 mg, 34%). LCMS: [M+H]⁺ 346

Example 124b4-[1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124b

A round bottom flask was charged with 124a,1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101 l (271 mg, 0.58 mmol), PdCl₂(dppf) (50 mg, 0.06 mmol), K₃PO₄.3H₂O(323 mg, 1.16 mmol), THF (15 mL), and H₂O (5 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 70° C. for 2 h. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified on flash column chromatography eluting with 1:3 petroleum/ethylacetate to afford 124b as a yellow solid (200 mg, 53%). LCMS: [M+H]⁺ 651

Example 1243-Hydroxymethyl-4-[1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridine-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine124

A mixture of4-[1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124b (200 mg, 0.31 mmol), NaBH₄ (35 mg, 0.92 mmol) and CH₃OH (10 mL) wasstirred at 25° C. for 1 h. The mixture was then extracted with CH₂Cl₂(10 mL×2). The combined CH₂Cl₂ extract was concentrated under reducedpressure. The residue was purified with reverse-phase prep-HPLC toafford 124 (100 mg, 50%) as a yellow solid. LCMS: [M+H]⁺ 653. ¹H NMR(500 MHz, DMSO) δ 8.64 (d, J=2.0 Hz, 1H), 8.57 (d, J=5.0 Hz, 1H),8.46-8.48 (m, 2H), 7.88 (d, J=3.0 Hz, 1H), 7.54 (d, J=5.0 Hz, 1H), 7.48(d, J=2.5 Hz, 1H), 7.37-7.39 (m, 1H), 7.24 (d, J=9.0 Hz, 1H), 4.85-4.87(m, 1H), 4.55-4.57 (m, 2H), 4.45-4.47 (m, 2H), 3.67-4.39 (m, 2H), 3.60(s, 3H), 3.42-3.45 (m, 1H), 3.06-3.08 (m, 4H), 2.95 (s, 2H), 2.87 (s,2H), 2.38-2.40 (m, 4H), 1.87-1.89 (m, 4H).

Example 125a (3-Nitro-1H-pyrazol-5-yl)methanol 125a

A 3-L three-neck round-bottomed flask equipped with a mechanicalstirrer, addition funnel and nitrogen inlet was purged with nitrogen andcharged with 3-nitropyrazole-5-carboxylic acid (28.0 g, 178 mmol) andTHF (420 mL) and cooled to −5° C. using an ice/acetone bath. Borane-THFcomplex solution (1.0 M, 535 mL, 535 mmol) was added at a rate thatmaintained the internal reaction temperature below 5° C. After theaddition was complete the cooling bath was removed and the reaction wasstirred at room temperature for 18 h. After this time the reaction wascooled to −5° C. using an ice/acetone bath, water (70 mL) and 4Nhydrochloric acid (70 mL) was added and the reaction was stirred atreflux for 1 h in order to destroy the borane complex with pyrazole. Thereaction was cooled to room temperature and concentrated under reducedpressure to a volume of approximately 30 mL. Ethyl acetate (175 mL) wasadded and the mixture stirred for 15 min. The aqueous layer wasseparated and extracted with ethyl acetate (4×200 mL). The combinedorganic layers were washed with saturated aqueous sodium bicarbonate(2×50 mL), brine (50 mL) and dried over sodium sulfate, the drying agentwas removed by filtration, and the filtrate concentrated under reducedpressure to afford 125a in a 94% yield (24.0 g) as a light yellow solid:¹H NMR (300 MHz, DMSO-d₆) δ 13.90 (br s, 1H), 6.87 (s, 1H), 5.58 (t, 1H,J=5.4 Hz), 4.53 (d, 2H, J=5.1 Hz); MS (ESI+) m/z 144.0 (M+H)

Example 125b (1-(2-Bromoethyl)-3-nitro-1H-pyrazol-5-yl)methanol 125b

A 1-L three-necked round-bottomed flask equipped with a mechanicalstirrer and thermoregulator was purged with nitrogen and charged with125a (25.0 g, 175 mmol), DMF (250 mL), and cesium carbonate (70.0 g, 215mmol) was heated at 104° C. for 5 min. The reaction mixture was thencooled to 0° C. using an ice/acetone bath and dibromoethane (329 g, 1.75mol) was added portionwise (no exotherm). The reaction was stirred at 0°C. for 1 then at room temperature for 4 h. After this time a solution ofKH₂PO4 (40 g) in water (400 mL) was added slowly. The reaction mixturestirred at room temperature for 30 min. Ethyl acetate (450 mL) was addedand the aqueous layer was separated and extracted with ethyl acetate(2×100 mL). The combined organic layers were washed with water (200 mL),brine (200 mL), dried over sodium sulfate, and the drying agent wasremoved by filtration. The filtrate was concentrated under reducedpressure to afford an 86% yield (37.5 g) of crude 125b as an orange oil:¹H NMR (300 MHz, CDCl₃) δ 6.85 (s, 1H), 4.82 (d, 2H, J=5.4 Hz), 4.66 (t,2H, J=6.3 Hz), 3.83 (t, 2H, J=6.3 Hz); MS (ESI+) m/z 249.9 (M+H).

Example 125c 1-(2-Bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole 125c

A 500-mL three-necked round-bottomed flask equipped with a magneticstirrer, nitrogen inlet and reflux condenser was purged with nitrogenand charged with 125b (37.0 g, 148 mmol) and chloroform (160 mL). Thereaction was cooled to −5° C. using an ice/acetone bath and phosphoroustribromide (40.0 g, 148 mmol) was added portionwise. The cooling bathwas removed and the reaction stirred at reflux for 2 h. After this time,the reaction was cooled to −5° C. and saturated aqueous sodiumbicarbonate (250 mL) was added until a pH of 8.5 was reached. Themixture was extracted with ethyl acetate (3×150 mL) and the combinedorganic layers were washed with saturated aqueous sodium carbonate (2×50mL), brine (75 mL), dried over sodium sulfate and the drying agent wasremoved by filtration. The filtrate was concentrated under reducedpressure to afford a yellow residue that was dissolved with gentleheating in methylene chloride (60 mL). Hexanes (approximately 20 mL) wasadded and the solution became cloudy. The mixture was heated until asolid precipitate formed, methylene chloride (9 mL) was added and thesolution became clear. The solution was left to cool to room temperatureand after 4 h the resulting crystals were collected by in vacuumfiltration. The filter cake was washed with a ice cold 1:2 mixture ofmethylene chloride:hexanes (2×20 mL) to afford1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole (19.7 g). Thecombined filtrates were evaporated and the procedure was performed againto afford an additional 9.70 g of1-(2-bromoethyl)-5-(bromo-methyl)-3-nitro-1H-pyrazole. The solids werecombined and dried under high vacuum for 18 h to afford a 57% yield(26.0 g) of 125c as white crystals: mp 95-97° C.; ¹H NMR (300 MHz,CDCl₃) δ 6.93 (s, 1H), 4.63 (t, 2H, J=6.0 Hz), 4.54 (s, 2H), 3.86 (t,2H, J=6.0 Hz).

Example 125d 2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 125d

A sealed tube equipped with a magnetic stirrer was charged with 125c (4g, 12.9 mmol) 0.5M ammonia solution in dioxane (200 mL). The resultingmixture was carefully heated to 50° C. overnight. After this time, thereaction mixture was concentrated under reduced pressure, and to theresidue was added H₂O (50 mL) and EtOAc (50 mL). The aqueous layer wasseparated and extracted with EtOAc (2×50 mL). The combined organicextracts were washed with brine (100 mL) and dried over sodium sulfate.The resulting solution was concentrated under reduced pressure to afforda 100% yield (2.1 g) of crude 125d.

Example 125e1-(2-nitro-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethanone 125e

A 200 mL round bottom flask was charged with 125d (2.1 g, 12.9 mmol),triethylamine (5.5 mL, 38.7 mmol), acetyl chloride (1.1 mL, 15.5 mmol)and CH₂Cl₂ (100 mL). The mixture stirred at room temperature over night.After this time, the reaction mixture was concentrated under reducedpressure, and to the residue was added H₂O (50 mL) and EtOAc (50 mL).The aqueous layer was separated and extracted with EtOAc (2×50 mL). Thecombined organic extracts were washed with brine (100 mL). The combinedaqueous extracts were back extracted with 9:1 CH₂Cl₂:MeOH (2×50 mL). Thecombined organics were dried over sodium sulfate. The resulting residuewas purified by column chromatography eluting with a gradient ofCH₂Cl₂—9:1 CH₂Cl₂: MeOH to afford a 84% yield (2.3 g) of 125e.

Example 125f1-(2-amino-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethanone 125f

A 500-mL Parr hydrogenation bottle was charged with 125e (2.3 g, 10.9mmol), 10% palladium on carbon (50% wet, 570 mg dry weight) and ethanol(100 mL). The bottle was evacuated, charged with hydrogen gas to apressure of 50 psi and shaken for 2 h on a Parr hydrogenation apparatus.The catalyst was removed by filtration through a pad of CELITE® 521washing with 1:1 CH₂Cl₂:MeOH (500 mL). The resulting solution wasconcentrated under reduced pressure to afford a 95% yield (1.9 g) ofcrude 125f.

Example 125g3-(5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-bromo-1-methylpyridin-2(1H)-one125g

A sealed tube was equipped with a magnetic stirrer and charged with 125f(860 mg, 4.8 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (1.8 g, 6.7mmol), and cesium carbonate (3.4 g, 10.5 mmol) in 1,4-dioxane (67 mL).After bubbling nitrogen through the solution for 30 min, Xantphos (330mg, 0.6 mmol) and tris(dibenzylideneacetone) dipalladium(0) (300 mg, 0.3mmol) were added, and the reaction mixture was heated to 100° C. for 16h. After this time, H₂O (50 mL) and EtOAc (50 mL) were added. Theaqueous layer was separated and extracted with EtOAc (2×50 mL). Thecombined organic extracts were washed with brine (100 mL) and dried oversodium sulfate. The resulting residue was purified by columnchromatography eluting with a gradient of CH₂Cl₂—60:35:5CH₂Cl₂:Et₂O:MeOH to afford a 41% yield of 125g (720 mg).

Experiment 125h5-Bromo-1-methyl-3-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridin-2(1H)-one125h

A 50 mL round bottom flask with a magnetic stirrer and reflux condenserwas charged with 125g (250 mg, 0.7 mmol), aqueous NaOH (5N, 6 mL),ethanol (6 mL). The mixture stirred at reflux for 30 min. After thistime, ethyl acetate (5 mL) and water (5 mL) were added. The separatedaqueous layer was extracted with ethyl acetate (2×5 mL). The combinedorganics were washed with brine (10 mL), dried over sodium sulfate,filtered and concentrated under reduced pressure to afford a 91% yield(200 mg) of crude 125h.

Example 125i5-Bromo-1-methyl-3-(5-(oxetan-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridin-2(1H)-one125i

Compound 125i was synthesized using the same procedure as 101k, where5-bromo-1-methyl-3-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridin-2(1H)-one(125h) (250 mg, 0.78 mmol), and oxetan-3-one (600 mg, 8.3 mmol) inmethanol (8 mL) were mixed. Sodium cyanoborohydride (148 mg, 3 mmol) andzinc chloride (165 mg, 1.5 mmol) in methanol (8 mL) was added, and thereaction was heated at 48° C. for 12 hours. Work-up and flash columnchromatography (silica, 60:35:5 methylene chloride/diethylether/methanol) afford a 34% yield (100 mg) of5-bromo-1-methyl-3-(5-(oxetan-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridin-2(1H)-one(125i) as a light green solid: MS (ESI+) m/z 382.1 (M+H).

Example 125j(4-(1-Methyl-5-(5-(oxetan-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 125j

Following the procedures as described for compound 113j,3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (200 mg, 0.52 mmol) and 125i (198 mg, 0.52 mmol) were reactedto give 125j as a yellow solid (200 mg, 60%). LCMS: [M+H]⁺ 639

Example 1252-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(oxetan-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one125

Following the procedures as described in Example 123, 125j (200 mg 0.31mmol) was hydrolyzed by lithium hydroxide to give 125 as a white solid(116 mg, 62%). LCMS: [M+H]⁺ 597. ¹H NMR (500 MHz, CDCl₃) δ 8.48 (d,J=5.0, 1H), 7.95 (d, J=2.0, 1H), 7.69 (d, J=2.0, 1H), 7.43 (s, 1H), 7.34(d, J=5.5, 1H), 6.89 (s, 1H), 5.73 (s, 1H), 5.02 (t, J=6.5, 1H), 4.75(t, J=6.5, 2H), 4.67 (t, J=6.5, 2H), 4.61-4.63 (m, 1H), 4.50 (s, 1H),4.31-4.35 (m, 1H), 4.10-4.16 (m, 4H), 3.86-3.88 (m, 1H), 3.74-3.79 (m,1H), 3.70 (s, 3H), 3.56 (d, J=4.5, 2H), 2.82 (t, J=4.5, 2H), 2.50-2.62(m, 4H), 1.88-1.92 (m, 2H), 1.78-1.82 (m, 2H)

Example 126a3-Bromo-5-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)isonicotinaldehyde126a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (15 mL),3,5-dibromoisonicotinaldehyde (604 mg, 2.28 mmol),6,7,8,9-tetrahydropyrazino[1,2-a]indol-1(2H)-one (142 mg, 0.76 mmol) andcesium carbonate (485 mg, 1.5 mmol). CuI (143 mg, 0.76 mmol) and4,7-dimethoxy-1,10-phenanthroline (127 mg, 0.52 mmol) were added, andthe reaction mixture was heated at 100° C. for 5 h. After this time, thereaction was cooled to room temperature. It was then filtered and thefiltrate was concentrated under reduced pressure. The residue waspurified on flash column eluting with EtOAC/PE (1:2) to afford 126a (100mg, 35%) as a yellow solid. MS: [M+H]⁺ 372.

Example 126b3-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-5-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)isonicotinaldehyde126b

A sealed tube was charged with 126a (100 mg, 0.27 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101 l (125 mg, 0.27 mmol), PdCl₂(dppf) (18 mg, 0.02 mmol), K₃PO₄ (30mg), and NaOAc (20 mg) in CH₃CN (5 mL) and H₂O (1 mL). The system wasevacuated and refilled with N₂. The reaction mixture was heated at 100°C. for 2 h, and then cooled to room temperature. It was then filteredand the filtrate was concentrated under reduced pressure. The resultingresidue was purified by flash column chromatography eluting with 10:1 ofDCM/MeOH to afford 126b (80 mg, 48%) as a yellow solid. MS: [M+H] 633.

Example 1262-(4-(Hydroxymethyl)-5-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1(2H)-one126

To a suspension of 126b (76 mg, 0.12 mmol) at 0° C. in methanol (4 mL)was added sodium borohydride (20 mg, 0.7 mmol) and the mixture wasstirred for 30 minutes. Then the reaction mixture was quenched withwater (1.0 mL) and concentrated. The residue was purified byreverse-phase prep-HPLC to afford 126 (28 mg, 37%). LCMS: [M+H]⁺ 635. ¹HNMR (500 MHz, DMSO) δ 8.61 (d, J=2.5, 1H), 8.59 (s, 1H), 8.50 (s, 1H),8.43 (s, 1H), 7.86 (d, J=3.0, 1H), 7.38-7.36 (m, 2H), 7.27-7.22 (m, 2H),6.82-6.78 (m, 2H), 5.18-5.11 (m, 1H), 4.55 (t, J=6.0, 2H), 4.45 (t,J=6.0, 2H), 4.41-4.29 (m, 2H), 3.60 (s, 3H), 3.44-3.42 (m, 1H), 3.06 (t,J=4.5, 4H), 2.75-2.73 (m, 2H), 2.62-2.60 (m, 2H), 2.38 (t, J=4.5, 4H),1.86-1.75 (m, 4H).

Example 127a(4-(1-Methyl-6-oxo-5-(5-(piperazin-1-yl)pyridin-2-ylamino)-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 127a

A 100-mL single-neck round-bottomed flask equipped with magnetic stirrerand reflux condenser was charged with5-bromo-1-methyl-3-(5-(piperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one101j (200 mg, 0.55 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (210 mg, 0.55 mmol), Pd(dppf)Cl₂ (45 mg, 0.055 mmol), K₃PO₄(284 mg, 1.65 mmol), and tetrahydrofuran (20 mL). After three cycles ofvacuum/argon flush, the mixture was heated at reflux for 5 h. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting withdichloromethane/methanol (33:1) to afford 127a as a brown solid (200 mg,58.3%). MS: [M+H]⁺ 623.7.

Example 1272-(3-(Hydroxymethyl)-4-(1-methyl-6-oxo-5-(5-(piperazin-1-yl)pyridin-2-ylamino)-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one127

A mixture of 127a (190 mg, 0.31 mmol) and LiOH (571 mg, 13.6 mmol) in^(i)PrOH/THF (1:1, 3.5 mL) and H₂O (0.5 mL) was stirred at 35° C. for0.5 h. It was then evaporated in vacuo and the residue was extractedwith EtOAc (5 mL×2). The combined EtOAc extract was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 127 (50 mg, 26.9%). MS: [M+H]⁺ 581.3. ¹H NMR (500 MHz, CDCl₃)δ 8.63 (d, J=2.0, 1H), 8.49 (d, J=5.0, 1H), 7.91 (d, J=3.5, 1H), 7.82(d, J=2.0, 1H), 7.77 (s, 1H), 7.37 (d, J=5.0, 1H), 7.20-7.25 (m, 1H),6.89 (s, 1H), 6.81 (d, J=9.0, 1H), 5.04-5.02 (m, 1H), 4.64-4.61 (m, 1H),4.50 (d, J=5.0, 1H), 4.34-4.31 (m, 1H), 4.18-4.08 (m, 2H), 3.89-3.86 (m,1H), 3.71 (s, 3H), 3.05-3.06 (m, 8H), 2.62-2.56 (m, 4H), 1.92-1.88 (m,2H), 1.81-1.78 (m, 3H)

Example 128a5-Cyclopropyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 128a

A mixture of 1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole 113c(4 g, 12.9 mmol) and cyclopropanamine (7.35 g, 129 mmol) in THF (40 mL)was stirred at 30° C. overnight. After the completion of the reaction,the mixture was filtered and the solid was washed with THF (100 mL). Thefiltrate was concentrated under reduced pressure to give 128a (2.68 g,99%). MS: [M+H]⁺ 209.

Example 128b5-Cyclopropyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine 128b

A mixture of 128a (2.68 g, 12.9 mmol), Fe (3.6 g, 64.4 mmol) and NH₄Cl(4.1 g, 77.4 mmol) in ethanol (30 mL) and water (5 mL) was heated atreflux for 2 h. After the completion of the reaction, the mixture wasfiltered and the solid was washed with ethanol (150 mL). The filtratewas evaporated in vacuo and the residue was extracted withmethanol/methylene chloride (1/7). The combined extracts were dried overNa₂SO₄ and evaporated. The residue was purified on reverse phaseCombi-flash to give 128b (1.8 g, 75%). MS: [M+H]⁺ 179.

Example 128c5-Bromo-3-(5-cyclopropyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methylpyridin-2(1H)-one128c

A mixture of 128b (1.39 g, 7.8 mmol), XantPhos (450 mg, 0.78 mmol), Pd₂dba₃ (476 mg, 0.52 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (1.72 g,6.5 mmol) and Cs₂CO₃ (6.3 mg. 19.5 mmol) in 1,4-dioxane (30 mL) washeated at reflux for 1 h. After the completion of the reaction themixture was filtered off and the solid was washed with methanol (60 mL).The filtrate was evaporated in vacuo and the residue was purified onreverse phase Combi-flash to give 128c (0.84 g, 30%). MS: [M+H]⁺ 364.

Example 128d(4-(5-(5-Cyclopropyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydro-pyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 128d

Following the procedures as described in Example 113j, reaction of 128c(230 mg, 0.6 mmol) and3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (218 mg, 0.6 mmol) afforded 128d as a yellow solid (331 mg,89%). LCMS: [M+H]⁺ 623

Example 1282-(4-(5-(5-Cyclopropyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one128

Following the procedures as described in Example 113, 128d (331 mg, 0.53mmol) was hydrolyzed with lithium hydroxide afforded 128 as a whitesolid (54 mg, 20%). LCMS: [M+H]⁺ 581. ¹H NMR (500 MHz, CDCl₃) δ 8.48 (d,J=5.0, 1H), 7.93 (d, J=2.0, 1H), 7.72 (d, J=2.0, 1H), 7.40 (s, 1H), 7.34(d, J=5.0, 1H), 6.90 (s, 1H), 5.70 (s, 1H), 5.03-5.02 (m, 1H), 4.64-4.62(m, 1H), 4.52 (s, 1H), 4.32 (s, 1H), 4.16-4.03 (m, 4H), 3.89-3.87 (m,1H), 3.80 (s, 2H), 3.70 (s, 3H), 3.12-3.10 (m, 2H), 2.61-2.57 (m, 4H),1.90 (d, J=5.5, 3H), 1.79 (s, 2H), 0.56 (d, J=6.0, 2H), 0.53 (s, 2H)

Example 129a 2-Nitro-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine 129a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole 113c (3.00 g, 9.59mmol) and 4M aqueous hydrobromic acid (120 mL), and the resultingmixture was heated at reflux for 24 h. After this time, the reactionmixture was concentrated under reduced pressure to approximately 6 mLvolume, and the residue was stirred in 2M aqueous sodium hydroxide (40mL) for 2 h. After this time methylene chloride was added (40 mL) andthe mixture was stirred for 15 min. The aqueous layer was separated andextracted with methylene chloride (2×50 mL). The combined organicextracts were washed with brine (100 mL) and dried over sodium sulfate.The drying agent was removed by filtration and the filtrate concentratedunder reduced pressure to afford a 62% yield (1.01 g) of 129a as a whitesolid: mp 110-112° C.; ¹H NMR (300 MHz, CDCl₃) δ 6.68 (s, 1H), 4.87 (s,2H), 4.28 (t, 2H, J=5.4 Hz), 4.20 (t, 2H, J=5.1 Hz); MS (ESI+) m/z 170.0(M+H).

Example 129b 6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-amine 129b

A 500-mL Parr hydrogenation bottle was purged with nitrogen and chargedwith 129a (1.01 g, 5.92 mmol), 10% palladium on carbon (50% wet, 125 mgdry weight) and ethanol (50 mL). The bottle was evacuated, charged withhydrogen gas to a pressure of 25 psi and shaken for 2 h on a Parrhydrogenation apparatus. The hydrogen was then evacuated and nitrogencharged to the bottle. The catalyst was removed by filtration through apad of CELITE® 521 and the filtrate concentrated under reduced pressure.The resulting residue was purified by column chromatography using 400 ccof silica gel and eluting with 3% methanol in methylene chloride. Thefractions containing 129b were collected to afford, after concentratingunder reduced pressure, a 73% yield (601 mg) of 129b as a yellow solid:mp 74-76° C. ¹H NMR (300 MHz, CDCl₃ δ 5.37 (s, 1H), 4.72 (s, 2H), 4.07(t, 2H, J=5.1 Hz), 3.98 (t, 2H, J=5.1 Hz), 3.57 (br s, 2H); MS (ESI+)m/z 140.4 (M+H).

Example 129c5-Bromo-3-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methylpyridin-2(1H)-one129c

A 50-mL three-neck round-bottomed flask equipped with a magneticstirrer, reflux condenser and nitrogen inlet was charged with1,4-dioxane (20 mL), 129b (600 mg, 4.31 mmol),3,5-dibromo-1-methylpyridine-2(1H)-one (1.44 g, 5.40 mmol) and cesiumcarbonate (3.08 g, 9.48 mmol). After bubbling nitrogen through theresulting solution for 30 min, Xantphos (300 mg, 0.52 mmol) andtris(dibenzylideneacetone)dipalladium(0) (320 mg, 0.35 mmol) were added,and the reaction mixture was heated at reflux for 2 h. After this timethe reaction was cooled to room temperature, partitioned between ethylacetate (75 mL) and water (75 mL) and filtered. The aqueous layer wasseparated and extracted with ethyl acetate (2×25 mL). The organic layerswere combined and washed with brine (50 mL) and dried over sodiumsulfate. The drying agent was removed by filtration and the filtrateconcentrated under reduced pressure. The resulting residue was purifiedby column chromatography using 500 cc of silica gel and eluting with 1%methanol in methylene chloride. The fractions containing 129c werecollected to afford, after concentrating under reduced pressure, a 31%yield (433 mg) of 129c as a green solid: mp 195-197° C.; ¹H NMR (300MHz, CDCl₃) δ 7.92 (d, 1H, J=2.4 Hz), 7.44 (s, 1H), 6.90 (d, 1H, J=2.4Hz), 5.65 (s, 1H), 4.80 (s, 2H), 4.13 (s, 2H), 3.61 (s, 5H); MS (ESI+)m/z 324.9 (M+H).

Example 129d (4-(5-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 129d

Following the procedures as described in Example 113j, reaction of3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (200 mg, 0.52 mmol) and 129c (170 mg, 0.52 mmol) gave 129d asa yellow solid (185 mg, 61%). LCMS: [M+H]⁺ 584

Example 1292-(4-(5-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one129

Following the procedures as described in Example 113, 129d (180 mg 0.31mmol) was hydrolyzed with lithium hydroxide to give 129 as a white solid(100 mg, 62%). LCMS: [M+H]⁺ 542. ¹H NMR (500 MHz, CDCl₃) δ 8.48 (d,J=5.0, 1H), 7.98 (d, J=2.0, 1H), 7.71 (d, J=2.0, 1H), 7.46 (s, 1H), 7.35(d, J=5.0, 1H), 6.89 (s, 1H), 5.72 (s, 1H), 5.03 (d, J=6.5, 1H), 4.79(s, 2H), 4.61-4.64 (m, 1H), 4.50 (s, 1H), 4.31-4.35 (m, 1H), 4.06-4.16(m, 6H), 3.86 (s, 1H), 3.71 (s, 3H), 2.56-2.62 (m, 4H), 1.88-1.92 (m,2H), 1.80 (m, 2H)

Example 130a (3S)-tert-Butyl3-methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 130a

Following the procedures as described for compound 101g, reaction of5-bromo-2-nitropyridine (10.5 g, 50 mmol), and(35)-tert-butyl-3-methylpiperazine-1-carboxylate (10.0 g, 50 mmol)afforded 130a as a yellow solid (8.05 g, 50%). LCMS: [M+H]⁺ 323

Example 130b(3S)-tert-butyl-4-(6-aminopyridin-3-yl)-3-methylpiperazine-1-carboxylate130b

Following the procedures as described for compound 101h, hydrogenationof 130a (5.8 g) afforded 130b as a brown solid (4.9 g, 96%). LCMS:[M+H]⁺ 293

Example 130c(3S)-tert-Butyl-4-(6-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridine-3-yl)-3-methylpiperazine-1-carboxylate130c

Following the procedures as described for compound 101i, reaction of130b (4.0 g) and 3,5-dibromo-1-methylpyridin-2(1H)-one (5.5 g) afforded130c as a yellow solid (5.4 g, 83%). LCMS: [M+H]⁺ 478

Example 130d(3S)-5-Bromo-1-methyl-3-(5-(2-methylpiperazin-1-yl)pyridin-2-ylamino)pyridine-2(1H)-one130d

Following the procedures as described for compound 101j, acidichydrolysis of the Boc group of 130c (3.1 g) afforded 130d as a yellowsolid (2.3 g, 95%). LCMS: [M+H]⁺ 380.

Example 130e(3S)-5-Bromo-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridine-2-ylamino)pyridin-2(1H)-one130e

Following the procedures as described for compound 101k, reductiveamination of 130d (2.35 g) with oxetan-3-one (0.4 mL) afforded 130e as ayellow solid (2.6 g, 98%). LCMS: [M+H]⁺ 434.

Example 130f(3S)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one130f

A 100 mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 130e (1.0 g, 1.0 eq.,2.3 mmol), Pin₂B₂ (1.46 g, 2.50 eq., 5.75 mmol), Pd₂(dba)₃ (105 mg, 0.05eq., 0.125 mmol), X-Phos (93 mg, 0.1 eq., 0.23 mmol), AcOK (676 mg, 3.0eq., 6.9 mmol), and dioxane (50 mL). After three cycles of vacuum/argonflush, the mixture was heated at 90° C. for 4 hrs, then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was washed with 3:1 PE/EA (80 mL) toafford 130f as yellow solid (1.0 g, 90%). MS: [M+H]⁺ 482.

Example 130g (3S)-4-[1-methyl-5-({5-[2-methyl4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde130g

A 50 mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 130f (420 mg, 1.0 eq.,0.44 mmol),4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (200 mg, 2 eq., 0.88 mmol):

PdCl₂(dppf) (36 mg, 0.1 eq., 0.044 mmol), K₃PO₄ (279 mg, 3 eq., 1.32mmol), and THF (20 mL). After three cycles of vacuum/argon flush, themixture was heated at reflux for 5 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was washed with 3:1 PE/EA (80 mL) toafford 130g (90 mg, 31%) as a yellow solid. MS: [M+H]⁺ 663.

Example 130 (3S)-10-[4-[1-methyl-5-({5-[2-methyl4-(oxetan-3-yl)piperazin-1-yl]pyridine-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-3-(hydroxymethyl)pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one130

A 50 mL single-neck round-bottomed flask equipped with a magneticstirrer and was charged with 130g (90 mg, 1 eq., 0.11 mmol), LiOH (7.9mg, 3 eq., 0.33 mmol), i-PrOH (3 mL), THF (3 mL) and H₂O (2 mL). Themixture was stirred at 30° C. for 2 h. It was then filtered andconcentrated. The residue was purified by reverse-phase prep-HPLC toafford 130 (40 mg, 44%) as a yellow solid. LCMS: [M+H]⁺ 665.4. ¹H NMR(500 MHz, CDCl₃) δ 8.65 (d, J=2.0, 1H), 8.48 (d, J=5.0, 1H), 7.96 (d,J=2.0, 1H), 7.84-7.83 (m, 2H), 7.36 (d, J=5.0, 1H), 7.31 (dd, J=3.0,9.0, 1H), 6.84 (s, 1H), 6.81 (d, J=9.0, 1H), 5.08-5.05 (m, 1H),4.71-4.61 (m, 5H), 4.51-4.29 (m, 2H), 4.16-4.15 (m, 2H), 3.87-3.85 (m,1H), 3.72 (s, 3H), 3.55-3.45 (m, 2H), 3.06-3.08 (m, 2H), 2.59-2.47 (m,7H), 2.22-2.17 (m, 1H), 1.27 (s, 6H), 0.98 (d, J=6.5, 3H).

Example 131a(S)-(4-(5-(5-(2-ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 131a

A sealed tube equipped with a magnetic stirrer was charged with(S)-5-bromo-3-(5-(2-ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one161e (269 mg, 0.60 mmol):

113i (230 mg, 0.60 mmol), Pd(dppf)Cl₂ (25 mg, 0.03 mmol), NaOAc (98 mg,1.2 mmol), K₃PO₄ (254 mg, 1.2 mmol), and acetonitrile (4 mL). Afterthree cycles of vacuum/argon flush, the mixture was heated at 100° C.for 1 h. It was then filtered and the filtrate was evaporated in vacuo.The residue was purified by silica gel column chromatography elutingwith dichloromethane/methanol (25:1, UV) to afford 131a (150 mg, 40%) asa brown solid. LCMS: [M+H]⁺ 707

Example 131(S)-2-(4-(5-(5-(2-ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one131

A mixture of 131a (150 mg, 0.21 mmol) and LiOH (50 mg, 2.1 mmol) in^(i)PrOH/THF (1:1, 4 mL) and H₂O (1 mL) was stirred at 30° C. for 1 h.The mixture was evaporated in vacuo and the residue was extracted withEtOAc (10 mL×2). The combined EtOAc extract was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 131 (26 mg, 25%) as a white solid. LCMS: [M+H]⁺ 665. ¹H NMR(500 MHz, CDCl₃) δ 8.64 (d, J=2.0, 1H), 8.50 (d, J=5.0, 1H), 7.93 (d,J=2.5, 1H), 7.83 (d, J=1.5, 2H), 7.38 (d, J=5.0, 1H), 7.27 (d, J=5.0,1H), 6.90 (s, 1H), 6.83 (d, J=8.5, 1H), 4.73-4.64 (m, 5H), 4.50 (s, 1H),4.33-4.31 (m, 1H), 4.20-4.16 (m, 2H), 3.88-3.86 (m, 1H), 3.73 (s, 3H),3.53-3.51 (m, 1H), 3.33 (s, 1H), 3.13 (t, J=5.0, 2H), 2.61-2.56 (m, 4H),2.45 (d, J=4.0, 2H), 2.37 (s, 1H), 1.91-1.79 (m, 7H), 1.39-1.40 (m, 1H),0.83 (t, J=7.0, 3H).

Example 132a6-Chloro-4-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-2-methylpyridazin-3(2H)-one132a

A mixture of 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-amine 129b (0.8g, 5.76 mmol), xantophos (360 mg, 0.623 mmol), Pd₂ dba₃ (384 mg, 0.42mmol), 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (1.28 g, 5.76 mmol)and Cs₂CO₃ (5.05 g. 17.3 mmol) in 1,4-dioxane (40 mL) was heated atreflux for 2 h. After the completion of the reaction, the mixture wasfiltered off, and washed with MeOH (60 mL). The filtrate was evaporatedin vacuo. The residue was purified on reverse phase Combi-flash to give132a (1.3 g, 81%). MS: [M+H]⁺ 282.

Example 132b (4-(5-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 132b

Following the procedures as described for compound 131a, reaction of3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (200 mg, 0.52 mmol) and 132a (146 mg, 0.52 mmol) afforded 132bas a yellow solid (100 mg, 53%). LCMS: [M+H]⁺ 585

Example 1322-(4-(5-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one132

Following the procedures as described for compound 131, hydrolysis of132b (100 mg 0.171 mmol) with lithium hydroxide afforded 132 as a whitesolid (60 mg, 65%). LCMS: [M+H]⁺ 543. ¹H NMR (500 MHz, CDCl₃) δ 8.55 (d,J=5.0, 1H), 8.01 (s, 1H), 7.94 (s, 1H), 7.43 (d, J=5.5, 1H), 6.87 (s,1H), 5.97 (s, 1H), 4.80 (s, 2H), 4.58 (s, 3H), 4.47 (s, 1H), 4.15-1.14(m, 2H), 4.11 (s, 4H), 3.90 (s, 4H), 2.61-2.60 (m, 2H), 2.57 (t, J=6.5,2H), 1.89-1.91 (m, 2H), 1.79-1.80 (m, 2H)

Example 133a6-Chloro-2-methyl-4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridazin-3(2H)-one133a

A 250-mL three-neck round-bottomed flask equipped with a refluxcondenser, magnetic stirrer and nitrogen inlet was charged with4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (1.90 g, 8.53 mmol):

113e (1.18 g, 7.75 mmol) and 1,4-dioxane (40 mL). The flask was purgedwith nitrogen and cooled to 0° C. A 1 M solution of lithiumhexamethyldisilazide in THF (39 mL, 39.0 mmol) was added. After bubblingnitrogen through the resulting suspension for 30 min, Xantphos (381 mg,0.659 mmol) and tris(dibenzylidene-acetone)dipalladium(0) (355 mg, 0.388mmol) were added, and the reaction mixture was heated at reflux for 2 h.After this time, the mixture was cooled to room temperature and dilutedwith water (10 mL). The pH of the solution was adjusted to 7.6 with 2 Nhydrochloric acid. The organic layer was separated, and the aqueouslayer was extracted with ethyl acetate (3×40 mL). The combined organiclayers were dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by column chromatography on silica toafford a 76% yield (1.74 g) of 133a as an off-white solid: mp 184-186°C.; ¹H NMR (300 MHz, DMSO-d₆) δ 9.62 (s, 1H), 7.72 (s, 1H), 6.00 (s,1H), 4.04 (t, 2H, J=5.1 Hz), 3.65 (s, 3H), 3.53 (s, 2H), 2.82 (t, 2H,J=5.1 Hz), 2.37 (s, 3H); MS (ESI+) m/z 295.1 (M+H).

Example 133b(4-(1-Methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridazin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 133b

Following the procedures as described for compound 131a and startingwith3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (200 mg, 0.52 mmol) and 132a (153 mg, 0.52 mmol) afforded 132bas a yellow solid (170 mg, 55%). LCMS: [M+H]⁺ 598

Example 1332-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one133

Hydrolysis of 133b (160 mg 0.267 mmol) with lithium hydroxide afforded133 as a white solid (94 mg, 63%). LCMS: [M+H]⁺ 556. ¹H NMR (500 MHz,CDCl₃) δ 8.55 (d, J=5.0, 1H), 7.98 (s, 1H), 7.89 (s, 1H), 7.43 (d,J=5.0, 1H), 6.87 (s, 1H), 5.94 (s, 1H), 4.57 (s, 3H), 4.47 (s, 1H),4.11-4.15 (m, 4H), 3.89 (s, 3H), 3.87 (s, 1H), 3.61 (d, J=4.0, 2H), 2.90(s, 2H), 2.61 (d, J=4.0, 2H), 2.57 (t, J=6.0, 2H), 2.49 (s, 3H),1.89-1.91 (m, 2H), 1.79-0.80 (m, 2H)

Example 134a 10-Bromo-1H,2H,3H,4H,6H,7H,8H,9H-pyrazino[1,2-a]indol-1-one134a

Into a 250-mL 3-necked round-bottom flask was placed a solution of1H,2H,3H,4H,6H,7H,8H,9H-pyrazino[1,2-a]indol-1-one 101e (9.5 g, 49.94mmol, 1.00 equiv) in N,N-dimethylformamide (100 mL), followed by theaddition of N-bromosuccinimide (9.8 g, 55.06 mmol, 1.10 equiv) inseveral batches at 0° C. The resulting solution was stirred at roomtemperature for 2 h and diluted with 500 mL of water. The precipitatewas filtered and dried in a vacuum oven to afford 9.5 g (71%) of 119a asa light brown solid.

Example 134b10-Fluoro-1H,2H,3H,4H,6H,7H,8H,9H-pyrazino[1,2-a]indol-1-one 134b

Into a 2-L 4-necked round-bottom flask purged and maintained with aninert atmosphere of nitrogen was placed a solution of 134a (40 g, 148.62mmol, 1.00 equiv) in tetrahydrofuran (200 mL), followed by the additionof n-BuLi (2.4 M) (218 mL, 3.50 equiv) dropwise with stirring at −78° C.The resulting solution was stirred at −40° C. for 3 h. To this was addeda solution of N-fluorobenzesulfonimide (98.7 g, 313.33 mmol, 2.10 equiv)in tetrahydrofuran (200 mL) dropwise with stirring at −78° C. Theresulting solution was stirred at room temperature for 3 h, quenched bythe addition of 200 mL of water and extracted with 3×500 mL of ethylacetate. The combined organic layers were dried over anhydrous sodiumsulfate and concentrated under vacuum. The crude product (30 g) waspurified by Prep-HPLC with the following conditions (mobile phase, A:0.05% trifluoroacetic acid/water; B: CH₃CN; gradient: 10% B-25% B) toafford 5.05 g (16%) of 134b as a white solid. MS: [M+H]⁺ 209. 1H NMR(300 MHz, CDCl₃) δ 6.16 (br, 1H), 3.90-3.86 (m, 2H), 3.65-3.62 (m, 2H),2.53-2.47 (m, 4H), 1.88-1.80 (m, 2H), 1.77-1.72 (m, 2H).

Example 134c4-Chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (60 mL), 134b(500 mg, 2.4 mmol):

2-bromo-4-chloronicotinaldehyde 103a (1.60 g, 7.2 mmol), and potassiumacetate (471 mg, 4.8 mmol). After bubbling nitrogen through theresulting mixture for 30 minutes, Xantphos (140 mg, 0.24 mmol) andtris(dibenzylideneacetone)dipalladium(0) (220 mg, 0.24 mmol) were added,and the reaction mixture was heated at 80° C. for 10 h. After this timethe reaction was cooled to room temperature, partitioned between ethylacetate (40 mL) and water (40 mL), and filtered. The aqueous layer wasseparated and extracted with ethyl acetate (50 mL×3). The combinedorganic layer was washed with brine (30 mL) and dried over sodiumsulfate. The drying agent was removed by filtration and the filtrate wasconcentrated under reduced pressure. The residue was purified on flashcolumn eluting with 3:1 PE/EA to afford 134c (678 mg, 81%) as yellowsolid. MS: [M+H]⁺ 348. ¹H NMR (500 MHz, DMSO-d6) δ 9.87 (s, 1H), 8.60(d, J=5.5, 1H), 7.56 (d, J=5.5, 1H), 4.23-4.25 (m, 2H), 4.13-4.15 (m,2H), 2.59 (t, J=6.0, 2H), 2.41 (t, J=6.0, 2H), 1.75-1.80 (m, 2H),1.66-1.70 (m, 2H)

Example 134d2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)nicotinaldehyde134d

A mixture of 134c (300 mg, 0.86 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101l (403 mg, 0.86 mmol), CH₃COONa (142 mg, 1.72 mmol), K₃PO₄ (460 mg,1.72 mmol), PdCl₂(dppf) (71 mg, 0.086 mmol) in CH₃CN (25 mL) and H₂O (1mL) was heated at 100° C. for 3 hours. After reaction it was evaporatedthe residue was purified by silical-gel column eluting with methylenechloride/methanol (30:1) to afford 134d (312 mg, yield 55%) as a brownsolid. MS: (M+H)⁺ 653.

Example 13410-Fluoro-2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one134

To a solution of 134d (200 mg, 0.30 mmol) in MeOH (20 mL) was addedNaBH₄ (40 mg, 0.9 mmol). The mixture was stirred at 20° C. for 2 h.After reaction it was evaporated and the residue was purified byreverse-phase prep-HPLC to afford 134 (108 mg, yield 54%) as a yellowsolid. MS: (M+H)⁺ 655. ¹H NMR (500 MHz, DMSO-d6) δ 8.61 (d, J=2.0, 1H),8.49 (d, J=5.0, 1H), 8.43 (s, 1H), 7.85 (d, J=2.5, 1H), 7.45 (d, J=1.5,1H), 7.37-7.39 (m, 1H), 7.35 (d, J=5.0, 1H), 7.24 (d, J=9.0, 1H), 4.99(s, 1H), 4.56 (t, J=6.5, 2H), 4.40-4.47 (m, 4H), 4.18-4.22 (m, 2H),4.05-4.09 (m, 1H), 3.84-3.96 (m, 1H), 3.60 (s, 3H), 3.41-3.46 (m, 1H),3.07 (s, 4H), 2.54-2.61 (m, 2H), 2.39-2.42 (m, 6H), 1.78 (s, 2H), 1.69(s, 2H)

Example 135a1-Methyl-3-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one135a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a condenser was charged with compound 113h (1.0 g, 3 mmol),Pin₂B₂ (3.8 g, 15 mmol), Pd(dppf)Cl₂ (137 mg, 0.15 mmol), X-phos (143mg, 0.3 mmol), KOAc (88 mg, 9 mmol), and 1,4-dioxane (50 mL). Afterthree cycles of vacuum/argon flush, the reaction mixture was heated at60° C. for 15 h. It was then cooled to room temperature and filtered.The filtrate was concentrated under reduced pressure and the resultingresidue was washed with petroleum ether to afford 135a as a yellow solid(0.87 g, 75%). MS: [M+H]⁺ 386

Example 135b2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)nicotinaldehyde135b

A suspension of 135a (385 mg, 1 mmol),4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (347 mg, 1 mmol), K₃PO₄ (424 mg, 2 mmol), NaOAc (164 g, 2 mmol) and1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (41 mg, 0.05mmol) in CH₃CN (50 ml) was heated at 100° C. under an N₂ balloon for 4h. Analysis of reaction mixture by LCMS showed completed conversion tothe desired product. The reaction mixture was cooled to room temperatureand diluted with DCM (50 ml) and water (80 mL). The aqueous layer wasseparated and extracted with DCM (3×50 mL). The combined organic layerwas dried over Na₂SO₄, filtered, and concentrated. The dark residue waspurified by silica gel column chromatography eluting with DCM/MeOH (from80/1 to 30/1) to afford 135b (285 g, 50%) as yellow solid. MS: [M+H]⁺571

Example 13510-Fluoro-2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one135

To a solution of 135b (280 g, 0.49 mmol) in MeOH (50 mL) was added NaBH₄(56 g, 1.47 mmol) at room temperature. After the reaction was stirredfor 3 h, LCMS indicated the reaction was completed. Then the mixture waspoured into H₂O (50 mL) and extracted with DCM (50 mL×3). The combinedorganic layer was washed with brine (50 mL), dried over Na₂SO₄,filtered, and concentrated. The residue was purified by reverse-phaseprep-HPLC to afford 135 (187 mg, 67%) as a white solid. MS: [M+H]⁺ 572.¹H NMR (500 MHz, CDCl₃) δ 8.47 (d, J=5.5, 1H), 7.95 (d, J=2.0, 1H), 7.70(d, J=2.0, 1H), 7.42 (s, 1H), 7.35 (d, J=5.5, 1H), 5.70 (s, 1H), 4.96(t, J=7.0, 1H), 4.62 (s, 1H), 4.45 (s, 1H), 4.33 (s, 1H), 4.07-4.12 (m,4H), 3.84 (s, 1H), 3.70 (s, 3H), 3.60 (s, 2H), 2.88 (t, J=5.5, 2H), 2.61(s, 2H), 2.57 (s, 2H), 2.48 (s, 3H), 1.86-1.90 (m, 2H), 1.77 (s, 2H)

Example 136a(S)-2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)nicotinaldehyde 136a

A 50 mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with(5)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one130f (225 mg, 1.5 eq., 0.47 mmol),4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (150 mg, 1 eq., 0.43 mmol):

PdCl₂(dppf) (35 mg, 0.1 eq., 0.043 mmol), K₃PO₄ (273 mg, 3 eq., 1.29mmol), and THF (20 mL). After three cycles of vacuum/argon flush, themixture was heated at reflux for 5 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by column chromatographywith DCM/EtOH (40:1) to afford 136a as yellow solid (100 mg, 34%). MS:[M+H]⁺ 667.3.

Example 136(S)-10-Fluoro-2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one136

A 25 mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 136a (100 mg, 1.0 eq., 0.15 mmol), NaBH₄(17 mg,3.0 eq., 0.45 mmol), and MeOH (10 mL). The mixture was stirred at roomtemperature for 1 h. The residue was purified by reverse-phase prep-HPLCto afford 136 (64 mg, 64%). LCMS: [M+H]⁺ 669.3. ¹H NMR (500 MHz, CDCl₃)δ 8.64 (d, J=2.0, 1H), 8.48 (d, J=5.0, 1H), 7.96 (d, J=2.5, 1H),7.83-7.82 (m, 2H), 7.36 (d, J=5.0, 1H), 7.30 (dd, J=2.5, 9.0, 1H), 6.81(d, J=8.5, 1H), 4.99-4.96 (m, 1H), 4.71-4.61 (m, 5H), 4.45-3.83 (m, 5H),3.71 (s, 3H), 3.54-3.45 (m, 2H), 3.08-3.06 (m, 2H), 2.56-2.47 (m, 7H),2.21-2.17 (m, 1H), 1.89-1.76 (m, 4H), 0.98 (d, J=6.5, 3H)

Example 137a(R)-(4-(1-Methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 137a

A mixture of(R)-5-bromo-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one151f, the enantiomer of 130f (283 mg, 0.65 mmol):

3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (250 mg, 0.65 mmol), PdCl₂(dppf) (53 mg, 0.065 mmol), NaOAc(107 mg, 1.3 mmol), K₃PO₄ (347 mg, 1.3 mmol) in acetonitrile (30 mL) washeated at 100° C. for 3 h. The solvent was evaporated in vacuo and theresidue was purified by flash column chromatography eluting with 30:1DCM/MeOH to afford 137a (216 mg, 48%) as a brown solid. LCMS: [M+H]⁺693.4

Example 137(R)-2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexa-hydropyrazino[1,2-a]indol-1(2H)-one137

To a solution of 137a (200 mg, 0.29 mmol) in propan-2-ol (8 mL),tetrahydrofuran (8 mL), and water (2.0 mL) was added LiOH (690 mg, 29mmol). The mixture was stirred at 30° C. for 2 h. It was then evaporatedand the residue was purified by reverse-phase prep-HPLC to afford 137(143 mg, 76%) as a white solid. LCMS: (M+H)⁺ 651.4. ¹H NMR (500 MHz,DMSO-d6) δ 8.63 (d, J=2.0, 1H), 8.49 (d, J=5.0, 1H), 8.45 (s, 1H), 7.84(d, J=2.5, 1H), 7.47 (d, J=2.0, 1H), 7.37-7.39 (m, 1H), 7.35 (d, J=5.5,1H), 7.25 (d, J=9.5, 1H), 6.58 (s, 1H), 4.95 (t, J=4.0, 1H), 4.54-4.58(m, 2H), 4.40-4.49 (m, 4H), 4.11-4.26 (m, 3H), 3.86-3.88 (m, 1H), 3.68(s, 1H), 3.61 (s, 3H), 3.37-3.42 (m, 1H), 3.08-3.11 (m, 1H), 2.95 (t,J=9.0, 1H), 2.62-2.67 (m, 1H), 2.54-2.59 (m, 2H), 2.48 (t, J=6.0, 2H),2.30-2.36 (m, 2H), 2.19 (t, J=8.0, 1H), 1.81 (s, 2H), 1.68-1.72 (m, 2H),0.93 (d, J=6.0, 3H)

Example 138a3-(1-Methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-5-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)isonicotinaldehyde138a

A 100-mL single-neck round-bottomed flask was charged with3-bromo-5-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)isonicotinaldehyde101f (298 mg, 0.7 mmol),1-methyl-3-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one135a (325 mg, 0.84 mmol), PdCl₂(dppf) (30 mg, 0.035 mmol), K₃PO₄ (300mg, 1.4 mmol), and NaOAc.3H₂O (200 mg, 1.4 mmol) in CH₃CN (70 mL). Thesystem was evacuated and refilled with Argon. The reaction mixture washeated at 100° C. for 2 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by flash column chromatography elutingwith 25:1 DCM/MeOH to afford 138a (220 mg, 55%) as a pale yellow solid.MS: [M+H]⁺ 553.3.

Example 1382-(4-(Hydroxymethyl)-5-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one138

A mixture of 138a (200 mg, 0.36 mmol) and NaBH₄ (50 mg, 1.2 mmol) inMeOH (60 mL) was stirred at room temperature for 2 h. The mixture wasquenched with water and extracted with EtOAc (10 mL×3). The combinedEtOAc extract was concentrated under reduced pressure and the residuewas purified with reverse-phase prep-HPLC to afford 138 (162 mg, 85%).LCMS: [M+H]⁺: 555.3. ¹H NMR (500 MHz, CDCl₃) δ 8.64 (s, 1H), 8.49 (s,1H), 7.97 (d, J=2.5, 1H), 7.42 (s, 1H), 7.33 (d, J=2, 1H), 6.88 (s, 1H),5.68 (s, 1H), 4.65-4.63 (m, 1H), 4.57-4.55 (m, 1H), 4.37 (t, J=11, 1H),4.20-4.16 (m, 3H), 4.07-3.98 (m, 3H), 3.70 (s, 3H), 3.59 (s, 2H), 2.87(t, J=5.5, 2H), 2.61-2.56 (m, 4H), 2.48 (s, 3H), 1.92-1.90 (m, 2H),1.80-1.79 (m, 2H)

Example 139a4-Chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde139a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (50 mL),2-bromo-4-chloronicotin-aldehyde 103a (1.4 g, 6.4 mmol),3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1(2H)-one 112d (0.6 g, 3.2mmol), Pd₂(dba)₃ (293 mg, 0.32 mmol), XantPhos (370 mg, 0.64 mmol), andpotassium carbonate (627 mg, 6.4 mmol). After three cycles ofvacuum/argon flush, the mixture was heated at 80° C. overnight. Afterthis time the reaction was cooled to room temperature. It was thenfiltered and the filtrate was evaporated in vacuo. The residue waspurified by silica gel column chromatography eluting with DCM/CH₃OH(20:1, UV) to afford 139a (528 mg, 50%) as a yellow solid. MS: [M+H]⁺330. ¹H NMR (500 MHz, CDCl₃) δ 10.09 (s, 1H), 8.37 (d, J=5.5, 1H), 7.16(d, J=5.5, 1H), 6.25 (s, 1H), 4.29-4.32 (m, 2H), 3.83-3.86 (m, 2H),2.96-2.99 (m, 2H), 2.75-2.78 (m, 2H), 2.00-2.07 (m, 2H), 1.82-1.85 (m,2H)

Example 139b4-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde139b

A round-bottomed flask was charged with 139a (100 mg, 0.30 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101 l (140 mg, 0.30 mmol), PdCl₂(dppf) (25 mg, 0.03 mmol), K₃PO₄.3H₂O(160 mg, 0.60 mmol), NaOAc (59 mg, 0.60 mmol), acetonitrile (10 mL), andH₂O (5 mL). After three cycles of vacuum/argon flush, the mixture washeated at 100° C. for 3 h. It was then filtered and the filtrate wasevaporated in vacuo. The residue was purified on flash columnchromatography eluting with 1:3 petroleum/ethyl acetate to afford 139bas a yellow solid (95 mg, 50%). LCMS: [M+H]⁺ 635

Example 1392-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridine-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1(2H)-one139

A mixture of 139b (95 mg, 0.15 mmol), NaBH₄ (17 mg, 0.45), and CH₃OH (10mL) was stirred at 25° C. for 1 h. The mixture was extracted with CH₂Cl₂(10 mL×2). The combined CH₂Cl₂ extract was concentrated under reducedpressure. The residue was purified with reverse-phase prep-HPLC toafford 139 (60 mg, 63%). LCMS: [M+H]⁺ 637. ¹H NMR (500 MHz, DMSO-d6) δ8.63 (d, J=2.0, 1H), 8.47 (d, J=5.5, 1H), 8.42 (s, 1H), 7.85 (d, J=2.5,1H), 7.49 (d, J=2.0, 1H), 7.37-7.39 (m, 1H), 7.30 (d, J=5.0, 1H), 7.24(d, J=9.0, 1H), 6.05 (s, 1H), 4.47-4.57 (m, 2H), 4.41-4.47 (m, 2H),4.39-4.41 (m, 1H), 4.33-4.35 (m, 1H), 4.11-4.16 (m, 1H), 3.93-3.96 (m,1H), 3.76-3.82 (m, 2H), 3.59 (s, 3H), 3.41-3.45 (m, 2H), 3.06-3.08 (m,4H), 2.98-3.01 (m, 1H), 2.92-2.95 (m, 1H), 2.71-2.72 (m, 2H), 2.36-2.39(m, 4H), 1.91-1.93 (m, 2H), 1.72-1.78 (m, 2H)

Example 140a(S)-2-(7,7-Difluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)nicotinaldehyde140a

Following the procedures as described in Example 130g, reaction of(S)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one130f and4-chloro-2-(7,7-difluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotin-aldehyde(170 mg):

afforded 140a was as a yellow solid (200 mg, 60%). LCMS: [M+H]⁺ 684.3.4-Chloro-2-(7,7-difluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotin-aldehydewas prepared from7,7-difluoro-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-oneaccording to the reaction scheme in FIG. 25.

Example 140(S)-7,7-Difluoro-2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one140

Following the procedures as described in Example 130, sodium borohydridereduction of 140a (200 mg) afforded 140 as a yellow solid (104 mg, 51%).LCMS: [M+H]⁺ 686.3. ¹H NMR (500 MHz, DMSO) δ 8.62 (d, J=2.0, 1H),8.46-8.49 (m, 2H), 7.83 (d, J=3.0, 1H), 7.45 (d, J=2.5, 1H), 7.35-7.38(m, 2H), 7.25 (d, J=9.5, 1H), 6.64 (s, 1H), 4.95-4.97 (m, 1H), 4.54-4.57(m, 2H), 4.38-4.48 (m, 4H), 4.15-4.27 (m, 3H), 3.87-3.90 (m, 1H), 3.67(s, 1H), 3.59 (s, 3H), 3.26-3.39 (m, 3H), 3.08-3.10 (m, 1H), 2.92-2.96(m, 1H), 2.63-2.67 (m, 2H), 2.52-2.55 (m, 1H), 2.30-2.36 (m, 2H),2.18-2.24 (m, 3H), 0.93 (d, J=6.0, 3H)

Example 141a4-Chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde141a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with2-bromo-4-chloronicotinaldehyde 103a (3.0 g, 13.6 mmol),4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one107e (1.84 g, 9.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (826mg, 0.9 mmol), XantPhos (1.04 mg, 1.8 mmol), Cs₂CO₃ (5.8 g, 18.0 mmol),and 1,4-dioxane (40 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 5 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was recrystallized from ethyl acetateto afford 141a as yellow solid (730 mg, 31.7%). MS: [M+H]⁺ 344.0.

Example 141b2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-methyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridine-3-carbaldehyde141b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 141a (130 mg, 0.38mmol),1-methyl-3-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one135a (146 mg, 0.38 mmol), Pd(dppf)Cl₂ (31 mg, 0.038 mmol), K₃CO₃ (105mg, 0.76 mmol), and DMF (20 mL). After three cycles of vacuum/argonflush, the mixture was heated at 110° C. for 2 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with dichloromethane/methanol (30:1) toafford 141b as brown solid (160 mg, 74.6%). MS: [M+H]⁺ 567.3.

Example 1412-[3′-Hydroxymethyl-1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one141

To a solution of 141b (150 mg, 0.26 mmol) at room temperature inmethanol (10 mL) was added sodium borohydride (29 mg, 0.78 mmol) and theresulting mixture was stirred for 30 minutes. It was quenched with water(1.0 mL) and concentrated. The residue was purified by reverse-phaseprep-HPLC to afford 141 (35 mg, 23.2%). LCMS: [M+H]⁺ 569.3. ¹H NMR (500MHz, CDCl₃) δ 8.46 (d, J=5.0, 1H), 7.94 (d, J=2.5, 1H), 7.72 (d, J=2.0,1H), 7.41 (s, 1H), 7.33 (d, J=5.5, 1H), 6.83 (s, 1H), 5.68 (s, 1H),5.03-5.00 (m, 1H), 4.64-4.61 (m, 1H), 4.51-4.48 (m, 1H), 4.32-4.27 (m,1H), 4.21-4.09 (m, 4H), 3.91-3.82 (m, 1H), 3.69 (s, 3H), 3.62-3.58 (m,2H), 2.87 (t, J=2.5, 2H), 2.57 (d, J=4.0, 2H), 2.54 (s, 2H), 2.51 (s,3H), 1.27 (s, 6H)

Example 142a 5-Bromo-1-methyl-3-(pyrimidin-4-ylamino)pyridin-2(1H)-one142a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and nitrogen inlet was charged with3,5-dibromo-1-methylpyridin-2(1H)-one (2.00 g, 21.0 mmol),2-aminopyrimidine (5.61 g, 21.0 mmol), cesium carbonate (13.7 g, 42.1mmol), DMF (5 mL) and 1,4-dioxane (70 mL). After bubbling nitrogenthrough the resulting suspension for 30 min, Xantphos (1.10 g, 1.89mmol) and tris(dibenzylideneacetone)dipalladium(0) (963 mg, 1.05 mmol)were added. A reflux condenser was attached to the flask, and thereaction mixture was heated at 100° C. for 4 h. After this time, themixture was cooled to room temperature and diluted with 90:10 methylenechloride/methanol (150 mL) and water (100 mL), and the layers wereseparated. The aqueous layer was extracted with 90:10 methylenechloride/methanol (50 mL), and the combined organic layers were washedwith brine and dried over sodium sulfate. The drying agent was removedby filtration. The filtrate was concentrated under reduced pressure, andthe resulting residue was purified by flash column chromatography(silica, 90:10 methylene chloride/methanol) to afford 142a in 58% yield(3.42 g) as an amorphous light green solid: mp 217-219° C.; ¹H NMR (500MHz, CDCl₃) δ 9.29 (s, 1H), 8.77 (s, 1H), 8.72 (d, J=2.5 Hz, 1H), 8.36(d, J=6.0 Hz, 1H), 7.69 (d, J=2.5 Hz, 1H), 7.37 (dd, J=5.5, 1.0 Hz, 1H),3.53 (s, 3H); LCMS (ESI+) m/z 281.0 (M+H).

Example 142b(4-(1-Methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 142b

A sealed tube equipped with a magnetic stirrer was charged with 142a(154.5 mg, 0.55 mmol),(2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 113i (252.5 mg, 0.55 mmol), Pd(dppf)Cl₂ (25.9 mg, 0.03135 mmol),NaOAc (108 mg, 1.1 mmol), K₃PO₄.3H₂O (293 mg, 1.1 mmol), acetonitrile (6mL), and water (0.5 mL). After three cycles of vacuum/argon flush, themixture was heated at 110° C. for 2 h. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica gelcolumn chromatography eluting with dichloromethane/methanol (15:1, UV)to afford 142b (117 mg, 30%) as a brown solid. LCMS: [M+H]⁺ 540.2

Example 1422-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one142

A mixture of 142b (121.6 mg, 0.225 mmol) and LiOH (100 mg, 4.2 mmol) in^(i)PrOH/THF (1:1, 4 mL) and H₂O (1 mL) was stirred at 35° C. for 0.5 h.The mixture was evaporated in vacuo and the residue was extracted withEtOAc (20 mL×3). The combined EtOAc extract was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 142 (54 mg, 48.2%) as a pale yellow solid. LCMS: [M+H]⁺ 498.1.¹H NMR (500 MHz, DMSO-d6) δ 9.23 (s, 1H), 8.76 (d, J=2.5, 1H), 8.65 (s,1H), 8.50 (d, J=5.0, 1H), 8.31 (d, J=6.0, 1H), 7.69 (d, J=2.5, 1H), 7.37(d, J=5.0, 1H), 7.31-7.33 (m, 1H), 6.58 (s, 1H), 4.97 (t, J=4.5, 1H),4.39-4.43 (m, 2H), 4.10-4.24 (m, 3H), 3.87 (d, J=12.0, 1H), 3.61 (s,3H), 2.57-2.64 (m, 2H), 2.47 (d, J=6, 2H), 1.79 (d, J=4.0, 2H), 1.69 (d,J=6.0, 2H)

Example 143a1-Methyl-3-(pyrimidin-4-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one143a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a condenser was charged with5-bromo-1-methyl-3-(pyrimidin-4-ylamino)pyridin-2(1H)-one 142a (4.0 g,14 mmol), X-phos (400 mg, 0.7 mmol), Pd2(dba)₃ (635 mg, 0.7 mmol), KOAc(7.3 mg, 28 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (10.6 g, 42mmol), and 1,4-dioxane (100 mL). After three cycles of vacuum/argonflush, the reaction mixture was heated at 60° C. for 8 h. It was thencooled to room temperature and filtered. The filtrate was concentratedunder reduced pressure and the resulting residue was purified by flashcolumn chromatography eluting with 5:1 petroleum ether/ethyl acetate toafford 143a as a pale yellow solid (3.8 mg, 82%). MS: [M+H]⁺ 329.5.

Example 143b4-(1-Methyl-5-(pyrimidin-4-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}nicotinaldehyde143b

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a condenser was charged with 143a (150 mg, 0.46 mmol),4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde109a (164 mg, 0.46 mmol):

Pd(dppf)Cl2 (16 mg, 0.02 mmol), K3PO4.3H₂O (223 mg, 0.92 mmol) in CH₃CN(5 mL) and H₂O (1 mL). After three cycles of vacuum/argon flush, thereaction mixture was heated at 100° C. for 3 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by flash columnchromatography eluting with 20:1 of DCM/MeOH to afford 143b as a yellowsolid (110 mg, 48%). MS: [M+H]⁺ 527.

Example 1436-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-2,2-dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza-cyclopenta[α]inden-7-one143

A mixture of 143b (110 mg, 0.2 mmol), NaBH4 (30 mg, 0.8 mmol), and MeOH(5 mL) was stirred at 25° C. for 30 mins. The mixture was evaporated invacuo and the residue was extracted with EtOAc (10 mL×2). The combinedEtOAc extract was concentrated under reduced pressure and the residuewas purified with reverse-phase prep-HPLC to afford 143 (48 mg, 44%).LCMS: [M+H]⁺ 529. ¹H NMR (500 MHz, DMSO) δ 9.23 (s, 1H), 8.76 (d, J=2.5,1H), 8.65 (s, 1H), 8.51-8.49 (m, 1H), 8.31 (m, 1H), 7.67 (d, J=3.0, 1H),7.38-7.37 (m, 1H), 7.33-7.31 (m, 1H), 5.02-5.01 (m, 1H), 4.43 (d, J=2.5,2H), 4.18-4.15 (m, 1H), 3.83-3.81 (m, 1H), 3.61-3.59 (m, 3H), 3.03-2.99(m, 1H), 2.91-2.89 (m, 1H), 2.76 (s, 2H), 2.60-2.53 (m, 2H), 1.23-1.22(m, 6H)

Example 144a4-(1-Methyl-5-(pyrimidin-4-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}nicotinaldehyde144a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a condenser was charged with1-methyl-3-(pyrimidin-4-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one143a (150 mg, 0.46 mmol),4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (157 mg, 0.46 mmol):

Pd(dppf)Cl2 (16 mg, 0.02 mmol), K₃PO₄.3H₂O (223 mg, 0.92 mmol) in CH₃CN(5 mL) and H₂O (1 mL). After three cycles of vacuum/argon flush, thereaction mixture was heated at 100° C. for 3 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by flash columnchromatography eluting with 20:1 of DCM/MeOH to afford 144a as a yellowsolid (98 mg, 48%). MS: [M+H]⁺ 510.

Example 1442-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta-[4,5]pyrrolo[1,2-a]pyrazin-1-one144

A mixture of 144a (98 mg, 0.19 mmol), NaBH₄ (30 mg, 0.8 mmol) and MeOH(5 mL) was stirred at 25° C. for 30 mins. The mixture was evaporated invacuo and the residue was extracted with EtOAc (10 mL×2). The combinedEtOAc extract was concentrated under reduced pressure and the residuewas purified with reverse-phase prep-HPLC to give 144 (25 mg, 42%).LCMS: [M+H]⁺ 512. ¹H NMR (500 MHz, DMSO) δ 9.18 (s, 1H), 8.76-8.74 (m,1H), 8.64 (s, 1H), 8.50-8.47 (m, 1H), 8.31-8.30 (m, 1H), 7.68-7.69 (m,1H), 7.37-7.36 (m, 1H), 7.33-7.31 (m, 1H), 6.56 (s, 1H), 5.07-5.04 (m,1H), 4.44-4.41 (m, 2H), 4.23-4.18 (m, 3H), 3.86-3.84 (m, 1H), 3.61 (s,3H), 2.61-2.56 (m, 2H), 2.42 (s, 2H), 1.21-1.20 (m, 6H)

Example 145a(S)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}nicotinaldehyde145a

A 50 mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with(S)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one130f (160 mg, 1 eq., 0.33 mmol),4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde109a (120 mg, 1 eq., 0.33 mmol):

PdCl₂(dppf) (27 mg, 0.1 eq., 0.033 mmol), K₃PO₄ (140 mg, 2 eq., 0.66mmol), NaOAc (54 mg, 2 eq., 0.66 mmol), and CH₃CN (20 mL). After threecycles of vacuum/argon flash, the mixture was heated at 100° C. for 2 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by column chromatography eluting with DCM/EtOH (40/1) to afford145a as yellow solid (97 mg, 43%). MS: [M+H]⁺ 680.3.

Example 1456-{3′-Hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-2,2-dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza-cyclopenta[a]inden-7-one145

A 25 mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 145a (97 mg, 1.0 eq., 0.14 mmol), NaBH₄(16 mg,3.0 eq., 0.42 mmol), and MeOH (10 mL). The mixture was stirred at roomtemperature for 1 h. The residue was purified by reverse-phase prep-HPLCto afford 145 (61 mg, 63%). LCMS: [M+H]⁺ 682.3. ¹H NMR (500 MHz, CDCl₃)δ 8.65 (d, J=2.5, 1H), 8.50 (d, J=5.0, 1H), 7.97 (d, J=2.5, 1H), 7.84(s, 1H), 7.80 (d, J=2.5, 1H), 7.37 (d, J=5.0, 1H), 7.30 (dd, J=3.0, 9.0,1H), 6.81 (d, J=9.0, 1H), 4.82-4.79 (m, 1H), 4.71-4.61 (m, 5H),4.45-4.31 (m, 2H), 3.85-3.80 (m, 1H), 3.71 (s, 3H), 3.54-3.46 (m, 2H),3.07 (d, J=5.0, 2H), 2.98-2.93 (m, 2H), 2.79 (s, 2H), 2.60-2.46 (m, 5H),2.21-2.18 (m, 1H), 1.28 (s, 6H), 0.98 (d, J=6.0, 3H)

Example 146a4-Chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde146a

To a solution of 2-bromo-4-chloronicotinaldehyde 103a (1600 mg, 7.27mmol), 10-fluoro-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one(500 mg, 2.40 mmol):

in dioxane (50 mL) was added KOAc (471 mg, 4.82 mmol), Pd₂(dba)₃ (220mg, 0.24 mmol), and 4,5-bis(diphenylphosphino)-9,9-dimethyl-xanthene(140 mg, 0.24 mmol). After bubbling argon through the resulting solutionfor 30 min, the mixture was stirred at 80° C. for 10 h. It was allowedto cool to room temperature and H₂O (100 mL) was added. The aqueouslayer was separated and extracted with ethyl acetate (2×200 mL). Thecombined organic layer was washed with brine (100 mL) and dried oversodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified on flash column eluting with PE/EA (3:1) to afford 146a as ayellow solid (420 mg, 49%). LCMS: [M+H]⁺ 348

Example 146b2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl)nicotinaldehyde146b

A round-bottomed flask was charged with 146a (200 mg, 0.58 mmol),1-methyl-3-(pyrimidin-4-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one143a (227 mg, 0.69 mmol), PdCl₂(dppf) (47 mg, 0.06 mmol), K₃PO₄ (244 mg,1.15 mmol), NaOAc (94 mg, 1.15 mmol), acetonitrile (30 mL), and H₂O (3mL). After three cycles of vacuum/argon flush, the mixture was heated at100° C. for 3 h. It was then filtered and the filtrate was evaporated invacuo. The residue was purified on flash column chromatography elutingwith 1:20 methanol/dichloro-methane to afford 146b as a red solid (79mg, 27%). LCMS: [M+H]⁺ 514

Example 14610-Fluoro-2-(3-(hydroxymethyl)-4-(1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one146

A mixture of 146b (79 mg, 0.15 mmol), NaBH₄ (22 mg, 0.60), and CH₃OH (10mL) was stirred at 25° C. for 1 h. The mixture was extracted with CH₂Cl₂(10 mL×2). The combined CH₂Cl₂ extract was concentrated under reducedpressure. The residue was purified with reverse-phase prep-HPLC toafford 146 (39 mg, 49%). LCMS: [M+H]⁺ 516. ¹H NMR (500 MHz, CDCl₃) δ8.83 (d, J=2.0, 1H), 8.78 (s, 1H), 8.52 (d, J=5.0, 1H), 8.35 (d, J=5.5,1 H), 8.12 (s, 1H), 8.03 (d, J=2.0, 1H), 7.36 (d, J=5.0, 1H), 6.76-6.77(m, 1H), 5.07 (s, 1H), 4.65 (d, J=9.5, 1H), 4.48 (d, J=9.5, 1H), 4.29(d, J=1.5, 1H), 4.02-4.13 (m, 2H), 3.79 (d, J=6.5, 1H), 3.73 (s, 3H),2.52-2.58 (m, 4H), 1.85-1.90 (m, 2H), 1.77 (d, J=5.0, 2 H)

Example 147a4-Chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde147a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 1,4-dioxane (50 mL),2-bromo-4-chloronicotin-aldehyde 103a (1.4 g, 6.4 mmol),3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1(2H)-one 112d (0.6 g, 3.2mmol), Pd₂(dba)₃ (293 mg, 0.32 mmol), XantPhos (370 mg, 0.64 mmol), andpotassium acetate (627 mg, 6.4 mmol). After three cycles of vacuum/argonflush, the mixture was heated at 80° C. overnight. After this time thereaction was cooled to room temperature. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica gelcolumn chromatography eluting with CH₂Cl₂/CH₃OH (20:1, UV) to afford147a (528 mg, 50%) as a yellow solid. MS: [M+H]⁺ 330. ¹H NMR (500 MHz,CDCl₃) δ 10.09 (s, 1H), 8.37 (d, J=5.5, 1H), 7.16 (d, J=5.5, 1H), 6.25(s, 1H), 4.29-4.32 (m, 2H), 3.83-3.86 (m, 2H), 2.96-2.99 (m, 2H),2.77-2.78 (m, 2H), 2.00-2.07 (m, 2H), 1.83-1.85 (m, 2H)

Example 147b2-(3-Formyl-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1(2H)-one147b

A round-bottomed flask was charged with4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde147a (100 mg, 0.30 mmol),1-methyl-3-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one135a (116 mg, 0.30 mmol), PdCl₂(dppf) (25 mg, 0.03 mmol), K₃PO₄.3H₂O(160 mg, 0.60 mmol), NaOAc (59 mg, 0.60 mmol), acetonitrile (10 mL), andH₂O (5 mL). After three cycles of vacuum/argon flush, the mixture washeated at 100° C. for 3 h. It was then filtered and the filtrate wasevaporated in vacuo. The residue was purified on flash columnchromatography eluting with 1:3 petroleum/ethyl acetate to afford 147bas a yellow solid (100 mg, 60%). LCMS: [M+H]⁺ 553

Example 1472-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1(2H)-one147

A mixture of 147b (100 mg, 0.18 mmol), NaBH₄ (21 mg, 0.54), and CH₃OH(10 mL) was stirred at 25° C. for 1 h. The mixture was extracted withCH₂Cl₂ (10 mL×2). The combined CH₂Cl₂ extract was concentrated underreduced pressure. The residue was purified with reverse-phase prep-HPLCto afford 147 (60 mg, 60%). LCMS: [M+H]⁺ 555. ¹H NMR (500 MHz, DMSO) δ8.45 (d, J=5.0, 1H), 8.19 (s, 1H), 8.06 (d, J=5.0, 1H), 7.41 (d, J=2.0,1H), 7.29 (d, J=5.0, 1H), 6.04 (s, 1H), 5.88 (s, 1H), 4.92 (s, 1H),4.33-4.42 (m, 2H), 4.11-4.16 (m, 1H), 3.91-3.96 (m, 3H), 3.77-3.82 (m,2H), 3.57 (s, 3H), 3.45-3.48 (m, 2H), 2.91-3.01 (m, 2H), 2.71-2.79 (m,4H), 2.35 (s, 3H), 1.90-1.92 (m, 2H), 1.71-1.79 (m, 2H)

Example 148a 3-(2-Bromo-4-chloropyridin-3-yl)oxetan-3-ol 148a

To a solution of 2-bromo-4-chloropyridine (14 g, 70 mmol) in dry THF(200 mL) was added LDA (42.0 mL, 84.0 mmol, 2.0 M) dropwise at −70° C.After stirring for 0.5 h at this temperature, a solution of oxetan-3-one(6.6 g, 90 mmol) in dry THF (40 mL) was added slowly and the reactionmixture was stirred at 0° C. for an additional 1 h. Saturated aqueousNH4CI (50 mL) and EA (200 mL) were added. The mixture was partitionedbetween water and ethyl acetate. The aqueous layer was extracted withethyl acetate. The combined organic layer was washed with water andbrine. After drying over anhydrous magnesium sulfate, the solvent wasevaporated and the crude material was purified by SGC eluting with DCM)to afford 148a as a yellow solid (8.8 g, 45%). MS: [M+H] 266.0.

Example 148b2-(4-Chloro-3-(3-hydroxyoxetan-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one148b

A 100 mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 101e (190 mg, 1.0mmol), 148a (795 mg, 3.0 mmol), CuI (95 mg, 0.5 mmol), DMEDA (88 mg, 1.0mmol), KOAc (294 mg, 3.0 mmol), and 1,4-dioxane (50 ml). The system wasevacuated and then refilled with N₂. A reflux condenser was attached tothe flask, and the reaction mixture was heated at 85° C. for 15 h. Then,the mixture was cooled to room temperature and filtered. The filtratewas concentrated under reduced pressure and the resulting residue waspurified by flash column chromatography eluting with 2:1 petroleumether/ethyl acetate to afford 148b as a yellow solid (156 mg, 42%). MS:[M+H] 374.2.

Example 148(S)-2-(3-(3-Hydroxyoxetan-3-yl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one148

A 100-mL single-neck round-bottomed flask was charged with 148b (100 mg,0.3 mmol),(S)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridine-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one130f (173 mg, 0.36 mmol), Pd(dppf)Cl₂ (15 mg, 0.015 mmol), K₃PO₄ (130mg, 0.6 mmol), and NaOAc.3H₂O (90 mg, 0.6 mmol) in CH₃CN (30 mL). Thesystem was evacuated and refilled with N₂. The reaction mixture washeated at 100° C. for 2 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by flash column chromatography elutingwith 25:1 DCM/MeOH to afford 148 (30 mg, 20%) as a pale yellow solid.MS: [M+H]⁺ 693.3. ¹H NMR (500 MHz, CDCl₃) δ 8.69 (d, J=2, 1H), 8.50 (d,J=5, 1H), 8.01 (d, J=2.5, 1H), 7.85 (s, 1H), 7.67 (s, 1H), 7.38-7.32 (m,2H), 6.89 (s, 1H), 6.83 (d, J=8.5, 1H), 6.67 (s, 1H), 4.93 (d, J=6, 1H),4.71-4.63 (m, 6H), 4.46 (d, J=7.5, 1H), 4.24-4.18 (m, 2H), 4.10-4.05 (m,1H), 3.90 (d, J=12.5, 1H), 3.70 (s, 3H), 3.55-3.46 (m, 2H), 3.10 (t,J=4.5, 2H), 2.63-2.48 (m, 7H), 2.22 (t, J=7.5, 1H), 1.92-1.88 (m, 2H),1.82-1.77 (m, 2H), 1.02-1.00 (m, 3H)

Example 149a(S)-4-(1-Methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde149a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde139a (100 mg, 0.30 mmol),(5)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)-piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one191j (146 mg, 0.30 mmol), PdCl₂(dppf) (25 mg, 0.030 mmol),K₃PO₄.trihydrate (160 mg, 0.60 mmol), sodium acetate (49 mg, 0.60 mmol),acetonitrile (20 mL), and water (3 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 3 h. It wasthen filtered and the filtrate was evaporated under reduced pressure.The residue was purified by silica-gel column chromatography elutingwith 1:3 petroleum/ethyl acetate to afford 149a as a yellow solid (97mg, 50%). MS-ESI: [M+H]⁺ 649

Example 1492-{3′-Hydroxymethyl-1-methyl-5-[54(S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-T-yl}-2,3,5,6,7,8-hexahydro-4H-2,4-b-diaza-fluoren-1-one149

A mixture of 149a (97 mg, 0.15 mmol), NaBH₄ (17 mg, 0.45), and methanol(10 mL) was stirred at 25° C. for 1 h. The reaction mixture was thenquenched with water (10 mL) and concentrated under reduced pressure. Theresidue was extracted with dichloromethane (2×10 mL). The combineddichloromethane extract was concentrated under reduced pressure and theresidue was purified with reverse-phase prep-HPLC to afford 149 (62 mg,63%). MS-ESI: [M+H]⁺ 651.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.63 (s, 1H),8.46 (d, J=5.0 Hz, 1H), 8.43 (s, 1H), 7.83 (d, J=3.0 Hz, 1H), 7.48 (d,J=2.0 Hz, 1H), 7.38-7.36 (m, 1H), 7.31 (J=5.0 Hz, 1H), 7.25-7.23 (m,1H), 6.04 (s, 1H), 4.57-4.55 (m, 2H), 4.48-4.46 (m, 1H), 4.42-4.38 (m,2H), 4.35-4.33 (m, 1H), 4.15-4.12 (m, 1H), 3.96-3.94 (m, 1H), 3.82-3.78(m, 2H), 3.69-3.67 (m, 1H), 3.59 (s, 3H), 3.41-3.38 (m, 2H), 3.18-3.15(m, 2H), 3.00-2.95 (m, 3H), 2.73-2.71 (m, 2H), 2.30-2.28 (m, 2H),2.20-2.16 (m, 1H), 1.93-1.89 (m, 3H), 1.77-1.75 (m, 1H), 0.93 (d, J=6.5Hz, 3H).

Example 150a3-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-5-[1-methyl-5-({5-methyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridine-4-carbaldehyde150a

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with3-bromo-5-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-4-carbaldehyde107f (233 mg, 0.60 mmol),1-methyl-3-({5-methyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-dihydropyridin-2-one135a (231 mg, 0.60 mmol), Pd(dppf)Cl₂ (49 mg, 0.060 mmol), potassiumacetate (118 mg, 1.2 mmol), K₃PO₄.trihydrate (320 mg, 1.2 mmol),acetonitrile (12 mL), and water (5 drops). After three cycles ofvacuum/argon flush, the mixture was heated at 110° C. for 2 h. It wasthen filtered and the filtrate was evaporated under reduced pressure.The residue was purified by silica-gel column chromatography elutingwith 30:1 dichloromethane/methanol to afford 150a (168 mg, 49%) as asolid. MS-ESI: [M+H]⁺ 567

Example 1502-[4-Hydroxymethyl-1′-methyl-5′-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6′-oxo-1′,6′-dihydro-[3,3]bipyridinyl-5-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one150

To a solution of 150a (170 mg, 0.30 mmol) in methanol (10 mL) was addedsodium borohydride (68 mg, 1.8 mmol) at 0° C. The mixture was stirred atroom temperature for 30 minutes. Then the reaction mixture was quenchedwith water (2 mL) and concentrated. The residue was purified withreverse-phase prep-HPLC to afford 150 (42 mg, 25%) as a pale yellowsolid. MS-ESI: [M+H]⁺ 569. ¹H NMR (500 MHz, CDCl₃) δ 8.63 (s, 1H), 8.48(s, 1H), 7.95 (d, J=2.0 Hz, 1H), 7.40 (s, 1H), 7.32 (d, J=2.5 Hz, 1H),6.82 (s, 1H), 5.67 (s, 1H), 4.63-4.55 (m, 2H), 4.37-4.35 (m 1H),4.22-4.18 (m, 3H), 4.05-3.97 (m, 3H), 3.69 (s, 3H), 3.59-3.57 (m, 2H),2.86 (t, J=6.0 Hz, 2H), 2.56 (s, 2H), 2.50 (s, 2H), 2.46 (s, 3H), 1.26(s, 6H).

Example 151a (R)-tert-Butyl3-Methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 151a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (60 mL),5-bromo-2-nitropyridine (2.0 g, 10.0 mmol), (R)-tert-butyl3-methylpiperazine-1-carboxylate (2.0 g, 10.0 mmol), and cesiumcarbonate (6.5 g, 20 mmol). After bubbling nitrogen through theresulting mixture for 10 minutes,tris(dibenzylideneacetone)dipalladium(0) (915 mg, 1.0 mmol) and XantPhos(579 mg, 1.0 mmol) were added. The system was subjected to three cyclesof vacuum/argon flush and heated at 100° C. for 15 h. After this timethe reaction was cooled to room temperature and filtered. The filtratewas partitioned between ethyl acetate (100 mL) and water (100 mL). Theaqueous layer was separated and extracted with ethyl acetate (3×50 mL).The combined organic layer was washed with brine (100 mL) and dried oversodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 30:1dichloromethane/methanol to afford 151a (1.6 g, 44%) as yellow solid.MS-ESI: [M+H]⁺ 323. ¹H NMR (500 MHz, DMSO-d₆) δ 8.21 (d, J=3.5 Hz, 1H),8.18 (d, J=9.0 Hz, 1H), 7.45-7.43 (m, 1H), 4.34-4.33 (m, 1H), 3.92-3.99(m, 1H), 3.80 (d, J=12.5 Hz, 2H), 3.06-3.23 (m, 3H), 1.43 (s, 9H), 1.09(d, J=6.5 Hz, 3H).

Example 151b (R)-tert-Butyl4-(6-Aminopyridin-3-yl)-3-methylpiperazine-1-carboxylate 151b

A 250-mL flask was purged with nitrogen and charged with 151a (1.5 g,4.6 mmol), 10% palladium on carbon (50% wet, 200 mg), and methanol (70mL). It was evacuated, charged with hydrogen gas, and stirred at roomtemperature for 10 h. The hydrogen was then evacuated and nitrogen wascharged into the flask. The catalyst was removed by filtration through apad of CELITE® and the filtrate was concentrated under reduced pressureto afford 151b (1.1 g, 81%) as brown solid. MS-ESI: [M+H]⁺ 293

Example 151c (R)-tert-Butyl4-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridin-3-yl)-3-methylpiperazine-1-carboxylate151c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (40 mL),151b (1.0 g, 3.4 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (2.7 g,10.2 mmol), and cesium carbonate (2.2 g, 6.8 mmol). After bubblingnitrogen through the resulting mixture for 10 minutes, XantPhos (198 mg,0.34 mmol) and tris(dibenzylideneacetone)dipalladium(0) (313 mg, 0.34mmol) were added. The reaction mixture was subjected to three cycles ofvacuum/argon flush and heated at 100° C. for 5 h. After this time thereaction was cooled to room temperature and filtered. The filtrate waspartitioned between ethyl acetate (50 mL) and water (50 mL). The aqueouslayer was separated and extracted with ethyl acetate (3×30 mL). Thecombined organic layer was washed with brine (50 mL) and dried oversodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 30:1dichloromethane/methanol to afford 151c as yellow solid (1.1 g, 63%).MS-ESI: [M+H]⁺ 478.

Example 151d(R)-5-Bromo-1-methyl-3-(5-(2-methylpiperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one151d

To a mixture of 151c (600 mg, 1.26 mmol) in methanol (20 mL) was addedHCl/dioxane (4M, 4 mL). The reaction mixture was stirred at roomtemperature for 4 h. It was then concentrated under reduced pressure.The residue was basified with aqueous 1M NaOH and extracted withdichloromethane (3×30 mL). The combined organic layer was washed withbrine and concentrated under reduced pressure to afford 151d (450 mg,95%) as yellow solid. MS-ESI: [M+H]⁺ 378.

Example 151e(R)-5-Bromo-1-methyl-3-(542-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one151f

A mixture of 151d (40.0 g, 106 mmol), oxetan-3-one (11.4 g, 159 mmol),NaBH₃CN (10.0 g, 159 mmol), and zinc chloride (21.3 g, 159 mmol) inmethanol (700 mL) was stirred at 50° C. for 5 hours. water (50 mL) wasadded to the mixture and concentrated under reduced pressure. Theresidue was extracted with dichloromethane (3×200 mL) and the combinedorganic layer was concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 40:1dichloromethane/methanol to afford 151e (35 g, 73%). MS: [M+H]⁺ 434.

Example 151f(R)-1-Methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one151f

To a solution of 151e (2.0 g, 4.60 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (3.50 g,13.80 mmol) in dioxane (50 mL) was added PdCl₂(dppf) (377.10 mg, 0.46mmol) and potassium acetate (2.70 g, 27.80 mmol). The mixture wasstirred at 10° C. for 12 h under argon atmosphere. After reaction themixture was filtered and the filtrate was evaporated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 15:1 methylene chloride/methanol to afford 151f (1.10 g,49%) as a brown solid. MS: [M+H]⁺ 482.3

Example 151g(R)-4-(1-Methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde151g

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde103b (150 mg, 0.45 mmol), 151f (331 mg, 0.69 mmol), PdCl₂(dppf) (37 mg,0.045 mmol), K₃PO₄ (190 mg, 0.90 mmol), sodium acetate (74 mg, 0.90mmol), acetonitrile (15 mL), and water (1.5 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 3 h. It wasthen filtered and the filtrate was evaporated under reduced pressure.The residue was purified with silica-gel column chromatography elutingwith 1:20 methanol/dichloromethane to afford 151g as a red solid (89 mg,30%). MS-ESI: [M+H]⁺ 647

Example 1512-{3′-Hydroxymethyl-1-methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one151

A mixture of 151g (89 mg, 0.14 mmol), NaBH₄ (22 mg, 0.60), and methanol(10 mL) was stirred at 25° C. for 1 h. The mixture was quenched withwater (8 mL) and concentrated under reduced pressure. The residue wasextracted with dichloromethane (2×10 mL). The combined dichloromethaneextract was concentrated under reduced pressure and the residue waspurified with reverse-phase prep-HPLC to afford 151 (35 mg, 39%).MS-ESI: [M+H]⁺ 649. ¹H NMR (500 MHz, CDCl₃) δ 8.65 (d, J=2.0 Hz, 1H),8.55 (d, J=5.0 Hz, 1H), 8.46 (s, 1H), 7.83 (d, J=2.5 Hz, 1H), 7.50-7.48(m, 2H), 7.38-7.36 (m, 1H), 7.26-7.24 (m, 2H), 6.83-6.80 (m, 2H), 4.98(bs, 1H), 4.57-4.54 (m, 2H), 4.48-4.33 (m, 4H), 3.67-3.66 (m, 1H), 3.60(s, 3H), 3.39-3.38 (m, 2H), 3.09-3.08 (m, 1H), 2.96-2.94 (m, 1H),2.76-2.74 (m, 2H), 2.64-2.62 (m, 2H), 2.36-2.31 (m, 2H), 2.20-2.17 (t,J=7.5 Hz, 1H), 1.88-1.86 (m, 2H), 1.75-1.74 (m, 2H), 0.93 (d, J=6.5 Hz,3H).

Example 152a tert-Butyl8-(6-Nitropyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate 152a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (100 mL),5-bromo-2-nitropyridine (2.5 g, 12.4 mmol), tert-butyl3,8-diazabicyclo[3.2.1]octane-3-carboxylate (869 g, 4.1 mmol), Pd₂(dba)₃(193 mg, 0.21 mmol), XantPhos (237 mg, 0.41 mmol), and cesium carbonate(2.7 g, 8.2 mmol). After three cycles of vacuum/argon flush, the mixturewas stirred at 110° C. overnight. The reaction was cooled to roomtemperature. It was then filtered and the filtrate was evaporated invacuo. The residue was purified by silica-gel column chromatographyeluting with 3:1 petroleum ether/ethyl acetate to afford 152a (2.63 g,66.8%) as a yellow solid. MS-ESI: [M+H]⁺ 335.2.

Example 152b tert-Butyl8-(6-Aminopyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate 152b

A 100-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 152a (2.5 g, 7.5 mmol), 10% palladium on carbon (50% wet,250 mg) and methanol (40 mL). The mixture was evacuated, charged withhydrogen gas, and stirred at room temperature for 16 h. The hydrogen wasthen evacuated and nitrogen was charged into the flask. The catalyst wasremoved by filtration through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure to afford 152b (1.51 g, 66%) as acolorless oil. MS-ESI: [M+H]⁺ 305.3

Example 152c tert-Butyl8-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridin-3-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate152c

A sealed tube equipped with a magnetic stirrer was charged with 152b(1.3 g, 4.3 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (1.2 g, 4.3mmol), tris(dibenzylideneacetone)dipalladium(0) (394 mg, 0.43 mmol),XantPhos (497 mg, 0.86 mmol), Cs₂CO₃ (2.8 g, 8.6 mmol), and 1,4-dioxane(15 mL). After three cycles of vacuum/argon flush, the mixture wasstirred at 120° C. for 2 h. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 50:1 dichloromethane/methanol to afford 152cas a yellow solid (900 mg, 43%). MS-ESI: [M+H]⁺ 490.3.

Example 152d3-(5-(3,8-Diazabicyclo[3.2.1]octan-8-yl)pyridin-2-ylamino)-5-bromo-1-methyl-pyridin-2(1H)-one152d

A mixture of 152c (900 mg, 1.84 mmol) and 4.0M HCl/dioxane (60 mL) wasstirred at room temperature for 5 h. It was then concentrated underreduced pressure to afford crude 152d as a yellow solid (700 mg, 98%),which was used in the next step without further purification. MS-ESI:[M+H]⁺ 390.3.

Example 152e5-Bromo-1-methyl-3-(5-(3-(oxetan-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyridin-2-ylamino)pyridine-2(1H)-one152e

A mixture of 152d (676 mg, 1.7 mmol), oxetan-3-one (251 mg, 3.5 mmol),NaBH₃CN (274 mg, 4.4 mmol), and zinc chloride (592 mg, 4.4 mmol) inmethanol (30 mL) was stirred at 50° C. for 5 hours. water was added andthe mixture was concentrated under reduced pressure. The residue wasextracted with dichloromethane three times. The combined extract wasconcentrated under reduced pressure to afford crude 152e as a yellowsolid (650 mg, 84%), which was used in the next step without furtherpurification. MS-ESI: [M+H]⁺ 446.2.

Example 152f(4-(1-Methyl-5-(5-(3-(oxetan-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyridine-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 152f

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 152e (300 mg, 0.67mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113h (257 mg, 0.67 mmol), Pd(dppf)Cl₂ (55 mg, 0.067 mmol), K₃PO₄(284 mg, 1.34 mmol), sodium acetate (110 mg, 1.34 mmol), water (6drops), and acetonitrile (20 mL). After three cycles of vacuum/argonflush, the mixture was stirred at reflux for 3 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 30:1 dichloromethane/methanol toafford 152f as a brown solid (200 mg, 42%). MS-ESI: [M+H]⁺ 705.4.

Example 1522-{3′-Hydroxymethyl-1-methyl-5-[5-((1S,5R)-3-oxetan-3-yl-3,8-diaza-bicyclo[3.2.1]oct-8-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one152

A mixture of 152f (180 mg, 0.26 mmol) and lithium hydroxide (215 mg, 5.1mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at 35°C. for 1 h. The mixture was evaporated in vacuo and the residue wasdiluted with water and ethyl acetate. The water phase was separated andextracted with ethyl acetate (2×10 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 152 (12 mg, 71%) as ayellow solid. MS-ESI: [M+H]⁺0 663.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.55(d, J=2.5 Hz, 1H), 8.48 (d, J=5.0 Hz, 1H), 8.32 (s, 1H), 7.80 (d, J=2.5Hz, 1H), 7.43 (d, J=2.0 Hz, 1H), 7.33 (d, J=5.0 Hz, 1H), 7.25-7.23 (m,1H), 7.20 (d, J=9.0 Hz, 1H), 6.57 (s, 1H), 4.96-4.94 (m, 1H), 4.48-4.43(m, 3H), 4.39-4.37 (m, 3H), 4.25-4.19 (m, 5H), 3.85 (d, J=11.5 Hz, 1H),3.59 (s, 3H), 2.66-2.54 (m, 4H), 2.40-2.36 (m, 3H), 2.17 (d, J=10.5 Hz,2H), 1.94-1.65 (m, 8H).

Example 153a2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-[(2R)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridine-3-carbaldehyde153a

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyri-dine-3-carbaldehyde108a (105 mg, 0.30 mmol),1-methyl-3-({5-[(2R)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-5-(tetra-methyl-1,3,2-dioxaborolan-2-yl)-1,2-dihydropyridin-2-one151g (216 mg, 0.45 mmol), PdCl₂(dppf) (25 mg, 0.030 mmol), K₃PO₄ (126mg, 0.60 mmol), sodium acetate (49 mg, 0.60 mmol), acetonitrile (15 mL),and water (1.5 mL). After three cycles of vacuum/argon flush, themixture was heated at 80° C. for 2 h. It was then filtered and thefiltrate was evaporated under reduced pressure. The residue was purifiedby silica-gel column chromatography eluting with 1:20methanol/dichloromethane to afford 153a as a red solid (82 mg, 41%).MS-ESI: [M+H]⁺ 663

Example 1532-{3′-Hydroxymethyl-1-methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one153

A mixture of 153a (82 mg, 0.12 mmol), NaBH₄ (22 mg, 0.60), and methanol(10 mL) was stirred at 25° C. for 1 h. It was then quenched with water(5 mL) and concentrated under reduced pressure. The residue wasextracted with dichloromethane (2×10 mL). The combined dichloromethaneextract was concentrated under reduced pressure and the residue waspurified with reverse-phase prep-HPLC to afford 153 (22 mg, 28%).MS-ESI: [M+H]⁺ 665. ¹H NMR (500 MHz, CDCl₃) δ 8.65 (d, J=2.0 Hz, 1H),8.48 (d, J=5.0 Hz, 1H), 7.96 (s, 1H), 7.84 (s, 1H), 7.83 (s, 1H), 7.36(d, J=5.0 Hz, 1H), 7.32-7.26 (m, 1H), 6.84-6.80 (m, 2H), 5.30 (s, 1H),4.71-4.32 (m, 7H), 4.15 (d, J=5.0 Hz, 2H), 3.85 (t, J=8.0 Hz, 1H), 3.71(s, 3H), 3.57-3.43 (m, 2H), 3.08-3.06 (m, 2H), 2.57-2.48 (m, 7H),2.22-2.20 (m, 1H), 1.27 (s, 6H), 0.98 (d, J=6.5 Hz, 3H).

Example 154a4-[1-Methyl-5-({5-[(2R)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde154a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a (84 mg, 0.24 mmol),(R)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one151g (173 mg, 0.36 mmol), PdCl₂(dppf) (20 mg, 0.024 mmol), K₃PO₄ (100mg, 0.48 mmol), sodium acetate (40 mg, 0.48 mmol), acetonitrile (20 mL),and water (2 mL). After three cycles of vacuum/argon flush, the mixturewas heated at 100° C. for 3 h. It was then filtered and the filtrate wasevaporated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 1:20methanol/dichloromethane to afford 154a as a red solid (112 mg, 70%).MS-ESI: [M+H]⁺ 665

Example 1543-{3′-Hydroxymethyl-1-methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one154

A mixture of 154a (150 mg, 0.23 mmol), NaBH₄ (35 mg, 0.92), and methanol(10 mL) was stirred at room temperature for 1 h. The mixture was thenquenched with water (8 mL) and concentrated under reduced pressure. Theresidue was extracted with dichloromethane (2×10 mL). The combineddichloromethane extract was concentrated under reduced pressure and theresidue was purified with reverse-phase prep-HPLC to afford 154 (29 mg,19%). MS-ESI: [M+H]⁺ 667. ¹H NMR (500 MHz, DMSO-d₆) δ 8.64 (d, J=2.5 Hz,1H), 8.56 (d, J=5.0 Hz, 1H), 8.49-8.47 (m, 2H), 7.85 (d, J=3.0 Hz, 1H),7.53 (d, J=5.0 Hz, 1H), 7.48 (d, J=2.5 Hz, 1H), 7.38-7.36 (m, 1H), 7.24(d, J=8.5 Hz, 1H), 4.85 (t, J=9.5 Hz, 1H), 4.57-4.54 (m, 2H), 4.43-4.36(m, 4H), 3.69-3.68 (m, 1H), 3.60 (s, 3H), 3.40-3.36 (m, 1H), 3.11-3.07(m, 1H), 2.97-2.86 (m, 6H), 2.33-2.31 (m, 2H), 2.16 (t, J=8.5 Hz, 1H),1.89-1.86 (m, 4H), 0.92 (d, J=6.5 Hz, 3H).

Example 155a3-(5-((2S,5R)-2,5-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one155a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-bromo-3-(5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one122e (3.0 g, 6.70 mmol), Pin₂B₂ (8442 mg, 33.5 mmol), Pd₂(dba)₃ (311 mg,0.34 mmol), X-phos (319 mg, 0.67 mmol), potassium acetate (1970 mg, 20.1mmol), and dioxane (50 mL). After three cycles of vacuum/argon flush,the mixture was heated at 60° C. for 16 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure. The resulting residue was washed with 8:1 petroleumether/ethyl acetate (80 mL) to afford 155a as a yellow solid (3 g, 90%).MS: [M+H]⁺ 496.4.

Example 155b4-(5-(5-(2,5-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde155b

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde139a (133 mg, 0.40 mmol), 155a (198 mg, 0.40 mmol), Pd(dppf)Cl₂ (17 mg,0.020 mmol), K₃PO₄ (254 mg, 1.2 mmol), sodium acetate (98 mg, 1.2 mmol),water (5 drops), and acetonitrile (10 mL). After three cycles ofvacuum/argon flush, the mixture was heated at reflux for 3 h. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 30:1dichloromethane/methanol to afford 155b as white solid (80 mg, 30%).MS-ESI: [M+H]⁺ 663.3.

Example 1552-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-2,3,5,6,7,8-hexahydro-4H-2,4-b-diaza-fluoren-1-one155

To a solution of 155b (80 mg, 0.12 mmol) at 0° C. in methanol (5 mL) wasadded sodium borohydride (12 mg, 0.36 mmol). The reaction mixture wasstirred for 30 minutes. It was then quenched with water (1 mL) andconcentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford 155 (32 mg, 40%). MS-ESI: [M+H]⁺665.3. ¹H NMR (500 MHz, CDCl₃) δ 8.68 (d, J=2.0 Hz, 1H), 8.50 (d, J=5.0Hz, 1H), 8.04 (d, J=2.5 Hz, 1H), 7.88 (s, 1H), 7.86 (d, J=2.5 Hz, 1H),7.37-7.33 (m, 2H), 6.82 (d, J=9.0 Hz, 1H), 6.32 (s, 1H), 5.02 (d, J=13.0Hz, 1H), 4.78-4.71 (m, 2H), 4.67-4.61 (m, 3H), 4.44-4.39 (m, 1H),4.31-4.29 (m, 1H), 3.96-3.91 (m, 1H), 3.86-3.80 (m, 2H), 3.78-3.75 (m,1H), 3.72 (s, 3H), 3.21-3.19 (m, 1H), 3.01-2.93 (m, 3H), 2.85-2.83 (m,2H), 2.72 (d, J=10.0 Hz, 2H), 2.49-2.47 (m, 1H), 2.05-2.03 (m, 2H),1.98-1.97

Example 156a4-(5-(5-((2S,5R)-2,5-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde156a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with3-(5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one155a (171 mg, 0.35 mmol),4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (120 mg, 0.35 mmol), K₃PO₄ (146 mg, 0.69 mmol), PdCl₂(dppf) (28 mg,0.035 mmol), sodium acetate (56 mg, 0.69 mmol), water (5 drops) andacetonitrile (20 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 40/1 dichloromethane/methanol to afford 156aas a yellow solid (60 mg, 25%). MS-ESI: [M+H]⁺ 681.3

Example 1562-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-10-fluoro-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one156

A 50-mL round-bottomed flask equipped with a magnetic stirrer wascharged with 156a (60 mg, 0.088 mmol), NaBH₄ (17 mg, 0.44 mmol), andmethanol (10 mL). The mixture was stirred at room temperature for 1 h.It was then quenched with water and concentrated under reduced pressure.The residue was purified by reverse-phase prep-HPLC to afford 156 (15mg, 25%). MS-ESI: [M+H]⁺ 683.5. ¹H NMR (500 MHz, CDCl₃) δ 8.67 (d, J=2.5Hz, 1H), 8.48 (d, J=5.0 Hz, 1H), 8.02 (d, J=2.5 Hz, 1H), 7.87 (s, 1H),7.84 (d, J=2.0 Hz, 1H), 7.37-7.35 (m, 2H), 6.81 (d, J=9.0 Hz, 1H),4.99-4.59 (m, 6H), 4.45-4.32 (m, 2H), 4.12-4.03 (m, 2H), 3.85-3.73 (m,2H), 3.71 (s, 3H), 3.19-3.16 (m, 1H), 2.91-2.89 (m, 1H), 2.75-2.69 (m,2H), 2.57-2.47 (m, 5H), 1.97-1.76 (m, 5H), 0.89-0.87 (m, overlap, 6H).

Example 1572-{5′-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-4-hydroxymethyl-1′-methyl-6′-oxo-1′,6′-dihydro-[3,3]bipyridinyl-5-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one157

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with3-bromo-5-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2a]indol-2(1H)-yl)isonicotinaldehyde101f (200 mg, 0.54 mmol),3-(5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one155a (267 mg, 0.54 mmol), Pd(dppf)Cl₂ (44 mg, 0.054 mmol), K₃PO₄ (229mg, 1.08 mmol), sodium acetate (89 mg, 1.08 mmol), water (0.2 mL) andacetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at reflux for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the residue was purified by reverse-phase prep-HPLC toafford 157 (35.5 mg, 11%) as a yellow solid. MS-ESI: [M+H]⁺ 665.4. ¹HNMR (500 MHz, CDCl₃) δ 8.65-8.63 (m, 2H), 8.50 (s, 1H), 7.80 (s, 1H),7.87 (s, 1H), 7.48-7.47 (m, 1H), 7.36 (d, J=7.5 Hz, 1H), 6.88 (s, 1H),6.81 (d, J=9.0 Hz, 1H), 4.75-4.54 (m, overlap, 6H), 4.37-4.13 (m,overlap, 4H), 4.00-3.95 (m, 1H), 3.74-3.73 (m, 1H), 3.72 (s, 3H),3.19-3.15 (m, 1H), 2.91-2.90 (m, 1H), 2.74-2.44 (m, overlap, 7H),1.92-1.88 (m, 2H), 1.81-1.79 (m, 2H), 0.90-0.89 (m, 6H).

Example 158a4-[5-({5-[(2S,5R)-2,5-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-2-{4,4-dimethyl-9-oxo-1,10-diazatri-cyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde158a

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with(4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde)108a (280 mg, 0.80 mmol),3-(5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one155a (480 mg, 0.96 mmol), Pd(dppf)Cl₂ (33 mg, 0.040 mmol), K₃PO₄ (339mg, 1.6 mmol), sodium acetate.trihydrate (218 mg, 1.6 mmol), andacetonitrile (100 mL). The system was evacuated and refilled with N₂.The reaction mixture was heated at 100° C. for 2 h. It was then cooledto room temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 25:1 of dichloromethane/methanol toafford 158a (300 mg, 54%) as a yellow brown solid. MS-ESI: [M+H]⁺ 677.3.

Example 1582-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one158

A mixture of 158a (200 mg, 0.30 mmol) and NaBH₄ (36 mg, 0.90 mmol) inmethanol (30 mL) was stirred at 30° C. for 1 h. The mixture was quenchedwith water (5 mL) and extracted with ethyl acetate (3×10 mL). Thecombined ethyl acetate extract was concentrated under reduced pressureand the residue was purified by reverse-phase prep-HPLC to afford 158(110 mg, 55%) as a white solid. MS-ESI: [M+H]⁺ 679.4. ¹H NMR (500 MHz,CDCl₃) δ 8.68 (d, J=2.0 Hz, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.03 (d, J=2.5Hz, 1H), 7.88 (s, 1H), 7.87 (d, J=2.0 Hz, 1H), 7.37-7.36 (m, 2H), 6.85(s, 1H), 6.81 (d, J=3.5 Hz, 1H), 5.07 (t, J=7.0 Hz, 1H), 4.77-4.71 (m,2H), 4.67-4.61 (m, 3H), 4.53-4.51 (m, 1H), 4.34-4.32 (m, 1H), 4.16 (d,J=5.5 Hz, 2H), 3.88-3.86 (m, 1H), 3.76 (t, J=7.5 Hz, 1H), 3.72 (s, 3H),3.20-3.17 (m, 1H), 2.92 (dd, J=3.0, 11.5 Hz, 1H), 2.76-2.70 (m, 2H),2.58 (d, J=6.0 Hz, 2H), 2.52 (s, 2H), 2.49-2.46 (m, 1H), 1.97-1.93 (m,1H), 1.28 (s, 6H), 0.92-0.89 (m, 6H).

Example 159a4-[5-({5-[2,5-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde159a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,6)]-trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a (200 mg, 0.58 mmol),3-({5-[(2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-dihydropyridin-2-one155a (1.0 g, 2.0 mmol), PdCl₂(dppf) (47 mg, 0.060 mmol), K₃PO₄ (280 mg,1.2 mmol), sodium acetate (95 mg, 1.2 mmol), acetonitrile (15 mL), andwater (1.5 mL). After three cycles of vacuum/argon flush, the mixturewas heated at 100° C. for 3 h. It was then filtered and the filtrate wasevaporated under reduced pressure. The residue was purified withsilica-gel column chromatography eluting with 1:20methanol/dichloromethane to afford 159a as a red solid (150 mg, 38%).MS-ESI: [M+H]⁺ 679

Example 1593-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one159

A mixture of 159a (130 mg, 0.19 mmol), NaBH₄ (22 mg, 0.60), and methanol(10 mL) was stirred at 25° C. for 1 h. The mixture was then quenchedwith water (8 mL) and concentrated under reduced pressure. The residuewas extracted with dichloromethane (2×10 mL). The combineddichloromethane extract was concentrated under reduced pressure and theresidue was purified with reverse-phase prep-HPLC to afford 159 (28 mg,22%). MS-ESI: [M+H]⁺ 681. ¹H NMR (500 MHz, CDCl₃) δ 8.71 (d, J=2.5 Hz,1H), 8.65 (d, J=5.0 Hz, 1H), 8.30 (s, 1H), 8.04 (s, 1H), 7.87 (s, 1H),7.70 (d, J=2.0 Hz, 1H), 7.55 (d, J=5.0 Hz, 1H), 7.37 (d, J=9.0 Hz, 1H),6.81 (d, J=9.0 Hz, 1H), 4.67-4.61 (m, 2H), 4.71-4.64 (m, 2H), 4.44-4.42(m, 2H), 4.34-4.33 (m, 1H), 3.83-3.76 (m, 1H), 3.72 (s, 3H), 3.20-3.16(m, 1H), 2.99-2.84 (m, 6H), 2.79-2.71 (m, 2H), 2.50-2.48 (m, 1H),2.02-1.98 (m, 4H), 0.91 (d, J=6.0 Hz, 6H).

Example 160a4-(5-(5-((2S,5R)-2,5-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde160a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde103b (150 mg, 1.0 eq., 0.46 mmol),3-(5-((2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one155a (228 mg, 0.46 mmol), K₃PO₄ (195 mg, 0.92 mmol), PdCl₂(dppf) (37 mg,0.046 mmol), sodium acetate (75 mg, 0.92 mmol), water (8 drops), andacetonitrile (20 mL). After three cycles of vacuum/argon flush, themixture was heated at 80° C. for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 40:1 dichloromethane/ethanol to afford 160aas yellow solid (80 mg, 26%). MS-ESI: [M+H]⁺ 661.4.

Example 1602-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one160

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 160a (80 mg, 0.12 mmol), NaBH₄ (23 mg, 0.60mmol), and methanol (10 mL). The mixture was stirred at room temperaturefor 1 h. It was quenched with water (1 mL) and filtered. The filtratewas concentrated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 160 (44 mg, 55%). MS-ESI: [M+H] 663.3.¹H NMR (500 MHz, CDCl₃) δ 8.72-8.70 (m, 1H), 8.57 (d, J=5.0 Hz, 1H),8.03 (d, J=2.5 Hz, 1H), 7.89-7.87 (m, 2H), 7.50 (d, J=5.0 Hz, 1H),7.37-7.35 (m, 1H), 7.06 (s, 1H), 6.97 (d, J=6.0 Hz, 1H), 6.81 (d, J=9.0Hz, 1H), 6.68 (d, J=6.0 Hz, 1H), 5.10-5.08 (m, 1H), 4.76-4.32 (m, 6H),3.76-3.72 (m, 4H), 3.20-3.17 (m, 1H), 2.93-2.90 (m, 1H), 2.76-2.69 (m,6H), 2.49-2.46 (m, 1H), 1.97-1.94 (m, 3H), 1.87-1.84 (m, 2H), 0.89 (t,J=6.5 Hz, 6H).

Example 161a (S)-tert-Butyl3-Ethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 161a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (50 mL),5-bromo-2-nitropyridine (2.02 g, 10 mmol), (S)-tert-butyl3-ethylpiperazine-1-carboxylate (2.14 g, 10.0 mmol), Pd₂(dba)₃ (458 mg,0.50 mmol), XantPhos (576 mg, 1.0 mmol), and cesium carbonate (6.52 g,20 mmol). After three cycles of vacuum/argon flush, the mixture washeated at 100° C. overnight. After this time the reaction was cooled toroom temperature. It was then filtered and the filtrate was evaporatedunder reduced pressure. The residue was purified by silica-gel columnchromatography eluting with 3:1 petroleum ether/ethyl acetate to afford161a (700 mg, 22%) as a yellow solid. MS: [M+H]⁺ 336

Example 161b (5)-tert-Butyl4-(6-Aminopyridin-3-yl)-3-ethylpiperazine-1-carboxylate 161b

A 100-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 161a (0.7 g, 2.08 mmol), 10% palladium on carbon (50% wet,208 mg), and methanol (40 mL). The mixture was evacuated, charged withhydrogen gas, and stirred at room temperature for 6 h. The hydrogen wasthen evacuated and nitrogen was charged into the flask. The catalyst wasremoved by filtration through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure to afford 161b (568 mg, 89%). MS:[M+H]⁺ 306

Example 161c (S)-tert-Butyl4-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridin-3-yl)-3-ethylpiperazine-1-carboxylate 161c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (50 mL),161b (568 mg, 1.86 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (498 mg,1.86 mmol), Pd₂(dba)₃ (85 mg, 0.093 mmol), XantPhos (107 mg, 0.186mmol), and cesium carbonate (1.198 g, 3.72 mmol). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 6 h. It wasthen filtered and the filtrate was evaporated under reduced pressure.The residue was purified by silica-gel column chromatography elutingwith 100:1 dichloromethane/methanol to afford 161c (502 mg, 55%) as ayellow solid. MS: [M+H]⁺ 492.

Example 161d(5)-5-Bromo-3-(5-(2-ethylpiperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one161d

A mixture of 161c (502 mg, 1.02 mmol), dichloromethane (2 mL), and 4.0 MHCl/dioxane (4 mL) was stirred at room temperature for 5 h. It was thenconcentrated under reduced pressure to afford crude 161d as a yellowsolid (263 mg, 66%), which was used in the next step without furtherpurification. MS: [M+H]⁺ 392.

Example 161e(5)-5-Bromo-3-(5-(2-ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one161e

A mixture of 161d (263 mg, 0.67 mmol), oxetan-3-one (96 mg, 1.34 mmol),NaBH₃CN 104 mg, 1.68 mmol), and zinc chloride (227 mg, 1.68 mmol) inmethanol (10 mL) was stirred at 50° C. for 5 hours. Water (10 mL) wasthen added to the reaction. The resulting mixture was concentrated underreduced pressure. The residue was extracted with dichloromethane threetimes. The combined organic layer was concentrated under reducedpressure and the residue was purified by silica-gel columnchromatography eluting with 50:1 dichloromethane/methanol to afford 161e(203 mg, 68%). MS: [M+H]⁺ 448.

Example 161f(S)-3-(5-(2-Ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one161f

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 161e (3219 mg, 7.20mmol), Pin₂B₂ (9072 mg, 36.0 mmol), Pd₂(dba)₃ (329 mg, 0.36 mmol),X-phos (302 mg, 0.72 mmol), potassium acetate (2117 mg, 21.6 mmol), anddioxane (50 mL). After three cycles of vacuum/argon flush, the mixturewas heated at 60° C. for 16 h. It was then cooled to room temperatureand filtered. The filtrate was concentrated under reduced pressure andthe resulting residue was washed with 8:1 petroleum ether/ethyl acetate(80 mL) to afford 161f as yellow solid (3.0 g, 84%). MS: [M+H]⁺ 496.4.

Example 161g4-(5-(5-(2-Ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde161g

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 161f (200 mg, 0.40 mmol),4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde139a (132 mg, 0.40 mmol), K₃PO₄ 3 water (213 mg, 0.80 mmol), sodiumacetate (66 mg, 0.80 mmol),1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (16 mg, 0.020mmol), and acetonitrile (20 mL). After three cycles of vacuum/N₂ flush,the mixture was heated at 100° C. under N₂ protection for 2 h. Analysisof the reaction mixture by LCMS showed complete conversion to thedesired product. The reaction mixture was cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure. Theresidue was diluted with dichloromethane (50 mL) and water (50 mL). Theaqueous layer was separated and extracted with dichloromethane (3×20mL). The combined organic layer was dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The dark residue was purified bysilica-gel column chromatography eluting with dichloromethane/methanol(80/1 to 30/1) to afford 161g (150 mg, 57%) as yellow solid. MS-ESI:[M+H]+ 663

Example 1612-{5-[5-((S)-2-Ethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-2,3,5,6,7,8-hexahydro-4H-2,4-b-diaza-fluoren-1-one161

To a solution of 161g (120 mg, 0.18 mmol) in methanol (20 mL) was addedNaBH₄ (21 mg, 0.54 mmol) at room temperature. After the reaction wasstirred for 1 h, LCMS indicated the reaction was complete. Then themixture was poured into water (20 mL) and concentrated under reducedpressure. The residue was extracted with dichloromethane (3×40 mL). Thecombined organic layer was washed with brine (20 mL), dried over Na₂SO₄,filtered, and concentrated. The residue solid was purified by prep-HPLCto afford 161 (97 mg, 81%) as white solid. MS-ESI: [M+H]⁺ 665. ¹H NMR(500 MHz, CDCl₃) δ 8.63 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 7.93 (s, 1H),7.84-7.82 (m, 2H), 7.35 (d, J=4.5 Hz, 1H), 7.28 (s, 1H), 6.82 (d, J=9.0Hz, 1H), 6.32 (s, 1H), 5.01-4.99 (m, 1H), 4.73-4.64 (m, 5H), 4.45-4.40(m, 1H), 4.30 (t, J=12.0 Hz, 1H), 3.94-3.91 (m, 1H), 3.85-3.83 (m, 2H),3.72 (s, 3H), 3.55-3.53 (m, 1H), 3.34-3.32 (m, 1H), 3.14-3.12 (m, 2H),3.04-2.92 (m, 2H), 2.84-2.82 (m, 2H), 2.59-2.57 (m, 1H), 2.46-2.44 (m,2H), 2.38-2.36 (m, 1H), 2.06-2.01 (m, 2H), 1.90-1.86 (m, 2H), 1.68-1.66(m, 1H), 1.43-1.39 (m, 1H), 0.82 (t, J=7.5 Hz, 3H).

Example 162a 5-Bromo-1-methyl-3-(pyrazin-2-ylamino)pyridin-2(1H)-one162a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with pyrazin-2-amine (500 mg,5.3 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (1335 mg, 5.3 mmol),Pd₂(dba)₃ (229 mg, 0.25 mmol), XantPhos (289 mg, 0.50 mmol), cesiumcarbonate (3.26 g, 10 mmol) and 1,4-dioxane (50 mL). After three cyclesof vacuum/argon flush, the mixture was stirred at 100° C. for 2 h. Itwas then filtered and the filtrate was evaporated in vacuo. The residuewas purified by silica-gel column chromatography eluting with 50:1dichloromethane/methanol to afford 162a (420 mg, 30%) as a yellow solid.MS-ESI: [M+H]⁺ 281.0.

Example 162b(4-(1-Methyl-6-oxo-5-(pyrazin-2-ylamino)-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 162b

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 162a (170 mg, 0.61 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (280 mg, 0.72 mmol), Pd(dppf)Cl₂ (30 mg, 0.037 mmol),K₃PO₄.trihydrate (270 mg, 1.2 mmol), sodium acetate (180 mg, 1.2 mmol),acetonitrile (20 mL), and water (0.5 mL). The system was evacuated andrefilled with N₂. The reaction mixture was stirred at 100° C. for 2 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 25:1 ofdichloromethane/methanol to afford 162b (130 mg, 40%) as a yellow brownsolid. MS-ESI: [M+H]⁺ 540.3

Example 1622-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrazin-2-ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one162

A mixture of 162b (110 mg, 0.20 mmol) and lithium hydroxide (84 mg, 2.0mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at 30°C. for 1 h. The mixture was evaporated in vacuo and the residue wasdiluted with water and ethyl acetate. The water phase was separated andextracted with ethyl acetate (2×10 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 162 (85 mg, 85%) as paleyellow solid. MS-ESI: [M+H]⁺ 498.3. ¹H NMR (500 MHz, CHCl₃) δ 8.73 (d,J=2.5 Hz, 1H), 8.54 (d, J=5 Hz, 1H), 8.29 (s, 1H), 8.15-8.14 (m, 2H),8.01 (d, J=2.5 Hz, 1H), 8.00 (d, J=2.0 Hz, 1H), 7.37 (d, J=5 Hz, 1H),6.91 (s, 1H), 4.66-4.65 (m, 1H), 4.52-4.51 (m, 1H), 4.32-4.31 (m, 1H),4.18-4.17 (m, 1H), 4.14-4.12 (m, 1H), 3.90-3.88 (m, 1H), 3.75 (s, 3H),2.62-2.57 (m, 4H), 1.92-1.88 (m, 3H), 1.80-1.79 (m, 2H).

Example 163a1-Methyl-5-(5-(oxetan-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-ylboronicacid 163a

A 100-mL round bottomed flask equipped with a magnetic stirrer wascharged with5-bromo-1-methyl-3-(5-(oxetan-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridin-2(1H)-one125i (1.0 g, 2.64 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.0 g, 7.92mmol), PdCl₂(dppf) (190 mg, 0.26 mmol), potassium acetate (776 mg, 7.92mmol), and dioxane (40 mL). After bubbling argon into the mixture for 30minutes, a reflux condenser was attached to the flask and mixture wasstirred at 100° C. for 6 h under an argon atmosphere. The resultingmixture was filtered and the filtrate was evaporated under reducedpressure. The residue was purified by reverse-phase Combiflash elutingwith 0.3% NH₄HCO₃ water/CH₃CN to afford 163a as a white solid (300 mg,33%). MS: [M+H]⁺ 346.

Example 163b2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(1-methyl-5-{[5-(oxetan-3-yl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-6-oxo-1,6-dihydropyridin-3-yl)pyridine-3-carbaldehyde163b

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with(4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde)108a (280 mg, 0.81 mmol), 163a (440 mg, 0.96 mmol), Pd(dppf)Cl₂ (40 mg,0.049 mmol), K₃PO₄ (360 mg, 1.6 mmol), sodium acetate trihydrate (240mg, 1.6 mmol), water (6 drops), and acetonitrile (20 mL). The system wasevacuated and refilled with N₂. The reaction mixture was stirred at 100°C. for 2 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with25:1 dichloromethane/methanol to afford 163b (150 mg, 31%) as a yellowbrown solid. MS-ESI: [M+H]⁺ 609.3

Example 1632-[3′-Hydroxymethyl-1-methyl-5-(5-oxetan-3-yl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one163

A mixture of 163b (80 mg, 0.12 mmol) and NaBH₄ (15 mg, 0.36 mmol) inmethanol (5 mL) was stirred at 30° C. for 2 h. The mixture was quenchedwith water and concentrated under reduced pressure. The residue wasextracted with ethyl acetate (3×10 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 163 (30 mg, 50%) as darkred solid. MS-ESI: [M+H]⁺ 611.4. ¹H NMR (500 MHz, CHCl₃) δ 8.48 (d,J=5.5 Hz, 1H), 7.96 (d, J=2.5 Hz, 1H), 7.70 (d, J=2, 1H), 7.43 (s, 1H),7.34 (d, J=5 Hz, 1H), 6.8 (s, 1H), 5.70 (s, 1H), 5.03 (t, J=6, 1H),4.77-4.73 (m, 3H), 4.68 (t, J=6.5 Hz, 2H), 4.51-4.50 (m, 1H), 4.34-4.33(m, 1H), 4.23-4.16 (m, 2H), 4.09 (t, J=5.5 Hz, 2H), 3.86-3.85 (m, 1H),3.79-3.74 (m, 1H), 3.71 (s, 3H), 3.56 (d, J=4, 2H), 2.83 (t, J=5.5 Hz,2H), 2.58 (d, J=5.5 Hz, 2H), 2.52 (s, 2H), 1.28 (s, 6H).

Example 164a2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[5-({5-[(2S)-2-ethyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]pyridine-3-carbaldehyde164a

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with(4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde)108a (280 mg, 0.8 mmol),(S)-3-(5-(2-ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-5-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one161f (500 mg, 0.96 mmol), Pd(dppf)Cl₂ (33 mg, 0.040 mmol), K₃PO₄ (360mg, 1.6 mmol), sodium acetate trihydrate (240 mg, 1.6 mmol), andacetonitrile (100 mL). The system was evacuated and refilled with N₂.The reaction mixture was heated at 100° C. for 2 h. It was then cooledto room temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 25:1 dichloromethane/methanol toafford 164a (320 mg, 60%) as a yellow brown solid. MS-ESI: [M+H]⁺ 677.3.

Example 1642-{5-[5-((S)-2-Ethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one164

A mixture of 164a (200 mg, 0.30 mmol) and NaBH₄ (36 mg, 0.90 mmol) inmethanol (30 mL) was stirred at 30° C. for 2 h. The mixture was quenchedwith water and concentrated under reduced pressure. The residue wasextracted with ethyl acetate (3×10 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 164 (140 mg, 72%) as lightgreen solid. MS-ESI: [M+H]⁺ 679.3. ¹H NMR (500 MHz, CDCl₃) δ 8.63 (d,J=2.5 Hz, 1H), 8.49 (d, J=5.0 Hz, 1H), 7.93 (d, J=2.5 Hz, 1H), 7.83 (s,1H), 7.82 (s, 1H), 7.37 (d, J=5.0 Hz, 1H), 7.27 (s, 1H), 6.85 (s, 1H),6.82 (d, J=9.0 Hz, 1H), 5.06 (s, 1H), 4.71-4.61 (m, 5H), 4.52-4.50 (m,1H), 4.34-4.32 (m, 1H), 4.16 (d, J=4.5 Hz, 2H), 3.87-3.85 (m, 1H), 3.72(s, 3H), 3.55-3.50 (m, 1H), 3.33-3.30 (m, 1H), 3.12 (t, J=5.0 Hz, 2H),2.58-2.55 (m, 3H), 2.52 (s, 2H), 2.44 (d, J=3.5 Hz, 2H), 2.35 (t, J=5.5Hz, 1H), 1.68-1.64 (m, 1H), 1.42-1.37 (m, 1H), 1.28 (s, 6H), 0.82 (t,J=7.5 Hz, 3H).

Example 165a(S)-4-(5-(5-(2-Ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde165a

A 50-mL flask equipped with a reflux condenser was charged with4-chloro-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde103b (164 mg, 0.50 mmol),(S)-3-(5-(2-ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one161f (347 mg, 0.70 mmol), potassium acetate (137 mg, 1.4 mmol),1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (29 mg, 0.035mmol), water (5 drops), and acetonitrile (20 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. under argonatmosphere for 3 h. The reaction mixture was cooled to room temperatureand filtered. The filtrate was concentrated under reduced pressure. Theresidue was diluted with dichloromethane (50 mL) and water (50 mL). Theaqueous layer was separated and extracted with dichloromethane (3×20mL). The combined organic layer was dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The dark residue was purified bysilica-gel column chromatography eluting with dichloromethane/methanol(80/1 to 25/1) to afford 165a (151 mg, 46%) as yellow solid. MS-ESI:[M+H]⁺ 661

Example 1652-{5-[5-(S)-2-Ethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one165

To a solution of 165a (100 mg, 0.15 mmol) in methanol (10 mL) was addedNaBH₄ (34 mg, 0.90 mmol) at room temperature. After the reaction wasstirred for 1 h, LCMS indicated the reaction was complete. Then themixture was quenched with water (8 mL) and concentrated under reducedpressure. The residue was extracted with dichloromethane (3×10 mL). Thecombined organic layer was washed with brine (30 mL), dried over Na₂SO₄,filtered, and concentrated under reduced pressure. The residue waspurified by reverse-phase prep-HPLC to afford 165 (35 mg, 35%) as lightyellow solid. MS-ESI: [M+H]⁺ 663. ¹H NMR (500 MHz, DMSO-d₆) δ 8.64 (s,1H), 8.57 (d, J=5.0 Hz, 1H), 8.44 (s, 1H), 7.82 (d, J=2.0 Hz, 1H),7.51-7.48 (m, 2H), 7.35 (dd, J=2.0 Hz, 9.0 Hz, 1H), 7.27-7.23 (m, 2H),6.83-6.81 (m, 2H), 4.97 (bs, 1H), 4.59-4.55 (m, 2H), 4.49-4.32 (m, 4H),3.61 (s, 3H), 3.51-3.47 (m, 1H), 3.42-3.37 (m, 1H), 3.17-3.16 (m, 1H),3.01-2.98 (m, 1H), 2.76-2.74 (m, 2H), 2.63-2.61 (m, 3H), 2.55-2.54 (m,1H), 2.19-2.16 (m, 1H), 2.12-2.07 (m, 1H), 1.90-1.85 (m, 2H), 1.77-1.66(m, 3H), 1.27-1.25 (m, 1H), 0.79 (t, J=7.0 Hz, 3H).

Example 166a2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-5-(5-(oxetan-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)nicotinaldehyde166a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with1-methyl-3-(5-(oxetan-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one163a (354 mg, 0.83 mmol),4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (289 mg, 0.83 mmol), PdCl₂(dppf) (68 mg, 0.08 mmol), K₃PO₄ (352 mg,1.66 mmol), sodium acetate (136 mg, 1.66 mmol), acetonitrile (50 mL),and water (3 mL). The system was evacuated and refilled with N₂. Thereaction mixture was heated at 100° C. for 2 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 30:1 dichloromethane/methanol toafford 166a (305 mg, 60%) as a brown solid. MS-ESI: [M+H]⁺: 613.6.

Example 16610-Fluoro-2-[3′-hydroxymethyl-1-methyl-5-(5-oxetan-3-yl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one166

To a suspension of 166a (250 mg, 0.41 mmol) in methanol (20 mL) wasadded sodium borohydride (47 mg, 1.23 mmol) at 0° C. The mixture wasstirred for 30 minutes. It was then quenched with water (2 mL) andconcentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford 166 (20 mg, 6.6%). MS-ESI: [M+H]⁺615.6. ¹H NMR (500 MHz, CDCl₃) δ 8.46 (d, J=5.0 Hz, 1H), 7.94 (d, J=3.0Hz, 1H), 7.66 (d, J=2.0 Hz, 1H), 7.43 (s, 1H), 7.34 (d, J=5.0 Hz, 1H),5.75 (s, 1H), 4.95 (t, J=6.5 Hz, 1H), 4.76-4.74 (m, 2H), 4.69-4.65-4.67(m, 3H), 4.46-4.44 (m, 1H), 4.35-4.33 (m, 1H), 4.10-4.08 (m, 4H),3.38-3.35 (m, 2H), 3.69 (s, 3H), 3.58-3.56 (m, 2H), 2.84-2.82 (m, 2H),2.58-2.53 (m, 4H), 1.89-1.84 (m, 2H), 1.77-1.76 (m, 2H).

Example 167a 3-Chlorobicyclo[2.2.1]hept-2-ene-2-carbaldehyde 167a

A 250-mL three-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was purged with nitrogen and charged withanhydrous 1,2-dichloroethane (24 mL) and anhydrous DMF (9.12 g, 125mmol). The reaction mixture was cooled to 0° C. and phosphorusoxychloride (15.3 g, 100 mmol) was added over a period of 5 minuteswhile maintaining the reaction temperature between 0 and 10° C. Thecooling bath was removed and the reaction was stirred at roomtemperature for 30 minutes. A solution of bicyclo[2.2.1]heptan-2-one(5.50 g, 50.0 mmol) in 1,2-dichloroethane (10 mL) was added and theresulting mixture was heated at 80° C. overnight. After this time, thereaction was poured into a solution of potassium monohydrogen phosphate(43.5 g, 250 mmol) in water (200 mL) and stirred for 15 minutes. Theorganic layer was separated and concentrated under reduced pressure. Theresidue was dissolved in methylene chloride (300 mL) and washed withwater (2×50 mL). The methylene chloride layer was dried over sodiumsulfate, filtered, and concentrated under reduced pressure. The residuewas purified by silica-gel column chromatography eluting with 1:100ethyl acetate/petroleum ether to afford 167a as a yellow oil (2.2 g,28%). MS: [M+H]⁺ 157. ¹H NMR (500 MHz, CDCl₃) δ 9.80 (s, 1H), 3.42-3.41(m, 1H), 3.08-3.07 (m, 1H), 1.95-1.77 (m, 2H), 1.68-1.66 (m, 1H),1.41-1.17 (m, 3H).

Example 167b (E)-Ethyl 3-(3-Chlorobicyclo[2.2.1]hept-2-en-2-yl)acrylate167b

To a solution of 167a (9.0 g, 57.7 mmol) in methylene chloride (250 mL)was added ethyl 2-(triphenyl-λ⁵-phosphanylidene)acetate (20 g, 57.7mmol). The mixture was stirred at room temperature overnight. It wasthen evaporated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 1:100 ethylacetate/petroleum ether to afford 167b as a yellow oil (6.0 g, 46%). MS:[M+H]⁺ 227.

Example 167c Ethyl3-Azatricyclo[5.2.1.0^(2,6)]deca-2(6),4-diene-4-carboxylate 167c

To a solution of 167b (5.0 g, 22 mmol) in DMSO (30 mL) was added NaN₃(2.2 g, 33 mmol). The mixture was heated at 105° C. for 6 hours. Water(13 mL) was added to the reaction mixture after cooling down to roomtemperature and the resulting mixture was extracted with methylenechloride (3×50 mL). The combined organic phase was dried over Na₂SO₄ andevaporated under reduced pressure to dryness. The residue was purifiedby silica-gel column chromatography eluting with 20:1 methylenechloride/methanol to afford 167c as a brown solid (2.7 g, 60%). MS:[M+H]⁺ 206. ¹H NMR (500 MHz, CDCl₃) δ 11.51 (s, 1H), 6.45 (s, 1H), 4.16(q, J=6.5 Hz, 2H), 3.26-3.24 (m, 2H), 1.82-1.79 (m, 2H), 1.74-1.72 (m,2H), 1.24 (t, J=6.5 Hz, 3H), 0.91-0.89 (m, 2H).

Example 167d Ethyl3-(Cyanomethyl)-3-azatricyclo[5.2.1.0^(2,6)]deca-2(6),4-diene-4-carboxylate167d

Into a solution of 167c (3.0 g, 14.6 mmol) in anhydrous DMF (30 mL) wasadded NaH (880 mg, 22 mmol). The mixture was stirred at room temperaturefor 30 minutes. 2-Bromoacetonitrile (3.5 g, 29.3 mmol) was added and theresulting mixture was heated at 65° C. for 1 hour. It was then stirredat room temperature overnight. After reaction water (30 mL) was addedand the resulting mixture was extracted with ethyl acetate (200 mL×3).The combined organic phase was evaporated under reduced pressure todryness. The residue was purified by silica-gel column chromatographyeluting with 20:1 methylene chloride/methanol to afford 167d as a brownsolid (2.6 g, 72%). MS: [M+H]⁺ 245.

Example 167e Ethyl3-(2-Aminoethyl)-3-azatricyclo[5.2.1.0^(2,6)]deca-2(6),4-diene-4-carboxylate167e

A suspension of 167d (4.0 g, 16 mmol) and Raney Ni (400 mg) in methanol(60 mL) was hydrogenated in a Parr apparatus at 50 psi overnight. Themixture was filtered through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 20:1 methylenechloride/methanol to afford 167e as a yellow solid (2.0 g, 50%). MS:[M+H]⁺ 249.

Example 167f3,6-Diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-7-one167f

Into a solution of 167e (1.8 g, 7.2 mmol) in ethanol (40 mL) was addedsodium methoxide (2.5 g, 36 mmol). The mixture was heated at 65° C. for12 hours. It was then cooled to room temperature. The solvent wasevaporated to dryness under reduced pressure. The residue was purifiedby silica-gel column chromatography eluting with 20:1 methylenechloride/methanol to afford the racemate as a brown solid (800 mg, 53%),chiral resolution of which afforded 167f and 170a. MS: [M+H]⁺ 203.

Example 167g4-Chloro-2-[(1S,11R)-7-oxo-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-6-yl]pyridine-3-carbaldehyde167g

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (30 mL),167f (400 mg, 2.0 mmol), 2-bromo-4-chloronicotinaldehyde (1.30 g, 6.0mmol), and potassium acetate (390 mg, 4.0 mmol). After bubbling nitrogenthrough the resulting mixture for 30 minutes, Xantphos (110 mg, 0.20mmol) and tris(dibenzylideneacetone)dipalladium(0) (180 mg, 0.20 mmol)were added and the reaction mixture was heated at 80° C. for 10 h. Itwas then cooled to room temperature and filtered. The filtrate waspartitioned between ethyl acetate (50 mL) and water (30 mL). The aqueouslayer was separated and extracted with ethyl acetate (3×30 mL). Thecombined organic layer was washed with brine (20 mL) and dried oversodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified with silica-gel column chromatography eluting with 2:1petroleum ether/ethyl acetate to afford 167g (391 mg, 57%) as yellowsolid. MS-ESI: [M+H]⁺ 342.2

Example 167h4-[1-Methyl-5-({5-methyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-[(1S,11R)-7-oxo-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-6-yl]pyridine-3-carbaldehyde167h

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with 167g (150 mg, 0.44 mmol),1-methyl-3-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one135a (169 mg, 0.44 mmol), sodium acetate (72 mg, 0.88 mmol), K₃PO₄ (234mg, 0.88 mmol), PdCl₂(dppf) (36 mg, 0.044 mmol), acetonitrile (20 mL),and water (1 mL). After bubbling nitrogen through the mixture for 30minutes, it was heated at 100° C. under N₂ for 3 hours. The reactionmixture was cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the residue was purified bysilica-gel column chromatography eluting with 25:1dichloromethane/methanol to afford 167h (132 mg, 53%) as a brown solid.MS-ESI: [M+H] 565.3

Example 1672-(3-(hydroxymethyl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydro-6,9-methanopyrazino[1,2-a]indol-1(2H)-one167

A solution of 167h (120 mg, 0.21 mmol) in methanol (20 mL) was addedNaBH₄ (24 mg, 0.63 mmol). The mixture was stirred at 20° C. for 2 h. Thereaction was quenched with water and concentrated under reducedpressure. The residue was purified by reverse-phase prep-HPLC to afford167 (98 mg, 83%) as a yellow solid. MS-ESI: [M+H] 567.3. ¹H NMR (500MHz, DMSO-d₆) δ 8.48 (d, J=5.0 Hz, 1H), 8.19 (s, 1H), 8.05 (d, J=2.5 Hz,1H), 7.40 (s, 1H), 7.32 (d, J=5.0 Hz, 1H), 6.53 (d, J=5.5 Hz, 1H), 5.89(s, 1H), 4.98 (t, J=5.0 Hz, 1H), 4.48-4.30 (m, 3H), 4.27-4.22 (m, 2H),3.92-3.91 (m, 2H), 3.86-3.84 (m, 1H), 3.60 (s, 3H), 3.52-3.33 (m, 3H),3.29 (ps, 1H), 2.79-2.77 (m, 2H), 2.35 (s, 3H), 1.87-1.76 (m, 3H),1.60-1.59 (m, 1H), 1.09-0.91 (m, 2H).

Example 168a3-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one168a

A 250-mL round bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with the mixture of5-bromo-3-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methylpyridin-2(1H)-one129c (1.3 g, 4.0 mmol), bis(pinacolato)diboron (2.03 g, 8.0 mmol),PdCl₂(dppf) (439 mg, 0.60 mmol), potassium acetate (784 mg, 8.0 mmol),and 1,4-dioxane (60 mL). After bubbling nitrogen through the mixture for30 minutes, it was heated at reflux for 15 h. The mixture was cooled toroom temperature upon completion of the reaction and filtered. The solidwas washed with ethyl acetate (100 mL). The combined filtrate wasevaporated under reduced pressure and the residue was purified bysilica-gel column chromatography eluting with 30:1dichloromethane/methanol to afford 168a (446 mg, 30%). MS: [M+H]⁺ 373.

Example 168b4-(1-Methyl-5-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl)nicotinaldehyde168b

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (200 mg, 0.58 mmol), 168a (433 mg, 1.16 mmol), PdCl₂(dppf) (48 mg,0.052 mmol), K₃PO₄ (246 mg, 1.16 mmol), sodium acetate (96 mg, 1.16mmol), acetonitrile (10 mL), and water (0.5 mL). The system wasevacuated and refilled with N₂. The reaction mixture was stirred at 100°C. for 2 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with30:1 dichloromethane/methanol to afford 168b (250 mg, 78%) as a yellowsolid. MS-ESI: [M+H]⁺ 554.6.

Example 1682-[5-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one168

To a suspension of 168b (200 mg, 0.36 mmol) at 0° C. in methanol (10 mL)was added sodium borohydride (42 mg, 1.1 mmol). The reaction mixture wasstirred for 30 minutes and quenched with water (2 mL). It was thenconcentrated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 168 (53 mg, 21%) as a yellow solid.MS-ESI: [M+H]⁺ 556.6. ¹H NMR (400 MHz, CDCl₃) δ 8.46 (d, J=5.2 Hz, 1H),7.97 (d, J=2.4 Hz, 1H), 7.71 (d, J=2.0 Hz, 1H), 7.45 (s, 1H), 7.33 (d,J=5.2 Hz, 1H), 6.83 (s, 1H), 5.71 (s, 1H), 5.04-5.01 (m, 1H), 4.78 (s,2H), 4.64-4.62 (m, 1H), 4.49 (d, J=2.8 Hz, 1H), 4.32-4.28 (m, 1H), 4.14(d, J=4.4 Hz, 2H), 4.09-4.08 (m, 4H), 3.87-3.83 (m, 1H), 3.70 (s, 3H),2.56 (d, J=2.8 Hz, 2H), 2.50 (s, 2H), 1.26 (s, 6H).

Example 169a4-Chloro-2-{6-oxo-8-thia-5-azatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7)-dien-5-yl}pyridine-3-carbaldehyde169a

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 2-bromo-4-chloronicotinaldehyde 103a (1276mg, 5.80 mmol),8-thia-5-azatricyclo[7.4.0.0^(2,7)}]trideca-1(9),2(7)-dien-6-one 105e(600 mg, 2.90 mmol), CuI (551 mg, 2.90 mmol), K₂CO₃ (800 mg, 5.80 mmol),4,7-dimethoxy-1,10-phenanthroline (696 mg, 2.90 mmol), and dioxane (20mL). After bubbling nitrogen through the resulting solution for 10 min,the mixture was stirred at 95° C. for 16 h. It was then cooled to roomtemperature and filtered. To the residue was added water (20 mL). Theaqueous layer was separated and extracted with ethyl acetate (3×20 mL).The combined organic layer was washed with brine (50 mL) and dried oversodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 10:1 petroleumether/ethyl acetate to afford 169a (171 mg, 17%). LCMS-ESI: [M+H]⁺ 347

Example 169b4-[1-Methyl-5-({5-[4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-5-azatricyclo[7.4.0.0^(2,7)]-trideca-1(9),2(7)-dien-5-yl}pyridine-3-carbaldehyde169b

A 50-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 169a (150 mg, 0.43 mmol),3-(5-(2-ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridine-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101 l (200 mg, 0.43 mmol), Pd₂(dba)₃ (37 mg, 0.040 mmol),tricyclohexylphospine (120 mg, 0.43 mmol), Cs₂CO₃ (281 mg, 0.86 mmol),dioxane (10 mL), and water (0.1 mL). After three cycles of vacuum/argonflush, the mixture was heated at 110° C. for 4 h. It was then filteredand the filtrate was evaporated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 1:3petroleum/ethyl acetate to afford 169b as a yellow solid (45 mg, 16%).LCMS-ESI: [M+H]⁺ 652

Example 1692-{3′-Hydroxymethyl-1-methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-3,4,5,6,7,8-hexahydro-2H-benzo[4,5]thieno[2,3-c]pyridin-1-one169

A mixture of 169b (45 mg, 0.070 mmol), NaBH₄ (8 mg, 0.21) and methanol(5 mL) was stirred at room temperature for 1 h. The reaction mixture wasquenched with water (5 mL) and concentrated under reduced pressure. Theresidue was extracted with dichloromethane (2×10 mL). The combineddichloromethane extract was concentrated under reduced pressure. Theresidue was purified with reverse-phase prep-HPLC to afford 169 (14 mg,30%). LCMS-ESI: [M+H]⁺ 654. ¹H NMR (500 MHz, DMSO-d₆) δ 8.62 (s, 1H),8.50 (d, J=2.0 Hz, 1H), 8.43 (s, 1H), 7.86 (d, J=4.5 Hz, 1H), 7.45 (d,J=2.5 Hz, 1H), 7.39-7.34 (m, 2H), 7.25-7.22 (m, 1H), 4.95-4.93 (m, 1H),4.57-4.55 (m, 2H), 4.47-4.41 (m, 4H), 4.19-4.17 (m, 1H), 3.82-3.80 (m,1H), 3.60 (s, 3H), 3.45-3.43 (m, 1H), 3.32-3.30 (m, 1H), 3.09-3.07 (m,4H), 3.01-2.90 (m, 1H), 2.89-2.88 (m, 1H), 2.80-2.79 (m, 2H), 2.51-2.50(m, 1H), 2.40-2.38 (m, 4H), 1.83-1.80 (m, 4H).

Example 170b4-Chloro-2-[(1R,11S)-7-oxo-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-6-yl]pyridine-3-carbaldehyde170b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (30 mL),(1S,11R)-3,6-diazatetracyclo[9.2.1.0²¹⁰.0^(3,8)]tetradeca-2(10),8-dien-7-one170a (400 mg, 2.0 mmol), 2-bromo-4-chloronicotinaldehyde 103a (1.30 g,6.0 mmol), and potassium acetate (390 mg, 4.0 mmol). After bubblingnitrogen through the resulting mixture for 30 minutes, Xantphos (110 mg,0.20 mmol) and tris(dibenzylideneacetone)dipalladium(0) (180 mg, 0.20mmol) were added, and the reaction mixture was heated at 80° C. for 10h. After this time the reaction was cooled to room temperature andfiltered. The filtrate was partitioned between ethyl acetate (50 mL) andwater (30 mL). The aqueous layer was separated and extracted with ethylacetate (3×30 mL). The combined organic layer was washed with brine (20mL) and dried over sodium sulfate. The drying agent was removed byfiltration and the filtrate was concentrated under reduced pressure. Theresidue was purified by silica-gel column chromatography eluting with2:1 petroleum ether/ethyl acetate to afford 170b (405 mg, 59%) as ayellow solid. MS-ESI: [M+H]⁺ 342.2

Example 170c4-[1-Methyl-5-({5-methyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-[(1R,11S)-7-oxo-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-6-yl]pyridine-3-carbaldehyde170c

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with 170b (150 mg, 0.44 mmol),1-methyl-3-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one135a (169 mg, 0.44 mmol), sodium acetate (72 mg, 0.88 mmol), K₃PO₄ (234mg, 0.88 mmol), Pd (dppf) Cl₂ (36 mg, 0.044 mmol), acetonitrile (20 mL),and water (1 mL). After bubbling nitrogen through the reaction mixturefor 30 minutes, it was heated at 100° C. for 3 hours. The reactionmixture was evaporated under reduced pressure and the residue waspurified by silica-gel column chromatography eluting with 25:1dichloromethane/methanol to afford 170c (146 mg, 52%) as a brown solid.MS-ESI: [M+H]⁺ 565.3

Example 1702-(3-(hydroxymethyl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydro-6,9-methanopyrazino[1,2-a]indol-1(2H)-one170

A solution of 170c (122 mg, 0.22 mmol) in methanol (20 mL) was addedNaBH₄ (24 mg, 0.64 mmol). The mixture was stirred at 20° C. for 2 h. Thereaction was evaporated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford the title compound (98 mg,75%) as a white solid. MS-ESI: [M+H]⁺ 567.3. ¹H NMR (500 MHz, DMSO-d₆) δ8.48 (d, J=5.0 Hz, 1H), 8.19 (s, 1H), 8.05 (d, J=2.5 Hz, 1H), 7.40 (s,1H), 7.32 (d, J=5.0 Hz, 1H), 6.53 (s, 1H), 5.89 (s, 1H), 4.98 (t, J=5.0Hz, 1H), 4.48-4.30 (m, 3H), 4.27-4.22 (m, 2H), 3.92-3.91 (m, 2H),3.86-3.84 (m, 1H), 3.59 (s, 3H), 3.49-3.47 (m, 3H), 3.30-3.28 (m, 1H),2.79-2.77 (m, 2H), 2.35 (s, 3H), 1.87-1.76 (m, 3H), 1.61-1.59 (m, 1H),1.09-0.88 (m, 2H).

Example 171a4-[1-Methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-[(1S,11R)-7-oxo-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-6-yl]pyridine-3-carbaldehyde171a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with acetonitrile (30 mL),4-chloro-2-[(1S,11R)-7-oxo-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-6-yl]pyridine-3-carbaldehyde167g (170 mg, 0.50 mmol),(S)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one130f (336 mg, 0.70 mmol), water (3 mL), and potassium acetate (147 mg,1.5 mmol). After bubbling argon through the suspension for 30 minutes,1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (408 mg, 0.05mmol) was added. The system was subjected to three cycles ofvacuum/argon flush and heated at 80° C. for 3 h. It was then cooled toroom temperature and filtered. The solid was washed with dichloromethane(2×100 ml). The combined filtrate was concentrated under reducedpressure and the residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (50:1 to 30:1) toafford 171a (95 mg, 29%) as a light yellow solid. MS-ESI: [M+H]⁺ 661.3

Example 171(S)-2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydro-6,9-methanopyrazino[1,2-a]indol-1(2H)-one171

To a solution of 171a (90 mg, 0.136 mmol) in methanol (10 mL) was addedNaBH₄ (26 mg, 0.7 mmol) at room temperature. After the reaction wasstirred for 1 h, LCMS indicated the reaction was complete. It wasquenched with water (30 mL) and concentrated under reduced pressure. Theresidue was extracted with dichloromethane (3×30 mL). The combinedorganic layer was washed with brine (30 mL), dried over Na₂SO₄,filtered, and concentrated under reduced pressure. The residue solid waspurified by reverse-phase prep-HPLC to afford 171 (35 mg, 31.5%) aslight yellow solid. MS-ESI: [M+H]⁺ 663.3. ¹H NMR (500 MHz, DMSO-d₆) δ8.62 (s, 1H), 8.48 (d, J=5.0 Hz, 1H), 8.44 (s, 1H), 7.83 (d, J=2.5 Hz,1H), 7.47 (s, 1H), 7.38 (dd, J=2.5, 9.0 Hz 1H), 7.34 (d, J=5.0 Hz, 1H),7.24 (d, J=9.5 Hz, 1H), 6.51 (s, 1H), 4.97 (t, J=4.5 Hz, 1H), 4.58-4.54(m, 2H), 4.50-4.37 (m, 4H), 4.30-4.24 (m, 2H), 3.86-3.84 (m, 1H),3.69-3.67 (m, 1H), 3.60 (s, 3H), 3.47 (s, 1H), 3.42-3.37 (m, 1H), 3.30(s, 2H), 3.10-3.07 (m, 1H), 2.95-2.92 (m, 1H), 2.36-2.29 (m, 3H),2.21-2.16 (m, 1H), 1.88-1.754 (m, 3H), 1.60-1.58 (m, 1H), 1.08-1.05 (m,1H), 0.98-0.96 (m, 1H), 0.93 (d, J=6.0 Hz, 3H).

Example 172a3-(1,2,4-Triazin-3-ylamino)-5-bromo-1-methylpyridin-2(1H)-one 172a

A 500-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (100 mL),1,2,4-triazin-3-amine (1.5 g, 15.6 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (4.2 g, 15.6 mmol), Pd₂(dba)₃ (458mg, 1.56 mmol), XantPhos (1.8 g, 3.12 mmol), and cesium carbonate (10 g,31.2 mmol). After three cycles of vacuum/argon flush, the mixture wasstirred at 90° C. for 2.5 h. After this time the reaction was filteredand the filtrate was evaporated in vacuo. The resulting residue wasrecrystallized from ethyl acetate to afford 172a as a yellow solid (1.76g, 40%). MS-ESI: [M+H]⁺ 282.

Example 172b(4-(5-(1,2,4-Triazin-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 172b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 172a (200 mg, 0.71mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (272 mg, 0.71 mmol), Pd(dppf)Cl₂ (58 mg, 0.071 mmol), sodiumacetate (193 mg, 1.42 mmol), K₃PO₄ (321 mg, 1.42 mmol), water (0.5 mL)and acetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was stirred at 100° C. for 3 h. After this time the reaction wasfiltered and the filtrate was evaporated in vacuo. The resulting residuewas recrystallized from ethyl acetate to afford 172b as yellow solid(380 mg, 99%). MS-ESI: [M+H]⁺ 541.2

Example 1722-(4-(5-(1,2,4-triazin-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one

A mixture of 172b (350 mg, 0.65 mmol) and lithium hydroxide (273 mg, 6.5mmol) in i-propanol/THF (1:1, 5 mL) and water (0.5 mL) was stirred at36° C. for 0.5 h. It was then cooled to room temperature and filtered.The filtrate was concentrated under reduced pressure and the resultingresidue was washed by reverse-phase prep-HPLC to afford 172 (90 mg,28%). MS-ESI: [M+H]⁺ 499.2. ¹H NMR (500 MHz, CDCl₃) δ 8.77 (d, J=2.5 Hz,1H), 8.72 (d, J=2.0 Hz, 1H), 8.67 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.34(d, J=2.0 Hz, 1H), 8.05 (d, J=2.5 Hz, 1H), 7.35 (d, J=5.0 Hz, 1H), 6.89(s, 1H), 5.10 (t, J=6.5 Hz, 1H), 4.65-4.51 (m, 2H), 4.31-4.27 (m, 1H),4.16-4.08 (m, 2H), 3.90-3.87 (m, 1H), 3.75 (s, 3H), 2.62-2.56 (m, 4H),1.92-1.87 (m, 2H), 1.79-1.78 (m, 2H).

Example 173a5-Bromo-3-(2,6-dimethylpyrimidin-4-ylamino)-1-methylpyridin-2(1H)-one173a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (150 mL),2,6-dimethylpyrimidin-4-amine (2.5 g, 20.3 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (5.4 g, 20.3 mmol), Pd₂(dba)₃(1.86 mg, 2.03 mmol), XantPhos (2.3 g, 4.06 mmol), and cesium carbonate(13.2 g, 40.6 mmol). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 2.5 h. After this time the reaction wasfiltered and the filtrate was evaporated in vacuo. The resulting residuewas recrystallized from ethyl acetate to afford 173a as a yellow solid(4.4 g, 40%). MS-ESI: [M+H]⁺ 309.0.

Example 173b3-(2,6-Dimethylpyrimidin-4-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one173b

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 173a (1.5 g, 4.9 mmol),Pin₂B₂ (6.2 g, 24.5 mmol), Pd₂(dba)₃ (449 mg, 0.49 mmol), X-phos (467mg, 0.98 mmol), potassium acetate (1.4 g, 14.7 mmol), and dioxane (60mL). After three cycles of vacuum/argon flush, the mixture was heated at65° C. for 16 h. The reaction was filtered and the filtrate wasevaporated in vacuo. The resulting residue was recrystallized from ethylacetate to afford 173b as a light gray solid (1.2 g, 72%). MS-ESI:[M+H]⁺ 357.2.

Example 173c2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{5-[(2,6-dimethylpyrimidin-4-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}pyridine-3-carbaldehyde173c

A 100-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 173b (250 mg, 0.70 mmol),4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (240 mg, 0.70 mmol), Pd(dppf)Cl₂ (57 mg, 0.071 mmol), sodiumacetate (19 mg, 1.4 mmol), K₃PO₄ (316 mg, 1.4 mmol), water (0.5 mL), andacetonitrile (15 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 3 h. After this time the reaction wasfiltered and the filtrate was evaporated in vacuo. The resulting residuewas recrystallized from ethyl acetate to afford 173c as a brown solid(300 mg, 80%). MS-ESI: [M+H]⁺ 538.3.

Example 1732-[5-(2,6-Dimethyl-pyrimidin-4-ylamino)-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one173

At 0° C., to a solution of 173c (290 mg, 0.54 mmol) in methanol (5 mL)was added sodium borohydride (62 mg, 1.62 mmol). The reaction mixturewas stirred at room temperature for 20 minutes and quenched with water(1 mL). It was then concentrated under reduced pressure and the residuewas purified by reverse-phase prep-HPLC to afford 173 as white solid (50mg, 17%). MS-ESI: [M+H]⁺ 540.3. ¹H NMR (500 MHz, CDCl₃) δ 8.90 (d, J=2.5Hz, 1H), 8.51 (d, J=5.0 Hz, 1H), 8.01 (d, J=2.0 Hz, 1H), 8.00 (s, 1H),7.35 (d, J=5.5 Hz, 1H), 6.85 (s, 1H), 6.45 (s, 1H), 5.16-5.13 (m, 1H),4.67-4.52 (m, 2H), 4.33-4.29 (m, 1H), 4.16 (d, J=5.0 Hz, 2H), 3.90-3.86(m, 1H), 3.72 (s, 3H), 2.58-2.56 (m, overlap, 5H), 2.51 (s, 2H), 2.40(s, 3H), 2.02 (s, 6H).

Example 174a4-[1-Methyl-5-({5-[(25)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-[(1R,11S)-7-oxo-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-6-yl]pyridine-3-carbaldehyde 174a

A round-bottomed flask was charged with4-chloro-2-[(1R,11S)-7-oxo-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-6-yl]pyridine-3-carbaldehyde170b (200 mg, 0.59 mmol),1-methyl-3-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-dihydropyridin-2-one191j (400 mg, 0.88 mmol), PdCl₂(dppf) (50 mg, 0.06 mmol), K₃PO₄ 3 water(300 mg, 1.20 mmol), sodium acetate (100 mg, 1.20 mmol), acetonitrile(15 mL), and water (1.5 mL). After three cycles of vacuum/argon flush,the mixture was heated at 100° C. for 3 h. It was then filtered and thefiltrate was evaporated under reduced pressure. The residue was purifiedwith silica-gel column chromatography eluting with 1:20methanol/dichloromethane to afford 174a as a red solid (170 mg, 44%).MS-ESI: [M+H]⁺ 661.3

Example 174(1R,11S)-6-[3-(Hydroxymethyl)-4-[1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridin-2-yl]-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-7-one174

A mixture of 174a (150 mg, 0.23 mmol), NaBH₄ (34 mg, 0.90), and methanol(10 mL) was stirred at room temperature for 1 h. The mixture wasquenched with water (30 ml) and concentrated under reduced pressure. Theresidue was extracted with dichloromethane (2×10 mL). The combineddichloromethane extract was concentrated under reduced pressure and theresidue was purified with reverse-phase prep-HPLC to afford 174 (42 mg,28%). MS-ESI: [M+H]⁺ 663.3. ¹H NMR (500 MHz, CDCl₃) δ 8.65 (d, J=3.0 Hz,1H), 8.48 (d, J=6.0 Hz, 1H), 7.96 (d, J=2.5 Hz, 1H), 7.85-7.84 (m, 2H),7.36 (d, J=6.5 Hz, 1H), 7.32 (dd, J=3.5, 11.0 Hz, 1H), 6.82-6.80 (m,2H), 5.16-5.06 (m, 1H), 4.72-4.61 (m, 5H), 4.08-4.05 (m, 1H), 4.32-4.21(m, 3H), 3.88-3.85 (m, 1H), 3.71 (s, 3H), 3.54-3.50 (m, 2H), 3.38-3.37(m, 2H), 3.08-3.06 (m, 2H), 2.57-2.54 (m, 1H), 2.48-2.45 (m, 2H),2.21-2.17 (m, 1H), 1.93-1.91 (m, 3H), 1.66-1.64 (m, 1H), 1.14-1.08 (m,2H), 0.98 (d, J=8.0 Hz, 3H).

Example 175a4-Chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde175a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a (150 mg, 0.43 mmol),3-(5-(2-ethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one161f (215 mg, 0.43 mmol), PdCl₂(dppf) (33 mg, 0.040 mmol), K₃PO₄trihydrate (202 mg, 0.86 mmol), sodium acetate (71 mg, 0.86 mmol),acetonitrile (10 mL), and water (2 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 3 h. It wasthen filtered and the filtrate was evaporated under reduced pressure.The residue was purified by silica-gel column chromatography elutingwith 1:3 petroleum/ethyl acetate to afford 175a as a yellow solid (108mg, 37%). MS-ESI: [M+H]⁺ 679

Example 1753-{5-[5-((S)-2-Ethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one175

A mixture of 175a (200 mg, 0.16 mmol), NaBH₄ (18 mg, 0.48), and methanol(8 mL) was stirred at 25° C. for 1 h. Then the reaction mixture wasquenched with water (10 mL) and evaporated under reduced pressure. Theresidue was extracted with dichloromethane (2×10 mL). The combineddichloromethane extract was concentrated under reduced pressure and theresidue was purified with reverse-phase prep-HPLC to afford 175 (55 mg,50%). MS-ESI: [M+H]⁺ 681. ¹H NMR (500 MHz, DMSO-d₆) 8.61 (d, J=2.0 Hz,1H), 8.57-8.56 (m, 1H), 8.47 (s, 1H), 8.43 (s, 1H), 7.83 (d, J=3.0 Hz,1H), 7.54-7.53 (m, 1H), 7.47 (d, J=2.0 Hz, 1H), 7.35-7.32 (m, 1H),7.24-7.22 (m, 1H), 4.85-4.83 (m, 1H), 4.59-4.55 (m, 2H), 4.47-4.44 (m,1H), 4.40-4.36 (m, 2H), 3.60 (s, 3H), 3.51-3.49 (m, 1H), 3.40-3.38 (m,1H), 3.17-3.14 (m, 1H), 3.00-2.95 (m, 3H), 2.87-2.85 (m, 2H), 2.66-2.60(m, 1H), 2.55-2.53 (m, 1H), 2.18-2.15 (m, 1H), 2.10-2.06 (m, 1H),1.89-1.86 (m, 4H), 1.68-1.64 (m, 1H), 1.28-1.25 (m, 2H), 0.79 (t, J=9.5Hz, 3H).

Example 176a(S)-4-(1-Methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde176a

A round-bottomed flask was charged with4-chloro-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde121a (180 mg, 0.55 mmol),(S)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one191j (397 mg, 0.82 mmol), PdCl₂(dppf) (45 mg, 0.06 mmol), K₃PO₄trihydrate (286 mg, 1.10 mmol), sodium acetate (90 mg, 1.10 mmol),acetonitrile (15 mL), and water (1.5 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 3 h. It wasthen filtered and the filtrate was evaporated under reduced pressure.The residue was purified by silica-gel column chromatography elutingwith 1:20 methanol/dichloromethane to afford 176a as a red solid (228mg, 64%). MS-ESI: [M+H]⁺ 647.3

Example 176(S)-2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1(2H)-one176

A mixture of 176a (200 mg, 0.31 mmol), NaBH₄ (47 mg, 1.20), and methanol(10 mL) was stirred at room temperature for 1 h. The reaction mixturewas then quenched with water (10 mL) and concentrated under reducedpressure. The residue was extracted with dichloromethane (2×10 mL). Thecombined dichloromethane extract was concentrated under reduced pressureand the residue was purified with reverse-phase prep-HPLC to afford 176(42 mg, 28%). MS-ESI: [M+H]⁺ 649.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.66 (d,J=2.5 Hz, 1H), 8.56 (d, J=5.5 Hz, 1H), 8.47 (s, 1H), 7.84 (d, J=2.5 Hz,1H), 7.50-7.48 (m, 2H), 7.39-7.36 (m, 1H), 7.26-7.24 (m, 2H), 6.83-6.80(m, 2H), 4.57-4.54 (m, 2H), 4.48-4.40 (m, 3H), 4.35-4.33 (m, 1H),3.69-3.67 (m, 1H), 3.60 (s, 3H), 3.41-3.38 (m, 2H), 3.11-3.08 (m, 1H),2.97-2.93 (m, 1H), 2.76-2.74 (m, 2H), 2.62-2.60 (m, 2H), 2.52-2.51 (m,1H), 2.35-2.32 (m, 2H), 2.19-2.17 (m, 1H), 1.90-1.87 (m, 2H), 1.77-1.75(m, 2H), 0.94 (d, J=6.5 Hz, 3H).

Example 177a(4-(5-(5-Ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 177a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-bromo-3-(5-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methylpyridin-2(1H)-one208c (300 mg, 0.85 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (1.21 g, 3.16 mmol), PdCl₂(dppf) (35 mg, 0.043 mmol), K₃PO₄(361 mg, 1.70 mmol), sodium acetate (140 mg, 1.70 mmol), acetonitrile(10 mL), and water (0.5 mL). The system was evacuated and refilled withN₂. The reaction mixture was stirred at 100° C. for 2 h. It was thencooled to room temperature and filtered. The filtrate was concentratedunder reduced pressure and the resulting residue was purified bysilica-gel column chromatography eluting with 30:1dichloromethane/methanol to afford 177a (365 mg, 60%) as a brown oil.MS-ESI: [M+H]⁺ 611

Example 1772-(4-(5-(5-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one177

To a solution of 177a (300 mg, 0.49 mmol) in propan-2-ol (4 mL),tetrahydrofuran (4 mL), and water (1 mL) was added lithium hydroxide (35mg, 1.47 mmol). The mixture was stirred at room temperature for 0.5 h.It was evaporated and the residue was purified by reverse-phaseprep-HPLC to afford 177 (79 mg, 28%) as a white solid. MS-ESI: [M+H]⁺569. ¹H NMR (500 MHz, CDCl₃) δ 8.46 (d, J=5.5 Hz, 1H), 7.92 (d, J=2.0Hz, 1H), 7.70 (d, J=2.0 Hz, 1H), 7.39 (s, 1H), 7.33 (d, J=5.5 Hz, 1H),6.88 (s, 1H), 5.69 (s, 1H), 4.99-4.97 (m, 1H), 4.61-4.60 (m, 1H),4.48-4.46 (m, 1H), 4.33-4.31 (m, 1H), 4.14-4.06 (m, 4H), 3.87-3.85 (m,1H), 3.69 (s, 3H), 3.62 (d, J=5.5 Hz, 2H), 2.91 (d, J=5.0 Hz, 2H),2.63-2.55 (m, 6H), 1.91-1.87 (m, 2H), 1.79-1.78 (m, 2H), 1.17 (t, J=7.5Hz, 3H).

Example 178a 5-Bromo-1-methyl-3-(pyridin-2-ylamino)pyridin-2(1H)-one178a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (60 mL),5-bromo-2-nitropyridine (8.0 g, 31.8 mmol), pyridin-2-amine (1.0 g, 10.6mmol), and cesium carbonate (7.0 g, 21.2 mmol). After bubbling nitrogenthrough the resulting mixture for 30 minutes, XantPhos (616 mg, 1.0mmol) and tris(dibenzylideneacetone)dipalladium(0) (973 mg, 1.0 mmol)were added. The reaction mixture was subjected to three cycles ofvacuum/argon flush and heated at 100° C. for 12 h. After this time thereaction was cooled to room temperature and filtered. The filtrate waspartitioned between ethyl acetate (100 mL) and water (100 mL). Theaqueous layer was separated and extracted with ethyl acetate (3×150 mL).The combined organic layer was washed with brine (50 mL) and dried oversodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified on silica-gel column eluting with 30:1 dichloromethane/methanolto afford 178a (1.5 g, 51%) as yellow solid. MS: [M+H]⁺ 280

Example 178b1-Methyl-3-(pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one178b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 178a (1.06 g, 3.8 mmol),Pin₂B₂ (4.8 g, 19.0 mmol), Pd₂(dba)₃ (348 mg, 0.38 mmol), X-Phos (350mg, 0.76 mmol), potassium acetate (1.12 g, 11.40 mmol), and dioxane (30mL). After three cycles of vacuum/argon flush, the mixture was heated at60° C. for 6 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with3:1 petroleum ether/ethyl acetate to afford 178b as yellow solid (1.2 g,96%). MS-ESI: [M+H]⁺ 328.2

Example 178c4-{1-Methyl-6-oxo-5-[(pyridin-2-yl)amino]pyridin-3-yl}-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde178c

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 178b (131 mg, 0.40mmol),4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a (138 mg, 0.40 mmol), Pd(dppf)Cl₂ (33 mg, 0.040 mmol), K₃PO₄ (170mg, 0.80 mmol), sodium acetate (66 mg, 0.80 mmol), water (6 drops), andacetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at reflux for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 30:1 dichloromethane/methanol to afford 178cas a yellow solid (180 mg, 88%). MS-ESI: [M+H]⁺ 511.2

Example 1783-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyridin-2-ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one178

To a solution of 178c (179 mg, 0.35 mmol) in methanol (6 mL) was addedsodium borohydride (39 mg, 1.05 mmol) at 0° C. The reaction mixture wasstirred for 30 minutes and quenched with water (1.0 mL). It was thenconcentrated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 178 (100 mg, 56%). MS-ESI: [M+H]⁺513.3. ¹H NMR (500 MHz, CDCl₃) δ 8.81 (s, 1H), 8.68 (d, J=5.0 Hz, 1H),8.32 (s, 1H), 8.27 (d, J=4.0 Hz, 1H), 7.94 (bs, 1H), 7.76 (d, J=1.5 Hz,1H), 7.58-7.56 (m, 2H), 6.85-6.80 (m, 2H), 4.47-4.45 (m, 2H), 4.38-4.36(m, 1H), 3.74 (s, 3H), 3.01-2.99 (m, 2H), 2.89-2.87 (m, 2H), 2.02-1.99(m, 4H).

Example 179a4-(1-Methyl-5-(2-methylpyrimidin-4-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl)nicotinaldehyde179a

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with1-methyl-3-(2-methylpyrimidin-4-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one213b (510 mg, 1.5 mmol),4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (343 mg, 1.0 mmol), K₃PO₄ (424 mg, 2.0 mmol), sodium acetate (272mg, 2.0 mmol), 1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II)(40 mg, 0.044 mmol), acetonitrile (20 mL), and water (0.5 mL). Afterbubbling nitrogen through the mixture for 30 minutes, it was was heatedat 100° C. under N₂ protection for 2 h. Analysis of the reaction mixtureby LCMS showed complete conversion to the desired product. The reactionmixture was cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure. The residue was diluted withdichloromethane (30 mL) and water (30 mL). The aqueous layer wasseparated and extracted with dichloromethane (3×20 mL). The combinedorganic layer was dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The dark residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (80/1 to 30/1) toafford 179a (300 mg, 57%) as a yellow solid. MS-ESI: [M+H]⁺ 524

Example 1792-[3′-Hydroxymethyl-1-methyl-5-(2-methyl-pyrimidin-4-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one179

To a solution of 179a (262 mg, 0.50 mmol) in methanol/dichloromethane(10/10 mL) was added NaBH₄ (57 mg, 1.5 mmol) at room temperature. Afterthe reaction was stirred for 1 h, LCMS indicated the reaction wascomplete. Then the mixture was concentrated under reduced pressure. Theresidue was diluted with water (5 mL) and dichloromethane (20 mL. Thewater phase was separated and extracted with dichloromethane (3×10 mL).The combined organic layer was washed with brine (30 mL), dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The residuesolid was purified by reverse-phase prep-HPLC to afford 179 (180 mg,69%) as white solid. MS-ESI: [M+H]⁺ 526. ¹H NMR (500 MHz, CDCl₃) δ 8.93(d, J=2.0 Hz, 1H), 8.53 (d, J=5.5 Hz, 1H), 8.28 (d, J=5.5 Hz, 1H), 8.07(s, 1H), 8.03 (d, J=2.0 Hz, 1H), 7.36 (s, 1H), 6.86 (s, 1H), 6.60 (d,J=6.0 Hz, 1H), 5.18-5.16 (m, 1H), 4.70-4.67 (m, 1H), 4.55-4.53 (m, 1H),4.33-4.31 (m, 1H), 4.18-4.16 (m, 2H), 3.91-3.90 (m, 1H), 3.74 (s, 3H),2.60 (s, 3H), 2.58 (d, J=5.5 Hz, 2H), 2.52 (s, 2H), 1.28 (s, 6H).

Example 180a5-Bromo-1-methyl-3-(6-methylpyrimidin-4-ylamino)pyridin-2(1H)-one 180a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with6-methylpyrimidin-4-amine (800 mg, 2.6 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (694 mg, 2.6 mmol),tris(dibenzylideneacetone)dipalladium(0) (238 mg, 0.26 mmol), XantPhos(300 mg, 0.52 mmol), Cs₂CO₃ (1.7 g, 5.2 mmol), and 1,4-dioxane (30 mL).After three cycles of vacuum/argon flush, the mixture was heated at 90°C. for 2.5 h. The mixture was cooled to room temperature and filtered.The filtrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with50:1 dichloromethane/methanol to afford 180a as a yellow solid (800 mg,36%). MS-ESI: [M+H]⁺ 295.1

Example 180b1-Methyl-3-(6-methylpyrimidin-4-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one180b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 180a (1.0 g, 3.4 mmol),Pin₂B₂ (4.3 g, 17 mmol), Pd₂(dba)₃ (312 mg, 0.34 mmol), X-phos (324 mg,0.68 mmol), potassium acetate (666 mg, 6.8 mmol), and dioxane (40 mL).After three cycles of vacuum/argon flush, the mixture was heated at 65°C. for 14 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was washed with 3:1 petroleum ether/ethyl acetate (80 mL) toafford 180b as a yellow solid (600 mg, 50%). MS-ESI: [M+H]⁺ 343.2.

Example 180c2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(6-methylpyrimidin-4-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridine-3-carbaldehyde180c

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 180b (239 mg, 0.70mmol),4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (239 mg 0.70 mmol), Pd(dppf)Cl₂ (57 mg, 0.070 mmol), sodium acetate(115 mg, 1.4 mmol), K₃PO₄ (320 mg, 1.4 mmol), water (5 mL), andacetonitrile (15 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 3 h. After this time the reaction wasfiltered and the filtrate was concentrated under reduced pressure. Theresulting residue was purified by silica-gel column chromatographyeluting with 40:1 dichloromethane/methanol to afford 180c as a yellowsolid (170 mg, 47%). MS-ESI: [M+H]⁺ 524.2.

Example 1802-[3′-Hydroxymethyl-1-methyl-5-(6-methyl-pyrimidin-4-ylamino)-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one180

At 0° C., to a solution of 180c with water (1 mL). It was thenconcentrated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 180 (47 mg, 32%). MS-ESI: [M+H]⁺526.2. ¹H NMR (500 MHz, CDCl₃) δ 8.82 (d, J=2.5 Hz, 1H), 8.68 (s, 1H),8.51 (d, J=2.5 Hz, 1H), 8.02-8.00 (m, 2H), 7.35 (d, J=5.0 Hz, 1H), 6.84(s, 1H), 6.62 (s, 1H), 5.13 (t, J=6.5 Hz, 1H), 4.67-4.52 (m, 2H),4.29-4.15 (m, 3H), 3.88-3.86 (m, 1H), 3.72 (s, 3H), 2.57 (d, J=5.5 Hz,2H), 2.51 (s, 2H), 2.43 (s, 3H), 1.28 (s, 6H).

Example 181a4-[1-Methyl-5-({5-methyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde 181a

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a (210 mg, 0.60 mmol),1-methyl-3-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one135a (346 mg, 0.90 mmol), Pd(dppf)Cl₂ (30 mg, 0.030 mmol), K₃PO₄ (270mg, 1.2 mmol), sodium acetate trihydrate (180 mg, 1.2 mmol), water (6drops), and acetonitrile (40 mL). The system was evacuated and refilledwith N₂. The reaction mixture was heated at 100° C. for 2 h. It was thencooled to room temperature and filtered. The filtrate was concentratedunder reduced pressure and the resulting residue was purified bysilica-gel column chromatography eluting with 25:1dichloromethane/methanol to afford 181a (300 mg, 88%) as a yellow brownsolid. MS-ESI: [M+H]⁺ 569.3.

Example 1813-[3′-Hydroxymethyl-1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one181

A mixture of 181a (300 mg, 0.50 mmol) and NaBH₄ (60 mg, 1.5 mmol) inmethanol (20 mL) was stirred at 30° C. for 1 h. The mixture was quenchedwith water and concentrated under reduced pressure. The residue wasextracted with ethyl acetate (3×10 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 181 (100 mg, 35%). MS-ESI:[M+H]⁺ 571.2. ¹H NMR (500 MHz, CHCl₃) δ 8.64 (d, J=5.0 Hz, 1H), 8.30 (s,1H), 8.00 (d, J=2.0 Hz, 1H), 7.57 (d, J=2.0 Hz, 1H), 7.53 (d, J=5.0 Hz,1H), 7.43 (s, 1H), 5.70 (s, 1H), 4.45-4.43 (m, 2H), 4.32 (bs, 1H),4.11-4.09 (m, 2H), 3.71 (s, 3H), 3.63 (s, 2H), 2.99-2.97 (m, 2H),2.93-2.91 (m, 2H), 2.88-2.86 (m, 2H), 2.50 (s, 3H), 2.00-1.98 (m, 4H).

Example 182a4-{1-Methyl-6-oxo-5-[(pyrimidin-4-yl)amino]-1,6-dihydropyridin-3-yl}-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde182a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a (345 mg, 1.0 mmol),1-methyl-3-(pyrimidin-4-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one143a (328 mg, 1.0 mmol), Pd(dppf)Cl₂ (82 mg, 0.10 mmol), sodium acetate(162 mg, 2.0 mmol), K₃PO₄ (424 mg, 2.0 mmol), and acetonitrile/water(20/1 mL). After three cycles of vacuum/argon flush, the mixture washeated at 100° C. for 3 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by silica-gel column chromatographyeluting with 40:1 dichloromethane/methanol to afford 182a as a yellowsolid (156 mg, 30%). MS-ESI: [M+H]⁺ 512.1.

Example 1823-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one182

At room temperature, to a solution of 182a (140 mg, 0.27 mmol) inmethanol (5 mL) was added sodium borohydride (31 mg, 0.82 mmol). Thereaction mixture was stirred for 20 minutes and quenched with water (1mL). It was then concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with60:1 dichloromethane/methanol to afford 182 as a white solid (60 mg,43%). MS-ESI: [M+H]⁺ 514.2. ¹H NMR (500 MHz, CDCl₃) δ 8.89 (d, J=2.5 Hz,1H), 8.82 (s, 1H), 8.70 (d, J=5.5 Hz, 1H), 8.36 (d, J=6.5 Hz, 1H), 8.31(s, 1H), 8.20 (s, 1H), 7.89 (d, J=2.0 Hz, 1H), 7.55 (d, J=5.0 Hz, 1H),6.80 (d, J=9.5 Hz, 1H), 4.44-4.42 (m, 3H), 3.75 (s, 3H), 2.99-2.98 (m,2H), 2.88-2.87 (m, 2H), 2.03-1.98 (m, 4H).

Example 183a2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-6-oxo-5-(pyridin-2-ylamino)-1,6-dihydropyridin-3-yl)nicotinaldehyde183a

A 100-mL flask equipped with a reflux condensor was charged with4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (297 mg, 0.57 mmol),1-methyl-3-(pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one178b (186 mg, 0.57 mmol), sodium acetate (90 mg, 1.1 mmol), K₃PO₄ (234mg, 1.1 mmol), PdCl₂(dppf) (50 mg, 0.057 mmol), acetonitrile (25 mL),and water (1 mL). After bubbling nitrogen through the mixture for 30minutes, it was heated at 100° C. under nitrogen atmosphere for 3 hours.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the residue was purified bysilica-gel column chromatography eluting with 20:1 methylenechloride/methanol to afford 183a (178 mg, 61%) as a brown solid. MS-ESI:[M+H]⁺ 513.3.

Example 18310-fluoro-2-(3-(hydroxymethyl)-4-(1-methyl-6-oxo-5-(pyridin-2-ylamino)-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one183

A mixture of 183a (160 mg, 0.31 mmol) and NaBH₄ (59 mg, 1.55 mmol) inmethanol (20 mL) was stirred at 20° C. for 2 h. The reaction was thenquenched with water and evaporated under reduced pressure. The residuewas purified by reverse-phase prep-HPLC to afford 183 (42 mg, 26%) as anoff-white solid. MS-ESI: [M+H]⁺ 515.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.74(d, J=2.5 Hz, 1H), 8.65 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.18-8.17 (m,1H), 7.61-7.58 (m, 1H), 7.53 (d, J=2.0 Hz, 1H), 7.36 (d, J=5.0 Hz, 1H),7.31 (d, J=8.5 Hz, 1H), 6.81-6.79 (m, 1H), 4.95 (t, J=5.0 Hz, 1H),4.49-4.40 (m, 2H), 4.22-4.14 (m, 2H), 4.10-4.05 (m, 1H), 3.87-3.85 (m,1H), 3.62 (s, 3H), 2.64-2.60 (m, 1H), 2.57-2.53 (m, 1H), 2.43-2.41 (m,2H), 1.81-1.75 (m, 2H), 1.71-1.67 (m, 2H).

Example 184a1-Methyl-3-(pyrazin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one184a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-bromo-1-methyl-3-(pyrazin-2-ylamino)pyridin-2(1H)-one 162a (600 mg,2.1 mmol), Pin₂B₂ (2540 mg, 10 mmol), Pd₂(dba)₃ (100 mg, 0.11 mmol),X-phos (100 mg, 0.25 mmol), potassium acetate (600 mg, 6.1 mmol), anddioxane (30 mL). After three cycles of vacuum/argon flush, the mixturewas heated at 65° C. for 15 h. It was then cooled to room temperatureand filtered. The filtrate was concentrated under reduced pressure andthe resulting residue was washed by petroleum ether to afford 184a as ayellow solid (700 mg, 90%). MS-ESI: [M+H]⁺ 329.4

Example 184b2-{4,4-Dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}-4-{1-methyl-6-oxo-5-[(pyrazin-2-yl)amino]-1,6-dihydropyridin-3-yl}pyridine-3-carbaldehyde184b

A 25-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde109a (100 mg, 0.30 mmol), 184a (170 mg, 0.60 mmol), Pd(dppf)Cl₂ (12 mg,0.015 mmol), K₃PO₄ (130 mg, 0.60 mmol), sodium acetate trihydrate (85mg, 0.60 mmol), acetonitrile (10 mL), and water (6 drops). The systemwas evacuated and refilled with N₂. The reaction mixture was stirred at100° C. for 2 h. It was then cooled to room temperature and filtered.The filtrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with25:1 of dichloromethane/methanol to afford 184b (80 mg, 54%) as a yellowbrown solid. MS-ESI: [M+H]⁺ 527.2.

Example 1846-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrazin-2-ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-2,2-dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza-cyclopenta[a]inden-7-one184

A mixture of 184b (80 mg, 0.15 mmol) and NaBH₄ (18 mg, 0.45 mmol) inmethanol (5 mL) was stirred at 30° C. for 2 h. The mixture was quenchedwith water and concentrated under reduced pressure. The residue wasextracted with ethyl acetate (3×10 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 184 (24 mg, 35%) as awhite solid. MS-ESI: [M+H]⁺ 529.3. ¹H NMR (500 MHz, CHCl₃) δ 8.73 (d,J=2.0 Hz, 1H), 8.54 (d, J=5.0 Hz, 1H), 8.29 (s, 1H), 8.14 (d, J=8.0 Hz,2H), 8.02 (s, 1H), 7.96 (d, J=2.5 Hz, 1H), 7.37 (d, J=5.5 Hz, 1H),4.86-4.83 (m, 1H), 4.71-4.68 (m, 1H), 4.46-4.41 (m, 1H), 4.32 (t, J=11.0Hz, 1H), 3.85-3.81 (m, 1H), 3.74 (s, 3H), 2.99-2.94 (m, 2H), 2.81 (s,2H), 2.61-2.51 (m, 2H), 1.30 (s, 6H).

Example 185a5-Bromo-3-(imidazo[1,2-a]pyridin-7-ylamino)-1-methylpyrazin-2(1H)-one185a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with imidazo[1,2-a]pyridin-7-amine (665 mg, 5.0 mmol), Cs₂CO₃(3.26 g, 10 mmol), 3,5-dibromo-1-methylpyrazin-2(1H)-one (1.86 g, 7.0mmol), Xantphos (289 mg, 0.50 mmol), Pd₂(dba)₃ (458 mg, 0.50 mmol), and1,4-dioxane (30 mL). After bubbling nitrogen through the mixture for 30minutes, it was heated at 100° C. under nitrogen atmosphere for 16 h.Analysis of the reaction mixture by LCMS showed little starting materialremained. The reaction mixture was cooled to room temperature andfiltered. The filtrate was diluted with dichloromethane (60 mL) andwater (50 mL). The aqueous layer was separated and extracted withdichloromethane (3×20 mL). The combined organic layers was dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The darkresidue was purified by silica-gel column chromatography eluting withdichloromethane/methanol (60/1 to 30/1) to afford 185a (700 mg, 44%) asa light yellow solid. MS-ESI: [M+H]⁺ 320

Example 185b6-(Imidazo[1,2-a]pyridin-7-ylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-ylboronicAcid 185b

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with 185a (638 mg, 1.99 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (Pin₂B₂,2.54 mg, 10 mmol),1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (163 mg, 0.18mmol), Cs₂CO₃ (1.3 g, 3.98 mmol), and 1,4-dioxane (20 mL). Afterbubbling nitrogen through the mixture for 30 minutes, it was heated at80° C. under nitrogen atmosphere for 3 h. The reaction mixture wascooled to room temperature and filtered. The filtrate was diluted withpetroleum ether (150 mL) and ethyl acetate (15 mL). The resultingsuspension was stirred at room temperature for 30 minutes. The solid wascollected by filtration and further purified by silica-gel columnchromatography eluting with dichloromethane/methanol (60/1 to 15/1) toafford 185b (400 mg, 70%) as an off-white solid. MS-ESI: [M+H]⁺ 286

Example 185c2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(6-{imidazo[1,2-a]pyridin-7-ylamino}-4-methyl-5-oxopyrazin-2-yl)pyridine-3-carbaldehyde185c

A 100-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 185b (400 mg, 1.40 mmol),4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (192 mg, 0.56 mmol), potassium acetate (220 mg, 2.24 mmol),acetonitrile (20 mL), and water (0.5 mL). After bubbling nitrogenthrough the suspension for 30 minutes,1,1′-bis(diphenylphosphino)Ferrocenedichloropalladium(II) (49 mg, 0.054mmol) was added. The system was subjected to three cycles ofvacuum/argon flush and heated at 80° C. for 3 h. It was then cooled toroom temperature and filtered. The solid was washed with dichloromethane(2×20 mL). The combined filtrate was concentrated under reduced pressureand the residue was purified by silica-gel column chromatography elutingwith dichloromethane/methanol (40:1 to 10:1) to afford 185c (90 mg, 29%)as a light yellow solid. MS-ESI: [M+H]⁺ 549

Example 1852-{3-Hydroxymethyl-4-[6-(imidazo[1,2-a]pyridin-7-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-pyridin-2-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one185

To a solution of 185c (80 mg, 0.146 mmol) in methanol (5 mL) was addedNaBH₄ (34 mg, 0.90 mmol) at room temperature. After the reaction wasstirred for 1 h, LCMS indicated the reaction was complete. The reactionmixture was quenched with water (3 mL) and concentrated under reducedpressure. The residue was extracted with dichloromethane (3×10 mL). Thecombined organic layer was washed with brine (30 mL), dried over Na₂SO₄,filtered, and concentrated under reduced pressure. The residue waspurified by reverse-phase prep-HPLC to afford 185 (49 mg, 61%) as lightyellow solid. MS-ESI: [M+H]⁺ 551. ¹H NMR (500 MHz, DMSO-d₆) δ 9.67 (s,1H), 8.57 (d, J=10.5 Hz, 1H), 8.51 (s, 1H), 8.41 (d, J=7.0 Hz, 1H), 7.77(s, 1H), 7.75 (s, 1H), 7.63 (s, 1H), 7.46 (d, J=6.0 Hz, 1H), 7.42 (s,1H), 6.59 (s, 1H), 5.04-5.02 (m, 1H), 4.67-4.64 (m, 1H), 4.519-4.481 (m,1H), 4.31-4.20 (m, 3H), 3.88 (d, J=7.0 Hz, 1H), 3.58 (s, 3H), 2.63-2.55(m, 2H), 2.44-2.42 (m, 2H), 1.23 (s, 6H).

Example 186a 5-Bromo-1-methyl-3-(pyridin-3-ylamino)pyrazin-2(1H)-one186a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with pyridin-3-amine (940 mg,10 mmol), 3,5-dibromo-1-methylpyrazin-2(1H)-one (5.4 g, 20 mmol),i-propanol (50 mL), and di-1-propylethylamine (10 mL). The mixture washeated at reflux for 5 h. After the completion of the reaction, it wascooled to room temperature. The solvent was removed under reducedpressure. The crude was purified by silica-gel column chromatographyeluting with 30:1 dichloromethane/methanol to afford 186a (1.4 g, 50%)as a yellow solid. MS-ESI: [M+H]⁺ 281.6.

Example 186b4-Methyl-5-oxo-6-(pyridin-3-ylamino)-4,5-dihydropyrazin-2-ylboronic acid186b

A 250-mL round-bottomed flask equipped with a reflux condenser wascharged with 186a (800 mg, 2.86 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.18 g,8.57 mmol), Pd (dppf) Cl₂ (204 mg, 0.28 mmol), potassium acetate (560mg, 5.71 mmol), and dioxane (60 mL). After bubbling nitrogen through themixture for 30 minutes, it was stirred at 100° C. for 3 h undernitrogen. The mixture was cooled to room temperature and filtered. Thefiltrate was evaporated under reduce pressure. The residue solid waswashed with petroleum ether (2×30 mL) to afford 186b (406 mg, 58%) as abrown solid. MS-ESI: [M+H]⁺ 247.3.

Example 186c2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(4-methyl-5-oxo-6-(pyridin-3-ylamino)-4,5-dihydropyrazin-2-yl)nicotinaldehyde186c

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 186b (127 mg, 0.52 mmol),4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (180 mg, 0.52 mmol), Na₂CO₃ (110 mg, 1.04 mmol), PdCl₂(dppf) (38mg, 0.052 mmol), DMF (12 mL), and water (1 mL). After bubbling nitrogenthrough the mixture for 30 minutes, it was heated at 50° C. for 8 hoursunder nitrogen. The reaction was then cooled to room temperature andconcentrated under reduce pressure. The residue was purified bysilica-gel column chromatography eluting with 30:1 methylenechloride/methanol to afford 186c (132 mg, 49%) as a brown solid. MS-ESI:[M+H]⁺ 514.3.

Example 18610-fluoro-2-(3-(hydroxymethyl)-4-(4-methyl-5-oxo-6-(pyridin-3-ylamino)-4,5-dihydropyrazin-2-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one186

To a solution of 186c (118 mg, 0.23 mmol) in methanol (15 mL) was addedNaBH4 (27 mg, 0.70 mmol). The mixture was stirred at 20° C. for 2 h. Thereaction was quenched with water and evaporated under reduced pressure.The residue was purified by reverse-phase prep-HPLC to afford 186 (33mg, 28%) as a white solid. MS-ESI: [M+H]⁺ 516.3. ¹H NMR (500 MHz,DMSO-d₆) δ 9.78 (s, 1H), 8.54 (d, J=5.0 Hz, 1H), 8.39-8.37 (m, 2H),8.06-8.04 (m, 2H), 7.76 (s, 1H), 7.59 (d, J=5.5 Hz, 1H), 4.97 (t, J=5.0Hz, 1H), 4.68-4.65 (m, 1H), 4.51-4.47 (m, 1H), 4.25-4.19 (m, 2H),4.10-4.05 (m, 1H), 3.91-3.88 (m, 1H), 3.58 (s, 3H), 2.66-2.60 (m, 1H),2.57-2.53 (m, 1H), 2.44-2.42 (m, 2H), 1.82-1.75 (m, 2H), 1.71-1.67 (m,2H).

Example 187a(4-(5-(5-(2,2-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 187a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-bromo-3-(5-(2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one190e (200 mg, 1.0 eq., 0.45 mmol),(2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 113i (345 mg, 2 eq., 0.90 mmol), PdCl₂(dppf) (36 mg, 0.1 eq.,0.045 mmol), K₃PO₄ (191 mg, 2 eq., 0.90 mmol), sodium acetate (74 mg,2.0 eq., 0.90 mmol), acetonitrile (15 mL), and water (0.1 mL). Afterthree cycles of vacuum/argon flush, the mixture was stirred at 90° C.for 2 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with50:1 dichloromethane/ethanol to afford 187a (100 mg, 31%) as yellowsolid. MS-ESI: [M+H]⁺ 707.4.

Example 1872-(4-(5-(5-(2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one187

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 187a (100 mg, 1 eq., 0.14 mmol), lithiumhydroxide (54 mg, 10 eq., 1.4 mmol), i-propanol (3 mL), THF (3 mL) andwater (2 mL). The mixture was stirred at 30° C. for 1 h. It was thenfiltered and the filtrate was concentrated under reduced pressure. Theresidue was purified by reverse-phase prep-HPLC to afford 187 as a whitesolid (43 mg, 46%). MS-ESI: [M+H]⁺ 665.3. ¹H NMR (500 MHz, DMSO-d₆) δ8.69 (d, J=2.0 Hz, 1H), 8.60 (s, 1H), 8.48 (d, J=5.0 Hz, 1H), 7.93 (d,J=2.0 Hz, 1H), 7.51 (d, J=1.5 Hz, 1H), 7.42-7.40 (m, 1H), 7.35 (d, J=5.0Hz, 1H), 7.24 (d, J=8.5 Hz, 1H), 6.58 (s, 1H), 4.98 (brs, 1H), 4.54 (t,J=6.0 Hz, 2H), 4.46-4.38 (m, 4H), 4.25-3.85 (m, 4H), 3.60 (s, 3H),3.38-3.35 (m, 1H), 3.03-2.54 (m, 4H), 2.47 (t, J=6.0 Hz, 2H), 2.32-2.12(m, 4H), 1.79-1.67 (m, 4H), 0.97 (s, 6H).

Example 188a(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-6-oxo-5-[(pyrazin-2-yl)amino]-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 188a

A 50-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with5-bromo-1-methyl-3-(pyrazin-2-ylamino)pyridin-2(1H)-one 162a (210 mg,0.70 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (560 mg, 1.4 mmol), Pd(dppf)Cl₂ (70 mg, 0.035 mmol), K₃PO₄(320 mg, 1.4 mmol), sodium acetate trihydrate (210 mg, 1.4 mmol),acetonitrile (10 mL), and water (6 drops). The system was evacuated andrefilled with N₂. The reaction mixture was stirred at 100° C. for 2 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 25:1 ofdichloromethane/methanol to afford 188a (150 mg, 40%) as a yellow brownsolid. MS-ESI: [M+H]⁺ 554.2.

Example 1882-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrazin-2-ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one188

A mixture of 188a (150 mg, 0.27 mmol) and lithium hydroxide (103 mg, 2.7mmol) in i-propanol/THF (5:3, 8 mL) and water (2 mL) was stirred at 30°C. for 1 h. The mixture was evaporated in vacuo and the residue wasextracted with ethyl acetate (2×20 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 188 (40 mg, 35%) as awhite solid. MS-ESI: [M+H]⁺ 512.3. ¹H NMR (500 MHz, CHCl₃) δ 8.73 (d,J=2.0 Hz, 1H), 8.53 (d, J=5.0 Hz, 1H), 8.29 (s, 1H), 8.15-8.13 (m,overlap, 2H), 8.02-8.00 (m, 2H), 7.38 (d, J=5.0 Hz, 1H), 6.86 (s, 1H),5.12 (s, 1H), 4.68-4.51 (m, 2H), 4.33-4.29 (m, 1H), 4.18 (t, J=5.5 Hz,2H), 3.91-3.86 (m, 1H), 3.75 (s, 3H), 2.60-2.58 (m, 2H), 2.53 (s, 2H),1.28 (s, 6H).

Example 189a tert-Butyl 4-(Pyrazin-2-yl)piperazine-1-carboxylate 189a

A 500-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with DMSO (250 mL),tert-butyl piperazine-1-carboxylate (15.8 g, 85.0 mmol),2-chloropyrazine (9.7 g, 85.0 mmol), and Cs₂CO₃ (55.3 g, 170 mmol). Themixture was heated at 60° C. for 3 days. After this time the reactionwas cooled to room temperature. It was then filtered and the filtratewas evaporated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 5:1 petroleum ether/ethylacetate to afford 189a (13.3 g, 60%) as a yellow solid. MS: [M+H]⁺ 265.3

Example 189b tert-Butyl 4-(5-Bromopyrazin-2-yl)piperazine-1-carboxylate189b

A 500-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with acetonitrile (150 mL),189a (3.0 g, 8.8 mmol), and N-bromosuccinimide (1.56 g, 8.8 mmol). Themixture was stirred at room temperature overnight. It was thenconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 10:1 petroleumether/ethyl acetate to afford 189b as a yellow solid (2.85 g, 73.4%).MS: [M+H]⁺ 343.3. ¹H NMR (500 MHz, (CD₃)₂CO) δ 8.03 (s, 1H), 7.94 (s,1H), 3.48-3.46 (m, 4H), 3.42-3.40 (m, 4H), 1.33 (s, 9H).

Example 189c tert-Butyl4-(5-(Diphenylmethyleneamino)pyrazin-2-yl)piperazine-1-carboxylate 189c

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 189b (3.3 g, 9.6 mmol),diphenylmethanimine (1.74 g, 9.6 mmol), palladium diacetate (440 mg,0.48 mmol), (R)-(+)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (598 mg,0.96 mmol), Cs₂CO₃ (6.2 g, 19.2 mmol), and 1,4-dioxane (80 mL). Afterthree cycles of vacuum/argon flush, the mixture was heated at 115° C.for 64 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with5:1 petroleum ether/ethyl acetate to afford 189c as a yellow solid (3.2g, 75%). MS: [M+H]⁺ 444.2.

Example 189d tert-Butyl 4-(5-Aminopyrazin-2-yl)piperazine-1-carboxylate189d

To a solution of 189c (2.5 g, 5.6 mmol) in methanol (25 mL) was addedsodium acetate (0.56 g, 6.8 mmol) and hydroxylamine hydrochloride (0.7g, 10 mmol). The reaction mixture was stirred for 0.5 h. It was thenconcentrated under reduced pressure and the residue was purified bycolumn chromatography eluting with 15:1 dichloromethane/methanol toafford 189d (1.3 g, 71%). MS: [M+H]⁺ 280.3.

Example 189e tert-Butyl4-(5-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyrazin-2-yl)piperazine-1-carboxylate189e

A mixture of 189d (1.1 g, 3.94 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (1.1 g, 3.94 mmol), palladiumdiacetate (45 mg, 0.20 mmol),(R)-(+)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (245 mg, 0.39 mmol),and Cs₂CO₃ (2.6 g, 7.9 mmol) in 1,4-dioxane (150 mL) was heated at 120°C. for 2 hours. It was then cooled to room temperature and concentratedunder reduced pressure. The residue was purified by columnchromatography eluting with 30:1 dichloromethane/methanol to afford 189e(900 mg, 54%). MS: [M+H]⁺ 465.1.

Example 189f5-Bromo-1-methyl-3-(5-(piperazin-1-yl)pyrazin-2-ylamino)pyridin-2(1H)-one189f

A mixture of 189e (1.0 g, 2.2 mmol) and 4.0 M HCl/dioxane (60 mL) wasstirred at room temperature for 5 h. It was then concentrated underreduced pressure to afford crude 189f as a yellow solid (760 mg, 98%),which was used in the next step without further purification. MS: [M+H]⁺395.1.

Example 189g5-Bromo-1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-ylamino)pyridine-2(1H)-one189g

A mixture of 189f (740 mg, 2.0 mmol), oxetan-3-one (288 mg, 4.0 mmol),NaBH₃CN (315 mg, 5.0 mmol), and zinc chloride (680 mg, 5.0 mmol) inmethanol (60 mL) was stirred at 50° C. for 5 hours. It was then quenchedwith water and concentrated under reduced pressure. The residue wasextracted with dichloromethane three times. The combined extract wasconcentrated under reduced pressure to afford crude 189g as a yellowsolid (660 mg, 78%), which was used in the next step without furtherpurification. MS: [M+H]⁺ 423.1.

Example 189h(4-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 189h

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 189g (180 mg, 0.43 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (165 mg, 0.43 mmol), Pd(dppf)Cl₂ (35 mg, 0.043 mmol), sodiumacetate (71 mg, 0.86 mmol), K₃PO₄ (194 mg, 0.86 mmol), acetonitrile (10mL), and water (0.5 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 3 h. After this time the reaction wasfiltered and the filtrate was concentrated under reduced pressure. Theresulting residue was purified by silica-gel column chromatographyeluting with 40:1 dichloromethane/methanol to afford 189h as a yellowsolid (100 mg, 34%). MS-ESI: [M+H]⁺ 680.3.

Example 1892-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one189

At room temperature, to a solution of 189h (90 mg, 0.13 mmol) ini-propanol/THF (1:1, 5 mL) and water (0.5 mL) was added lithiumhydroxide (126 mg, 2.9 mmol). The reaction mixture was stirred at 35° C.for 0.5 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified with by reverse-phase prep-HPLC to afford 189 (60mg, 71%) as yellow solid. MS-ESI: [M+H]⁺ 638.3. ¹H NMR (500 MHz, CDCl₃)δ 8.48 (d, J=5.0 Hz, 1H), 8.43 (d, J=2.0 Hz, 1H), 7.98 (s, 1H), 7.82 (d,J=1.5 Hz, 1H), 7.80 (s, 1H), 7.78 (s, 1H), 7.33 (d, J=5.0 Hz, 1H), 6.89(s, 1H), 5.04-5.01 (m, 1H), 4.72-4.50 (m, 6H), 4.32-4.30 (m, 1H),4.15-4.09 (m, 2H), 3.88-3.86 (m, 1H), 3.72 (s, 3H), 3.57-3.49 (m, 5H),2.61-2.43 (m, 8H), 1.92-1.78 (m, 4H).

Example 190a tert-Butyl3,3-Dimethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 190a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 5-bromo-2-nitropyridine(5.6 g, 28.0 mmol), tert-butyl 3,3-dimethyl-4-piperazine-1-carboxylate(3.0 g, 14.0 mmol), cesium carbonate (9.1 g, 28 mmol), and 1,4-dioxane(50 mL). After bubbling nitrogen through the resulting solution for 30min, Binap (870 mg, 1.4 mmol) andtris(dibenzylideneacetone)-dipalladium(0) (1.2 g, 1.4 mmol) were added.The reaction mixture was subjected to three cycles of vacuum/argon flushand stirred at 120° C. for 24 h. After this time the reaction was cooledto room temperature, filtered and the filtrate was partitioned betweenethyl acetate (200 mL) and water (50 mL). The aqueous layer wasseparated and extracted with ethyl acetate (3×50 mL). The combinedorganic layers were washed with brine (50 mL) and dried over sodiumsulfate. The drying agent was removed by filtration and the filtrate wasconcentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 5:1 petroleum ether/ethylacetate to afford 190a (1.27 g, 27%). LCMS: [M+H]⁺ 337.2.

Example 190b tert-Butyl4-(6-Aminopyridin-3-yl)-3,3-dimethylpiperazine-1-carboxylate 190b

A 50-mL round-bottomed flask was purged with nitrogen and charged withtert-butyl 3,3-dimethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate190a (1100 mg, 3.2 mmol), 10% palladium on carbon (10% wet, 110 mg), andmethanol (20 mL). It was then evacuated, charged with hydrogen gas, andstirred at room temperature for 5 h. The hydrogen was evacuated andnitrogen was charged into the flask. The catalyst was removed byfiltration through a pad of diatomaceous earth filter agent (CELITE®,Imerys Minerals California, Inc.) and the filtrate was concentratedunder reduced pressure to afford 190b (950 mg, 94%). LCMS: [M+H]⁺ 307.3

Example 190c tert-Butyl4-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridin-3-yl)-3,3-dimethylpiperazine-1-carboxylate 190c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with tert-butyl4-(6-aminopyridin-3-yl)-3,3-dimethylpiperazine-1-carboxylate 190b (950mg, 3.1 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (1240 mg, 4.6mmol), 1,4-dioxane (30 mL), and cesium carbonate (2015 mg, 6.2 mmol).After bubbling nitrogen through the resulting solution for 5 min,Xantphos (179 mg, 0.31 mmol) andtris(dibenzylideneacetone)dipalladium(0) (283 mg, 0.31 mmol) were added.The reaction mixture was subjected to three cycles of vacuum/argon flushand heated at reflux for 10 h. After this time the reaction was cooledto room temperature and filtered. The filtrate was partitioned betweenethyl acetate (50 mL) and water (10 mL). The aqueous layer was separatedand extracted with ethyl acetate (3×20 mL). The combined organic layerwas washed with brine (30 mL) and dried over sodium sulfate. The dryingagent was removed by filtration and the filtrate was concentrated underreduced pressure. The residue was purified by silica-gel columnchromatography eluting with 4:1 petroleum ether/ethyl acetate to afford190c (1.21 g, 79%). LCMS: [M+H]⁺ 492.1.

Example 190d5-Bromo-3-(5-(2,2-dimethylpiperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one190d

To a solution of tert-butyl4-(6-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridin-3-yl)-3,3-dimethylpiperazine-1-carboxylate 190c (1.19 g, 1.9mmol) in dichloromethane (20 mL) was added 3M HCl in diethyl ether (15mL). The reaction mixture was stirred at room temperature for 4 h. Itwas then concentrated under reduced pressure to afford 190d (900 mg,95%). LCMS: [M+H]⁺ 392.1.

Example 190e5-Bromo-3-(5-(2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one190e

A mixture of5-bromo-3-(5-(2,2-dimethylpiperazin-1-yl)pyridin-2-ylamino)-1-methyl-pyridin-2(1H)-one190d (900 mg, 2.3 mmol), oxetan-3-one (497 mg, 6.9 mmol), NaBH₃CN (435mg, 6.9 mmol), and zinc chloride (311 mg, 2.3 mmol) in methanol (30 mL)was stirred at 50° C. for 4 hours. It was then concentrated underreduced pressure. Water (10 mL) was added to the residue and the mixturewas extracted with chloroform (3×50 mL). The combined organic layer wasconcentrated under reduced pressure. The residue was purified bysilica-gel column-chromatography eluting with 50:1dichloromethane/methanol to afford 190e (800 mg, 78%). LCMS: [M+H]⁺448.1. ¹H NMR (500 MHz, CDCl₃) δ 8.65 (d, J=2.0 Hz, 1H), 8.11 (d, J=2.5Hz, 1H), 7.85 (s, 1H), 7.37-7.34 (m, 1H), 6.96 (d, J=2.5 Hz, 1H), 6.72(d, J=8.5 Hz, 1H), 4.69-4.61 (m, 4H), 3.60 (s, 3H), 3.50-3.14 (m, 3H),2.43-2.17 (m, 4H), 1.06 (s, 6H).

Example 190f2-(4-Chloro-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one190f

To a solution of4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-nicotinaldehyde103b (1.0 g, 3.0 mmol) in methanol (30 mL) was added sodium borohydride(380 mg, 9.0 mmol) at 10° C. The reaction mixture was stirred for 30minutes and quenched with water (10 mL). It was then concentrated underreduced pressure and the residue was dissolved in dichloromethane (50mL). The mixture was washed with water (10 mL), dried over anhydrousNa₂SO₄, filtered, and evaporated under reduced pressure to afford 190fas a yellow solid (900 mg, 90%). MS-ESI: [M+H]⁺ 332.

Example 190g(4-Chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridine-3-yl)methylAcetate 190g

To a mixture of2-(4-chloro-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one190f (900 mg, 2.7 mol) and triethylamine (900 mg, 9.0 mol) indichloromethane (25 mL) was added dropwise acetyl chloride (600 mg, 6.0mol) while stirring at room temperature. The reaction mixture wasstirred for 1 h and concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting withdichloromethane to afford 190g as white solid (950 mg, 94%). MS-ESI:[M+H]⁺ 374.

Example 190h(4-Chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 190h

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with(4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydro-pyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 190g (950 mg, 2.5 mmol),Pin₂B₂(4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.6g, 2.0 eq., 5 mmol), Pd₂(dba)₃ (230 mg, 0.1 eq., 0.25 mmol), X-phos (232mg, 0.2 eq., 0.50 mmol), potassium acetate (735 mg, 3 eq., 7.5 mmol),and dioxane (20 mL). After three cycles of vacuum/argon flush, themixture was heated at 65° C. for 15 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was washed with 3:1 petroleumether/ethyl acetate to afford 190h as yellow solid (950 mg, 87%).MS-ESI: [M+H]⁺ 383.

Example 190i(4-(5-(5-(2,2-Dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 190i

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-bromo-3-(5-(2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one190e (200 mg, 1.0 eq., 0.45 mmol),(2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 190h (345 mg, 2 eq., 0.90 mmol), PdCl₂(dppf) (36 mg, 0.1 eq.,0.045 mmol), K₃PO₄ (191 mg, 2 eq., 0.90 mmol), sodium acetate (74 mg,2.0 eq., 0.90 mmol), acetonitrile (15 mL), and water (0.1 mL). Afterthree cycles of vacuum/argon flush, the mixture was stirred at 90° C.for 2 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with50:1 dichloromethane/ethanol to afford 190i (100 mg, 31%) as yellowsolid. MS-ESI: [M+H]⁺ 707.4.

Example 1902-[4-[5-[[5-[2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one190

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with(4-(5-(5-(2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 190i (100 mg, 1 eq., 0.14 mmol), lithium hydroxide (54 mg, 10eq., 1.4 mmol), i-propanol (3 mL), THF (3 mL) and water (2 mL). Themixture was stirred at 30° C. for 1 h. It was then filtered and thefiltrate was concentrated under reduced pressure. The residue waspurified by reverse-phase prep-HPLC to afford 190 as a white solid (43mg, 46%). MS-ESI: [M+H]⁺ 665.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.69 (d,J=2.0 Hz, 1H), 8.60 (s, 1H), 8.48 (d, J=5.0 Hz, 1H), 7.93 (d, J=2.0 Hz,1H), 7.51 (d, J=1.5 Hz, 1H), 7.42-7.40 (m, 1H), 7.35 (d, J=5.0 Hz, 1H),7.24 (d, J=8.5 Hz, 1H), 6.58 (s, 1H), 4.98 (brs, 1H), 4.54 (t, J=6.0 Hz,2H), 4.46-4.38 (m, 4H), 4.25-3.85 (m, 4H), 3.60 (s, 3H), 3.38-3.35 (m,1H), 3.03-2.54 (m, 4H), 2.47 (t, J=6.0 Hz, 2H), 2.32-2.12 (m, 4H),1.79-1.67 (m, 4H), 0.97 (s, 6H)

Example 191aN-tert-Butyl-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide 191a

A mixture of 4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxylic acid (500g, 2.75 mol, 1.0 equiv) and thionyl chloride (655 g, 5.5 mol, 2.0 equiv)was heated under reflux for 3 h. Excess thionyl chloride was removed bydistillation under reduced pressure. The residue was taken up indichloromethane (1.0 L) and a solution of tert-butylamine (402 g, 5.5mol, 2.0 equiv) in dichloromethane (500 mL) was added with stirringwhile the temperature of the mixture being kept below 10° C. Theresulting solution was stirred at 25° C. for 16 h. Most of the solventwas removed under reduced pressure. The residue was chilled in anice-bath and 2M KOH solution was introduced slowly to adjust the pH to11 with stirring. The suspension was filtered and the solid collected,washed three times with water, and dried in vacuum to afford 191a as awhite solid (580 g, 80%, over two steps). MS: [M+H]⁺ 238. ¹H NMR (500MHz, CDCl₃) δ 7.02 (s, 1H), 5.77 (s, 1H), 2.65 (t, J=6.0 Hz, 1H), 2.47(t, J=6.0 Hz, 1H), 1.74-1.70 (m, 4H), 1.35 (s, 9H).

Example 191cN-tert-Butyl-3-(diazenylmethyl)-4,5,6,7-tetrahydrobenzo-[b]thiophene-2-carboxamide191c

A solution of 191a (100 g, 0.42 mol, 1.0 equiv) in THF (500 mL) wasslowly added to n-butyl lithium (672 mL, 2.5M in THF, 1.68 mol, 4.0equiv) at −78° C. under argon protection. The mixture was stirred for 2h. N,N-Dimethylformamide (306 g, 4.2 mol, 10.0 equiv) was added to themixture while the temperature being sustained at −78° C. After another2.0 h, the reaction mixture was quenched by addition of methanol (500mL) at −78° C. It was stirred for 0.50 h at room temperature to afford191b in situ. Then 80% aqueous hydrazine hydrate (131 g, 2.1 mol) wasadded and the mixture was refluxed at 65° C. overnight. The organicsolvent was removed under reduced pressure. The residue was filtered andthe resulting yellow solid was washed with water. The solid was dried invacuum to afford 191c, which was used for the next step without furtherpurification. MS: [M+H]⁺ 280.

Example 191d8-Thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-(9),2(7),3-trien-6-one191d

A mixture ofN-tert-butyl-3-(diazenylmethyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide191c (40 g, 144 mmol) in H₂SO₄ (30% aqueous, 3 L) was refluxed at 105°C. for 24 h. It was then filtered and the filtrate was extracted withdichloromethane (3×1 L). The combined extract was dried over Na₂SO₄ andevaporated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 100:1dichloromethane/methanol to afford 191d as a white solid (9.0 g, 31%).MS: [M+H]⁺ 207. ¹H NMR (500 MHz, CDCl₃) δ 8.15 (s, 1H), 2.96-2.94 (m,2H), 2.86-2.84 (m, 2H), 1.96-1.94 (m, 4H).

Example 191e (3S)-tert-Butyl3-Methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 191e

Following the procedure described for compound 101g and starting with(3S)-tert-butyl 3-methylpiperazine-1-carboxylate (10.0 g, 50 mmol) and5-bromo-2-nitropyridine (10.5 g, 50 mmol) afforded 191e as a yellowsolid (8.05 g, 50%). MS-ESI: [M+H]⁺ 323

Example 191f (3S)-tert-Butyl4-(6-Aminopyridin-3-yl)-3-methylpiperazine-1-carboxylate 191f

Following the procedure described for compound 101h and starting with(3S)-tert-butyl 3-methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate191e (5.8 g, 18 mmol) afforded 191f as a brown solid (4.9 g, 93%).MS-ESI: [M+H]⁺ 293

Example 191g (3S)-tert-Butyl4-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridine-3-yl)-3-methylpiperazine-1-carboxylate191g

Following the procedure described for compound 101i and starting with(3S)-tert-butyl-3-methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate191f (4.0 g, 13.7 mmol) and 3,5-dibromo-1-methylpyridin-2(1H)-one (5.5g, 20.6 mmol) afforded 191g as a yellow solid (5.4 g, 83%). MS-ESI:[M+H]⁺ 478

Example 191h(3S)-5-Bromo-1-methyl-3-(5-(2-methylpiperazin-1-yl)pyridin-2-ylamino)pyridine-2(1H)-one191h

Following the procedure described for compound 101j and starting with(3S)-tert-butyl4-(6-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridine-3-yl)-3-methyl-piperazine-1-carboxylate191g (3.1 g, 6.5 mmol) afforded 191h as a yellow solid (2.3 g, 94%).MS-ESI: [M+H]⁺ 378.

Example 191i(S)-5-Bromo-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one191i

A mixture of(S)-5-bromo-1-methyl-3-(5-(2-methylpiperazin-1-yl)pyridin-2-ylamino)pyridin-2(1H)-one191h (40.0 g, 106 mmol), oxetan-3-one (11.4 g, 159 mmol), NaBH₃CN (10.0g, 159 mmol), and zinc chloride (21.3 g, 159 mmol) in methanol (700 mL)was stirred at 50° C. for 5 hours. The mixture was added to water (100mL) and concentrated under reduced pressure. The residue was extractedwith dichloromethane (200 mL×3). The combined organic layer wasconcentrated under reduced pressure and the residue was purified bysilica-gel column chromatography eluting with 40:1dichloromethane/methanol to afford 191i (35 g, 73%). MS: [M+H]⁺ 434.

Example 191j(3S)-1-Methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)-pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one191j

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with(S)-tert-butyl-4-(6-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridine-3-yl)-3-methylpiperazine-1-carboxylate191i (1.0 g, 1.0 eq., 2.3 mmol), Pin₂B₂ (1.46 g, 2.50 eq., 5.75 mmol),Pd₂(dba)₃ (105 mg, 0.05 eq., 0.125 mmol), X-Phos (93 mg, 0.1 eq., 0.23mmol), potassium acetate (676 mg, 3.0 eq., 6.9 mmol), and dioxane (50mL). After three cycles of vacuum/argon flush, the mixture was heated at90° C. for 4 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was washed with 3:1 petroleum ether/ethyl acetate (80 mL) toafford 191j as yellow solid (1.0 g, 90%). MS: [M+H]⁺ 482.

Example 191k4-[1-Methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diaza-tricyclo[7.4.0.0^(2,7)]tri-deca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde191k

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with(S)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one191j (168 mg, 0.35 mmol),4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a (121 mg, 0.35 mmol), K₃PO₄ (148 mg, 0.70 mmol),1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (13 mg, 0.0175mmol), sodium acetate trihydrate (95 mg, 0.70 mmol), water (6 drops),and acetonitrile (10 mL). After bubbling nitrogen through the mixturefor 30 minutes, it was heated at 100° C. under N₂ protection for 1 h.Analysis of reaction mixture by LCMS showed completed conversion to thedesired product. The reaction mixture was cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure. Theresidue was diluted with dichloromethane (30 mL) and water (30 mL). Theaqueous layer was separated and extracted with dichloromethane (3×20mL). The combined organic layer was dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The dark residue was purified bysilica-gel column chromatography eluting with dichloromethane/methanol(80/1 to 30/1) to afford 191k (118 mg, 51%) as yellow solid. MS-ESI:[M+H]⁺ 665

Example 1915-[3-(Hydroxymethyl)-4-[1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)pipera-zin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridin-2-yl]-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-6-one191

To a solution of4-[1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo-[7.4.0.0^(2,7)]-trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde191k (118 mg, 0.18 mmol) in methanol/dichloromethane (10/10 mL) wasadded NaBH₄ (21 mg, 0.54 mmol) at room temperature. After the reactionwas stirred for 1 h, LCMS indicated the reaction was completed. Then themixture was poured into water (20 mL) and concentrated under reducedpressure. The residue was extracted with dichloromethane (20 mL×3). Thecombined organic layer was washed with brine (30 mL), dried over Na₂SO₄,filtered, and concentrated under reduced pressure. The residue solid waspurified by reverse-phase prep-HPLC to afford 191 (71 mg, 60%) as whitesolid. MS-ESI: [M+H]⁺ 667. ¹H NMR (500 MHz, DMSO-d₆) δ 8.64 (d, J=2.5Hz, 1H), 8.58 (d, J=5.0 Hz, 1H), 8.48-8.46 (m, 2H), 7.86 (d, J=3.0 Hz,1H), 7.54 (d, J=5.5 Hz, 1H), 7.48 (d, J=2.0 Hz, 1H), 7.37 (dd, J=3.0,9.0 Hz, 1H), 7.25 (d, J=9.5 Hz, 1H), 4.86-4.85 (m, 1H), 4.58-4.55 (m,2H), 4.48-4.46 (m, 2H), 4.42-4.40 (m, 2H), 3.65-3.64 (m, 1H), 3.61 (s,3H), 3.41-3.99 (m, 1H), 3.05-3.04 (m, 1H), 2.97-2.95 (m, 3H), 2.87-2.86(m, 2H), 2.52-2.51 (m, 1H), 2.34-2.32 (m, 2H), 2.21-2.20 (m, 1H),1.89-1.87 (m, 4H), 0.94 (d, J=6.0 Hz, 3H).

Example 192a Methyl 1-Formyl-5,6,7,8-tetrahydroindolizine-2-carboxylate192a

A 100-mL round-bottomed flask equipped with a magnetic stirrer waspurged with nitrogen and charged with anhydrous dichloroethane (10 mL)and anhydrous DMF (0.7 mL, 9.0 mmol). The reaction mixture was cooled to0° C. and phosphorus oxychloride (0.7 mL, 7.3 mmol) was added over aperiod of 2 min, while maintaining the reaction temperature between 0°C. and 10° C. The cooling bath was removed and the reaction was stirredat room temperature for 1 hour. A solution of methyl5,6,7,8-tetrahydroindolizine-2-carboxylate 112a (1.0 g, 5.6 mmol) inacetonitrile (10 mL) was added and the mixture was stirred at roomtemperature for additional 3 hours. After this time, the solvent wasconcentrated under reduced pressure and the oily residue was taken upwith saturated aqueous NaHCO₃ (20 mL). The aqueous layer was extractedwith ethyl acetate (3×70 mL). The combined organic layer was washed withwater (20 mL), dried over Na₂SO₄ and evaporated under reduced pressure.The residue was purified by silica-gel column chromatography elutingwith 1:1 ethyl acetate/petroleum ether to afford 192a as a white solid(406 mg, 33%). MS: (M+H)⁺ 208.3. ¹H NMR (500 MHz, DMSO) δ 10.29 (s, 1H),7.43 (s, 1H), 3.99 (t, J=6.0 Hz, 2H), 3.76 (s, 3H), 2.95 (t, J=6.5 Hz,2H), 1.90-1.85 (m, 2H), 1.78-1.74 (m, 2H).

Example 192b 7,8,9,10-Tetrahydropyridazino[4,5-a]indolizin-4(3H)-one192b

A 100 mL single-neck round-bottomed flask was charged with hydraziniumhydroxide (20 mL), methyl1-formyl-5,6,7,8-tetrahydroindolizine-2-carboxylate 192a (2.5 g, 12.0mmol). The reaction mixture was heated at 100° C. for 4 hours. Afterthis time the reaction was cooled to room temperature and filtered toafford 192b as a yellow solid (1.9 g, 83%). MS: (M+H)⁺ 190.3. ¹H NMR(500 MHz, DMSO) δ 11.44 (s, 1H), 8.03 (s, 1H), 7.42 (s, 1H), 4.18 (t,J=6.0 Hz, 2H), 2.96 (t, J=6.5 Hz, 2H), 1.98-1.93 (m, 2H), 1.87-1.82 (m,2H).

Example 192c4-Chloro-2-(4-oxo-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-3(4H)-yl)nicotinaldehyde192c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (50 mL),potassium carbonate (1.5 g, 10.6 mmol),7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-4(3H)-one 192b (1.0 g, 5.3mmol), and 2-bromo-4-chloronicotinaldehyde (3.5 g, 15.9 mmol). Afterbubbling nitrogen through the resulting mixture for 30 minutes,copper(I) bromide (75.0 mg, 0.53 mmol) and sarcosine (47.0 mg, 0.53mmol) were added, and the reaction mixture was heated at 95° C. for 12h. After this time the reaction was cooled to room temperature andfiltered. The filtrate was partitioned between methylene chloride (60mL) and water (40 mL). The aqueous layer was separated and extractedwith methylene chloride (3×70 mL). The combined organic layer was washedwith brine (30 mL) and dried over sodium sulfate. The drying agent wasremoved by filtration and the filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 10:1 ethyl acetate/petroleum ether to afford 192c as abrown solid (521 mg, 30%). MS-ESI: [M+H]⁺ 329.2.

Example 192d(S)-4-(1-Methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(4-oxo-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-3(4H)-yl)nicotinaldehyde192d

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-(4-oxo-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-3(4H)-yl)nicotinaldehyde192c (196 mg, 0.60 mmol),(5)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)-piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one191j (290 mg, 0.60 mmol), sodium acetate (100 mg, 1.2 mmol), K₃PO₄ (320mg, 1.2 mmol), PdCl₂(dppf) (50 mg, 0.060 mmol), acetonitrile (25 mL),and water (1 mL). After bubbling nitrogen through the mixture for 30minutes, it was heated at 100° C. for 3 hours under N₂ protection. Thereaction mixture was cooled to room temperature and evaporated underreduced pressure. The residue was purified by silica-gel columnchromatography eluting with 20:1 methylene chloride/methanol to afford192d 173 mg, 44%) as a brown solid. MS-ESI: [M+H]⁺ 648.4.

Example 1923-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-4-one192

To a solution of 192d (160 mg, 0.25 mmol) in MeOH (20 mL) was addedNaBH₄ (28 mg, 0.75 mmol). The mixture was stirred at 20° C. for 2 h andevaporated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford 192 (97 mg, 60%) as a yellow solid.MS-ESI: [M+H]⁺ 650.4. ¹H NMR (500 MHz, DMSO-d₆) δ 8.65 (d, J=2.5 Hz,1H), 8.54 (d, J=4.5 Hz, 1H), 8.45 (s, 1H), 8.25 (s, 1H), 7.86 (d, J=2.5Hz, 1H), 7.62 (s, 1H), 7.51 (d, J=2.5 Hz, 1H), 7.47 (d, J=5.0 Hz, 1H),7.38-7.36 (m, 1H), 7.25 (d, J=9.5 Hz, 1H), 4.66 (s, 1H), 4.57-4.54 (m,2H), 4.48-4.46 (m, 1H), 4.43-4.41 (m, 1H), 4.33 (s, 2H), 4.25-4.21 (m,2H), 3.69-3.66 (m, 1H), 3.60 (s, 3H), 3.42-3.37 (m, 1H), 3.11-3.07 (m,1H), 3.06-3.04 (m, 2H), 2.97-2.92 (m, 1H), 2.55-2.53 (m, 1H), 2.35-2.29(m, 2H), 2.19-2.17 (m, 1H), 2.04-1.96 (m, 2H), 1.93-1.85 (m, 2H), 0.93(d, J=6.5 Hz, 3H).

Example 193a Methyl 2-(Hydroxy(pyridin-2-yl)methyl)acrylate 193a

A 250-mL single-neck round-bottomed flask was charged with chloroform(100 mL), picolinaldehyde (10.7 g, 0.10 mol), methyl acrylate (8.60 g,0.10 mol), and 1,4-diaza-bicyclo[2.2.2]octane (0.560 g, 5.00 mmol). Thereaction mixture stirred at room temperature for 48 h. After this timethe reaction was concentrated under reduced pressure and the residue waspurified by silica-gel column chromatography eluting with 3:1 petroleumether/ethyl acetate to afford 193a as dark yellow oil (11.6 g, 60%).MS-ESI: (M+H)⁺ 194.2. ¹H NMR (500 MHz, CDCl₃) δ 8.54 (d, J=5.0 Hz, 1H),7.69-7.66 (m, 1H), 7.42 (d, J=8.0 Hz, 1H), 7.22-7.20 (m, 1H), 6.36 (s,1H), 5.97 (s, 1H), 5.62 (s, 1H), 4.85 (s, 1H), 3.74 (s, 3H).

Example 193b Methyl Indolizine-2-carboxylate 193b

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with acetic anhydride (80 mL)and 193a (6.68 g, 34.6 mmol). The reaction mixture was heated at refluxunder nitrogen for 4 h. After this time the reaction was cooled to roomtemperature, poured onto the mixture of ice (100 g) and aqueoussaturated sodium bicarbonate (200 mL), and stirred for 1 h. Theresulting solution was neutralized with saturated aqueous sodiumbicarbonate and extracted with methylene chloride (3×200 mL). Thecombined organic extract was dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by silica-gel columnchromatography eluting with 10:1 petroleum ether/ethyl acetate (10:1) toafford 193b as a white solid (2.1 g, 35%). MS-ESI: (M+H)⁺ 176.2. ¹H NMR(500 MHz, CDCl₃) δ 7.86-7.84 (m, 1H), 7.79 (d, J=1.0 Hz, 1H), 7.36-7.34(m, 1H), 6.82 (s, 1H), 6.70-6.66 (m, 1H), 6.55-6.51 (m, 1H), 3.88 (s,3H).

Example 193c Methyl 5,6,7,8-Tetrahydroindolizine-2-carboxylate 193c

A 250-mL round-bottomed flask was purged with nitrogen and charged with193b (2.0 g, 11.4 mmol), 10% palladium on carbon (50% wet, 200 mg), andmethanol (50 mL). It was evacuated, charged with hydrogen gas, andstirred under 5 atm hydrogen at room temperature for 8 h. The hydrogenwas then evacuated and nitrogen was charged into the flask. The catalystwas removed by filtration through a pad of CELITE® and the filtrateconcentrated under reduced pressure to afford 193c as a white solid (1.1g, 81%). MS-ESI: [M+H]⁺ 180.3. ¹H NMR (500 MHz, DMSO-d₆) δ 7.25 (d,J=2.0 Hz, 1H), 6.09 (s, 1H), 3.93 (t, J=6.0 Hz, 2H), 3.66 (s, 3H), 2.67(t, J=6.0 Hz, 2H), 1.87-1.83 (m, 2H), 1.75-1.70 (m, 2H).

Example 193d Methyl 3-Formyl-5,6,7,8-tetrahydroindolizine-2-carboxylate193d

A 100-mL round-bottomed flask equipped with a magnetic stirrer waspurged with nitrogen and charged with anhydrous dichloroethane (20 mL)and anhydrous DMF (0.70 mL, 9.0 mmol). To the mixture at 0° C. was addedphosphorus oxychloride (0.70 mL, 7.3 mmol) over a period of 2 min, whilemaintaining the reaction temperature between 0° C. and 10° C. Thecooling bath was removed and the reaction was stirred at roomtemperature for 1 hour. A solution of 193c (1.0 g, 5.6 mmol) inacetonitrile (10 mL) was added and the reaction mixture was stirred atroom temperature for 3 hours. After this time, it was concentrated underreduced pressure. The oily residue was taken up with saturated aqueousNaHCO₃ (20 mL) and extracted with ethyl acetate (3×50 mL). The combinedorganic layer was washed with water (50 mL), dried over Na₂SO₄, andevaporated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 1:5 ethylacetate/petroleum ether to afford 193d as a white solid (703 mg, 58%).MS-ESI: (M+H)⁺ 208.3. ¹H NMR (500 MHz, DMSO-d₆) δ 10.14 (s, 1H), 6.40(s, 1H), 4.27 (t, J=6.0 Hz, 2H), 3.78 (s, 3H), 2.78 (t, J=6.0 Hz, 2H),1.94-1.85 (m, 2H), 1.78-1.69 (m, 2H).

Example 193e 6,7,8,9-Tetrahydropyridazino[4,5-b]indolizin-1(2H)-one 193e

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 193d (600 mg, 2.9 mmol) and hydrazine hydrate(20 mL). The reaction mixture was heated at 100° C. for 4 hours. Afterthis time the reaction was cooled to room temperature and filtered toafford 193e as a yellow solid (413 mg, 75%). MS-ESI: (M+H)⁺ 190.1. ¹HNMR (500 MHz, DMSO-d₆) δ 12.17 (s, 1H), 8.24 (s, 1H), 6.33 (s, 1H), 4.16(t, J=6.0 Hz, 2H), 2.88 (t, J=6.5 Hz, 2H), 2.00-1.96 (m, 2H), 1.84-1.79(m, 2H).

Example 193f4-Chloro-2-(1-oxo-6,7,8,9-tetrahydropyridazino[4,5-b]indolizin-2(1H)-yl)nicotinaldehyde193f

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 1,4-dioxane (40 mL), 193e (800 mg, 3.6 mmol),2-bromo-4-chloronicotinaldehyde (2.8 g, 12.6 mmol), and potassiumcarbonate (1.2 g, 8.4 mmol). After bubbling nitrogen through theresulting mixture for 30 minutes, copper(I) iodide (800 mg, 4.2 mmol)and 4,7-dimethoxy-1,10-phenanthroline (1.0 g, 4.2 mmol) were added, andthe reaction mixture was heated at 90° C. for 12 h. After this time thereaction was cooled to room temperature and filtered. The filtrate waspartitioned between methylene chloride (60 mL) and water (40 mL). Theaqueous layer was separated and extracted with methylene chloride (3×40mL). The combined organic layer was washed with brine (30 mL) and driedover sodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 1:1 ethylacetate/petroleum ether to afford 193f as a brown solid (513 mg, yield37%). MS-ESI: [M+H]⁺ 329.1.

Example 193g(S)-4-(1-Methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)-pyridin-2-yl-amino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-6,7,8,9tetrahydro-pyridazino[4,5-b]indolizin-2(1H)-yl)nicotinaldehyde 193g

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with 193f (200 mg, 0.61 mmol), 191j (293 mg, 0.60 mmol), sodiumacetate (98 mg, 1.2 mmol), K₃PO₄ (254 mg, 1.2 mmol), PdCl₂(dppf) (50 mg,0.060 mmol), acetonitrile (25 mL), and water (1 mL). After bubblingnitrogen through the mixture for 30 minutes, it was heated at 100° C.for 3 hours. The mixture was cooled to room temperature and filtered.The filtrate was concentrated under reduced pressure and the residue waspurified by silica-gel column chromatography eluting with 25:1 methylenechloride/methanol to afford 193g (206 mg, 53%) as a brown solid. MS-ESI:[M+H]⁺ 648.3.

Example 1932-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydropyridazino[4,5-b]indolizin-1-one193

To a solution of 193g (180 mg, 0.28 mmol) in methanol (20 mL) was addedNaBH4 (32 mg, 0.84 mmol). The mixture was stirred at 20° C. for 2 h andquenched with water. It was then evaporated under reduced pressure andthe residue was purified by reverse-phase prep-HPLC to afford 193 (140mg, 78%) as an off-white solid. MS-ESI: [M+H]⁺ 650.4. ¹H NMR (500 MHz,DMSO-d₆) δ 8.67 (d, J=2.0 Hz, 1H), 8.55 (d, J=5.5 Hz, 1H), 8.47 (s, 1H),8.48 (s, 1H), 7.85 (d, J=2.5 Hz, 1H), 7.52-7.50 (m, 2H), 7.38-7.36 (m,1H), 7.25 (d, J=8.5 Hz, 1H), 6.49 (s, 1H), 4.72 (t, J=5.0 Hz, 1H),4.57-4.54 (m, 2H), 4.47 (t, J=6.0 Hz, 1H), 4.41 (t, J=6.0 Hz, 1H),4.33-4.29 (m, 2H), 4.28-4.25 (m, 2H), 3.71-3.65 (m, 1H), 3.60 (s, 3H),3.41-3.77 (m, 1H), 3.10-3.08 (m, 1H), 2.98-2.90 (m, 3H), 2.57-2.52 (m,1H), 2.35-2.30 (m, 2H), 2.18-2.16 (m, 1H), 2.06-2.0 (m, 2H), 1.89-1.82(m, 2H), 0.93 (d, J=6.0 Hz, 3H).

Example 194a1-Methyl-3-(pyrazin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one194a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-bromo-1-methyl-3-(pyrazin-2-ylamino)pyridin-2(1H)-one 142a (600 mg,2.0 mmol), Pin₂B₂ (2.54 g, 10 mmol), Pd₂(dba)₃ (100 mg, 0.10 mmol),X-phos (100 mg, 0.20 mmol), potassium acetate (600 mg, 6.0 mmol), anddioxane (80 mL). After three cycles of vacuum/argon flush, the mixturewas heated at 65° C. for 16 h. It was then cooled to room temperatureand filtered. The filtrate was concentrated under reduced pressure andthe resulting residue was washed with petroleum ether to afford 194a asa yellow solid (crude product) (1.0 g, LCMS purity: 70%). MS-ESI: [M+H]⁺329.4.

Example 194b4-{1-Methyl-6-oxo-5-[(pyrazin-2-yl)amino]-1,6-dihydropyridin-3-yl}-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde194b

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a (345 mg, 1.0 mmol), 194a (659 mg, 2.0 mmol), Pd(dppf)Cl₂ (50 mg,0.050 mmol), K₃PO₄ (450 mg, 2.0 mmol), sodium acetate trihydrate (300mg, 2.0 mmol), water (6 drops) and, acetonitrile (40 mL). The system wasevacuated and refilled with N₂. The reaction mixture was heated at 100°C. for 2 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with25:1 dichloromethane/methanol to afford 194b (250 mg, 49%) as a yellowbrown solid. MS-ESI: [M+H]⁺ 512.3.

Example 1943-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(pyrazin-2-ylamino)-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one194

A mixture of 194b (200 mg, 0.4 mmol) and NaBH₄ (48 mg, 1.2 mmol) inmethanol (20 mL) was stirred at 30° C. for 2 h. The mixture was quenchedwith water (5 mL) and concentrated under reduced pressure. The residuewas extracted with ethyl acetate (3×10 mL). The combined with ethylacetate extract was concentrated under reduced pressure and the residuewas purified by reverse-phase prep-HPLC to afford 194 (60 mg, 30%) as awhite solid. MS-ESI: [M+H]⁺ 514.2. ¹H NMR (500 MHz, CDCl₃) δ 8.78 (d,J=2.0 Hz, 1H), 8.69 (d, J=5.0 Hz, 1H), 8.31 (s, 1H), 8.29 (s, 1H), 8.17(s, 1H), 8.13 (s, 1H), 8.04 (d, J=2.5 Hz, 1H), 7.83 (d, J=2.5 Hz, 1H),7.56 (d, J=5 Hz, 1H), 4.44-4.37 (m, 3H), 3.76 (s, 3H), 3.01-2.99 (m,2H), 2.88-2.86 (m, 2H), 2.01-1.96 (m, 4H).

Example 195a Ethyl 4,5,6,7-Tetrahydro-1H-indole-2-carboxylate 195a

To a mixture of ethyl 3-(2-chlorocyclohex-1-enyl)acrylate (21.4 g, 100mmol) in DMSO (100 mL) was added sodium azide (9.75 g, 150 mmol). Thereaction mixture was heated at 105° C. for 4 h. After cooling to roomtemperature, the mixture was poured into ice water. The resultingprecipitate was collected by filtration to afford 195a (18.0 g, 93.3%).MS-ESI: [M+H]⁺ 194.

Example 195b Ethyl1-(2,2-Diethoxyethyl)-4,5,6,7-tetrahydro-1H-indole-2-carboxylate 195b

To a suspension of NaH (1.44 g, 60.2 mmol) in N,N-dimethylformamide(DMF)(30 mL) was slowly added 195a (5.80 g, 30.1 mmol) at 0° C. Theresulting mixture was stirred at room temperature for 0.5 h, followed bythe addition of 2-bromo-1,1-diethoxyethane (11.9 g, 60.2 mmol). Thereaction was heated at 70° C. for 30 h and quenched with water (100 mL).The mixture was then extracted with ethyl acetate (3×100 mL). Thecombined organic phase was concentrated under reduced pressure and theresidue was purified with silica-gel column chromatography eluting with40:1 petroleum ether/ethyl acetate to 195b (4.7 g, 51%). MS-ESI:[M-EtOH+H]⁺ 264. ¹H NMR (500 MHz, DMSO-d₆) δ 6.65 (s, 1H), 4.59 (t,J=5.0 Hz, 1H), 4.17-4.16 (m, 4H), 3.59-3.57 (m, 2H), 3.27-3.26 (m, 2H),2.61 (t, J=6.0 Hz, 2H), 2.51 (t, J=6.0 Hz, 2H), 1.73-1.71 (m, 2H),1.63-1.61 (m, 2H), 1.25 (t, J=7.0 Hz, 3H), 1.02 (t, J=7.0 Hz, 6H).

Example 195c1-(2,2-Diethoxyethyl)-4,5,6,7-tetrahydro-1H-indole-2-carboxylic Acid195c

To a mixture of 195b (4.7 g, 15.2 mmol) in a mixed solvent of ethanol(20 mL), tetrahydrofuran (20 mL), and water (30 mL) was added sodiumhydroxide (3.0 g, 75.0 mmol). The reaction was heated at 75° C. for twodays and concentrated under reduced pressure. The residue was suspendedin water and neutralized with diluted aqueous citric acid solution. Themixture was extracted with ethyl acetate (3×100 mL) and the combinedorganic phase was concentrated under reduced pressure to afford 195c(3.32 g, 78%). MS-ESI: [M-EtOH+H]⁺ 236.

Example 195d1-(2,2-Diethoxyethyl)-4,5,6,7-tetrahydro-1H-indole-2-carboxamide 195d

To a mixture of 195c (2.8 g, 10.0 mmol) in N,N-dimethylformamide (30 mL)was added O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HATU) (5.7 g, 15.0 mmol), Et₃N (1.5 g, 15.0 mmol),and DMAP (128 mg, 1.0 mmol). The reaction mixture was stirred at roomtemperature for overnight. Saturated ammonium hydroxide (30 mL) wasadded and the resulting mixture was further stirred for 2 h. It was thendiluted with water (100 mL) and extracted with ethyl acetate (3×100 mL).The combined organic phase was concentrated under reduced pressure andthe residue was purified by silica-gel column chromatography elutingwith petroleum ether/ethyl acetate (6:1 to 3:1) to afford 195d (2.7 g,96%). MS-ESI: [M-EtOH+H]⁺ 235. ¹H NMR (500 MHz, DMSO) δ 7.35 (bs, 1H),6.70 (bs, 1H), 6.60 (s, 1H), 4.60 (t, J=5.5 Hz, 1H), 4.18 (d, J=4.0 Hz,2H), 3.57-3.56 (m, 2H), 3.25 (m, 2H), 2.57 (t, J=6.0 Hz, 2H), 2.40 (t,J=6.0 Hz, 2H), 1.71 (t, J=5.0 Hz, 2H), 1.64 (t, J=5.0 Hz, 2H), 1.01 (t,J=7.0 Hz, 6H).

Example 195e 6,7,8,9-Tetrahydropyrazino[1,2-a]indol-1(2H)-one 195e

A mixture of 195d (2.7 g, 9.6 mmol) and acetic acid (10 mL) was heatedat 110° C. for 2 h. The mixture was cooled to room temperature andneutralized with aqueous sodium carbonate solution and extracted withethyl acetate (3×30 mL). The combined organic phase was concentratedunder reduced pressure to afford 195e as a yellow solid (1.6 g, 88%).MS-ESI: [M+H]⁺ 189.3. ¹H NMR (500 MHz, DMSO-d₆) δ 10.28 (s, 1H), 7.02(d, J=5.5 Hz, 1H), 6.63 (s, 1H), 6.52 (pt, J=5.5 Hz, 1H), 2.66 (t, J=6.0Hz, 2H), 2.57 (t, J=6.0 Hz, 2H), 1.83-1.82 (m, 2H), 1.73-1.72 (m, 2H).

Example 195f4-Chloro-2-(1-oxo-6,7,8,9-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde195f

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (15 mL),2-bromo-4-chloronicotinaldehyde 103a (503 mg, 2.28 mmol), 195e (142 mg,0.76 mmol), cesium carbonate (490 mg, 1.5 mmol), CuI (143 mg, 0.76mmol), and 4,7-dimethoxy-1,10-phenanthroline (127 mg, 0.52 mmol). Afterthree cycles of vacuum/argon flush, the mixture was heated at 80° C. for10 hrs. It was then cooled to room temperature and filtered. Thefiltrate was washed with brine and concentrated under reduced pressure.The resulting residue was purified with silica-gel column chromatographyeluting with 1:4 ethyl acetate/petroleum ether to afford 195f (160 mg,65%) as a yellow solid. MS-ESI: [M+H]⁺ 328.

Example 195g2-(3-(Formyl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-6,7,8,9-tetrahydro-pyrazino[1,2-a]indol-1(2H)-one195g

A 50-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 195f (130 mg, 0.40 mmol),1-methyl-3-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one135a (154 mg, 0.40 mmol), Pd(dppf)Cl₂ (29 mg, 0.040 mmol), K₃PO₄ (170mg, 0.80 mmol), sodium acetate (66 mg, 0.80 mmol), water (6 drops), andacetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at reflux for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 30:1 dichloromethane/methanol to afford 195gas yellow solid (120 mg, 54%). MS-ESI: [M+H]⁺ 551.2

Example 1952-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1-one195

To a solution of 195g (120 mg, 0.22 mmol) in methanol (5 mL) at 0° C.was added sodium borohydride (25 mg, 0.66 mmol). The reaction mixturewas stirred for 30 minutes. It was then quenched with water (1.0 mL) andconcentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford 195 (70 mg, 58%). MS-ESI: [M+H]⁺553.3. 1H NMR (500 MHz, CDCl₃) δ 8.56 (d, J=5.0 Hz, 1H), 7.99 (d, J=2.0Hz, 1H), 7.75 (d, J=2.0 Hz, 1H), 7.49 (d, J=4.5 Hz, 1H), 7.43 (s, 1H),7.07 (s, 1H), 6.97 (d, J=6.0 Hz, 1H), 6.67 (d, J=6.0 Hz, 1H), 5.70 (s,1H), 5.08-5.06 (m, 1H), 4.51-4.49 (m, 1H), 4.36-4.34 (m, 1H), 4.14-4.05(m, 2H), 3.72 (s, 3H), 3.62-3.60 (m, 2H), 2.91-2.89 (m, 2H), 2.75-2.70(m, 4H), 2.49 (s, 3H), 1.97-1.95 (m, 2H), 1.86-1.84 (m, 2H).

Example 196a 2-cyclopropylpyrimidin-4-amine 196a

Cyclopropylcarbamidine hydrochloride (1.0 g, 8.3 mmol) was dissolved inethanol (25 mL) and triethylamine (1.26 g, 12.5 mmol), followed by theaddition of 2-chloroacrylo-nitrile (870 mg, 10 mmol). The resultingorange-yellow solution was refluxed for 1 h. The mixture was cooled toroom temperature and filtered. The filtrate was concentrated in vacuoand the residue was purified by reverse-phase Combiflash to afford 196a(300 mg, 27%) as a light brown solid. MS-ESI: [M+H]⁺ 136

Example 196b5-Bromo-3-(2-cyclopropylpyrimidin-4-ylamino)-1-methylpyridin-2(1H)-one196b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 196a (300 mg, 2.22mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (593 mg, 2.22 mmol), andcesium carbonate (1.45 g, 4.44 mmol). After bubbling nitrogen throughthe suspension for 30 minutes, Xantphos (127 mg, 0.22 mmol) andtris(dibenzyl-ideneacetone)dipalladium(0) (100 mg, 0.11 mmol) wereadded. The system was subject to three cycles of vacuum/argon flush andheated at reflux for 5 h. It was then cooled to room temperature andfiltered. The solid was washed with dichloromethane (2×50 mL). Thecombined filtrate was concentrated under reduced pressure and theresidue was washed with acetonitrile (5 mL) to afford 196b (420 mg, 59%)as a yellow solid. MS-ESI: [M+H]⁻ 321

Example 196c3-(2-Cyclopropylpyrimidin-4-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one196c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a condenser was charged with 196b (380 mg, 1.2 mmol), Pin₂B₂(1.5 g, 5.9 mmol), Pd₂(dba)₃ (55 mg, 0.060 mmol), X-phos (57 mg, 0.060mmol), potassium acetate (350 mg, 3.6 mmol), and 1,4-dioxane (20 mL).The reaction mixture was subjected to three cycles of vacuum/argon flushand was heated at 60° C. for 15 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was washed with petroleum ether toafford 196c (410 mg, 94%) as yellow solid, which was used directly fornext step without further purification. MS-ESI: [M+H]⁺ 369

Example 196d4-{5-[(2-Cyclopropylpyridin-4-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde196d

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 196c (258 mg, 0.70 mmol),4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (240 mg, 0.70 mmol), K₃PO₄ (297 mg, 1.4 mmol), sodium acetate (190mg, 1.4 mmol), 1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II)(29 mg, 0.035 mmol), acetonitrile (10 mL), and water (0.5 mL). Afterbubbling nitrogen through the mixture for 30 minutes, it was heated at100° C. under N₂ protection for 1 h. Analysis of reaction by LCMS showedcompleted conversion to the desired product. The mixture was cooled toroom temperature and diluted with dichloromethane (20 mL) and water (20mL). The aqueous layer was separated and extracted with dichloromethane(3×20 mL). The combined organic layer was dried over Na₂SO₄, filtered,and concentrated under reduced pressure. The dark residue was purifiedby silica-gel column chromatography eluting withdichloromethane/methanol (80/1 to 30/1) to afford 196d (220 mg, 57%) asyellow solid. MS-ESI: [M+H]⁺ 549

Example 1963-[4-[5-[(2-cyclopropylpyrimidin-4-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one196

To a solution of 196d (200 mg, 0.36 mmol) in methanol/dichloromethane(5/5 mL) was added NaBH₄ (42 mg, 1.1 mmol) at room temperature. Afterthe reaction was stirred for 1 h, LCMS indicated the reaction wascompleted. The mixture was concentrated under reduced pressure and water(10 mL) was added to the residue. It was then extracted withdichloromethane (20 mL×3). The combined organic layer was washed withbrine (30 mL), dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was purified by prep-HPLC to afford 196(135 mg, 68%) as a white solid. MS-ESI: [M+H]⁺ 551. ¹H NMR (500 MHz,CDCl₃) δ 8.84 (d, J=2.5 Hz, 1H), 8.53 (d, J=5.0 Hz, 1H), 8.22 (d, J=6.0Hz, 1H), 8.13 (d, J=1.5 Hz, 1H), 8.01 (s, 1H), 7.38 (d, J=5.0 Hz, 1H),6.86 (s, 1H), 6.52 (d, J=6.0 Hz, 1H), 5.22-5.19 (m, 1H), 4.72-4.69 (m,1H), 4.56-4.54 (m, 1H), 4.31 (t, J=11.0 Hz, 1H), 4.17 (d, J=5.0 Hz, 2H),3.94-3.91 (m, 1H), 3.74 (s, 3H), 2.58 (d, J=5.5 Hz, 2H), 2.53 (s, 2H),2.18-2.13 (m, 1H), 1.29 (s, 6H), 1.16-1.13 (m, 1H), 1.06-0.95 (m, 3H).

Example 197a tert-Butyl 4-(5-Nitropyridin-2-yl)piperazine-1-carboxylate197a

A mixture of 2-bromo-5-nitropyridine (5.0 g, 24.6 mmol), tert-butylpiperazine-1-carboxylate (13.8 g, 74.2 mmol), acetonitrile (150 mL) wasstirred at reflux for 2.5 h. After the reaction was completed, thesolvent was removed under reduced pressure to afford 197a as a yellowsolid (4.1 g, 54%). MS-ESI: [M+H]⁺ 309.

Example 197b tert-Butyl 4-(5-Aminopyridin-2-yl)piperazine-1-carboxylate197b

A 250-mL round-bottomed flask was purged with nitrogen and charged with197a (4.0 g, 13.0 mmol), 10% palladium on carbon (10% wet, 500 mg), andmethanol (130 mL). The flask was evacuated, charged with hydrogen gas,and stirred at room temperature for 15 h. Hydrogen was then evacuatedand nitrogen was charged to the flask. The catalyst was removed byfiltration through a pad of CELITE® and the filtrate was concentratedunder reduced pressure to afford 197b (3.3 g, 91%). MS-ESI: [M+H]⁺ 279

Example 197c tert-Butyl4-(5-(6-Bromo-4-methyl-3-oxo-3,4-dihydropyrazin-2-ylamino)pyridin-2-yl)piperazine-1-carboxylate197c

A mixture of 197b (500 mg, 1.8 mmol),3,5-dibromo-1-methylpyrazin-2(1H)-one (530 mg, 2.0 mmol),N-ethyl-N-isopropylpropan-2-amine (1.5 mL, 0.90 mmol), and propan-2-ol(20 mL) was stirred at 100° C. for 15 h. After the reaction wascompleted, the solvent was removed under reduced pressure to afford 197cas a brown solid (375 mg, 45%). MS-ESI: [M+H]⁺ 465.

Example 197d5-Bromo-1-methyl-3-(6-(piperazin-1-yl)pyridin-3-ylamino)-pyrazin-2(1H)-one197d

To a solution of 197c (500 mg, 1.08 mmol) in dichloromethane (10 mL) wasadded 4.0 M HCl/dioxane (10 mL). The reaction mixture was stirred atroom temperature for 5 h. It was then concentrated under reducedpressure to afford 197d (358 mg, 91%). MS-ESI: [M+H]⁺ 365.

Example 197e5-Bromo-1-methyl-3-(6-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-3-ylamino)pyrazin-2(1H)-one197e

A mixture of 197d (0.75 g, 2.1 mmol), oxetan-3-one (0.24 mL, 4.2 mmol),NaBH₃CN (0.32 g, 5.1 mmol), and zinc chloride/diethyl ether (5.1 mL, 5.1mmol) in methanol (30 mL) was stirred at 50° C. for 5 hours. The solidwas removed by filtration and the filtrate was concentrated underreduced pressure. The residue was purified by silica-gel columnchromatography eluting with 10:1 dichloromethane/methanol to afford 197e(550 mg, 64%). MS-ESI: [M+H]⁺ 421.

Example 197f(4-(4-Methyl-6-(6-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-3-ylamino)-5-oxo-4,5-dihydropyrazin-2-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 197f

A round-bottomed flask equipped with a reflux condenser was charged with197e (200 mg, 0.48 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (364 mg, 0.95 mmol), PdCl₂(dppf) (40 mg, 0.049 mmol),K₃PO₄3H₂O (250 mg, 0.95 mmol), sodium acetate (80 mg, 0.95 mmol),acetonitrile (10 mL), and water (0.5 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 80° C. for 3 h. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified by silica-gel column chromatography eluting with 1:20methanol/dichloromethane to afford 197f as a red solid (230 mg, 70%).MS-ESI: [M+H]⁺ 680

Example 1972-[3-(hydroxymethyl)-4-[4-methyl-6-[[6-[4-(oxetan-3-yl)piperazin-1-yl]-3-pyridyl]amino]-5-oxo-pyrazin-2-yl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one197

A mixture of 197f (200 mg, 0.30 mmol) and lithium hydroxide (70 mg, 3.0mmol) in THF (9 mL), i-propanol (6 mL), and water (1 mL) was stirred atroom temperature for 0.5 h. The mixture was concentrated under reducedpressure and diluted with water (4 mL). It was then extracted withdichloromethane (2×10 mL) and the combined dichloromethane extract wasconcentrated under reduced pressure. The residue was purified withreverse-phase prep-HPLC to afford 197 (59 mg, 30%) as yellow solid.MS-ESI: [M+H]⁺ 638. ¹H NMR (500 MHz, DMSO-d₆) δ 9.30 (s, 1H), 8.70 (d,J=2.5 Hz, 1H), 8.49 (d, J=5.5 Hz, 1H), 8.14-8.11 (m, 1H), 7.59 (s, 1H),7.55 (d, J=5.0 Hz, 1H), 6.82 (d, J=9.5 Hz, 1H), 6.58 (s, 1H), 4.93 (t,J=5.5 Hz, 1H), 4.60-4.54 (m, 3H), 4.48-4.42 (m, 3H), 4.26-4.08 (m, 3H),3.86 (d, J=12.0 Hz, 1H), 3.54 (s, 3H), 3.44-3.40 (m, overlap, 5H),2.66-2.53 (m, 2H), 2.46-2.47 (m, 2H), 2.35-2.33 (m, 4H), 1.80-1.68 (m,4H).

Example 198a4-(1-Methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(4-oxo-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-3(4H)-yl)nicotinaldehyde198a

A 50-mL round bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-(4-oxo-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-3(4H)-yl)nicotinaldehyde192c (118 mg, 0.36 mmol),1-methyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl-amino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one101l (171 mg, 0.36 mmol), Na₂CO₃ (78 mg, 0.72 mmol), Pd (dppf)Cl₂ (30mg, 0.036 mmol), DMF (10 mL), and water (1 mL). After bubbling nitrogenthrough the mixture for 30 minutes, it was heated at 50° C. for 10 hoursunder N₂ protection. It was then cooled to room temperature andevaporated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 20:1dichloromethane/methanol to afford 198a (93 mg, 40%) as a brown solid.MS-ESI: [M+H]⁺ 634.3.

Example 1983-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-4-one198

To a solution of 198a (80 mg, 0.13 mmol) in methanol (4 mL) was addedNaBH4 (14 mg, 0.39 mmol). The mixture was stirred at 20° C. for 2 h. Itwas then evaporated under reduced pressure and the residue was purifiedby reverse-phase prep-HPLC to afford 198 (38 mg, 43%) as an off-whitesolid. MS-ESI: [M+H]⁺ 636.4. ¹H NMR (500 MHz, DMSO-d₆) δ 8.65 (d, J=2.0Hz, 1H), 8.54 (d, J=5.0 Hz, 1H), 8.44 (s, 1H), 8.25 (s, 1H), 7.88 (d,J=2.5 Hz, 1H), 7.62 (s, 1H), 7.50 (d, J=2.0 Hz, 1H), 7.46 (d, J=4.5 Hz,1H), 7.39-7.36 (m, 1H), 7.25-7.23 (m, 1H), 4.67 (bs, 1H), 4.55 (t, J=6.5Hz, 2H), 4.46 (t, J=6.0 Hz, 2H), 4.33-4.31 (m, 2H), 4.26-4.20 (m, 2H),3.59 (s, 3H), 3.46-3.41 (m, 1H), 3.09-3.03 (m, 6H), 2.39-2.37 (m, 4H),2.04-1.96 (m, 2H), 1.93-1.86 (m, 2H).

Example 199a Imidazo[1,2-a]pyrimidin-7-amine 199a

To the solution of pyrimidine-2,4-diamine (3.0 g, 0.027 mol) in ethanol(90 mL) and aqueous NaHCO₃ (2M, 20 mL) was added 2-chloroacetaldehyde(4.3 g, 0.055 mol). The mixture was stirred at 70° C. overnight. TLCshowed the starting material disappeared. The solvent was removed underreduced pressure and the residue was extracted with ethyl acetate (3×30mL). The combined organic layer was concentrated under reduced pressureand the residue was purified by silica-gel column chromatography elutingwith 1:5 petroleum ether/ethyl acetate to afford 199a as a white solid(2.2 g, 60%). MS: [M+H]⁺ 135.1.

Example 199b5-Bromo-3-(imidazo[1,2-a]pyrimidin-7-ylamino)-1-methylpyridin-2(1H)-one199b

A 250-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 199a (2.2 g, 16.4 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (8.77 g, 32.8 mmol), Pd₂ dba₃ (1.5g, 1.64 mmol), Xantphos (1.88 g, 3.28 mmol), Cs₂CO₃ (10.7 g. 32.8 mmol),and 1,4-dioxane (150 mL). The system was evacuated and then refilledwith N₂. It was then heated at reflux for 3 h. After the completion ofthe reaction, the mixture was filtered off and the solid was washed withmethanol (60 mL). The combined filtrate was evaporated under reducedpressure and the residue was purified by silica-gel columnchromatography eluting with 20:1 dichloromethane/methanol to afford 199bas a light green solid (1.63 g, 31%). MS: [M+H]⁺ 320.1

Example 199c10-[4-chloro-3-(hydroxymethyl)pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one199c

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (9.0 g, 26.1 mmol, 1.0 eq.), methanol (50 mL), dichloromethane (30mL), and NaBH₄ (5.95 g, 156.6 mmol, 5.0 eq.) at 0° C. The reactionmixture was stirred for 1 h. After the reaction was completed, thereaction was quenched with water and concentrated under reducedpressure. The residue was extracted with dichloromethane. The combinedorganic layer was dried over Na₂SO₄ and concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 1:4 ethyl acetate/petroleum ether to afford 199c as a whitesolid (7.0 g, 77%). MS-ESI: [M+H]⁺ 345.9.

Example 199d(4-Chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo-[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl)methylAcetate 199d

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 199c (7.0 g, 20.2 mmol, 1.0 eq.), triethylamine(4.08 g, 40.4 mmol, 2.0 eq.), and THF (50 mL). To the mixture was addedthe solution of acetyl chloride (2.36 g, 30.3 mmol, 1.5 eq.) in THF (20mL) dropwise. The reaction mixture was stirred at room temperature forone hour. After the reaction was completed, it was quenched with icewater and evaporated under reduced pressure. The residue was extractedwith dichloromethane. The combined organic layer was dried over Na₂SO₄and concentrated under reduced pressure. The resulting residue waswashed with 1:8 ethyl acetate/petroleum to afford 199d as a white solid(5.9 g, 76%). MS-ESI: [M+H]⁺ 388.3.

Example 199e{3-[(Acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicAcid 199e

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 199d (4.5 g, 1.0 eq.,11.6 mmol), Pin₂B₂ (7.38 g, 2.5 eq., 29.0 mmol), PdCl₂(dppf) (473 mg,0.05 eq., 0.58 mmol), x-phos (470 mg, 0.1 eq., 1.16 mmol), potassiumacetate (3.41 g, 3.0 eq., 34.8 mmol), and dioxane (100 mL). After threecycles of vacuum/argon flush, the mixture was heated at 65° C. for 4 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure to afford crude 199e as a brown-redliquid (4.0 g, purity: 65%). MS-ESI: [M+H]⁺ 398.3.

Example 199f(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[5-({imidazo[1,2-a]pyrimidin-7-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]pyridin-3-yl)methylAcetate 199f

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 199b (500 mg, 1.5 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatri-cyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (1200 mg, 3.0 mmol), Pd(dppf)Cl₂ (65 mg, 0.075 mmol), K₃PO₄(650 mg, 3.0 mmol), sodium acetate trihydrate (420 mg, 3.0 mmol), water(6 drops), and acetonitrile (20 mL). The system was evacuated andrefilled with N₂. The reaction mixture was heated at 100° C. for 2 h. Itwas then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 25:1dichloromethane/methanol to afford 199f (240 mg, 40%) as a yellow-brownsolid. MS-ESI: [M+H]⁺ 593.4.

Example 1993-[3-(hydroxymethyl)-4-[5-(imidazo[1,2-a]pyrimidin-7-ylamino)-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one199

A mixture of 199f (180 mg, 0.30 mmol) and lithium hydroxide (130 mg, 3.0mmol) in i-propanol/THF (5:3, 8 mL) and water (2 mL) was stirred at 30°C. for 1 h. The mixture was evaporated in vacuo and the residue wasdiluted with water (3 mL). It was then extracted with ethyl acetate(2×10 mL). The combined ethyl acetate extract was concentrated underreduced pressure and the residue was purified by prep-HPLC to afford 199(40 mg, 30%) as white solid. MS-ESI: [M+H]⁺ 551.3. ¹H NMR (500 MHz,CHCl₃) δ 9.09 (d, J=1.5 Hz, 1H), 8.51 (d, J=5.0 Hz, 1H), 8.23 (s, 1H),8.13 (d, J=7.0 Hz, 1H), 7.93 (d, J=2.0 Hz, 1H), 7.45 (s, 1H), 7.38 (d,J=5.0 Hz, 1H), 7.27 (s, 1H), 6.84 (s, 1H), 6.47 (d, J=7.5 Hz, 1H), 5.10(s, 1H), 4.67-4.50 (m, 2H), 4.32-4.18 (m, 3H), 3.93-3.88 (m, 1H), 3.74(s, 3H), 2.60-2.58 (m, 2H), 2.52 (s, 2H), 1.28 (s, 6H).

Example 200a tert-Butyl4-(6-Nitropyridin-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate 200a

A mixture of 5-bromo-2-nitropyridine (2.0 g, 9.7 mmol), tert-butyl4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate(3.0 g, 9.7 mmol), Pd(dppf)Cl₂ (792 mg, 0.97 mmol), K₃PO₄.3H₂O (5.2 g,19.4 mmol), and sodium acetate (1.59 g, 19.4 mmol) in acetonitrile (100mL) and water (5 mL) was evacuated and then refilled with N₂. Thereaction mixture was heated at 80° C. for 6 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 1:5 ethyl acetate/petroleum ether toafford 200a as a yellow solid (2.2 g, 74%).

Example 200b tert-Butyl 4-(6-Aminopyridin-3-yl)piperidine-1-carboxylate200b

A 500-mL round-bottomed flask was purged with nitrogen and charged with200a (2.5 g, 8.2 mmol), 10% palladium on carbon (50% wet, 300 mg), andmethanol (80 mL). The flask was evacuated, charged with hydrogen gas,and stirred at room temperature under hydrogen atmosphere for 12 h. Thehydrogen was then evacuated and nitrogen was charged to the flask. Thecatalyst was removed by filtration through a pad of CELITE® and thefiltrate was concentrated under reduced pressure to afford 200b (1.8 g,78%) as a white solid. MS-ESI: [M+H]⁺ 278.1

Example 200c tert-Butyl4-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridin-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate200c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged 200b (2.0 g, 7.2 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (1.9 g, 7.2 mmol), cesiumcarbonate (4.7 g, 14.4 mmol), and 1,4-dioxane (50 mL). After bubblingnitrogen through the resulting mixture for 30 min, Xantphos (418 mg,0.72 mmol) and tris(dibenzylideneacetone)dipalladium(0) (661 mg, 0.72mmol) were added. The reaction mixture was subject to three cycles ofvacuum/argon flush and heated at 100° C. for 6 h. After this time thereaction was cooled to room temperature and filtered. The filtrate waspartitioned between ethyl acetate (120 mL) and water (60 mL). Theaqueous layer was separated and extracted with ethyl acetate (3×80 mL).The combined organic layer was washed with brine (30 mL) and dried oversodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 1:4 ethylacetate/petroleum ether to afford 200c (2.0 g, 61%) as a yellow solid.MS-ESI: [M+H]⁺ 463.2

Example 200d5-Bromo-1-methyl-3-(5-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-2-ylamino)pyridin-2(1H)-one200d

A mixture of 200c (1.0 g, 2.3 mmol) and 4 M HCl/dioxane (10 mL) wasstirred at room temperature for 4 h. The mixture was concentrated underreduced pressure. The residue was basified with aqueous sodium hydroxideand extracted with dichloromethane. The combined organic layer waswashed with water and brine, dried over Na₂SO₄, and concentrated underreduced pressure to afford 200d (650 mg, 84%) as a yellow solid. MS-ESI:[M+H]⁺ 363.0

Example 200e5-Bromo-1-methyl-3-(5-(1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)pyridin-2-ylamino)pyridin-2(1H)-one200e

A mixture of 200d (500 mg, 1.4 mmol), oxetan-3-one (298 mg, 4.2 mmol),NaBH₃CN (261 mg, 4.2 mmol), and 1 mol/L zinc chloride in ethoxyethane (4mL, 4.2 mmol) in methanol (20 mL) was stirred at 50° C. for 5 hours.Water (20 mL) was added to the reaction and the resulting mixture wasextracted with dichloromethane (3×50 mL). The combined organic layer wasconcentrated under reduced pressure and the residue was purified bysilica-gel column chromatography eluting with 10:1 methylenechloride/methanol to afford 200e (450 mg, 78%) as a yellow solid.MS-ESI: [M+H]⁺ 419.1

Example 200f(4-(1-Methyl-5-(5-(1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 200f

A round-bottomed flask equipped with a reflux condenser was charged with200e (300 mg, 0.72 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (414 mg, 1.08 mmol), PdCl₂(dppf) (57 mg, 0.070 mmol), K₃PO₄3H₂O (560 mg, 2.16 mmol), sodium acetate (177 mg, 2.16 mmol),acetonitrile (10 mL), and water (0.5 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 80° C. for 3 h. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified with silica-gel column chromatography eluting with 1:20methanol/dichloromethane to afford 200f as a red solid (324 mg, 68%).MS-ESI: [M+H]⁺ 676.2

Example 2002-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[1-(oxetan-3-yl)-3,6-dihydro-2H-pyridin-4-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one200

A mixture of 200f (260 mg, 0.39 mmol) and lithium hydroxide (92.4 mg,3.85 mmol) in THF (9 mL), isopropanol (6 mL), and water (1 mL) wasstirred at room temperature for 0.5 h. The mixture was extractedconcentrated under reduced pressure and diluted with water (4 mL). Itwas then extracted with dichloromethane (2×10 mL) and the combined Cdichloromethane extract was concentrated under reduced pressure. Theresidue was purified with reverse-phase prep-HPLC to afford 200 (53.1mg, 20%) as yellow solid. MS-ESI: [M+H]⁺ 634.2. ¹H NMR (500 MHz,DMSO-d₆) δ 8.76 (d, J=1.5 Hz, 1H), 8.74 (s, 1H), 8.49 (d, J=5.5 Hz, 1H),8.24 (d, J=2.0 Hz, 1H), 7.73-7.71 (m, 1H), 7.54 (d, J=2.5 Hz, 1H), 7.36(d, J=5.0 Hz, 1H), 7.30 (d, J=8.5 Hz, 1H), 6.58 (s, 1H), 6.11 (s, 1H),4.97 (s, 1H), 4.57 (t, J=6.5 Hz, 2H), 4.38-4.49 (m, 4H), 4.08-4.26 (m,3H), 3.86 (d, J=12.0 Hz, 1H), 3.61 (s, 3H), 3.54-3.45 (m, 1H), 2.95 (s,2H), 2.68-2.54 (m, 2H), 2.48-2.46 (m, overlap, 6H),1.83-1.75 (m, 2H),1.73-1.65 (m, 2H).

Example 201a5-Bromo-3-(imidazo[1,2-a]pyridin-7-ylamino)-1-methylpyrazin-2(1H)-one201a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with imidazo[1,2-a]pyridin-7-amine (665 mg, 5.0 mmol), Cs₂CO₃(3.26 g, 10 mmol), 3,5-dibromo-1-methylpyrazin-2(1H)-one (1.86 g, 7.0mmol), Xantphos (289 mg, 0.50 mmol), Pd₂(dba)₃ (458 mg, 0.50 mmol), and1,4-dioxane (30 mL). After bubbling nitrogen through the mixture for 30minutes, it was heated at 100° C. under nitrogen atmosphere for 16 h.Analysis of the reaction mixture by LCMS showed little starting materialremained. The reaction mixture was cooled to room temperature andfiltered. The filtrate was diluted with dichloromethane (60 mL) andwater (50 mL). The aqueous layer was separated and extracted withdichloromethane (3×20 mL). The combined organic layers was dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The darkresidue was purified by silica-gel column chromatography eluting withdichloromethane/methanol (60/1 to 30/1) to afford 201a (700 mg, 44%) aslight yellow solid. MS-ESI: [M+H]⁺ 320

Example 201b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[6-({imidazo[1,2-a]pyridin-6-yl}amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl]pyridin-3-yl)methylAcetate 201b

A 25-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 201a (64 mg, 0.20 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (160 mg, 0.40 mmol), Pd(dppf)Cl₂ (10 mg, 0.012 mmol), K₃PO₄(100 mg, 0.39 mmol), NaOAc.3H₂O (60 mg, 0.44 mmol), water (6 drops), andacetonitrile (5 mL). The system was evacuated and refilled with N₂. Thereaction mixture was stirred at 100° C. for 2 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 20:1 dichloromethane/methanol toafford 201b (40 mg, 34%) as a yellow brown solid. MS-ESI: [M+H]⁺ 593.2.

Example 2013-[3-(hydroxymethyl)-4-[6-(imidazo[1,2-a]pyridin-6-ylamino)-4-methyl-5-oxo-pyrazin-2-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one201

A mixture of 201b (40 mg, 0.067 mmol) and lithium hydroxide (25 mg, 0.60mmol) in i-propanol/THF (3:2, 5 mL) and water (1 mL) was stirred at 30°C. for 1 h. The mixture was evaporated in vacuo and the residue wasextracted with ethyl acetate (2×10 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 201 (10 mg, 30%) as awhite solid. MS-ESI: [M+H]⁺ 551.3. ¹H NMR (500 MHz, CHCl₃) δ 9.58 (s,1H), 8.58 (d, J=5.0 Hz, 1H), 8.18 (s, 1H), 8.12 (s, 1H), 7.73 (d, J=5.0Hz, 1H), 7.63-7.61 (m, 2H), 7.55 (s, 1H), 7.13-7.11 (m, 1H), 6.87 (s,1H), 5.19-5.17 (m, 1H), 4.77-4.75 (m, 1H), 4.57-4.42 (m, 2H), 4.20-4.17(m, 2H), 3.92-3.90 (m, 1H), 3.70 (s, 3H), 2.60-2.53 (m, 4H), 1.29 (s,6H).

Example 202a4-(1-Methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(4-oxo-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-3(4H)-yl)nicotinaldehyde202a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-(4-oxo-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-3(4H)-yl)nicotinaldehyde192c (200 mg, 0.60 mmol),1-methyl-3-(5-methyl-4,5,6,7-tetrahydropyra-zolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one135a (230 mg, 0.60 mmol), sodium acetate (100 mg, 1.2 mmol), K₃PO₄ (320mg, 1.2 mmol), PdCl₂(dppf) (50 mg, 0.060 mmol), acetonitrile (25 mL),and water (1 mL). After bubbling nitrogen through the mixture for 30minutes, it was heated at 100° C. for 3 hours under N₂ protection. Thereaction was cooled to room temperature and evaporated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 25:1 methylene chloride/methanol to afford 202a (205 mg,62%) as a brown solid. MS-ESI: [M+H]⁺ 552.3.

Example 2023-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-4-one202

To a solution of 202a (180 mg, 0.33 mmol) in methanol (25 mL) was addedNaBH₄ (37 mg, 0.99 mmol). The mixture was stirred at 20° C. for 2 h andquenched with water. It was then evaporated under reduced pressure andthe residue was purified by reverse-phase prep-HPLC to afford 202 (120mg, 66%) as a white solid. MS-ESI: [M+H]⁺ 554.3. ¹H NMR (500 MHz,DMSO-d₆) δ 8.53 (d, J=5.0 Hz, 1H), 8.25 (s, 1H), 8.19 (s, 1H), 8.07 (d,J=2.0 Hz, 1H), 7.61 (s, 1H), 7.45 (d, J=5.0 Hz, 1H), 7.43 (d, J=2.5 Hz,1H), 5.89 (s, 1H), 4.65 (t, J=5.0 Hz, 1H), 4.34-4.32 (m, 2H), 4.26-4.20(m, 2H), 3.93-3.91 (m, 2H), 3.58 (s, 3H), 3.49 (s, 2H), 3.06-3.04 (m,2H), 2.79-2.77 (m, 2H), 2.35 (s, 3H), 2.04-1.96 (m, 2H), 1.93-1.86 (m,2H).

Example 203a 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-amine203a

A solution of 1-methyl-4-piperidone (11.3 g, 100 mmol) in 2-propanol (80mL) was heated to 50° C. To the solution were sequentially added asolution of cyanamide (4.2 g, 100 mmol) in 2-propanol (25 mL) and sulfurpowder (3.2 g, 100 mmol). After a catalytic amount of pyrrolidine (1.3mL) was added, the resultant mixture was stirred at 50° C. for 2 hours.The reaction mixture was allowed to cool to room temperature and stirredovernight. It was then cooled to or below 10° C. in an ice-water bathand stirred for 1 hour at the same temperature. The precipitatedcrystals were collected by filtration and washed with 2-propanol (20mL). The wet crystals were dried in vacuum to afford 203a (10 g, 59%).MS: [M+H]⁺ 170. ¹H NMR (500 MHz, DMSO-d₆) δ 6.70 (s, 2H), 3.31 (s, 2H),2.61 (t, J=5.5 Hz, 2H), 2.45 (m, 2H), 2.33 (s, 3H).

Example 203b5-Bromo-1-methyl-3-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-ylamino)pyridin-2(1H)-one203b

Following the procedures described for 191g and starting with 203a (4.0g, 23.5 mmol) and 3,5-dibromo-1-methylpyridin-2(1H)-one (3.0 g, 17.8mmol) afforded 203b as yellow solid (2.8 g, 44%). MS: [M+H]⁺ 357.

Example 203c10-[3-(Acetoxymethyl)-4-[1-methyl-5-({5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one203c

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 203b (178 mg, 0.50 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (200 mg, 0.50 mmol), K₃PO₄ (212 mg, 1.0 mmol), sodium acetate(82 mg, 1.0 mmol),1,1′-bis(diphenylphosphino)ferrocene-dichloropalladium(II) (21 mg, 0.025mmol), acetonitrile (10 mL), and water (0.5 mL). After bubbling nitrogenthrough the mixture for 30 minutes, it was heated at 100° C. under N₂protection for 1 h. Analysis of reaction mixture by LCMS showed completeconversion to the desired product. The reaction mixture was cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the residue was diluted with dichloromethane (20mL) and water (10 mL). The aqueous layer was separated and extractedwith dichloromethane (2×20 mL). The combined organic layer was driedover Na₂SO₄, filtered, and concentrated under reduced pressure. The darkresidue was purified by silica-gel column chromatography eluting withdichloromethane/methanol (80/1 to 30/1) to afford 203c (135 mg, 43%) asyellow solid. MS-ESI: [M+H]⁺ 584

Example 2033-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one203

To a solution of 203c (140 g, 0.22 mmol) in THF/i-propanol/water (5/2/2mL) was added LiOH (54 mg, 2.2 mmol) at room temperature. After thereaction was stirred for 1 h, LCMS indicated the reaction was completed.Then the mixture was concentrated under reduced pressure and dilutedwith water (3 mL). It was then extracted with dichloromethane (3×10 mL).The combined organic layer was washed with brine (30 mL), dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The residuewas purified by prep-HPLC to afford 203 (85 mg, 66%) as white solid.MS-ESI: [M+H]⁺ 586. ¹H NMR (500 MHz, CDCl₃) δ 8.50 (d, J=5.5 Hz, 1H),8.37 (d, J=2.0 Hz, 1H), 8.32 (s, 1H), 7.95 (d, J=2.0 Hz, 1H), 7.34 (d,J=5.0 Hz, 1H), 6.85 (s, 1H), 5.11-5.09 (m, 1H), 4.67-4.64 (m, 1H), 4.52(bs, 1H), 4.30-4.28 (m, 1H), 4.16 (d, J=4.5 Hz, 2H), 3.89-3.86 (m, 1H),3.72 (s, 3H), 3.60 (s, 2H), 2.84-2.81 (m, 4H), 2.58 (d, J=5.0 Hz, 2H),2.53 (s, 3H), 2.52 (s, 2H), 1.28 (s, 6H).

Example 204a4-(1-Methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-6,7,8,9-tetrahydropyridazino[4,5-b]indolizin-2(1H)-yl)nicotinaldehyde204a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-(1-oxo-6,7,8,9-tetrahydropyridazino[4,5-b]indolizin-2(1H)-yl)nicotinaldehyde193f (200 mg, 0.60 mmol),1-methyl-3-(5-methyl-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one135a (230 mg, 0.60 mmol), sodium acetate (100 mg, 1.2 mmol), K₃PO₄ (320mg, 1.2 mmol), PdCl₂(dppf) (50 mg, 0.060 mmol), acetonitrile (25 mL),and water (1 mL). After bubbling nitrogen through the resulting mixturefor 30 minutes, the mixture was heated at 100° C. for 3 hours. Thereaction mixture was cooled to room temperature and concentrated underreduced pressure. The residue was purified by silica-gel columnchromatography eluting with 20:1 methylene chloride/methanol to afford204a (185 mg, 55%) as a brown solid. MS-ESI: [M+H]⁺ 552.3.

Example 2042-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydropyridazino[4,5-b]indolizin-1-one204

To a solution of 204a (160 mg, 0.29 mmol) in methanol (20 mL) was addedNaBH₄ (33.0 mg, 0.87 mmol). The mixture was stirred at 20° C. for 2 hand quenched with water. It was then evaporated under reduced pressureand the residue was purified by reverse-phase prep-HPLC to afford 204(120 mg, 75%) as a white solid. MS-ESI: [M+H]⁺ 554.3. ¹H NMR (500 MHz,DMSO-d₆) δ 8.55 (d, J=5.0 Hz, 1H), 8.46 (s, 1H), 8.23 (s, 1H), 8.09 (d,J=2.5 Hz, 1H), 7.49 (d, J=5.0 Hz, 1H), 7.40 (d, J=2.0 Hz, 1H), 6.49 (s,1H), 5.89 (s, 1H), 4.73 (bs, 1H), 4.30 (s, 2H), 4.27-4.25 (m, 2H),3.93-3.91 (m, 2H), 3.58 (s, 3H), 3.49 (s, 2H), 2.95-2.93 (m, 2H),2.78-2.76 (m, 2H), 2.34 (s, 3H), 2.04-1.99 (m, 2H), 1.88-1.83 (m, 2H).

Example 205a 2-Nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 205a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole 125c (3.0 g, 9.64mmol) in THF (35 mL) and aqueous ammonia (135 mL, 25-28%). The mixturewas stirred at room temperature for 72 h under nitrogen. The reactionmixture was then concentrated under reduced pressure and the resultingresidue was partitioned between ethyl acetate (100 mL) and water (100mL). The aqueous layer was extracted with ethyl acetate (2×50 mL). Thecombined organic layer was washed with 10% potassium carbonate (2×100mL), brine (200 mL), and dried over sodium sulfate. The drying agent wasremoved by filtration, and the filtrate was concentrated under reducedpressure to afford 205a as a yellow solid (1.23 g, 76%). MS: [M+H]⁺ 169

Example 205b tert-Butyl2-Nitro-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate 205b

To a solution of 205a (504 mg, 3.0 mmol) in THF (20 mL) was added(Boc)₂O (785 mg, 3.60 mmol) and DMAP (74 mg, 0.60 mmol). The reactionmixture was stirred at room temperature overnight. Then it was filteredand the filtrate was concentrated under reduced pressure. The resultingresidue was purified by silica-gel column chromatography eluting with100:1 dichloromethane/methanol to afford 205b as white solid (750 mg,80%). MS-ESI: [M+H]⁺ 269.3

Example 205c tert-Butyl2-Amino-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate 205c

A 100-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 205b (0.75 g, 2.80 mmol), 10% palladium on carbon (50% wet,280 mg), and methanol (30 mL). The mixture was evacuated, charged withhydrogen gas, and stirred at room temperature for 2 h. The hydrogen wasthen evacuated and nitrogen was charged into the flask. The catalyst wasremoved by filtration through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure to afford 205c (524 mg, 79%).MS-ESI: [M+H]⁺ 239.1

Example 205d tert-Butyl2-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate205d

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 205c (524 mg, 2.2 mmol),Pd₂(dba)₃ (201 mg, 0.22 mmol), XantPhos (254 mg, 0.44 mmol), cesiumcarbonate (1434 mg, 4.4 mmol), and 1,4-dioxane (20 mL). After threecycles of vacuum/argon flush, the mixture was heated at 100° C. for 4 h.After this time the reaction was cooled to room temperature. It was thenfiltered and the filtrate was evaporated in vacuo. The residue waspurified by silica-gel column chromatography eluting with 50:1dichloromethane/methanol to afford 205d (600 mg, 70%) as a yellow solid.MS-ESI: [M+H]⁺ 424.2

Example 205e tert-Butyl2-(5-(3-(Acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-yl)-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate205e

A sealed tube equipped with a magnetic stirrer was charged with 205d(213 mg, 0.50 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (192 mg, 0.50 mmol), Pd(dppf)Cl₂ (41 mg, 0.050 mmol), sodiumacetate (82 mg, 1.0 mmol), K₃PO₄ (212 mg, 1.0 mmol), acetonitrile (10mL), and water (0.5 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 2 h. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 25:1 dichloromethane/methanol toafford 205e (280 mg, 82%) as a yellow solid. MS-ESI: [M+H]⁺ 683.3

Example 205f(4-(1-Methyl-6-oxo-5-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 205f

A mixture of 205e (280 mg, 0.41 mmol), 4.0 M HCl/dioxane (4 mL), anddichloromethane (4 mL) was stirred at room temperature for 2 h. It wasthen concentrated under reduced pressure to afford 205f as a yellowsolid (165 mg, 66%), which was used for the next step without furtherpurification. MS-ESI: [M+H]⁺ 583.3.

Example 2052-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one205

A mixture of 205f (165 mg, 0.28 mmol) and lithium hydroxide (67 mg, 2.80mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at roomtemperature for 1 h. The mixture was evaporated in vacuo and dilutedwith water (4 mL). It was then extracted with ethyl acetate (10 mL×2).The combined ethyl acetate extract was concentrated under reducedpressure and the residue was purified by reverse-phase prep-HPLC toafford 205 (70 mg, 46%) as a white solid. MS-ESI: [M+H]⁺ 541.2. ¹H NMR(500 MHz, CDCl₃) δ 8.48 (d, J=5.0 Hz, 1H), 7.96 (d, J=2.0 Hz, 1H), 7.72(d, J=2.0 Hz, 1H), 7.43 (s, 1H), 7.35 (d, J=5.5 Hz, 1H), 6.90 (s, 1H),5.70 (s, 1H), 5.01 (s, 1H), 4.64-4.61 (m, 1H), 4.50 (s, 1H), 4.34 (s,1H), 4.16-3.99 (m, 6H), 3.89-3.87 (m, 1H), 3.71 (s, 3H), 3.30 (t, J=5.5Hz, 2H), 2.63-2.57 (m, 4H), 1.92-1.89 (m, 2H), 1.80-1.78 (m, 3H).

Example 206a tert-Butyl 3-Iodoazetidine-1-carboxylate 206a

A solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (3.5 g, 0.020mol) in toluene (200 mL) was treated with imidazole (4.08 g, 0.060 mol),triphenylphosphine (0.60 g, 0.040 mol), and iodine (7.62 g, 0.030 mol).The mixture was heated at 100° C. for 1 h. It was then cooled to roomtemperature and poured into saturated NaHCO₃ solution (30 mL). Excesstriphenylphosphine was destroyed by addition of iodine until iodinecoloration persisted in organic layer. The mixture was washed with 5%Na₂SO₃ solution, dried over Na₂SO₄, and evaporated in vacuo. The residuewas purified by silica-gel column chromatography to afford 206a (5.31 g,93%). MS-ESI: [M+H]⁺ 284.

Example 206b tert-Butyl3-(6-Nitropyridin-3-yloxy)azetidine-1-carboxylate 206b

A mixture of 206a (2.24 g, 7.9 mmol), 6-nitropyridin-3-ol (1.0 g, 7.2mmol), and Cs₂CO₃ (2.6 g, 7.9 mmol) in DMF (8 mL) was heated at 125° C.in a sealed tube overnight. The solid was filtered and washed with ethylacetate (2×20 mL). The combined filtrate was evaporated in vacuo and theresidue was purified on reverse-phase Combiflash to afford 206b (1.25 g,59%). MS-ESI: [M+H]⁺ 296.

Example 206c tert-Butyl3-(6-Aminopyridin-3-yloxy)azetidine-1-carboxylate 206c

A 100-mL Parr hydrogenation bottle was purged with nitrogen and chargedwith 206b (1.07 g, 3.6 mmol), 10% palladium on carbon (50% wet, 0.30 g),and methanol (60 mL). The bottle was evacuated, charged with hydrogengas to a pressure of 25 psi, and shaken for 2 h on a Parr hydrogenationapparatus. The hydrogen was then evacuated and nitrogen charged to thebottle. The catalyst was removed by filtration through a pad of CELITE®and the filtrate was concentrated under reduced pressure to afford 206c(0.95 g, 99%). MS-ESI: [M+H]⁺ 266.

Example 206d tert-Butyl3-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridin-3-yloxy)azetidine-1-carboxylate206d

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with 206c (950 mg, 3.6 mmol), XantPhos (125 mg, 0.29 mmol), Pd₂dba₃ (260 mg, 0.29 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (1.03 g,3.9 mmol), Cs₂CO₃ (1.8 g, 7.2 mmol), and 1,4-dioxane (20 mL). The systemwas evacuated and refilled with N₂. It was then heated at reflux for 2h. After the completion of the reaction, the mixture was filtered offand washed with methanol (100 mL). The combined filtrate was evaporatedin vacuo and the residue was purified on reverse-phase Combiflash toafford 206d (1.46 g, 90%). MS-ESI: [M+H]⁺ 451.

Example 206e3-(5-(Azetidin-3-yloxy)pyridin-2-ylamino)-5-bromo-1-methylpyridin-2(1H)-oneHydrochloride 206e

A mixture of 206d (1.46 g, 3.2 mmol) and HCl/1,4-dioxane (3.2 mL, 4M,12.8 mmol) in methanol (20 mL) was heated at 80° C. for 1 h. The mixturewas then concentrated under reduced pressure to afford 206e (1.24 g,99%). MS-ESI: [M+H]⁺ 351.

Example 206f5-Bromo-1-methyl-3-(5-(1-methylazetidin-3-yloxy)pyridin-2-ylamino)pyridine-2(1H)-one206f

A mixture of 206e (1.24 g, 3.2 mmol), 37% aqueous formaldehyde solution(15 mL), acetic acid (1 mL), and NaBH(OAc)₃ (1.36 g, 6.4 mmol) inmethanol (10 mL) was stirred at room temperature for 4 h. The solventwas evaporated in vacuo and the residue was extracted with ethyl acetate(3×20 mL). The combined extract was dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified onreverse-phase Combiflash to afford 206f (940 mg, 80%). MS-ESI: [M+H]⁺365.

Example 206g(4-(1-Methyl-5-(5-(1-methylazetidin-3-yloxy)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 206g

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with 206f (108 mg, 0.30 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (115 mg, 0.30 mmol), Pd(dppf)Cl₂ (15 mg, 0.015 mmol), K₃PO₄(135 mg, 0.60 mmol), sodium acetate trihydrate (90 mg, 0.60 mmol) inacetonitrile (10 mL) and water (0.5 mL). The system was evacuated andrefilled with N₂. The reaction mixture was heated at 100° C. for 2 h. Itwas then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 25:1dichloromethane/methanol to afford 206g (90 mg, 52%) as a yellow brownsolid. MS-ESI: [M+H]⁺ 624.2.

Example 206 2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methylazetidin-3-yl)oxy-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one206

A mixture of 206g (93.6 mg, 0.15 mmol) and lithium hydroxide (65 mg, 1.5mmol) in THF/i-propanol (5:3, 8 mL) and water (2 mL) was stirred at 30°C. for 1 h. The mixture was evaporated in vacuo and diluted with water(3 mL). It was then extracted with ethyl acetate (2×10 mL). The combinedethyl acetate extract was concentrated under reduced pressure and theresidue was purified by reverse-phase prep-HPLC to afford 206 (35 mg,42%) as white solid. MS-ESI: [M+H]⁺ 582.3. ¹H NMR (500 MHz, CHCl₃) δ8.62 (d, J=1.5 Hz, 1H), 8.51 (d, J=5.0 Hz, 1H), 7.86 (d, J=2.0 Hz, 1H),7.84 (s, 1H), 7.76 (d, J=3.0 Hz, 1H), 7.37 (d, J=5.0 Hz, 1H), 7.12-7.10(m, 1H), 6.90 (s, 1H), 6.81-6.80 (m, 1H), 5.07-5.04 (m, 1H), 4.77 (t,J=5.5 Hz, 1H), 4.64-4.62 (m, 1H), 4.52-4.50 (m, 1H), 4.33-4.30 (m, 1H),4.16-4.10 (m, 2H), 3.97-3.88 (m, 3H), 3.72 (s, 3H), 3.25-3.24 (m, 2H),2.63-2.57 (m, 4H), 2.51 (s, 3H), 1.93-1.91 (m, 2H), 1.80-1.79 (m, 2H).

Example 207a(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-[(1-methylazetidin-3-yl)oxy]pyridin-2-yl}amino)-6-oxopyridin-3-yl]pyridin-3-yl)methylAcetate 207a

A 50-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with5-bromo-1-methyl-3-(5-(1-methylazetidin-3-yloxy)pyridin-2-ylamino)-pyridin-2(1H)-one206f (108 mg, 0.40 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diaza-tricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (240 mg, 0.60 mmol), Pd(dppf)Cl₂ (20 mg, 0.02 mmol), K₃PO₄(180 mg, 0.80 mmol), sodium acetate trihydrate (120 mg, 0.80 mmol),water (0.5 mL), and acetonitrile (10 mL). The system was evacuated andrefilled with N₂. The reaction mixture was heated at 100° C. for 2 h. Itwas then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 10:1dichloromethane/methanol to afford 207a (100 mg, 45%) as a yellow brownsolid. LCMS-ESI: [M+H]⁺ 638.4.

Example 2073-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methylazetidin-3-yl)oxy-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one207

A mixture of 207a (90 mg, 0.15 mmol) and lithium hydroxide (65 mg, 1.5mmol) in THF/i-propanol (5:3, 8 mL) and water (2 mL) was stirred at 30°C. for 1 h. The mixture was evaporated under reduced pressure anddiluted with water (4 mL). It was then extracted with ethyl acetate(2×20 mL). The combined ethyl acetate extract was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 207 (30 mg, 38%) as white solid. LCMS: [M+H]⁺ 596.3. ¹H NMR(500 MHz, CDCl₃) δ 8.61 (d, J=2.0 Hz, 1H), 8.51 (d, J=5.0 Hz, 1H),7.86-7.83 (m, 2H), 7.77 (d, J=3.0 Hz, 1H), 7.37 (d, J=5.0 Hz, 1H),7.12-7.10 (m, 1H), 6.85 (s, 1H), 6.81 (d, J=3.5 Hz, 1H), 5.07-5.04 (m,1H), 4.74-4.64 (m, 2H), 4.52-4.51 (m, 1H), 4.34-4.32 (m, 1H), 4.17-4.16(m, 2H), 3.88-3.87 (m, 3H), 3.72 (s, 3H), 3.17-3.16 (m, 2H), 2.58 (d,J=5.5 Hz, 2H), 2.52 (s, 2H), 2.45 (s, 3H), 1.28 (s, 6H).

Example 208a 5-Ethyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine208a

A 150-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with methanol (60 mL),2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 205a (1.5 g, 8.9mmol), ZnCl₂ (2.43 g, 17.8 mmol), acetaldehyde (784 mg, 17.8 mmol), andNaBH₃CN (1.12 g, 17.8 mmol). The mixture was stirred at room temperaturefor 2 h and concentrated under reduced pressure. The residue waspurified with silica-gel column chromatography eluting with 40:1petroleum ether/ethyl acetate to afford 208a (1.4 g, 81%) as a yellowoil. MS-ESI: [M+H]⁺ 197

Example 208b 5-Ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine208b

A 50-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 208a (1.4 g, 7.1 mmol), 10% palladium on carbon (50% wet,208 mg), methanol (30 mL), and hydrogen gas. The mixture was stirred atroom temperature under hydrogen atmosphere for 2 h. The catalyst wasremoved by filtration through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure to afford 208b (1.0 g, 84%) asyellow oil. MS-ESI: [M+H]⁺ 167

Example 208c5-Bromo-3-(5-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methylpyridin-2(1H)-one208c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 208b (1.0 g, 6.0 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (1.6 g, 6.0 mmol), Pd₂(dba)₃ (274mg, 0.30 mmol), XantPhos (347 mg, 0.60 mmol), cesium carbonate (3.9 g,12.0 mmol), and 1,4-dioxane (50 mL). After three cycles of vacuum/argonflush, the mixture was stirred at 100° C. for 3 h. It was then filteredand the filtrate was evaporated in vacuo. The residue was purified bysilica-gel column chromatography eluting with 40:1dichloromethane/methanol to afford 208c (630 mg, 29%) as a yellow solid.MS-ESI: [M+H]⁺ 352

Example 208d3-(5-Ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one208d

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (20 mL),208c (350 mg. 0.99 mmol), bis (pinacolato) diboron (1.31 g, 4.99 mmol),Pd₂(dba)₃ (45 mg, 0.050 mmol), X-phos (58 mg, 0.10 mmol), and potassiumacetate (291 mg, 2.97 mmol). After bubbling nitrogen through the mixturefor 30 minutes, it was heated at 90° C. for 3 h. Then it was filteredand the filtrate was evaporated in vacuo. The residue was washed withpetroleum ether to afford 208d (120 mg, 30%) as a brown solid. MS-ESI:[M+H]⁺ 400.2

Example 208e4-(5-(5-Ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydro-pyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde208e

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 208d (120 mg, 0.30mmol),4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido-[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde139a (99 mg, 0.30 mmol), PdCl₂(dppf) (13 mg, 0.015 mmol), K₃PO₄ (127 mg,0.60 mmol), sodium acetate (49 mg, 0.60 mmol), acetonitrile (10 mL), andwater (0.5 mL). The system was evacuated and refilled with N₂. Thereaction mixture was heated at 100° C. for 2 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 30:1 dichloromethane/methanol toafford the 208e (95 mg, 56%) as a yellow solid. MS-ESI: [M+H]⁺ 567.2.

Example 2082-[4-[5-[(5-ethyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one208

To a mixture of 208e (95 mg, 0.16 mmol) at 0° C. in methanol (10 mL) wasadded sodium borohydride (19 mg, 0.50 mmol). The reaction mixture wasstirred for 30 minutes and quenched with water (2.0 mL). It was thenconcentrated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 208 (8 mg, 9%) as white solid. MS-ESI:[M+H]⁺ 569.3. ¹H NMR (500 MHz, CDCl₃) δ 8.46 (d, J=5.0 Hz, 1H), 7.92 (d,J=2.0 Hz, 1H, 7.70 (d, J=2.0 Hz, 1H), 7.40 (s, 1H), 7.30 (d, J=5.0 Hz,1H), 6.30 (s, 1H), 5.71 (s, 1H), 4.93-4.96 (m, 1H), 4.63-4.61 (m, 1H),4.42-4.26 (m, 2H), 4.09 (s, 2H), 3.94-3.81 (m, 3H), 3.69-3.68 (m,overlap, 5H), 3.06-2.90 (m, 4H), 2.81 (d, J=3.0 Hz, 2H), 2.66 (d, J=3.5Hz, 2H), 2.04-2.00 (m, 2H), 1.88-1.85 (m, 2H), 1.20 (t, J=7.5 Hz, 3H).

Example 209a1-(2-Nitro-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethanone 209a

To a solution of 2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 205a(672 mg, 4.0 mmol) in dichloromethane (20 mL) was added acetyl chloride(936 mg, 12.0 mmol) and K₂CO₃ (1104 mg, 8.0 mmol). The mixture wasstirred overnight. It was then filtered and the filtrate wasconcentrated under reduced pressure. The resulting residue was purifiedby silica-gel column chromatography eluting with 100:1dichloromethane/methanol to afford 209a as white solid (500 mg, 60%).MS: [M+H]⁺ 211.2

Example 209b1-(2-Amino-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethanone 209b

A 50-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 209a (492 mg, 2.34 mmol), 10% palladium on carbon (50% wet,234 mg), and methanol (20 mL). The mixture was evacuated, charged withhydrogen gas, and stirred at room temperature for 2 h. The hydrogen wasthen evacuated and nitrogen was charged into the flask. The catalyst wasremoved by filtration through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure to afford 209b (380 mg, 80%). MS:[M+H]⁺ 181.1

Example 209c3-(5-Acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-bromo-1-methylpyridin-2(1H)-one209c

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with3,5-dibromo-1-methylpyridin-2(1H)-one (481 mg, 1.8 mmol), 209b (270 mg,1.5 mmol), 1,4-dioxane (20 mL), Pd₂(dba)₃ (137 mg, 0.15 mmol), XantPhos(173 mg, 0.30 mmol), and cesium carbonate (978 mg, 3.0 mmol). Afterthree cycles of vacuum/argon flush, the mixture was heated at 100° C.for 6 h. After this time the reaction was cooled to room temperature. Itwas then filtered and the filtrate was evaporated in vacuo. The residuewas purified by silica-gel column chromatography eluting with 50:1dichloromethane/methanol to afford 209c (540 mg, 89%) as a yellow solid.MS: [M+H]⁺ 368.0

Example 209d3-(5-Acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one209d

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 209c (365 mg, 1.0 mmol),Pin₂B₂ (1.26 g, 5.0 mmol), Pd₂(dba)₃ (91 mg, 0.10 mmol), X-phos (92 mg,0.20 mmol), AcOK (294 mg, 3.0 mmol), and dioxane (10 mL). After threecycles of vacuum/argon flush, the mixture was heated at 60° C. for 16 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the residue was purified bysilica-gel column chromatography eluting with 50:1 methylenechloride/methanol to afford 209d as a brown solid (330 mg, 80%). MS:[M+H]⁺ 414.2

Example 209e(4-(5-(5-Acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 209e

A sealed tube equipped with a magnetic stirrer was charged with 209d(185 mg, 0.50 mmol),(4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino-[1,2-a]indol-2(1H)-yl)pyridine-3-yl)methylacetate 113h (192 mg, 0.50 mmol), Pd(dppf)Cl₂ (41 mg, 0.050 mmol),sodium acetate (82 mg, 1.0 mmol), K₃PO₄ (212 mg, 1.0 mmol), water (0.5mL), and acetonitrile (10 mL). After three cycles of vacuum/argon flush,the mixture was heated at 100° C. for 2 h. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 25:1 dichloromethane/methanol toafford 209e (150 mg, 48%) as a yellow solid. MS-ESI: [M+H]⁺ 625.4

Example 2092-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one209

A mixture of 209e (150 mg, 0.24 mmol) and lithium hydroxide (58 mg, 2.4mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at roomtemperature for 1 h. The mixture was evaporated in vacuo and dilutedwith water (4 mL). It was then extracted with ethyl acetate (2×10 mL).The combined ethyl acetate extract was concentrated under reducedpressure and the residue was purified by reverse-phase prep-HPLC toafford 209 (75 mg, 53%) as a white solid. MS-ESI: [M+H]⁺ 583.3. ¹H NMR(500 MHz, T=80° C., DMSO-d₆) δ 8.44 (d, J=8.5 Hz, 1H), 7.93-7.90 (m,2H), 7.34 (d, J=4.5 Hz, 1H), 7.29 (d, J=8.5 Hz, 1H), 6.56 (s, 1H), 5.98(s, 1H), 4.72-4.63 (m, 3H), 4.45-4.43 (m, 2H), 4.16-4.10 (m, 3H),3.99-3.86 (m, overlap, 5H), 3.58 (s, 3H), 2.62-2.57 (m, 2H), 2.49-2.47(m, 2H), 2.08 (s, 3H), 1.83-1.77 (m, 2H), 1.72-1.68 (m, 2H).

Example 210a4-Chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo-[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carboxylicAcid 210a

To a mixture of4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (500 mg, 1.46 mmol), tert-butyl alcohol (20 mL), anddichloromethane (5 mL) was added 2-methyl-2-butene (3066 mg, 43.8 mmol).An aqueous solution (8 mL) of NaClO₂ (263 mg, 2.92 mmol) and NaH₂PO₄.2water (683 mg, 4.38 mmol) was added dropwise at −10° C. and the reactionmixture was stirred at −10° C. for overnight. It was concentrated underreduced pressure and the residue was extracted with ethyl acetate (4×20mL). The combined organic extract was dried over MgSO₄ and concentrated.The residue was purified with reverse-phase prep-HPLC to afford 210a(315 mg, 60%) as a pale yellow solid. MS-ESI: [M+H]⁺ 360.1

Example 210b2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-[(25)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridine-3-carboxylicAcid 210b

A 25-mL round-bottomed flask equipped with a reflux condenser wascharged with 210a (400 mg, 1.1 mmol),(5)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one191j (536 mg, 1.1 mmol), PdCl₂(dppf) (81 mg, 0.11 mmol), K₃PO₄ (466 mg,2.2 mmol), sodium acetate (216 mg, 2.2 mmol), acetonitrile (10 mL), andwater (0.2 mL). After three cycles of vacuum/argon flush, the mixturewas heated at 100° C. for 3 h. It was then filtered and the filtrate wasevaporated in vacuo. The residue was purified by silica-gel columnchromatography eluting with 1:3 petroleum/ethyl acetate to afford 210bas a yellow solid (306 mg, 41%). MS-ESI: [M+H]⁺ 679.3

Example 2102-(7,7-dimethyl-4-oxo-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]pyridine-3-carboxamide210

A 25-mL round-bottomed flask was charged with 210b (300 mg, 0.44 mmol),triethylamine (1 mL), DMAP (5 mg, 0.040 mmol), HATU (250 mg, 0.66 mmol),and DMF (10 mL). The mixture was stirred at room temperature for 0.5 h.Then 37% aqueous ammonia (15 mL) was added slowly and the reaction wasstirred at room temperature for another 2.5 h. The mixture was treatedwith 20 mL water and extracted with dichloromethane (3×20 mL). Thecombined organic extract was concentrated under reduced pressure andresidue was purified with reserve-phase prep-HPLC to afford 210 (98 mg,33%) as yellow solid. MS-ESI: [M+H]⁺ 678.3. ¹H NMR (500 MHz, DMSO) δ8.71 (d, J=2.0 Hz, 1H), 8.55 (d, J=2.5 Hz, 1H), 8.41 (s, 1H), 7.84 (d,J=3.0 Hz, 1H), 7.61 (s, 1H), 7.49 (s, 1H), 7.45-7.42 (m, 2H), 7.38-7.36(m, 1H), 7.24-7.22 (m, 1H), 6.49 (s, 1H), 4.57-4.54 (m, 2H), 4.48-4.47(m, 1H), 4.43-4.40 (m, 1H), 4.12-4.11 (m, 2H), 4.04-4.00 (m, 2H),3.67-3.66 (m, 1H), 3.57 (s, 3H), 3.42-3.37 (m, 1H), 3.10-3.08 (m, 1H),2.97-2.92 (m, 1H), 2.55-2.53 (m, 3H), 2.41 (s, 2H), 2.36-2.29 (m, 2H),2.21-2.18 (m, 1H), 1.21 (s, 6H), 0.93 (d, J=6.0 Hz, 3H)

Example 2112-(7,7-dimethyl-4-oxo-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-N-methyl-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]pyridine-3-carboxamide211

A round-bottomed flask was charged with2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridine-3-carboxylicacid 210b (300 mg, 0.44 mmol), triethylamine (1 mL), DMAP (5 mg, 0.040mmol), HATU (250 mg, 0.66 mmol), and DMF (10 mL). The mixture wasstirred at room temperature for 0.5 h. Then CH₃NH₂ (27 mg, 0.88 mmol)was added slowly and the reaction was stirred at room temperature foranother 2.5 h. The mixture was treated with water (20 mL) and extractedwith dichloromethane (20 mL×3). The combined organic extract wasconcentrated under reduced pressure and the residue was purified withreserve-phase prep-HPLC to afford 211 (106 mg, 35%) as yellow solid.MS-ESI: [M+H]⁺ 692.5. ¹H NMR (500 MHz, DMSO-d₆) δ 8.71 (d, J=2.5 Hz,1H), 8.55 (d, J=5.0 Hz, 1H), 8.42 (s, 1H), 8.11-8.08 (m, 1H), 7.86 (d,J=2.5 Hz, 1H), 7.44-7.41 (m, 2H), 7.38-7.35 (m, 1H), 7.24-7.22 (m, 1H),6.48 (s, 1H), 4.58-4.56 (m, 2H), 4.48-4.46 (m, 1H), 4.43-4.41 (m, 1H),4.08-4.07 (m, 2H), 3.97-3.94 (m, 2H), 3.66-3.65 (m, 1H), 3.58 (s, 3H),3.41-3.39 (m, 1H), 3.10-3.08 (m, 1H), 2.97-2.93 (m, 1H), 2.56 (s, 2H),2.53-2.48 (m, overlap, 4H), 2.37-2.36 (m, 2H), 2.35-2.31 (m, 2H),2.29-2.19 (m, 1H), 1.21 (s, 6H), 0.93 (d, J=6.0 Hz, 3H).

Example 212a{4-[5-({5-Acetyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-1-methyl-6-oxopyridin-3-yl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]-dodeca-2(6),7-dien-10-yl}pyridin-3-yl}methylAcetate 212a

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with3-(5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-bromo-1-methylpyridin-2(1H)-one209c (185 mg, 0.50 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (200 mg, 0.50 mmol), Pd(dppf)Cl₂ (41 mg, 0.050 mmol), sodiumacetate (82 mg, 1.0 mmol), K₃PO₄ (212 mg, 1.0 mmol), water (0.5 mL), andacetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 2 h. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 25:1 dichloromethane/methanol toafford 212a (180 mg, 56%) as a yellow solid. MS-ESI: [M+H]⁺ 639.3

Example 2123-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one212

A mixture of 212a (180 mg, 0.28 mmol) and lithium hydroxide (67 mg, 2.8mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at 30°C. for 1 h. The mixture was evaporated in vacuo and diluted with water(4 mL). It was then extracted with ethyl acetate (2×10 mL). The combinedethyl acetate extract was concentrated under reduced pressure and theresidue was purified by reverse-phase prep-HPLC to afford 212 (70 mg,42%) as a white solid. MS-ESI: [M+H]⁺ 597.3. ¹H NMR (500 MHz, T=80° C.,DMSO-d₆) δ 8.47 (d, J=8.0 Hz, 1H), 7.95 (d, J=4.0 Hz, 1H), 7.92 (s, 1H),7.37 (d, J=3.5 Hz, 1H), 7.31 (d, J=8.5 Hz, 1H), 6.57 (s, 1H), 6.00 (s,1H), 4.66 (bs, 2H), 4.47 (s, 2H), 4.20-4.18 (m, 3H), 4.00-3.99 (m, 3H),3.92-3.88 (m, 3H), 3.61 (s, 3H), 2.59 (s, 2H), 2.46 (s, 2H), 2.11 (s,3H), 1.25 (s, 6H).

Example 213a5-Bromo-1-methyl-3-(2-methylpyrimidin-4-ylamino)pyridin-2(1H)-one 213a

Following the procedures described in Example 196, reaction of2-methylpyrimidin-4-amine (2.0 g, 18.3 mmol) and3,5-dibromo-1-methylpyridin-2(1H)-one (9.6 g, 36 mmol) afforded 213a asa yellow solid (2.3 g, 43.4%). MS: [M+H]⁺ 295. ¹H NMR (500 MHz, DMSO-d₆)δ 9.20 (s, 1H), 8.78 (s, 1H), 8.26 (d, J=4.5 Hz, 1H), 7.68 (s, 1H), 7.18(d, J=4.5 Hz, 1H), 3.59 (s, 3H), 2.52 (s, 3H).

Example 213b1-Methyl-3-(2-methylpyrimidin-4-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one213b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with bis(pinacolato) diboron(689 mg, 2.61 mmol), 1,4-dioxane (30 mL), 213a (307 mg, 1.04 mmol),Pd₂(dba)₃ (47 mg, 0.050 mmol), X-phos (48 mg, 0.10 mmol), and potassiumacetate (305 mg, 3.12 mmol). The mixture was heated at 65° C. for 6 h.It was then filtered and the filtrate was evaporated in vacuo to afford213b (300 mg, 84%) as a brown solid. MS: [M+H]⁺ 342.2

Example 213c2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-5-(2-methylpyrimidin-4-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)nicotinaldehyde213c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (150 mg, 0.43 mmol), 213b (147 mg 0.43 mmol), Pd(dppf)Cl₂ (35 mg,0.043 mmol), sodium acetate (71 mg, 0.86 mmol), K₃PO₄ (182 mg, 0.86mmol), water (0.5 mL), and acetonitrile (15 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 2.5 h. Aftercooling to room temperature the reaction was filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 40:1dichloromethane/methanol to afford 213c as a yellow solid (130 mg, 57%).MS-ESI: [M+H]⁺ 528.2.

Example 21310-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one213

To a solution of 213c (120 mg, 0.23 mmol) at 0° C. in methanol (10 mL)was added sodium borohydride (26 mg, 0.69 mmol). The reaction mixturewas stirred for 20 minutes and quenched with water (10 mL). It was thenextracted with dichloromethane (3×20 mL) and the combined organic layerwas concentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford 213 (62 mg, 44%) as a white solid.MS-ESI: [M+H]⁺ 530.3. ¹H NMR (500 MHz, DMSO-d₆) δ 9.11 (s, 1H), 8.93 (d,J=2.5 Hz, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.21 (d, J=6.0 Hz, 1H), 7.69 (d,J=2.5 Hz, 1H), 7.37 (d, J=5.0 Hz, 1H), 7.13 (d, J=5.5 Hz, 1H), 4.96 (t,J=5.5 Hz, 1H), 4.57-4.45 (m, 2H), 4.23-4.18 (m, 2H), 4.08-4.05 (m, 1H),3.90-3.87 (m, 1H), 3.62 (s, 3H), 2.64-2.56 (m, 2H), 2.45 (s, 3H),2.43-2.42 (m, 2H), 1.78-1.76 (m, 2H), 1.72-1.66 (m, 2H).

Example 214a 3-Bromo-5-iodopyridin-2-ol 214a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with acetonitrile (50 mL), trifluoroacetic acid (10mL), 3-bromopyridin-2-ol (4.0 g, 11.56 mmol) and N-iodosuccinimide (5.2g, 11.56 mmol). The mixture was stirred at room temperature for 15 h.The mixture was diluted with water (100 mL) and resulting white solidwas collected by filtration to afford 214a (6.6 g, 96%) as a whitesolid. MS-ESI: [M+H]⁺ 300

Example 214b 3-Bromo-5-iodo-1-methylpyridin-2(1H)-one 214b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with DMF (50 mL), 214a (6.0 g, 20.0 mmol),iodomethane (4.26 g, 30.0 mmol), and K₂CO₃ (5.52 g, 40.0 mmol). Themixture was stirred at room temperature for 2 h and diluted with water(200 mL). The resulting white solid was collected by filtration toafford 214b (5.97 g, 95%) as a white solid. MS-ESI: [M+H]⁺ 314

Example 214c[4-(5-Bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylAcetate 214c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 214b (1.57 g, 5.0 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]-dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (1.98 g, 5.0 mmol), PdCl₂(dppf) (205 mg, 0.25 mmol), K₃PO₄(2.12 g, 10.0 mmol), Sodium acetate (820 mg, 10.0 mmol), acetonitrile(45 mL), and water (1 mL). The system was evacuated and refilled withN₂. The reaction mixture was stirred at 30° C. for 3 h. It was thenfiltered and the filtrate was concentrated under reduced pressure. Theresulting residue was purified by silica-gel column chromatographyeluting with 30:1 dichloromethane/methanol to afford 214c (580 mg, 22%)as a white solid. MS-ESI: [M+H]⁺ 539.2. ¹H NMR (500 MHz, CDCl₃) δ 8.49(d, J=5.0 Hz, 1H), 7.84 (d, J=2.5 Hz, 1H), 7.45 (d, J=2.0 Hz, 1H), 7.09(d, J=5.0 Hz, 1H), 6.79 (s, 1H), 5.15 (s, 2H), 4.55-4.51 (m, 1H),4.27-4.25 (m, 1H), 4.15-4.13 (m, 1H), 4.06-4.04 (m, 1H), 3.68 (s, 3H),2.58-2.56 (m, 2H), 2.51 (s, 2H), 1.86 (s, 3H), 1.28 (s, 6H).

Example 214d(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-6-oxo-5-({4H,6H,7H-pyrano[4,3-d][1,3]thiazol-2-yl}amino)-1,6-dihydro-pyridin-3-yl]pyridin-3-yl)methylAcetate 214d

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (10 mL),214c (150 mg, 0.28 mmol), Pd₂(dba)₃ (27 mg, 0.030 mmol), XantPhos (35mg, 0.060 mmol), and cesium carbonate (183 mg, 0.56 mmol). After threecycles of vacuum/argon flash, the mixture was heated at 100° C. for 10h. After this time the reaction was cooled to room temperature. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified by silica-gel column chromatography eluting with 50:1dichloromethane/methanol to afford 214d (89 mg, 52%) as a yellow solid.MS-ESI: [M+H]⁺ 615.2

Example 2143-[4-[5-(6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-ylamino)-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one214

A mixture of 214d (89 mg, 0.14 mmol), lithium hydroxide (35 mg, 1.45mmol), and water/THF/i-propanol (3 mL/5 mL/5 mL) was stirred at 30° C.for 2 h. The reaction mixture was then concentrated under reducedpressure and the residue was extracted with dichloromethane (2×10 mL).The combined dichloromethane extract was concentrated under reducedpressure. The residue was purified with reverse-phase prep-HPLC toafford 214 (45 mg, 50%) as a yellow solid. MS-ESI: [M+H]⁺ 573.2. ¹H NMR(500 MHz, DMSO-d₆) δ 10.01 (s, 1H), 8.67 (d, J=2.5 Hz, 1H), 8.50 (d,J=5.0 Hz, 1H), 8.59 (d, J=2.5 Hz, 1H), 7.34 (d, J=5.0 Hz, 1H), 6.56 (s,1H), 4.96-4.94 (m, 1H), 4.61 (s, 2H), 4.46-4.43 (m, 2H), 4.22-4.17 (m,3H), 3.89-3.87 (m, 3H), 3.61 (s, 3H), 2.62-2.57 (m, 4H), 2.43 (s, 2H),1.22 (s, 6H).

Example 215a3-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-5-{1-methyl-5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridine-4-carbaldehyde215a

A sealed tube was charged with3-bromo-5-{4,4-dimethyl-9-oxo-1,10-diazatricyclo-[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-pyridine-4-carbaldehyde107f (210 mg, 0.54 mmol),1-methyl-3-(pyrimidin-4-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-one213b (177 mg, 0.54 mmol), PdCl₂(dppf) (42 mg, 0.050 mmol), K₃PO₄ (210mg, 1.0 mmol), and sodium acetate (85 mg, 1.0 mmol), acetonitrile (8mL), and water (0.5 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 4 h. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 20:1 dichloromethane/methanol toafford 215a (150 mg, 53%). MS-ESI: [M+H]⁺ 524.2.

Example 2153-[4-(hydroxymethyl)-5-[1-methyl-5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-3-pyridyl]-3-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one215

A mixture of 215a (150 mg, 0.28 mmol) and NaBH₄ (20 mg, 0.50 mmol) inmethanol (5 mL) was stirred at 25° C. for 0.2 h. The mixture wasquenched by water (5 mL) and evaporated in vacuo. The residue wasextracted with ethyl acetate (3×10 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified with reverse-phase prep-HPLC to afford 215 (80 mg, 53%).MS-ESI: [M+H]⁺ 526.3. ¹H NMR (500 MHz, DMSO-d₆) δ 9.09 (s, 1H), 8.89 (s,1H), 8.56 (s, 1H), 8.53 (s, 1H), 8.20 (d, J=4.0 Hz, 1H), 7.61 (s, 1H),7.13 (d, J=6.0 Hz, 1H), 6.52 (s, 1H), 5.19-5.18 (m, 1H), 4.47-4.46 (m,2H), 4.23-4.20 (m, 3H), 3.95-3.93 (m, 1H), 3.62 (s, 3H), 2.57 (s, 2H),2.42 (s, 3H), 2.41 (s, 2H), 1.21 (s, 6H).

Example 216a1-Methyl-3-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one216a

5-Bromo-1-methyl-3-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-ylamino)pyridin-2(1H)-one203b (997 mg, 2.8 mmol) was dissolved in dioxane (50 mL), followed byaddition of bis(pinacolato)diboron (3.0 g, 12.0 mmol), Pd₂(dba)₃ (128mg, 0.14 mmol), X-phos (134 mg, 0.28 mmol), and potassium acetate (823mg, 8.4 mmol). After three cycles of vacuum/argon flush, the mixture washeated at 65° C. for 2 h. The mixture was cooled to room temperature andfiltered. The filtrate was concentrated under pressure and the residualwas washed with petroleum ether (2×10 mL) to afford 216a as a yellowsolid (968 mg, 86%), which was used in the next step without furtherpurification. MS-ESI: [M+H]⁺ 403.2

Example 216b4-[1-Methyl-5-({5-methyl-4H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-2-yl}amino)-6-oxopyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde216b

A round-bottomed flask equipped with a magnetic stirrer and a refluxcondenser was charged with4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a (138 mg, 0.40 mmol), 216a (240 mg, 0.60 mmol), PdCl₂(dppf) (20 mg,0.020 mmol), K₃PO₄ (180 mg, 0.80 mmol), sodium acetate trihydrate (120mg, 0.80 mmol), water (6 drops), and acetonitrile (15 mL). After threecycles of vacuum/argon flush, the mixture was heated at 100° C. for 2 h.Then, it was cooled to room temperature and filtered. The filtrate wasevaporated under reduced pressure and the residue was purified bysilica-gel column chromatography eluting with 25:1dichloromethane/methanol to afford 216b as a yellow solid (100 mg, 45%).MS-ESI: [M+H]⁺ 586.2.

Example 2163-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one216

To a solution of 216b (100 mg, 0.15 mmol) in methanol (6 mL) was addedNaBH₄ (18 mg, 0.45 mmol). The reaction mixture was stirred at 30° C. for1 h and quenched with brine (10 mL). It was then evaporated underreduced pressure. The residue was extracted with dichloromethane (2×20mL) and the combined organic layer was concentrated under reducedpressure. The resulting residue was purified by reverse-phase prep-HPLCto afford 216 as a white solid (40 mg, 40%). MS-ESI: [M+H]⁺ 588.3. ¹HNMR (500 MHz, CDCl₃) δ 8.68 (d, J=5.0 Hz, 1H), 8.43 (d, J=2.0 Hz, 1H),8.31 (s, 1H), 8.29 (s, 1H), 7.79 (d, J=2.5 Hz, 1H), 7.55 (d, J=5.0 Hz,1H), 4.43-4.39 (m, 3H), 3.73 (s, 3H), 3.57-3.55 (m, 2H), 3.00-2.98 (m,2H), 2.88-2.86 (m, 2H), 2.82-2.80 (m, 4H), 2.50 (s, 3H), 2.03-1.95 (m,4H).

Example 217a(4-(5-Bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 217a

A sealed tube equipped with a magnetic stirrer was charged with3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (766 mg, 2.0 mmol), 3-bromo-5-iodo-1-methylpyridin-2(1H)-one214b (626 mg, 2.0 mmol), Pd(dppf)Cl₂ (164 mg, 0.20 mmol), sodium acetate(328 mg, 4.0 mmol), K₃PO₄ (848 mg, 4.0 mmol), acetonitrile (10 mL), andwater (0.5 mL). After three cycles of vacuum/argon flush, the mixturewas stirred at room temperature for 5 h. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 50:1 dichloromethane/methanol toafford 217a (700 mg, 67%) as a yellow solid. MS-ESI: [M+H]⁺ 525.2

Example 217b(4-(5-(1H-Imidazo[4,5-b]pyridin-5-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 217b

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 217a (158 mg, 0.30 mmol),1H-imidazo[4,5-b]pyridin-5-amine (80 mg, 0.60 mmol), Pd₂(dba)₃ (27 mg,0.030 mmol), XantPhos (35 mg, 0.061 mmol), cesium carbonate (200 mg,0.60 mmol), and 1,4-dioxane (5 mL). After three cycles of vacuum/argonflush, the mixture was stirred at 100° C. for 6 h. After this time thereaction was cooled to room temperature. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 30:1 dichloromethane/methanol toafford 217b (40 mg, 23%) as a yellow solid. MS-ESI: [M+H]⁺ 579.4

Example 2172-[3-(hydroxymethyl)-4-[5-(1H-imidazo[4,5-b]pyridin-5-ylamino)-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one217

A mixture of 217b (40 mg, 0.070 mmol) and lithium hydroxide (26 mg, 0.70mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at roomtemperature for 1 h. The mixture was evaporated in vacuo and the residuewas diluted with water and ethyl acetate. The water phase was separatedand extracted with ethyl acetate (2×10 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 217 (15 mg, 40%) as awhite solid. MS-ESI: [M+H]⁺ 537.3. ¹H NMR (500 MHz, DMSO-d₆) δ 12.62 (s,1H), 8.91-8.64 (m, 2H), 8.52 (d, J=4.5 Hz, 1H), 8.19-8.06 (m, 1H),7.89-7.79 (m, 1H), 7.57-7.53 (m, 1H), 7.43-7.40 (m, 1H), 7.22 (d, J=8.5Hz, 1H), 6.59 (s, 1H), 5.06-4.96 (m, 1H), 4.5-4.40 (m, 2H), 4.26-4.11(m, 3H), 3.88-3.85 (m, 1H), 3.62 (s, 3H), 2.62-2.54 (m, 2H), 2.50-2.48(m, 2H), 1.81-1.79 (m, 2H), 1.71-1.67 (m, 2H).

Example 218a5-Bromo-3-(1,5-dimethyl-1H-pyrazol-3-ylamino)-1-methylpyridin-2(1H)-one218a

A solution of5-bromo-1-methyl-3-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2(1H)-one (2.8g, 9.9 mmol) in anhydrous DMF (10 mL) was treated with 60% dispersion ofNaH in mineral oil (0.51 g, 13 mmol) while stirring under nitrogen.After effervescence the reaction was stirred for an additional 30minutes. At this time the reaction was treated with iodomethane (0.98 g,7.0 mmol) with continued stirring under nitrogen for 2 hours. Water (50mL) was added slowly and the mixture was filtered. The filtrate wasextracted with ethyl acetate (3×30 mL). The combined extract wasconcentrated under reduced pressure and the residue was purified byflush column chromatography eluting with 3:1 petroleum ether/ethylacetate to afford 218a (0.70 g, 24%). MS: [M+H]⁺ 297.

Example 218b(4-{5-[(1,5-Dimethyl-1H-pyrazol-3-yl)amino]-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl}-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl)methylAcetate 218b

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 218a (130 mg, 0.44 mmol),(3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclo-penta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)pyridin-4-yl)boronicacid 199e (175 mg, 0.44 mmol), PdCl₂(dppf) (36 mg, 0.044 mmol), K₃PO₄(343 mg, 1.32 mmol), sodium acetate (108 mg, 1.32 mmol), acetonitrile(10 mL), and water (0.5 mL). After three cycles of vacuum/argon flush,the mixture was heated at 100° C. for 3 h. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 1:20 methanol/dichloromethane toafford 218b as a red solid (103 mg, 42%). MS-ESI: [M+H]⁺ 570.2

Example 2183-[4-[5-[(1,5-dimethylpyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one218

A mixture of 218b (103 mg, 0.17 mmol), lithium hydroxide (42 mg, 1.75mmol), THF (3 mL), i-propanol (2 mL), and water (1 mL) was stirred atroom temperature for 0.5 h. The reaction mixture was concentrated underreduced pressure and diluted with water (4 mL). It was then extractedwith dichloromethane (10 mL×2) and the combined dichloromethane extractwas concentrated under reduced pressure. The residue was purified withreverse-phase prep-HPLC to afford 218 (29 mg, 48%) as white solid.MS-ESI: [M+H]⁺ 528.4. ¹H NMR (500 MHz, DMSO-d₆) δ 8.48 (d, J=5.0 Hz,1H), 8.04 (s, 1H), 8.02 (d, J=2.5 Hz, 1H), 7.38 (d, J=2.0 Hz, 1H), 7.32(d, J=5.0 Hz, 1H), 6.55 (s, 1H), 5.89 (s, 1H), 4.97 (s, 1H), 4.48-4.39(m, 2H), 4.24-4.16 (m, 3H), 3.86-3.84 (m, 1H), 3.58 (s, 3H), 3.57 (s,3H), 2.62-2.56 (m, 2H), 2.42 (s, 2H), 2.16 (s, 3H), 1.22 (s, 6H).

Example 219a 3-(3-Aminophenylamino)-5-bromo-1-methylpyrazin-2(1H)-one219a

To a solution of 3,5-dibromo-1-methylpyrazin-2(1H)-one (536 mg, 2.0mmol) and benzene-1,3-diamine (324 mg, 3.0 mmol) in isopropanol (18 mL)was added triethylamine (2.8 mL). The reaction mixture was stirred at80° C. overnight. Then the mixture was evaporated under reduced pressureto afford 219a (480 mg, 81%) as a white solid. MS-ESI: [M+H]⁺ 295.0

Example 219b(4-{6-[(3-Aminophenyl)amino]-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl}-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl)methylAcetate 219b

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 219a (480 mg, 1.62mmol),(3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)pyridin-4-yl)boronicacid 199e (1.61 g, 4.05 mmol), Pd(dppf)Cl₂ (134 mg, 0.162 mmol),potassium acetate (318 mg, 3.24 mmol), K₃PO₄ (706 mg, 3.24 mmol),acetonitrile (20 mL), and water (8 drops). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 2 h. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified by silica-gel column chromatography eluting with 20:1 ethylacetate/methanol to afford 219b (354 mg, 38%) as a yellow solid. MS-ESI:[M+H]⁺ 568.3

Example 2193-[4-[6-(3-aminoanilino)-4-methyl-5-oxo-pyrazin-2-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one219

A mixture of 219b (283.5 mg, 0.50 mmol) and lithium hydroxidemonohydrate (630 mg, 15.0 mmol) in i-propanol/THF (1:1, 8 mL) and water(2 mL) was stirred at 35° C. for 0.5 h. The mixture was evaporated invacuo and the residue was diluted with water (3 mL). It was thenextracted with dichloromethane (3×20 mL). The combined dichloromethaneextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 219 (170 mg, 79%) as apale yellow solid. MS-ESI: [M+H]⁺ 526.4. ¹H NMR (500 MHz, DMSO-d₆) δ8.85 (s, 1H), 8.47 (d, J=5.5 Hz, 1H), 7.63 (s, 1H), 7.56 (s, 1H), 7.51(d, J=5.0 Hz, 1H), 6.92-6.91 (m, 2H), 6.57 (s, 1H), 6.24-6.22 (m, 1H),5.13 (s, 2H), 4.84-4.75 (m, 2H), 4.49-4.46 (m, 1H), 4.30-4.26 (m, 1H),4.20-4.19 (m, 2H), 3.95-3.92 (m, 1H), 3.56 (s, 3H), 2.62-2.54 (m, 2H),2.43 (s, 2H), 1.23 (s, 6H).

Example 220a(S)-2-Chloro-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)nicotinaldehyde220a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with(S)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one191j (1.5 g, 1.0 eq., 3.11 mmol), 4-bromo-2-chloronicotinaldehyde 104a(1.02 g, 1.5 eq., 4.67 mmol), PdCl₂(dppf) (130 mg, 0.05 eq., 0.16 mmol),K₃PO₄ (1.32 g, 2 eq., 6.22 mmol), sodium acetate (510 mg, 2.0 eq., 6.22mmol), acetonitrile (35 mL), and water (1.0 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 90° C. for 2 h. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 50:1dichloromethane/ethanol to afford the 220a (1.1 g, 71%) as yellow solid.MS-ESI: [M+H]⁺ 495.3.

Example 220b(S)-2-(3,4,6,7,8,9-Hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)nicotinaldehyde220b

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 220a (300 mg, 1.0 eq.,0.61 mmol), 1,2,3,4,6,7,8,9-octahydropyrazino[1,2-a]indole (128 mg, 1.2eq., 0.73 mmol), Pd₂(dba)₃ (55 mg, 0.1 eq., 0.060 mmol), X-Phos (30 mg,0.1 eq., 0.060 mmol), Cs₂CO₃ (390 mg, 2.0 eq., 1.22 mmol), and dioxane(15.0 mL). After three cycles of vacuum/argon flush, the mixture washeated at 100° C. for 16 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by silica-gel column chromatographyeluting with 40:1 dichloromethane/EtOH to afford 220b (100 mg, 26%) asyellow solid. MS-ESI: [M+H]⁺ 635.3.

Example 2205-[2-(3,4,6,7,8,9-hexahydro-1H-pyrazino[1,2-a]indol-2-yl)-3-(hydroxymethyl)-4-pyridyl]-1-methyl-3-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]pyridin-2-one220

A 50-mL single-neck round-bottomed flask was charged with 220b (100 mg,1.0 eq., 0.15 mmol), NaBH₄ (30 mg, 5.0 eq., 0.75 mmol), methanol (5 mL),and dichloromethane (5 mL). The mixture was stirred at 0° C. for 10 minand quenched with water (5 mL). It was then filtered and the filtratewas concentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford the title compound (10 mg, 10%).MS-ESI: [M+H]⁺ 637.5. ¹H NMR (500 MHz, DMSO-d₆) δ 8.61 (d, J=2.0 Hz,1H), 8.44 (s, 1H), 8.24 (d, J=5.0 Hz, 1H), 7.82 (d, J=3.0 Hz, 1H), 7.53(d, J=2.0 Hz, 1H), 7.39-7.36 (m, 1H), 7.24 (d, J=9.0 Hz, 1H), 6.99 (d,J=5.0 Hz, 1H), 5.55 (s, 1H), 5.36-5.35 (m, 1H), 4.57-4.54 (m, 2H),4.48-4.40 (m, 6H), 3.92-3.90 (m, 2H), 3.79-3.67 (m, 3H), 3.59 (s, 3H),3.40-3.37 (m, 2H), 3.09-3.07 (m, 1H), 2.95-2.92 (m, 1H), 2.55-2.51 (m,2H), 2.38-2.30 (m, 4H), 2.17-2.16 (m, 1H), 1.75-1.74 (m, 2H), 1.68-1.65(m, 2H), 0.92 (d, J=6.5 Hz, 3H).

Example 221a3-[(6-aminopyridin-2-yl)amino]-5-bromo-1-methyl-1,2-dihydropyridin-2-one221a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (20 mL),3,5-dibromo-1-methylpyridin-2(1H)-one (1.06 g, 4.0 mmol),pyridine-2,6-diamine (872 mg, 8.0 mmol), Pd₂(dba)₃ (732 mg, 0.80 mmol),XantPhos (462.4 mg, 0.80 mmol), and cesium carbonate (2.6 g, 8.0 mmol).After three cycles of vacuum/argon flush, the mixture was heated at 110°C. for 1 h. After this time the reaction was cooled to room temperature.It was then filtered and the filtrate was evaporated in vacuo. Theresidue was purified by silica-gel column chromatography eluting with20:1 ethyl acetate/methanol to afford 221a (570 mg, 48%) as a whitesolid. MS-ESI: [M+H]⁺ 295.0

Example 221b(4-{5-[(6-Aminopyridin-2-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl)methylAcetate 221b

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 221a (354 mg, 1.2 mmol),(3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)pyridin-4-yl)boronicacid 199e (1.20 g, 3.0 mmol), Pd(dppf)Cl₂ (99 mg, 0.12 mmol), potassiumacetate (235 mg, 2.4 mmol), K₃PO₄ (532 mg, 2.4 mmol), acetonitrile (12mL), and water (10 drops). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 2 h. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 30:1 ethyl acetate/methanol to afford221b (210 mg, 31%) as a yellow solid. MS-ESI: [M+H]⁺ 568.3

Example 2213-[4-[5-[(6-amino-2-pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one221

A mixture of 221b (181 mg, 0.32 mmol) and lithium hydroxide monohydrate(148 mg, 3.2 mmol) in i-propanol/THF (1:1, 6 mL) and water (1.5 mL) wasstirred at 35° C. for 0.5 h. The mixture was concentrated under reducedpressure and the residue was purified by reverse-phase prep-HPLC toafford 221 (82 mg, 49%) as a pale yellow solid. MS-ESI: [M+H]⁺ 526.3. ¹HNMR (500 MHz, DMSO-d₆) δ 8.84 (d, J=2.0 Hz, 1H), 8.46 (d, J=5.0 Hz, 1H),8.11 (s, 1H), 7.54 (d, J=2.0 Hz, 1H), 7.38 (d, J=5.0 Hz, 1H), 7.23 (d,J=8.0 Hz, 1H), 6.57 (s, 1H), 6.36 (d, J=7.5 Hz, 1H), 5.91 (d, J=8.0 Hz,1H), 5.79 (bs, 2H), 5.07 (t, J=5.0 Hz, 1H), 4.58-4.47 (m, 2H), 4.27-4.20(m, 3H), 3.90 (d, J=10.5 Hz, 1H), 3.60 (s, 3H), 2.62-2.57 (m, 2H), 2.43(s, 2H), 1.22 (s, 6H).

Example 222aN-(5-Chloro-2-methoxypyridin-3-yl)-2-methylpyrimidin-4-amine 222a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (30 mL),3-bromo-5-chloro-2-methoxypyridine (865 mg, 3.9 mmol),2-methylpyrimidin-4-amine (327 mg, 3.0 mmol), Pd₂(dba)₃ (275 mg, 0.30mmol), XantPhos (173.4 mg, 0.30 mmol), and cesium carbonate (1.96 g, 6.0mmol). After three cycles of vacuum/argon flush, the mixture was heatedat 100° C. for 5 h. After this time the reaction was cooled to roomtemperature. It was then filtered and the filtrate was evaporated invacuo. The residue was purified by silica-gel column chromatographyeluting with 5:1 ethyl acetate/petroleum ether to afford 222a (555 mg,74%) as a white solid. MS-ESI: [M+H]⁺ 251.0

Example 222b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{6-methoxy-5-[(2-methylpyrimidin-4-yl)amino]pyridin-3-yl}pyridin-3-yl)methylAcetate 222b

A sealed tube equipped with a magnetic stirrer was charged with 222a(550 mg, 2.2 mmol),(3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo-[1,2-a]pyrazin-2(6H)-yl)pyridin-4-yl)boronicacid 199e (2.18 g, 5.5 mmol), Pd₂(dba)₃ (201 mg, 0.22 mmol),tricyclohexylphospine (84 mg, 0.30 mmol), Cs₂CO₃ (1.43 g, 4.4 mmol),dioxane (12 mL), and water (1 mL). After three cycles of vacuum/argonflush, the mixture was heated at 110° C. for 4 h. It was then filteredand the filtrate was evaporated in vacuo. The residue was purified bysilica-gel column chromatography eluting with 30:1 ethylacetate/methanol to afford 222b (310 mg, 25%) as a yellow solid. MS-ESI:[M+H]⁺ 568.6

Example 222c10-[3-(Hydroxymethyl)-4-{6-methoxy-5-[(2-methylpyrimidin-4-yl)amino]pyridin-3-yl}pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one222c

A mixture 222b (283.5 mg, 0.50 mmol) and lithium hydroxide monohydrate(630 mg, 15.0 mmol) in i-propanol/THF (1:1, 10 mL) and water (2.5 mL)was stirred at 35° C. for 0.5 h. The mixture was evaporated in vacuo andthe residue was diluted with water (3 mL). It was then extracted withdichloromethane (3×20 mL). The combined organic extract was concentratedunder reduced pressure to afford 222c (240 mg, 92%) as a white solid.MS-ESI: [M+H]⁺ 526.2

Example 2223-[3-(hydroxymethyl)-4-[5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-1H-pyridin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one222

To a solution of 222c (226 mg, 0.43 mmol) in dioxane (8 mL) was addedconcentrated HCl (1.1 mL). The reaction was stirred at 100° C. for 1 h.Then the mixture was adjusted to pH 7.0 by introducing saturated aqueousNaHCO₃. It was extracted with dichloromethane (3×20 mL) and the combinedextract was evaporated under reduced pressure. The resulting residue waspurified by reverse-phase prep-HPLC to afford 222 (30 mg, 14%) as awhite solid. MS-ESI: [M+H]⁺ 512.3. ¹H NMR (500 MHz, DMSO-d₆) δ 12.24 (s,1H), 9.10 (s, 1H), 8.96 (d, J=2.0 Hz, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.22(d, J=6.5 Hz, 1H), 7.50 (d, J=2.0 Hz, 1H), 7.40 (d, J=5.0 Hz, 1H), 7.13(d, J=6.0 Hz, 1H), 6.57 (s, 1H), 5.08-5.06 (m, 1H), 4.50-4.42 (m, 2H),4.25-4.19 (m, 3H), 3.87-3.85 (m, 1H), 2.62-2.53 (m, 2H), 2.45 (s, 3H),2.43 (s, 2H), 1.23 (s, 3H), 1.22 (s, 3H)

Example 223a2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)nicotinaldehyde223a

A 50-mL round-bottomed flush equipped with a reflux condenser wascharged with1-methyl-3-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-ylamino)-5-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one216a (200 mg, 0.50 mmol),4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (174 mg, 0.50 mmol), K₃PO₄ (212 mg, 1.0 mmol), sodium acetate (82mg, 1.0 mmol), 1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II)(21 mg, 0.025 mmol), and acetonitrile/water (15/1 mL). After bubblingnitrogen through the mixture for 30 minutes, it was heated at 100° C.for 1 h under N₂ protection. Analysis of reaction mixture by LCMS showedcomplete conversion to the desired product. The reaction mixture wascooled to room temperature and filtered. The filtrate was concentratedunder reduced pressure. The residue was diluted with dichloromethane (50mL) and water (50 mL). The aqueous layer was extracted withdichloromethane (3×20 mL). The combined organic layer was dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The darkresidue was purified by silica-gel column chromatography eluting withdichloromethane/methanol (70/1 to 30/1) to afford 223a (167 mg, 57%) asyellow solid. MS-ESI: [M+H]⁺ 588.1

Example 22310-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one223

Compound 223a (160 mg, 0.27 mmol) was dissolved in methanol (30 mL),followed by addition of NaBH₄ (31 mg, 082 mmol) at 0° C. The reactionmixture was stirred for 30 min and then quenched with water (10 mL). Itwas concentrated under reduced pressure and the residue was extractedwith dichloromethane (3×30 mL). The combined organic phase wasconcentrated under reduced pressure and the residual was purified byreverse-phase prep-HPLC to afford 223 (56 mg, 35%) as a white solid.MS-ESI: [M+H]⁺ 590.2. ¹H NMR (500 MHz, DMSO-d₆): δ 9.92 (s, 1H), 8.64(d, J=2.5 Hz, 1H), 8.48 (d, J=5.5 Hz, 1H), 7.56 (d, J=2.0 Hz, 1H), 7.34(d, J=5.0 Hz, 1H), 4.93 (t, J=5.5 Hz, 1H), 4.46-4.41 (m, 2H), 4.19-4.17(m, 2H), 4.08-4.03 (m, 1H), 3.88-3.85 (m, 1H), 3.60 (s, 3H), 3.42 (s,2H), 2.63-2.58 (m, 6H), 2.41 (s, 3H), 2.34 (s, 2H), 1.78-1.76 (m, 2H),1.68-1.66 (m, 2H).

Example 224a (S)-tert-Butyl4-(6-(6-Chloro-2-methyl-3-oxo-2,3-dihydropyridazin-4-ylamino)pyridin-3-yl)-3-methylpiperazine-1-carboxylate224a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with (S)-tert-butyl4-(6-aminopyridin-3-yl)-3-methylpiperazine-1-carboxylate 191f (2.5 g,8.5 mmol), 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (2.2 g, 10.0mmol), XantPhos (240 mg, 0.40 mmol),tris(dibenzylideneacetone)dipalladium(0) (360 mg, 0.40 mmol), Cs₂CO₃(5.5 g, 17 mmol), and 1,4-dioxane (100 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 2.5 h. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting withdichloromethane/methanol (40:1 to 30:1) to afford 224a as a pale yellowsolid (3.2 g, 86%). MS-ESI: [M+H]⁺ 435.1.

Example 224b(S)-6-Chloro-2-methyl-4-(5-(2-methylpiperazin-1-yl)pyridin-2-ylamino)pyridazin-3(2H)-one224b

A mixture of 224a (3.0 g, 6.9 mmol) and 4.0M HCl/ethanol (20 mL) wasstirred at room temperature for 2 h. The mixture was then concentratedunder reduced pressure to afford crude 224b as a yellow solid (2.5 g,98%), which was used for the next step without further purification.MS-ESI: [M+H]⁺ 335.1.

Example 224c(S)-6-Chloro-2-methyl-4-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)pyridazin-3(2H)-one224c

A mixture of 224b (2.3 g, 6.8 mmol), oxetan-3-one (1.4 g, 20.0 mmol),NaBH₃CN (620 mg, 10 mmol), and zinc chloride (1.36 g, 10 mmol) inmethanol (20 mL) was stirred at 50° C. for 3 hours. The mixture wasadded to water (40 mL) and concentrated under reduced pressure. Theresidue was extracted with dichloromethane three times. The combinedorganic layer was dried and concentrated under reduced pressure. Theresidue was purified by silica-gel column chromatography eluting with50:1 dichloromethane/methanol to afford 224c (2.0 g, 75%). MS-ESI:[M+H]⁺ 391.2.

Example 224d(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridazin-3-yl]pyridin-3-yl)methylAcetate 224d

A sealed tube equipped with a magnetic stirrer was charged with 224c(200 mg, 0.50 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (240 mg, 0.60 mmol), Pd(dppf)Cl₂ (18 mg, 0.025 mmol), sodiumacetate (74 mg, 0.90 mmol), K₃PO₄ (191 mg, 0.90 mmol), andacetonitrile/water (6:1, 3.5 mL). After three cycles of vacuum/argonflush, the mixture was heated at 100° C. for 1 h. It was then cooled toroom temperature and filtered. The filtrate was evaporated under reducedpressure and the residue was purified by silica-gel columnchromatography eluting with 25:1 dichloromethane/methanol to afford 224d(180 mg, 51%) as a brown solid. MS-ESI: [M+H]⁺ 708.3.

Example 2243-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one224

A mixture of 224d (180 mg, 0.25 mmol) and lithium hydroxide (72 mg, 3.0mmol) in i-propanol/THF (5/3 mL) and water (2 mL) was stirred at 35° C.for 0.2 h. The mixture was evaporated under reduced pressure and theresidue was extracted with ethyl acetate (10 mL×2). The combined ethylacetate extract was concentrated under reduced pressure and the residuewas purified by reverse phase Combiflush eluting with 0.3% NH₄HCO₃ inwater/acetonitrile to afford 224 (54 mg, 33%) as a white solid. MS-ESI:[M+H]⁺ 666.3. ¹H NMR (500 MHz, DMSO-d₆) δ 9.29 (s, 1H), 8.52 (d, J=4.0Hz, 1H), 8.43 (s, 1H), 7.91 (s, 1H), 7.43-7.42 (m, 2H), 7.40-7.39 (m,1H), 6.55 (s, 1H), 4.77-4.75 (m, 1H), 4.57-4.55 (m, 3H), 4.48-4.47 (m,1H), 4.43-4.41 (m, 2H), 4.28-4.26 (m, 1H), 4.19-4.18 (m, 2H), 3.88-3.86(m, 2H), 3.77 (s, 3H), 3.38-3.37 (m, 1H), 3.21-3.19 (m, 1H), 2.98-2.96(m, 1H), 2.64-2.62 (m, 1H), 2.58-2.56 (m, 2H), 2.42-2.41 (m, 3H),2.26-2.25 (m, 1H), 2.11-2.09 (m, 1H), 1.21 (s, 6H), 0.98 (d, J=5.5 Hz,3H).

Example 225a6-Chloro-2-methyl-4-(2-methylpyrimidin-4-ylamino)pyridazin-3(2H)-one225a

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 2-methylpyrimidin-4-amine (330 mg, 3.03mmol), 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (675 mg, 3.03 mmol),Pd₂(dba)₃ (274 mg, 0.30 mmol), XantPhos (143 mg, 0.30 mmol), Cs₂CO₃(2960 mg, 9.09 mmol), and dioxane (40 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for overnight. Itwas then filtered and the filtrate was evaporated in vacuo. The residuewas purified by silica-gel column chromatography eluting with 1:20methanol/dichloromethane to afford 225a as a yellow solid (560 mg, 73%).MS-ESI: [M+H]⁺ 252.1

Example 225b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-1,6-dihydropyridazin-3-yl}pyridin-3-yl)methylAcetate 225b

A round-bottomed flask equipped with a reflux condenser was charged with225a (200 mg, 0.80 mmol),(3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)pyridin-4-yl)boronicacid 199e (318 mg, 0.80 mmol), PdCl₂(dppf) (65.3 mg, 0.080 mmol), K₃PO₄(624 mg, 2.4 mmol), sodium acetate (200 mg, 2.4 mmol), acetonitrile (10mL), and water (0.5 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 3 h. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 1:20 methanol/dichloromethane toafford 225b as a red solid (150 mg, 47%). MS-ESI: [M+H]⁺ 569.3

Example 2253-[3-(hydroxymethyl)-4-[1-methyl-5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one225

A mixture of 225b (120 mg, 0.21 mmol), lithium hydroxide (59 mg, 2.11mmol), THF (6 mL), i-propanol (4 mL), and water (2 mL) was stirred atroom temperature for 0.5 h. The mixture was concentrated under reducedpressure and diluted with water (3 mL). It was then extracted withdichloromethane (2×10 mL). The combined dichloromethane extract wasconcentrated under reduced pressure and the residue was purified withreverse-phase prep-HPLC to afford 225 as a white solid (29 mg, 48%).MS-ESI: [M+H]⁺ 527.3. ¹H NMR (500 MHz, DMSO-d₆) δ 9.82 (s, 1H), 8.88 (s,1H), 8.54 (d, J=5.0 Hz, 1H), 8.37 (d, J=6.0 Hz, 1H), 7.44 (d, J=4.5 Hz,1H), 7.34 (d, J=3.5 Hz, 1H), 6.56 (d, J=4.0 Hz, 1H), 4.87 (t, J=1.5 Hz,1H), 4.67 (d, J=11.5 Hz, 1H), 4.42 (d, J=12.5 Hz, 1H), 4.29-4.25 (m,1H), 4.20 (bs, 2H), 3.93 (d, J=9.5 Hz, 1H), 3.81 (s, 3H), 2.62-2.58 (m,2H), 2.50-2.49 (m, underneath solvent peak, 2H), 2.40 (s, 3H), 1.22 (s,6H).

Example 226a6-Chloro-2-methyl-4-({5-[(morpholin-4-yl)carbonyl]pyridin-2-yl}amino)-2,3-dihydropyridazin-3-one226a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (40 mL),(6-aminopyridin-3-yl)(morpholino)methanone 111a (2.07 g, 10.0 mmol),4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (3.35 g, 15.0 mmol),Pd₂(dba)₃ (915 mg, 1.0 mmol), XantPhos (578 mg, 1.0 mmol), and cesiumcarbonate (6.52 g, 20 mmol). After three cycles of vacuum/argon flush,the mixture was heated at 100° C. for 8 h. It was then cooled to roomtemperature and filtered. The solid was washed with dichloromethane(2×20 mL). The combined filtrate was dried over anhydrous Na₂SO₄ andconcentrated under reduced pressure to afford 226a (2.45 g, 51%) as ayellow solid. MS: [M+H]⁺ 350.1

Example 226b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-[(morpholin-4-yl)carbonyl]pyridin-2-yl}amino)-6-oxo-1,6-dihydro-pyridazin-3-yl]pyridin-3-yl)methylAcetate 226b

A sealed tube equipped with a magnetic stirrer was charged with 226a(279 mg, 0.80 mmol),(2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 199e (1.53 g, 3.2 mmol), Pd₂(dba)₃ (73.2 mg, 0.080 mmol),tricyclohexyl-phospine (44.6 mg, 0.16 mmol), cesium carbonate (521.6 mg,1.6 mmol), 1,4-dioxane (10 mL), and water (8 drops). After three cyclesof vacuum/argon flush, the mixture was stirred at 110° C. for 4 h. Itwas then filtered and the filtrate was evaporated in vacuo. The residuewas purified by silica-gel column chromatography eluting with 40:1 ethylacetate/methanol to afford 226b as a yellow solid (120 mg, 23%). MS-ESI:[M+H]⁺ 667.3

Example 2263-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one226

A mixture of 226b (120 mg, 0.18 mmol) and lithium hydroxide monohydrate(227 mg, 5.4 mmol) in i-propanol/THF/water (3 mL/3 mL/2 mL) was stirredat 35° C. for 0.5 h. The mixture was evaporated in vacuo and the residuewas extracted with dichloromethane (3×10 mL). The combineddichloromethane extract was concentrated under reduced pressure and theresidue was purified by reverse-phase prep-HPLC to afford 226 as a whitesolid (53 mg, 47%). MS-ESI: [M+H]⁺ 625.3. ¹H NMR (500 MHz, DMSO-d₆) δ9.75 (s, 1H), 8.64 (s, 1H), 8.54 (d, J=5.0 Hz, 1H), 8.36 (d, J=2.5 Hz,1H), 7.79-7.77 (m, 1H), 7.59 (d, J=8.5 Hz, 1H), 7.43 (d, J=5.0 Hz, 1H),6.56 (s, 1H), 4.82 (s, 1H), 4.60-4.57 (m, 1H), 4.40-4.37 (m, 1H),4.27-4.25 (m, 1H), 4.20-4.17 (m, 2H), 3.91-3.88 (m, 1H), 3.80 (s, 3H),3.60-3.45 (m, overlap, 8H), 2.62-2.56 (m, 2H), 2.42 (s, 2H), 1.22 (s,6H).

Example 227a{4-[1-Methyl-5-({5-[(morpholin-4-yl)carbonyl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridazin-3-yl]-2-{1-oxo-1H,2H,3H,4H,6H,7H,8H,9H-pyrazino[1,2-a]indol-2-yl}pyridin-3-yl}methylAcetate 227a

A sealed tube equipped with a magnetic stirrer was charged with6-chloro-2-methyl-4-({5-[(morpholin-4-yl)carbonyl]pyridin-2-yl}amino)-2,3-dihydropyridazin-3-one226a (244 mg, 0.70 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (558 mg, 1.5 mmol), Pd₂(dba)₃ (64 mg, 0.070 mmol),tricyclohexylphospine (39 mg, 0.14 mmol), cesium carbonate (456 mg, 1.4mmol), 1,4-dioxane (7 mL), and water (6 drops). After three cycles ofvacuum/argon flush, the mixture was stirred at 110° C. for 4 h. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified by silica-gel column chromatography eluting with 40:1 ethylacetate/methanol to afford 227a as a yellow solid (290 mg, 63%). MS-ESI:[M+H]⁺ 653.3

Example 2272-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one227

A mixture of 227a (131 mg, 0.20 mmol) and lithium hydroxide·1 water (120mg, 2.0 mmol) in i-propanol/THF/water (4 mL/4 mL/2 mL) was stirred at35° C. for 0.5 h. The mixture was evaporated in vacuo and the residuewas extracted with dichloromethane (3×10 mL). The combineddichloromethane extract was concentrated under reduced pressure and theresidue was purified by reverse-phase prep-HPLC to afford 227 as a whitesolid (75 mg, 62%). MS-ESI: [M+H]⁺ 611.2. ¹H NMR (500 MHz, DMSO-d₆) δ9.75 (s, 1H), 8.64 (s, 1H), 8.54 (d, J=5.0 Hz, 1H), 8.36 (d, J=2.0 Hz,1H), 7.79-7.77 (m, 1H), 7.59 (d, J=8.5 Hz, 1H), 7.43 (d, J=5.0 Hz, 1H),6.58 (s, 1H), 4.82 (s, 1H), 4.60-4.57 (m, 1H), 4.38-4.36 (m, 1H),4.29-4.19 (m, 2H), 4.10-4.05 (m, 1H), 3.93-3.90 (m, 1H), 3.80 (s, 3H),3.60-3.50 (m, overlap, 8H), 2.66-2.54 (m, 2H), 2.48-2.46 (m, 2H),1.81-1.66 (m, 4H).

Example 228a(S)-(4-(1-Methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-yl-amino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 228a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with(S)-5-bromo-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-ylamino)pyridin-2(1H)-one(90 mg, 0.21 mmol) 191i,3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (80.4 mg, 0.21 mmol), Pd(dppf)Cl₂ (17.2 mg, 0.021 mmol), K₃PO₄(89 mg, 0.42 mmol), sodium acetate (57.1 mg, 0.42 mmol), water (0.5 mL),and acetonitrile (30 mL). After three cycles of vacuum/argon flush, themixture was heated at reflux for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (50:1 to 30:1) toafford 228a as brown solid (60 mg, 42%). MS-ESI: [M+H]⁺ 694.3.

Example 2282-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one228

A mixture of 228a (50 mg, 0.070 mmol) and lithium hydroxide (43 mg, 1.8mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at 35°C. for 30 mins. The reaction mixture was concentrated under reducedpressure and the residue was purified by reverse-phase prep-HPLC toafford 228 (10 mg, 21%). MS-ESI: [M+H]⁺ 652.3. ¹H NMR (500 MHz, DMSO-d₆)δ 8.61 (s, 1H), 8.48 (d, J=4.5 Hz, 1H), 8.39 (s, 1H), 8.34 (s, 1H), 7.84(s, 1H), 7.48 (s, 1H), 7.34 (d, J=5.0 Hz, 1H), 6.58 (s, 1H), 4.94 (bs,1H), 4.56-4.55 (m, 2H), 4.49-4.47 (m, 1H), 4.42-4.36 (m, overlap, 4H)4.25-4.17 (m, 2H), 4.13-4.10 (m, 1H), 3.86-3.76 (m, 2H), 3.60 (s, 3H),3.39-3.37 (m, 1H), 3.01-2.96 (m, 1H), 2.78-2.76 (m, 1H), 2.62-2.57 (m,overlap, 3H), 2.50-2.47 (m, 2H), 2.10-2.07 (m, 1H), 1.94-1.90 (m, 1H),1.80-1.78 (m, 2H), 1.70-1.69 (m, 2H), 1.12 (d, J=6.5 Hz, 3H).

Example 229a 2-Ethylpyrimidin-4-amine 229a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with2-chloropyrimidin-4-amine (2.60 g, 20.0 mmol), triethylborane (20.0 mL,1.0 M in THF, 20.0 mmol), Pd(dppf)Cl₂ (816 mg, 1.0 mmol), K₃PO₄ (13.0 g,40.0 mmol), water (2 mL), and tetrahydrofuran (50 mL). After threecycles of vacuum/argon flush, the mixture was heated at reflux for 14 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 40:1dichloromethane/methanol to afford 229a as yellow solid (600 mg, 24%).MS-ESI: [M+H]⁺ 124.3

Example 229b5-Bromo-3-(2-ethylpyrimidin-4-ylamino)-1-methylpyridin-2(1H)-one 229b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 229a (246 mg, 2.0 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (534 mg, 2.0 mmol), Pd₂(dba)₃ (182mg, 0.20 mmol), XantPhos (231 mg, 0.40 mmol), Cs₂CO₃ (1.30 g, 4.0 mmol),and 1,4-dioxane (20 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 4 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 40:1 dichloromethane/methanol to afford 229bas off-white solid (308 mg, 50%). MS-ESI: [M+H]⁺ 309.1

Example 229c(2′-(7,7-Dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta-[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)-5-((2-ethylpyrimidin-4-yl)amino)-1-methyl-6-oxo-1,6-dihydro-[3,4′-bipyridin]-3′-yl)methylAcetate 229c

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with 229b (277 mg, 0.90 mmol),(3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)pyridin-4-yl)boronicacid 199e (358 mg, 0.90 mmol), Pd(dppf)Cl₂ (74 mg, 0.090 mmol), K₃PO₄(381 mg, 1.80 mmol), water (2 mL), and tetrahydrofuran (20 mL). Afterthree cycles of vacuum/argon flush, the mixture was heated at reflux for3 h. It was then cooled to room temperature and filtered. The filtratewas concentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 60:1dichloromethane/methanol to afford 229c as white solid (291 mg, 50%).MS-ESI: [M+H]⁺ 582.4

Example 2293-[4-[5-[(2-ethylpyrimidin-4-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one229

To a solution of 229c (291 mg, 0.45 mmol) in tetrahydrofuran (10 mL) andwater (2 mL) was added lithium hydroxide (48 mg, 2.0 mmol). The reactionmixture was stirred at 25° C. for 1 h and concentrated under reducedpressure. The residue was purified by reverse-phase prep-HPLC to afford229 (165 mg, 61%) as yellow solid. MS-ESI: [M+H]⁺ 540.3. ¹H NMR (500MHz, DMSO-d₆) δ 9.12 (s, 1H), 8.96 (d, J=2.5 Hz, 1H), 8.50 (d, J=5.0 Hz,1H), 8.25 (d, J=5.5 Hz, 1H), 7.72 (d, J=2.5 Hz, 1H), 7.38 (d, J=5.5 Hz,1H), 7.15 (d, J=6.0 Hz, 1H), 6.56 (s, 1H), 5.00 (t, J=5.5 Hz, 1H),4.55-4.44 (m, 2H), 4.26-4.19 (m, overlap, 3H), 3.88-3.86 (m, 1H), 3.62(s, 3H), 2.74 (q, J=7.5 Hz, 2H), 2.59-2.54 (m, 2H), 2.43 (s, 2H),1.22-1.20 (m, overlap, 9H).

Example 230a (S)-tert-Butyl4-(5-Bromopyrazin-2-yl)-3-methylpiperazine-1-carboxylate 230a

A mixture of (S)-tert-butyl 3-methylpiperazine-1-carboxylate (6.0 g, 30mmol) and 2,5-dibromopyrazine (14.1 g, 60 mmol) was stirred at 80° C.for 15 h. It was then cooled to room temperature and purified bysilica-gel column chromatography eluting with petroleum ether/ethylacetate (10:1 to 2:1) to afford 230a as a yellow solid (1.14 g, 19%).MS: [M+H]⁺ 359.1.

Example 230b (S)-tert-Butyl4-(5-(Diphenylmethyleneamino)pyrazin-2-yl)-3-methylpiperazine-1-carboxylate230b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 230a (2.6 g, 7.3 mmol),diphenylmethanimine (1.3 g, 7.3 mmol), Pd₂(dba)₃ (669 mg, 0.73 mmol),(R)-(+)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (968 mg, 1.46 mmol),Cs₂CO₃ (4.7 g, 14.6 mmol), and 1,4-dioxane (40 mL). After three cyclesof vacuum/argon flush, the mixture was heated at 96° C. for 3 hrs. Itwas then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with petroleumether/ethyl acetate (10:1 to 3:1) to afford 230b as red oil (3.3 g,75%). MS: [M+H]⁺ 458.3.

Example 230c (S)-tert-Butyl4-(5-Aminopyrazin-2-yl)-3-methylpiperazine-1-carboxylate 230c

To a solution of 230b (3.3 g, 7.2 mmol) in methanol (25 mL) were addedsodium acetate (708 mg, 8.6 mmol) and hydroxylamine hydrochloride (907mg, 8.6 mmol). The reaction mixture was stirred for 0.5 h. It was thenconcentrated in vacuo. The residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (50:1 to 30:1) toafford 230c as yellow oil (1.35 g, 64%). MS: [M+H]⁺ 294.3.

Example 230d (S)-tert-Butyl4-(5-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyrazin-2-yl)-3-methylpiperazine-1-carboxylate230d

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 230c (1.25 g, 4.3 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (3.4 g, 12.9 mmol), Pd₂(dba)₃ (394mg, 0.43 mmol), Xantphos (497 mg, 0.86 mmol), Cs₂CO₃ (4.7 g, 14.6 mmol),and 1,4-dioxane (80 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 2 hrs. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (50:1 to 30:1) toafford 230d (1.9 g, 72%). MS: [M+H]⁺ 481.2.

Example 230e(S)-5-Bromo-1-methyl-3-(5-(2-methylpiperazin-1-yl)pyrazin-2-ylamino)pyridin-2(1H)-one230e

A mixture of 230d (1.9 g, 3.97 mmol) and trifluoroacetic acid (4 mL) wasstirred at room temperature for 1 h. It was then concentrated underreduced pressure to afford crude 230e (1.45 g, 97%), which was used inthe next step without further purification. MS: [M+H]⁺ 381.2.

Example 230f(S)-5-Bromo-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-ylamino)pyridin-2(1H)-one230f

A mixture of 230e (2.0 g, 5.3 mmol), oxetan-3-one (763 mg, 10.6 mmol),NaBH₃CN (835 mg, 13.3 mmol), and zinc chloride (1.8 g, 13.3 mmol) inmethanol (60 mL) was stirred at 50° C. for 30 min. The mixture wasconcentrated under reduced pressure. To the residue was added water andthe resulting mixture was extracted with dichloromethane three times.The combined organic layer was then concentrated under reduced pressureand the resulting residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (50:1 to 20:1) toafford 230f as a yellow oil (1.6 g, 70%). MS: [M+H]⁺ 437.2.

Example 230g5-[4-Chloro-3-(hydroxymethyl)pyridin-2-yl]-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-6-one230g

A mixture of4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trine-5-yl}pyridine-3-carbaldehyde124a (797 mg, 2.31 mmol), NaBH₄ (263 mg, 6.92 mmol), and CH₃OH (50 mL)was stirred at room temperature for 1 h. Then the reaction mixture wasquenched with water (30 mL) and concentrated under reduced pressure. Theresidue was extracted with dichloromethane (2×30 mL) and the combineddichloromethane extract was concentrated under reduced pressure. Theresidue was purified by silica-gel chromatography eluting with 5:1 toafford 230g (649 mg, 81%) as a yellow solid. MS-ESI: [M+H]⁺ 348.1

Example 230h(4-Chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridin-3-yl)methylAcetate 230h

A round-bottomed flask was charged with 230g (597 mg, 1.72 mmol),dichloromethane (50 mL), and triethylamine (5 mL). The solution wasstirred at 0° C. for 0.5 h and acetyl chloride (135 mg, 1.72 mmol) wasadded slowly. The mixture was stirred at 0° C. for another 2.5 h. It wasthen concentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 9:1 petroleum ether/ethylacetate to afford 230h (602 mg, 90%) as a yellow solid. MS-ESI: [M+H]⁺390.1

Example 230i4-(Dihydroxyboranyl)-2-{6-oxo-8-thia-4,5-diazatricyclo-[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridin-3-yl]methylacetate 230i

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 230h (595 mg, 1.53mmol), Pin₂B₂ (1.94 g, 7.65 mmol), PdCl₂(dppf) (65 mg, 0.080 mmol),X-Phos (73 mg, 0.15 mmol), potassium acetate (304 mg, 3.1 mmol), anddioxane (50 mL). After three cycles of vacuum/argon flush, the mixturewas heated at 65° C. for 5 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was washed with petroleum ether to afford 230i (409mg, 67%) as a yellow solid. MS-ESI: [M+H]⁺ 400.1

Example 230j{4-[1-Methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl]pyridin-3-yl}methylAcetate 230j

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 230f (100 mg, 0.23mmol), 230i (140 mg, 0.35 mmol), Pd(dppf)Cl₂ (19 mg, 0.023 mmol), sodiumacetate (63 mg, 0.46 mmol), K₃PO₄ (98 mg, 0.46 mmol), water (0.5 mL),and acetonitrile (20 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 3 h. After cooling to room temperaturethe reaction was filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (50:1 to 30:1) toafford 230j as a yellow solid (90 mg, 55%). MS-ESI: [M+H]⁺ 710.2.

Example 2303-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one230

A mixture of 230j (80 mg, 0.11 mmol) and lithium hydroxide (27 mg, 1.1mmol) in i-propanol/THF (1:1, 10 mL) and water (2 mL) was stirred at 35°C. for 0.5 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by reverse-phase prep-HPLC to afford 230 (34 mg,45%). MS-ESI: [M+H]⁺ 668.2. ¹H NMR (500 MHz, DMSO-d₆) δ 8.64 (s, 1H),8.56 (d, J=6.0 Hz, 1H), 8.46 (s, 1H), 8.40 (d, J=2.5 Hz, 1H), 8.34 (d,J=1.5 Hz, 1H), 7.85 (s, 1H), 7.53 (d, J=6.0 Hz, 1H), 7.49 (d, J=2.5 Hz,1H), 4.84 (bs, 1H), 4.58-4.54 (m, 2H), 4.50-4.47 (m, 1H), 4.43-4.36 (m,overlap, 4H), 3.78-3.75 (m, 1H), 3.59 (s, 3H), 3.39-3.35 (m, 1H),3.02-3.0 (m, 1H), 2.98-2.95 (m, 2H), 2.90-2.82 (m, 2H), 2.78-2.76 (m,1H), 2.60-2.56 (m, 1H), 2.10-2.09 (m, 1H), 1.95-1.88 (m, overlap, 5H),1.10 (d, J=8.0 Hz, 3H).

Example 231a2-(4-Chloro-3-(hydroxymethyl)pyridin-2-yl)-10-fluoro-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one231a

A mixture of4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (800 mg, 2.31 mmol), NaBH₄ (263 mg, 6.92 mmol), and methanol (50mL) was stirred at 0° C. for 1 h. Then the reaction mixture was quenchedwith water (30 mL) and concentrated under reduced pressure. The residuewas extracted with dichloromethane (2×30 mL) and the combineddichloromethane extract was concentrated under reduced pressure. Theresidue was purified by silica-gel chromatography eluting with 5:1petroleum ether/ethyl acetate to afford 231a (650 mg, 81%) as a yellowsolid. MS-ESI: [M+H]⁺ 340.1

Example 231b(4-Chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 231b

A round-bottomed flask was charged with 231a (600 mg, 1.72 mmol),dichloromethane (50 mL), and triethylamine (5 mL). The solution wasstirred at 0° C. for 0.5 h and acetyl chloride (135 mg, 1.72 mmol) wasadded slowly. The mixture was stirred at 0° C. for another 2.5 h. It wasthen evaporated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 9:1 petroleum ether/ethylacetate to afford 231b (605 mg, 90%) as a yellow solid. MS-ESI: [M+H]⁺392.1

Example 231c3-(Acetoxymethyl)-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicAcid 231c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 231b (600 mg, 1.53mmol), Pin₂B₂ (1.94 g, 7.65 mmol), PdCl₂(dppf) (65 mg, 0.080 mmol),X-Phos (73 mg, 0.15 mmol), potassium acetate (304 mg, 3.1 mmol), anddioxane (30 mL). After three cycles of vacuum/argon flush, the mixturewas heated at 65° C. for 5 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was washed with petroleum ether to afford 231c (412mg, 67%) as yellow solid. MS-ESI: [M+H]⁺ 402.1

Example 231d(S)-(2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)methylAcetate 231d

A round-bottomed flask equipped with a reflux condenser was charged with231c (200 mg, 0.50 mmol),(S)-6-chloro-2-methyl-4-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)pyridazin-3(2H)-one224c (195 mg, 0.50 mmol), PdCl₂(dppf) (24 mg, 0.030 mmol), K₃PO₄ (212mg, 1.0 mmol), sodium acetate (98 mg, 1.0 mmol), acetonitrile (30 mL),and water (3 mL). After three cycles of vacuum/argon flush, the mixturewas heated at 100° C. for 2 h. It was then cooled to room temperatureand filtered. The filtrate was evaporated under reduced pressure. Theresidue was purified with silica-gel column chromatography eluting with1:3 petroleum/ethyl acetate to afford 231d as a yellow solid (213 mg,60%). MS-ESI: [M+H]⁺ 712.3

Example 23110-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one231

A mixture of 231d (150 mg, 0.21 mmol) and lithium hydroxide (51 mg, 2.1mmol) in i-propanol/THF (1:1, 10 mL) and water (3 mL) was stirred atroom temperature for 1 h. The mixture was evaporated under reducedpressure and the residue was extracted with ethyl acetate (2×10 mL). Thecombined ethyl acetate extract was concentrated under reduced pressureand the residue was purified with reverse-phase prep-HPLC to afford 231(83 mg, 59%) as a yellow solid. MS-ESI: [M+H]⁺ 670.3. ¹H NMR (500 MHz,DMSO-d₆) δ 9.29 (s, 1H), 8.53 (d, J=5.5 Hz, 1H), 8.42 (s, 1H), 7.91 (s,1H), 7.43-7.40 (m, 3H), 4.76 (bs, 1H), 4.60-4.54 (m, 3H), 4.49-4.46 (m,1H), 4.43-4.37 (m, 2H), 4.21-4.56 (m, 2H), 4.07-4.03 (m, 1H), 3.89-3.83(m, 2H), 3.78 (s, 3H), 3.41-3.37 (m, 1H), 3.22-3.19 (m, 1H), 3.00-2.93(m, 1H), 2.65-2.60 (m, 2H), 2.55-2.54 (m, 1H), 2.43-2.39 (m, 3H),2.27-2.24 (m, 1H), 2.12-2.07 (m, 1H), 1.76-1.66 (m, 4H), 0.97 (d, J=9.0Hz, 3H).

Example 232a 2-Nitro-5-(1,2,3,6-tetrahydropyridin-4-yl)pyridine 232a

A mixture of tert-butyl4-(6-nitropyridin-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate 200a (2.0g, 6.6 mmol) in HCl/dioxane (20 mL, 4M) was stirred at room temperaturefor 2 hours. It was then evaporated under reduced pressure. The residuewas washed with ethyl acetate (3×7 mL) to afford 232a as a yellow solid(1.0 g, 74%). MS-ESI: [M+H]⁺ 206.

Example 232b 5-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-nitropyridine232b

To a solution of 232a (1.2 g, 5.8 mmol) in CH₃OH (25 mL) was added HCHO(1 mL, 35 mmol) and acetic acid (1 mL), followed by the addition ofNaBHCN₃ (1.0 g, 12 mmol). The mixture was stirred at room temperaturefor 2 h. It was then evaporated under reduced pressure and the residuewas purified by reverse-phase Combiflush eluting with 0.3% NH₄HCO₃ inwater/acetonitrile to afford 232b as a yellow solid (1.0 g, 78%).MS-ESI: [M+H]⁺ 220.

Example 232c 5-(1-Methylpiperidin-4-yl)pyridin-2-amine 232c

A 250-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 232b (2.0 g, 9.0 mmol), 10% palladium on carbon (50% wet,200 mg), and methanol (40 mL). The flask was evacuated, charged withhydrogen gas, and stirred under hydrogen at room temperature for 12 h.The hydrogen was then evacuated and nitrogen was charged to the flask.The catalyst was removed by filtration through a pad of CELITE® and thefiltrate was concentrated under reduced pressure to afford 232c (1.6 g,92.5%), which was used directly in the next step without furtherpurification. MS-ESI: [M+H]⁺ 192

Example 232d5-Bromo-1-methyl-3-(5-(1-methylpiperidin-4-yl)pyridin-2-ylamino)pyridine-2(1H)-one232d

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 232c (1.5 g, 7.9 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (2.0 g, 7.9 mmol), cesiumcarbonate (5.0 g, 16 mmol), and 1,4-dioxane (50 mL). After bubblingnitrogen through the resulting suspension for 30 minutes, XantPhos (455mg, 0.79 mmol) and tris(dibenzylideneacetone)dipalladium(0) (718 mg,0.79 mmol) were added. The system was subject to three cycles ofvacuum/argon flush and heated at 100° C. for 2 h. After this time thereaction was cooled to room temperature and filtered. The filtrate waspartitioned between ethyl acetate (100 mL) and water (100 mL). Theaqueous layer was separated and extracted with ethyl acetate (3×50 mL).The combined organic layer was washed with brine (3×20 mL) and driedover sodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 1:3 ethylacetate/petroleum ether to afford 232d as a brown solid (1.5 g, 50%).MS-ESI: [M+H]⁺ 377.

Example 232e(4-(1-Ethyl-5-(5-(1-methylpiperidin-4-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 232e

A round-bottomed flask equipped with a reflux condenser was charged with232d (160 mg, 0.40 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (191 mg, 0.50 mmol), Pd(dppf)Cl₂ (20 mg, 0.024 mmol), K₃PO₄(180 mg, 0.80 mmol), sodium acetate trihydrate (120 mg, 0.80 mmol),water (0.5 mL), and acetonitrile (10 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 2 h. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified by silica-gel column chromatography eluting with 25:1dichloromethane/CH₃OH to afford 232e as a yellow solid (180 mg, 55%).MS-ESI: [M+H]⁺ 636.3

Example 2322-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methyl-4-piperidyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one

A mixture of 232e (180 mg, 0.30 mmol) and lithium hydroxide (130 mg, 3.0mmol) in THF/i-propanol (6:3, 9 mL) and water (3 mL) was stirred at 30°C. for 1 h. The mixture was evaporated under reduced pressure and theresidue was extracted with ethyl acetate (2×20 mL). The combined ethylacetate extract was concentrated under reduced pressure and the residuewas purified by reverse-phase prep-HPLC to 232 (55 mg, 35%) as whitesolid. MS-ESI: [M+H]⁺ 594.3. ¹H NMR (500 MHz, CDCl₃) δ 8.72 (d, J=3.0Hz, 1H), 8.51 (d, J=6.0 Hz, 1H), 8.11 (d, J=3.0 Hz, 1H), 7.88 (d, J=2.0Hz, 1H), 7.44-7.36 (m, 2H), 6.90 (s, 1H), 6.80-6.78 (m, 1H), 5.08-5.04(m, 1H), 4.64-4.50 (m, 2H), 4.34-4.29 (m, 1H), 4.16-4.10 (m, 2H),3.91-3.87 (m, 1H), 3.72 (s, 3H), 3.03-3.00 (m, 2H), 2.62-2.56 (m, 4H),2.46-2.42 (m, 1H), 2.36 (s, 1H) 2.13-2.07 (m, 2H), 1.92-1.82 (m,overlap, 8H).

Example 233a tert-Butyl2-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino-1-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate 233a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with tert-butyl2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (600 mg,2.35 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (942 mg, 3.53 mmol),Pd₂(dba)₃ (214 mg, 0.235 mmol), Xantphos (270.5 mg, 0.47 mmol), Cs₂CO₃(1.53 g, 4.7 mmol), and dioxane (30 mL). After bubbling nitrogen throughthe mixture for 30 minutes, it was heated at 110° C. under N₂ protectionfor 12 h. Analysis of reaction mixture by LCMS showed completeconversion to the desired product. The mixture was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the residue was washed with acetonitrile to afford 233a(600 mg, 54%) as yellow solid. MS-ESI: [M+H]⁺ 441.1

Example 233b tert-Butyl2-[(5-{3-[(Acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino]-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate233b

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 233a (300 mg, 0.68 mmol),(3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo-[1,2-a]pyrazin-2(6H)-yl)pyridin-4-yl)boronicacid 199e (1.8 g, 2.72 mmol), Pd(dppf)Cl₂ (27.7 mg, 0.034 mmol), K₃PO₄(288.3 mg, 1.36 mmol), sodium acetate (111.5 mg, 1.36 mmol), water (10drops), and acetonitrile (10 mL). After bubbling nitrogen through themixture for 30 minutes, it was heated at 100° C. under N₂ protection for1 h. Analysis of reaction mixture by LCMS showed complete conversion tothe desired product. The mixture was filtered and the filtrate wasconcentrated under reduced pressure and the residue was purified bysilica-gel column chromatography eluting with 100:1dichloromethane/methanol to afford 233b (220 mg, 45%) as a yellow solid.MS-ESI: [M+H]⁺ 714.3

Example 233c(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-6-oxo-5-({4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-2-yl}amino)-1,6-dihy-dropyridin-3-yl]pyridin-3-yl)methylAcetate 233c

To a solution of 233b (220 mg, 0.308 mmol) in ethyl acetate (5 mL) wasadded a solution of HCl in ethyl acetate (0.123 mL, 2.5M, 0.308 mmol).The mixture was stirred at room temperature for 1 h. It was thenconcentrated under reduced pressure to afford 233c (180 mg, crude),which was used directly for next step without further purification.MS-ESI: [M+H]⁺ 614.3

Example 2333-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-ylamino)-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one233

To a solution of 233c (180 mg, 0.29 mmol) in THF (3 mL) and propan-2-ol(3 mL) was added water (1 mL) and lithium hydroxide (14.0 mg, 0.58mmol). The reaction mixture was stirred at room temperature for 1 h. Itwas then concentrated under reduced pressure and the resulting residuewas purified by reverse-phase prep-HPLC to afford 233 (28.6 mg, 17%) aswhite solid. MS-ESI: [M+H]⁺ 572.3. ¹H NMR (500 MHz, DMSO-d₆) δ 9.85 (s,1H), 8.63 (d, J=2.5 Hz, 1H), 8.48 (d, J=6.5 Hz, 1H), 7.57 (d, J=2.5 Hz,1H), 7.32 (d, J=6.0 Hz, 1H), 6.55 (s, 1H), 4.95-4.92 (m, 1H), 4.47-4.37(m, 2H), 4.25-4.18 (m, 3H), 3.86-3.84 (m, 1H), 3.71 (s, 2H), 3.59 (s,3H), 2.92-2.90 (m, 2H), 2.62-2.56 (m, 2H), 2.50-2.39 (m, 5H), 1.21 (s,6H).

Example 235a(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridin-3-yl)methylAcetate 235a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with(S)-5-bromo-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-ylamino)pyridin-2(1H)-one230f (200 mg, 0.46 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]-dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (366 mg, 0.92 mmol), Pd(dppf)Cl₂ (38 mg, 0.046 mmol), sodiumacetate (126 mg, 0.92 mmol), K₃PO₄ (196 mg, 0.92 mmol), water (0.5 mL),and acetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at 65° C. for 3 hrs. After cooling to roomtemperature the reaction was filtered. The filtrate was concentratedunder reduced pressure and the resulting residue was purified bysilica-gel column chromatography eluting with dichloromethane/methanol(50:1 to 30:1) to afford 235a as brown solid (100 mg, 31%). MS-ESI:[M+H]⁺ 708.5.

Example 2353-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one235

A mixture of 235a (90.0 mg, 0.13 mmol) and lithium hydroxide (36.4 mg,3.25 mmol) in i-propanol/THF (1:1, 5 mL) and water (1 mL) was stirred at35° C. for 0.5 h. It was then cooled to room temperature and filtered.The filtrate was concentrated under reduced pressure and the resultingresidue was purified by reverse-phase prep-HPLC to afford 235 (18.2 mg,22%). MS-ESI: [M+H]⁺ 666.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.61 (s, 1H),8.48 (d, J=4.5 Hz, 1H), 8.39 (d, J=1.5 Hz, 1H), 8.34 (s, 1H), 7.83 (s,1H), 7.47 (d, J=2.0 Hz, 1H), 7.33 (d, J=5.0 Hz, 1H), 6.56 (s, 1H), 4.96(bs, 1H), 4.57-4.55 (m, 2H), 4.49-4.47 (m, 1H), 4.42-4.37 (m, overlap,4H), 4.22-4.18 (m, overlap, 3H), 3.84-3.76 (m, 2H), 3.60 (s, 3H),3.39-3.37 (m, 1H), 3.02-2.81 (m, 1H), 2.78-2.76 (m, 1H), 2.62-2.56 (m,3H), 2.43-2.41 (m, 2H), 2.10-2.07 (m, 1H), 1.92-1.90 (m, 1H), 1.22 (s,6H), 1.12 (d, J=6.0 Hz, 3H).

Example 236a(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(1-methyl-5-{[5-(1-methylpiperidin-4-yl)pyridin-2-yl]amino}-6-oxopyridin-3-yl)pyridin-3-yl)methylAcetate 236a

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with5-bromo-1-methyl-3-(5-(1-methylpiperidin-4-yl)pyridin-2-ylamino)pyridin-2(1H)-one232d (160 mg, 0.40 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (240 mg, 0.60 mmol), Pd(dppf)Cl₂ (20 mg, 0.020 mmol), K₃PO₄(180 mg, 0.80 mmol), sodium acetate trihydrate (120 mg, 0.80 mmol),water (0.5 mL), and acetonitrile (10 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 2 h. It wasthen filtered and the filtrate was evaporated under reduced pressure.The residue was purified on silica-gel column chromatography elutingwith 25:1 dichloromethane/methanol to afford 236a as a yellow solid (150mg, 38%). MS-ESI: [M+H]⁺ 650.3

Example 2363-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methyl-4-piperidyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one236

A mixture of 236a (150 mg, 0.25 mmol) and lithium hydroxide (105 mg, 2.5mmol) in THF/i-propanol (6:3, 9 mL) and water (3 mL) was stirred at 30°C. for 1 h. The mixture was evaporated in vacuo and the residue wasextracted with ethyl acetate (2×20 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 236 (40 mg, 30%) as lightgreen solid. MS-ESI: [M+H]⁺ 608.3. ¹H NMR (500 MHz, CDCl₃) δ 8.73 (s,1H), 8.52 (d, J=4.0 Hz, 1H), 8.13 (s, 1H), 7.90-7.88 (m, 2H), 7.45-7.37(m, 2H), 6.86-6.80 (m, 2H), 5.11 (bs, 1H), 4.67-4.65 (m, 1H), 4.53-4.51(m, 1H), 4.35-4.33 (m, 1H), 4.18 (bs, 2H), 3.90-3.89 (m, 1H), 3.73 (s,3H), 3.24-3.22 (m, 2H), 2.59-2.50 (m, overlap, 8H), 2.36-2.32 (m, 2H),2.01-1.87 (m, 4H), 1.29 (s, 6H).

Example 237a2-{10-Fluoro-1-oxo-1H,2H,3H,4H,6H,7H,8H,9H-pyrido[3,4-b]indolizin-2-yl}-4-[1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridine-3-carbaldehyde237a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde134c (70 mg, 0.20 mmol),1-methyl-3-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-dihydropyridin-2-one191j (192 mg, 0.40 mmol), Pd(dppf)Cl₂ (33 mg, 0.040 mmol), potassiumacetate (39 mg, 0.40 mmol), K₃PO₄ (87 mg, 0.40 mmol), acetonitrile (7mL), and water (6 drops). After three cycles of vacuum/argon flush, themixture was heated at 95° C. for 2 h. It was then filtered and thefiltrate was evaporated under reduced pressure. The residue was purifiedby silica-gel column chromatography eluting with 50:1 ethylacetate/methanol to afford 237a (286 mg, purity: 46%, yield: 98%) as asolid. MS-ESI: [M+H]⁺ 667.3

Example 23710-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one237

To a solution of 237a (131 mg, 0.197 mmol) in methanol (7 mL) was addedsodium borohydride (59.8 mg, 1.57 mmol) at 0° C. The reaction wasstirred at 0-25° C. for 1.5 h. It was then quenched with water (1.5 mL).The mixture was evaporated under reduced pressure and the residue wasextracted with dichloromethane (3×30 mL). The combined dichloromethaneextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 237 (36 mg, 28%) as awhite solid. MS-ESI: [M+H]⁺ 669.3. ¹H NMR (500 MHz, CDCl₃) δ 8.66 (d,J=1.5 Hz, 1H), 8.51 (d, J=5.0 Hz, 1H), 7.99 (s, 1H), 7.85 (s, 1H), 7.83(d, J=2.0 Hz, 1H), 7.36-7.32 (m, 2H), 6.84 (d, J=9.0 Hz, 1H), 4.90-4.86(m, 1H), 4.73-4.65 (m, 5H), 4.39-4.30 (m, 2H), 3.90-3.77 (m, 3H), 3.72(s, 3H), 3.56-3.48 (m, 2H), 3.10-3.09 (m, 2H), 2.98-2.92 (m, 2H),2.79-2.75 (m, 2H), 2.59-2.57 (m, 1H), 2.50-2.49 (m, 2H), 2.22-2.21 (s,1H), 2.04-1.99 (m, 2H), 1.88-1.84 (m, 2H), 1.01 (d, J=6.0 Hz, 3H).

Example 238a (E)-Methyl3-((tert-Butylsulfinylimino)methyl)-5,6,7,8-tetrahydroindolizine-2-carboxylate238a

A 500-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with methyl3-formyl-5,6,7,8-tetrahydroindolizine-2-carboxylate (10.0 g, 48.3 mmol,1.0 eq.), 2-methylpropane-2-sulfinamide (11.7 g, 96.6 mmol, 2.0 eq.),KHSO₄ (32.8 g, 241.5 mmol, 5 eq.), and dichloromethane (250 mL). Themixture was stirred at room temperature for 10 h. It was then filteredand filtrate was concentrated under reduced pressure. The resultingresidue was purified by silica-gel column chromatography eluting with1:3 ethyl acetate/petroleum ether to afford 238a (12.4 g, 83%) as ayellow solid. MS: [M+H]⁺ 311.3.

Example 238b Methyl3-((1,1-Dimethylethylsulfinamido)methyl)-5,6,7,8-tetrahydroindolizine-2-carboxylate238b

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 238a (4.0 g, 12.8 mmol, 1.0 eq.), NaBH₄ (2.9 g,76.9 mmol, 6.0 eq.), and methanol (100 mL). The reaction mixture wasstirred at room temperature for 1 h. After this time water (50 mL) wasadded to the reaction and the resulting mixture was concentrated underreduced pressure. The residue was extracted with dichloromethane (3×50mL). The combined organic layer was evaporated under reduced pressure toafford 238b (3.9 g, 96%), which was directly used in next step withoutfurther purification. MS: [M-C₄H₁₀NOS]⁺ 192.3.

Example 238c Methyl3-(Aminomethyl)-5,6,7,8-tetrahydroindolizine-2-carboxylate 238c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 238b (3.5 g, 11.2 mmol), saturated HCl/diethylether solution (15 mL), and dichloromethane (15 mL). The mixture wasstirred at room temperature for 4 h. After the reaction was completed,saturated aqueous NaHCO₃ solution (50 mL) was added to the reactionmixture and the mixture was extracted with dichloromethane (3×50 mL).The combined organic layer was evaporated under reduced pressure toafford 238c (2.2 g, 94%), which was directly used in the next stepwithout further purification. MS: [M-NH₂]⁺ 192.1. ¹H NMR (500 MHz, MeOD)δ 6.28 (s, 1H), 4.38 (s, 2H), 4.03 (t, J=6.5 Hz, 2H), 3.84 (s, 3H), 2.78(t, J=6.5 Hz, 2H), 2.06-2.02 (m, 2H), 1.87-1.82 (m, 2H).

Example 238d 2,3,5,6,7,8-Hexahydropyrrolo[3,4-b]indolizin-1-one 238d

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 238c (1.3 g, 6.25 mmol, 1.0 eq.) and THF (20mL). At −78° C., to the solution was added lithiumhexamethyldisilazane/THF (18.7 mL, 18.7 mmol, 3.0 eq.). It was thenstirred at room temperature for 2 hrs. After the reaction was completed,saturated aqueous NH₄Cl solution (30 mL) was added and the mixture wasconcentrated under reduced pressure. The residue was extracted withdichloromethane (3×50 mL) and the combined organic layer was evaporatedunder reduced pressure. The resulting residue was purified by silica-gelcolumn chromatography eluting with 60:1 dichloromethane/methanol toafford 238d (585 mg, 53%) as a yellow solid. MS: [M+H]⁺ 177.3. ¹H NMR(500 MHz, DMSO-d₆) δ 7.38 (s, 1H), 5.82 (s, 1H), 4.13 (s, 2H), 3.86 (t,J=6.5 Hz, 2H), 2.73 (t, J=6.5 Hz, 2H), 191-1.88 (m, 2H), 1.75-1.73 (m,2H).

Example 238e4-Chloro-2-(1-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[3,4-b]indolizin-2(3H)-yl)nicotinaldehyde238e

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 238d (400 mg, 2.27mmol), 2-bromo-4-chloronicotinaldehyde (1.50 g, 6.90 mmol, 3.0 eq.),Pd₂(dba)₃ (208 mg, 0.227 mmol, 0.1 eq.), xantphos (131 mg, 0.227 mmol,0.1 eq.), Cs₂CO₃ (1.50 g, 4.54 mmol, 2.0 eq.), and dioxane (30 mL).After bubbling nitrogen through the resulting mixture for 30 minutes,the reaction mixture was stirred at 90° C. for 16 h. After the reactionwas complete, the mixture was cooled to room temperature and filtered.The filtrate was concentrated under reduced pressure and the residualwas purified by silica-gel column chromatography eluting with 1:3 ethylacetate/petroleum ether to afford 238e (300 mg, 42%) as a light yellowsolid. MS-ESI: [M+H]⁺ 316.1.

Example 238fS)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl-amino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[3,4-b]indolizin-2(3H)-yl)nicotinaldehyde238f

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 238e (150 mg, 0.48 mmol,1.0 eq.),(S)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one191j (459 mg, 0.95 mmol, 2.0 eq.), Pd(dppf)Cl₂ (39 mg, 0.048 mmol, 0.1eq.), sodium acetate (78 mg, 0.95 mmol, 2.0 eq.), K₃PO₄ (202 mg, 0.95mmol, 2.0 eq.), acetonitrile (10 mL), and water (1 mL). After threecycles of vacuum/argon flush, the mixture was heated at 85° C. for 2 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 40:1dichloromethane/ethanol to afford 238f (90 mg, 30%) as a yellow solid.MS-ESI: [M+H]⁺ 635.3.

Example 2382-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-5,6,7,8-tetrahydro-1H-pyrrolo[3,4-b]indolizin-3-one238

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 238f (90 mg, 1.0 eq., 0.14 mmol), NaBH₄ (23 mg,5 eq., 0.60 mmol), and methanol (5 mL). The resulting mixture wasstirred at room temperature for 20 minutes and quenched with water. Itwas then concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 238 (60 mg, 66%) as awhite solid. MS-ESI: [M+H]⁺ 637.3. ¹H NMR (500 MHz, CDCl₃) δ 8.69 (d,J=1.5 Hz, 1H), 8.47 (d, J=5.0 Hz, 1H), 7.99 (d, J=2.5 Hz, 1H), 7.93 (d,J=2.0 Hz, 1H), 7.86 (s, 1H), 7.36-7.31 (m, 2H), 6.83 (d, J=9.0 Hz, 1H),6.15 (s, 1H), 5.71 (t, J=6.5 Hz, 1H), 4.96 (s, 2H), 4.72-4.63 (m, 4H),4.52-4.51 (m, 2H), 3.97-3.95 (m, 2H), 3.75 (s, 3H), 3.55-3.53 (m, 1H),3.48-3.46 (m, 1H), 3.10-3.08 (m, 2H), 2.91-2.89 (m, 2H), 2.58-2.56 (m,1H), 2.49-2.48 (m, 2H), 2.23-2.19 (m, 1H), 2.08-2.02 (m, 2H), 1.93-1.89(m, 2H), 1.00 (d, J=6.0 Hz, 3H).

Example 239a tert-Butyl3-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridine-3-yl)azetidine-1-carboxylate239a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (50 mL),tert-butyl 3-(6-aminopyridin-3-yl)azetidine-1-carboxylate (1.8 g, 7.2mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (1.9 g, 7.2 mmol), andcesium carbonate (4.7 g, 14.4 mmol). After bubbling nitrogen through theresulting suspension for 30 minutes, XantPhos (418 mg, 0.72 mmol) andtris(dibenzylideneacetone)dipalladium(0) (661 mg, 0.72 mmol) were added.The reaction mixture was subjected to three cycles of vacuum/argon flushand heated at 105° C. for 0.5 h. After this time the reaction was cooledto room temperature and filtered. The filtrate was partitioned betweenethyl acetate (120 mL) and water (60 mL). The aqueous layer wasseparated and extracted with ethyl acetate (3×80 mL). The combinedorganic layer was washed with brine (30 mL) and dried over sodiumsulfate. The drying agent was removed by filtration and the filtrate wasconcentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 1:4 ethylacetate/petroleum ether to afford the 239a as a yellow solid (3.06 g,98%). MS-ESI: [M+H]⁺ 435.

Example 239b3-(5-(Azetidin-3-yl)pyridin-2-ylamino)-5-bromo-1-methylpyridin-2(1H)-one239b

Compound 239a (1.0 g, 2.3 mmol) was suspended in 4M HCl/dioxane (10 mL).The reaction mixture was stirred at room temperature for 4 h. It wasthen concentrated under reduced pressure. The residue was basified withaqueous NaOH and the resulting mixture was extracted withdichloromethane. The combined organic layer was washed with brine andconcentrated under reduced pressure to afford 239b as a yellow solid(650 mg, 84%). MS-ESI: [M+H]⁺ 335.

Example 239c5-Bromo-1-methyl-3-(5-(1-methylazetidin-3-yl)pyridin-2-ylamino)pyridine-2(1H)-one239c

A mixture of 239b (469 mg, 1.4 mmol), 37% aqueous formaldehyde (4.0 g,50 mmol), NaBH₃CN (261 mg, 4.2 mmol), and 1M zinc chloride inethoxyethane (4 mL, 4.2 mmol) in methanol (40 mL) was stirred at roomtemperature for 2 hours. The mixture was added to water (20 mL) andconcentrated under reduced pressure. The residue was extracted withdichloromethane (3×50 mL). The combined organic layer was concentratedunder reduced pressure and the residue was purified by silica-gel columnchromatography eluting with 10:1 methylene chloride/methanol to afford239c as a yellow solid (300 mg, 83%). MS-ESI: [M+H]⁺ 349.

Example 239d(4-(1-Methyl-5-(4-(1-methylazetidin-3-yl)phenylamino)-6-oxo-1,6-dihydro-pyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 239d

A 50-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 239c (106 mg, 0.30 mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexa-hydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (115 mg, 0.30 mmol), Pd(dppf)Cl₂ (25 mg, 0.030 mmol), K₃PO₄(127 mg, 0.60 mmol), sodium acetate (49 mg, 0.60 mmol), water (1 mL) andacetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated under reflux for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 15:1 dichloromethane/methanol to afford 239das white solid (100 mg, 49%). MS-ESI: [M+H]⁺ 607.3

Example 2392-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methylazetidin-3-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one239

To a solution of 239d (100 mg, 0.16 mmol) in propan-2-ol (2 mL),tetrahydrofuran (2 mL), and water (1 mL) was added lithium hydroxide (38mg, 1.60 mmol). The mixture was stirred at 30° C. for 2 h. It was thenevaporated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 239 (22.5 mg, 26%) as a white solid.MS-ESI: [M+H]⁺ 566.4. ¹H NMR (500 MHz, CDCl₃) δ 8.75 (d, J=1.5 Hz, 1H),8.52 (d, J=5.0 Hz, 1H), 8.17 (d, J=2.0 Hz, 1H), 7.91-7.89 (m, 2H), 7.59(d, J=8.5 Hz, 1H), 7.38 (d, J=5.0 Hz, 1H), 6.91 (s, 1H), 6.84 (d, J=8.5Hz, 1H), 5.09-5.06 (m, 1H), 4.66-4.64 (m, 1H), 4.54-4.50 (m, 1H),4.36-4.33 (m, 1H), 4.18-4.11 (m, 2H), 3.92-3.88 (m, 1H), 3.75-3.72 (m,overlap, 5H), 3.63-3.58 (m, 1H), 3.16-3.14 (m, 2H), 2.64-2.58 (m, 4H),2.40 (s, 3H), 1.93-1.90 (m, 2H), 1.84-1.79 (m, 2H).

Example 240a(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(1-methyl-5-{[5-(1-methylazetidin-3-yl)pyridin-2-yl]amino}-6-oxopyridin-3-yl)pyridin-3-yl)methylAcetate 240

A 50-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with5-bromo-1-methyl-3-(5-(1-methylazetidin-3-yl)pyridin-2-ylamino)-pyridin-2(1H)-one239c (106 mg, 0.30 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (119 mg, 0.30 mmol), Pd(dppf)Cl₂ (25 mg, 0.031 mmol), K₃PO₄(127 mg, 0.60 mmol), sodium acetate (49 mg, 0.60 mmol), water (0.5 mL),and acetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at reflux for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 15:1 dichloromethane/methanol to afford 240aas white solid (80 mg, 48%). MS-ESI: [M+H]⁺ 622.7

Example 2403-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methylazetidin-3-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one240

To a solution of 240a (80 mg, 0.130 mmol) in propan-2-ol (2 mL),tetrahydrofuran (2 mL), and water (1 mL) was added lithium hydroxide (38mg, 1.60 mmol). The mixture was stirred at 30° C. for 1 h. The reactionwas evaporated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 240 24.3 mg, 33%) as a white solid.MS-ESI: [M+H]⁺ 580.4. ¹H NMR (500 MHz, CDCl₃) δ 8.76 (d, J=2.0 Hz, 1H),8.52 (d, J=5.0 Hz, 1H), 8.17 (d, J=2.0 Hz, 1H), 7.92-7.90 (m, 2H), 7.59(dd, J=1.5, 8.5 Hz, 1H), 7.38 (d, J=5.0 Hz, 1H), 6.87 (s, 1H), 6.84 (d,J=8.5 Hz, 1H), 5.09-5.06 (m, 1H), 4.68-4.66 (m, 1H), 4.56-4.54 (m, 1H),4.37-4.35 (m, 1H), 4.19-4.17 (m, 2H), 3.90-3.88 (m, 1H), 3.75-3.72 (m,overlap, 5H), 3.64-3.62 (m, 1H), 3.19-3.16 (m, 2H), 2.60 (d, J=5.0 Hz,2H), 2.54 (s, 2H), 2.42 (s, 3H), 1.30 (s, 6H).

Example 241a2-{10-Fluoro-1-oxo-1H,2H,3H,4H,6H,7H,8H,9H-pyrido[3,4-b]indolizin-2-yl}-4-[1-methyl-5-({5-methyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridine-3-carbaldehyde241a

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde134c (59.6 mg, 0.17 mmol),1-methyl-3-({5-methyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-5-(tetramethyl-1,3,2-dioxa-borolan-2-yl)-1,2-dihydropyridin-2-one135a (261.8 mg, 0.68 mmol), Pd(dppf)Cl₂ (25.0 mg, 0.030 mmol), Na₂CO₃(54.1 mg, 0.51 mmol), DMF (6 mL), and water (0.75 mL). After threecycles of vacuum/argon flush, the mixture was heated at 70° C. for 1 h.It was then filtered and the filtrate was evaporated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 50:1 dichloromethane/methanol to afford 241a (100 mg,purity: 54%, yield: 56%) as a yellow solid. MS-ESI: [M+H]⁺ 571.3

Example 24110-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one241

To the solution of 241a (54.0 mg, 0.095 mmol) in methanol (5 mL) wasadded sodium borohydride (28.9 mg, 0.76 mmol) at 0° C. The reaction wasstirred at 0-25° C. for 1.5 h. It was then quenched with water (5 mL).The mixture was evaporated under reduced pressure and the residue wasextracted with dichloromethane (3×30 mL). The combined dichloromethaneextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 241 (8.0 mg, 15%) as awhite solid. MS-ESI: [M+H]⁺ 573.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.47 (d,J=5.0 Hz, 1H), 8.21 (s, 1H), 8.06 (d, J=2.0 Hz, 1H), 7.40 (d, J=2.0 Hz,1H), 7.31 (d, J=5.0 Hz, 1H), 5.88 (s, 1H), 4.87-4.85 (m, 1H), 4.44-4.35(m, 2H), 4.13-4.08 (m, 1H), 3.92-3.89 (m, 3H), 3.79-3.76 (m, 2H), 3.58(s, 3H), 3.49 (s, 2H), 2.99-2.94 (m, 2H), 2.79-2.77 (m, 2H), 2.66-2.64(m, 2H), 2.35 (s, 3H), 1.90-1.78 (m, 2H), 1.75-1.73 (m, 2H).

Example 242a3-(1,5-Dimethyl-1H-pyrazol-3-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one242a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-bromo-3-(1,5-dimethyl-1H-pyrazol-3-ylamino)-1-methylpyridin-2(1H)-one218a (800 mg, 2.69 mmol, 1.0 eq.),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.70 g,6.73 mmol, 2.5 eq.), Pd₂(dba)₃ (123 mg, 0.13 mmol, 0.05 eq.), X-Phos(128 mg, 0.27 mmol, 0.1 eq.), potassium acetate (528 mg, 5.38 mmol, 2.0eq.), and dioxane (50 mL). After three cycles of vacuum/argon flush, themixture was heated at 70° C. for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 1:70 methanol/dichloromethane to afford 242a(740 mg, 79%) as a green solid. MS-ESI: [M+H]⁺ 345.3

Example 242b4-(5-(1,5-Dimethyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde242b

A-100 mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 242a (282 mg, 0.82 mmol,1.5 eq.),4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde139a (180 mg, 0.55 mmol, 1.0 eq.), Pd(dppf)Cl₂ (45 mg, 0.055 mmol, 0.1eq.), sodium acetate (90 mg, 1.25 mmol, 2.0 eq.), K₃PO₄ (232 mg, 1.25mmol, 2.0 eq.), acetonitrile (20 mL), and water (1 mL). After threecycles of vacuum/argon flush, the mixture was heated at 90° C. for 1 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 50:1dichloromethane/methanol to afford 242b (150 mg, 48%) as a yellow solid.MS-ESI: [M+H]⁺ 512.3.

Example 2422-[4-[5-[(1,5-dimethylpyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one242

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 242b (150 mg, 0.29 mmol, 1.0 eq.), NaBH₄ (55mg, 1.46 mmol, 5.0 eq.), and methanol (10 mL). The resulting mixture wasstirred at room temperature for 20 min. It was then filtered and thefiltrate was concentrated under reduced pressure. The residue waspurified by reverse-phase prep-HPLC to afford 242 (100 mg, 66%) as awhite solid. MS-ESI: [M+H]⁺ 514.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.47 (d,J=5.5 Hz, 1H), 8.04-8.03 (m, 2H), 7.42 (d, J=2.0 Hz, 1H), 7.30 (d, J=5.0Hz, 1H), 6.05 (s, 1H), 5.90 (s, 1H), 4.87-4.85 (m, 1H), 4.43-4.35 (m,2H), 4.18-4.12 (m, 1H), 3.98-3.93 (m, 1H), 3.84-3.78 (m, 2H), 3.59 (s,3H), 3.58 (s, 3H), 3.06-2.92 (m, 2H), 2.75-2.68 (m, 2H), 2.18 (s, 3H),1.94-1.92 (m, 2H), 1.79-1.73 (m, 2H).

Example 243a tert-Butyl 4-(Methylsulfonyloxy)piperidine-1-carboxylate243a

To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (14.0 g,70.0 mmol) at 0° C. in triethylamine (9.9 g, 98 mmol) anddichloromethane (100 mL) was added dropwise methanesulfonyl chloride(11.2 g, 98.0 mmol). The reaction was brought to ambient temperature andstirred for 1 h. Then the reaction mixture was quenched with water (50mL). The aqueous layer was separated and extracted with ethyl acetate(2×50 mL). The combined organic layer was washed with brine (50 mL), anddried over sodium sulfate. The drying agent was removed by filtrationand the filtrate was concentrated under reduced pressure to afford 243a,which was used in the next step without further purification (19.5 g,100%). MS-ESI: [M-t-Bu]⁺ 224.1

Example 243b tert-Butyl4-(4-Nitro-1H-imidazol-1-yl)piperidine-1-carboxylate 243b

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 243a (7.0 g, 25.1 mmol),DMF (120 mL), 4-nitro-1H-imidazole (2.80 g, 25.1 mmol), and K₂CO₃ (6.9g, 50.2 mmol). The mixture was heated at 120° C. for overnight. Afterthis time the reaction was cooled to room temperature and filtered. Thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 2:2:1 ethyl acetate/petroleumether/dichloromethane to afford 243b (2.4 g, 32.4%) as a yellow solid.MS-ESI: [M+H]⁺ 297.3

Example 243c tert-Butyl4-(4-Amino-1H-imidazol-1-yl)piperidine-1-carboxylate 243c

A 100-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 243b (2.3 g, 7.8 mmol), 10% palladium on carbon (10% wet,230 mg), and ethanol (40 mL). The mixture was evacuated, charged withhydrogen gas, and stirred at room temperature for 3 h. The hydrogen wasthen evacuated and nitrogen was charged into the flask. The catalyst wasremoved by filtration through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure to afford 243c (2.0 g, 95%). MS-ESI:[M+H]⁺ 267.2.

Example 243d tert-Butyl4-(4-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)-1H-imidazol-1-yl)piperidine-1-carboxylate243d

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 243c (2.3 g, 8.6 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (2.3 g, 8.6 mmol),tris-(dibenzylideneacetone)dipalladium(0) (789 mg, 0.86 mmol), XantPhos(994 mg, 1.72 mmol), Cs₂CO₃ (5.6 g, 17.2 mmol), and 1,4-dioxane (80 mL).After three cycles of vacuum/argon flush, the mixture was heated at 95°C. for 4 hrs. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting withdichloromethane/methanol (50:1 to 20:1) to afford 243d as yellow oilsolid (2.3 g, 59%). MS-ESI: [M+H]⁺ 452.3.

Example 243e5-Bromo-1-methyl-3-(1-(piperidin-4-yl)-1H-imidazol-4-ylamino)pyridin-2(1H)-one243e

A mixture of 243d (2.2 g, 4.88 mmol) and trifluoroacetic acid (20 mL)was stirred at room temperature for 1 h. It was then concentrated underreduced pressure to afford crude 243e (1.5 g, 88%), which was used inthe next step without further purification. MS-ESI: [M+H]⁺ 352.2

Example 243f5-Bromo-1-methyl-3-(1-(1-(oxetan-3-yl)piperidin-4-yl)-1H-imidazol-4-ylamino)pyridin-2(1H)-one243f

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 243e (2.2 g, 6.3 mmol),NaBH₃CN (995 mg, 15.8 mmol), oxetan-3-one (907 mg, 12.6 mmol), zincchloride (2.1 g, 15.8 mmol), and methanol (60 mL). The reaction mixturewas stirred at 50° C. for 5 hrs and concentrated under reduced pressure.To the residue was added water and the resulting mixture was extractedwith dichloromethane three times. The combined organic layer was thenconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 1%triethylamine in methanol. The fractions containing the desired productwere concentrated under reduced pressure. Dichloromethane was added tothe residue and the resulting suspension was filtered. The filtrate wasconcentrated under reduced pressure afford 243f as a yellow solid (800mg, 62%). MS-ESI: [M+H]⁺ 408.2

Example 243g(4-(1-Methyl-5-(1-(1-(oxetan-3-yl)piperidin-4-yl)-1H-imidazol-4-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 243g

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 243f (300 mg, 0.74mmol),3-(acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-4-ylboronicacid 113i (567 mg, 1.48 mmol), Pd(dppf)Cl₂ (60.5 mg, 0.074 mmol), K₃PO₄(314 mg, 1.48 mmol), sodium acetate (201 mg, 1.48 mmol), water (0.5 mL),and acetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 1:1 dichloromethane/methanol containing 0.5%triethylamine to afford 243g as yellow solid (100 mg, 20%). MS-ESI:[M+H]⁺ 667.4.

Example 2432-[3-(hydroxymethyl)-4-[1-methyl-5-[[1-[1-(oxetan-3-yl)-4-piperidyl]imidazol-4-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one243

A mixture of 243g (80 mg, 0.12 mmol) and lithium hydroxide (100 mg, 2.4mmol) in i-propanol/THF/water (2:2:1, 8 mL) was stirred at 35° C. for 30mins. The reaction mixture was then concentrated under reduced pressure.To the residue was added water and the resulting mixture was extractedwith dichloromethane three times. The combined organic layer wasconcentrated under reduced pressure and the resulting residue waspurified by reverse-phase prep-HPLC to afford 243 (28.0 mg, 30%).MS-ESI: [M+H]⁺ 625.4. ¹H NMR (500 MHz, DMSO-d₆) δ 8.48 (d, J=6.5 Hz,1H), 7.54 (d, J=1.5 Hz, 1H), 7.53 (s, 1H), 7.45 (d, J=3.0 Hz, 1H),7.35-7.34 (m, 2H), 7.11 (d, J=1.0 Hz, 1H), 6.58 (s, 1H), 5.14 (bs, 1H),4.54 (t, J=7.5 Hz, 2H), 4.43-4.40 (m, 4H), 4.23-4.11 (m, 3H), 3.99-3.96(m, 1H), 3.91-3.84 (m, 1H), 3.59 (s, 3H), 3.43-3.39 (m, 1H), 2.77-2.76(m, 2H), 2.62-2.57 (m, 2H), 2.47-2.46 (m, 2H), 1.94-1.89 (m, 6H),1.79-1.78 (m, 2H), 1.69-1.66 (m, 2H).

Example 244a2-(4-Chloro-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1(2H)-one244a

To a solution of4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde139a (1.0 g, 3.0 mmol) in methanol (30 mL) was added sodium borohydride(380 mg, 9.0 mmol) at 30° C. The reaction mixture was stirred foranother 1 h and quenched with water (10 mL). It was then concentratedunder reduced pressure and the residue was extracted withdichloromethane (3×20 mL). The combined organic extract was dried overanhydrous Na₂SO₄, filtered, and evaporated under reduced pressure toafford 244a as a yellow solid (920 mg, 92%). MS-ESI: [M+H]⁺ 332.3

Example 244b(4-Chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)pyridin-3-yl)methylacetate 244b

To a mixture of 244a (900 mg, 2.7 mmol) and triethylamine (810 mg, 8.1mmol) in dichloromethane (30 mL) was added acetyl chloride (630 mg, 8.1mmol) dropwise. The reaction mixture was stirred at 30° C. for 1 h. Itwas then concentrated under reduced pressure and the residue waspurified by silica-gel column chromatography eluting withdichloromethane to afford 244b as white solid (900 mg, 90%). MS-ESI:[M+H]⁺ 374.2

Example 244c3-(Acetoxymethyl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)pyridin-4-ylboronicAcid 244c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 244b (900 mg, 2.4 mmol),Pin₂B₂ (3.05 g, 12 mmol), Pd(dppf)Cl₂ (98 mg, 0.12 mmol), X-phos (114mg, 0.24 mmol), potassium acetate (720 mg, 7.2 mmol), and dioxane (20mL). After three cycles of vacuum/argon flush, the mixture was heated at65° C. for 4 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was washed with 5:1 petroleum ether/ethyl acetate (10 mL) toafford 244c as a yellow solid (1.0 g, purity: 60%). MS-ESI: [M+H]⁺384.1.

Example 244d(4-(1-Methyl-5-(5-(1-methylazetidin-3-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)pyridin-3-yl)methylAcetate 244d

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with5-bromo-1-methyl-3-(5-(1-methylazetidin-3-yl)pyridin-2-ylamino)pyridin-2(1H)-one239c (140 mg, 0.40 mmol), 244c (230 mg, 0.60 mmol), Pd(dppf)Cl₂ (20 mg,0.020 mmol), K₃PO₄ (180 mg, 0.80 mmol), sodium acetate·3 water (120 mg,0.80 mmol), water (0.5 mL), and acetonitrile (10 mL). After three cyclesof vacuum/argon flush, the mixture was heated at 100° C. for 2 h. It wasthen filtered and the filtrate was evaporated under reduced pressure.The residue was purified on silica-gel column chromatography elutingwith 25:1 dichloromethane/methanol to afford 244d as a yellow solid (90mg, 43%). MS-ESI: [M+H]⁺ 608.3

Example 2442-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methylazetidin-3-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one244

A mixture of 244d (90 mg, 0.15 mmol) and lithium hydroxide (60 mg, 1.5mmol) in THF/i-propanol (5:3, 8 mL) and water (2 mL) was stirred at 30°C. for 1 h. The mixture was evaporated in vacuo and the residue wasdiluted with water (3 mL). It was then extracted with ethyl acetate (20mL×2). The combined ethyl acetate extract was concentrated under reducedpressure and the residue was purified by reverse-phase prep-HPLC toafford 244 (25 mg, 30%) as white solid. MS-ESI: [M+H]⁺ 566.4. ¹H NMR(500 MHz, CDCl₃) δ 8.74 (d, J=2.5 Hz, 1H), 8.51 (d, J=5.5 Hz, 1H), 8.16(d, J=2.0 Hz, 1H), 7.91 (s, 1H), 7.87 (d, J=2.0 Hz, 1H), 7.59-7.57 (m,1H), 7.35 (d, J=5.0 Hz, 1H), 6.85-6.83 (m, 1H), 6.33 (s, 1H), 5.04-5.01(m, 1H), 4.67-4.65 (m, 1H), 4.44-4.39 (m, 1H), 4.33-4.29 (m, 1H),3.95-3.91 (m, 1H), 3.86-3.83 (m, 2H), 3.76-3.74 (m, 1H), 3.73 (s, 3H),3.62-3.59 (m, 1H), 3.16-3.13 (m, 2H), 3.02-2.95 (m, 2H), 2.84-2.83 (m,2H), 2.39 (s, 3H), 2.05-2.02 (m, 2H), 1.90-1.87 (m, 2H).

Example 245a4-Chloro-2-(1-oxo-6,7,8,9-tetrahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde245a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with6,7,8,9-tetrahydropyrido[3,4-b]indolizin-1(2H)-one 112d (1.48 g, 7.9mmol, 1.0 eq.), 2-bromo-4-chloronicotinaldehyde (3.48 g, 15.8 mmol, 2.0eq.), CuI (1.50 g, 7.9 mmol, 1.0 eq.), 4,7-dimethoxy-1,10-phenanthroline(2.13 g, 7.9 mmol, 1.0 eq.), K₂CO₃ (2.18 g, 15.8 mmol, 2.0 eq.) anddioxane (50 mL). The reaction mixture was stirred at 100° C. for 24 h.After the reaction was completed, the mixture was filtered and thefiltrate was concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 1:2 ethylacetate/petroleum ether to afford 245a (550 mg, 21%) as a slight yellowsolid. MS-ESI: [M+H]⁺ 328.1.

Example 245b4-Fluoro-2-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-6-(1-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[3,4-b]indolizin-2(3H)-yl)benzaldehyde245b

A 50-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 245a (140 mg, 0.42 mmol, 1.0 eq.),(S)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one191i (308 mg, 0.63 mmol, 1.5 eq.), Pd(dppf)Cl₂ (35 mg, 0.042 mmol, 0.1eq.), sodium acetate (70 mg, 0.84 mmol, 2.0 eq.), K₃PO₄ (175 mg, 0.84mmol, 2.0 eq.), acetonitrile (20 mL), and water (1 mL). After threecycles of vacuum/argon flush, the mixture was heated at 90° C. for 2 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 40:1dichloromethane/methanol to afford 245b (100 mg, 36%) as a yellow solid.MS-ESI: [M+H]⁺ 647.4.

Example 245(S)-2-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-6,7,8,9-tetrahydropyrido[3,4-b]indolizin-1(2H)-one245

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 245b (100 mg, 0.15 mmol, 1.0 eq.), NaBH₄ (29mg, 0.77 mmol, 5.0 eq.), and methanol (10 mL). The resulting mixture wasstirred at room temperature for 20 min. It was then filtered and thefiltrate was concentrated under reduced pressure. The residue waspurified by reverse-phase prep-HPLC to afford 245 (80 mg, 79%) as awhite solid. MS-ESI: [M+H]⁺ 649.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.69-8.68(m, 1H), 8.57 (d, J=5.0 Hz, 1H), 8.46 (s, 1H), 7.85 (d, J=3.0 Hz, 1H),7.55 (d, J=2.5 Hz, 1H), 7.52 (d, J=5.0 Hz, 1H), 7.39-7.36 (m, 1H),7.26-7.24 (m, 2H), 6.69 (d, J=7.5 Hz, 1H), 6.31 (s, 1H), 4.97 (bs, 1H),4.58-4.54 (m, 2H), 4.49-4.41 (m, 2H), 4.34-4.27 (m, 2H), 4.09-4.06 (m,2H), 3.69-3.68 (m, 1H), 3.61 (s, 3H), 3.41-3.39 (m, 1H), 3.12-3.19 (m,1H), 2.97-2.93 (m, 1H), 2.87 (t, J=6.0 Hz, 2H), 2.56-2.54 (m, 1H),2.37-2.30 (m, 2H), 2.21-2.16 (m, 1H), 2.03-1.98 (m, 2H), 1.85-1.82 (m,2H), 0.94 (d, J=5.5 Hz, 3H).

Example 246a4-(5-(1,5-Dimethyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-6,7,8,9-tetrahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde246a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-(1-oxo-6,7,8,9-tetrahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde245a (130 mg, 0.39 mmol, 1.0 eq.),3-(1,5-dimethyl-1H-pyrazol-3-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one218a (600 mg, 1.75 mmol, 4.0 eq.), Pd(dppf)Cl₂ (32 mg, 0.040 mmol, 0.1eq.), sodium acetate (64 mg, 0.78 mmol, 2.0 eq.), K₃PO₄ (165 mg, 0.78mmol, 2.0 eq.), acetonitrile (15 mL), and water (1 mL). After threecycles of vacuum/argon flush, the mixture was heated at 90° C. for 2 h.It was then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 50:1dichloromethane/ethanol to afford 246a (38 mg, 19%) as a yellow solid.MS-ESI: [M+H]⁺ 510.3.

Example 2462-[4-[5-[(1,5-dimethylpyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-6,7,8,9-tetrahydropyrido[3,4-b]indolizin-1-one246

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 246a (38 mg, 0.074 mmol, 1.0 eq.), NaBH₄ (29mg, 0.37 mmol, 5.0 eq.), and methanol (5 mL). The resulting mixture wasstirred at room temperature for 20 min. It was then filtered and thefiltrate was concentrated. The residue was purified by reverse-phaseprep-HPLC to afford the title compound (18 mg, 48%) as a white solid.MS-ESI: [M+H]⁺ 512.3. ¹H NMR (500 MHz, CDCl₃) δ 8.58 (d, J=5.0 Hz, 1H),7.98 (d, J=2.5 Hz, 1H), 7.78 (d, J=2.5 Hz, 1H), 7.52 (d, J=5.0 Hz, 1H),7.37 (s, 1H), 7.17 (d, J=7.0 Hz, 1H), 6.58-6.57 (m, 2H), 5.74 (s, 1H),5.41-5.39 (m, 1H), 4.42-4.32 (m, 2H), 4.08 (t, J=6.5 Hz, 2H), 3.72 (s,3H), 3.70 (s, 3H), 2.98 (t, J=6.5 Hz, 2H), 2.25 (s, 3H), 2.13-2.09 (m,2H), 1.97-1.92 (m, 2H).

Example 247a{4-[5-({5-Acetyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridin-3-yl}methylAcetate 247a

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with3-(5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-bromo-1-methylpyridin-2(1H)-one209c (183 mg, 0.50 mmol),{3-[(acetoxy)methyl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridin-4-yl}boronicacid 230i (200 mg, 0.50 mmol), Pd(dppf)Cl₂ (37 mg, 0.05 mmol), K₃PO₄(212 mg, 1.0 mmol), sodium acetate (82 mg, 1.0 mmol), water (0.5 mL),and acetonitrile (5 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 1 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (50:1 to 20:1) toafford 247a as yellow solid (100 mg, 31%). MS-ESI: [M+H]⁺ 641.2.

Example 2473-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one247

A mixture of{4-[5-({5-acetyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridin-3-yl}methylacetate 247a (100 mg, 0.16 mmol) and lithium hydroxide (96 mg, 4.0 mmol)in i-propanol/THF/water (2:2:1, 10 mL) was stirred at 35° C. for 30 min.The mixture was concentrated under reduced pressure. To the residue wasadded water (5 mL) and the resulting mixture was extracted withdichloromethane three times. The combined organic layer was thenconcentrated under reduced pressure and the resulting residue waspurified by reverse-phase prep-HPLC to afford 247 (51 mg, 53%). MS-ESI:[M+H]⁺ 599.3. ¹H NMR (500 MHz, DMSO-d₆, T=80° C.) δ 8.54-8.51 (m, 1H),8.38 (d, J=3.0 Hz, 1H), 7.93-7.91 (m, 2H), 7.48 (d, J=8.5 Hz, 1H), 7.35(d, J=3.0 Hz, 1H), 6.00 (s, 1H), 4.64-4.62 (m, 2H), 4.39 (s, 2H),3.98-3.95 (m, 2H), 3.89-3.86 (m, 2H), 3.58 (s, 3H), 2.95-2.93 (m, 2H),2.87-2.84 (m, 2H), 2.08 (s, 3H), 1.89-1.87 (m, 4H).

Example 248a (R)-(6-Aminopyridin-3-yl)(3-methylmorpholino)methanone 248a

To a solution of (R)-3-methylmorpholine (2.02 g, 20 mmol) in ethanol (25mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (3.33g, 17.4 mmol), hydroxybenzotriazole (HOBt) (2.35 g, 17.4 mmol), and6-aminonicotinic acid (2.0 g, 14.5 mmol). After stirring for 18 h atroom temperature, the reaction suspension was filtered and the filtratewas concentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 3:1 ethylacetate/petroleum ether to afford 248a as white solid (1.6 g, 36%).MS-ESI: [M+H]⁺ 222.3.

Example 248b6-Chloro-2-methyl-4-[(5-{[(3R)-3-methylmorpholin-4-yl]carbonyl}pyridin-2-yl)amino]-2,3-dihydropyridazin-3-one248b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (50 mL),248a (330 mg, 1.5 mmol), 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one(446 mg, 2.0 mmol), cesium carbonate (978 mg, 3.0 mmol), Xantphos (88mg, 0.15 mmol), and tris(dibenzylideneacetone)dipalladium(0) (68 mg,0.075 mmol). The system was subjected to three cycles of vacuum/argonflush and heated at reflux for 4 h. It was then cooled to roomtemperature and filtered. The solid was washed with dichloromethane(3×30 mL) and the combined filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with petroleum ether/ethyl acetate (2:1 to 1:2) to afford 248b(430 mg, 79%) as yellow solid. MS-ESI: [M+H]⁺ 364.3

Example 248c(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(5-{[(3R)-3-methylmorpholin-4-yl]carbonyl}pyridin-2-yl)amino]-6-oxo-1,6-dihydropyridazin-3-yl}pyridin-3-yl)methylAcetate 248c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 248b (364 mg, 1.0 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (596 mg, 1.5 mmol), K₃PO₄ (424 mg, 2.0 mmol),1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (73 mg, 0.10mmol), sodium acetate (164 mg, 2.0 mmol), acetonitrile (10 mL), andwater (0.5 mL). After three cycles of vacuum/argon flush, the reactionmixture was heated at 100° C. for 2.5 h. Analysis of the reactionmixture by LCMS showed complete conversion to the desired product. Thereaction mixture was cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure. The residue wasdiluted with dichloromethane (50 mL) and water (50 mL). The aqueouslayer was separated and extracted with dichloromethane (3×20 mL). Thecombined organic layer was dried over Na₂SO₄ and filtered. The filtratewas concentrated under reduced pressure and the dark residue waspurified by silica-gel column chromatography eluting withdichloromethane/methanol (80:1 to 50:1) to afford 248c (250 mg, 37%) asyellow oil. MS-ESI: [M+H]⁺ 681.3

Example 2483-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(3R)-3-methylmorpholine-4-carbonyl]-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one248

To a solution of 248c (250 mg, 0.37 mmol) in THF/i-propanol/water(2.5/2/0.5 mL) was added lithium hydroxide (86 mg, 3.6 mmol) at roomtemperature. After the reaction was stirred for 3 h, LCMS indicated thereaction was complete. Then the mixture was poured into water (20 mL)and extracted with dichloromethane (3×20 mL). The combined organic layerwas washed with brine (30 mL), dried over Na₂SO₄, filtered. The filtratewas concentrated under reduced pressure. The residue solid was purifiedby reverse-phase prep-HPLC to afford 248 (110 mg, 48%) as a white solid.MS-ESI: [M+H]⁺ 639.3. ¹H NMR (500 MHz, MeOD) δ 8.85 (s, 1H), 8.58 (d,J=5.0 Hz, 1H), 8.44 (d, J=2.0 Hz, 1H), 7.79 (dd, J=2.5, 8.5 Hz, 1H),7.57 (d, J=5.0 Hz, 1H), 7.32 (d, J=8.5 Hz, 1H), 6.74 (s, 1H), 4.85-4.83(m, 1H), 4.66-4.64 (m, 1H), 4.42-4.27 (m, 4H), 4.02-3.88 (m, over lap,6H), 3.74-3.67 (m, 2H), 3.56-3.46 (m, 2H), 2.67-2.59 (m, 2H), 2.51 (s,2H), 1.39 (d, J=6.5 Hz, 3H), 1.28 (s, 6H).

Example 249a(R)-5-Bromo-1-methyl-3-(5-(3-methylmorpholine-4-carbonyl)pyridin-2-ylamino)pyridin-2(1H)-one249a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (15 mL),(R)-(6-aminopyridin-3-yl) (3-methylmorpholino)methanone 248a (332 mg,1.5 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (480 mg, 1.8 mmol), andcesium carbonate (978 mg, 3.0 mmol). After bubbling nitrogen through thesuspension for 3 minutes, Xantphos (87 mg, 0.15 mmol) andtris(dibenzylideneacetone)dipalladium(0) (69 mg, 0.075 mmol) were added.The system was subjected to three cycles of vacuum/argon flush andheated at reflux for 2.5 h. It was then cooled to room temperature andfiltered. The solid was washed with dichloromethane (2×50 mL) and thecombined filtrate was concentrated under reduced pressure. The residuewas purified by silica-gel column chromatography eluting with petroleumether/ethyl acetate (2:1 to 1:2) to afford 249a (430 mg, 70%) as ayellow solid. MS-ESI: [M+H]⁺ 407.3

Example 249b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(5-{[(3R)-3-methylmorpholin-4-yl]carbonyl}pyridin-2-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 249b

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 249a (407 mg, 1.0 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (800 mg, 2.0 mmol), K₃PO₄ (424 mg, 2.0 mmol),1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (73 mg, 0.1mmol), sodium acetate (164 mg, 2.0 mmol), acetonitrile (8 mL), and water(0.2 mL). After three cycles of vacuum/argon flush, the mixture washeated at 100° C. for 1.5 h. Analysis of the reaction mixture by LCMSshowed complete conversion to the desired product. The reaction mixturewas cooled to room temperature and concentrated under reduced pressure.The residue was diluted with dichloromethane (20 mL) and water (20 mL).The aqueous layer was separated and extracted with dichloromethane (20mL×3). The combined organic layer was dried over Na₂SO₄ and filtered.The filtrate was concentrated under reduced pressure. The dark residuewas purified by silica-gel column chromatography eluting with 60:1dichloromethane/methanol to afford 249b (200 mg, 29%) as yellow solid.MS-ESI: [M+H]⁺ 680.1

Example 2493-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(3R)-3-methylmorpholine-4-carbonyl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one249

To a solution of 249b (204 mg, 0.30 mmol) in THF/i-propanol/water(3/3/0.5 mL) was added lithium hydroxide (72 mg, 3 mmol) at roomtemperature. After the reaction was stirred for 3 h, LCMS indicated thereaction was complete. The mixture was concentrated under reducedpressure and the residue was diluted with water (10 mL). It was thenextracted with dichloromethane (3×10 mL). The combined organic layer waswashed with brine (30 mL), dried over Na₂SO₄ and filtered. The filtratewas concentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC (A: 1% NH₄HCO₃ in water, B: acetonitrile) toafford 249 (85 mg, 44%) as a white solid. MS-ESI: [M+H]⁺ 638.3. ¹H NMR(500 MHz, MeOD) δ 8.93 (d, J=2.0 Hz, 1H), 8.52 (d, J=5.0 Hz, 1H), 8.33(d, J=2.0 Hz, 1H), 7.69 (dd, J=2.0, 6.5 Hz, 1H), 7.61 (d, J=2.0 Hz, 1H),7.48 (d, J=5.0 Hz, 1H), 7.13 (d, J=8.5 Hz, 1H), 6.74 (s, 1H), 4.70 (d,J=12.0 Hz, 1H), 4.58 (d, J=12.0 Hz, 1H), 4.40-4.27 (m, 4H), 3.99-3.89(m, 3H), 3.74 (S, 3H), 3.55-3.46 (m, overlap, 4H), 2.67-2.59 (m, 2H),2.51 (s, 2H), 1.39 (d, J=6.5 Hz, 3H), 1.28 (s, 6H).

Example 250a 1-(5-(Hydroxymethyl)-3-nitro-1H-pyrazol-1-yl)propan-2-ol250a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with (3-nitro-1H-pyrazol-5-yl)methanol (0.57 g, 4.0mmol), Cs₂CO₃ (261 mg, 0.8 mmol), and 2-methyloxirane (20 mL). Themixture was stirred at 30° C. for 2 days. The mixture was cooled to roomtemperature and diluted with dichloromethane (100 mL). The resultingmixture was filtered and the filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 30:1 dichloromethane/methanol to afford 250a (0.40 g, 50%)as a white solid. MS-ESI: [M+H]⁺0 202.3

Example 250b 1-(5-(Bromomethyl)-3-nitro-1H-pyrazol-1-yl)propan-2-ol 250b

To a mixture of 250a (4.0 g, 20.0 mmol) in chloroform (100 mL) cooled at0° C. was added the solution of POBr₃ (22.9 g, 80 mmol) in chloroform(20 mL) over 30 minutes while maintaining the internal temperature below5° C. The reaction mixture was warmed to 50° C. and stirred at thistemperature for 3 h. It was then cooled to 0° C. and quenched withwater. The organic layer was separated and evaporated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 30:1 dichloromethane/methanol to afford 250b (3.3 g, 62%)as yellow solid. MS-ESI: [M+H]⁺ 264.1

Example 250c1-(5-((Methylamino)methyl)-3-nitro-1H-pyrazol-1-yl)propan-2-ol 250c

To a solution of 250b (3.0 g, 11.4 mmol) in dichloromethane (30 mL) wasadded the solution of CH₃NH₂ (3.0 g, 34.2 mmol, 35% in water). Thisreaction mixture was stirred at room temperature for 1 h. Then theorganic layer was separated, dried over Na₂SO₄, and filtered. Thefiltrate was concentrated under reduced pressure to afford 250c (1.9 g,78%) as yellow solid. MS-ESI: [M+H]⁺ 215.3

Example 250d5,6-Dimethyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 250d

To a mixture of 250c (1.129 g, 5.27 mmol) and triphenylphosphine (4.14g, 15.8 mmol) in anhydrous THF (40 mL) cooled at 0° C. was added thesolution of di-isopropyl azodicarboxylate (DIAD) (3.19 g, 15.8 mmol) inTHF (15 mL) over a period of 30 minutes while maintaining the internaltemperature below 5° C. The reaction mixture was warmed to 30° C. andstirred at this temperature for 5 h. The mixture was then quenched withwater (50 mL) and concentrated under reduced pressure. The residue wasextracted with dichloromethane (3×80 mL). The combined organic layer wasdried over Na₂SO₄ and filtered. The filtrate was concentrated underreduced pressure. The residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (80:1 to 30:1) toafford 250d (0.83 g, 80%) as yellow solid. MS-ESI: [M+H]⁺ 197.2

Example 250e5,6-Dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine 250e

A solution of 250d (550 mg, 2.8 mmol) in methanol (20 mL) was addedRaney Ni (about 600 mg). The reaction was charged with hydrogen gas (viaballoon) and stirred for 2 h at room temperature. It was then filteredthrough a plug of CELITE® and the filtrate was concentrated underreduced pressure to afford 250e as a yellow solid (400 mg, 86%), whichwas used directly in the next step without further purification. MS-ESI:[M+H]⁺ 167.3

Example 250f(4-(5-(5,6-Dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 250f

A 50-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with(4-(5-bromo-1-methyl-6-oxo-1,6-di-hydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 217a (525 mg, 1.0 mmol), 250e (166 mg, 1.0 mmol), cesiumcarbonate (652 mg, 2.0 mmol), and 1,4-dioxane (10 mL). After bubblingnitrogen through the suspension for 30 minutes, xantphos (116 mg, 0.20mmol) and tris(dibenzylideneacetone)dipalladium(0) (92 mg, 0.10 mmol)were added. The system was subjected to three cycles of vacuum/argonflush and heated at reflux for 5 h. It was then cooled to roomtemperature and filtered. The solid was washed with dichloromethane(2×30 mL) and the combined filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with dichloromethane/methanol (80:1 to 30:1) to afford 250f (80mg, 13%) as yellow solid. MS-ESI: [M+H]⁺ 611.4

Example 2502-[4-[5-[(5,6-dimethyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one250

To a solution of 250f (75 mg, 0.123 mmol) in THF/i-propanol/water (4/2/2mL) was added lithium hydroxide (15 mg, 0.62 mmol). The mixture wasstirred at 30° C. for 1 h. After the reaction was complete, the mixturewas evaporated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 250 as a white solid (40 mg, 57%).MS-ESI: [M+H]⁺ 569.3. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, J=5.0 Hz, 1H),7.96 (bs, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.43 (s, 1H), 7.36 (d, J=5.0 Hz,1H), 6.91 (s, 1H), 5.71 (s, 1H), 5.03 (t, J=3.5 Hz, 1H), 4.65-4.62 (m,1H), 4.52-4.50 (m, 1H), 4.35-4.33 (m, 1H), 4.17-4.05 (m, 3H), 3.91-3.88(m, 2H), 3.73-3.71 (m, 1H), 3.71 (s, 3H), 3.55-3.52 (m, 1H), 2.90-2.87(m, 1H), 2.64-2.58 (m, 4H), 2.43 (s, 3H), 1.93-1.90 (m, 2H), 1.81-1.80(m, 2H), 1.24 (d, J=6.5 Hz, 3H).

Example 252a5-Bromo-3-(1-ethyl-5-methyl-1H-pyrazol-3-ylamino)-1-methylpyridin-2(1H)-one252a

A 100-mL round-bottomed flask was charged with5-bromo-1-methyl-3-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2(1H)-one 115a(800 mg, 2.83 mmol), bromoethane (216 mg, 1.98 mmol), K₂CO₃ (780 mg,5.66 mmol), and DMF (20 mL). The mixture was heated at 85° C. overnight.It was then filtered and the filtrate was evaporated in vacuo. Theresidue was purified by silica-gel column chromatography eluting with1:20 methanol/dichloromethane to afford 252a as a red solid (298 mg,37%). MS-ESI: [M+H]⁺ 311.0. ¹H NMR (500 MHz, DMSO-d₆) δ 8.28 (s, 1H),7.99 (d, J=2.5 Hz, 1H), 7.35 (d, J=2.5 Hz, 1H), 5.85 (s, 1H), 3.98-3.94(m, 2H), 3.48 (s, 3H), 2.19 (s, 3H), 1.27 (t, J=7.0 Hz, 3H).

Example 252b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{5-[(1-ethyl-5-methyl-1H-pyrazol-3-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 252b

A round-bottomed flask equipped with a reflux condenser was charged with252a (200 mg, 0.64 mmol),(3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)pyridin-4-yl)boronicacid 199e (309 mg, 0.64 mmol), PdCl₂(dppf) (52.5 mg, 0.060 mmol), K₃PO₄(333 mg, 1.29 mmol), sodium acetate (105 mg, 1.29 mmol), acetonitrile(10 mL), and water (0.5 mL). After three cycles of vacuum/argon flush,the mixture was heated at 100° C. for 3 h. It was then filtered and thefiltrate was evaporated in vacuo. The residue was purified by silica-gelcolumn chromatography eluting with 1:20 methanol/dichloromethane toafford 252b as a yellow solid (120 mg, 27.6%). MS-ESI: [M+H]⁺ 584.3

Example 2523-[4-[5-[(1-ethyl-5-methyl-pyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one252

A mixture of 252b (120 mg, 0.21 mmol) and lithium hydroxide (23 mg, 0.82mmol) in THF (6 mL), i-propanol (4 mL), and water (2 mL) was stirred atroom temperature for 0.5 h. It was then concentrated under reducedpressure and the residue was diluted with water (5 mL). The resultingmixture was extracted with dichloromethane (2×10 mL). The combineddichloromethane extract was concentrated under reduced pressure. Theresidue was purified with reverse-phase prep-HPLC to afford 252 (52 mg,47%) as a white solid. MS-ESI: [M+H]⁺ 542.3. ¹H NMR (500 MHz, DMSO-d₆) δ9.06 (d, J=5.5 Hz, 1H), 8.09 (s, 1H), 8.07 (s, 1H), 7.41 (s, 1H), 7.33(d, J=5.0 Hz, 1H), 6.56 (s, 1H), 5.88 (s, 1H), 4.97 (t, J=4.5 Hz, 1H),4.50-4.41 (m, 2H), 4.24-4.19 (m, 3H), 3.93-3.85 (m, 3H), 3.59 (s, 3H),2.62-2.57 (m, 2H), 2.43 (s, 2H), 2.19 (s, 3H), 1.27-1.23 (m, overlap,9H).

Example 253a4-Bromo-6-chloro-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one253a

A 500-mL single-neck round-bottomed flask equipped with a magneticstirrer was purged with nitrogen and charged with anhydrous DMF (150 mL)and 4-bromo-6-chloro-pyridazin-3(2H)-one (10.0 g, 47.8 mmol). Thereaction mixture was cooled to 0° C. and sodium hydride was added. Thereaction was stirred at 0° C. for 20 min. After this time,2-(trimethylsilyl)ethoxymethyl chloride (11.9 g, 71.6 mmol) was addedand the cooling bath was removed, and the reaction was stirred at roomtemperature for 3 h. The reaction was then quenched with saturatedaqueous sodium bicarbonate (30 mL). The mixture was extracted with ethylacetate (2×300 mL). The extracts were dried over sodium sulfate,filtered and concentrated under reduced pressure. The resulting residuewas purified by flash chromatography to afford 253a in a 56% yield (9.00g) as a yellow oil: ¹H NMR (300 MHz, CDCl₃) δ 8.02 (s, 1H), 5.42 (s,2H), 3.79 (t, 2H, J=5.4 Hz), 0.96 (t, 2H, J=5.4 Hz), 0.01 (s, 9H).

Example 253b (S)-tert-Butyl4-(6-(6-Chloro-3-oxo-2-((2-(trimethylsilyl)ethoxy)-methyl)-2,3-dihydropyridazin-4-ylamino)pyridin-3-yl)-3-methylpiperazine-1-carboxylate253b

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with (S)-tert-butyl4-(6-aminopyridin-3-yl)-3-methylpiperazine-1-carboxylate 191f (580 mg,2.0 mmol), 253a (1.36 g, 4.0 mmol), Pd₂(dba)₃ (180 mg, 0.20 mmol),Xantphos (230 mg, 0.40 mmol), Cs₂CO₃ (1.3 g, 4.0 mmol), and dioxane (20mL). After three cycles of vacuum/argon flush, the mixture was heated at100° C. for 2 h. It was then cooled to room temperature and filtered.The filtrate was evaporated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with4:1 petroleum ether/ethyl acetate to afford 253b (1.0 g, 91%) as yellowsolid. MS-ESI: [M+H]⁺ 551.2

Example 253c(S)-6-Chloro-4-(5-(2-methylpiperazin-1-yl)pyridin-2-ylamino)pyridazin-3(2H)-one253c

A 50-mL round-bottomed flask was charged with 253b (551 mg, 1.0 mmol),concentrated HCl (2 mL), and methanol (10 mL). The mixture was stirredat room temperature overnight. It was then concentrated under reducedpressure to afford 253c, which was used directly in the next stepwithout further purification. MS-ESI: [M+H]⁺ 321.1

Example 253d(S)-6-Chloro-4-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)pyridazin-3(2H)-one253d

A 50-mL round-bottomed flask equipped with a magnetic stirrer wascharged with 253c (321 mg, 1.0 mmol), 3-oxetanone (142 mg, 2.0 mmol),NaBH₃CN (125 mg, 2.0 mmol), ZnCl₂ (272 mg, 2.0 mmol), and methanol (10mL). The mixture was stirred at room temperature overnight andconcentrated under reduced pressure. Water (20 mL) was added to theresidue and the resulting mixture was extracted with dichloromethane(3×20 mL). The combined organic layer was concentrated under reducedpressure and the residue was purified by silica-gel columnchromatography eluting with ethyl acetate to afford 253d (210 mg, 56%)as yellow solid. MS-ESI: [M+H]⁺ 377.3.

Example 253e(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridazin-3-yl]pyridin-3-yl)methylAcetate 253e

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 253d (172 mg, 0.46mmol),(3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)pyridin-4-yl)boronicacid 199e (0.91 g, 2.29 mmol), Pd(dppf)Cl₂ (36 mg, 0.050 mmol), K₃PO₄(195 mg, 0.92 mmol), sodium acetate (75 mg, 0.050 mmol), water (0.5 mL),and acetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was evaporated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 20:1 ethyl acetate/methanol to afford the253e (100 mg, 31%) as brown solid. MS-ESI: [M+H]⁺ 694.3.

Example 2533-[3-(hydroxymethyl)-4-[5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-1H-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one253

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 253e (92 mg, 0.13 mmol), lithium hydroxide (16mg, 0.65 mmol), THF (2 mL), i-propanol (2 mL), and water (0.5 mL). Themixture was stirred at room temperature for 1 h. It was thenconcentrated under reduced pressure. Water (10 mL) was added to theresidue and the resulting mixture was extracted with dichloromethane(3×20 mL). The combined organic layer was concentrated under reducedpressure and the residue was purified by reverse-phase prep-HPLC toafford 253 (22 mg, 26%) as white solid. MS-ESI: [M+H]⁺ 652.2. ¹H NMR(500 MHz, CDCl₃) δ 10.83 (s, 1H), 8.61 (s, 1H), 8.58 (d, J=5.0 Hz, 1H),8.12 (s, 1H), 8.05 (d, J=2.5 Hz, 1H), 7.45 (d, J=5.0 Hz, 1H), 7.32 (dd,J=3.0 Hz, 5.5 Hz, 1H), 7.00 (d, J=3.5 Hz, 1H), 6.84 (s, 1H), 4.74-4.68(m, 3H), 4.65-4.58 (m, 3H), 4.26-4.14 (m, 2H), 3.99-3.96 (m, 1H),3.71-3.69 (m, 1H), 3.55-3.53 (m, 1H), 3.18-3.14 (m, 2H), 2.64-2.59 (m,3H), 2.53-2.47 (m, 4H), 2.40-2.33 (m, 2H), 1.29 (s, 6H), 1.09 (d, J=7.0Hz, 3H).

Example 254a4-[5-({5-Acetyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde254a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with3-(5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl-amino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one209d (344 mg, 0.83 mmol),4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde109a (202 mg, 0.56 mmol), Pd(dppf)Cl₂ (20 mg, 0.028 mmol), K₃PO₄ (235mg, 1.11 mmol), sodium acetate (91 mg, 1.11 mmol), water (0.5 mL), andacetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 1 h. Analysis of the reaction mixtureby LCMS showed complete conversion to the desired product. The mixturewas cooled down to room temperature and filtered. The filtrate wasconcentrated under reduced pressure to afford 254a (400 mg, crude),which was directly used in next step without further purification.MS-ESI: [M+H]⁺ 612.3

Example 2543-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one254

To a solution of 254a (98 mg, 0.16 mmol) in methanol and dichloromethanewas added NaBH₄ (13 mg, 0.33 mmol). The reaction mixture was stirred atroom temperature for 1 h. Analysis of the reaction mixture by LCMSshowed complete conversion to the desired product. The mixture wasquenched with aqueous NH₄Cl solution (5 mL) and concentrated underreduced pressure. The residue was extracted with dichloromethane (3×10mL). The combined extract was concentrated under reduced pressure andthe residue was purified by reverse-phase prep-HPLC to afford 254 (53mg, 54%) as white solid. MS-ESI: [M+H]⁺ 613.9. ¹H NMR (500 MHz, DMSO-d₆,T=80° C.) δ 8.45 (d, J=8.5 Hz, 1H), 7.93-7.92 (m, 2H), 7.33 (d, J=3.5Hz, 1H), 7.30 (d, J=8.5 Hz, 1H), 5.97 (s, 1H), 4.67-4.63 (m, 3H),4.46-4.45 (m, 2H), 3.97-3.93 (m, 2H), 3.89-3.86 (m, 3H), 3.56 (s, 3H),2.97-2.91 (m, 2H), 2.53-2.55 (m, 2H), 2.49-2.46 (m, 2H), 2.08 (s, 3H),1.21 (s, 6H).

Example 255a4-(5-(5-Acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde255a

Following the procedure described in Example 246, and starting with4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (200 mg, 0.575 mmol) and3-(5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one209d (356 mg, 0.863 mmol), 255a was obtained as a red oil (320 mg, 93%).MS-ESI: [M+H]⁺ 599.3

Example 2552-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-10-fluoro-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one255

Following the procedure described in Example 254, and starting with 255a(200 mg, 0.334 mmol), 255 was obtained as a white solid (55.5 mg, 28%).MS-ESI: [M+H]⁺ 601.3. ¹HNMR (500 MHz, DMSO-d₆, T=80° C.) δ 8.45 (d,J=8.0 Hz, 1H), 7.93 (d, J=3.5 Hz, 2H), 7.33 (d, J=4.0 Hz, 1H), 7.30 (d,J=8.5 Hz, 1H), 5.97 (s, 1H), 4.70-4.63 (m, 3H), 4.46 (d, J=8.5 Hz, 2H),4.10-3.86 (m, overlap, 8H), 3.58 (s, 3H), 2.57-2.55 (m, 2H), 2.43-2.39(m, 2H), 2.08 (s, 3H), 1.79-1.67 (m, 4H).

Example 256a (S)-(6-Aminopyridin-3-yl)(3-methylmorpholino)methanone 256a

To a solution of (S)-3-methylmorpholine (1.5 g, 15.0 mmol) in ethanol(20 mL) was added EDCI (3.33 g, 17.4 mmol), HOBt (2.35 g, 17.4 mmol),and 6-aminonicotinic acid (2.07 g, 15.0 mmol) at room temperature. Afterstirring for 18 h, the resulting suspension was filtered. The solid waspurified by silica-gel column chromatography eluting with 2:1 petroleumether/ethyl acetate to straight ethyl acetate to afford 256a (1.0 g,30%) as white solid. MS-ESI: 222.3 (M+H)⁺.

Example 256b (S)-5-Bromo-1-methyl-3-(5-(3-methylmorpholine-4-carbonylpyridine-2-ylamino)pyridin-2(1H)-one 256b

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (10 ml),256a (111 mg, 0.50 mmol), 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one(134 mg, 0.60 mmol), cesium carbonate (326 mg, 1.0 mmol), Xantphos (29mg, 0.05 mmol), and tris(dibenzylideneacetone)dipalladium(0) (23 mg,0.025 mmol). The system was subjected to three cycles of vacuum/argonflush and heated at 100° C. for 5 h. It was then cooled to roomtemperature and filtered. The solid was washed with dichloromethane(3×30 mL) and the combined filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with petroleum ether/ethyl acetate (2:1 to 1:2) to afford 256b(140 mg, 77%) as a yellow solid. MS-ESI: [M+H]⁺ 364.3

Example 256c(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(5-{[(35)-3-methylmorpholin-4-yl]carbonyl}pyridin-2-yl)amino]-6-oxo-1,6-dihydropyridazin-3-yl}pyridin-3-yl)methylAcetate 256c

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 256b (140 mg, 0.38mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (159 mg, 0.40 mmol), K₃PO₄ (85 mg, 0.40 mmol), sodium acetate(33 mg, 0.40 mmol), 1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (15 mg, 0.020 mmol), acetonitrile (10mL), and water (0.5 mL). The system was subjected to three cycles ofvacuum/argon flush and heated at 100° C. for 2.5 h. Analysis of thereaction mixture by LCMS showed complete conversion to the desiredproduct. The reaction mixture was cooled to room temperature and dilutedwith dichloromethane (30 mL) and water (30 mL). The aqueous layer wasseparated and extracted with dichloromethane (3×20 mL). The combinedorganic layer was dried over Na₂SO₄ and filtered. The filtrate wasconcentrated under reduced pressure. The dark residue was purified bysilica-gel column chromatography eluting with 60:1dichloromethane:/methanol to afford 256c (90 mg, 35%) as yellow solid.MS-ESI: [M+H]⁺ 681.3

Example 2563-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(3S)-3-methylmorpholine-4-carbonyl]-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one256

To a solution of 256c (90 mg, 0.13 mmol) in THF/i-propanol/water(2.0/1/0.5 ml) was added lithium hydroxide (31 mg, 1.3 mmol) at roomtemperature. After the reaction was stirred for 3 h, LCMS indicated thereaction was complete. Then the mixture was poured into water (15 mL)and extracted with dichloromethane (3×10 mL). The combined organic layerwas washed with brine (30 mL), dried over Na₂SO₄, and filtered. Thefiltrate was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 256 (40 mg, 48%) as whitesolid. MS-ESI: [M+H]⁺ 639.3. ¹H NMR (500 MHz, MeOD) δ 8.86 (s, 1H), 8.58(d, J=5.0 Hz, 1H), 8.44 (d, J=2.0 Hz, 1H), 7.79 (dd, J=2.0, 6.5 Hz, 1H),7.57 (d, J=5.0 Hz, 1H), 7.32 (d, J=8.5 Hz, 1H), 6.74 (s, 1H), 4.85-4.82(m, 1H), 4.66-4.64 (m, 1H), 4.42-4.27 (m, 4H), 4.02-3.88 (m, overlap,6H), 3.74-3.67 (m, 2H), 3.56-3.46 (m, 2H), 2.67-2.59 (m, 2H), 2.51 (s,2H), 1.39 (d, J=7.0 Hz, 3H), 1.28 (s, 6H).

Example 257(S)-5-Bromo-1-methyl-3-(5-(3-methylmorpholine-4-carbonyl)pyridine-2-ylamino)pyridin-2(1H)-one257a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with(S)-(6-aminopyridin-3-yl)(3-methylmorpholino)methanone (222 mg, 1.0mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (320 mg, 1.2 mmol), cesiumcarbonate (652 mg, 2 mmol), and 1,4-dioxane (10 mL). After bubblingnitrogen through the suspension for 10 minutes, Xantphos (58 mg, 0.10mmol) and tris(dibenzylideneacetone)dipalladium(0) (46 mg, 0.050 mmol)were added. The system was subject to three cycles of vacuum/argon flushand heated at reflux for 2.5 h. It was then cooled to room temperatureand filtered. The solid was washed with dichloromethane (2×30 mL) andthe combined filtrate was concentrated under reduced pressure. Theresidue was purified by silica-gel column chromatography eluting withpetroleum ether/ethyl acetate (2:1 to 1:2) to afford 257a (280 mg, 69%)as a yellow solid. MS-ESI: [M+H]⁺ 407.3

Example 257b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(5-{[(3S)-3-methylmorpholin-4-yl]carbonyl}pyridin-2-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 257b

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 257a (203 mg, 0.50mmol),β-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (640 mg, 1.6 mmol), K₃PO₄ (212 mg, 1.0 mmol),1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (18 mg, 0.025mmol), sodium acetate (82 mg, 1.0 mmol), acetonitrile (10 mL), and water(0.2 mL). After three cycles of vacuum/argon flush, the mixture washeated at 100° C. for 2.5 h. Analysis of the reaction mixture by LCMSshowed complete conversion to the desired product. The reaction mixturewas cooled to room temperature and concentrated under reduced pressure.The residue was diluted with dichloromethane (20 mL) and water (20 mL).The aqueous layer was separated and extracted with dichloromethane (3×20mL). The combined organic layer was dried over Na₂SO₄ and filtered. Thefiltrate was concentrated under reduced pressure. The dark residue waspurified by silica-gel column chromatography eluting with 60:1dichloromethane/methanol to afford 257b (160 mg, 47%) as black solid.MS-ESI: [M+H]⁺ 680.1

Example 2573-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(3S)-3-methylmorpholine-4-carbonyl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one257

To a solution of 257b (157 mg, 0.23 mmol) in THF/i-propanol/water(2/2/0.5 mL) was added lithium hydroxide (55 mg, 2.3 mmol) at roomtemperature. After the reaction was stirred for 3 h, LCMS indicated thereaction was completed. The mixture was poured into water (15 mL) andextracted with dichloromethane (3×15 mL). The combined organic layer waswashed with brine (30 mL), dried over Na₂SO₄ and filtered. The filtratewas concentrated under reduced pressure. The residue solid was purifiedby reverse-phase prep-HPLC (A: 1% NH₄HCO₃ in water; B: acetonitrile) toafford 257 (52 mg, 35%) as yellow solid. MS-ESI: [M+H]⁺ 668.3. ¹H NMR(500 MHz, MeOD) δ 8.94 (d, J=2.0 Hz, 1H), 8.53 (d, J=5.0 Hz, 1H), 8.33(d, J=2.0 Hz, 1H), 7.69 (dd, J=2.0, 6.5 Hz, 1H), 7.61 (d, J=2.0 Hz, 1H),7.48 (d, J=5.0 Hz, 1H), 7.13 (d, J=8.5 Hz, 1H), 6.74 (s, 1H), 4.70 (d,J=12.0 Hz, 1H), 4.58 (d, J=12.0 Hz, 1H), 4.41-4.27 (m, 4H), 3.99-3.89(m, 3H), 3.74-3.66 (m, overlap, 5H), 3.55-3.46 (m, 2H), 2.67-2.59 (m,2H), 2.51 (s, 2H), 1.39 (d, J=6.5 Hz, 3H), 1.28 (s, 6H).

Example 258a6-Chloro-2-methyl-4-({5-[(morpholin-4-yl)carbonyl]pyridin-2-yl}amino)-2,3-dihydropyridazin-3-one258a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (40 mL),(6-aminopyridin-3-yl)(morpholino)-methanone (2.07 g, 10.0 mmol),4-bromo-6-chloro-2-methylpyridazin-3(2H)-one 111a (3.35 g, 15.0 mmol),Pd₂(dba)₃ (915 mg, 1.0 mmol), XantPhos (578 mg, 1.0 mmol), and cesiumcarbonate (6.52 g, 20 mmol). After three cycles of vacuum/argon flush,the mixture was heated at 100° C. for 8 h. It was then cooled to roomtemperature and filtered. The solid was washed with dichloromethane(2×20 mL). The combined filtrate was dried over anhydrous Na₂SO₄ andconcentrated under reduced pressure to afford 258a (2.45 g, 51%) as ayellow solid. MS: [M+H]⁺ 350.1

Example 258b1-Methyl-5-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridazin-3-ylboronicAcid 258b

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 258a (2.0 g, 5.73 mmol,1.0 eq.), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane)(7.56 g, 28.6 mmol, 5.0 eq.), Pd(dppf)Cl₂ (465 mg, 0.57 mmol, 0.1 eq.),X-Phos (461 mg, 1.14 mmol, 0.2 eq.), potassium acetate (1.11 g, 11.4mmol, 2.0 eq.), and dioxane (50 mL). After three cycles of vacuum/argonflush, the mixture was heated at 50° C. for 6 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was washed with 1:3 ethylacetate/petroleum ether to afford 258b (1.70 g, 83%) as a yellow solid,which was used in the next step without further purification. MS: [M+H]⁺360.1

Example 258c4-Chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde258c

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridine-3-carbaldehyde124a (100 mg, 0.29 mmol), 258b (128 mg, 0.36 mmol), PdCl₂(dppf) (24 mg,0.031 mmol), K₃PO₄ (123 mg, 0.58 mmol), sodium acetate (57 mg, 0.58mmol), acetonitrile (30 mL), and water (3 mL). After three cycles ofvacuum/argon flush, the mixture was stirred at 100° C. for 3 h. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified with silica-gel column chromatography eluting with 1:3petroleum/ethyl acetate to afford 258c as a yellow solid (45 mg, 25%).MS-ESI: [M+H]⁺ 625.2

Example 2583-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one258

A mixture of 258c (45 mg, 0.071 mmol), NaBH₄ (8 mg, 0.21 mmol), andmethanol (7 mL) was stirred at room temperature for 2 h. Then thereaction mixture was quenched with water (5 mL) and concentrated underreduced pressure. The residue was extracted with dichloromethane (2×10mL) and the combined dichloromethane extract was concentrated underreduced pressure. The residue was purified by reverse-phase prep-HPLC toafford 258 (24 mg, 53%) as a yellow solid. MS-ESI: [M+H]⁺ 627.2. ¹H NMR(500 MHz, DMSO-d₆) δ 9.80 (s, 1H), 8.68 (s, 1H), 8.65 (d, J=4.5 Hz, 1H),8.50 (s, 1H), 8.39 (d, J=2.0 Hz, 1H), 7.80-7.78 (m, 1H), 7.67 (d, J=5.0Hz, 1H), 7.60 (d, J=8.5 Hz, 1H), 4.85 (t, J=5.5 Hz, 1H), 4.52-4.35 (m,2H), 3.82 (s, 3H), 3.60-3.49 (m, 8H), 2.95-2.93 (m, 2H), 2.89-2.84 (m,2H), 1.94-1.83 (m, 4H).

Example 259a2-{4,4-Dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}-4-[1-methyl-5-({5-[(morpholin-4-yl)carbonyl]pyridin-2-yl}amino)-6-oxopyridazin-3-yl]pyridine-3-carbaldehyde259a

A round-bottomed flask equipped with a reflux condenser was charged with4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde109a (144 mg, 0.40 mmol),1-methyl-5-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridazin-3-ylboronicacid 258a (215 mg, 0.60 mmol), PdCl₂(dppf) (16 mg, 0.020 mmol), K₃PO₄trihydrate (207 mg, 0.80 mmol), sodium acetate (66 mg, 0.80 mmol),acetonitrile (15 mL), and water (1.5 mL). After three cycles ofvacuum/argon flush, the mixture was stirred at 100° C. for 2 h. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified with silica-gel column chromatography eluting with 25:1dichloromethane/methanol to afford 259a as a yellow solid (80 mg, 30%).MS-ESI: [M+H]⁺ 640.3.

Example 2593-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one259

A mixture of 259a (80 mg, 0.12 mmol), NaBH₄ (14 mg, 0.36 mmol), andmethanol (5 mL) was stirred at room temperature for 1 h. It was thenquenched with brine (5 mL) and evaporated under reduced pressure. Theresidue was extracted with dichloromethane (2×10 mL) and the combineddichloromethane extract was concentrated under reduced pressure. Theresulting residue was purified by reverse-phase prep-HPLC to afford 259as a white solid (38 mg, 49%). MS-ESI: [M+H]⁺ 642.8. ¹H NMR (500 MHz,CDCl₃) δ 8.78 (s, 1H), 8.61 (d, J=5.0 Hz, 1H), 8.44 (d, J=2.5 Hz, 2H),7.80-7.77 (m, 1H), 7.45 (d, J=5.0 Hz, 1H), 7.06-7.04 (m, 1H), 4.65-4.59(m, 2H), 4.42 (s, 1H), 4.30-4.27 (m, 1H), 3.95 (s, 3H), 3.90-3.87 (m,1H), 3.76-3.68 (m, 8H), 3.04-2.92 (m, 2H), 2.82-2.80 (m, 2H), 2.59-2.54(m, 2H), 1.30 (s, 6H).

Example 260a(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(5-methyl-1H-pyrazol-3-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 260a

A round-bottomed flask equipped with a reflux condenser was charged with5-bromo-1-methyl-3-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2(1H)-one 218a(201 mg, 0.71 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (282 mg, 0.71 mmol), Pd(dppf)Cl₂ (51 mg, 0.07 mmol), K₃PO₄(301 mg, 1.42 mmol), sodium acetate (116 mg, 1.42 mmol), acetonitrile(10 mL), and water (0.2 mL). After three cycles of vacuum/argon flush,the mixture was heated at 100° C. for 3 h. It was then filtered and thefiltrate was evaporated under reduced pressure. The residue was purifiedby silica-gel column chromatography eluting with 1:20methanol/dichloromethane to afford 260a as a red solid (150 mg, 38%).MS-ESI: [M+H]⁺ 556.3

Example 2603-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-1H-pyrazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one260

A mixture of 260a (150 mg, 0.27 mmol) and lithium hydroxide (13 mg, 0.54mmol) in THF (6 mL), i-propanol (4 mL), and water (2 mL) was stirred atroom temperature for 0.5 h. The mixture was concentrated under reducedpressure and the residue was diluted with water (5 mL). It was thenextracted with dichloromethane (2×10 mL) and the combineddichloromethane extract was concentrated under reduced pressure. Theresidue was purified with reverse-phase prep-HPLC to afford 260 (28 mg,20%) as a white solid. MS-ESI: [M+H]⁺ 514.3. ¹H NMR (500 MHz, DMSO-d₆) δ11.76 (s, 1H), 8.47 (d, J=5.0 Hz, 1H), 8.07-8.05 (m, 2H), 7.38-7.31 (m,2H), 6.55 (s, 1H), 5.88 (s, 1H), 4.95-4.93 (m, 1H), 4.48-4.39 (m, 2H),4.22-4.18 (m, 3H), 3.83 (d, J=5.5 Hz, 1H), 3.58 (s, 3H), 2.64-2.56 (m,2H), 2.36-2.34 (m, 2H), 2.16 (s, 3H), 1.22 (s, 6H).

Example 261a4-{5-[(1,5-Dimethyl-1H-pyrazol-3-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-2-{10-fluoro-1-oxo-1H,2H,3H,4H,6H,7H,8H,9H-pyrido[3,4-b]indolizin-2-yl}pyridine-3-carbaldehyde261a

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde134c (97 mg, 0.28 mmol),3-[(1,5-dimethyl-1H-pyrazol-3-yl)amino]-1-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-dihydropyridin-2-one218a (192.6 mg, 0.56 mmol), Pd₂(dba)₃ (54.9 mg, 0.060 mmol),tri(cyclohexyl)phosphine (50.2 mg, 0.18 mmol), Cs₂CO₃ (182.6 mg, 0.56mmol), dioxane (8 mL), and water (0.25 mL). After three cycles ofvacuum/argon flush, the mixture was stirred at 110° C. for 2 h. It wasthen filtered and the filtrate was evaporated in vacuo. The residue waspurified by silica-gel column chromatography eluting with 35:1 ethylacetate/methanol to afford 261a (90 mg, 61%) as a black solid. MS-ESI:[M+H]⁺ 530.2

Example 2612-[4-[5-[(1,5-dimethylpyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-10-fluoro-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one261

To a solution of 261a (90.0 mg, 0.17 mmol) in methanol (5 mL) was addedsodium borohydride (64.6 mg, 1.7 mmol) at room temperature. The reactionwas stirred for 0.5 h. It was then quenched with water (2 mL) andevaporated in vacuo. The residue was extracted with dichloromethane(3×10 mL). The combined dichloromethane extract was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 261 (47.0 mg, 52%) as a white solid. MS-ESI: [M+H]⁺ 532.3. ¹HNMR (500 MHz, DMSO-d₆) δ 8.47 (d, J=5.0 Hz, 1H), 8.05 (s, 1H), 8.03 (d,J=2.5 Hz, 1H), 7.39 (d, J=2.5 Hz, 1H), 7.31 (d, J=5.0 Hz, 1H), 5.89 (s,1H), 4.87-4.85 (m, 1H), 4.45-4.36 (m, 2H), 4.11-4.09 (m, 1H), 3.93-3.91(m, 1H), 3.79-3.76 (m, 2H), 3.59 (s, 3H), 3.58 (s, 3H), 3.00-2.94 (m,2H), 2.66-2.63 (m, 2H), 2.18 (s, 3H), 1.90-1.88 (m, 2H), 1.78-1.73 (m,2H)

Example 262a5-Bromo-1-methyl-3-(5-methyloxazol-2-ylamino)pyridin-2(1H)-one 262a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 5-methyloxazol-2-amine(276 mg, 2.82 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (753 mg, 2.82mmol), tris-(dibenzylideneacetone)dipalladium(0) (256 mg, 0.28 mmol),XantPhos (324 mg, 0.56 mmol), Cs₂CO₃ (1.8 g, 5.64 mmol), and 1,4-dioxane(30 mL). After three cycles of vacuum/argon flush, the mixture washeated at 92° C. for 3 hrs. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by silica-gel column chromatographyeluting with 100:1 dichloromethane/methanol to afford 262a as whitesolid (702 mg, 88%). MS-ESI: [M+H]⁺ 284.1.

Example 262b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(5-methyl-1,3-oxazol-2-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 262b

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 262a (150 mg, 0.53mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (421 mg, 1.06 mmol), Pd(dppf)Cl₂ (37 mg, 0.050 mmol), K₃PO₄(225 mg, 1.06 mmol), sodium acetate (87 mg, 1.06 mmol), water (0.5 mL),and acetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 1 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (50:1 to 30:1) toafford 262b as yellow solid (100 mg, 34%). MS-ESI: [M+H]⁺ 556.9.

Example 2623-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyloxazol-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one262

A mixture of 262b (100 mg, 0.18 mmol) and lithium hydroxide (108 mg, 4.5mmol) in i-propanol/THF/water (4/4/2 mL) was stirred at 35° C. for 30min. The mixture was concentrated under reduced pressure. To the residuewas added water (5 mL) and the resulting mixture was extracted withdichloromethane three times. The combined organic layer was concentratedunder reduced pressure and the resulting residue was purified byreverse-phase prep-HPLC to afford 262 as white solid (21.0 mg, 23%).MS-ESI: [M+H]⁺ 515.3. ¹H NMR (500 MHz, DMSO-d₆) δ 9.19 (s, 1H), 8.49 (d,J=5.0 Hz, 1H), 8.30 (s, 1H), 7.60 (d, J=1.0 Hz, 1H), 7.32 (d, J=4.5 Hz,1H), 6.62 (s, 1H), 6.56 (s, 1H), 4.96-4.94 (m, 1H), 4.45-4.36 (m, 2H),4.24-4.14 (m, 3H), 3.84 (d, J=10.5 Hz, 1H), 3.59 (s, 3H), 2.62-2.56 (m,2H), 2.44-2.42 (m, 2H), 2.22 (s, 3H), 1.22 (s, 6H).

Example 263a6-Chloro-2-methyl-4-(pyrimidin-4-ylamino)pyridazin-3(2H)-one 263a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (150 mL),pyrimidin-4-amine (1.7 g, 18.0 mmol),4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (4.0 g, 18.0 mmol), andcesium carbonate (11.74 g, 36.0 mmol). After bubbling nitrogen throughthe suspension for 30 minutes, Xantphos (1.04 g, 1.8 mmol) andtris(dibenzylideneacetone)dipalladium(0) (823 mg, 0.9 mmol) were added.The system was subjected to three cycles of vacuum/argon flush andheated at reflux for 15 h. It was then cooled to room temperature andfiltered. The solid was washed with dichloromethane (2×50 mL). Thecombined filtrate was concentrated and the residue was washed withacetonitrile (5 mL) to afford 263a (2.99 g, 70%) as a yellow solid. MS:[M+H]⁺ 238

Example 263b1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridazin-3-yl-boronicacid 263b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 263a (500 mg, 2.11mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.68g, 10.6 mmol), Pd(dppf)Cl₂ (170 mg, 0.20 mmol), X-phos (170 mg, 0.40mmol), potassium acetate (410 mg, 4.21 mmol), and dioxane (30 mL). Thesystem was subjected to 3 cycles of vacuum/argon flush and stirred at50° C. for 6 h. LCMS indicated that 263a was totally converted to 263b.

Example 263c2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridazin-3-yl)nicotinaldehyde263c

To the mixture of 263b at room temperature was added4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (300 mg, 0.90 mmol), Pd(dppf)Cl₂ (170 mg, 0.20 mmol), K₃PO₄ (103mg, 0.40 mmol), and water (2 mL). The system was subjected to 3 cyclesof vacuum/argon flush again and stirred at 80° C. for 4 h. The reactionmixture was then cooled to room temperature, diluted with water (30 mL),and filtered. The filtrate was extracted with dichloromethane (2×30 mL).The combined dichloromethane extract was concentrated under reducedpressure and the residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (40:1 to 20:1) toafford 263c as a yellow solid (210 mg, 45%). MS-ESI: [M+H]⁺ 515.3

Example 26310-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(pyrimidin-4-ylamino)pyridazin-3-yl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one263

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 263c (100 mg, 0.19 mmol), NaBH₄ (30 mg, 0.78mmol), and methanol (20 mL). The mixture was stirred at room temperaturefor 0.5 h. It was then diluted with water (30 mL) and concentrated underreduced pressure. The residue was extracted with dichloromethane (2×30mL) and the combined dichloromethane extract was dried and concentratedunder reduced pressure. The residue was purified with reverse-phaseprep-HPLC to afford 263 as a white solid (67 mg, 68%). MS-ESI: [M+H]⁺517.3. ¹H NMR (500 MHz, DMSO-d₆) δ 9.93 (s, 1H), 8.81 (s, 1H), 8.67 (s,1H), 8.55 (d, J=4.5 Hz, 1H), 8.49 (d, J=5.5 Hz, 1H), 7.56 (dd, J=1.0,6.0 Hz, 1H), 7.43 (d, J=5.0 Hz, 1H), 4.83 (t, J=5.5 Hz, 1H), 4.62-4.58(m, 1H), 4.39-4.36 (m, 1H), 4.25-4.19 (m, 2H), 4.06-4.04 (m, 1H),3.92-3.90 (m, 1H), 3.81 (s, 3H), 2.64-2.54 (m, 2H), 2.43-2.41 (m 2H),1.78-1.76 (m, 2H), 1.69-1.67 (m, 2H).

Example 264a 2-(4-Aminopyrimidin-2-yl)propan-2-ol 264a

To a solution of ethyl 4-aminopyrimidine-2-carboxylate (840 mg, 5.0mmol) in anhydrous tetrahydrofuran (50 mL) cooled at −20° C. was added asolution of methylmagnesium bromide in THF (8.5 mL, 25.0 mmol, 3.0 M)over a period of 5 minutes. The reaction mixture was stirred at 0° C.for another 2 h. It was then quenched with saturated NH₄Cl (20 mL) andconcentrated under reduced pressure. The residue was extracted withethyl acetate (5×40 mL). The combined organic layer was dried overanhydrous Mg₂SO₄, filtered, and evaporated under reduced pressure. Theresidue was purified by reverse-phase Combiflash to afford 264a asyellow solid (240 mg, 32%) MS-ESI: [M+H]⁺ 154.1

Example 264b5-Bromo-3-(2-(2-hydroxypropan-2-yl)pyrimidin-4-ylamino)-1-methylpyridin-2(1H)-one264b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 264a (300 mg, 2.0 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (800 mg, 3.0 mmol), Pd₂(dba)₃ (182mg, 0.20 mmol), XantPhos (231 mg, 0.40 mmol), Cs₂CO₃ (1.30 g, 4.0 mmol),and 1,4-dioxane (20 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 15 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure. The resulting residue was purified by silica-gel columnchromatography eluting with 40:1 dichloromethane/methanol (40:1) andfurther purified by reverse-phase Combiflash to afford 264b as whitesolid (200 mg, 30%). MS-ESI: [M+H]⁺ 339.0

Example 264c(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(5-{[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]amino}-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)pyridin-3-yl)methylAcetate 264c

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 264b (170 mg, 0.50 mmol),(3-(acetoxymethyl)-2-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)pyridin-4-yl)boronicacid 199e (200 mg, 0.50 mmol), Pd(dppf)Cl₂ (40 mg, 0.050 mmol), K₃PO₄(212 mg, 1.0 mmol), water (0.5 mL), and tetrahydrofuran (10 mL). Afterthree cycles of vacuum/argon flush, the mixture was heated at reflux for6 h. It was then cooled to room temperature and filtered. The filtratewas concentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 40:1dichloromethane/methanol to afford 264c as brown solid (200 mg, 54%).MS-ESI: [M+H]⁺ 612.3

Example 2643-[3-(hydroxymethyl)-4-[5-[[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-4-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one264

To a solution of 264c (170 mg, 0.27 mmol) in tetrahydrofuran (10 mL) andwater (2 mL) was added lithium hydroxide (64 mg, 3.0 mmol). The reactionmixture was stirred at 35° C. for 2 h. It was then concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 264 (86 mg, 46%) as yellow solid. MS-ESI: [M+H]⁺ 570.1. ¹H NMR(500 MHz, DMSO-d₆) δ 9.27 (s, 1H), 8.94 (d, J=2.0 Hz, 1H), 8.50 (d,J=5.0 Hz, 1H), 8.33 (d, J=6.0 Hz, 1H), 7.76 (d, J=2.5 Hz, 1H), 7.41 (d,J=5.0 Hz, 1H), 7.22 (d, J=5.5 Hz, 1H), 6.56 (s, 1H), 5.14 (t, J=5.0 Hz,1H), 4.89 (s, 1H), 4.48-4.42 (m, 2H), 4.23-4.19 (m, overlap, 3H),3.85-3.84 (m, 1H), 3.62 (s, 3H), 2.67-2.56 (m, 2H), 2.42 (s, 2H), 1.42(s, 3H), 1.40 (s, 3H), 1.21 (s, overlap, 6H).

Example 265a1-(2-Nitro-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)propan-1-one 265a

To a solution of 2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 209a(200 mg, 1.19 mmol) in dichloromethane (8 mL) was added Et₃N (240 mg,2.38 mmol). After stirring for 5 minutes, a solution of propionylchloride (121 mg, 1.31 mmol) in dichloromethane (2 mL) was added and thereaction mixture was stirred at room temperature for 1 h. Analysis ofthe reaction mixture by LCMS showed complete conversion to the desiredproduct. The mixture was washed with water and brine, dried over Na₂SO₄,and filtered. The filtrate was concentrated under reduced pressure toafford 265a (260 mg, 98%) as white solid, which was used in the nextstep without further purification. MS-ESI: [M+H]⁺ 225.0

Example 265b1-(2-Amino-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)propan-1-one 265b

To a solution of 265a (260 mg, 1.16 mmol) in methanol (10 mL) was added10% Pd/C (26 mg). The system was evacuated and then refilled with H₂.After stirring for 2 h, analysis of the reaction mixture by LCMS showedcomplete conversion to the desired product. The mixture was filtered,and the filtrate was concentrated under reduced pressure to afford 265bas a yellow solid (225 mg, 99%). MS-ESI: [M+H]⁺ 195.1

Example 265c5-Bromo-1-methyl-3-(5-propionyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridin-2(1H)-one265c

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 265b (200 mg, 1.03mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (414 mg, 1.55 mmol),Pd₂(dba)₃ (47 mg, 0.052 mmol), Xantphos (60 mg, 0.103 mmol), Cs₂CO₃(671.6 mg, 2.06 mmol), and dioxane (20 mL). After three cycles ofvacuum/argon flush, the reaction mixture was heated at 100° C. for 3 h.Analysis of the reaction mixture by LCMS showed complete conversion tothe desired product. The reaction mixture was cooled to room temperatureand filtered. The filtrate was concentrated under reduced pressure andthe residue was purified by silica-gel column chromatography elutingwith 80:1 dichloromethane/methanol to afford 265c (280 mg, 72%) as whitesolid. MS-ESI: [M+H]⁺ 380.2

Example 265d(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-6-oxo-5-({5-propanoyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-1,6-dihydropyridin-3-yl]pyridin-3-yl)methylAcetate 265d

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 265c (200 mg, 0.53mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (834 mg, 2.10 mmol), Pd(dppf)Cl₂ (19 mg, 0.0263 mmol), K₃PO₄(223 mg, 1.052 mmol), sodium acetate (86 mg, 1.052 mmol), acetonitrile(10 mL), and water (5 drops). After three cycles of vacuum/argon flush,the reaction mixture was heated at 100° C. for 3 h. Analysis of thereaction mixture by LCMS showed complete conversion to the desiredproduct. The reaction mixture was cooled down to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresidue was purified by silica-gel column chromatography eluting with60:1 dichloromethane/methanol to afford 265d (100 mg, 29%) as yellowoil. MS-ESI: [M+H]⁺ 653.3

Example 2653-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-[(5-propanoyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one265

To a solution of 265d (100 mg, 0.153 mmol) in THF (3 mL), i-propanol (3mL), and water (5 mL) was added lithium hydroxide (37 mg, 1.53 mmol).The reaction mixture was stirred at room temperature for 1 h. Analysisof the reaction mixture by LCMS showed complete conversion to thedesired product. The mixture was concentrated under reduced pressure andthe residue was purified by reverse-phase prep-HPLC to afford 265 (50mg, 54%) as white solid. MS-ESI: [M+H]⁺ 611.3. ¹H NMR (500 MHz, DMSO-d₆,T=80° C.) δ 8.45 (d, J=8.5 Hz, 1H), 7.93-7.90 (m, 2H), 7.35 (d, J=3.5Hz, 1H), 7.29 (d, J=8.5 Hz, 1H), 6.55 (s, 1H), 5.98 (s, 1H), 4.74-4.71(m, 1H), 4.65 (s, 2H), 4.46-4.44 (m, 2H), 4.18-4.16 (m, 2H), 3.97-3.87(m, overlap, 5H), 3.58 (s, 3H), 2.57-2.56 (m, 2H), 2.49-2.37 (m, 4H),1.22 (s, 6H), 1.03 (t, J=12.0 Hz, 3H).

Example 266a5-bromo-1-methyl-3-((5-(oxetan-3-yl)-1H-pyrazol-3-yl)amino)pyridin-2(1H)-one266a

Following the reaction scheme of FIG. 26, 266 a was prepared.

Example 266b(2′-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)-1-methyl-5-(5-(oxetan-3-yl)-1H-pyrazol-3-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-3′-yl)methylacetate 266b

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 266a (33 mg, 0.10 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (60 mg, 0.15 mmol), Pd(dppf)Cl₂ (7 mg, 0.010 mmol), K₃PO₄ (42mg, 0.20 mmol), sodium acetate (16 mg, 0.20 mmol), acetonitrile (6 mL),water (0.1 mL). After three cycles of vacuum/argon flush, the mixturewas heated at reflux for 2 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by silica-gel column chromatographyeluting with 30:1 dichloromethane/methanol to afford 266b as a whitesolid (17 mg, 28%). MS-ESI: [M+H]⁺ 598.4

Example 2663-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(oxetan-3-yl)-1H-pyrazol-3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one266

A mixture of 266b (15 mg, 0.025 mmol) and lithium hydroxide (6 mg, 0.25mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at 30°C. for 1 h. The mixture was evaporated under reduced pressure and theresidue was diluted with water (5 mL). It was then extracted with ethylacetate (2×10 mL). The combined ethyl acetate extract was concentratedunder reduced pressure and the residue was purified by reverse-phaseprep-HPLC to afford 266 (4.5 mg, 33%) as a white solid. MS-ESI: [M+H]⁺556.3. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, J=5.0 Hz, 1H), 7.98 (s, 1H),7.68 (s, 1H), 7.58 (s, 1H), 7.33 (d, J=5.0 Hz, 1H), 6.86 (s, 1H), 6.09(s, 1H), 5.07-5.04 (m, 2H), 4.79-4.76 (m, 2H), 4.68-4.66 (m, 1H),4.54-4.51 (m, 1H), 4.37-4.34 (m, 1H), 4.28-4.25 (m, 1H), 4.18 (d, J=5.5Hz, 2H), 3.89-3.87 (m, 1H), 3.73 (s, 3H), 2.59-2.57 (m, 2H), 2.54-2.52(m, 3H), 1.29 (s, 6H).

Example 267a5-Bromo-1-methyl-3-(5-methyl-1,3,4-thiadiazol-2-ylamino)pyridin-2(1H)-one267a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-methyl-1,3,4-thiadiazol-2-amine (1.15 g, 10.0 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (4.00 g, 15.0 mmol), Pd₂(dba)₃(916 mg, 1.0 mmol), Xantphos (1.16 g, 2.0 mmol), Cs₂CO₃ (6.52 g, 20.0mmol), and dioxane (50 mL). After three cycles of vacuum/argon flush,the mixture was heated at 100° C. for 3 h. It was then cooled to roomtemperature and filtered. The filtrate was evaporated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 20:1 dichloromethane/methanol to afford 267a(2.2 g, 73%) as white solid. MS-ESI: [M+H]⁺ 301.2

Example 267b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 267b

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 267a (150 mg, 0.50 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (640 mg, 1.5 mmol), PdCl₂(dppf) (37 mg, 0.050 mmol), K₃PO₄(212 mg, 1.0 mmol), sodium acetate (82 mg, 1.0 mmol), acetonitrile (10mL), and water (0.2 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was evaporated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 50:1 dichloromethane/methanol to afford 267b(80 mg, 28%) as yellow solid. MS-ESI: [M+H]⁺ 574.2

Example 2673-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one267

A 25-mL round-bottomed flask equipped with a magnetic stirrer wascharged 267b (80 mg, 0.14 mmol), lithium hydroxide (17 mg, 0.70 mmol),THF (2 mL), i-propanol (2 mL), and water (0.5 mL). The mixture wasstirred at room temperature for 1 h and concentrated under reducedpressure. The residue was diluted with water (5 mL) extracted withdichloromethane (10 mL×3) and the combined organic layer wasconcentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford 267 (32 mg, 43%) as white solid.MS-ESI: [M+H]⁺ 532.3. ¹H NMR (500 MHz, DMSO-d₆) δ 10.19 (s, 1H), 8.57(d, J=3.0 Hz, 1H), 8.49 (d, J=6.0 Hz, 1H), 7.63 (d, J=3.0 Hz, 1H), 7.32(d, J=6.0 Hz, 1H), 6.56 (s, 1H), 4.92 (t, J=6.5 Hz, 1H), 4.45-4.37 (m,2H), 4.22-4.17 (m, 3H), 3.85-3.80 (m, 1H), 3.60 (s, 3H), 2.58-2.56 (m,2H), 2.52 (s, 3H), 2.42 (s, 2H), 1.17 (s, 6H).

Example 268a 1-Methyl-4-nitro-1H-imidazole 268a

To a mixture of 4-nitro-1H-imidazole (2.0 g, 17.7 mmol) and K₂CO₃ (3.67g, 26.5 mmol) in acetonitrile (20 mL) was added iodomethane (1.3 mL, 3.0g, 21.2 mmol) dropwise while stirring at room temperature. The resultingmixture was stirred at 60° C. overnight. It was then evaporated underreduced pressure and the residue was diluted with water (20 mL). Themixture was extracted with dichloromethane (2×20 mL). The combinedextract was concentrated under reduced pressure and the residue waspurified by silica-gel column chromatography eluting with 100:1dichloromethane/methanol to afford 268a as a yellow solid (1.8 g, 82%).MS-ESI: [M+H]⁺ 128.1. ¹H NMR (500 MHz, DMSO-d₆) δ 8.37 (s, 1H), 7.82 (s,1H), 3.76 (s, 3H).

Example 268b 1-Methyl-1H-imidazol-4-amine 268b

A 100-mL round-bottomed flask was charged with 268a (1.6 g, 12.6 mmol),10% palladium on carbon (50% wet, 160 mg), and ethanol (15 mL). Theflask was evacuated, charged with hydrogen gas, and stirred at roomtemperature overnight. The catalyst was removed by filtration through apad of CELITE® and the filtrate was concentrated under reduced pressureto afford 268b (1.2 g, 98%) as a yellow solid. MS-ESI: [M+H]⁺ 98.2

Example 268c5-Bromo-1-methyl-3-(1-methyl-1H-imidazol-4-ylamino)pyridin-2(1H)-one268c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (50 mL),268b (1.1 g, 11.3 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (3.0 g,11.3 mmol), Pd₂(dba)₃ (1.0 g, 1.13 mmol), XantPhos (1.3 g, 2.26 mmol),and cesium carbonate (7.3 g, 22.6 mmol). After three cycles ofvacuum/argon flush, the mixture was heated at 92° C. for 4.5 hrs. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting withdichloromethane/methanol (100:1 to 50:1) to afford 268c (2.4 g, 76%) asyellow solid. MS-ESI: [M+H]⁺ 283.1

Example 268d(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(1-methyl-1H-imidazol-4-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 268d

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 268c (150 mg, 0.53 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (80.4 mg, 0.21 mmol), Pd(dppf)Cl₂ (17.2 mg, 0.021 mmol), K₃PO₄(89 mg, 0.42 mmol), sodium acetate (57.1 mg, 0.42 mmol), water (0.2 mL),and acetonitrile (10 mL). After three cycles of vacuum/argon flush, themixture was heated at 90° C. for 2.5 hrs. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (30:1 to 20:1) toafford 268d (110 mg, 37.2%) as brown solid. MS-ESI: [M+H]+ 556.4.

Example 2683-[3-(hydroxymethyl)-4-[1-methyl-5-[(1-methylimidazol-4-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one268

A mixture of 268d (100 mg, 0.18 mmol) and lithium hydroxide (189 mg, 4.5mmol) in i-propanol/THF (1:1, 4.0 mL) and water (1.0 mL) was stirred at35° C. for 30 min. The mixture was concentrated under reduced pressure.To the residue was added water (5 mL) and the resulting mixture wasextracted with dichloromethane (3×10 mL). The combined organic layer wasconcentrated under reduced pressure and the resulting residue waspurified by reverse-phase prep-HPLC to afford 268 (19.8 mg, 22%) as ayellow solid. MS-ESI: [M+H]⁺ 514.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.47 (d,J=5.5 Hz, 1H), 7.57 (s, 1H), 7.44 (d, J=2.5 Hz, 1H), 7.39 (s, 1H), 7.36(d, J=2.5 Hz, 1H), 7.34 (d, J=5.0 Hz, 1H), 6.95 (s, 1H), 6.56 (s, 1H),5.12-5.10 (m, 1H), 4.44-4.41 (m, 2H), 4.22-4.18 (m, 3H), 3.84-3.82 (m,1H), 3.60 (s, 3H), 3.59 (s, 3H), 2.59-2.56 (m, 2H), 2.44-2.42 (m, 2H),1.22 (s, 6H).

Example 269a2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-[(morpholin-4-yl)carbonyl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridine-3-carbaldehyde269a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with4-chloro-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde108a (100 mg, 0.29 mmol),1-methyl-3-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-di-oxaborolan-2-yl)pyridin-2(1H)-one111c (192 mg, 0.44 mmol), Pd(dppf)Cl₂ (12 mg, 0.015 mmol), K₃PO₄ (123mg, 0.58 mmol), sodium acetate (47 mg, 0.58 mmol), acetonitrile (10 mL),and water (5 drops). After three cycles of vacuum/N₂ flush, the mixturewas heated at 100° C. for 1 h. Analysis of the reaction mixture by LCMSshowed complete conversion to the desired product. It was cooled to roomtemperature, and filtered. The filtrate was concentrated under reducedpressure and the residue was purified by silica-gel columnchromatography (dichloromethane/methanol 40:1) to afford 269a (150 mg,83%) as a brown solid. MS-ESI: [M+H]⁺ 621.8

Example 2693-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one269

To a solution of 269a (150 mg, 0.24 mmol) in dichloromethane (5 mL) andmethanol (5 mL) was added NaBH₄ (18.2 mg, 0.482 mmol). After stirring atroom temperature for 1 h, the mixture was quenched with aqueous NH₄Cl(10 mL) and concentrated under reduced pressure. The residue wasextracted with dichloromethane (3×20 m). The combined extract was washedwith brine, dried over Na₂SO₄, concentrated under reduced pressure, andpurified by reverse-phase prep-HPLC to afford 269 (114 mg, 76%) as awhite solid. MS-ESI: [M+H]⁺ 624.3. ¹H NMR (500 MHz, DMSO-d₆) δ 9.00 (s,1H), 8.79 (d, J=2.0 Hz, 1H), 8.50 (d, J=4.5 Hz, 1H), 8.26 (d, J=1.5 Hz,1H), 7.67 (dd, J=2.0, 9.0 Hz, 1H), 7.61 (d, J=1.5 Hz, 1H), 7.38-7.36 (m,2H), 6.56 (s, 1H), 5.00 (s, 1H), 4.47-4.40 (m, 2H), 4.25-4.19 (m, 3H),3.86-3.84 (m, 1H), 3.62-3.60 (overlap, m, 4H), 3.51 (s, 3H), 3.52-3.50(m, 4H), 2.59-2.57 (m, 2H), 2.43 (s, 2H), 1.22 (s, 6H).

Example 270a Ethyl N-[(Pyrazin-2-yl)carbamothioyl]carbamate 270a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with pyrazin-2-amine (7.6 g, 80.0 mmol, 1.0 eq.),O-ethyl carbonisothiocyanatidate (12.5 g, 95.4 mmol, 1.2 eq.), anddioxane (150 mL). The reaction mixture was stirred at room temperaturefor 24 hours. After the reaction was complete, it was concentrated to avolume of around 20 mL under reduced pressure and the resultingsuspension was filtered. The solid was collected and washed with ethylacetate (3×20 mL) to afford 270a (14.0 g, 77%) as a white solid. MS-ESI:[M+H]⁺ 227.3

Example 270b [1,2,4]Triazolo[1,5-a]pyrazin-2-amine 270b

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 270a (6.00 g, 26.43mmol, 1.0 eq.), hydroxylamine hydrochloride (3.32 g, 47.52 mmol, 1.8eq.), DIPEA (12 mL), ethanol (40 mL), and methanol (40 mL). The reactionmixture was stirred at 65° C. for 16 hours. After the reaction wascomplete, it was cooled to room temperature and concentrated to a volumeof around 20 mL under reduced pressure. The resulting suspension wascollected by filtration and the solid was washed with 60:1dichloromethane/ethanol (50 mL) to afford 270b (3.3 g, 92%) as a whitesolid. MS-ESI: [M+H]⁺ 136.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.84 (d, J=1.0Hz, 1H), 8.70 (dd, J=1.0, 4.0 Hz, 1H), 7.98 (d, J=5.0 Hz, 1H), 6.47 (s,2H).

Example 270c tert-Butyl[1,2,4]Triazolo[1,5-a]pyrazin-2-ylcarbamate 270c

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 270b (2.00 g, 14.8 mmol, 1.0 eq.), Boc₂O (3.87g, 17.77 mmol, 1.2 eq.), and anhydrous THF (60 mL). The system wasevacuated and refilled with N₂. The reaction mixture was cooled to −78°C., followed by the addition of LHMDS (37.0 mL, 37.0 mmol, 2.5 eq., 1.0Min THF). After the reaction was stirred at −78° C. for 2 hours, it wasquenched with saturated aqueous NH₄Cl solution (30 mL). The mixture wasconcentrated under reduced pressure and the residue extracted withdichloromethane (3×50 mL). The combined organic layer was dried oversodium sulfate, filtered, and concentrated under reduced pressure. Theresulting residue was purified by silica-gel column chromatographyeluting with 1:4 ethyl acetate/petroleum ether to afford 270c (1.87 g,53%) as a white solid. MS-ESI: [M-t-Bu]⁺ 180.0. ¹H NMR (500 MHz,DMSO-d₆) δ 10.31 (s, 1H), 8.94 (s, 1H), 8.72 (d, J=3.5 Hz, 1H), 7.95 (d,J=4.0 Hz, 1H), 1.25 (s, 9H).

Example 270d tert-Butyl5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-ylcarbamate 270d

A 100-mL round-bottomed flask was purged with nitrogen and charged with270c (1.0 g, 4.25 mmol), 20% palladium on carbon (10% wet, 200 mg), andethanol (40 mL). It was then evacuated, charged with hydrogen gas (25atm), and stirred at 60° C. for 24 h. The hydrogen was evacuated andnitrogen was charged into the flask. The catalyst was removed byfiltration through a pad of CELITE® and the filtrate was concentratedunder reduced pressure to afford 270d (700 mg, 68%). MS-ESI: [M-t-Bu]⁺184.0

Example 270e tert-Butyl7-Methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-yl-carbamate270e

Following the procedure in Example 191i, and starting with 270d (500 mg,2.1 mmol, 1.0 eq.), paraformaldehyde (630 mg, 21.0 mmol, 10.0 eq.),ZnCl2/diethyl ether (2.1 mL, 2.1 mmol, 1.0 M), NaBH3CN (390 mg, 6.3mmol, 3.0 eq.), and methanol (20 mL) afforded 270e as a yellow solid(500 mg, 94%). MS-ESI: [M-tBu]⁺ 198.0.

Example 270f7-Methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-amine 270f

Following the procedure in Example 131e, and starting with 270e (500 mg,1.97 mmol) Boc deprotection with acid afforded 270f as a yellow solid(200 mg, 66%). MS-ESI: [M+H]⁺ 154.1.

Example 270g(4-(1-Methyl-5-(7-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 270g

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 270f (100 mg, 0.65 mmol,1.7 eq.),(4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 217a (200 mg, 0.38 mmol, 1.0 eq.), DMF (10 mL), and cesiumcarbonate (499 mg, 1.52 mmol, 4.0 eq.). After bubbling nitrogen throughthe resulting solution for 10 minutes, Xantphos (44 mg, 0.076 mmol, 0.20eq.) and tris(dibenzylideneacetone)dipalladium(0) (35 mg, 0.038 mmol,0.10 eq.) were added. The reaction mixture was subjected to three cyclesof vacuum/argon flush and heated at 100° C. for 16 h. After this timethe reaction was cooled to room temperature and filtered. The filtratewas partitioned between ethyl acetate (50 mL) and water (10 mL). Theaqueous layer was separated and extracted with ethyl acetate (3×20 mL).The combined organic layer was concentrated under reduced pressure. Theresidue was purified on silica-gel column chromatography eluting with50:1 dichloromethane/methanol to afford 270g (90 mg, 41%). MS-ESI:[M+H]⁺ 598.3.

Example 2702-[3-(hydroxymethyl)-4-[1-methyl-5-[(7-methyl-6,8-dihydro-5H-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one270

Following the procedure for Example 241, and starting with 270g (90 mg,0.15 mmol), afforded 270 as a white solid (47 mg, 56%). MS-ESI: [M+H]⁺556.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.50 (d, J=5.0 Hz, 1H), 8.03 (d,J=2.5 Hz, 1H), 7.83 (s, 1H), 7.50 (d, J=2.5 Hz, 1H), 7.33 (d, J=5.5 Hz,1H), 6.58 (s, 1H), 4.93 (t, J=5.5 Hz, 1H), 4.44-4.38 (m, 2H), 4.24-4.02(m, 5H), 3.88-3.85 (m, 1H), 3.61-3.59 (m, overlap, 5H), 2.87 (t, J=5.5Hz, 2H), 2.64-2.58 (m, 2H), 2.49-2.46 (m, 2H), 2.40 (s, 3H), 1.80-1.69(m, 4H).

Example 271a (S)-tert-Butyl4-(6-(5-Chloro-2-methoxypyridin-3-ylamino)pyridin-3-yl)-3-methylpiperazine-1-carboxylate271a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (40 mL),(S)-tert-butyl 4-(6-amino pyridin-3-yl)-3-methylpiperazine-1-carboxylate101h (2.04 g, 7.0 mmol), 3-bromo-5-chloro-2-methoxypyridine (2.8 g, 12.6mmol), Pd₂(dba)₃ (640 mg, 0.70 mmol), XantPhos (404.6 mg, 0.70 mmol),and cesium carbonate (4.56 g, 14.0 mmol). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 4 h. Afterthis time the reaction was cooled to room temperature. It was thenfiltered and the filtrate was evaporated under reduced pressure. Theresidue was purified by silica-gel column chromatography eluting with1:3 ethyl acetate/petroleum ether to afford 271a (1.7 g, 57%) as ayellow solid. MS-ESI: [M+H]⁺ 434.2

Example 271b tert-Butyl(3S)-4-(6-{[5-(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-3-(hydroxymethyl)pyridin-4-yl)-2-methoxypyridin-3-yl]amino}pyridin-3-yl)-3-methylpiperazine-1-carboxylate271b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 271a (650 mg, 1.50mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (1.79 g, 4.5 mmol), Pd₂(dba)₃ (137.2 mg, 0.15 mmol),P(cy)₃(167.4 mg, 0.60 mmol), Cs₂CO₃ (978 mg, 3.0 mmol), dioxane (20 mL),and water (0.5 mL). After three cycles of vacuum/argon flush, themixture was heated at 110° C. for 16 h. After this time the reaction wascooled to room temperature. Lithium hydroxide monohydrate (1.89 g, 45mmol) and water (2.0 mL) were added. The resulting mixture was stirredat 45° C. for 4 h. It was then filtered and the filtrate was evaporatedunder reduced pressure. The residue was purified by silica-gel columnchromatography eluting with 3:1 ethyl acetate/petroleum ether to afford271b (290 mg, 27%) as a yellow solid. MS-ESI: [M+H]⁺ 709.3

Example 271c10-[3-(Hydroxymethyl)-4-[5-({5-[(2S)-2-methylpiperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one271c

A solution of 271b (286.6 mg, 0.40 mmol) in dioxane/HCl (30 mL) wasstirred at 50° C. for 2 h. It was evaporated under reduced pressure toafford 271c (450 mg, crude) as a black solid. MS-ESI: [M+H]⁺ 595.3

Example 2713-[3-(hydroxymethyl)-4-[5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-1H-pyridin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one271

To a solution of 271c (450 mg, 0.75 mmol) in methanol (10 mL) was addedoxetan-3-one (162 mg, 2.25 mmol), NaBH₃CN (141.8 mg, 2.25 mmol), andZnCl₂ (306 mg, 2.25 mmol). The reaction was stirred at room temperaturefor 3 h. The mixture was evaporated under reduced pressure and theresidue was diluted with water (5 mL). It was then extracted withdichloromethane (3×10 mL) and the combined dichloromethane extract wasconcentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford 271 (23.0 mg, 8.8%, over two steps) asa yellow solid. MS-ESI: [M+H]⁺ 651.3. ¹H NMR (500 MHz, CDCl₃) δ 9.76 (s,1H), 8.74 (d, J=2.0 Hz, 1H), 8.53 (d, J=5.0 Hz, 1H), 7.99 (d, J=3.0 Hz,1H), 7.84 (s, 1H), 7.73 (s, 1H), 7.41 (d, J=4.5 Hz, 1H), 7.35 (dd, J=2.5Hz, 8.5 Hz, 1H), 6.87 (s, 1H), 6.85 (d, J=9.0 Hz, 1H), 5.16-5.13 (m,1H), 4.72-4.69 (m, 5H), 4.54-4.53 (m, 1H), 4.36-4.35 (m, 1H), 4.19-4.17(m, 2H), 3.89-3.87 (m, 1H), 3.56-3.49 (m, 2H), 3.11-3.09 (m, 2H),2.60-2.48 (m, overlap, 7H), 2.24-2.21 (m, 1H), 1.29 (s, 6H), 1.02 (d,J=6.0 Hz, 3H)

Example 272a5-Bromo-1-methyl-3-(5-(1-(oxetan-3-yl)azetidin-3-yl)pyridin-2-ylamino)pyridine-2(1H)-one272a

A mixture of3-(5-(azetidin-3-yl)pyridin-2-ylamino)-5-bromo-1-methylpyridin-2(1H)-one239b (140 mg, 0.42 mmol), oxetan-3-one (91 mg, 1.26 mmol), NaBH₃CN (78mg, 1.26 mmol), and zinc chloride (171 mg, 1.26 mmol) in methanol (10mL) was stirred at 50° C. for 2 hours. The mixture was concentratedunder reduced pressure and water (5 mL) was added to the residue. It wasthen extracted with dichloromethane (3×10 mL). The combined organiclayer was concentrated under reduced pressure. The residue was purifiedby column chromatography eluting with 50:1 dichloromethane/methanol toafford 272a (145 mg, 85%). MS-ESI: [M+H]⁺ 390.8

Example 272b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-[1-(oxetan-3-yl)azetidin-3-yl]pyridin-2-yl}amino)-6-oxopyridin-3-yl]pyridin-3-yl)methylAcetate 272b

A 25-ml round-bottomed flask equipped with a reflux condenser wascharged with 272a (140 mg, 0.35 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diaza-tricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (140 mg, 0.35 mmol), Pd(dppf)Cl₂ (28 mg, 0.035 mmol), sodiumacetate (58 mg, 0.70 mmol), K₃PO₄ (148 mg, 0.70 mmol), water (6 drops),and acetonitrile (6 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 2 h. It was then filtered and thefiltrate was evaporated under reduced pressure. The residue was purifiedby silica-gel column chromatography eluting with 25:1dichloromethane/methanol to afford 272b (114 mg, 46%) as a brown solid.MS-ESI: [M+H]⁺ 664.4

Example 2723-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[1-(oxetan-3-yl)azetidin-3-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one272

A mixture of 272b (114 mg, 0.17 mmol) and lithium hydroxide (41 mg, 1.7mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at 30°C. for 1 h. The mixture was evaporated in vacuo and the residue wasdiluted with water (5 mL). It was then extracted with ethyl acetate(3×10 mL). The combined ethyl acetate extract was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 272 (52 mg, 50%) as a white solid. MS-ESI: [M+H]⁺ 622.3. ¹HNMR (500 MHz, CDCl₃) δ 8.77 (d, J=2.0 Hz, 1H), 8.52 (d, J=5.0 Hz, 1H),8.19 (d, J=1.5 Hz, 1H), 7.94 (s, 1H), 7.90 (d, J=2.0 Hz, 1H), 7.61 (dd,J=2.0, 8.5 Hz, 1H), 7.38 (d, J=5.0 Hz, 1H), 6.86-6.84 (m, 2H), 5.12-5.09(m, 1H), 4.77-4.74 (m, 2H), 4.69-4.66 (m, 1H), 4.61-4.59 (m, 2H), 4.54(bs, 1H), 4.36-4.32 (m, 1H), 4.19-4.17 (m, 2H), 3.90-3.83 (m, 2H),3.80-3.77 (m, 2H), 3.74 (s, 3H), 3.71-3.68 (m, 1H), 3.30-3.27 (m, 2H),2.60-2.59 (m, 2H), 2.54 (s, 2H), 1.30 (s, 6H).

Example 273a[4-(5-Bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylacetate 273a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 3-bromo-5-iodo-1-methylpyridin-2(1H)-one 214b(1.57 g, 5.0 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (1.98 g, 5.0 mmol), PdCl₂(dppf) (205 mg, 0.25 mmol), K₃PO₄(2.12 g, 10.0 mmol), sodium acetate (820 mg, 10.0 mmol), acetonitrile(45 mL), and water (1 mL). The system was evacuated and refilled withN₂. The reaction mixture was stirred at 30° C. for 3 h. It was thenfiltered and the filtrate was concentrated under reduced pressure. Theresulting residue was purified by silica-gel column chromatographyeluting with 30:1 dichloromethane/methanol to afford 273a (580 mg, 22%)as a white solid. MS-ESI: [M+H]⁺ 539.2. ¹H NMR (500 MHz, CDCl₃) δ 8.49(d, J=5.0 Hz, 1H), 7.84 (d, J=2.5 Hz, 1H), 7.45 (d, J=2.0 Hz, 1H), 7.09(d, J=5.0 Hz, 1H), 6.79 (s, 1H), 5.15 (s, 2H), 4.55-4.51 (m, 1H),4.27-4.25 (m, 1H), 4.15-4.13 (m, 1H), 4.06-4.04 (m, 1H), 3.68 (s, 3H),2.58-2.56 (m, 2H), 2.51 (s, 2H), 1.86 (s, 3H), 1.28 (s, 6H).

Example 273b(2′-(7,7-dimethyl-1-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2(6H)-yl)-1-methyl-6-oxo-5-(pyridin-2-ylamino)-1,6-dihydro-[3,4′-bipyridin]-3′-yl)methylacetate 273b

Into a 1-dram vial was added 273a (40 mg, 0.074 mmol), 2-aminopyridine,(1.2 equiv), cesium carbonate (1.5 equiv), Xantphos (10 mol %) andtris(dibenzylideneacetone) dipalladium(0) (5 mol %) in dry 1,4-dioxane(0.2 M). The reaction was then stirred at 80° C. for 3 hours. Aftercooling to room temperature, the reaction was then diluted withdichloromethane (3 mL) and washed with water (2×3 mL). The organic layerwas dried over magnesium sulfate, filtered and concentrated in vacuo.The crude product 273b was then carried on to the subsequent stepwithout purification.

Example 2733-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(2-pyridylamino)-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one273

Into a 1 dram vial was added 273b (1 equiv) in a 4:1 mixture of THF andwater (1 mL). Lithium hydroxide (1.5 equiv) was then added to themixture and the reaction was stirred at room temperature for 16 hours.The reaction was then diluted with dichloromethane (3 mL) and washedwith water (2×3 mL). The organic layer was collected, dried overmagnesium sulfate, filtered, and concentrated in vacuo. The crudematerial was purified by reverse-phase chromatography to give 273. ¹HNMR (400 MHz, DMSO-d6) δ 8.73 (d, J=2.4 Hz, 1H), 8.62 (s, 1H), 8.49 (d,J=5.0 Hz, 1H), 8.17 (dd, J=5.1, 1.9 Hz, 1H), 7.62-7.56 (m, 1H), 7.54 (d,J=2.5 Hz, 1H), 7.35 (d, J=5.1 Hz, 1H), 7.30 (d, J=8.5 Hz, 1H), 6.80 (dd,J=7.0, 5.1 Hz, 1H), 6.56 (s, 1H), 4.96-4.93 (m, 1H), 4.48-4.39 (m, 2H),4.24-4.17 (m, 2H), 3.89-3.84 (m, 1H), 3.61 (s, 3H), 2.58 (d, J=8.0 Hz,2H), 2.43 (s, 3H), 1.22 (s, 6H).

Example 2743-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylpyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one274

Following the procedures of Example 273, and substituting2-amino-5-methylpyrazine for 2-aminopyridine, 274 was prepared. ¹H NMR(400 MHz, DMSO-d6) δ 8.98 (s, 1H), 8.68-8.58 (m, 2H), 8.49 (d, J=5.1 Hz,1H), 8.04 (s, 1H), 7.58 (d, J=2.4 Hz, 1H), 7.34 (d, J=5.1 Hz, 1H), 6.56(s, 1H), 5.75 (s, 1H), 4.93 (t, J=5.2 Hz, 1H), 4.47-4.37 (m, 2H),4.25-4.16 (m, 2H), 3.88-3.82 (m, 1H), 3.62 (s, 3H), 2.57 (d, J=8.0 Hz,2H), 2.43 (s, 2H), 2.34 (s, 3H), 1.22 (s, 6H).

Example 2753-[4-[5-[(5-fluoro-2-pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one275

Following the procedures of Example 273, and substituting2-amino-5-fluoropyridine for 2-aminopyridine, 275 was prepared. ¹H NMR(400 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.65 (d, J=2.4 Hz, 1H), 8.49 (d,J=5.1 Hz, 1H), 8.14 (d, J=3.1 Hz, 1H), 7.58 (td, J=8.7, 3.1 Hz, 1H),7.54 (d, J=2.4 Hz, 1H), 7.40 (dd, J=9.2, 3.9 Hz, 1H), 7.35 (d, J=5.0 Hz,1H), 6.56 (s, 1H), 4.98-4.91 (m, 1H), 4.46-4.38 (m, 2H), 4.23-4.16 (m,2H), 3.88-3.82 (m, 1H), 3.61 (s, 3H), 2.61-2.51 (m, 2H), 2.43 (s, 2H),1.22 (s, 6H).

Example 2766-[[5-[2-(7,7-dimethyl-4-oxo-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-3-(hydroxymethyl)-4-pyridyl]-1-methyl-2-oxo-3-pyridyl]amino]pyridine-3-carbonitrile276

Following the procedures of Example 273, and substituting2-amino-5-cyanopyridine for 2-aminopyridine, 276 was prepared. ¹H NMR(400 MHz, DMSO-d6) δ 9.38 (s, 1H), 8.73 (d, J=2.2 Hz, 1H), 8.58 (d,J=2.4 Hz, 1H), 8.49 (d, J=5.0 Hz, 1H), 7.94 (dd, J=9.0, 2.4 Hz, 1H),7.68 (d, J=2.4 Hz, 1H), 7.44 (d, J=8.9 Hz, 1H), 7.36 (d, J=5.2 Hz, 1H),6.56 (s, 1H), 5.75 (s, 1H), 4.97 (t, J=5.3 Hz, 1H), 4.46-4.38 (m, 2H),4.21 (s, 3H), 3.84 (s, 1H), 3.62 (s, 3H), 2.58 (d, J=8.1 Hz, 2H), 2.45(s, 2H), 1.22 (s, 6H).

Example 2773-[3-(hydroxymethyl)-4-[5-[(5-methoxy-2-pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one277

Following the procedures of Example 273, and substituting2-amino-5-methoxypyridine for 2-aminopyridine, 277 was prepared. ¹H NMR(400 MHz, DMSO-d6) δ 8.61 (d, J=2.4 Hz, 1H), 8.51-8.47 (m, 2H), 7.91 (d,J=2.4 Hz, 1H), 7.48 (d, J=2.4 Hz, 1H), 7.34 (d, J=5.0 Hz, 1H), 7.33-7.29(m, 2H), 6.56 (s, 1H), 4.94 (t, J=5.3 Hz, 1H), 4.47-4.38 (m, 2H),4.24-4.16 (m, 2H), 3.87-3.83 (m, 1H), 3.75 (s, 3H), 3.60 (s, 3H), 2.58(d, J=7.9 Hz, 2H), 2.43 (s, 2H), 1.22 (s, 6H).

Example 2783-[4-[5-[(5-cyclopropyl-2-pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one278

Following the procedures of Example 273, and substituting2-amino-5-cyclopropylpyridine for 2-aminopyridine, 278 was prepared. ¹HNMR (400 MHz, DMSO-d6) δ 8.67 (d, J=2.4 Hz, 1H), 8.53-8.45 (m, 2H), 8.01(d, J=2.5 Hz, 1H), 7.50 (d, J=2.4 Hz, 1H), 7.34 (d, J=5.0 Hz, 1H), 7.28(dd, J=8.6, 2.5 Hz, 1H), 7.21 (d, J=8.6 Hz, 1H), 6.56 (s, 1H), 4.96-4.92(m, 1H), 4.47-4.41 (m, 2H), 4.24-4.16 (m, 2H), 3.89-3.85 (m, 1H), 3.60(s, 3H), 2.58 (d, J=7.9 Hz, 2H), 2.44 (s, 2H), 1.86-1.77 (m, 1H), 1.22(s, 6H), 0.93 (t, J=8.0 Hz, 1H), 0.90-0.85 (m, 1H), 0.67-0.58 (m, 2H).

Example 2793-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-[[5-(trifluoromethyl)-2-pyridyl]amino]-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one279

Following the procedures of Example 273, and substituting2-amino-5-trifluoromethylpyridine for 2-aminopyridine, 279 was prepared.¹H NMR (400 MHz, DMSO-d6) δ 9.23 (s, 1H), 8.80 (d, J=2.4 Hz, 1H),8.54-8.46 (m, 2H), 7.88 (dd, J=8.7, 2.6 Hz, 1H), 7.66 (d, J=2.3 Hz, 1H),7.48 (d, J=8.8 Hz, 1H), 7.37 (d, J=5.1 Hz, 1H), 6.56 (s, 1H), 4.97 (t,J=5.1 Hz, 1H), 4.50-4.40 (m, 2H), 4.26-4.16 (m, 2H), 3.90-3.81 (m, 1H),3.62 (s, 3H), 2.58 (d, J=8.2 Hz, 2H), 2.43 (s, 2H), 1.22 (s, 6H).

Example 2803-[3-(hydroxymethyl)-4-[1-methyl-5-[[1-methyl-5-(morpholine-4-carbonyl)pyrazol-3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one280

Following the procedures of Example 273, and substituting(3-amino-1-methyl-1H-pyrazol-5-yl)(morpholino)methanone for2-aminopyridine, 280 was prepared. ¹H NMR (400 MHz, DMSO-d6) δ 8.48 (d,J=5.0 Hz, 1H), 8.27 (s, 1H), 8.05 (d, J=2.4 Hz, 1H), 7.43 (d, J=2.4 Hz,1H), 7.33 (d, J=5.1 Hz, 1H), 6.55 (s, 1H), 6.30 (s, 2H), 4.99-4.91 (m,1H), 4.48-4.39 (m, 2H), 4.23-4.15 (m, 7H), 3.89-3.82 (m, 2H), 3.72 (s,3H), 3.59 (s, 3H), 3.27 (s, 2H), 2.58 (d, J=7.5 Hz, 2H), 2.43 (s, 2H),1.22 (s, 6H).

Example 2813-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-2-pyridyl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one281

Following the procedures of Example 273, and substituting2-amino-5-methylpyridine for 2-aminopyridine, 281 was prepared. ¹H NMR(400 MHz, DMSO-d6) δ 8.67 (d, J=2.4 Hz, 1H), 8.48 (d, J=5.4 Hz, 2H),8.01 (d, J=2.3 Hz, 1H), 7.51 (d, J=2.4 Hz, 1H), 7.44 (dd, J=8.5, 2.4 Hz,1H), 7.34 (d, J=5.1 Hz, 1H), 7.21 (d, J=8.5 Hz, 1H), 6.56 (s, 1H), 5.75(s, 1H), 4.93 (t, J=5.4 Hz, 1H), 4.46-4.36 (m, 2H), 4.26-4.16 (m, 2H),3.86-3.80 (m, 1H), 3.60 (s, 3H), 2.58 (d, J=7.8 Hz, 2H), 2.43 (s, 2H),2.17 (s, 3H), 1.22 (s, 6H).

Example 282a 3,3-Dimethylcyclopentanone 282a

To a suspension of CuI (81.0 g, 420 mmol) in anhydrous ethyl ether (500mL) cooled to 0° C. was added the solution of methyllithium in ethylether (430 mL, 860 mmol, 2.0M) over a period of 30 minutes. The mixturewas stirred at 0° C. for 2 h. To the above mixture was added3-methylcyclopent-2-enone (33.6 g, 350 mmol) dropwise over a period of 1h at 0° C. The resulting mixture was stirred at 0° C. for another 2 h.It was then quenched with saturated NH₄Cl (300 mL) and filtered. Thefiltrate was extracted with ethyl ether (2×200 mL). The combined organiclayer was dried over anhydrous Mg₂SO₄ and filtered. The filtrate wasevaporated under reduced pressure to afford 282a as a colorless oil (28g, 71%). ¹H NMR (500 MHz, DMSO-d₆) δ 2.31 (t, J=8.0 Hz, 2H), 2.05 (s,2H), 1.79 (t, J=8.0 Hz, 2H), 1.12 (s, 6H).

Example 282b 2-Chloro-4,4-dimethylcyclopent-1-enecarbaldehyde 282b

To a solution of DMF (18.3 g, 250 mmol) in dichloromethane (300 mL)cooled to 0° C. was added POCl₃ (40.5 g, 250 mmol) over a period of 10minutes. The mixture was stirred at 20° C. for 1 h. To the above mixturewas added 282a (28.0 g, 250 mmol) dropwise over a period of 20 minutes.The resulting mixture was heated at reflux for 20 h. The reactionmixture was cooled to room temperature and poured into a solution ofsodium acetate (60 g) in ice-water (400 g). The mixture was extractedwith dichloromethane (2×300 mL). The combined organic layer was washedwith water (2×200 mL), dried over anhydrous Mg₂SO₄ and filtered. Thefiltrate was evaporated under reduced pressure to afford 282b as acolorless oil (33.0 g, crude). ¹H NMR (500 MHz, DMSO-d₆) δ 9.99 (s, 1H),2.62 (d, J=2.0 Hz, 2H), 2.38 (d, J=2.0 Hz, 2H), 1.15 (s, 6H).

Example 282c Ethyl5,5-Dimethyl-5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxylate 282c

To a solution of 282b (33.0 g, crude) in dichloromethane (400 mL) andtriethylamine (60 g, 600 mmol) was added ethyl 2-mercaptoacetate (19.2g, 160 mmol). The reaction mixture was heated at reflux for 6 h. It wasthen concentrated under reduced pressure. The residue was dissolved inethanol (400 mL) and triethylamine (60 g, 600 mmol). The mixture washeated at reflux for 12 h. It was concentrated again under reducedpressure and the residue was purified by silica-gel columnchromatography eluting with 40:1 petroleum ether/ethyl acetate to afford282c as yellow solid (18.0 g, 32%, over two steps). MS-ESI: [M+H]⁺225.3. ¹H NMR (500 MHz, DMSO-d₆) δ 7.49 (s, 1H), 4.32 (q, J=7.0 Hz, 2H),2.72 (s, 2H), 2.56 (s, 2H), 1.35 (t, J=7.0 Hz, 3H), 1.22 (s, 6H).

Example 282d5,5-Dimethyl-5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxylic acid282d

To the solution of 282c (16.0 g, 71.0 mmol) in propan-2-ol (200 mL),tetrahydrofuran (200 mL), and water (200 mL) was added lithium hydroxide(6.82 g, 284 mmol). The reaction mixture was heated at 65° C. for 5 h.The organic solvents were removed under reduced pressure. The pH of theresidue was adjusted to 1.0 with hydrochloride acid (12M). Theprecipitate was collected by filtration and dried in vacuo to afford282d (12.0 g, 86%) as white solid. MS-ESI: [M+H]⁺ 196.9

Example 282eN-tert-Butyl-5,5-dimethyl-5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxamide282e

A suspension of 282d (12.0 g, 61.0 mmol) in SOCl₂ (80 mL) was heated at65° C. for 2 h. The reaction mixture was concentrated under reducedpressure. The residue was diluted with dichloromethane (20 mL), whichwas added to the solution of 2-methylpropan-2-amine (4.45 g, 61.0 mmol)and triethylamine (18.0 g, 180 mmol) in dichloromethane (180 mL). Theresulting mixture was stirred for 16 h and diluted with dichloromethane(200 mL). It was washed with water (3×50 mL), dried over anhydrousMg₂SO₄, filtered, and evaporated under reduced pressure to afford 282e(15.0 g, 97%) as yellow solid. MS-ESI: [M+H]⁺ 252.0

Example 282fN-tert-Butyl-3-formyl-5,5-dimethyl-5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxamide282f

To a solution of 282e (1.5 g, 6.0 mmol) in anhydrous THF (60 mL) cooledat −70° C. was added the solution of n-butyl lithium (10.0 mL, 25 mmol,2.5 Min hexane) over a period of 5 minutes. It was stirred at −70° C.for 6 h. DMF (1.3 g, 18.0 mmol) was added over a period of 5 minutes andthe result mixture was stirred at room temperature for overnight. It wasthen quenched with saturated NH₄Cl (40 mL) and concentrated underreduced pressure. The residue was extracted with ethyl acetate (2×30mL). The combined organic layer was dried over anhydrous Mg₂SO₄ andfiltered. The filtrate was evaporated under reduced pressure to afford282f as yellow solid (1.34 g, 80%). MS-ESI: [M+H]⁺ 280.3

Example 282gN-tert-Butyl-3-(hydrazonomethyl)-5,5-dimethyl-5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxamide282g

To a solution of 85% aqueous hydrazine (10 mL) in THF (180 mL) was added282f (5.6 g, 20.0 mmol) in anhydrous THF (20 mL) over a period of 5minutes. It was stirred at 20° C. for 3 h. The reaction mixture wasconcentrated under reduced pressure to afford 282g as black solid (6.0g, yield: 95%, purity: 95%). MS-ESI: [M+H]⁺ 294.0

Example 282h4,4-Dimethyl-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6),11-trien-9-one282h

A solution of 282g (3.8 g, 13.0 mmol) in 30% H₂SO₄ (100 mL) was heatedat reflux for 16 h. The reaction mixture was cooled to room temperatureand extracted with dichloromethane (3×200 mL). The combined organiclayer was concentrated under reduced pressure and the residue waspurified by silica-gel column chromatography eluting with 100:1dichloromethane/methanol to afford 282h as yellow solid (1.72 g, 60%).MS-ESI: [M+H]⁺ 221.0

Example 282i4-Chloro-2-{4,4-dimethyl-9-oxo-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6),11-trien-10-yl}pyridine-3-carbaldehyde282i

Following the procedures as described in Example 108a, and starting with282h (330 mg, 1.5 mmol) and 2-bromo-4-chloronicotinaldehyde (950 mg, 4.5mmol), 282i was obtained as a yellow solid (260 mg, 48%). MS-ESI: [M+H]⁺359.9

Example 282j2-{4,4-Dimethyl-9-oxo-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6),11-trien-10-yl}-4-[1-methyl-5-({5-[(25)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridine-3-carbaldehyde282j

Following the procedure for preparation in Example 191k, and startingwith 282i (216 mg, 0.60 mmol), and(5)-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one191j (482 mg, 0.90 mmol), 282j was obtained as a yellow solid (407 mg,48%). MS-ESI: [M+H]⁺ 678.8

Example 2823-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one282

Following the procedures in Example 191, and starting with 282j (370 mg,0.55 mmol), 282 was obtained as a yellow solid (64 mg, 17%). MS-ESI:[M+H]⁺ 681.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.63 (d, J=2.0 Hz, 1H), 8.56(d, J=5.0 Hz, 1H), 8.46-8.45 (m, 2H), 7.85 (d, J=3.0 Hz, 1H), 7.53 (d,J=5.0 Hz, 1H), 7.47 (d, J=2.5 Hz, 1H), 7.36 (dd, J=3.0, 9.0 Hz, 1H),7.24 (d, J=9.0 Hz, 1H), 4.85 (t, J=5.0 Hz, 1H), 4.57-4.54 (m, 2H), 4.47(t, J=6.0 Hz, 1H), 4.4-4.37 (m, 3H), 3.68-3.67 (m, 1H), 3.60 (s, 3H),3.40-3.38 (m, 1H), 3.11-3.08 (m, 1H), 2.96-2.90 (m, 3H), 2.81-2.79 (m,2H), 2.56-2.53 (m, 1H), 2.33-2.32 (m, 2H), 2.19-2.16 (m, 1H), 1.28 (s,3H), 1.27 (s, 3H), 0.93 (d, J=6.0 Hz, 3H).

Example 283a5-Bromo-1-methyl-3-(5-methylisoxazol-3-ylamino)pyridin-2(1H)-one 283a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 5-methylisoxazol-3-amine(1.0 g, 10.2 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (4.09 g, 15.3mmol), Pd₂(dba)₃ (467 mg, 0.51 mmol), Xantphos (598 mg, 1.02 mmol),Cs₂CO₃ (6.65 g, 20.4 mmol), and dioxane (50 mL). After three cycles ofvacuum/argon flush, the reaction mixture was heated at 100° C. for 3 h.Analysis of the reaction mixture by LCMS showed complete conversion tothe desired product. It was filtered when the mixture was still hot. Thefiltrate was cooled down to room temperature and the resultingprecipitation was collected by filtration to afford 283a (1.6 g, 55%) asa yellow solid. MS-ESI: [M+H]⁺ 284.1

Example 283b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(5-methyl-1,2-oxazol-3-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 283b

A 50-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 283a (150 mg, 0.53 mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (834 mg, 2.1 mmol), Pd(dppf)Cl₂ (21 mg, 0.026 mmol), K₃PO₄(224 mg, 0.053 mmol), sodium acetate (87 mg, 1.1 mmol), acetonitrile (10mL), and water (5 drops). After three cycles of vacuum/N₂ flush, themixture was heated at 100° C. for 1 h. Then it was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the residue was washed with acetonitrile to afford the 283b(100 mg, 34%) as white solid. MS-ESI: [M+H]⁺ 557.3

Example 2833-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one283

To a solution of 283b (90 mg, 0.162 mmol) in THF (5 mL), i-propanol (5mL), and water (5 mL) was added lithium hydroxide (3.8 mg, 1.62 mmol).The reaction mixture was stirred at room temperature for 1 h andconcentrated under reduced pressure. The residue was extracted withdichloromethane (20 mL×3). The combined organic layer was washed withbrine, dried over Na₂SO₄, filtered, and concentrated under reducedpressure. The residue was purified by reverse-phase prep-HPLC to afford283 (65 mg, 78%) as white solid. MS-ESI: [M+H]⁺ 514.9. ¹H NMR (500 MHz,DMSO-d₆) δ 8.98 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.02 (d, J=2.0 Hz, 1H),7.56 (d, J=2.5 Hz, 1H), 7.32 (d, J=5.0 Hz, 1H), 6.57 (s, 1H), 6.25 (s,1H), 4.93 (t, J=5.0 Hz, 1H), 4.48-4.38 (m, 2H), 4.25-4.19 (m, 3H),3.87-3.85 (m, 1H), 3.60 (s, 3H), 2.62-2.54 (m, 2H), 2.43 (s, 2H), 2.31(s, 3H), 1.22 (s, 6H).

Example 284a2-(10-Fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-4-(1-methyl-5-(5-(oxetan-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)nicotinaldehyde284a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with1-methyl-3-(5-(oxetan-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one163a (354 mg, 0.83 mmol),4-chloro-2-(10-fluoro-1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)nicotinaldehyde134c (289 mg, 0.83 mmol), PdCl₂(dppf) (68 mg, 0.08 mmol), K₃PO₄ (352 mg,1.66 mmol), sodium acetate (136 mg, 1.66 mmol), acetonitrile (50 mL),and water (3 mL). The system was evacuated and refilled with N₂. Thereaction mixture was heated at 100° C. for 2 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 30:1 dichloromethane/methanol toafford 284a (305 mg, 60%) as a brown solid. MS-ESI: [M+H]⁺: 613.6.

Example 28410-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(oxetan-3-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one284

To a suspension of 284a (250 mg, 0.41 mmol) in methanol (20 mL) wasadded sodium borohydride (47 mg, 1.23 mmol) at 0° C. The mixture wasstirred for 30 minutes. It was then quenched with water (2 mL) andconcentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford 284 (20 mg, 6.6%). MS-ESI: [M+H]⁺615.6. ¹H NMR (500 MHz, CDCl₃) δ 8.46 (d, J=5.0 Hz, 1H), 7.94 (d, J=3.0Hz, 1H), 7.66 (d, J=2.0 Hz, 1H), 7.43 (s, 1H), 7.34 (d, J=5.0 Hz, 1H),5.75 (s, 1H), 4.95 (t, J=6.5 Hz, 1H), 4.76-4.74 (m, 2H), 4.69-4.65-4.67(m, 3H), 4.46-4.44 (m, 1H), 4.35-4.33 (m, 1H), 4.10-4.08 (m, 4H),3.38-3.35 (m, 2H), 3.69 (s, 3H), 3.58-3.56 (m, 2H), 2.84-2.82 (m, 2H),2.58-2.53 (m, 4H), 1.89-1.84 (m, 2H), 1.77-1.76 (m, 2H).

Example 285a 4-Nitro-1-(oxetan-3-yl)-1H-imidazole 285a

A sealed tube was charged with 4-nitro-1H-imidazole (500 mg, 4.42 mmol),3-iodooxetane (920 mg, 5.0 mmol), Cs₂CO₃ (2.90 g, 8.84 mmol), anddioxane (12 mL). The sealed tube was heated at 120° C. for 16 h. It wasthen cooled to room temperature and filtered. The filtrate wasevaporated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 30:1dichloromethane/methanol to afford 285a as a white solid (250 mg, 33%).MS-ESI: [M+H]⁺ 170.2.

Example 285b 1-(Oxetan-3-yl)-1H-imidazol-4-amine 285b

A 25-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 285a (100 mg, 0.6 mmol), 10% palladium on carbon (10% wet,10 mg) and methanol (10 mL). The flask was evacuated, charged withhydrogen gas (via balloon), and stirred for 1 h at room temperature. Thehydrogen was then evacuated and nitrogen was charged to the flask. Thecatalyst was removed by filtration through a pad of CELITE® and thefiltrate was concentrated under reduced pressure to afford 285b (70 mg,85%). MS-ESI: [M+H]⁺ 140.3.

Example 285c(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(1-methyl-5-{[1-(oxetan-3-yl)-1H-imidazol-4-yl]amino}-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methylAcetate 285c

A 25-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 285b (40 mg, 0.28 mmol),[4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatri-cyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylacetate 273a (150 mg, 0.28 mmol), Pd₂(dba)₃ (15 mg, 0.015 mmol),XantPhos (18 mg, 0.03 mmol), cesium carbonate (200 mg, 0.6 mmol), and1,4-dioxane (6 mL). After three cycles of vacuum/argon flush, themixture was heated at 100° C. for 2 h. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the residue was purified by silica-gel columnchromatography eluting with 25:1 dichloromethane/methanol to afford 285cas a yellow solid (80 mg, 47%). MS-ESI: [M+H]⁺ 598.3.

Example 2853-[3-(hydroxymethyl)-4-[1-methyl-5-[[1-(oxetan-3-yl)imidazol-4-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one285

A mixture of 285c (80 mg, 0.13 mmol) and lithium hydroxide water (55 mg,1.3 mmol) in i-propanol/THF (3:2, 5 mL) and water (2 mL) was stirred at30° C. for 1 h. The mixture was evaporated under reduced pressure andwater (5 mL) was added to the residue. It was then extracted withdichloromethane (3×10 mL). The combined dichloromethane extract wasconcentrated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 285 (36 mg, 50%) as a white solid.MS-ESI: [M+H]⁺ 556.3. ¹H NMR (500 MHz, CDCl₃) δ 8.48 (d, J=5.0 Hz, 1H),7.53 (d, J=2.0 Hz, 1H), 7.47-7.45 (m, 2H), 7.35-7.34 (m, 2H), 7.28 (s,1H), 6.88 (s, 1H), 5.27-5.19 (m, 2H), 5.10-5.07 (m, 2H), 4.94-4.91 (m,2H), 4.69-4.65 (m, 1H), 4.52-4.44 (m, 2H), 4.17-4.16 (m, 2H), 3.87-3.84(m, 1H), 3.72 (s, 3H), 2.59-2.58 (m, 2H), 2.53 (s, 2H), 1.29 (s, 6H).

Example 286a(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(1,2-oxazol-3-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 286a

A 25-mL round-bottomed flask equipped with a reflux condenser wascharged with[4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricy-clo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylacetate 273a (161 g, 0.30 mmol), isoxazol-3-amine (25 mg, 0.30 mmol),cesium carbonate (196 mg, 0.60 mmol), and 1,4-dioxane (10 mL). Afterbubbling nitrogen through the suspension for 10 minutes,tris(dibenzylideneacetone)dipalladium(0) (14.0 mg, 0.015 mmol) andxantphos (17 mg, 0.030 mmol) were added. The system was subjected tothree cycles of vacuum/argon flush and heated at reflux for 5 h. It wasthen cooled to room temperature and filtered. The solid was washed withdichloromethane (2×10 mL). The combined organic filtrate wasconcentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with dichloromethane/methanol(80/1 to 30/1) to afford 286a (96 mg, 59%) as yellow solid. MS-ESI:[M+H]⁺ 542.8.

Example 2863-[3-(hydroxymethyl)-4-[5-(isoxazol-3-ylamino)-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one286

To a solution of 286a (96 mg, 0.18 mmol) in THF/i-propanol/water (5/3/2mL) was added lithium hydroxide (21 mg, 0.88 mmol). The mixture wasstirred at room temperature for 1 h. After the reaction was complete,the mixture was evaporated under pressure and the residue was purifiedby reverse-phase prep-HPLC to afford 286 as a white solid (75 mg, 85%).MS-ESI: [M+H]⁺ 501.3. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, J=6.5 Hz, 1H),8.19 (d, J=2.5 Hz, 1H), 8.10 (d, J=2.5 Hz, 1H), 8.97 (d, J=3.0 Hz, 1H),7.71 (s, 1H), 7.37 (d, J=6.5 Hz, 1H), 6.85 (s, 1H), 6.18 (d, J=2.5 Hz,1H), 5.12-5.11 (m, 1H), 4.66-4.64 (m, 1H), 4.52-4.51 (m, 1H), 4.29-4.27(m, 1H), 4.18-4.16 (m, 2H), 3.87-3.86 (m, 1H), 3.73 (s, 3H), 2.59-2.57(m, 2H), 2.53-2.51 (m, 2H), 1.28 (s, 6H).

Example 287a N-Methoxy-N-methyl-3-nitro-1H-pyrazole-5-carboxamide 287a

A 500-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 3-nitro-1H-pyrazole-5-carboxylic acid (15.7 g,1.0 eq., 100 mmol), N,O-dimethylhydroxylamine hydrochloride (19.5 g, 2.0eq., 200 mmol), HATU (76.0 g, 2.0 eq., 200 mmol), triethylamine (40.4 g,4.0 eq., 400 mmol), and dichloromethane (300 mL). The reaction mixturewas stirred at room temperature for overnight. The solvent was removedunder reduced pressure. The resulting residue was purified by silica-gelcolumn chromatography eluting with 100:1 dichloromethane/methanol toafford 287a (16.0 g, 80%) as white solid. MS-ESI: [M+H]⁺ 201.1

Example 287b 3-Amino-N-methoxy-N-methyl-1H-pyrazole-5-carboxamide 287b

A 250-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 287a (16.0 g, 1.0 eq., 80.0 mmol), 10% palladium on carbon(50% wet, 800 mg), and methanol (100 mL). The mixture was evacuated,charged with hydrogen gas, and stirred under hydrogen atmosphere at roomtemperature overnight. The hydrogen was then evacuated and nitrogen wascharged into the flask. The catalyst was removed by filtration through apad of CELITE®. The filtrate was concentrated under reduced pressure toafford 287b (11.0 g, 81%) as white solid. MS-ESI: [M+H]⁺ 171.1

Example 287c3-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-methoxy-N-methyl-1H-pyrazole-5-carboxamide287c

A 250-mL round-bottomed flask equipped with a magnetic stirrer and aDean-Stark trap was charged with 287b (11.0 g, 1.0 eq., 64.7 mmol),hexane-2,5-dione (11.1 g, 1.5 eq., 97.2 mmol), p-toluenesulfonic acidmonohydrate (558 mg, 0.05 eq., 3.24 mmol), and toluene (100 mL). Thereaction mixture was refluxed overnight. The resulting mixture wascooled to room temperature and concentrated under reduced pressure. Theresulting residue was purified by silica-gel column chromatographyeluting with 1:2 petroleum ether/ethyl acetate to afford 287c (10.4 g,65%) as white solid. MS-ESI: [M+H]⁺ 249.0

Example 287d tert-Butyl2-(3-(2,5-Dimethyl-1H-pyrrol-1-yl)-5-(methoxy(methyl)carbamoyl)-1H-pyrazol-1-yl)ethylcarbamate287d

A 250-mL round-bottomed flask equipped with a magnetic stirrer wascharged with 287c (10.4 g, 1.0 eq., 41.9 mmol), tert-butyl2-chloroethylcarbamate (37.7 g, 5.0 eq., 210.0 mmol), Na₂CO₃ (22.3 g,5.0 eq., 210.0 mmol), and DMF (100 mL). The reaction mixture was stirredat 110° C. overnight. After cooling to room temperature, the resultingmixture was poured into water (200 mL) and extracted with ethyl acetate(3×100 mL). The combined organic layer was concentrated under reducedpressure. The resulting residue was purified by silica-gel columnchromatography eluting with ethyl acetate to afford 287d (10.8 g, 66%)as yellow oil. MS-ESI: [M+H]⁺ 392.0

Example 287e tert-Butyl2-(5-Acetyl-3-(2,5-dimethyl-1H-pyrrol-1-yl)-1H-pyrazol-1-yl)ethylcarbamate287e

A 250-mL round-bottomed flask equipped with a magnetic stirrer wascharged with 287d (7.82 g, 1.0 eq., 20.0 mmol) and THF (100 mL) under N₂protection. A solution of MeMgBr (3.0 M in ether) (17 mL, 2.5 eq., 50.0mmol) was added at −78° C. The mixture was stirred at room temperaturefor 3 h and quenched with saturated NH₄Cl solution. It was thenconcentrated under reduced pressure and the residue was extracted withethyl acetate (3×50 mL). The combined organic layer was evaporated underreduced pressure. The residue was purified by silica-gel columnchromatography eluting with 4:1 petroleum ether/ethyl acetate to afford287e as colorless oil (5.40 g, 78%). MS-ESI: [M+H]⁺ 347.0. ¹H NMR (500MHz, CDCl₃) δ 6.57 (s, 1H), 5.91 (s, 2H), 4.93 (bs, 1H), 4.71 (t, J=5.5Hz, 2H), 3.62 (t, J=5.5 Hz, 2H), 2.57 (s, 3H), 2.16 (s, 6H), 1.28 (s,9H).

Example 287f2-(2,5-Dimethyl-1H-pyrrol-1-yl)-4-methyl-6,7-dihydropyrazolo[1,5-a]pyrazine287f

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 287e (5.40 g, 1.0 eq., 15.6 mmol), CF₃COOH (10mL), and dichloromethane (50 mL). The mixture was stirred at roomtemperature for 1 h and concentrated under reduced pressure to affordcrude 287f, which was used in the next step without furtherpurification. MS-ESI: [M+H]⁺ 229.1

Example 287g2-(2,5-Dimethyl-1H-pyrrol-1-yl)-4-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine287g

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 287f (3.56 g, 1.0 eq., 15.6 mmol), NaBH₄ (2.96g, 5.0 eq., 78.0 mmol), and methanol (50 mL). The mixture was stirred atroom temperature for 1 h and concentrated under reduced pressure. Theresidue was partitioned between water (50 mL) and dichloromethane (50mL). The water phase was extracted with dichloromethane (3×50 mL). Thecombined organic layer was concentrated under reduced pressure. Theresidue was purified by silica-gel column chromatography eluting with10:1 dichloromethane/methanol to afford 287g as a colorless oil (1.54 g,43% over two steps). MS-ESI: [M+H]⁺ 231.3. ¹H NMR (500 MHz, CDCl₃) δ5.91 (s, 1H), 5.86 (s, 2H), 4.17-4.11 (m, 3H), 3.51-3.48 (m, 1H),3.36-3.31 (m, 1H), 2.13 (s, 6H), 1.50 (d, J=6.5 Hz, 3H).

Example 287h2-(2,5-Dimethyl-1H-pyrrol-1-yl)-4,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine287h

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 287g (1.54 g, 1.0 eq., 6.70 mmol), formaldehyde(37% in water) (1.09 g, 2.0 eq., 13.4 mmol), NaBH₃CN (2.11 g, 5.0 eq.,33.5 mmol), HOAc (3 mL), and methanol (30 mL). The mixture was stirredat room temperature for 1 h and concentrated under reduced pressure. Theresidue was partitioned between water (50 mL) and dichloromethane (50mL). The water phase was extracted with dichloromethane (3×50 mL). Thecombined organic layer was concentrated under reduced pressure to affordcrude 287h, which was used in the next step without furtherpurification. MS-ESI: [M+H]⁺ 245.0

Example 287i4,5-Dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine 287i

A 100-mL single-neck round-bottomed flask equipped with a refluxcondenser was charged with 287h (1.63 g, 1.0 eq., 6.70 mmol), NH₂OH.HCl(2.33 g, 5.0 eq., 33.5 mmol), and ethanol (50 mL). The mixture wasrefluxed for 2 days. It was then cooled to room temperature andconcentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford 287i as a yellow solid (211 mg, 19%).MS-ESI: [M+H] 167.1. ¹H NMR (500 MHz, CDCl₃) δ 5.36 (s, 1H), 4.04-4.00(m, 1H), 3.94-3.92 (m, 1H), 3.61 (bs, 2H), 3.30 (q, J=6.5 Hz, 1H),3.10-3.08 (m, 1H), 2.81-2.75 (m, 1H), 2.43 (s, 3H), 1.38 (d, J=6.5 Hz,3H).

Example 287j(4-(5-(4,5-Dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 287j

A 25-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 287i (20 mg, 1.0 eq., 0.12 mmol),(4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 273a (127 mg, 2.0 eq., 0.24 mmol), Pd₂(dba)₃ (9.0 mg, 0.1 eq.,0.010 mmol), Xantphos (11 mg, 0.2 eq., 0.020 mmol), Cs₂CO₃ (78 mg, 2.0eq., 0.24 mmol), and dioxane (5 mL). After three cycles of vacuum/N₂flush, the mixture was stirred at 100° C. for 2 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure. The resulting residue was purified by silica-gelcolumn chromatography eluting with 20:1 dichloromethane/methanol toafford 287j as a brown solid (60 mg, 82%). MS-ESI: [M+H] 610.9

Example 2872-[4-[5-[(4,5-dimethyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one287

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 287j (60 mg, 1.0 eq., 0.098 mmol), lithiumhydroxide (12 mg, 5.0 eq., 0.49 mmol), i-propanol/THF (4/4 mL), andwater (1 mL). The mixture was stirred at room temperature for 1 h andconcentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford 287 as a yellow solid (24 mg, 43%).MS-ESI: [M+H]⁺ 568.9. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, J=5.0 Hz, 1H),7.99 (s, 1H), 7.72 (d, J=2.0 Hz, 1H), 7.44 (s, 1H), 7.36 (d, J=5.0 Hz,1H), 6.91 (s, 1H), 5.74 (s, 1H), 5.04-5.02 (m, 1H), 4.64-4.62 (m, 1H),4.56-4.54 (m, 1H), 4.39-4.37 (m, 1H), 4.17-3.92 (m, 4H), 3.86-3.84 (m,1H), 3.72 (s, 3H), 3.45-3.37 (m, 1H), 3.17-3.14 (m, 1H), 2.89-2.81 (m,1H), 2.64-2.58 (m, 4H), 2.48 (s, 3H), 1.93-1.89 (m, 2H), 1.81-1.80 (m,2H), 1.46 (d, J=6.5 Hz, 3H).

Example 288a1-Methyl-3-(5-methylisoxazol-3-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one288a

A 50-mL round bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with5-bromo-1-methyl-3-(5-methylisoxazol-3-ylamino)pyridin-2(1H)-one 283a(330 mg, 1.16 mmol), Pin₂B₂ (442 mg, 1.74 mmol), Pd₂(dba)₃ (53 mg, 0.058mmol), X-Phos (55 mg, 0.116 mmol), potassium acetate (227 mg, 2.32mmol), and dioxane in (20 mL). After three cycles of vacuum/N₂ flush,the mixture was heated at 70° C. for 2 h. Analysis of the reactionmixture by LCMS showed complete conversion to the desired product. Itwas cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the residue was washed withpetroleum ether to afford 288a (300 mg, 78%) as yellow solid. MS-ESI:[M+H]⁺ 332.3

Example 288b2-{4,4-Dimethyl-9-oxo-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6),11-trien-10-yl}-4-{1-methyl-5-[(5-methyl-1,2-oxazol-3-yl)amino]-6-oxo-1,6-dihydro-pyridin-3-yl}pyridine-3-carbaldehyde288b

A 50-mL round-bottomed flask equipped with a magnetic stirrer wascharged with4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6),11-trien-10-yl}pyridine-3-carbaldehyde282i (72 mg, 0.20 mmol), 288a (102 mg, 0.30 mmol), PdCl₂(dppf) (16 mg,0.020 mmol), K₃PO₄ (85 mg, 0.40 mmol), sodium acetate (33 mg, 0.40mmol), acetonitrile (10 mL), and water (0.5 mL). After bubbling nitrogeninto the mixture for 10 minutes, a reflux condenser was attached to theflask and the mixture was heated at 100° C. for 1 h. It was then cooledto room temperature and filtered. The filtrate was concentrated underreduced pressure to afford 288b, which was used in the next step withoutfurther purification. MS-ESI: [M+H]⁺ 529.3.

Example 2883-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one288

A mixture of 288a (82 mg, 0.16 mmol) and NaBH₄ (18.1 mg, 0.48 mmol) inmethanol (10 mL) was stirred at room temperature for 30 min. The mixturewas quenched with water (5 mL) and evaporated under reduced pressure.The residue was extracted with dichloromethane (3×10 mL). The combinedextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 288 (54 mg, two steps:34%) as white solid. MS-ESI: [M+H]⁺ 531.3. ¹H NMR (500 MHz, DMSO-d₆) δ9.0 (s, 1H), 8.57 (d, J=5.0 Hz, 1H), 8.46 (s, 1H), 8.00 (d, J=1.5 Hz,1H), 7.57 (d, J=2.0 Hz, 1H), 7.51 (d, J=5.0 Hz, 1H), 6.25 (s, 1H), 4.86(bs, 1H), 4.39 (d, J=8.5 Hz, 2H), 3.60 (s, 3H), 2.91 (s, 2H), 2.81 (s,2H), 2.31 (s, 3H), 1.28 (s, 6H).

Example 289a tert-Butyl 3-Amino-1H-pyrazole-1-carboxylate 289a

To a mixture of 3-cyclopropyl-1H-pyrazol-5-amine (3.0 g, 36 mmol) andtriethylamine (7.6 g, 75 mmol) in 1,4-dioxane (35 mL) was added (Boc)₂O(7.8 g, 36 mmol). The reaction mixture was stirred at 25° C. for 2 h. Itwas then concentrated under reduced pressure. The residue was purifiedby silica-gel column eluting with 3:1 petroleum ether/ethyl acetate toafford 289a as a white solid (3.4 g, 52%). MS-ESI: [M+H]⁺ 184.1.

Example 289b 3-(1H-Pyrazol-3-ylamino)-5-bromo-1-methylpyridin-2(1H)-one289b

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 289a (2.2 g, 12 mmol),XantPhos (0.69 g, 1.2 mmol), Pd₂(dba)₃ (1.1 g, 1.2 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (6.4 g, 24 mmol), Cs₂CO₃ (15.6 g,48 mmol), and 1,4-dioxane (50 mL). After bubbling nitrogen through theresulting mixture for 10 minutes, it was heated at 105° C. for 15 h. Themixture was cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the residue the mixture waswashed with methanol (8 mL) to afford 289b as a pale yellow solid (1.2g, 37%). MS-ESI: [M+H]⁺ 269.1.

Example 289c(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-6-oxo-5-[(1H-pyrazol-3-yl)amino]-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 289c

A 50-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 289b (200 mg, 0.74 mmol),(2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (360 mg, 0.90 mmol), PdCl₂(dppf) (41 mg, 0.050 mmol), K₃PO₄(320 mg, 1.5 mmol), sodium acetate (123 mg, 1.5 mmol), acetonitrile (10mL), and water (0.2 mL). The system was evacuated and then refilled withN₂. Then it was heated at 90° C. for 4 h. The mixture was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the residue was purified by silica-gel columnchromatography eluting with 10:1 dichloromethane/methanol to afford 289cas a pale yellow solid (150 mg, 38%). MS-ESI: [M+H]⁺ 542.3.

Example 2893-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(1H-pyrazol-3-ylamino)-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one289

A mixture of 289c (150 mg, 0.28 mmol) and lithium hydroxide hydrate (236mg, 5.6 mmol) in THF (4 mL), i-propanol (4 mL) and water (2 mL) wasstirred at 40° C. for 0.5 h. The mixture was evaporated under reducedpressure and diluted with water (10 mL). It was then extracted withethyl acetate (3×15 mL). The combined extract was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 289 as a pale yellow solid (25 mg, 18%). MS-ESI: [M+H]⁺ 499.9.¹H NMR (500 MHz, DMSO-d₆) δ 12.07 (s, 1H), 8.47 (d, J=5.0 Hz, 1H), 8.17(s, 1H), 8.08 (s, 1H), 7.55-7.54 (m, 1H), 7.40-7.39 (m, 1H), 7.32 (d,J=5.0 Hz, 1H), 6.55 (s, 1H), 6.12 (s, 1H), 4.94-4.92 (m, 1H), 4.48-4.47(m, 1H), 4.41-4.39 (m, 1H), 4.23-4.17 (m, 3H), 3.84-3.82 (m, 1H), 3.59(s, 3H), 2.58-2.56 (m, 2H), 2.50-2.42 (m, 2H), 1.22 (s, 6H).

Example 290a5-Bromo-1-methyl-3-(1-methyl-1H-pyrazol-3-ylamino)pyridin-2(1H)-one 290a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (100 mL),1-methyl-1H-pyrazol-3-amine (970 mg, 10.0 mmol),3,5-dibromo-1-methylpyridin-2-(1H)-one (2.9 g, 11 mmol), and cesiumcarbonate (6.5 g, 20.0 mmol). After bubbling nitrogen through thesuspension for 10 minutes, tris(dibenzylideneacetone)dipalladium(0) (457mg, 0.50 mmol) and Xantphos (587 mg, 1.0 mmol) were added. The systemwas subjected to three cycles of vacuum/argon flush and heated at refluxfor 2 h. It was then cooled to room temperature and filtered. The solidwas washed with dichloromethane (2×50 mL) and the combined organicfiltrate was concentrated. The residue was purified by silica-gel columnchromatography eluting with 30:1 dichloromethane/methanol to afford 290aas a yellow solid (900 mg, 32%). MS-ESI: [M+H]⁺ 283.1

Example 290b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(1-methyl-1H-pyrazol-3-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 290b

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatri-cyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (595 mg, 1.5 mmol), 290a (282 mg, 1.0 mmol), K₃PO₄ (424 mg,2.0 mmol), sodium acetate (164 mg, 2.0 mmol),1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (82 mg, 0.1mmol), and acetonitrile/water (15/1 mL). After three cycles of vacuum/N₂flush, the mixture was heated at 100° C. for 1.5 h. The mixture wascooled to room temperature and concentrated under reduced pressure. Theresidue was partitioned between dichloromethane (30 mL) and water (30mL). The aqueous layer was extracted with dichloromethane (3×20 mL). Thecombined organic layer was dried over Na₂SO₄, filtered, and concentratedunder reduced pressure. The dark residue was purified by silica-gelcolumn chromatography eluting with dichloromethane/methanol (80/1 to50/1) to 290b (300 mg, 54%) as yellow solid. MS-ESI: [M+H]⁺ 556.1

Example 2903-[3-(hydroxymethyl)-4-[1-methyl-5-[(1-methylpyrazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one290

To a solution of 290b (139 mg, 0.25 mmol) in THF (5 mL), propan-2-ol (5mL), and water (2 mL) was added lithium hydroxide (60 mg, 2.5 mmol). Thereaction mixture was stirred at room temperature for 2.5 h. It was thenconcentrated under reduced pressure. The residue was partitioned betweendichloromethane (20 mL) and water (10 mL). The aqueous layer wasextracted with dichloromethane (3×10 mL). The combined extract waswashed with brine, dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was purified by reverse-phase prep-HPLC toafford 290 (30 mg, 23%) as white solid. MS-ESI: [M+H]⁺ 514.3. ¹H NMR(500 MHz, DMSO-d₆) δ 8.47 (d, J=5.0 Hz, 1H), 8.16 (s, 1H), 8.03 (d,J=2.5 Hz, 1H), 7.48 (d, J=2.0 Hz, 1H), 7.39 (d, J=1.5 Hz, 1H), 7.33 (d,J=5.0 Hz, 1H), 6.55 (s, 1H), 6.07 (d, J=2.0 Hz, 1H), 4.97 (t, J=5.0 Hz,1H), 4.47-4.40 (m, 2H), 4.24-4.18 (m, 3H), 3.85-3.83 (m, 1H), 3.70 (s,3H), 3.58 (s, 3H), 2.58-2.56 (m, 2H), 2.42 (s, 2H), 1.22 (s, 6H).

Example 291a(4-{1-Methyl-5-[(5-methyl-1,2-oxazol-3-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}-2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}pyridin-3-yl)methylAcetate 291a

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with(2-{6-oxo-8-thia-4,5-diazatricyclo[7.4.0.0^(2,7)]trideca-1(9),2(7),3-trien-5-yl}-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 230i (150 mg, 0.31 mmol),5-bromo-1-methyl-3-(5-methylisoxazol-3-ylamino)pyridine-2(1H)-one 283a(88 mg, 0.31 mmol), PdCl₂(dppf) (24 mg, 0.031 mmol), K₃PO₄ (131 mg, 0.62mmol), sodium acetate (61 mg, 0.62 mmol), water (0.2 mL), andacetonitrile (10 mL). The system was subjected to three cycles ofvacuum/argon flush and stirred at 100° C. for 3 h. The reaction mixturewas cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure. The residue was partitioned betweendichloromethane (20 mL) and water (10 mL). The organic layer wasseparated and the water layer was extracted with dichloromethane (2×20mL). The combined organic layer was dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The dark residue was purified bysilica-gel column chromatography eluting with 30:1dichloromethane/methanol to afford 291a (104 mg, 60%) as a yellow solid.MS-ESI: [M+H]⁺ 559.1

Example 2913-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one291

To a solution of 291a (100 mg, 0.18 mmol) in THF/i-propanol/water(10/5/5 mL) was added lithium hydroxide (43 mg, 1.8 mmol) at roomtemperature. After being stirred for 1 h, MS indicated the reaction wascomplete. Then the mixture was concentrated under reduced pressure andthe residue was partitioned between water (10 mL) and dichloromethane(15 mL). The water phase was extracted with dichloromethane (3×10 mL).The combined organic layer was washed with brine (30 mL), dried overNa₂SO₄, filtered, and concentrated under reduced pressure. The residuewas purified by reverse-phase prep-HPLC to afford 291 (56 mg, 60%) aswhite solid. MS-ESI: [M+H]⁺ 517.2. ¹H NMR (500 MHz, DMSO-d₆) δ 9.02 (s,1H), 8.58 (d, J=5.0 Hz, 1H), 8.48 (s, 1H), 8.00 (d, J=2.0 Hz, 1H), 7.58(d, J=2.0 Hz, 1H), 7.52 (d, J=5.0 Hz, 1H), 6.25 (s, 1H), 4.87-4.85 (m,1H), 4.42-4.36 (m, 2H), 3.61 (s, 3H), 2.98-2.85 (m, 4H), 2.32 (s, 3H),1.92-1.86 (m, 4H).

Example 292a4-{5-[(1,5-Dimethyl-1H-pyrazol-3-yl)amino]-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl}-2-{4,4-dimethyl-9-oxo-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),(6),11-trien-10-yl}pyridine-3-carbaldehyde292a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with3-(1,5-dimethyl-1H-pyrazol-3-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one242a (344 mg, 1.0 mmol),4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6),11-trien-10-yl}pyridine-3-carbaldehyde282i (538.5 mg, 1.5 mmol), Pd₂(dba)₃ (91.5 mg, 0.10 mmol),tricyclohexylphospine (112 mg, 0.40 mmol), cesium carbonate (652 mg, 2.0mmol), 1,4-dioxane (20 mL), and water (0.5 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 75° C. for 2 h. It wasthen filtered and the filtrate was evaporated under reduced pressure.The residue was washed with petroleum ether to afford 292a (300 mg,crude) as a black solid. MS-ESI: [M+H]⁺ 542.2

Example 2923-[4-[5-[(1,5-dimethylpyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one292

To a solution of 292a (162.6 mg, 0.30 mmol) in methanol (6 mL) was addedsodium borohydride (114 mg, 3.0 mmol) at 0° C. The reaction was stirredat 25° C. for 0.5 h. It was then quenched with water (10 mL). Theresulting mixture was evaporated under reduced pressure and the residuewas extracted with dichloromethane (3×20 mL). The combineddichloromethane extract was concentrated under reduced pressure and theresidue was purified by reverse-phase prep-HPLC to afford 292 (35 mg,22%) as a yellow solid. MS-ESI: [M+H]⁺ 543.8. ¹H NMR (500 MHz, DMSO-d₆)δ 8.57 (d, J=5.0 Hz, 1H), 8.47 (s, 1H), 8.08 (s, 1H), 8.02 (d, J=1.5 Hz,1H), 7.52 (d, J=5.0 Hz, 1H), 7.40 (d, J=1.5 Hz, 1H), 5.90 (s, 1H), 4.88(s, 1H), 4.40 (d, J=5.0 Hz, 2H), 3.59 (s, 3H), 3.58 (s, 3H), 2.92 (d,J=4.5 Hz, 2H), 2.81 (s, 2H), 2.18 (s, 3H), 1.29 (s, 3H), 1.28 (s, 6H).

Example 293a 1-Methyl-4-nitro-1H-1,2,3-triazole 293a

To a 100-mL single-neck round-bottomed containing4-nitro-2H-1,2,3-triazole (2.0 g, 17.5 mmol) and THF (10 mL) at 0° C.was added NaH (1.7 g, 35.0 mmol, 2.0 eq.). The mixture was stirred at 0°C. for 15 min. A solution of iodomethane (3.68 g, 26.3 mmol, 1.5 eq.) inacetone (40 mL) was added and the resulting reaction mixture was stirredat room temperature for 2 h. After this time, the reaction was quenchedby water (20 mL) at 0° C. and concentrated under reduced pressure. Theresidue was diluted with dichloromethane (100 mL). It was then washedwith brine, dried over anhydrous Na₂SO₄, and concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 6:1 petroleum ether/ethyl acetate to afford 293a (800 mg,35%) as a light yellow solid and the regioisomer1-methyl-5-nitro-1H-1,2,3-triazole (1.34 g, 60%) as a white solid. ¹HNMR (500 MHz, CDCl₃) δ 8.34 (s, 1H), 4.26 (s, 3H).

Example 293b 1-Methyl-1H-1,2,3-triazol-4-amine 293b

Following the procedure in Example 130b, and starting with 293a (800 mg,6.25 mmol) and 10% palladium on carbon (50% wet, 160 mg) afforded 293bas a yellow solid (600 mg, 98%). ¹H NMR (500 MHz, CDCl₃) δ 6.91 (s, 1H),3.97 (s, 3H), 3.65 (brs, 2H).

Example 293c5-Bromo-1-methyl-3-(1-methyl-1H-1,2,3-triazol-4-ylamino)pyridin-2(1H)-one293c

Following the procedure in Example 130c, and starting with 293b (500 mg,5.10 mmol, 1.0 eq.) and 3,5-dibromo-1-methylpyridin-2(1H)-one (2.04 g,7.65 mmol, 1.5 eq.) afforded 293c as a yellow solid (760 mg, 52%).MS-ESI: [M+H]⁺ 283.9.

Example 293d(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(1-methyl-1H-1,2,3-triazol-4-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 293d

Following the procedure in Example 283b, and starting with 293c (150 mg,0.53 mmol, 1.0 eq.) and{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (629 mg, 1.59 mmol, 3.0 eq.) afforded 293d as a yellow solid(110 mg, 37%). MS-ESI: [M+H]⁺ 557.4.

Example 2933-[3-(hydroxymethyl)-4-[1-methyl-5-[(1-methyltriazol-4-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one293

Following the procedure in Example 283, and starting with 293d (110 mg,0.20 mmol) afforded 293 as a pale yellow solid (78 mg, 75%). MS-ESI:[M+H]⁺ 514.9. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, J=4.5 Hz, 1H), 7.78 (s,1H), 7.73 (s, 1H), 7.60 (s, 1H), 7.42 (s, 1H), 7.33 (d, J=4.0 Hz, 1H),6.87 (s, 1H), 5.25 (brs, 1H), 4.65-4.38 (m, 3H), 4.21-4.20 (m, 2H), 4.08(s, 3H), 3.89-3.85 (m, 1H), 3.73 (s, 3H), 2.59 (s, 2H), 2.54 (s, 2H),1.29 (s, 6H).

Example 2943-[4-[5-[(5-tert-butylisoxazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one294

Following the procedures in Example 273, and substituting5-(tert-butyl)isoxazol-3-amine for 2-aminopyridine, 294 was prepared(5.1 mg, 16% yield). ¹H NMR (400 MHz, DMSO-d6) δ 8.93 (s, 1H), 8.48 (d,J=5.0 Hz, 1H), 8.04 (d, J=2.3 Hz, 1H), 7.56 (d, J=2.3 Hz, 1H), 7.32 (d,J=5.0 Hz, 1H), 6.56 (s, 1H), 6.22 (s, 1H), 4.90 (t, J=5.3 Hz, 1H),4.51-4.36 (m, 2H), 4.26-4.16 (m, 3H), 3.85 (d, J=10.7 Hz, 1H), 3.60 (s,3H), 2.58 (d, J=7.7 Hz, 2H), 2.43 (s, 2H), 1.27 (s, 9H), 1.22 (s, 6H).ES-MS m/z 557.4 [M+1].

Example 295a 5-Ethylisoxazol-3-amine 295a

To a solution of 3-oxopentanenitrile (1.0 g, 10.3 mmol) in water (20 mL)was added NaOH (535.6 mg, 13.4 mmol). After stirring for 5 minutes,hydroxylamine hydrochloride (787.4 mg, 11.33 mmol) was added and mixturewas heated at 40° C. for 12 h. At this point, conc. HCl (3 mL) was addedand the reaction mixture was heated at 50° C. for 2 h. Analysis of thereaction mixture by LCMS showed complete conversion to the desiredproduct. It was then cooled to room temperature and adjusted the pH to10 with aqueous NaOH (30%). The mixture was extracted with ethyl acetate(3×50 mL). The combined organic layer was washed with brine, dried overNa₂SO₄, and concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 2:1 petroleumether/ethyl acetate to afford 295a as a yellow solid (300 mg, 25%).MS-ESI: [M+H]⁺ 113.3. ¹H NMR (500 MHz, DMSO-d₆) 5.55 (s, 1H), 5.40 (s,2H), 2.56-2.52 (m, 2H), 1.13 (t, J=7.5 Hz, 3H).

Example 295b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{5-[(5-ethyl-1,2-oxazol-3-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 295b

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 295a (24.8 mg, 0.222mmol),[4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatri-cyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylacetate 273a (100 mg, 0.185 mmol), Pd₂(dba)₃ (8.5 mg, 0.0093 mmol),Xantphos (10.7 mg, 0.019 mmol), Cs₂CO₃ (120.6 mg, 0.37 mmol), anddioxane (10 mL). The system was subjected to three cycles ofvacuum/nitrogen flush and heated at 100° C. under N₂ protection for 3 h.Analysis of the reaction mixture by LCMS showed complete conversion tothe desired product. It was cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure. The residue was washedwith acetonitrile (0.5 mL) to afford 295b as white solid (52 mg, 49.5%),which was used in the next step without further purification. MS-ESI:[M+H]⁺ 570.8

Example 2953-[4-[5-[(5-ethylisoxazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one295

To a solution of 295b (42 mg, 0.0736 mmol) in THF (4 mL), i-propanol (4mL), and water (4 mL) was added lithium hydroxide (17.7 mg, 0.736 mmol).The reaction mixture was stirred at room temperature for 1 h andconcentrated under reduced pressure. The residue was diluted with water(5 mL) and extracted with dichloromethane (3×20 mL). The combinedextract was dried over Na₂SO₄, filtered, and concentrated under reducedpressure. The residue was purified by reverse-phase prep-HPLC to afford295 (22 mg, 57%) as a white solid. MS-ESI: [M+H]⁺ 528.8. ¹H NMR (500MHz, DMSO-d₆) δ 8.99 (s, 1H), 8.49 (d, J=5.5 Hz, 1H), 8.03 (d, J=2.0 Hz,1H), 7.56 (d, J=2.0 Hz, 1H), 7.33 (d, J=5.0 Hz, 1H), 6.57 (s, 1H), 6.25(s, 1H), 4.94-4.92 (m, 1H), 4.48-4.38 (m, 2H), 4.26-4.19 (m, 3H),3.87-3.85 (m, 1H), 3.61 (s, 3H), 2.68-2.66 (m, 2H), 2.62-2.59 (m, 2H),2.43 (s, 2H), 1.22 (s, 6H), 1.19 (t, J=7.5 Hz, 3H).

Example 296a (3-Nitro-1H-pyrazol-5-yl)methanol 296a

A 100-mL three-neck round-bottomed flask equipped with a nitrogen inletwas purged with nitrogen and charged with 3-nitropyrazole-5-carboxylicacid (0.56 g, 3.56 mmol) and THF (8 mL). The system was cooled to −5° C.using an ice/acetone bath. Borane-THF complex solution (1.0M, 11 mL,11.0 mmol) was added at a rate that maintained the internal reactiontemperature below 5° C. After the addition was complete the cooling bathwas removed and the reaction was stirred at 60° C. for 3 h. After thistime the reaction was cooled to −5° C. using an ice/acetone bath, water(2 mL) and 4N hydrochloric acid (2 mL) was added. The reaction mixturewas stirred at 70° C. for 1 h in order to destroy the borane-pyrazolecomplex. It was cooled to room temperature and concentrated underreduced pressure to a volume of approximately 1 mL. Ethyl acetate (20mL) and water (10 mL) were added and the mixture was stirred for 15 min.The aqueous layer was separated and extracted with ethyl acetate (4×10mL). The combined organic layer was washed with saturated aqueous sodiumbicarbonate (2×10 mL), brine (10 mL), and dried over sodium sulfate. Thedrying agent was removed by filtration and the filtrate was concentratedunder reduced pressure to afford 296a (345 mg, 68%) as a light yellowsolid. MS-ESI: [M+H]⁺ 144

Example 296b (1-(2-Bromoethyl)-3-nitro-1H-pyrazol-5-yl)methanol 296b

A mixture of 296a (345 mg, 2.41 mmol), and cesium carbonate (965 mg,2.96 mmol) in DMF (5 mL) was cooled to 0° C. using an ice/acetone bathand dibromoethane (4.48 g, 24.1 mmol) was added portion-wise (noexotherm). The reaction was stirred at 0° C. for 1 h and roomtemperature for 4 h. After this time ethyl acetate (20 mL) and water (15mL) were added. The aqueous layer was separated and extracted with ethylacetate (2×10 mL). The combined organic layer was washed with water (10mL), brine (10 mL), and dried over sodium sulfate. The drying agent wasremoved by filtration. The filtrate was concentrated under reducedpressure to afford the crude product, which was purified by silica-gelcolumn chromatography eluting with 6:1 petroleum ether/ethyl acetate toafford 296b (300 mg, 50%). MS-ESI: [M+H]⁺ 250

Example 296c 1-(2-Bromoethyl)-5-(chloromethyl)-3-nitro-1H-pyrazole 296c

A 50-mL three-necked round-bottomed flask equipped with a nitrogen inletand a reflux condenser was purged with nitrogen and charged with 296b(438 mg, 1.76 mmol) and chloroform (10 mL). The reaction was cooled to−5° C. using an ice/acetone bath and SOCl₂ (628 mg, 5.28 mmol) was addedportion-wise. The cooling bath was removed and the reaction was stirredat 70° C. for 3 h. After this time, the solvent was removed underreduced pressure. ethyl acetate was added to the residue and theresulting solution was cooled to −5° C. Saturated aqueous sodiumbicarbonate (3 mL) was added until a pH of 8.5 was reached. The mixturewas partitioned between ethyl acetate and water. The combined organiclayer was washed with saturated aqueous sodium carbonate (2×5 mL), brine(10 mL), and dried over sodium sulfate. The drying agent was removed byfiltration. The filtrate was concentrated under reduced pressure toafford 296c (284 mg, 60%).

Example 296d5-(2-Methoxyethyl)-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine296d

A microwave vial equipped with a magnetic stirrer was charged with 296c(2.67 g, 10.0 mmol), 2-methoxyethanamine (2.25 g, 30.0 mmol), and DMSO(14 mL). The reaction mixture was heated at 120° C. under microwaveirradiation for 1.0 h. It was cooled to room temperature and dilutedwith ethyl acetate (40 mL). The mixture was washed with water (3×15 mL).The organic layer was dried and filtered. The filtrate was concentratedunder pressure and the residual was purified by silica-gel columnchromatography eluting with 30:1 dichloromethane/methanol to afford 296d(1.7 g, 75%) as a yellow solid. MS-ESI: [M+H]⁺ 227.0

Example 296e5-(2-Methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine 296e

To a solution of 296d (1.7 g, 7.5 mmol) in ethanol (50 mL) was addedPd/C (10%, 800 mg). The reaction was charged with hydrogen gas (viaballoon) and stirred at room temperature for 2 h. After reaction wascomplete, the mixture was filtered through a plug of CELITE®. Thefiltrate was concentrated reduced pressure to afford 296e as a yellowsolid (1.2 g, 82%), which was used directly without furtherpurification. MS-ESI: [M+H]⁺ 197.3

Example 296f5-Bromo-3-(5-(2-methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methylpyridin-2(1H)-one296f

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (40 mL),296e (588 mg, 3.0 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (800 mg,3.0 mmol), and cesium carbonate (1.96 g, 6.0 mmol). After bubblingnitrogen through the suspension for 20 minutes, xantphos (173 mg, 0.30mmol) and tris(dibenzylideneacetone)dipalladium(0) (137 mg, 0.15 mmol)were added. The system was subjected to three cycles of vacuum/argonflush and heated at reflux for 5 h. It was then cooled to roomtemperature and filtered. The solid was washed with dichloromethane(2×15 mL). The combined filtrate was concentrated under reducedpressure. The residue solid was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (80/1 to 30/1) toafford 296f (745 mg, 65%) as yellow solid. MS-ESI: [M+H]⁺ 382.9

Example 296g(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(5-{[5-(2-methoxyethyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methylAcetate 296g

A 25-mL round-bottomed flask equipped with a reflux condenser wascharged with{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (198 mg, 0.50 mmol), 296f (190 mg, 0.50 mmol), K₃PO₄ (212 mg,1.0 mmol), sodium acetate (82 mg, 1.0 mmol), Pd(dppf)Cl₂ (21 mg, 0.025mmol), acetonitrile (8 mL), and water (0.5 mL). The system was subjectedto three cycles of vacuum/nitrogen flush and heated at 100° C. under N₂protection for 1 h. Analysis of the reaction mixture by LCMS showedcomplete conversion to the desired product. The reaction mixture wascooled to room temperature and filtered. The filtrate was concentratedunder reduced pressure. The residue was partitioned betweendichloromethane (20 mL) and water (10 mL). The water layer was extractedwith dichloromethane (2×20 mL). The combined organic extract was driedover Na₂SO₄, filtered, and concentrated under reduced pressure. The darkresidue was purified by silica-gel column chromatography eluting withdichloromethane/methanol (80/1 to 30/1) to afford 296g (163 mg, 50%) asa yellow solid. MS-ESI: [M+H]⁺ 654.9

Example 2963-[3-(hydroxymethyl)-4-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one296

To a solution of 296g (160 mg, 0.245 mmol) in THF/i-propanol/water(8/5/3 mL) was added lithium hydroxide (29 mg, 1.22 mmol). The mixturewas stirred at room temperature for 1 h and evaporated under pressure.The residue was purified by reverse-phase prep-HPLC to afford 296 as awhite solid (117 mg, 78%). MS-ESI: [M+H]⁺ 613.3. ¹H NMR (500 MHz, CDCl₃)δ 8.48 (d, J=5.0 Hz, 1H), 7.93 (d, J=2.0 Hz, 1H), 7.73 (d, J=2.5 Hz,1H), 7.41 (s, 1H), 7.35 (d, J=5.0 Hz, 1H), 6.86 (s, 1H), 5.71 (s, 1H),5.05 (t, J=7.0 Hz, 1H), 4.66-4.65 (m, 1H), 4.52-4.50 (m, 1H), 4.36-4.34(m, 1H), 4.17-4.05 (m, 2H), 4.10-4.08 (m, 2H), 3.88-3.87 (m, 1H),3.75-3.73 (m, 2H), 3.71 (s, 3H), 3.61-3.59 (m, 2H), 2.40 (s, 3H),3.04-3.03 (m, 2H), 2.80 (t, J=5.5 Hz, 2H), 2.59-2.57 (m, 2H), 2.54-2.53(m, 2H), 1.29 (s, 6H).

Example 297a6-Chloro-2-methyl-4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridazin-3(2H)-one297a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (30 mL),5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine 113e (1.70 g,11.2 mmol), 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (2.68 g, 12.0mmol), and cesium carbonate (7.30 g, 22.4 mmol). After bubbling nitrogenthrough the suspension for 30 minutes, Xantphos (0.59 g, 1.02 mmol) andtris(dibenzylideneacetone)dipalladium(0) (467 mg, 0.51 mmol) were added.The system was subjected to three cycles of vacuum/argon flash andheated at 90° C. for 2 h. It was then cooled to room temperature andfiltered. The filtrate was evaporated in vacuo. The residue was purifiedby silica-gel column chromatography eluting with 30:1dichloromethane/methanol to afford 297a (1.9 g, 60%) as a brown solid.LCMS: [M+H]⁺ 295.1

Example 297b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-methyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridazin-3-yl]pyridin-3-yl)methylAcetate 297b

A 25-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 297a (195 mg, 0.66 mmol),(2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 199e (315 mg, 0.66 mmol), PdCl₂(dppf) (40 mg, 0.050 mmol), K₃PO₄(250 mg, 1.2 mmol), sodium acetate (100 mg, 1.20 mmol), acetonitrile (8mL), and water (1 mL). The system was evacuated and then refilled withN₂. It was then heated at 100° C. for 1 h. The mixture was cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the residue was purified by silica-gel columnchromatography eluting with 20:1 dichloromethane/methanol to afford 297bas a yellow solid (150 mg, 38%). MS-ESI: [M+H]⁺ 612.3.

Example 2973-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one297

A mixture of 297b (150 mg, 0.24 mmol) and lithium hydroxide hydrate (96mg, 2.4 mmol) in THF (8 mL), i-propanol (8 mL), and water (2 mL) wasstirred at 40° C. for 0.5 h. The mixture was evaporated under reducedpressure and the residue was partitioned between dichloromethane (15 mL)and water (10 mL). The combined extract was concentrated under reducedpressure and the residue was purified by reverse-phase prep-HPLC toafford 297 as a pale yellow solid (98 mg, 70%). MS-ESI: [M+H]⁺ 570.3. ¹HNMR (500 MHz, DMSO-d₆) δ 9.30 (s, 1H), 8.52 (d, J=4.5 Hz, 1H), 7.90 (s,1H), 7.38 (d, J=5.0 Hz, 1H), 6.55 (s, 1H), 5.99 (s, 1H), 4.74-4.73 (m,1H), 4.60-4.58 (m, 1H), 4.40-4.37 (m, 1H), 4.26-4.24 (m, 1H), 4.19-4.18(m, 2H), 3.96-3.95 (m, 2H), 3.89-3.87 (m, 1H), 3.75 (s, 3H), 3.53-3.52(m, 2H), 2.80-2.78 (m, 2H), 2.57-2.55 (m, 2H), 2.52-2.50 (m, 2H), 2.35(s, 3H), 1.22 (s, 6H).

Example 298a(4-{5-[(5-Cyanopyrazin-2-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl)methyla\Acetate 298a

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with[4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricy-clo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylacetate 273a (269 mg, 0.50 mmol), 5-aminopyrazine-2-carbonitrile (60 mg,0.50 mmol), XantPhos (29 mg, 0.050 mmol), Pd₂(dba)₃ (45 mg, 0.050 mmol),Cs₂CO₃ (326 mg, 1.0 mmol), and 1,4-dioxane (10 mL). The reaction mixturewas heated at 100° C. under microwave irradiation for 1 h after threetimes atmosphere/argon flush. The mixture was filtered off and the solidwas washed with methanol (50 mL). The combined filtrate was evaporatedunder reduced pressure and the residue was purified with silica-gelcolumn chromatography eluting with 50:1 dichloromethane/methanol toafford 298a (200 mg, 69%) as yellow solid. MS-ESI: [M+H]⁺ 579.3

Example 2985-[[5-[2-(7,7-dimethyl-4-oxo-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-3-(hydroxymethyl)-4-pyridyl]-1-methyl-2-oxo-3-pyridyl]amino]pyrazine-2-carbonitrile298

A mixture of 298a (200 mg, 0.35 mmol) and lithium hydroxide (84 mg, 3.5mmol) in i-propanol/THF (5 mL/5 mL) and water (2 mL) was stirred at roomtemperature for 2 h. The mixture was evaporated under reduced pressureand the residue was partitioned between ethyl acetate (20 mL) and water(10 mL). The combined extract was concentrated under reduced pressureand the residue was purified by reverse-phase prep-HPLC to afford 298(40 mg, 21%) as yellow solid. MS-ESI: [M+H]⁺ 537.3. ¹H NMR (500 MHz,DMSO-d₆) δ 9.96 (s, 1H), 8.77 (s, 1H), 8.701 (d, J=2.5 Hz, 1H), 8.67 (s,1H), 8.50 (d, J=5.0 Hz, 1H), 7.76 (d, J=2.0 Hz, 1H), 7.35 (d, J=5.0 Hz,1H), 6.56 (s, 1H), 5.00 (t, J=5.0 Hz, 1H), 4.42-4.39 (m, 2H), 4.24-4.19(m, 3H), 3.84 (m, 1H), 3.63 (s, 3H), 2.57 (m, 2H), 2.42 (s, 2H), 1.23(s, 6H)

Example 299a 5-Phenylisoxazol-3-amine 299a

To a stirred solution of 3-oxo-3-phenylpropanenitrile (1.5 g, 10.3 mmol)and NaOH (452 mg, 11.3 mmol) in water (10 mL)/EtOH (10 mL) was addedhydroxylamine hydrochloride (785 mg, 11.3 mmol). The mixture was stirredat 80° C. for overnight. At this point, conc. HCl (1.3 mL, 15.5 mmol)was added and the resulting mixture was heated at 80° C. for 2 h. It wasthen basified to pH 10 and extracted with ethyl acetate. The combinedextract was concentrated under reduced pressure and the residue waspurified by silica-gel column chromatography eluting with ethylacetate/petroleum ether (1:50 to 1:10) to afford 299a as a yellow solid(1.1 g, 68%). MS-ESI: [M+H]⁺ 161.3.

Example 299b5-Bromo-1-methyl-3-(5-phenylisoxazol-3-ylamino)pyridin-2(1H)-one 299b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (40 mL),299a (640 mg, 4.0 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (1.1 g,4.0 mmol), Pd₂(dba)₃ (366.8 mg, 0.40 mmol), XantPhos (462.4 mg, 0.80mmol), and cesium carbonate (2.6 g, 8.0 mmol). After three cycles ofvacuum/argon flush, the mixture was heated at 92° C. for 3 hrs. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue was washedwith acetonitrile to afford 299b (1.7 g, 87%). MS-ESI: [M+H]⁺ 346.0.

Example 299c(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-6-oxo-5-[(5-phenyl-1,2-oxazol-3-yl)amino]-1,6-dihydropyridin-pyridin-3-yl}pyridin-3-yl)methylAcetate 299c

A 50-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 299b (138 mg, 0.40 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diaza-tricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (158.8 mg, 0.40 mmol), Pd(dppf)Cl₂ (32.7 mg, 0.040 mmol),K₃PO₄ (169.6 mg, 0.80 mmol), sodium acetate (108.8 mg, 0.80 mmol), water(0.5 mL), and acetonitrile (10 mL). After three cycles of vacuum/argonflush, the mixture was heated at 100° C. for 3 hrs. It was then cooledto room temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 50:1 dichloromethane/methanol toafford 299c as a brown solid (120 mg, 49%). MS-ESI: [M+H]⁺ 618.8.

Example 2993-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-[(5-phenylisoxazol-3-yl)amino]-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one299

A mixture of 299c (100 mg, 0.16 mmol) and lithium hydroxide (96 mg, 4.0mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at 40°C. for 30 mins. The reaction mixture was concentrated under reducedpressure and diluted with water (5 mL). The resulting mixture wasextracted with dichloromethane for three times. The combined organiclayer was concentrated under reduced pressure and the resulting residuewas purified by reverse-phase prep-HPLC to afford 299 as a white solid(35 mg, 31%). MS-ESI: [M+H]⁺ 576.8. ¹H NMR (500 MHz, DMSO-d₆) δ 9.17 (s,1H), 8.51 (d, J=5.5 Hz, 1H), 8.11 (d, J=2.5 Hz, 1H), 7.79-7.77 (m, 2H),7.60 (d, J=2.0 Hz, 1H), 7.55-7.49 (m, 3H), 7.35 (d, J=4.5 Hz, 1H), 6.91(s, 1H), 6.57 (s, 1H), 4.96-4.93 (m, 1H), 4.50-4.40 (m, 2H), 4.26-4.19(m, 3H), 3.88-3.85 (m, 1H), 3.63 (s, 3H), 2.62-2.59 (m, 2H), 2.44-2.42(m, 2H), 1.23 (s, 6H).

Example 300a5-(1-Methoxypropan-2-yl)-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine300a

A microwave vial equipped with a magnetic stirrer was charged with1-(2-bromoethyl)-5-(chloromethyl)-3-nitro-1H-pyrazole 296c (1.0 g, 3.7mmol), 1-methoxypropan-2-amine (1.0 g, 11.2 mmol), and DMSO (6 mL). Themixture was heated at 120° C. under microwave irradiation for 1.0 h. Itwas the cooled to room temperature and diluted with water (30 mL). Theresulting mixture was extracted with ethyl acetate (3×20 mL). Thecombined organic layer was dried and concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with petroleum ether/ethyl acetate (60/1 to 1/1) to afford 300a(600 mg, 68%) as a yellow solid. MS-ESI: [M+H]⁺ 241.0

Example 300b5-(1-Methoxypropan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine300b

A solution of 300a (600 mg, 2.5 mmol) in EtOH (40 mL) was added Pd/C(10%, 60 mg). The reaction mixture was charged with hydrogen gas (viaballoon) and stirred at room temperature for 2 h. After reaction wascomplete, the mixture was filtered through a plug of CELITE®. Thefiltrate was concentrated reduced pressure to afford 300b as a yellowsolid (467 mg, 89%), which was used without further purification.MS-ESI: [M+H]⁺ 211.1

Example 300c5-Bromo-3-(5-(1-methoxypropan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]-pyrazin-2-ylamino)-1-methylpyridin-2(1H)-one300c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (40 mL),300b (400 mg, 1.9 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (H-001)(508 mg, 1.9 mmol), and cesium carbonate (1.24 g, 3.8 mmol). Afterbubbling nitrogen through the suspension for 20 minutes, xantphos (109mg, 0.19 mmol) and Pd₂(dba)₃ (87 mg, 0.095 mmol) were added. The systemwas subjected to three cycles of vacuum/argon flush and heated at refluxfor 5 h. It was then cooled to room temperature and filtered. The solidwas washed with dichloromethane (2×30 mL). The combined filtrate wasconcentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with dichloromethane/methanol(80/1 to 30/1) to afford 300c (436 mg, 58%) as yellow solid. MS-ESI:[M+H]⁺ 396.0

Example 300d(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(5-{[5-(1-methoxypropan-2-yl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methylAcetate 300d

A 50-mL round bottomed flask equipped with a reflux condenser wascharged with{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (238 mg, 0.60 mmol), 300c (240 mg, 0.80 mmol), K₃PO₄ (254 mg,1.2 mmol), sodium acetate (98 mg, 1.6 mmol), Pd(dppf)Cl₂ (22 mg, 0.030mmol), and acetonitrile/water (12/0.5 mL). The system was subjected tothree cycles of vacuum/nitrogen flush and heated at 100° C. under N₂protection for 1 h. Analysis of the reaction mixture by LCMS showedcomplete conversion to the desired product. The reaction mixture wascooled to room temperature and filtered. The filtrate was concentratedunder reduced pressure. The residue was partitioned betweendichloromethane (30 mL) and water (30 mL). The water layer was extractedwith dichloromethane (2×30 mL). The combined organic extract was driedover Na₂SO₄, filtered, and concentrated under reduced pressure. The darkresidue was purified by silica-gel column chromatography eluting withdichloromethane/methanol (80/1 to 30/1) to afford 300d (200 mg, 50%) asyellow solid. MS-ESI: [M+H]⁺ 669.4

Example 300(R)-2-(3′-(hydroxymethyl)-5-((5-(1-methoxypropan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one

To a solution of 300d (200 mg, 0.30 mmol) in THF/i-propanol/water (6/3/3mL) was added lithium hydroxide (36 mg, 1.5 mmol). The mixture wasstirred at 30° C. for 1 h and concentrated under reduced pressure. Theresidue was partition between ethyl acetate (15 mL) and (10 mL). Thewater phase was extracted with ethyl acetate (3×10 mL). The combinedorganic layer was dried, filtered, and concentrated under reducedpressure. Prep-HPLC and chiral resolution afforded the two enantiomers:300 (35 mg, 18.6%) as white solid; and 303 (28 mg, 15%) as white solid.MS-ESI: [M+H]⁺ 627.4. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, J=5.0 Hz, 1H),7.92 (d, J=2.5 Hz, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.41 (s, 1H), 7.35 (d,J=5.0 Hz, 1H), 6.85 (s, 1H), 5.72 (s, 1H), 5.05-5.03 (m, 1H), 4.67-4.45(m, 1H), 4.52-4.50 (m, 1H), 4.35-4.31 (m, 1H), 4.18-4.16 (m, 2H),4.09-4.07 (m, 2H), 3.87-3.85 (m, 3H), 3.71 (s, 3H), 3.56-3.52 (m, 1H),3.45-3.43 (m, 1H), 3.38 (s, 3H), 3.11-3.08 (m, 3H), 2.60-2.58 (m, 2H),2.53 (s, 2H), 1.29 (s, 6H), 1.17 (d, J=6.0 Hz, 3H).

Example 301a 6-(Trifluoromethyl)pyridazin-3-amine 301a

A mixture of 3-chloro-6-trifluoromethylpyridazine (1.6 g, 8.80 mmol) andammonium hydroxide (9 mL) in THF (3 mL) was heated at 100° C. in amicrowave reactor for 1 h. After this period, the reaction mixture wasevaporated and the residue was extracted with dichloromethane. Thecombined extract was dried over with MgSO₄, filtered, and evaporatedunder reduce pressure to afford 301a (1.3 g, 93%) as a white solid.MS-ESI: [M+H]⁺ 164.1

Example 301b5-Bromo-1-methyl-3-(6-(trifluoromethyl)pyridazin-3-ylamino)pyridin-2(1H)-one301b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 301a (750 mg, 4.6 mmol),XantPhos (532 mg, 0.92 mmol), Pd₂ dba₃ (421 mg, 0.46 mmol),2-bromo-4-chloronicotinaldehyde (H-001) (1.84 g, 6.9 mmol), Cs₂CO₃ (3.0g, 9.2 mmol), and 1,4-dioxane (50 mL). The system was subjected to threecycles of vacuum/argon flush and heated at 90° C. for overnight. Afterthe completion of the reaction, the mixture was filtered and the solidwas washed with methanol (30 mL). The combined filtrate was evaporatedunder reduced pressure and the residue was purified by silica-gel columnchromatography eluting with 20:1 dichloromethane/methanol to afford 301b(1.38 g, 89%) as a yellow solid. MS-ESI: [M+H]⁺ 350.8

Example 301c(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(1-methyl-6-oxo-5-{[6-(trifluoromethyl)pyridazin-3-yl]amino}-1,6-dihydropyridin-3-yl)pyridin-3-yl)methylAcetate 301c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 301b (300 mg, 0.86mmol),(2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 199e (824 mg, 1.72 mmol), CH₃COONa (140 mg, 1.72 mmol),PdCl₂(dppf) (70 mg, 0.086 mmol), K₃PO₄ (360 mg, 1.72 mmol), acetonitrile(20 mL), and water (0.5 mL). After bubbling nitrogen through theresulting mixture for 20 minutes, it was heated at 100° C. undernitrogen atmosphere for 2 h. The mixture was cooled to room temperatureand filtered. The filtrate was evaporated under reduced pressure and theresidue was purified by silica-gel column chromatography eluting with50:1 dichloromethane/methanol to afford 301c as white solid (125 mg,23%). MS-ESI: [M+H]⁺ 622.3

Example 3013-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-[[6-(trifluoromethyl)pyridazin-3-yl]amino]-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one301

A mixture of 301c (90 mg, 0.14 mmol) and lithium hydroxide (24 mg, 0.56mmol) in i-propanol/THF/water (6 mL/4 mL/2 mL) was stirred at roomtemperature for 0.5 h. The mixture was evaporated under reduced pressureand the residue was portioned between dichloromethane (20 mL) and water(10 mL). The combined dichloromethane extract was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 301c as a white solid (39 mg, 48%). MS-ESI: [M+H]⁺ 580.3. ¹HNMR (500 MHz, DMSO-d₆) δ 9.57 (s, 1H), 8.87 (d, J=2.5 Hz, 1H), 8.51 (d,J=5.0 Hz, 1H), 7.96 (d, J=9.0 Hz, 1H), 7.88 (d, J=9.0 Hz, 1H), 7.74 (d,J=2.0 Hz, 1H), 7.38 (d, J=5.0 Hz, 1H), 6.58 (s, 1H), 4.98-4.97 (m, 1H),4.48-4.40 (m, 2H), 4.27-4.20 (m, 3H), 3.88-3.86 (m, 1H), 3.65 (s, 3H),2.62-2.53 (m, 2H), 2.42-2.41 (m, 2H), 1.2 (s, 6H).

Example 302a N-Methyl(1-methyl-3-nitro-1H-pyrazol-5-yl)methanamine 302a

To a stirred solution of MeNH₂ (30% wt in water) (2.5 g, 20 mmol) inacetone (10 mL) at 0° C. (ice bath) was added K₂CO₃ (415 mg, 3 mmol),followed by the dropwise addition of a solution of5-(bromomethyl)-1-methyl-3-nitro-1H-pyrazole (220 mg, 1 mmol) in acetone(5 mL). The reaction mixture was then warmed to room temperature andstirred for 3 h. The solvent was removed and the residue was extractedwith methylene chloride (3×15 mL), dried over Na₂SO₄ and concentrated toafford 302a as a yellow oil (170 mg, 99%), which was used in the nextstep without additional purification. LCMS: (M+H)⁺ 171

Example 302bN-Methyl-N-((1-methyl-3-nitro-1H-pyrazol-5-yl)methyl)oxetan-3-amine 302b

To a mixture of 302a (170 mg, 1 mmol) in methanol (4 mL), ZnCl₂ (1mmol/L in diethyl ether) (2 mL, 2 mmol) and oxetan-3-one (150 mg, 2mmol) were added at room temperature under nitrogen protection, followedby the addition of NaBH₃CN (130 mg, 2 mmol). The reaction mixture waswarmed to 50° C. and stirred for 3 h. The mixture was then cooled toroom temperature and the solvent was removed. The residue was purifiedon flush column eluting with 50:1 methylene chloride/methanol to afford302b as a yellow solid (180 mg, 80%, two steps). LCMS: (M+H)⁺ 227. ¹HNMR (500 MHz, DMSO) δ 6.99 (s, 1H), 4.52 (t, J=6.5, 2H), 4.42 (t, J=6,2H), 3.98 (s, 3H), 3.63 (m, 1H), 3.50 (s, 2H), 2.03 (s, 3H).

Example 302c1-Methyl-5-((methyl(oxetan-3-yl)amino)methyl)-1H-pyrazol-3-amine 302c

To a solution of 302b (1.8 g, 7.96 mmol) in ethanol (20 mL) and water(20 mL), NH₄Cl (3.3 g, 63.6 mmol) and iron powder (1.80 g, 31.8 mmol)were added. The reaction mixture was heated at 70° C. for 2 h. Afterthat, the mixture was cooled to room temperature and filtered. Thefiltrate was evaporated and the residue was extracted with methylenechloride (3×30 mL), dried Na₂SO₄, and concentrated to afford the crudeproduct, which was purified on flash column eluting with 50:1 methylenechloride/methanol containing 0.5% triethylamine to afford 302c as ayellow oil (1.3 g, 83%). LCMS: (M+H)⁺ 197

Example 302d5-Bromo-1-methyl-3-(1-methyl-5-((methyl(oxetan-3-yl)amino)methyl)-1H-pyrazol-3-ylamino)pyridin-2(1H)-one302d

Following the procedure in Example 292c, and starting with 302c and3,5-dibromo-1-methylpyridin-2(1H)-one afforded 302d in 63% yield. LCMS:(M+H)⁺ 383. ¹H NMR (500 MHz, DMSO) δ 8.35 (s, 1H), 7.99 (d, J=2.5, 1H),7.36 (d, J=2.5, 1H), 5.99 (s, 1H), 4.50 (t, J=7, 2H), 4.40 (t, J=6.5,2H), 3.77 (s, 3H), 3.57 (m, 1H), 3.49 (s, 3H), 3.35 (s, 2H), 2.01 (s,3H).

Example 302e(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(1-methyl-5-{[methyl(oxetan-3-yl)amino]methyl}-1H-pyrazol-3-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 302e

A 25-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 302d (200 mg, 0.52 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (210 mg, 0.53 mmol), PdCl₂(dppf) (37 mg, 0.050 mmol), K₃PO₄(250 mg, 1.2 mmol), sodium acetate (100 mg, 1.20 mmol), acetonitrile (8mL), and water (0.5 mL). The system was evacuated and then refilled withN₂. The mixture was heated at 100° C. for 1 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the residue was purified by silica-gel columnchromatography eluting with 20:1 dichloromethane/methanol to afford 302eas a yellow solid (150 mg, 44%). MS-ESI: [M+H]⁺ 655.3.

Example 3023-[3-(hydroxymethyl)-4-[1-methyl-5-[[1-methyl-5-[[methyl(oxetan-3-yl)amino]methyl]pyrazol-3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one302

A mixture of 302e (150 mg, 0.23 mmol) and lithium hydroxide hydrate (90mg, 2.3 mmol) in THF (8 mL), i-propanol (8 mL), and water (2 mL) wasstirred at 40° C. for 0.5 h. The mixture was concentrated under reducedpressure. The residue was partitioned between water (10 mL) anddichloromethane (3×15 mL). The combined organic extract was concentratedunder reduced pressure and the residue was purified by reverse-phaseprep-HPLC to afford 302 as a pale yellow solid (105 mg, 75%). MS-ESI:[M+H]⁺ 612.8. ¹H NMR (500 MHz, DMSO-d₆) δ 8.48 (d, J=5.0 Hz, 1H), 8.14(s, 1H), 8.05 (d, J=2.5 Hz, 1H), 7.40 (d, J=2.0 Hz, 1H), 7.33 (d, J=5.0Hz, 1H), 6.55 (s, 1H), 6.01 (s, 1H), 4.99-4.97 (m, 1H), 4.50-4.46 (m,3H), 4.40-4.38 (m, 3H), 4.25-4.18 (m, 3H), 3.85-3.84 (m, 1H), 3.72 (s,3H), 3.59 (s, 3H), 3.58-3.54 (m, 1H), 2.58-2.56 (m, 2H), 2.52-2.50 (m,2H), 2.43-2.42 (m, 2H), 2.00 (s, 3H), 1.22 (s, 6H).

Example 303(S)-10-[3-(hydroxymethyl)-4-[5-({5-[(2R)-1-methoxypropan-2-yl]-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one303

Following Example 300, single enantiomer 303 was obtained (28 mg, 15%)as a white solid. MS-ESI: [M+H]⁺ 627.4. ¹H NMR (500 MHz, CDCl₃) δ 8.49(d, J=5.0 Hz, 1H), 7.92 (d, J=2.5 Hz, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.41(s, 1H), 7.35 (d, J=5.0 Hz, 1H), 6.85 (s, 1H), 5.72 (s, 1H), 5.05-5.03(m, 1H), 4.67-4.45 (m, 1H), 4.52-4.50 (m, 1H), 4.35-4.31 (m, 1H),4.18-4.16 (m, 2H), 4.09-4.07 (m, 2H), 3.87-3.85 (m, 3H), 3.71 (s, 3H),3.56-3.52 (m, 1H), 3.45-3.43 (m, 1H), 3.38 (s, 3H), 3.11-3.08 (m, 3H),2.60-2.58 (m, 2H), 2.53 (s, 2H), 1.29 (s, 6H), 1.17 (d, J=6.0 Hz, 3H).

Example 304a5-(2-Methoxyethyl)-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine304a

To a solution of 2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (190mg, 1.13 mmol) 125i in acetonitrile (10 mL) was added K₂CO₃ (311.9 mg,2.26 mmol) and 1-bromo-2-methoxyethane (188.3 mg, 1.36 mmol). Thereaction mixture was heated at 80° C. for 17 h under microwaveirradiation. Analysis of reaction mixture by LCMS showed completeconversion to the desired product. The mixture was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure to afford 304a as a white solid (230 mg, 90%), which was usedin the next step without further purification. MS-ESI: [M+H]⁺ 227.0

Example 304b5-(2-Methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine 304b

To a solution of 304a (286 mg, 1.26 mmol) in methanol (10 mL) was addedPd/C (28.6 mg). The system was evacuated and then refilled with H₂.After stirring at room temperature for 2 h, the mixture was filteredoff. The filtrate was concentrated under reduced pressure to afford 304bas a yellow solid (240 mg, 97%), which was used in the next step withoutfurther purification. MS-ESI: [M+H]⁺ 197.0

Example 304c5-Bromo-3-(5-(2-methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methylpyridin-2(1H)-one304c

A 100-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 304b (230 mg, 1.17 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (468.4 mg, 1.76 mmol), Pd₂(dba)₃(53.5 mg, 0.0585 mmol), Xantphos (67.6 mg, 0.117 mmol), Cs₂CO₃ (762.8mg, 2.34 mmol), and dioxane (20 mL). After three cycles of vacuum/N₂flush, the mixture was heated at 100° C. for 3 h. Analysis of thereaction mixture by LCMS showed complete conversion to the desiredproduct. It was cooled to room temperature and filtered. The filtratewas concentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 40:1dichloromethane/methanol to afford 304c as a dark solid (380 mg, 85%).MS-ESI: [M+H]⁺ 382.2

Example 304d3-(5-(2-Methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one304d

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 304c (330 mg, 0.86mmol), Pin₂B₂ (329 mg, 1.30 mmol), Pd₂(dba)₃ (40 mg, 0.043 mmol), X-phos(41 mg, 0.086 mmol), potassium acetate (169 mg, 1.726 mmol), and dioxane(10 mL). After three cycles of vacuum/N₂ flush, the mixture was heatedat 70° C. for 2 h. Analysis of reaction mixture by LCMS showed completeconversion to the desired product. It was cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure. Theresidue was washed with petroleum ether to afford 304d as a dark oil(240 mg, 80%), which was used in the next step without furtherpurification. MS-ESI: [M+H]⁺ 348.3

Example 304e2-{4,4-Dimethyl-9-oxo-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6),11-trien-10-yl}-4-(5-{[5-(2-methoxyethyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridine-3-carbaldehyde304e

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6),11-trien-10-yl}pyridine-3-carbaldehyde282i (60 mg, 0.167 mmol), 304d (143.4 mg, 0.334 mmol), Pd(dppf)Cl₂ (6.8mg, 0.0084 mol), K₃PO₄ (70.8 mg, 0.334 mmol), sodium acetate (27.4 mg,0.334 mmol), acetonitrile (10 mL), and water (3 drops). The system wassubjected to three cycles of vacuum/nitrogen flush and heated at 100° C.for 1 h under N₂ protection. Analysis of reaction mixture by LCMS showedcomplete conversion to the desired product. It was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 40:1 dichloromethane/methanol to afford 304e (80 mg, 77%)as white solid. MS-ESI: [M+H]⁺ 626.8

Example 3043-[3-(hydroxymethyl)-4-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one304

To a solution of 304e (80 mg, 0.128 mmol) in dichloromethane (4 mL) andmethanol (4 mL) was added NaBH₄ (9.7 mg, 0.256 mmol). The reactionmixture was stirred at room temperature for 1 h. It was quenched withaqueous NH₄Cl (10 mL) and concentrated under reduced pressure and theresidue was extracted with dichloromethane (3×20 mL). The combinedextract was dried over Na₂SO₄ and concentrated under reduced pressure.The residue was purified by reverse-phase prep-HPLC to afford 304 (23.5mg, 29%) as white solid. MS-ESI: [M+H]⁺ 628.8. ¹H NMR (500 MHz, DMSO-d₆)δ 8.57 (d, J=4.5 Hz, 1H), 8.46 (s, 1H), 8.23 (s, 1H), 8.05 (d, J=2.0 Hz,1H), 7.52 (d, J=5.5 Hz, 1H), 7.40 (d, J=2.5 Hz, 1H), 5.89 (s, 1H), 4.87(s, 1H), 4.39 (s, 2H), 3.92-3.90 (m, 2H), 3.61 (s, 2H), 3.59 (s, 3H),3.50 (t, J=5.5 Hz, 2H), 3.26 (s, 3H), 2.92-2.89 (m, 4H), 2.81 (s, 2H),2.68-2.66 (m, 2H), 1.29 (s, 3H), 1.28 (s, 3H).

Example 305a6-Chloro-4-(5-(2-methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-2-methylpyridazin-3(2H)-one305a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with5-(2-methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine 304b(392 mg, 2.0 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (446 mg, 2.0mmol), cesium carbonate (1.30 g, 4.0 mmol), and 1,4-dioxane (40 mL).After bubbling nitrogen through the suspension for 10 minutes, xantphos(115 mg, 0.20 mmol) and tris(dibenzylideneacetone)dipalladium(0) (92 mg,0.10 mmol) were added. The system was subjected to three cycles ofvacuum/argon flush and heated at 100° C. for 5 h. It was then cooled toroom temperature and filtered. The solid was washed with dichloromethane(2×15 mL). The combined filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with dichloromethane/methanol (80/1 to 30/1) to afford 305a (412mg, 61%) as a yellow solid. MS-ESI: [M+H]⁺ 338.9

Example 305b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(5-{[5-(2-methoxyethyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)methylAcetate 305b

A 25-mL round-bottomed flask equipped with a reflux condenser wascharged with 305a (200 mg, 0.60 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (238 mg, 0.60 mmol), K₃PO₄ (254 mg, 1.2 mmol), sodium acetate(98 mg, 1.2 mmol) and Pd(dppf)Cl₂ (22 mg, 0.030 mmol), andacetonitrile/water (8/0.5 mL). The system was subjected to three cyclesof vacuum/nitrogen flush and heated at 100° C. under N₂ protection for 1h. Analysis of the reaction mixture by LCMS showed complete conversionto the desired product. The reaction mixture was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure. The residue was partitioned between dichloromethane (30 mL)and water (20 mL). The water layer was extracted with dichloromethane(2×30 mL). The combined organic extract was dried over Na₂SO₄, filtered,and concentrated under reduced pressure. The dark residue was purifiedby silica-gel column chromatography eluting withdichloromethane/methanol (80/1 to 30/1) to afford 305b (169 mg, 43%) asa yellow solid. MS-ESI: [M+H]⁺ 655.9

Example 3053-[3-(hydroxymethyl)-4-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one305

To a solution of 305b (160 mg, 0.24 mmol) in THF/i-propanol/water (6/4/3mL) was added lithium hydroxide (29 mg, 1.2 mmol). The mixture wasstirred at room temperature for 1 h and concentrated under reducedpressure. The residue was partitioned between water (15 mL) and ethylacetate (20 mL). The water phase was extracted with ethyl acetate (3×20mL). The combined organic layer was dried and concentrated underpressure. The residue was purified by reverse-phase prep-HPLC to afford305 as a white solid (88 mg, 60%). MS-ESI: [M+H]⁺ 614.3. ¹H NMR (500MHz, CDCl₃) δ 8.56 (d, J=5.0 Hz, 1H), 7.99 (s, 1H), 7.87 (s, 1H), 7.44(d, J=5.0 Hz, 1H), 6.84 (s, 1H), 5.96 (s, 1H), 4.59-4.57 (m, 3H),4.49-4.47 (m, 1H), 4.17-4.12 (m, 4H), 3.92-3.90 (m, 4H, overlap),3.77-3.75 (m, 2H), 3.61-3.60 (m, 2H), 3.41 (s, 3H), 3.05-3.03 (m, 2H),2.81-2.79 (m, 2H), 2.60-2.58 (m, 2H), 2.52-2.50 (m, 2H), 1.28 (s, 6H).

Example 306a(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{5-[(6-methoxypyridazin-3-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 306a

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with6-methoxypyridazin-3-amine (65 mg, 0.52 mmol), XantPhos (29 mg, 0.050mmol), Pd₂ dba₃ (45 mg, 0.050 mmol),[4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricy-clo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylacetate 273a (281 mg, 0.52 mmol), Cs₂CO₃ (326 mg, 1.0 mmol), and1,4-dioxane (10 mL). After bubbling nitrogen through the resultingmixture for 20 minutes, it was heated at reflux for 2 h. After thecompletion of the reaction, the mixture was evaporated under reducedpressure and the residue was partitioned between ethyl acetate (20 mL)and water (10 mL). The ethyl acetate was concentrated under reducedpressure and the residue was purified by silica-gel columnchromatography eluting with 20:1 dichloromethane/methanol to afford 306a(180 mg, 60%). MS-ESI: [M+H]⁺ 584.3.

Example 3063-[3-(hydroxymethyl)-4-[5-[(6-methoxypyridazin-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one306

A mixture of 306a (180 mg, 0.32 mmol) and lithium hydroxide monohydrate(84 mg, 2.0 mmol) in THF (5 mL), i-propanol (5 mL), and water (1.5 mL)was stirred at 40° C. for 0.5 h. The mixture was evaporated underreduced pressure and the residue was partitioned between ethyl acetate(20 mL) and water (10 mL). The ethyl acetate was concentrated underreduced pressure and the residue was purified by reverse-phase prep-HPLCto afford 306 (80 mg, 49%). MS-ESI: [M+H]⁺ 542.3. ¹H NMR (500 MHz,DMSO-d₆) δ 8.86 (s, 1H), 8.76 (d, J=2.5 Hz, 1H), 8.51 (d, J=5.0 Hz, 1H),7.73 (d, J=10.0 Hz, 1H), 7.56 (d, J=2.5 Hz, 1H), 7.35 (d, J=5.0 Hz, 1H),7.11-7.10 (m, 1H), 6.56 (s, 1H), 4.94-4.93 (m, 1H), 4.48-4.45 (m, 1H),4.40-4.38 (m, 1H), 4.25-4.18 (m, 3H), 3.91 (s, 3H), 3.86-3.84 (m, 1H),3.62 (s, 3H), 2.58-2.56 (m, 2H), 2.50-2.49 (m, 2H), 1.21 (s, 6H).

Example 307a 1,3-Dimethyl-5-nitro-1H-indazole 307a

To a solution of 1-(2-chloro-5-nitrophenyl)ethanone (500 mg, 2.5 mmol)in anhydrous ethanol (15 mL) was added 1,1-dimethylhydrazinehydrochloride (3.38 g, 35.0 mmol) under nitrogen protection. The mixturewas heated at reflux for 10 h and evaporated under reduced pressure toafford crude 307a (3.0 g), which was used in the next step withoutfurther purification. MS-ESI: [M+H] 192.2

Example 307b 1,3-Dimethyl-1H-indazol-5-amine 307b

To a solution of 307a (crude, 2.5 mmol) in ethanol (95%, 30 mL) wasadded NH₂NH₂ water (1.25 g, 25.0 mmol), Pd/C (100 mg) under nitrogenprotection. The mixture was stirred at 50° C. for 1.5 h. It was thencooled to room temperature and filtered through a pad of CELITE®. Thefiltrate was concentrated under reduced pressure and the residue wasrecrystallized from anhydrous ethanol (5 mL) to afford 307b as whitesolid (340 mg, 84% over two steps). MS-ESI: [M+H] 162.3

Example 307c5-Bromo-3-(1,3-dimethyl-1H-indazol-5-ylamino-1-methylpyrazin-2(1H)-one307c

To a solution of 307b (280 mg, 1.74 mmol) in i-propanol (7 mL) was addedtriethylamine (352 mg, 3.48 mmol) and3,5-dibromo-1-methylpyrazin-2(1H)-one (H-005) (700 mg, 2.61 mmol). Afterbeing stirred at reflux for 6 h, the mixture was cooled to roomtemperature. The precipitate was filtered, washed with i-propanol (2×2mL), and dried at 60° C. under reduced pressure to afford 307c as abrown solid (560 mg, 92%). MS-ESI: [M+H]⁺ 347.8.

Example 307d(4-{6-[(1,3-Dimethyl-1H-indazol-5-yl)amino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl)methylAcetate 307d

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 307c (300 mg, 0.86mmol), 1,4-dioxane (20 mL), water (1 mL),[4-(dihydroxyboranyl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylacetate 199e (512 mg, 1.28 mmol), and cesium carbonate (560 mg, 1.72mmol). After bubbling nitrogen through the suspension for 10 minutes,Cy₃P (96 mg, 0.34 mmol) and Pd₂(dba)₃ (79 mg, 0.086 mmol) were added.The system was subjected to three cycles of vacuum/argon flush andheated at reflux for 3 h. It was then cooled to room temperature andfiltered. The solid was washed with dichloromethane (3×20 mL). Thecombined filtrate was concentrated under reduced pressure and theresidue was purified by silica-gel column chromatography eluting with100:1 dichloromethane/methanol to afford 307d (230 mg, 43%) as a yellowsolid. MS-ESI: [M+H] 620.9

Example 3073-[4-[6-[(1,3-dimethylindazol-5-yl)amino]-4-methyl-5-oxo-pyrazin-2-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one307

A mixture of 307d (230 mg, 0.37 mmol), lithium hydroxide (89 mg, 3.7mmol) in i-propanol/THF (1:1, 10 mL) and water (2 mL) was stirred atroom temperature for 1 h. It was filtered and the filtrate wasconcentrated under reduced pressure. The resulting residue was purifiedby reverse-phase prep-HPLC to afford 307 (41 mg, 19%) as a white solid.MS-ESI: [M+H]⁺ 578.4. ¹H NMR (500 MHz, CDCl₃) δ 8.58 (d, J=2.0 Hz, 1H),8.56 (d, J=5.0 Hz, 1H), 8.37 (s, 1H), 8.11 (s, 1H), 7.88 (d, J=5.0 Hz,1H), 7.51 (dd, J=2.0, 9.0 Hz, 1H), 7.33 (d, J=9.0 Hz, 1H), 6.86 (s, 1H),5.17-5.14 (m, 1H), 4.75-4.73 (m, 1H), 4.55-4.52 (m, 1H), 4.48-4.43 (m,1H), 4.20-4.16 (m, 2H), 4.02 (s, 3H), 3.92-3.70 (m, 1H), 3.70 (s, 3H),2.60 (d, J=7.0 Hz, 2H), 2.57 (s, 3H), 2.54 (s, 2H), 1.30 (s, 6H).

Example 308a2-{4,4-Dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}-4-(5-{[5-(2-methoxyethyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridine-3-carbaldehyde308a

Following the procedure in Example 304, and starting with4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde109a (250 mg, 0.693 mmol) and3-(5-(2-methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one304d (595 mg, 0.1.386 mmol), 308a was obtained as a yellow solid (250mg, 57%). MS-ESI: [M+H]⁺ 628.3

Example 3083-[3-(hydroxymethyl)-4-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one308

Following the procedures in Example 304, and starting with 308a (230 mg,0.366 mmol) and NaBH₄ (27.7 mg, 0.732 mmol), 308 was obtained as a whitesolid (53.2 mg, 23%). MS-ESI: [M+H]⁺ 629.8. ¹H NMR (500 MHz, DMSO-d₆) δ8.49 (d, J=5.0 Hz, 1H), 8.19 (s, 1H), 8.04 (d, J=2.0 Hz, 1H), 7.37 (d,J=2.5 Hz, 1H), 7.34 (d, J=5.0 Hz, 1H), 5.89 (s, 1H), 4.95-4.93 (m, 1H),4.47-4.39 (m, 2H), 4.20-4.14 (m, 1H), 3.92-3.91 (m, 2H), 3.84-3.80 (m,1H), 3.61 (s, 2H), 3.58 (s, 3H), 3.51-3.49 (m, 2H), 3.25 (s, 3H),3.06-3.00 (m, 1H), 2.91-2.87 (m, 3H), 2.77 (s, 2H), 2.68-2.53 (m, 4H),1.19 (s, 3H), 1.18 (s, 3H).

Example 309a5-(3-Methoxypropyl)-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine309a

A microwave vial equipped with a magnetic stirrer was charged with1-(2-bromoethyl)-5-(chloromethyl)-3-nitro-1H-pyrazole 296c (600 mg, 2.2mmol), 3-methoxypropan-1-amine (595 mg, 6.6 mmol), and DMSO (6 mL). Itwas heated at 120° C. under microwave irradiation for 0.5 h. The mixturewas then cooled to room temperature and diluted with ethyl acetate (30mL). The resulting mixture was washed with water (3×10 ml). The organiclayer was dried and filtered. The filtrate was concentrated underpressure and the residue was purified by silica-gel columnchromatography eluting with 30:1 dichloromethane/methanol to afford 309a(350 mg, 66%) as a yellow solid. MS-ESI: [M+H]⁺ 241.1

Example 309b5-(3-Methoxypropyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine309b

A solution of 309a (300 mg, 1.25 mmol) in ethanol (20 mL) was added Pd/C(10%, 30 mg). The reaction was charged with hydrogen gas (via balloon)and stirred at room temperature for 1 h. After the reaction wascomplete, the mixture was filtered through a plug of CELITE®. Thefiltrate was concentrated under reduced pressure to afford 309b as ayellow solid (250 mg, 92%), which was used without further purificationin the next step. MS-ESI: [M+H]⁺ 211.3

Example 309c5-Bromo-3-(5-(3-methoxypropyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl-amino)-1-methylpyridin-2(1H)-one309c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with3,5-dibromo-1-methylpyridin-2(1H)-one (320 mg, 1.2 mmol), 309b (250 mg,1.2 mmol), tris(dibenzylideneacetone) dipalladium(0) (55 mg, 0.060mmol), xantphos (70 mg, 0.12 mmol), cesium carbonate (782 mg, 2.4 mmol),and 1,4-dioxane (20 mL). The system was subjected to three cycles ofvacuum/argon flush and heated at 100° C. for 5 h. It was then cooled toroom temperature and filtered. The solid was washed with dichloromethane(2×10 mL). The combined filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with dichloromethane/methanol (80:1 to 30:1) to afford 309c (200mg, 42%) as yellow solid. MS-ESI: [M+H]⁺ 396.2

Example 309d(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(5-{[5-(3-methoxypropyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methylAcetate 309d

A 25-mL round-bottomed flask equipped with a reflux condenser wascharged with 309c (120 mg, 0.30 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (240 mg, 0.60 mmol), K₃PO₄ (127 mg, 0.60 mmol), sodium acetatemonohydrate (82 mg, 0.60 mmol), Pd(dppf)Cl₂ (12 mg, 0.015 mmol), andacetonitrile/water (8/0.5 mL). The system was subjected to three cyclesof vacuum/nitrogen flush and heated at 100° C. under N₂ protection for 2h. Analysis of the reaction mixture by LCMS showed complete conversionto the desired product. The reaction mixture was cooled to roomtemperature and concentrated under reduced pressure. The residue waspartitioned between dichloromethane (20 mL) and water (10 mL). The waterlayer was extracted with dichloromethane (2×10 mL). The combined organicextract was dried over Na₂SO₄, filtered, and concentrated under reducedpressure. The dark residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (80:1 to 30:1) toafford 309d (150 mg, 74%) as yellow solid. MS-ESI: [M+H]⁺ 668.9

Example 3093-[3-(hydroxymethyl)-4-[5-[[5-(3-methoxypropyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one309

To a solution of 309d (120 mg, 0.18 mmol) in THF/i-propanol/water (5/3/3mL) was added lithium hydroxide monohydrate (76 mg, 1.8 mmol). Themixture was stirred at 30° C. for 1 h. After the reaction was complete,the mixture was filtered and the solvent was evaporated under reducedpressure. The residue was purified by reverse-phase prep-HPLC to afford309 as a white solid (85 mg, 76%). MS-ESI: [M+H]⁺ 627.3. ¹H NMR (500MHz, CDCl₃) δ 8.48 (d, J=5.0 Hz, 1H), 7.95 (d, J=2.0 Hz, 1H), 7.72 (d,J=2.0 Hz, 1H), 7.42 (s, 1H), 7.35 (d, J=5.0 Hz, 1H), 6.86 (s, 1H), 5.71(s, 1H), 5.05 (t, J=6.0 Hz, 1H), 4.66-4.64 (m, 1H), 4.52-4.50 (m, 1H),4.36-4.32 (m, 1H), 4.17-4.16 (m, 2H), 4.08-4.06 (m, 2H), 3.88-3.85 (m,1H), 3.71 (s, 3H), 3.65-3.64 (m, 2H), 3.48 (t, J=6.0 Hz, 2H), 3.36 (s,3H), 2.93 (t, J=6.0 Hz, 2H), 2.65-2.62 (m, 2H), 2.59-2.58 (m, 2H), 2.53(s, 2H), 1.87-1.83 (m, 2H), 1.29 (s, 6H).

Example 310a(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{1-methyl-5-[(5-methyl-1,2-thiazol-3-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 310a

A 25-mL sealed tube was charged with[4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylacetate 273a (150 mg, 0.28 mmol), 5-methylisothiazol-3-aminehydrochloride (55 mg, 0.33 mmol), Cs₂CO₃ (183 mg, 0.56 mmol), Pd₂(dba)₃(27 mg, 0.030 mmol), XantPhos (35 mg, 0.060 mmol), and dioxane (10 mL).After three cycles of vacuum/argon flush, the mixture was heated at 110°C. under microwave irradiation for 0.5 hour. It was the cooled to roomtemperature and evaporated under reduced pressure. The residue waspurified by silica-gel column eluting with 20:1 methylenechloride/methanol to afford 310a as a yellow solid (50 mg, 31%). MS-ESI:[M+H]⁺ 573.2.

Example 3103-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylisothiazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one310

To a solution of 310a (50 mg, 0.090 mmol) in THF/i-propanol/water (4mL/4 mL/1 mL) was added lithium hydroxide (21 mg, 0.90 mmol). Thereaction mixture was stirred at room temperature for 0.5 h andconcentrated under reduced pressure. The residue was diluted with water(10 mL) and extracted with ethyl acetate (3×20 mL). The combined organiclayer was dried with Na₂SO₄ and concentrated under reduced pressure toafford a yellow solid, which was purified by reverse-phase prep-HPLC toafford 310 as a yellow solid (20 mg, 43%). MS-ESI: [M+H]⁺ 530.8. ¹H NMR(500 MHz, CDCl₃) δ 8.61 (d, J=2.0 Hz, 1H), 8.49 (d, J=5.5 Hz, 1H), 8.05(s, 1H), 7.93 (d, J=2.0 Hz, 1H), 7.37 (d, J=5.0 Hz, 1H), 6.84 (s, 1H),6.51 (s, 1H), 5.09-5.06 (m, 1H), 4.66-4.47 (m, 2H), 4.28-4.27 (m, 1H),4.17-4.12 (m, 2H), 3.89-3.82 (m, 1H), 3.71 (s, 3H), 2.57 (d, J=6.0 Hz,2H), 2.52-2.50 (m, overlap, 5H), 1.27 (s, 6H).

Example 311a(4-{5-[(5-Cyclopropyl-1,2-oxazol-3-yl)amino]-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl}-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl)methylAcetate 311a

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-cyclopropylisoxazol-3-amine (80 mg, 0.65 mmol), XantPhos (29 mg, 0.050mmol), Pd₂ dba₃ (45 mg, 0.050 mmol),[4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricy-clo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylacetate 273a (350 mg, 0.65 mmol), Cs₂CO₃ (390 mg, 1.2 mmol), and1,4-dioxane (10 mL). After bubbling nitrogen through the resultingmixture for 10 minutes, it was heated at reflux for 2 h. The mixture wasthen evaporated under reduced pressure and the residue was partitionedbetween ethyl acetate (20 mL) and water (10 mL). The organic layer wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting with 20:1dichloromethane/methanol to afford 311a (120 mg, 32%) as a brown solid.MS-ESI: [M+H]⁺ 583.2.

Example 3113-[4-[5-[(5-cyclopropylisoxazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one311

A mixture of 311a (120 mg, 0.20 mmol) and lithium hydroxide monohydrate(80 mg, 2.0 mmol) in THF (5 mL), i-propanol (5 mL) and water (1.5 mL)was stirred at 40° C. for 0.5 h. The mixture was evaporated underreduced pressure and the residue was diluted with water (5 mL). It wasthen extracted with ethyl acetate (2×10 mL). The combined extract wasconcentrated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 311 (65 mg, 58%) as pale yellow solid.MS-ESI: [M+H]⁺ 541.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.92 (s, 1H), 8.48 (d,J=5.0 Hz, 1H), 7.99 (d, J=2.0 Hz, 1H), 7.55 (d, J=2.0 Hz, 1H), 7.31 (d,J=5.0 Hz, 1H), 6.56 (s, 1H), 6.19 (s, 1H), 4.92-4.90 (m, 1H), 4.45-4.44(m, 1H), 4.40-4.39 (m, 1H), 4.24-4.18 (m, 3H), 3.86-3.83 (m, 1H), 3.59(s, 3H), 2.58-2.56 (m, 2H), 2.44-243 (m, 2H), 2.07-2.04 (m, 1H), 1.22(s, 6H) 1.03-0.99 (m, 2H), 0.84-0.81 (m, 2H).

Example 312a5-Bromo-1-methyl-3-(5-methyl-1-(oxetan-3-yl)-1H-pyrazol-3-ylamino)pyridin-2(1H)-one312a

A mixture of5-bromo-1-methyl-3-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2(1H)-one 115a(200 mg, 0.71 mmol), 3-iodooxetane (647 mg, 3.53 mmol), Cs₂CO₃ (1150 mg,3.53 mmol), and acetonitrile (5 mL) was heated at 80° C. in a sealedtube overnight. The mixture was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresidue was purified by silica-gel column chromatography eluting with20:1 dichloromethane/methanol to afford the 312a as a yellow solid (120mg, 50%). MS-ESI: [M+H]⁺ 339.1

Example 312b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(1-methyl-5-{[5-methyl-1-(oxetan-3-yl)-1H-pyrazol-3-yl]amino}-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methylAcetate 312b

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 312a (170 mg, 0.50mmol),(2-{4,4-dimethyl-9-oxo-1,{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (200 mg, 0.50 mmol), CH₃COONa (82 mg, 1.00 mmol), PdCl₂(dppf)(41 mg, 0.050 mmol), K₃PO₄ (212 mg, 1.00 mmol), acetonitrile (10 mL),and water (0.5 mL). After bubbling nitrogen through the resultingmixture for 20 minutes, it was heated at 100° C. under nitrogenatmosphere for 2 h. The mixture was cooled to room temperature andfiltered. The filtrate was evaporated under reduced pressure and theresidue was purified by silica-gel column chromatography eluting with50:1 dichloromethane/methanol to afford 312b as white solid (172 mg,56%). MS-ESI: [M+H]⁺ 612.4

Example 3123-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-methyl-1-(oxetan-3-yl)pyrazol-3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one312

A mixture of 312b (90 mg, 0.15 mmol) and lithium hydroxide (14 mg, 0.60mmol) in i-propanol/THF/water (6/4/2 mL) was stirred at room temperaturefor 0.5 h. The mixture was concentrated under reduced pressure. Theresidue was partitioned between water (10 mL) and dichloromethane (3×20mL). The combined dichloromethane extract was concentrated under reducedpressure and the residue was purified by reverse-phase prep-HPLC toafford 312 as a white solid (54 mg, 64%). MS-ESI: [M+H]⁺ 569.9. ¹H NMR(500 MHz, DMSO-d₆) δ 8.47 (d, J=5.0 Hz, 1H), 8.24 (d, J=2.0 Hz, 1H),8.23 (s, 1H), 7.48 (d, J=1.5 Hz, 1H), 7.36 (d, J=5.0 Hz, 1H), 6.55 (s,1H), 5.95 (s, 1H), 5.46-5.42 (m, 1H), 4.99-4.91 (m, 3H), 4.81-4.78 (m,2H), 4.52-4.41 (m, 2H), 4.24-4.18 (m, 3H), 3.87-3.84 (m, 1H), 3.60 (s,3H), 2.61-2.56 (m, 2H), 2.43 (s, 2H), 2.15 (s, 3H), 1.22 (s, 3H), 1.19(s, 3H).

Example 313a Ethyl 2-(5-(Hydroxymethyl)-3-nitro-1H-pyrazol-1-yl)acetate313a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with acetonitrile (30 mL),(3-nitro-1H-pyrazol-5-yl)methanol (1.43 g, 10.0 mmol), Cs₂CO₃ (490 mg,1.5 mmol), and ethyl 2-bromoacetate (2.00 g, 12 mmol). The mixture wasstirred at 40° C. for 5 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresidue was purified by silica-gel column chromatography eluting with30:1 dichloromethane/methanol to afford 313a (1.65 g, 72%) as a yellowsolid. MS-ESI: [M+H]⁺ 229.9

Example 313b Ethyl 2-(5-(Chloromethyl)-3-nitro-1H-pyrazol-1-yl)acetate313b

To a mixture of 313a (1.50 g, 6.55 mmol) in CHCl₃ (60 mL) cooled at 0°C. was slowly added SOCl₂ (2.34 g, 19.6 mmol) while maintaining theinternal temperature below 5° C. This reaction mixture was warmed to 50°C. and stirred at this temperature for 3 h. It was then cooled to 0° C.and quenched with water. The organic layer was separated and evaporatedunder reduced pressure. The residue was purified by silica-gel columnchromatography eluting with 30:1 dichloromethane/methanol to afford 313b(1.1 g, 68%) as a yellow solid. MS-ESI: [M+H]⁺ 247.9

Example 313c5-Methyl-2-nitro-4,5-dihydropyrazolo[1,5-a]pyrazin-6(7H)-one 313

To a solution of 313b (1.0 g, 4.0 mmol) in dichloromethane (30 mL) wasadded a solution of CH₃NH₂ (1.07 g, 12.0 mmol, 35% in methanol). Thisreaction mixture was stirred at room temperature for 3 h and dilutedwith water (30 mL). The organic layer was separated, dried over Na₂SO₄,and concentrated under reduced pressure. The residual was purified bysilica-gel column chromatography eluting with 30:1dichloromethane/methanol to afford 313c (450 mg, 57%) as a yellow solid.MS-ESI: [M+H]⁺ 196.9

Example 313d2-Amino-5-methyl-4,5-dihydropyrazolo[1,5-a]pyrazin-6(7H)-one 313d

A solution of 313c (450 mg, 2.3 mmol) in ethanol (30 mL) was added Pd/C(10%, 400 mg). The reaction was charged with hydrogen gas (via balloon)and stirred at room temperature for 2 h. After reaction was complete,the mixture was filtered through a plug of CELITE® and the filtrate wasconcentrated under reduced pressure to afford 313d as a yellow solid(320 mg, 84%), which was used without further purification in the nextstep. MS-ESI: [M+H]⁺ 167.1

Example 313e2-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)-5-methyl-4,5-dihydropyrazolo[1,5-a]pyrazin-6(7H)-one313e

A 100-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 313d (300 mg, 1.8 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (482 mg, 1.8 mmol), cesiumcarbonate (1.17 g, 3.6 mmol), and 1,4-dioxane (20 mL). After bubblingnitrogen through the suspension for 10 minutes, xantphos (104 mg, 0.18mmol) and tris(dibenzylideneacetone)dipalladium(0) (82 mg, 0.090 mmol)were added. The system was subjected to three cycles of vacuum/argonflush and heated at reflux for 5 h. It was then cooled to roomtemperature and filtered. The solid was washed with dichloromethane(2×30 m). The combined filtrate was concentrated under reduced pressure.The residue was purified by silica-gel column chromatography elutingwith dichloromethane/methanol (80/1 to 30/1) to afford 313e (390 mg,61%) as a yellow solid.

Example 313f(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[1-methyl-5-({5-methyl-6-oxo-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridin-3-yl)methylAcetate 313f

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 313e (150 mg, 0.43mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (170 mg, 0.43 mmol), K₃PO₄ (183 mg, 0.86 mmol), sodium acetate(71 mg, 0.86 mmol), Pd(dppf)Cl₂ (35 mg, 0.043 mmol), acetonitrile (10mL), and water (0.5 mL). The system was subjected to three cycles ofvacuum/nitrogen flush and heated at 100° C. for 3 h. After this time thereaction was cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 30:1dichloromethane/methanol to afford 313f (131 mg, 49%) as a yellow solid.MS-ESI: [M+H]⁺ 625.3.

Example 3133-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6-oxo-4,7-dihydropyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one313

A mixture of 313f (130 mg, 0.21 mmol) and lithium hydroxide (10 mg, 0.42mmol) in i-propanol/THF (1:1, 7 mL) and water (2 mL) was stirred at 0°C. for 0.5 h. The mixture was concentrated under reduced pressure. Theresidue was partitioned between water (10 mL) and ethyl acetate (3×10mL). The combined ethyl acetate extract was concentrated under reducedpressure and the residue was purified with reverse-phase prep-HPLC toafford 313 (60 mg, 49%) as a white solid. MS-ESI: [M+H]⁺ 582.8. ¹H NMR(500 MHz, DMSO-d₆) δ 8.48 (d, J=5.0 Hz, 1H), 8.37 (s, 1H), 8.10 (d,J=2.0 Hz, 1H), 7.43 (d, J=2.5 Hz, 1H), 7.33 (d, J=5.0 Hz, 1H), 6.57 (s,1H), 6.07 (s, 1H), 4.95 (bs, 1H), 4.62-4.54 (m, 4H), 4.46-4.42 (m, 2H),4.24-4.19 (m, 3H), 3.89-3.82 (m, 1H), 3.60 (s, 3H), 2.99 (s, 3H),2.60-2.57 (m, 2H), 2.45-2.44 (m, 2H), 1.23 (s, 6H).

Example 314a 1-(6-Nitropyridin-3-yl)azetidin-3-ol 314a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with acetonitrile (50 mL),5-fluoro-2-nitropyridine (1.2 g, 7.9 mmol), K₂CO₃ (2.1 g, 15.8 mmol),and azetidin-3-ol hydrochloride (1.3 g, 11.9 mmol). The mixture washeated at 60° C. for 1 h. After this time the reaction was cooled toroom temperature. It was then filtered and the filtrate was evaporatedunder reduced pressure. The residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (50:1 to 20:1) toafford 314a (1.1 g, 73%) as a yellow solid. MS-ESI: [M+H]⁺ 196.0.

Example 314b 1-(6-Aminopyridin-3-yl)azetidin-3-ol 314b

A 100-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 314a (1.0 g, 5.1 mmol), 10% palladium on carbon (10% wet,100 mg), and ethanol (40 mL). The mixture was evacuated, charged withhydrogen gas, and stirred at room temperature for 5 h. The hydrogen wasthen evacuated and nitrogen was charged into the flask. The catalyst wasremoved by filtration through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure to afford 314b as a yellow solid(792 mg, 85%). MS-ESI: [M+H]+ 166.1.

Example 314c5-Bromo-3-(5-(3-hydroxyazetidin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one314c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 314b (792 mg, 4.8 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (1.9 g, 7.2 mmol),tris-(dibenzylideneacetone)dipalladium(0) (440 mg, 0.48 mmol), XantPhos(555 mg, 0.96 mmol), Cs₂CO₃ (3.1 g, 9.6 mmol), and 1,4-dioxane (40 mL).After three cycles of vacuum/argon flush, the mixture was heated at 90°C. for 3.0 hrs. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting withdichloromethane/methanol (50:1 to 20:1) to afford 314c as a yellow solid(1.5 g, 89%). MS-ESI: [M+H]⁺ 351.1

Example 314d(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(5-{[5-(3-hydroxyazetidin-1-yl)pyridin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methyl Acetate 314d

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 314c (176 mg, 0.50 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatri-cyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (198 mg, 0.50 mmol), Pd(dppf)Cl₂ (41 mg, 0.050 mmol), K₃PO₄(212.0 mg, 1.0 mmol), sodium acetate (82.0 mg, 1.0 mmol), water (0.5mL), and acetonitrile (10 mL). After three cycles of vacuum/argon flush,the mixture was heated at 95° C. for 1 hour. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with 30:1 dichloromethane/methanol to affordcrude 314d as a brown solid, which was used in the next step withoutfurther purification. MS-ESI: [M+H]⁺ 623.8.

Example 3143-[4-[5-[[5-(3-hydroxyazetidin-1-yl)-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one314

A mixture of 314d (crude product 311.5 mg, 0.50 mmol) and lithiumhydroxide hydrate (300 mg, 12.5 mmol) in i-propanol/THF/water (2:2:1, 10mL) was stirred at room temperature for 30 min. The mixture wasconcentrated under reduced pressure. The residue was partitioned betweenwater (10 mL) and dichloromethane (3×10 mL). The combined extract wasconcentrated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 314 (46 mg, two step: 16%) as yellowsolid. MS-ESI: [M+H]⁺ 581.9. ¹H NMR (500 MHz, DMSO-d₆) δ 8.54 (d, J=2.5Hz, 1H), 8.47 (d, J=5.0 Hz, 1H), 7.78 (d, J=2.5 Hz, 1H), 7.70 (s, 1H),7.54 (d, J=2.5 Hz, 1H), 7.35 (d, J=5.0 Hz, 1H), 6.83-6.81 (m, 2H), 6.75(d, J=8.5 Hz, 1H), 5.04-5.02 (m, 1H), 4.77-4.75 (m, 1H), 4.64-4.62 (m,1H), 4.50-4.48 (m, 1H), 4.34-4.32 (m, 1H), 4.17-4.14 (m, 4H), 3.86-3.83(m, 1H), 3.70 (s, 3H), 3.64-3.62 (m, 2H), 2.57-2.56 (m, 2H), 2.51 (s,2H), 2.31-2.30 (m, 1H), 1.27 (s, 6H).

Example 3153-[3-(hydroxymethyl)-4-[1-methyl-5-[[1-methyl-5-(pyrrolidine-1-carbonyl)pyrazol-3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one315

Following the procedures of Example 273, and substituting(3-amino-1-methyl-1H-pyrazol-5-yl)(pyrrolidin-1-yl)methanone for2-aminopyridine, 315 was prepared. 27.3 mg, 60% yield. ¹H NMR (400 MHz,DMSO-d6) δ 8.48 (d, J=5.1 Hz, 1H), 8.23 (s, 1H), 8.05 (d, J=2.4 Hz, 1H),7.43 (d, J=2.4 Hz, 1H), 7.34 (d, J=5.1 Hz, 1H), 6.55 (s, 1H), 6.46 (s,1H), 4.95 (t, J=5.2 Hz, 1H), 4.42-4.47 (m, 1H), 4.17-4.21 (m, 3H), 3.79(s, 2H), 3.59 (s, 3H), 3.48 (dt, J=11.1, 6.6 Hz, 3H), 3.27 (s, 2H), 2.57(d, J=7.5 Hz, 2H), 2.43 (s, 2H), 1.90-1.84 (m, 3H), 1.22 (s, 6H). ES-MSm/z 611.4 [M+1].

Example 3163-[3-(hydroxymethyl)-4-[5-[[5-(methoxymethyl)-1-methyl-pyrazol-3-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one316

Following the procedures of Example 273, and substituting5-(methoxymethyl)-1-methyl-1H-pyrazol-3-amine for 2-aminopyridine, 316was prepared. 43.2 mg, 84% yield. ¹H NMR (400 MHz, DMSO-d6) δ 8.47 (d,J=5.0 Hz, 1H), 8.15 (s, 1H), 8.04 (d, J=2.4 Hz, 1H), 7.39 (d, J=2.1 Hz,1H), 7.33 (d, J=5.0 Hz, 1H), 6.55 (s, 1H), 6.11 (s, 1H), 4.96-4.90 (m,1H), 4.38-4.46 (m, 1H), 4.38 (s, 2H), 4.19 (d, J=9.8 Hz, 2H), 3.82-3.96(m, 1H), 3.65 (s, 3H), 3.58 (s, 3H), 3.27 (s, 2H), 2.57 (d, J=7.5 Hz,2H), 2.43 (s, 2H), 1.22 (s, 6H). ES-MS m/z 558.3 [M+1].

Example 317a5-Methyl-2-(1-methyl-2-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-dihydropyridin-3-ylamino)-4,5-dihydropyrazolo[1,5-a]pyrazin-6(7H)-one317a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with2-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)-5-methyl-4,5-dihydropyrazolo[1,5-a]pyrazin-6(7H)-one313e (270 mg, 1.0 eq., 0.68 mmol), Pin₂B₂ (863.6 mg, 5.0 eq., 3.4 mmol),Pd₂(dba)₃ (62.4 mg, 0.1 eq., 0.068 mmol), X-Phos (64.8 mg, 0.2 eq., 0.14mmol), potassium acetate (200 mg, 3.0 eq., 2.04 mmol), and dioxane (15mL). After three cycles of vacuum/argon flush, the mixture was heated at65° C. for 3 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure to afford crude 317a,which was used in the next step without further purification. MS-ESI:[M+H]⁺ 399.9.

Example 317b2-{4,4-Dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}-4-[1-methyl-5-({5-methyl-6-oxo-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridine-3-carbaldehyde317b

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 317a (100 mg, 0.28mmol),4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde109a (112 mg, 0.28 mmol), Pd(dppf)Cl₂ (22.9 mg, 0.028 mmol), K₃PO₄(118.7 mg, 0.56 mmol), sodium acetate (45.9 mg, 0.56 mmol), water (0.5mL), and acetonitrile (10 mL). After three cycles of vacuum/argon flush,the mixture was heated at reflux for 1 hour. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure and the resulting residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (50:1 to 30:1) toafford 317b as a yellow solid (60 mg, 36%). MS-ESI: [M+H]⁺ 597.8.

Example 3173-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6-oxo-4,7-dihydropyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one317

A mixture of 317b (60 mg, 0.10 mmol) and NaBH₄ (11.3 mg, 0.30 mmol) inmethanol (5 mL) was stirred at room temperature for 30 min. The mixturewas quenched with water (15 mL) and concentrated under reduced pressure.The residue was extracted with dichloromethane (3×10 mL). The combinedextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 317 (15 mg, 25%) as ayellow solid. MS-ESI: [M+H]+ 599.8. ¹H NMR (500 MHz, CDCl₃) δ 8.50 (d,J=5.0 Hz, 1H), 8.0 (d, J=2.0 Hz, 1H), 7.69 (d, J=2.5 Hz, 1H), 7.50 (s,1H), 7.34 (d, J=5.0 Hz, 1H), 5.86 (s, 1H), 4.82-4.66 (m, 4H), 4.56 (s,2H), 4.42-4.33 (m, 2H), 3.83-3.81 (m, 1H), 3.70 (s, 3H), 3.15 (s, 3H),2.98-2.94 (m, 2H), 2.80 (s, 2H), 2.57-2.52 (m, 2H), 1.28 (s, 6H).

Example 318a{4-[5-({4,5-Dimethyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl}methylAcetate 318a

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with4,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine 287i (123mg, 1.0 eq., 0.74 mmol),[4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylacetate 273a (400 mg, 1.0 eq., 0.74 mmol), Pd₂(dba)₃ (68 mg, 0.1 eq.,0.074 mmol), Xantphos (86 mg, 0.2 eq., 0.148 mmol), Cs₂CO₃ (487 mg, 2.0eq., 1.48 mmol), and dioxane (15 mL). After three cycles of vacuum/N₂flush, the mixture was stirred at 100° C. for 2 hr. The mixture wascooled to room temperature and filtered. The filtrate was concentratedunder reduced pressure. The resulting residue was purified by silica-gelcolumn chromatography eluting with 20:1 ethyl acetate/methanol to afford318a as a brown solid (221 mg, 48%). MS-ESI: [M+H]⁺ 624.9

Example 318b10-{4-[5-({4,5-Dimethyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-3-(hydroxymethyl)pyridin-2-yl}-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one318b

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 318a (200 mg, 1.0 eq., 0.32 mmol), lithiumhydroxide (38 mg, 5.0 eq., 1.60 mmol), i-propanol/THF (8/8 mL), andwater (2 mL). The mixture was stirred at room temperature for 1 h andconcentrated under reduced pressure. The residue was added partitionedbetween water and dichloromethane. The combined organic layer wasconcentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC to afford racemic mixture 318b as a yellow solid(91 mg, 43%).

Example 318(R)-2-(5-((4,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-3′-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one318

Chiral HPLC (column: OZ-H, 100% methanol (0.1% ethyl acetate))resolution of 318b separated enantiomers 318 and 319. 318: MS-ESI:[M+H]⁺ 582.8. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, J=5.0 Hz, 1H), 7.99 (s,1H), 7.72 (d, J=2.5 Hz, 1H), 7.44 (s, 1H), 7.36 (d, J=5.0 Hz, 1H), 6.86(s, 1H), 5.74 (s, 1H), 5.04 (t, J=6.5 Hz, 1H), 4.66-4.64 (m, 1H),4.52-4.48 (m, 1H), 4.36-4.34 (m, 1H), 4.18-4.05 (m, overlap, 4H),3.88-3.86 (m, 1H), 3.72 (s, 3H), 3.43-3.41 (m, 1H), 3.17-3.15 (m, 1H),2.87-2.85 (m, 1H), 2.60-2.59 (m, 2H), 2.53 (s, 2H), 2.48 (s, 3H), 1.46(d, J=6.5 Hz, 3H), 1.29 (s, 6H).

Example 319(S)-2-(5-((4,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-3′-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one319

Chiral HPLC (column: OZ-H, 100% methanol (0.1% ethyl acetate))resolution of racemic 318b separated enantiomers 318 and 319. 319:MS-ESI: [M+H]⁺ 582.8. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, J=5.0 Hz, 1H),7.99 (s, 1H), 7.72 (d, J=2.5 Hz, 1H), 7.44 (s, 1H), 7.36 (d, J=5.0 Hz,1H), 6.86 (s, 1H), 5.74 (s, 1H), 5.04 (t, J=6.5 Hz, 1H), 4.67-4.65 (m,1H), 4.52-4.48 (m, 1H), 4.36-4.34 (m, 1H), 4.18-4.05 (m, overlap, 4H),3.88-3.86 (m, 1H), 3.72 (s, 3H), 3.43-3.41 (m, 1H), 3.17-3.15 (m, 1H),2.87-2.85 (m, 1H), 2.60-2.59 (m, 2H), 2.53 (s, 2H), 2.48 (s, 3H), 1.46(d, J=6.5 Hz, 3H), 1.30 (s, 6H).

Example 320a(6-Aminopyridin-3-yl)((3R,5S)-3,5-dimethylmorpholino)methanone 320a

To a solution of (3S,5R)-3,5-dimethylmorpholine (1.15 g, 10 mmol) in DMF(15 mL) was added HATU (3.8 g, 10 mmol), DIPEA (2.6 g, 20 mmol), and6-aminonicotinic acid (1.38 g, 10 mmol) at room temperature. Thereaction mixture was stirred for 18 h. It was then filtered and thefiltrate was purified with Combiflash (A: 1% NH₄HCO₃/water, B: inacetonitrile) to afford 320a (650 mg, 27%) as a yellow solid. MS-ESI:[M+H]⁺ 236.1.

Example 320b5-Bromo-3-(5-((3R,5S)-3,5-dimethylmorpholine-4-carbonyl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one320b

A 50-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 320a (160 mg, 1.0 eq., 0.68 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (273 mg, 1.5 eq., 1.02 mmol),Pd₂(dba)₃ (64 mg, 0.1 eq., 0.070 mmol), Xantphos (79 mg, 0.2 eq., 0.14mmol), Cs₂CO₃ (444 mg, 2.0 eq., 1.36 mmol), and dioxane (20 mL). Afterthree cycles of vacuum/nitrogen flush, the mixture was heated at 100° C.for 2 h. It was then cooled to room temperature and filtered. Thefiltrate was evaporated under reduced pressure and the resulting residuewas purified by silica-gel column chromatography eluting with ethylacetate to afford 320b (190 mg, 66%) as a yellow solid. MS-ESI: [M+H]⁺420.8.

Example 320c(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{5-[(5-{[(3R,5S)-3,5-dimethylmorpholin-4-yl]carbonyl}pyridin-2-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 320c

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 320b (150 mg, 1.0 eq.,0.36 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (286 mg, 2.0 eq., 0.72 mmol), PdCl₂(dppf) (29 mg, 0.10 eq.,0.040 mmol), K₃PO₄ (153 mg, 2.0 eq., 0.72 mmol), sodium acetate (59 mg,2.0 eq., 0.72 mmol), acetonitrile (10 mL), and water (0.2 mL). Afterthree cycles of vacuum/nitrogen flush, the mixture was heated at 90° C.for 2 h. It was then cooled to room temperature and filtered. Thefiltrate was evaporated under reduced pressure and the resulting residuewas purified by silica-gel column chromatography eluting with 50:1dichloromethane/methanol to afford 320c (161 mg, 64%) as brown solid.MS-ESI: [M+H]⁺ 693.8

Example 3203-[4-[5-[[5-[(3S,5R)-3,5-dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one320

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 320b (145 mg, 1.0 eq., 0.21 mmol), lithiumhydroxide (26 mg, 5.0 eq., 1.05 mmol), THF (4.0 mL), i-propanol (4.0mL), and water (1.0 mL). The mixture was stirred at room temperature for1 h and filtered. The filtrate was concentrated under reduced pressure.The resulting residue was diluted with water (10 mL) and extracted withdichloromethane (3×15 mL). The combined organic layer was concentratedunder reduced pressure. The residue was purified by reverse-phaseprep-HPLC to afford 320 (35 mg, 26%) as white solid. MS-ESI: [M+H]⁺651.9

Example 321a6-Chloro-4-(5-((3R,5S)-3,5-dimethylmorpholine-4-carbonyl)pyridin-2-ylamino)-2-methylpyridazin-3(2H)-one321a

A 25-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with(6-aminopyridin-3-yl)((3R,5S)-3,5-dimethylmorpholino)methanone 320a (235mg, 1.0 mmol), 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (232 mg,1.05 mmol), cesium carbonate (652 mg, 2.0 mmol), and 1,4-dioxane (6.0mL). After bubbling nitrogen through the suspension for 10 minutes,Xantphos (116 mg, 0.20 mmol) andtris(dibenzylideneacetone)dipalladium(0) (70 mg, 0.10 mmol) were added.The system was subjected to three cycles of vacuum/nitrogen flush andheated at reflux for 2.5 h. It was then cooled to room temperature andfiltered. The solid was washed with dichloromethane (3×10 ml). Thecombined organic layer was concentrated under reduced pressure. Theresidue was purified by silica-gel column chromatography eluting withpetroleum ether/ethyl acetate (2:1 to 1:10) to afford 321a (140 mg, 37%)as a yellow solid. MS-ESI: [M+H]⁺ 378.3

Example 321b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{5-[(5-{[(3R,5S)-3,5-dimethylmorpholin-4-yl]carbonyl}pyridin-2-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl}pyridin-3-yl)methylAcetate 321b

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 321a (140 mg, 0.37 mmol),(2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 199e (355 mg, 0.74 mmol), K₃PO₄ (157 mg, 0.74 mmol), sodiumacetate (61 mg, 0.74 mmol), 1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (36 mg, 0.040 mmol), acetonitrile (10mL), and water (0.2 mL). The system was subjected to three cycles ofvacuum/nitrogen flush and heated at 100° C. under N₂ protection for 1.5h. Analysis of reaction mixture by LCMS showed complete conversion tothe desired product. The reaction mixture was cooled to room temperatureand concentrated under reduced pressure. The residue was partitionedbetween dichloromethane (30 mL) and water (30 mL). The aqueous layer wasseparated and extracted with dichloromethane (3×20 mL). The combinedorganic layer was dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The dark residue was purified by gel-silica columnchromatograph the by eluting with 60:1 dichloromethane/methanol toafford 320b (105 mg, 41%) as a black solid. MS-ESI: [M+H]⁺ 695.3

Example 3213-[4-[5-[[5-[(3S,5R)-3,5-dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1-methyl-6-oxo-pyridazin-3-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one321

To a solution of 321b (105 mg, 0.15 mmol) in THF/i-propanol/water(2/1/0.5 mL) was added lithium hydroxide (36 mg, 1.5 mmol) at roomtemperature. After the reaction was stirred for 3 h, LCMS indicated thereaction was complete. Then the mixture was poured into water (25 mL)and extracted with dichloromethane (3×20 mL). The combined organic layerwas washed with brine (30 mL), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The residue was purified byreverse-phase prep-HPLC (A: 1% NH₄HCO₃/water, B: acetonitrile) to afford321 (100 mg, 95%) as a white solid. MS-ESI: [M+H]⁺ 652.8. ¹H NMR (500MHz, DMSO-d₆) δ 9.69 (s, 1H), 8.63 (s, 1H), 8.53 (d, J=5.0 Hz, 1H), 8.31(d, J=1.5 Hz, 1H), 7.77-7.75 (m, 1H), 7.58 (d, J=8.5 Hz, 1H), 7.41 (d,J=5.0 Hz, 1H), 6.56 (s, 1H), 4.78 (t, J=5.5 Hz, 1H), 4.60-4.57 (m, 1H),4.41-4.37 (m, 1H), 4.30-4.25 (m, 1H), 4.19 (d, J=3.5 Hz, 2H), 4.01-4.00(m, 2H), 3.92-3.88 (m, 1H), 3.82 (s, 3H), 3.65-3.61 (m, 2H), 3.56-3.53(m, 2H), 2.61-2.58 (m, 2H), 2.42 (s, 2H), 1.25 (d, J=6.0 Hz, 6H), 1.21(s, 6H)

Example 322a(4-(5-(5-((3R,5S)-3,5-Dimethylmorpholine-4-carbonyl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylAcetate 322a

A 25-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with(6-aminopyridin-3-yl)((3R,5S)-3,5-dimethylmorpholino)methanone 320a (120mg, 0.50 mmol),(4-(5-bromo-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)pyridin-3-yl)methylacetate 217a (262 mg, 0.50 mmol), cesium carbonate (326 mg, 1.0 mmol),and 1,4-dioxane (6 mL). After bubbling nitrogen through the suspensionfor 10 minutes, Xantphos (58 mg, 0.10 mmol) andtris(dibenzylideneacetone)dipalladium(0) (45 mg, 0.050 mmol) were added.The system was subjected to three cycles of vacuum/nitrogen flush andheated at reflux for 2.5 h. It was then cooled to room temperature andfiltered. The solid was washed with dichloromethane (3×10 mL). Thecombined filtrate was concentrated under reduced pressure. The residuewas purified by silica-gel column chromatography eluting withdichloromethane/methanol (80/1 to 50/1) to afford 322a (200 mg, 59%) asa yellow solid. MS-ESI: [M+H]⁺ 680.3

Example 3222-[4-[5-[[5-[(3S,5R)-3,5-dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one322

To a solution of 322a (136 mg, 0.20 mmol) in THF/i-propanol/water (4/2/1mL) was added lithium hydroxide (48 mg, 2.0 mmol) at room temperature.After the reaction was stirred for 2 h, LCMS indicated the reaction wascomplete. Then the mixture was poured into water (15 mL) and extractedwith dichloromethane (3×15 mL). The combined organic layer was washedwith brine (30 mL), dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was purified by reverse-phase prep-HPLC(A: 1% NH₄HCO₃/water, B: acetonitrile) to afford 322 (50 mg, 40%) as awhite solid. MS-ESI: [M+H]⁺ 638.3. 1HNMR (500 MHz, DMSO-d₆) δ 8.94 (s,1H), 8.77 (d, J=5.5 Hz, 1H), 8.48 (d, J=5.0 Hz, 1H), 8.20 (d, J=2.0 Hz,1H), 7.64-7.62 (m, 1H), 7.59 (d, J=2.5 Hz, 1H), 7.37-7.35 (m, 2H), 6.57(s, 1H), 4.95 (t, J=4.5 Hz, 1H), 4.47-4.38 (m, 2H), 4.23-3.99 (m, 5H),3.88-3.87 (m, 1H), 3.65-3.61 (m, overlap, 5H), 3.56-3.53 (m, 2H),2.66-2.56 (m, 2H), 2.47-2.44 (m, 2H), 1.80-1.79 (m, 2H), 1.70-1.66 (m,2H), 1.25 (d, J=6.0 Hz, 6H)

Example 323a 5-(3-Methoxyazetidin-1-yl)-2-nitropyridine 323a

A 100-mL round bottomed flask was equipped with a reflux condenser wascharged with 3-methoxyazetidine hydrochloride (1.0 g, 8.09 mmol),5-bromo-2-nitropyridine (1.97 g, 9.71 mmol), Pd₂(dba)₃ (370.1 mg, 0.404mmol), Xantphos (467.6 mg, 0.809 mmol), Cs₂CO₃ (7.9 g, 24.3 mmol), anddioxane (50 mL). After bubbling nitrogen through the reaction mixturefor 20 minutes, it was heated at 100° C. under N₂ protection for 3 h.Analysis of the reaction mixture by LCMS showed complete conversion tothe desired product. It was cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the residue waspurified by silica-gel column chromatography eluting with 50:1dichloromethane/methanol to afford 323a as a yellow solid (1.63 g, 96%).MS-ESI: [M+H]⁺ 210.2

Example 323b 5-(3-Methoxyazetidin-1-yl)pyridin-2-amine 323b

To a solution of 323a (1.5 g, 7.17 mmol) in methanol (150 mL) was added10% Pd/C (150 mg). The system was evacuated and then refilled with H₂.After stirring at room temperature for 2 h, the mixture was filtered.The filtrate was concentrated under reduced pressure to afford 323b as ayellow oil (1.2 g, 93%), which was used in next step without furtherpurification. MS-ESI: [M+H]⁺ 180.1

Example 323c5-Bromo-3-(5-(3-methoxyazetidin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one323c

A 100-mL round bottomed flask was equipped with a reflux condenser wascharged with 323b (1.2 g, 6.7 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (2.14 g, 8.04 mmol), Pd₂(dba)₃(306.5 mg, 0.335 mmol), Xantphos (387.3 mg, 0.67 mmol), Cs₂CO₃ (4.37 g,13.4 mmol), and dioxane (50 mL). After bubbling nitrogen through thereaction mixture for 20 minutes, it was heated at 100° C. under N₂protection for 3 h. Analysis of the reaction mixture by LCMS showedcomplete conversion to the desired product. It was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure. The residue was washed with petroleum ether to afford 323c asa brown solid (1.16 g, 47%), which was used in next step without furtherpurification. MS-ESI: [M+H]⁺ 364.8.

Example 323d(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(5-{[5-(3-methoxyazetidin-1-yl)pyridin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methylAcetate 323d

A 50-mL round bottomed flask was equipped with a reflux condenser wascharged with 323c (150 mg, 0.411 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (326.5 mg, 0.822 mmol), Pd(dppf)Cl₂ (16.8 mg, 0.0205 mmol),K₃PO₄ (174.3 mg, 0.822 mmol), sodium acetate (67.5 mg, 0.822 mmol),acetonitrile (10 mL), and water (5 drops). After bubbling nitrogenthrough the reaction mixture for 20 minutes, it was heated 100° C. underN₂ protection for 1 h. Analysis of the reaction mixture by LCMS showedcomplete conversion to the desired product. It was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 40:1 dichloromethane/methanol to afford 323d as a yellowoil (180 mg, 68.7%). MS-ESI: [M+H]⁺ 637.8

Example 3233-[3-(hydroxymethyl)-4-[5-[[5-(3-methoxyazetidin-1-yl)-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one323

To a solution of 323d (160 mg, 0.251 mmol) in THF (5 mL), i-propanol (5mL), and water (5 mL) was added lithium hydroxide (95 mg, 2.51 mmol).The reaction mixture was stirred at room temperature for 1 h. Analysisof the reaction mixture by LCMS showed complete conversion to thedesired product. It was then concentrated under reduced pressure and theresidue was diluted with water (10 mL). The resulting mixture wasextracted with dichloromethane (3×15 mL). The combined organic layer wasdried over Na₂SO₄, filtered, and concentrated under reduced pressure.The residue was purified by reverse-phase prep-HPLC to afford 323 (33.8mg, 23%) as a white solid. MS-ESI: [M+H]⁺ 595.8. ¹H NMR (500 MHz,DMSO-d₆) δ 8.55 (d, J=2.0 Hz, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.31 (s, 1H),7.48 (d, J=3.5 Hz, 1H), 7.45 (d, J=2.0 Hz, 1H), 7.34 (d, J=5.0 Hz, 1H),7.21 (d, J=8.5 Hz, 1H), 6.91 (dd, J=2.5, 8.5 Hz, 1H), 6.56 (s, 1H),4.96-4.94 (m, 1H), 4.47-4.39 (m, 2H), 4.31-4.19 (m, 4H), 4.03-4.00 (m,2H), 3.85-3.83 (m, 1H), 3.60 (s, 3H), 3.55-3.53 (m, 2H), 3.23 (s, 3H),2.62-2.54 (m, 2H), 2.44-2.42 (m, 2H), 1.22 (s, 6H).

Example 324a(6-Aminopyridin-3-yl)((3S,5S)-3,5-dimethylmorpholino)methanone 324a

To a solution of (3S,5S)-3,5-dimethylmorpholine (115 mg, 1.0 mmol) inDMF (2 mL) was added HATU (380 mg, 1.0 mmol), DIPEA (260 mg, 2.0 mmol),and 6-aminonicotinic acid (138 mg, 1.0 mmol) at room temperature. Afterstirring for 18 h, the reaction mixture was filtered and purified withCombiflash (A: 1% NH₄HCO₃/water, B: acetonitrile) to afford 324a (80 mg,34%) as a yellow solid. MS (ESI): 236.1 (M+H).

Example 324b6-Chloro-4-(5-((3S,5S)-3,5-dimethylmorpholine-4-carbonyl)pyridine-2-ylamino)-2-methylpyridazin-3(2H)-one324b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 1,4-dioxane (8 mL),cesium carbonate (221 mg, 0.68 mmol), 324a (80 mg, 0.34 mmol), and4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (80 mg, 0.36 mmol). Afterbubbling nitrogen through the suspension for 5 minutes, Xantphos (40 mg,0.068 mmol) and tris(dibenzylideneacetone)dipalladium(0) (24 mg, 0.034mmol) were added. The system was subjected to three cycles ofvacuum/nitrogen flush and heated at reflux for 2.5 h. It was then cooledto room temperature and filtered. The solid was washed withdichloromethane (3×10 mL). The combined filtrate was concentrated underreduced pressure. The residue was purified by silica-gel columnchromatography eluting with petroleum ether/ethyl acetate (2/1 to 100%ethyl acetate) to afford 324b (40 mg, 31%) as a yellow solid. MS-ESI:[M+H]⁺ 378.3

Example 324c(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{5-[(5-{[(3S,5S)-3,5-dimethylmorpholin-4-yl]carbonyl}pyridin-2-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl}pyridin-3-yl)methylAcetate 324c

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 324b (40 mg, 0.11 mmol),(2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 199e (105 mg, 0.22 mmol), K₃PO₄ (47 mg, 0.22 mmol), sodiumacetate (18 mg, 0.22 mmol),1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (20 mg, 0.022mmol), acetonitrile (10 mL), and water (6 drops). The system wassubjected to three cycles of vacuum/nitrogen flush and heated at 100° C.under N₂ protection for 1.5 h. LCMS analysis showed complete conversionto the desired product. The reaction mixture was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure. The residue was diluted with dichloromethane (50 mL) and water(50 mL). The aqueous layer was separated and extracted withdichloromethane (3×20 mL). The combined extract was dried over Na₂SO₄,filtered, and concentrated under reduced pressure. The dark residue waspurified by silica-gel column chromatography eluting with 60:1dichloromethane/methanol to afford 324c (40 mg, 52%) as a black solid.MS-ESI: [M+H]⁺ 695.3

Example 3243-[4-[5-[[5-[(3S,5S)-3,5-dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1-methyl-6-oxo-pyridazin-3-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one324

To a solution of 324c (40 mg, 0.057 mmol) in THF/i-propanol/water(1/1/0.5 ml) was added lithium hydroxide (14 mg, 0.57 mmol) at roomtemperature. After the reaction was stirred for 3 h, LCMS indicated thereaction was complete. Then the mixture was poured into water (20 mL)and extracted with dichloromethane (3×15 mL). The combined organic layerwas washed with brine (30 mL), dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The residue solid was purified byreverse-phase prep-HPLC (A: 1% NH₄HCO₃/water, B: acetonitrile) to afford324 (10 mg, 27.7%) as a white solid. MS-ESI: [M+H]+ 653.3. ¹H NMR (500MHz, DMSO-d₆) δ 9.69 (s, 1H), 8.63 (s, 1H), 8.53 (d, J=5.0, 1H), 8.31(d, J=1.5 Hz, 1H), 7.77-7.75 (m, 1H), 7.58 (d, J=8.5 Hz, 1H), 7.41 (d,J=5.0 Hz, 1H), 6.56 (s, 1H), 4.78 (t, J=5.5 Hz, 1H), 4.60-4.57 (m, 1H),4.41-4.37 (m, 1H), 4.30-4.25 (m, 1H), 4.19 (d, J=3.5 Hz, 2H), 4.01 (s,2H), 3.92-3.88 (m, 1H), 3.82 (s, 3H), 3.65-3.61 (m, 2H), 3.56-3.53 (m,2H), 2.57 (d, J=6.5 Hz, 2H), 2.42 (s, 2H), 1.25 (d, J=6.0 Hz, 6H), 1.21(s, 6H)

Example 325a 3-Amino-5-bromo-1-methylpyridin-2(1H)-one 325a

To a solution of5-bromo-3-(diphenylmethyleneamino)-1-methylpyridin-2(1H)-one (3.82 g,10.4 mmol) in ethyl acetate (10 mL) was added 4 MHCl/dioxane (7.8 mL,31.3 mmol). The reaction mixture was stirred for 0.5 h and concentratedunder reduced pressure. The residue was washed with tert-butyl methylether and filtered. The solid was dissolved in ethyl acetate (10 mL) andwater (10 mL). The pH of the resulting mixture was adjusted to between 7and 8 by adding K₂CO₃ gradually. The water phase was separated andextracted with dichloromethane for three times. The combined organiclayer was concentrated under reduced pressure to afford 325a as a yellowsolid (1.1 g, 52%). MS-ESI: [M+H]⁺ 202.9.

Example 325b 1-(2-Bromo-5-fluoropyridin-4-yl)ethanol 325b

To a 250-mL 3-neck flask was added a THF solution (20 mL) of2-bromo-5-fluoropyridine (8.80 g, 50 mmol). At −78° C., to the solutionwas added LDA (25.0 mL, 50 mmol, 2.5 M in THF) dropwise. After stirringfor 5 min, diisopropylamine (7.0 mL, 50 mmol) was added dropwise via asyringe and the mixture was stirred at −78° C. for 4 h. A THF solutionof acetaldehyde (11 mL, 55 mmol, 5M in THF) was added dropwise via asyringe. The contents were removed from the cold bath and stirred withwarming to room temperature overnight. The mixture was diluted withwater (150 mL) and vigorously stirred for 5 min. The contents wereconcentrated under reduced pressure and the residue was extracted withethyl ether (3×150 mL). The combined organic layer was dried over MgSO₄,filtered, and concentrated under reduced pressure to afford yellow oil,which was purified by silica-gel column chromatography eluting withpetroleum ether/ethyl acetate (10:1 to 5:1) to afford 325b (8.0 g,72.7%) as a yellow solid. MS-ESI: [M+H]⁺ 220.1. ¹H NMR (500 MHz, CDCl₃)δ 8.15 (d, J=1.5 Hz, 1H), 7.68 (d, J=5.5 Hz, 1H), 5.17 (d, J=6.5 Hz,1H), 2.18-2.16 (m, 1H), 1.52 (d, J=6.5 Hz, 3H).

Example 325c 1-(2-Bromo-5-fluoropyridin-4-yl)ethanone 325c

A mixture of 325b (7.5 g, 34.2 mmol) and 2-iodoxybenzoic acid (38.4 g,137 mmol) in ethyl acetate (200 mL) was stirred at 85° C. for 20 hrs.The reaction mixture was filtered and the filtrate was concentratedunder reduced pressure. The resulting residue was purified by silica-gelcolumn chromatography eluting with petroleum ether/ethyl acetate (20:1to 10:1) to afford 325c (6.8 g, 92%) as a yellow oil. MS-ESI: [M+H]+217.9.

Example 325d 5-Bromo-3-methyl-1H-pyrazolo[3,4-c]pyridine 325d

To a 250-mL round-bottomed flask equipped with a reflux condenser wasadded dry ethylene glycol (30 mL) and 325c (4.3 g, 20 mmol). Thenhydrazine hydrate (5.0 mL, 4.8 g, 81.6 mmol) was added dropwise via asyringe. The mixture was heated at 165° C. for 3.5 h. The resultingorange-tan mixture was cooled to room temperature and the contents werepoured onto a stirring mixture of 100 mL ice/water (1:1), whereuponprecipitation occurred. After stirring for 10 min, the off-whiteprecipitate was collected, which was dried in vacuo to afford 325d as anoff-white solid (3.1 g, 74%). MS-ESI: [M+H]⁺ 211.9.

Example 325e 5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine 325e and5-Bromo-2,3-dimethyl-2H-pyrazolo[3,4-c]pyridine 326a

A mixture of 325d (3.0 g, 14.2 mmol), CH₃I (2.40 g, 17.0 mmol), andK₂CO₃ (2.9 g, 21.3 mmol) in acetonitrile (60 mL) was stirred at 30° C.for 1 h. The reaction mixture was filtered and the filtrate wasconcentrated under reduced pressure. The resulting residue was purifiedby silica-gel column chromatography eluting with 8:1 petroleumether/ethyl acetate to afford 325e (920 mg, 29.0%) as a white solid, andeluting with 2:1 petroleum ether/ethyl acetate to afford 326a (390 mg,12.0%) as a gray solid. MS-ESI: [M+H]⁺ 226.1.

Example 325f5-Bromo-3-(1,3-dimethyl-1H-pyrazolo[3,4-c]pyridin-5-ylamino)-1-methylpyridin-2(1H)-one325f

A sealed tube was charged with 325e (202 mg, 1.0 mmol), 325a (337.5 mg,1.5 mmol), Pd₂(dba)₃ (91.7 mg, 0.10 mmol), BINAP (124.6 mg, 0.20 mmol),cesium carbonate (650 mg, 2.0 mmol), and 1,4-dioxane (10 mL). Afterthree cycles of vacuum/nitrogen flush, the sealed tube was heated at100° C. for 2 hrs. It was then cooled to room temperature and filtered.The filtrate was concentrated under reduced pressure. The resultingresidue was purified by silica-gel column chromatography eluting withpetroleum ether/ethyl acetate (5:1 to 2:1) to afford 325f (140 mg, 40%)as a yellow solid. MS-ESI: [M+H]⁺ 348.2.

Example 325g{4-[5-({1,3-Dimethyl-1H-pyrazolo[3,4-c]pyridin-5-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl}methylAcetate 325g

A 100-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 325f (120 mg, 0.35 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (417 mg, 1.05 mmol), Pd(dppf)Cl₂ (29 mg, 0.035 mmol), K₃PO₄(148.0 mg, 0.70 mmol), sodium acetate (57.4 mg, 0.70 mmol), water (0.5mL), and acetonitrile (15 mL). After three cycles of vacuum/nitrogenflush, the mixture was heated at reflux for 1 hr. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 30:1 dichloromethane/methanol toafford 325g as a yellow solid (70 mg, 33%). MS-ESI: [M+H]+ 620.8.

Example 3253-[4-[5-[(1,3-dimethylpyrazolo[3,4-c]pyridin-5-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one325

A mixture of 325g (60 mg, 0.10 mmol) and lithium hydroxide (60 mg, 2.5mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at 35°C. for 30 min. To the reaction mixture was added water (10 mL) and theresulting mixture was concentrated under reduced pressure. The residuewas extracted with dichloromethane three times. The combined organiclayer was concentrated under reduced pressure and the resulting residuewas purified by reverse-phase prep-HPLC to afford 325 as a yellow solid(20 mg, 31%). MS-ESI: [M+H]+ 578.8. ¹H NMR (500 MHz, DMSO) δ 8.80 (s,1H), 8.49 (d, J=5.0 Hz, 1H), 8.36 (d, J=2.0 Hz, 1H), 8.29 (s, 1H), 7.55(s, 1H), 7.49 (d, J=2.0 Hz, 1H), 7.37 (d, J=5.0 Hz, 1H), 6.56 (s, 1H),5.06-5.05 (m, 1H), 4.51-4.43 (m, 2H), 4.25-4.19 (m, 3H), 4.00 (s, 3H),3.86-3.84 (m, 1H), 3.63 (s, 3H), 2.62-2.59 (m, 2H), 2.44-2.43 (m,overlap, 5H), 1.22 (s, 6H).

Example 326b5-Bromo-3-(2,3-dimethyl-2H-pyrazolo[3,4-c]pyridin-5-ylamino)-1-methylpyridin-2(1H)-one326b

A 100-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with5-bromo-2,3-dimethyl-2H-pyrazolo[3,4-c]pyridine 326a from Example 325(452 mg, 2.0 mmol), 3-amino-5-bromo-1-methylpyridin-2(1H)-one 325a (400mg, 2.0 mmol), cesium carbonate (1.3 g, 4.0 mmol), and 1,4-dioxane (10mL). After bubbling nitrogen through the suspension for 5 minutes, BINAP(124 mg, 0.2 mmol) and tris(dibenzylideneacetone)dipalladium(0) (140 mg,0.2 mmol) were added. The system was subjected to three cycles ofvacuum/nitrogen flush and heated at reflux for 2.5 h. It was then cooledto room temperature and filtered. The solid was washed withdichloromethane (3×10 mL). The combined filtrate was concentrated underreduced pressure. The residue was purified by silica-gel columnchromatography eluting with petroleum ether/ethyl acetate (2/1 to 100%ethyl acetate) to afford 326b (160 mg, 23%) as a yellow solid. MS-ESI:[M+H]⁺ 348.3

Example 326c{4-[5-({2,3-Dimethyl-2H-pyrazolo[3,4-c]pyridin-5-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl}methylAcetate 326c

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 326b (160 mg, 0.46 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (300 mg, 0.69 mmol), K₃PO₄ (195 mg, 0.92 mmol), sodium acetate(75 mg, 0.92 mmol), 1,1′-bis(diphenylphosphino)ferrocenedichloropalladium(II) (42 mg, 0.046 mmol), acetonitrile (10mL), and water (6 drops). The system was subjected to three cycles ofvacuum/nitrogen flush and heated at 100° C. under N₂ protection for 1.5h. LCMS Analysis showed complete conversion to the desired product. Thereaction mixture was cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure. The residue wasdiluted with dichloromethane (50 mL) and water (50 mL). The aqueouslayer was separated and extracted with dichloromethane (3×20 mL). Thecombined extract was dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The dark residue was purified by gel-silica columnchromatography eluting with 60:1 dichloromethane/methanol to afford 326c(130 mg, 45%) as a black solid. MS-ESI: [M+H]⁺ 621.3

Example 3263-[4-[5-[(2,3-dimethylpyrazolo[3,4-c]pyridin-5-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one326

To a solution of 326c (130 mg, 0.21 mmol) in THF/i-propanol/water (4/2/1mL) was added lithium hydroxide (50 mg, 2.0 mmol) at room temperature.After the reaction was stirred for 3 h, LCMS indicated the reaction wascomplete. Then the mixture was poured into water (30 mL) and extractedwith dichloromethane (3×30 mL). The combined organic layer was washedwith brine (30 mL), dried over Na₂SO₄, filtered, and concentrated underreduced pressure. The residue solid was purified by reverse-phaseprep-HPLC (A: 1% NH₄HCO₃/water, B: acetonitrile) to afford 326 (60 mg,50%) as a white solid. MS-ESI: [M+H]+ 579.3. ¹H NMR (500 MHz, DMSO-d₆) δ8.86 (s, 1H), 8.48 (d, J=5.0 Hz, 1H), 8.06 (d, J=1.5 Hz, 1H), 7.99 (s,1H), 7.47 (d, J=2.0 Hz, 1H), 7.41 (s, 1H), 7.38 (d, J=5.0 Hz, 1H), 6.57(s, 1H), 5.13 (t, J=5.0 Hz, 1H), 4.50-4.46 (m, 2H), 4.24-4.19 (m, 3H),4.09 (s, 3H), 3.86-3.85 (m, 1H), 3.62 (s, 3H), 2.62-2.53 (m, overlap,5H), 2.43 (s, 2H), 1.22 (s, 6H)

Example 327a5-(2-Methoxyethyl)-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine327a

To a solution of 2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (190mg, 1.13 mmol) 209a in acetonitrile (10 mL) was added K₂CO₃ (311.9 mg,2.26 mmol) and 1-bromo-2-methoxyethane (188.3 mg, 1.36 mmol). Thereaction mixture was heated at 80° C. for 17 h under microwaveirradiation. Analysis of the reaction mixture by LCMS showed completeconversion to the desired product. The mixture was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure to afford 327a as a white solid (230 mg, 90%), which was usedin the next step without further purification. MS-ESI: [M+H]⁺ 227.0

Example 327b5-(2-Methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-amine 327b

To a solution of 327a (286 mg, 1.26 mmol) in methanol (10 mL) was addedPd/C (28.6 mg). The system was evacuated and then refilled with H₂.After stirring at room temperature for 2 h, the mixture was filtered.The filtrate was concentrated under reduced pressure to afford 327b as ayellow solid (240 mg, 97%), which was used in the next step withoutfurther purification. MS-ESI: [M+H]⁺ 197.0

Example 327c 3,5-Dibromo-6-methylpyridin-2(1H)-one 327c6-Methyl-pyridin-2-ol (10.9 g, 0.10 mol) was suspended in anhydrousdichloromethane (300 mL) and stirred at ambient temperature. Undercooling with an ice/water cooling bath, N-bromosuccinimide (NBS) (11.4g, 0.20 mol) was added slowly portion-wise over a time interval of 5minutes. The suspension was stirred at reflux for 2 hours. Thereafter,the suspension was filtered. The filter cake was thoroughly washed withmethanol and dried in vacuo to afford 327c as a white solid (22.7 g,85%). MS-ESI: [M+H]⁺ 266. Example 327d3,5-Dibromo-1,6-dimethylpyridin-2(1H)-one 327d

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with DMF (50 mL), 327c (10.0 g, 37.5 mmol), CH₃I(5.3 g, 37.5 mmol), and K₂CO₃ (7.8 g, 56.2 mmol). The mixture wasstirred at room temperature for 5 h. Water (100 mL) was added and theresulting white solid was collected to afford 327d (8.2 g, 78%) as awhite solid. MS-ESI: [M+H]⁺ 280.

Example 327e5-Bromo-3-(5-(2-methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1,6-dimethylpyridin-2(1H)-one327e

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with 327b (392 mg, 2.0 mmol), 327d (562 mg, 2.0 mmol), cesiumcarbonate (1.30 g, 4.0 mmol), and 1,4-dioxane (20 mL). After bubblingnitrogen through the suspension for 10 minutes, xantphos (115 mg, 0.20mmol) and tris(dibenzylideneacetone)dipalladium(0) (92 mg, 0.10 mmol)were added. The system was subjected to three cycles of vacuum/nitrogenflush and heated at reflux for 5 h. It was then cooled to roomtemperature and filtered. The solid was washed with dichloromethane(2×15 mL). The combined filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with dichloromethane/methanol (80:1 to 30:1) to afford 327e (490mg, 62%) as a yellow solid. MS-ESI: [M+H]⁺ 396.2

Example 327f(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(5-{[5-(2-methoxyethyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-1,2-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methylAcetate 327f

A 25-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 327e (158 mg, 0.40mmol),{3-[(acetyloxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (159 mg, 0.40 mmol), K₃PO₄ (170 mg, 0.80 mmol), sodium acetate(66 mg, 0.80 mmol), Pd(dppf)Cl₂ (15 mg, 0.020 mmol), andacetonitrile/water (7/0.5 mL). After three cycles of vacuum/N₂ flush,the mixture was heated at 95° C. for 1 h. LCMS analysis showed completeconversion to the desired product. The reaction mixture was cooled toroom temperature, and diluted with dichloromethane (50 mL) and water (30mL). The water layer was extracted with dichloromethane (2×30 mL). Thecombined organic extract was dried over Na₂SO₄, filtered, andconcentrated under reduced pressure. The dark residue was purified bysilica-gel column chromatography eluting with dichloromethane/methanol(80:1 to 30:1) to afford 327f (120 mg, 45%) as a yellow solid. MS-ESI:[M+H]⁺ 668.8

Example 3273-[3-(hydroxymethyl)-4-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1,2-dimethyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one327

To a solution of 327f (120 mg, 0.18 mmol) in THF/i-propanol/water (6/4/3mL) was added lithium hydroxide (22 mg, 0.90 mmol). The mixture wasstirred at room temperature for 1 h. The mixture was concentrated underreduced pressure and the residue was diluted with water (15 mL). It wasthen extracted with ethyl acetate (3×20 mL). The combined organic layerwas dried over sodium sulfate and concentrated under pressure. Theresidue was purified by reverse-phase prep-HPLC to afford 327 as a whitesolid (55 mg, 49%). MS-ESI: [M+H]⁺ 626.9. ¹H NMR (500 MHz, CDCl₃) δ 8.49(d, J=5.0 Hz, 1H), 7.49 (s, 1H), 7.32 (s, 1H), 7.15 (d, J=4.5 Hz, 1H),6.82 (s, 1H), 5.61 (bs, 1H), 4.53-4.45 (m, 3H), 4.26-4.16 (m, 3H),4.03-3.97 (m, 3H), 3.71-3.69 (m, 5H, overlap), 3.58 (t, J=5.5 Hz, 2H),3.39 (s, 3H), 2.98 (t, J=5.0 Hz, 2H), 2.77 (t, J=5.0 Hz, 2H), 2.60-2.57(m, 2H), 2.53 (s, 2H), 2.17 (s, 3H), 1.29 (s, 6H).

Example 328a3-(5-(2-Methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one328a

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-bromo-3-(5-(2-methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methylpyridin-2(1H)-one296f (330 mg, 0.86 mmol), Pin₂B₂ (329 mg, 1.30 mmol), Pd₂(dba)₃ (40 mg,0.043 mmol), X-phos (41 mg, 0.086 mmol), potassium acetate (169 mg,1.726 mmol), and dioxane (10 mL). After three cycles of vacuum/N₂ flush,the mixture was heated at 70° C. for 2 h. Analysis of the reactionmixture by LCMS showed complete conversion to the desired product. Itwas cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure. The residue was washed withpetroleum ether to afford 328a as a dark oil (240 mg, 80%), which wasused in the next step without further purification. MS-ESI: [M+H]⁺ 348.3

Example 328b3-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-5-(5-{[5-(2-methoxyethyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridine-4-carbaldehyde328b

A sealed tube equipped with a magnetic stirrer was charged with3-bromo-5-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyri-dine-4-carbaldehyde107f (100 mg, 0.26 mmol), 328a (110 mg, 0.26 mmol), Pd(dppf)Cl₂ (10 mg,0.026 mmol), sodium acetate (50 mg, 0.50 mmol), K₃PO₄ (100 mg, 0.50mmol), and acetonitrile/water (5 mL/1 mL). After three cycles ofvacuum/nitrogen flush, the mixture was heated at 100° C. for 2 h. It wasthen filtered and the filtrate was evaporated under reduced pressure.The residue was purified by silica-gel column chromatography elutingwith 10:1 dichloromethane/methanol to afford 328b (50 mg, 32%) as abrown solid. MS-ESI: [M+H]⁺ 611.3.

Example 3283-[4-(hydroxymethyl)-5-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-3-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one328

A mixture of 328b (50 mg, 0.08 mmol) and NaBH₄ (8.0 mg, 0.20 mmol) inmethanol (4 mL) was stirred at 25° C. for 0.5 h. The reaction mixturewas quenched with water (10 mL) and evaporated under reduced pressure.The residue was added extracted with dichloromethane (2×10 mL). Thecombined extract was concentrated under reduced pressure and the residuewas purified by reverse-phase prep-HPLC to afford 328 (13 mg, 25%) as apale yellow solid. MS-ESI: [M+H]⁺ 613.3. ¹H NMR (500 MHz, CDCl₃) δ 8.62(s, 1H), 8.48 (s, 1H), 7.92 (d, J=2.0 Hz, 1H), 7.38 (s, 1H), 7.31 (d,J=2.0 Hz, 1H), 6.82 (s, 1H), 5.67 (s, 1H), 4.64-4.62 (m, 1H), 4.57-4.55(m, 1H), 4.38-4.34 (m, 1H), 4.22-4.17 (m, 3H), 4.05-4.02 (m, 2H),3.99-3.96 (m, 1H), 3.71-3.70 (m, 2H), 3.69 (s, 3H), 3.57 (t, J=5.0 Hz,2H), 3.37 (s, 3H), 2.99 (t, J=5.0 Hz, 2H), 2.77 (t, J=5.0 Hz, 2H), 2.56(s, 2H), 2.51 (s, 2H), 1.27 (s, 6H).

Example 329a2-Chloro-4-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridine-3-carbaldehyde329a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-9-one107e (612 mg, 3.0 mmol), 4-bromo-2-chloronicotinaldehyde (2.0 g, 9.0mmol), Pd₂(dba)₃ (275 mg, 0.30 mmol), XantPhos (347 mg, 0.60 mmol),cesium carbonate (1.95 g, 6.0 mmol), and 1,4-dioxane (30 mL). Afterthree cycles of vacuum/nitrogen flush, the mixture was heated at 97° C.overnight. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting with1:2 ethyl acetate/petroleum ether to afford 329a as a yellow solid (660mg, 65%). MS-ESI: [M+H]+ 344.1.

Example 329b4-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-2-(5-{[5-(2-methoxyethyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridine-3-carbaldehyde329b

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 329a (100 mg, 0.30mmol),3-(5-(2-methoxyethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one328a (257 mg, 0.60 mmol), Pd(dppf)Cl₂ (25 mg, 0.030 mmol), K₃PO₄ (127mg, 0.60 mmol), sodium acetate (49 mg, 0.60 mmol), water (0.50 mL), andTHF (10 mL). After three cycles of vacuum/nitrogen flush, the mixturewas heated at reflux for 1 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by silica-gel column chromatographyeluting with 30:1 dichloromethane/methanol to afford 329b as a brownsolid (60 mg, 34%). MS-ESI: [M+H]+ 611.3.

Example 3293-[3-(hydroxymethyl)-2-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-4-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one329

A mixture of 329b (50 mg, 0.080 mmol) and NaBH₄ (9.1 mg, 0.24 mmol) inmethanol (5 mL) was stirred at room temperature for 10 min. The mixturewas quenched with water (10 mL) and evaporated under reduced pressure.The residue was extracted with dichloromethane (3×10 m). The combinedextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 329 (15 mg, 30%) as ayellow solid. MS-ESI: [M+H]⁺ 613.3. ¹H NMR (500 MHz, CDCl₃) δ 8.66 (d,J=4.5 Hz, 1H), 8.13 (s, 1H), 7.63 (s, 1H), 7.35 (s, 1H), 7.12 (d, J=5.0Hz, 1H), 6.83 (s, 1H), 5.71 (s, 1H), 4.67-4.63 (m, 1H), 4.49-4.43 (m,1H), 4.24-4.23 (m, 2H), 4.19-4.17 (m, 1H), 4.06-4.04 (m, 2H), 4.01-3.97(m, 1H), 3.74-3.71 (m, 2H), 3.70 (s, 3H), 3.59-3.55 (m, 2H), 3.38 (s,3H), 3.00 (t, J=5.0 Hz, 2H), 2.77 (t, J=5.0 Hz, 2H), 2.56 (s, 2H), 2.51(s, 2H), 1.27 (s, 6H).

Example 330a10-[4-Chloro-3-(hydroxymethyl)pyridin-2-yl]-4,4-dimethyl-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-9-one330a

A mixture of4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridine-3-carbaldehyde109a (1.2 g, 3.3 mmol), NaBH₄ (228 mg, 6.0 mmol), and methanol (10 mL)was stirred at 0° C. for 0.5 h. Then the reaction mixture was quenchedwith water (10 mL) and concentrated under reduced pressure. The residuewas extracted with dichloromethane (2×15 mL). The combineddichloromethane extract was concentrated under reduced pressure toafford 330a as a pale yellow solid (1.0 g, 84%). MS-ESI: [M+H]⁺ 362.9

Example 330b(4-Chloro-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridin-3-yl)methylAcetate 330b

A mixture of 330a (1.0 g, 2.76 mmol), triethylamine (610 mg, 6.0 mmol),and acetic anhydride (5 mL) was stirred at 25° C. for 2 h. Then thereaction mixture was quenched with water (10 mL) and the pH was adjustedto around 8 with NaHCO₃ (aq.). The mixture was extracted withdichloromethane (2×15 mL). The combined dichloromethane extract wasconcentrated under reduced pressure and the residue was purified bysilica-gel column chromatography eluting with 1:1 ethylacetate/petroleum ether to afford 330b as a pale yellow solid (1.0 g,90%). MS-ESI: [M+H]⁺ 405.2

Example 330c(2-{4,4-Dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylAcetate 330c

A 50-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with 330b (1.0 g, 2.47 mmol),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.87 g,7.40 mmol), Pd(dppf)Cl₂ (100 mg, 0.13 mmol), X-phos (125 mg, 0.25 mmol),potassium acetate (500 mg, 5.0 mmol) and 1,4-dioxane (10 mL). Afterthree cycles of vacuum/nitrogen flush, the mixture was heated at 65° C.for 4 h. It was then filtered and the filtrate was evaporated underreduced pressure to afford 330c (1.0 g, 98%) as a brown oil withoutfurther purification. MS-ESI: [M+H]⁺ 415.2.

Example 330d (3-Nitro-1H-pyrazol-5-yl)methanol 330d

A mixture of 3-nitro-1H-pyrazole-5-carboxylic acid (4.71 g, 30 mmol),BH₃/THF (75 mL, 1 mol/L, 75 mmol) was stirred at 60° C. for 2 h. Themixture was cooled to room temperature and 4M HCl (19 mL, 75 mmol) wasadded. It was stirred at 70° C. for 2 h. After cooling to roomtemperature, the mixture was concentrated under reduced pressure. Theresidue was partitioned between ethyl acetate and brine (100:100 mL).The aqueous phase was extract with ethyl acetate (4×50 mL). The combinedorganic layer was dried on Na₂SO₄ and evaporated under reduced pressure.The residue was purified by silica-gel column chromatography elutingwith petroleum ether/ethyl acetate (5:1 to 1:1) to afford 330d (3.5 g,79%) as a white solid. MS-ESI: [M+H]⁺ 144.2

Example 330e1-(5-(Hydroxymethyl)-3-nitro-1H-pyrazol-1-yl)-2-methylpropan-2-ol 330e

A sealed tube was charged with 330d (2.145 g, 15 mmol), Cs₂CO₃ (978 mg,3.0 mmol), and 2,2-dimethyloxirane (15 mL). The mixture was stirred at70° C. for 3 h. After cooling to room temperature, the mixture wasconcentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with petroleum ether/ethylacetate (5:1 to 1:1) to afford 330e (1.2 g, 38%) as a white solid.MS-ESI: [M+H]⁺ 216.2

Example 330f6,6-Dimethyl-2-nitro-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine 330f

To a solution of 330e (1.1 g, 5.1 mmol) in DMF (10 mL), was added NaH(60 percent dispersion in mineral oil, 246 mg, 6.14 mmol) at 0° C. Theresulting suspension was stirred for 30 min, followed by the addition ofp-toluenesulfonyl chloride (1169 mg, 6.14 mmol). The mixture was stirredat 60° C. overnight. After cooling to room temperature, saturatedammonium chloride solution was added and the mixture was extracted withdichloromethane. The combined organic layer was washed with brine, driedover Na₂SO₄, and evaporated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with petroleumether/ethyl acetate gradient (9:1 to 2:1) to afford 330f (228 mg, 22%).MS-ESI: [M+H]⁺ 198.3

Example 330g6,6-Dimethyl-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-amine 330g

A 50-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 330f (0.21 g, 1.25 mmol), 10% palladium on carbon (50% wet,125 mg), and methanol (10 mL). The mixture was evacuated, charged withhydrogen gas, and stirred at room temperature for 2 h. The hydrogen wasthen evacuated and nitrogen was charged into the flask. The catalyst wasremoved by filtration through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure to afford 330g (167 mg, 93%).MS-ESI: [M+H]⁺ 168.1

Example 330h6-Chloro-4-(6,6-dimethyl-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-2-methylpyridazin-3(2H)-one330h

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 330g (250 mg, 1.5 mmol),4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (669 mg, 3.0 mmol),Pd₂(dba)₃ (137 mg, 0.15 mmol), Xantphos (173 mg, 0.30 mmol), Cs₂CO₃ (978mg, 3.0 mmol), and 1,4-dioxane (20 mL). After three cycles ofvacuum/argon flush, the mixture was heated at 100° C. for 3 h. It wasthen cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and washed with ethyl acetate toafford 330h as a yellow solid (209 mg, 45%). MS-ESI: [M+H]⁺ 310.1

Example 330i{4-[5-({6,6-Dimethyl-4H,6H,7H-pyrazolo[3,2-c][1,4]oxazin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl]-2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}pyridin-3-yl}methylAcetate 330i

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and reflux condenser was charged with 330h (133 mg, 0.43 mmol),330c (178 mg, 0.43 mmol), sodium acetate (71 mg, 0.86 mmol), K₃PO₄ (182mg, 0.86 mmol), Pd(dppf)Cl₂ (35 mg, 0.043 mmol), acetonitrile (15 mL),and water (0.5 mL). After bubbling nitrogen through the resultingmixture for 20 minutes, the reaction mixture was heated at 95° C. for 3h. After this time the reaction was cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure. Theresidue was purified with silica-gel column chromatography eluting with30:1 dichloromethane/methanol to afford 330i as a yellow solid (69 mg,25%). MS-ESI: [M+H]⁺ 644.3.

Example 3303-[4-[5-[(6,6-dimethyl-4,7-dihydropyrazolo[5,1-c][1,4]oxazin-2-yl)amino]-1-methyl-6-oxo-pyridazin-3-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one330

A mixture of 330i (69 mg, 0.11 mmol) and lithium hydroxide (10 mg, 0.42mmol) in i-propanol/THF (1:1, 3.5 mL) and water (1 mL) was stirred atroom temperature for 1 h. The mixture was then concentrated underreduced pressure and the residue was diluted with water (10 mL). It wasextracted with ethyl acetate (2×10 mL). The combined ethyl acetateextract was concentrated under reduced pressure and the residue waspurified with reverse-phase prep-HPLC to afford 330 (30 mg, 47%).MS-ESI: [M+H]⁺ 602.5. ¹H NMR (500 MHz, CDCl₃) δ 8.56 (d, J=5.0 Hz, 1H),8.00 (s, 1H), 7.90 (s, 1H), 7.43 (d, J=5.0 Hz, 1H), 5.94 (s, 1H), 4.82(s, 2H), 4.60-4.58 (m, 2H), 4.38-4.36 (m, 2H), 3.89 (s, 3H), 3.89-3.87(m, 3H), 3.02-2.93 (m, 2H), 2.79-2.75 (m, 2H), 2.59-2.54 (m, 2H), 1.37(s, 6H), 1.28 (s, 6H).

Example 331a5-Bromo-1-methyl-3-(3-methylisothiazol-5-ylamino)pyrazin-2(1H)-one 331a

A sealed tube equipped with a magnetic stirrer was charged with3-methylisothiazol-5-amine (170 mg, 1.5 mmol),3,5-dibromo-1-methylpyrazin-2(1H)-one (400 mg, 1.5 mmol), Pd(OAc)₂ (84mg, 0.375 mmol), BINAP (116 mg, 0.188 mmol), K₂CO₃ (450 mg, 4.5 mmol),and 1,4-dioxane (4 mL). After three cycles of vacuum/nitrogen flush, themixture was heated at 120° C. in a sealed tube for 18 h. It was thencooled to room temperature and filtered. The filtrate was evaporatedunder reduced pressure. The residue was purified by silica-gel columnchromatography eluting with dichloromethane/methanol (100:1 to 25:1) toafford 331a (220 mg, 50%) as a yellow solid. MS-ESI: [M+H]⁺ 301.0.

Example 331b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{4-methyl-6-[(3-methyl-1,2-thiazol-5-yl)amino]-5-oxo-4,5-dihydropyrazin-2-yl}pyridin-3-yl)methylAcetate 331b

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 331a (150 mg, 0.50 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (400 mg, 1.0 mmol), Pd(dppf)Cl₂ (25 mg, 0.025 mmol), K₃PO₄(220 mg, 1.0 mmol), sodium acetate trihydrate (136 mg, 1.0 mmol),acetonitrile (10 mL), and water (0.5 mL). The system was evacuated andrefilled with N₂. The reaction mixture was heated at 100° C. for 1 h. Itwas then cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the resulting residue waspurified by silica-gel column chromatography eluting withdichloromethane/methanol (100/1 to 25/1) to afford 331b (200 mg, 70%) asa yellow solid. MS-ESI: [M+H]⁺ 574.2.

Example 3313-[3-(hydroxymethyl)-4-[4-methyl-6-[(3-methylisothiazol-5-yl)amino]-5-oxo-pyrazin-2-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one331

A mixture of 331b (120 mg, 0.21 mmol) and lithium hydroxide monohydrate(88 mg, 2.1 mmol) in THF/i-propanol (4:2, 6 mL) and water (2 mL) wasstirred at 30° C. for 1 h. The mixture was evaporated under reducedpressure and diluted with water (10 mL). It was then extracted withethyl acetate (2×15 mL). The combined ethyl acetate extract wasconcentrated under reduced pressure and the residue was purified byreverse-phase prep-HPLC to afford 331 (50 mg, 45%) as a white solid.MS-ESI: [M+H]⁺ 532.2. ¹H NMR (500 MHz, CHCL₃) δ 9.13 (s, 1H), 8.61 (d,J=5 Hz, 1H), 8.37 (s, 1H), 7.99 (d, J=5.0 Hz, 1H), 6.87 (s, 1H), 6.74(s, 1H), 5.32-5.39 (m, 1H), 4.77-4.75 (m, 1H), 4.58-4.56 (m, 1H),4.32-4.37 (m, 1H), 4.21-4.18 (m, 2H), 3.96-3.94 (m, 1H), 3.72 (s, 3H),2.61-2.58 (m, 2H), 2.54 (s, 2H), 2.48 (s, 3H), 1.30 (s, 6H).

Example 332a5-Bromo-3-(5-ethyl-1,3,4-thiadiazol-2-ylamino)-1-methylpyridin-2(1H)-one332a

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-ethyl-1,3,4-thiadiazol-2-amine (500 mg, 3.88 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (1.55 g, 5.81 mmol), Pd₂(dba)₃(357 mg, 0.39 mmol), XantPhos (451 mg, 0.78 mmol), Cs₂CO₃ (2.5 g, 7.67mmol), and 1,4-dioxane (40 mL). The system was subjected to three cyclesof vacuum/nitrogen flush and heated at 100° C. for 2 h. The mixture wascooled to 90° C. and filtered. The filtrate was cooled in an ice-waterbath and then filtered again to afford 332a (574 mg, 47%) as a whitesolid. MS-ESI: [M+H]⁺ 315.1

Example 332b(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-{5-[(S-ethyl-1,3,4-thiadiazol-2-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 332b

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with 332a (200 mg, 0.63 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (754 mg, 1.89 mmol), PdCl₂(dppf) (51 mg, 0.063 mmol), K₃PO₄(267 mg, 1.26 mmol), CH₃COONa (103 mg, 1.26 mmol), acetonitrile (15 mL),and water (0.5 mL). After bubbling nitrogen through the resultingmixture for 20 minutes, it was heated at 100° C. under a nitrogenatmosphere for 2 h. The resulting mixture was cooled to room temperatureand filtered. The filtrate was evaporated under reduced pressure and theresidue was purified by silica-gel column chromatography eluting with50:1 dichloromethane/methanol to afford 332b as a brown solid (178 mg,48%). MS-ESI: [M+H]⁺ 588.2

Example 3323-[4-[5-[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one332

A mixture of 332b (158 mg, 0.27 mmol) and lithium hydroxide (19 mg, 0.81mmol) in i-propanol/THF/water (9 mL/6 mL/6 mL) was stirred at roomtemperature for 0.5 h. The mixture was evaporated under reduced pressureand the residue was extracted with dichloromethane (3×20 mL). Thecombined dichloromethane extract was concentrated under reduced pressureand the residue was purified by reverse-phase prep-HPLC to afford 332 asa white solid (80 mg, 54%). MS-ESI: [M+H]⁺ 546.2. ¹H NMR (500 MHz,DMSO-d₆) δ 10.20 (s, 1H), 8.60 (d, J=2.0 Hz, 1H), 8.49 (d, J=5.0 Hz,1H), 7.63 (d, J=2.5 Hz, 1H), 7.33 (d, J=5.0 Hz, 1H), 6.57 (s, 1H), 4.92(t, J=4.5 Hz, 1H), 4.49-4.39 (m, 2H), 4.25-4.19 (m, 3H), 3.87-3.85 (m,1H), 3.61 (s, 3H), 2.92-2.88 (m, 2H), 2.58-2.53 (m, 2H), 2.43 (s, 2H),1.27-1.22 (m, overlap, 9H).

Example 333a(2-{4,4-Dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}-4-{1-methyl-5-[(1-methyl-1H-1,2,3-triazol-4-yl)amino]-6-oxo-1,6-dihydropyridin-3-yl}pyridin-3-yl)methylAcetate 333a

A 50-mL round-bottomed flask equipped with a magnetic stirrer and areflux condenser was charged with(2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6)-dien-10-yl}-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 330c (180 mg, 0.37 mmol),5-bromo-1-methyl-3-(1-methyl-1H-1,2,3-triazol-4-ylamino)pyridin-2(1H)-one292c (125 mg, 0.43 mmol), Pd(dppf)Cl₂ (20 mg, 0.025 mmol), potassiumacetate (80 mg, 0.80 mmol), K₃PO₄ (165 mg, 0.80 mmol), andacetonitrile/water (10 mL/1 mL). After three cycles of vacuum/nitrogenflush, the mixture was heated at 100° C. for 1 h. It was then filteredand the filtrate was evaporated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 20:1dichloromethane/methanol to afford 333a (150 mg, 71%) as a brown solid.MS-ESI: [M+H]⁺ 574.1

Example 3333-[3-(hydroxymethyl)-4-[1-methyl-5-[(1-methyltriazol-4-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one333

A mixture of 333a (150 mg, 0.26 mmol) and lithium hydroxide hydrate (84mg, 2.0 mmol) in THF (5 mL), i-propanol (5 mL) and water (1.5 mL) wasstirred at 40° C. for 0.5 h. The mixture was evaporated under reducedpressure and diluted with water (10 mL). It was then extracted withdichloromethane (2×10 mL). The combined organic layer was concentratedunder reduced pressure and the residue was purified by reverse-phaseprep-HPLC to afford 333 (52 mg, 38%) as a pale yellow solid. MS-ESI:[M+H]⁺ 532.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.48-8.47 (m, 1H), 8.28 (s,1H), 7.78-7.77 (m, 2H), 7.42 (d, J=2.5 Hz, 1H), 7.34-7.33 (m, 1H),4.97-4.95 (t, J=5.0 Hz, 1H), 4.43-4.41 (m, 2H), 4.17-4.16 (m, 1H), 3.99(s, 3H), 3.94-3.92 (m, 1H), 3.59 (s, 3H), 3.04-3.02 (m, 1H), 2.90-2.89(m, 1H), 2.77-2.75 (m, 2H), 2.56-2.54 (m, 2H), 1.23 (s, 3H), 1.22 (s,3H).

Example 3343-[4-[5-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one334

Following the procedures of Example 273, and substituting5-cyclopropyl-1,3,4-thiadiazol-2-amine for 2-amino pyridine gave 334(8.7 mg, 22% yield). ¹H NMR (400 MHz, DMSO-d6) δ 8.48 (d, J=5.1 Hz, 1H),8.20 (s, 1H), 8.10 (d, J=2.4 Hz, 1H), 7.53 (d, J=2.4 Hz, 1H), 7.44 (d,J=5.1 Hz, 1H), 6.53 (s, 1H), 4.95 (t, J=5.2 Hz, 1H), 4.55-4.49 (m, 1H),4.27-4.23 (m, 3H), 3.78 (s, 2H), 3.51 (s, 3H), 3.48 (dt, J=12.3, 5.2 Hz,3H), 3.24 (s, 2H), 2.50 (d, J=7.2 Hz, 2H), 2.33 (s, 2H), 1.85-1.82 (m,3H), 1.23 (s, 6H). ES-MS m/z 531.3 [M+1].

Example 335a5-Bromo-3-(6,6-dimethyl-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methylpyridin-2(1H)-one335a

A 100-mL round-bottomed flask equipped with a reflux condenser wascharged with 1,4-dioxane (10 mL),6,6-dimethyl-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-amine 330g (167mg, 1.0 mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (320 mg, 1.2 mmol),Pd₂(dba)₃ (91 mg, 0.10 mmol), XantPhos (116 mg, 0.20 mmol), and cesiumcarbonate (652 mg, 2.0 mmol). After three cycles of vacuum/argon flush,the mixture was heated at 100° C. for 3 h. It was then filtered and thefiltrate was evaporated under reduced pressure. The residue was purifiedby silica-gel column chromatography eluting with 100:1dichloromethane/methanol to afford 335a (210 mg, 60%) as a yellow solid.MS-ESI: [M+H]⁺ 352.9

Example 335b3-(6,6-Dimethyl-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one335b

To a mixture of 335a (160 mg, 0.45 mmol) and4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (572 g, 2.25mmol) in dioxane (20 mL) was added PdCl₂(dppf) (36.8 mg, 0.045 mmol) andpotassium acetate (88.2 mg, 0.90 mmol). After three cycles ofvacuum/nitrogen flush, the mixture was stirred at 90° C. for 4 h undernitrogen atmosphere. It was then filtered and the filtrate wasevaporated under reduced pressure to afford 335b, which was used in thenext step without further purification. MS-ESI: [M+H]⁺ 401.3.

Example 335c4-[5-({6,6-Dimethyl-4H,6H,7H-pyrazolo[3,2-c][1,4]oxazin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-2-{4,4-dimethyl-9-oxo-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6),11-trien-10-yl}pyridine-3-carbaldehyde335c

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 335b (240 mg, 0.60mmol),4-chloro-2-{4,4-dimethyl-9-oxo-7-thia-10,11-diazatricyclo[6.4.0.0^(2,6)]dodeca-1(8),2(6),11-trien-10-yl}pyridine-3-carbaldehyde282i (107.7 mg, 0.30 mmol), Pd(dppf)Cl₂ (24.5 mg, 0.030 mmol), K₃PO₄(127.2 mg, 0.60 mmol), sodium acetate (49.2 mg, 0.60 mmol), water (0.5mL), and acetonitrile (10 mL). After three cycles of vacuum/nitrogenflush, the mixture was heated at 95° C. for 1 h. It was then cooled toroom temperature and filtered. The filtrate was concentrated underreduced pressure and the resulting residue was purified by silica-gelcolumn chromatography eluting with 30:1 dichloromethane/methanol toafford 335c as a brown solid (60 mg, 22%, two steps). MS-ESI: [M+H]⁺598.2.

Example 3353-[4-[5-[(6,6-dimethyl-4,7-dihydropyrazolo[5,1-c][1,4]oxazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one335

A mixture of 335c (50 mg, 0.080 mmol) and NaBH₄ (9.1 mg, 0.24 mmol) inmethanol (5 mL) was stirred at room temperature for 10 min. The mixturewas quenched with water (10 mL) and evaporated under reduced pressure.The residue was extracted with dichloromethane (3×10 mL). The combinedextract was concentrated under reduced pressure and the residue waspurified by reverse-phase prep-HPLC to afford 335 (15 mg, 30%) as ayellow solid. MS-ESI: [M+H]⁺ 600.2. ¹H NMR (500 MHz, DMSO-d₆) δ 8.56 (d,J=5.0 Hz, 1H), 8.46 (s, 1H), 8.31 (s, 1H), 8.07 (d, J=2.0 Hz, 1H), 7.52(d, J=5.0 Hz, 1H), 7.40 (d, J=2.5 Hz, 1H), 5.94 (s, 1H), 4.85-4.83 (m,1H), 4.72 (s, 2H), 4.38-4.37 (m, 2H), 3.79-3.78 (m, 2H), 3.3 (s, 3H),2.92-2.91 (m, 2H), 2.81 (s, 2H), 1.28 (s, 6H), 1.25 (s, 6H).

Example 336a 5-(Methoxymethyl)-1-methyl-3-nitro-1H-pyrazole 336a

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with5-(bromomethyl)-1-methyl-3-nitro-1H-pyrazole (8.8 g, 40 mmol), sodiummethoxide (4.3 g, 80 mmol), and methanol (50 mL). The reaction mixturewas heated at reflux for 2 h. After this time the reaction was cooled toroom temperature and concentrated under reduced pressure. The residuewas partitioned between ethyl acetate (60 mL) and water (60 mL). Theaqueous layer was separated and extracted with ethyl acetate (2×50 mL).The combined organic layer was washed with brine (50 mL) and dried oversodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure to afford 336a as ayellow oil (6.1 g, 90%). MS-ESI: [M+H]⁺ 172.

Example 336b 5-(Methoxymethyl)-1-methyl-1H-pyrazol-3-amine 336b

A 250-mL single-neck round-bottomed flask equipped with a magneticstirrer was charged with 336a (4.0 g, 23 mmol), Pd/C (1.0 g), andethanol (100 mL). The mixture was hydrogenated at room temperature for15 h. It was then filtered and the filtrate was concentrated underreduced pressure to afford 336b as a yellow oil (3.3 g, 99%), which wasused in the next step without further purification. MS-ESI: [M+H]⁺ 142.

Example 336c5-Bromo-3-(5-(methoxymethyl)-1-methyl-1H-pyrazol-3-ylamino)-1-methylpyridin-2(1H)-one336c

Following the procedure in Example 335a, and starting with 335b (1.7 g,12 mmol) and 3,5-dibromo-1-methylpyridin-2(1H)-one (3.2 g, 12 mmol)afforded 336c as a yellow solid (2.8 g, 71%). MS-ESI: [M+H]⁺ 327. ¹H NMR(500 MHz, CDCl₃) δ 7.86 (d, J=2.5 Hz, 1H), 7.38 (s, 1H), 6.88 (d, J=2.5Hz, 1H), 5.86 (s, 1H), 4.41 (s, 2H), 3.82 (s, 3H), 3.58 (s, 3H), 3.36(s, 3H).

Example 336d3-(5-(Methoxymethyl)-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one336d

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 336c (600 mg, 1.83mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.39g, 5.49 mmol), Pd₂(dba)₃ (183 mg, 0.20 mmol), X-phos (190 mg, 0.40mmol), porassium acetate (392 mg, 4.0 mmol), and 1,4-dioxane (30 mL).After three cycles of vacuum/nitrogen flush, the mixture was heated at85° C. for 3 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure to afford crude 336d asa black oil (400 mg, 75%), which was used in the next step withoutpurification. MS-ESI: [M+H]⁺ 293.1

Example 336e4-(5-(5-(Methoxymethyl)-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde336e

A 50-mL round-bottomed flask equipped with a reflux condenser wascharged with 336d (368 mg, 0.98 mmol),4-chloro-2-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-2(1H)-yl)nicotinaldehyde139a (270 mg, 0.82 mmol), PdCl₂(dppf) (60 mg, 0.082 mmol), K₃PO₄ (348mg, 1.64 mmol)), sodium acetate (135 mg, 1.65 mmol), acetonitrile (15mL), and water (0.5 mL). The system was subjected to three cycles ofvacuum/nitrogen flush and heated at 95° C. for 3 h. It was then cooledto room temperature and filtered. The filtrate was concentrated underreduced pressure and the residue was purified by silica-gel columnchromatography eluting with 20:1 ethyl acetate/methanol to afford 336e(100 mg, 22%). MS-ESI: [M+H]⁺ 542.2

Example 3362-[3-(hydroxymethyl)-4-[5-[[5-(methoxymethyl)-1-methyl-pyrazol-3-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one336

To a solution of 336e (100 mg, 0.18 mmol) in methanol (10 mL) was addedNaBH₄ (41 mg, 1.08 mmol). The mixture was stirred at room temperaturefor 1 h and LCMS showed the starting material had disappeared. Thereaction was quenched with 1.0 M HCl solution (10 mL) and evaporatedunder reduced pressure until most of methanol was distilled. The residuewas extracted with dichloromethane (3×15 mL). The combined organic layerwas dried with Na₂SO₄ and evaporated under reduced pressure. The residuewas purified by reverse-phase prep-HPLC to afford 336 as a white solid(41 mg, 41%). MS-ESI: [M+H]⁺ 544.2. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d,J=5.0 Hz, 1H), 7.96 (d, J=2.5 Hz, 1H), 7.73 (d, J=2.5 Hz, 1H), 7.41 (s,1H), 7.33 (d, J=5.0 Hz, 1H), 6.33 (s, 1H), 5.95 (s, 1H), 4.99-4.96 (m,1H), 4.67-4.64 (m, 1H), 4.42-4.41 (m, 3H), 4.36-4.26 (m, 1H), 3.98-3.91(m, 1H), 3.88-3.82 (m, 2H), 3.79 (s, 3H), 3.71 (s, 3H), 3.37 (s, 3H),3.06-2.91 (m, 2H), 2.87-2.79 (m, 2H), 2.08-2.01 (m, 2H), 1.91-1.86 (m,2H).

Example 337a 1,2-Dimethyl-4-nitro-1H-imidazole 337a

To a mixture of 2-methyl-4-nitro-1H-imidazole (10.0 g, 78.7 mmol) andK₂CO₃ (21.7 g, 160 mmol) in DMF (80 mL) was added CH₃I (13.4 g, 94 mmol)dropwise while stirring at room temperature. The mixture was stirred for2 h. Water (200 mL) was then added to the mixture. The resultingsuspension was filtered, washed with water, and dried in vacuo to afford337a as a white solid (5.0 g, 45%). MS-ESI: [M+H]⁺ 142.1.

Example 337b tert-Butyl 1,2-Dimethyl-1H-imidazol-4-ylcarbamate 337b

A 100-mL single-neck round-bottomed flask was purged with nitrogen andcharged with 337a (2.0 g, 14.1 mmol), 10% palladium on carbon (50% wet,400 mg), (Boc)₂O (9.22 g, 43.3 mmol), triethylamine (2.85 g, 28.2 mmol),and ethanol (20 mL). The mixture was evacuated, charged with hydrogengas, and stirred at room temperature for 5 h. The hydrogen was thenevacuated and nitrogen was charged into the flask. The catalyst wasremoved by filtration through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure. The residue was purified bysilica-gel column chromatography eluting with 40:1dichloromethane/methanol to afford 337b (1.2 g, 40%) as a brown solid.MS-ESI: [M+H]⁺ 212.1

Example 337c 1,2-Dimethyl-1H-imidazol-4-amine Hydrochloride 337c

To a solution of 337b (1.2 g, 5.68 mmol) in dichloromethane (5.0 mL) wasadded 3M HCl in dioxane (5.0 mL). This mixture was stirred at roomtemperature for 4 h and concentrated under reduced pressure. The crudeproduct was washed by ethyl acetate to afford 337c (450 mg, 55%) as apale yellow solid, which was used in the next step without furtherpurification. MS-ESI: [M+H]⁺ 112.2

Example 337d5-Bromo-3-(1,2-dimethyl-1H-imidazol-4-ylamino)-1-methylpyridin-2(1H)-one337d

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 337c (400 mg, 3.60mmol), 3,5-dibromo-1-methylpyridin-2(1H)-one (960 mg, 3.60 mmol),XantPhos (240 mg, 0.40 mmol), tris(dibenzylideneacetone)dipalladium(0)(360 mg, 0.40 mmol), Cs₂CO₃ (4.69 g, 14.4 mmol), and 1,4-dioxane (20mL). After three cycles of vacuum/nitrogen flush, the mixture was heatedat 90° C. for 2.5 h. It was then cooled to room temperature andfiltered. The filtrate was concentrated under reduced pressure and theresulting residue was purified by silica-gel column chromatographyeluting with dichloromethane/methanol (30:1 to 20:1) to afford 337d as apale yellow solid (350 mg, 33%). MS-ESI: [M+H]⁺ 297.1.

Example 337e(4-{5-[(1,2-Dimethyl-1H-imidazol-4-yl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.02,6]-dodeca-2(6),7-dien-10-yl}pyridin-3-yl)methylAcetate 337e

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 337d (20 mg, 0.67 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (270 mg, 0.67 mmol), Pd(dppf)Cl₂ (42 mg, 0.050 mmol), sodiumacetate (82 mg, 1.0 mmol), K₃PO₄ trihydrate (266 mg, 1.0 mmol), water (6drops), and acetonitrile (6 mL). After three cycles of vacuum/nitrogenflush, the mixture was heated at 95° C. for 2 h. It was then filteredand the filtrate was evaporated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 25:1dichloromethane/methanol to afford 337e (200 mg, 50%) as a brown solid.LCMS-ESI: [M+H]⁺ 570.3

Example 3373-[4-[5-[(1,2-dimethylimidazol-4-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one337

A mixture of 337e (100 mg, 0.19 mmol) and lithium hydroxide (34 mg, 1.4mmol) in i-propanol/THF (1:1, 4 mL) and water (1 mL) was stirred at 40°C. for 0.5 h. The mixture was evaporated under reduced pressure and theresidue was diluted with water (10 mL). It was then extracted with ethylacetate (2×10 mL). The combined ethyl acetate extract was concentratedunder reduced pressure and the residue was purified by reverse-phaseprep-HPLC to afford 337 (35 mg, 40%) as a white solid. LCMS-ESI: [M+H]⁺528.3. ¹H NMR (500 MHz, CDCl₃) δ 8.45 (d, J=5.0 Hz, 1H), 7.36 (s, 1H),7.28-7.27 (m, 2H), 7.25 (d, J=5.0 Hz, 1H), 6.84 (s, 1H), 6.79 (s, 1H),4.62-4.40 (m, 3H), 4.15-4.14 (m, 2H), 3.84-3.81 (m, 1H), 3.67 (s, 3H),3.52 (s, 3H), 2.57-2.56 (m, 2H), 2.51 (s, 2H), 2.32 (s, 3H), 1.27 (s,6H).

Example 338a3-(2-Nitro-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)propanenitrile338a

Following the procedure of Example 296d, and starting with1-(2-bromoethyl)-5-(chloromethyl)-3-nitro-1H-pyrazole 296d (268 mg, 1.00mmol) and 3-aminopropanenitrile (210 mg, 3.00 mmol) afforded 338a as awhite solid (180 mg, 81%). MS-ESI: [M+H]⁺ 222.1

Example 338b3-(2-Amino-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)propanenitrile338b

Following the procedure of Example 296e, and starting with 338a (180 mg,0.81 mmol) afforded 338b as a yellow solid (120 mg, 77%). MS-ESI: [M+H]⁺192.2

Example 338c3-(2-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)propanenitrile338c

Following the procedure of Example 309c, and starting with 338b (120 mg,0.63 mmol) and 3,5-dibromo-1-methylpyridin-2(1H)-one (169 mg, 0.63 mmol)afforded 338c as a yellow solid (150 mg, 63%). MS-ESI: [M+H]⁺ 377.2

Example 338d[4-(5-{[5-(2-Cyanoethyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-3-yl]methylAcetate 338d

Following the procedure of Example 309d, and starting with 338c (150 mg,0.45 mmol) and{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (358 mg, 0.90 mmol) afforded 338d as a yellow solid (150 mg,52%). MS-ESI: [M+H]⁺ 650.3

Example 3383-[2-[[5-[2-(7,7-dimethyl-4-oxo-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-3-(hydroxymethyl)-4-pyridyl]-1-methyl-2-oxo-3-pyridyl]amino]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-5-yl]propanenitrile338

Following the procedure of Example 309, and starting with 338e (150 mg,0.23 mmol) afforded 338 as a white solid (55 mg, 40%). MS-ESI: [M+H]⁺608.3. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, J=5.0 Hz, 1H), 7.96 (d, J=2.5Hz, 1H), 7.71 (d, J=2.0 Hz, 1H), 7.42 (s, 1H), 7.35 (d, J=5.0 Hz, 1H),6.85 (s, 1H), 5.74 (s, 1H), 5.05 (t, J=6.5 Hz, 1H), 4.66-4.64 (m, 1H),4.52-4.50 (m, 1H), 4.36-4.34 (m, 1H), 4.17-4.16 (m, 2H), 4.09-4.07 (m,2H), 3.88-3.84 (m, 1H), 3.75 (s, 2H), 3.71 (s, 3H), 3.05-3.03 (m, 2H),2.93-2.90 (m, 2H), 2.63-2.58 (m, 4H), 2.53 (s, 2H), 1.29 (s, 6H).

Example 339a tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-carboxylate339a

To a solution of 5-bromo-2-nitropyridin (30.0 g, 148 mmol) in DMSO (1 L)were added K₂CO₃ (40.0 g, 296 mmol) and tert-butylpiperazine-1-carboxylate (28.0 g, 148 mmol). The mixture was stirred at65° C. overnight. After cooling down, it was poured into water (2 L).The solid precipitated was collected and dried in vacuo. It was thenfurther purified by silica-gel column chromatography eluting with 20:1petroleum ether/ethyl acetate and then with dichloromethane to afford339a as a yellow solid (17.0 g, 37%). MS-ESI: [M+H]⁺ 309.

Example 339b tert-Butyl 4-(6-Aminopyridin-3-yl)piperazine-1-carboxylate339b

A 500-mL round-bottomed flask was purged with nitrogen and charged with339a (3.1 g, 10 mmol), 10% palladium on carbon (50% wet, 1.0 g), andethanol (100 mL). It was evacuated, charged with hydrogen gas via aballoon, and stirred at room temperature for 16 h. The hydrogen was thenevacuated and nitrogen was charged into the flask. The catalyst wasremoved by filtration through a pad of CELITE® and the filtrate wasconcentrated under reduced pressure to afford 339b (2.7 g, 97%). MS-ESI:[M+H]⁺ 279

Example 339c tert-Butyl4-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridine-3-yl)piperazine-1-carboxylate339c

A 100-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with 339b (1.3 g, 4.7 mmol),3,5-dibromo-1-methylpyridin-2(1H)-one (1.24 g, 4.7 mmol), cesiumcarbonate (3.8 g, 12 mmol), and 1,4-dioxane (50 mL). After bubblingnitrogen through the resulting mixture for 30 minutes, XantPhos (272 mg,0.47 mmol) and tris(dibenzylideneacetone)dipalladium(0) (430 mg, 0.47mmol) were added. The system was subjected to three cycles ofargon/vacuum flush and heated at reflux for 3 h. After this time thereaction was cooled to room temperature and filtered. The filtrate waspartitioned between ethyl acetate (100 mL) and water (100 mL). Theaqueous layer was separated and extracted with ethyl acetate (2×50 mL).The combined organic layer was washed with brine (50 mL) and dried oversodium sulfate. The drying agent was removed by filtration and thefiltrate was concentrated under reduced pressure. The residue waspurified by silica-gel column chromatography eluting with 50:1dichloromethane/methanol to afford 339c (1.3 g, 59%). MS-ESI: [M+H]⁺464.

Example 339d tert-Butyl4-{6-[(5-{3-[(Acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino]pyridin-3-yl}piperazine-1-carboxylate339d

A 50-mL single-neck round-bottomed flask equipped with a magneticstirrer and a reflux condenser was charged with(2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylacetate 199e (287.4 mg, 0.60 mmol), 339c (145 mg, 0.30 mmol),Pd(dppf)Cl₂ (24.5 mg, 0.030 mmol), K₃PO₄ (127.2 mg, 0.60 mmol), sodiumacetate (49.2 mg, 0.60 mmol), water (0.50 mL), and acetonitrile (10 mL).After three cycles of vacuum/nitrogen flush, the mixture was heated at95° C. for 1 h. It was then cooled to room temperature and filtered. Thefiltrate was concentrated under reduced pressure and the resultingresidue was purified by silica-gel column chromatography eluting withethyl acetate to afford 339d as a yellow solid (140 mg, 61%). MS-ESI:[M+H]⁺ 737.3.

Example 339e(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-(1-methyl-6-oxo-5-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-1,6-dihydropyridin-3-yl)pyridin-3-yl)methylAcetate 339e

A mixture of 339d (130 mg, 0.18 mmol) and HCl/methanol (4.0 mL) wasstirred at room temperature for 4 h. It was then concentrated underreduced pressure to afford crude 339e (100 mg, 87%), which was used inthe next step without further purification. MS-ESI: [M+H]⁺ 637.3.

Example 3393-[3-(hydroxymethyl)-4-[5-[[5-[4-(2-methoxyethyl)piperazin-1-yl]-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one339

A mixture of 339e (100 mg, 0.18 mmol), 1-bromo-2-methoxyethane (24.8 mg,0.18 mmol), and K₂CO₃ (49.7 mg, 0.36 mmol) in acetonitrile (5.0 mL) in asealed was stirred at 85° C. overnight. The mixture was cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure. To the residue was added water and the resulting mixture wasextracted with dichloromethane three times. The combined organic layerwas concentrated under reduced pressure and the resulting residue waspurified by reverse-phase prep-HPLC to afford 339 as a yellow solid(31.1 mg, 30%). MS-ESI: [M+H]⁺ 653.3. ¹H NMR (500 MHz, DMSO) δ 8.61 (d,J=2.0 Hz, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.40 (s, 1H), 7.84 (d, J=3.0 Hz,1H), 7.46 (d, J=2.0 Hz, 1H), 7.38-7.34 (m, 2H), 7.23 (d, J=9.5 Hz, 1H),6.57 (s, 1H), 4.97-4.95 (m, 1H), 4.45-4.40 (m, 2H), 4.23-4.19 (m, 3H),3.85-3.83 (m, 1H), 3.60 (s, 3H), 3.47-3.44 (m, 2H), 3.24 (s, 3H),3.04-3.02 (m, 4H), 2.59-2.53 (m, overlap, 8H), 2.43 (s, 2H), 1.23 (s,6H).

Example 340a (3S)-tert-Butyl3-Methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 340a

Following the procedure of Example 323a, and starting with(3S)-tert-butyl 3-methylpiperazine-1-carboxylate (10.0 g, 50 mmol) and5-bromo-2-nitropyridine (10.5 g, 50 mmol) afforded 340a as a yellowsolid (8.05 g, 50%). MS-ESI: [M+H]⁺ 323

Example 340b (3S)-tert-Butyl4-(6-Aminopyridin-3-yl)-3-methylpiperazine-1-carboxylate 340b

Following the procedure of Example 323b, and starting with 340a (5.8 g,18 mmol) afforded 340b as a brown solid (4.9 g, 93%). MS-ESI: [M+H]⁺ 293

Example 340c (3S)-tert-Butyl4-(6-(5-Bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridine-3-yl)-3-methylpiperazine-1-carboxylate 340c

Following the procedures of Example 323c, and starting with 340b (4.0 g,13.7 mmol) and 3,5-dibromo-1-methylpyridin-2(1H)-one (5.5 g, 20.6 mmol)afforded 340c as a yellow solid (5.4 g, 83%). MS-ESI: [M+H]⁺ 478

Example 340d(3S)-5-Bromo-1-methyl-3-(5-(2-methylpiperazin-1-yl)pyridin-2-ylamino)pyridine-2(1H)-one340d

Following the procedure of Example 271c, and starting with 340c (3.1 g,6.5 mmol) afforded 340d as a yellow solid (2.3 g, 94%). MS-ESI: [M+H]⁺378.

Example 340e(S)-5-Bromo-3-(5-(4-(2-methoxyethyl)-2-methylpiperazin-1-yl)pyridin-2-ylamino)-1-methylpyridin-2(1H)-one340e

A mixture of 340d (500 mg, 1.32 mmol), 1-bromo-2-methoxyethane (239.1mg, 1.72 mmol), K₂CO₃ (364 mg, 2.64 mmol), and acetonitrile (6 mL) in asealed tube was heated at 80° C. for 12 h. Analysis of the reactionmixture by LCMS showed complete conversion to the desired product. Itwas cooled to room temperature and filtered. The filtrate wasconcentrated under reduced pressure. The residue was dissolved in water(20 mL) and ethyl acetate (30 mL). The water phase was extracted withethyl acetate (3×30 mL). The combined organic layer was washed withbrine, dried over Na₂SO₄, concentrated under reduced pressure to affordcrude 340e as a dark oil (600 mg), which was used in the next stepwithout further purification. MS-ESI: [M+H]⁺ 436.1

Example 340f(2-{4,4-Dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}-4-[5-({5-[(25)-4-(2-methoxyethyl)-2-methylpiperazin-1-yl]pyridin-2-yl}amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]pyridin-3-yl)methylAcetate 340f

A 50-mL round bottomed flask equipped with a reflux condenser wascharged with 340e (180 mg, 0.412 mmol),{3-[(acetoxy)methyl]-2-{4,4-dimethyl-9-oxo-1,10-diazatricyclo[6.4.0.0^(2,6)]dodeca-2(6),7-dien-10-yl}pyridin-4-yl}boronicacid 199e (327.3 mg, 0.824 mmol), Pd(dppf)Cl₂ (16.8 mg, 0.0206 mmol),K₃PO₄ (174.7 mg, 0.824 mmol), sodium acetate (67.6 mg, 0.824 mmol),acetonitrile (10 mL), and water (3 drops). The system was subjected tothree cycles of vacuum/nitrogen flush and heated at 100° C. under N₂protection for 1 h. Analysis of the reaction mixture by LCMS showedcomplete conversion to the desired product. It was then cooled to roomtemperature and filtered. The filtrate was concentrated under reducedpressure. The residue was purified by silica-gel column chromatographyeluting with 20:1 dichloromethane/methanol to afford 340f as a yellowoil (190 mg, 65%). MS-ESI: [M+H]⁺ 709.4

Example 3403-[3-(hydroxymethyl)-4-[5-[[5-[(2S)-4-(2-methoxyethyl)-2-methyl-piperazin-1-yl]-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one340

To a solution of 340f (170 mg, 0.24 mmol) in THF (6 mL), i-propanol (6mL), and water (6 mL) was added lithium hydroxide (57.6 mg, 2.4 mmol).After stirring at room temperature for 1 h, The reaction mixture wasconcentrated under reduced pressure. The residue was dissolved indichloromethane (20 mL) and water (10 mL). The water phase was extractedwith dichloromethane (3×20 mL). The combined organic layer was washedwith brine, dried over Na₂SO₄, concentrated under reduced pressure, andpurified by reverse-phase prep-HPLC to afford 340 (48.5 mg, 30%) as awhite solid. MS-ESI: [M+H]⁺ 667.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.62 (d,J=2.5 Hz, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.42 (s, 1H), 7.82 (d, J=2.5 Hz,1H), 7.47 (d, J=2.5 Hz, 1H), 7.37-7.34 (m, 2H), 7.24 (d, J=9.0 Hz, 1H),6.56 (s, 1H), 4.97-4.95 (m, 1H), 4.47-4.41 (m, 2H), 4.25-4.19 (m, 3H),3.85-3.83 (m, 1H), 3.63-3.62 (m, 1H), 3.61 (s, 3H), 3.47-3.45 (m, 2H),3.25 (s, 3H), 3.06-3.04 (m, 1H), 2.93-2.89 (m, 1H), 2.70-2.68 (m, 1H),2.62-2.32 (m, overlap, 9H), 1.22 (s, 6H), 0.91 (d, J=6.5 Hz, 3H).

Example 901 Biochemical Btk Assay

A generalized procedure for a standard biochemical Btk Kinase Assay thatcan be used to test Formula I compounds is as follows. A master mixminus Btk enzyme is prepared containing 1× Cell Signaling kinase buffer(25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mMdithiothreitol, 0.1 mM Na₃VO₄, 10 mM MgCl₂), 0.5 μM Promega PTKBiotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btkenzyme is prepared containing 1× Cell Signaling kinase buffer, 0.5 μMPTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06mU/well) Btk enzyme. Btk enzyme is prepared as follows: full lengthhuman wildtype Btk (accession number NM-000061) with a C-terminal V5 and6×His tag was subcloned into pFastBac vector for making baculoviruscarrying this epitope-tagged Btk. Generation of baculovirus is donebased on Invitrogen's instructions detailed in its published protocol“Bac-to-Bac Baculovirus Expression Systems” (Cat. Nos. 10359-016 and10608-016). Passage 3 virus is used to infect Sf9 cells to overexpressthe recombinant Btk protein. The Btk protein is then purified tohomogeneity using Ni-NTA column. The purity of the final proteinpreparation is greater than 95% based on the sensitive Sypro-Rubystaining. A solution of 200 μM ATP is prepared in water and adjusted topH7.4 with 1N NaOH. A quantity of 1.25 μL of compounds in 5% DMSO istransferred to a 96-well ½ area Costar polystyrene plate. Compounds aretested singly and with an 11-point dose-responsive curve (startingconcentration is 10 μM; 1:2 dilution). A quantity of 18.75 μL of mastermix minus enzyme (as a negative control) and master mix plus enzyme istransferred to appropriate wells in 96-well ½ area costar polystyreneplate. 5 μL of 200 μM ATP is added to that mixture in the 96-well ½ areaCostar polystyrene plate for final ATP concentration of 40 μM. Thereaction is allowed to incubate for 1 hour at room temperature. Thereaction is stopped with Perkin Elmer 1× detection buffer containing 30mM EDTA, 20 nM SA-APC, and 1 nM PT66 Ab. The plate is read usingtime-resolved fluorescence with a Perkin Elmer Envision using excitationfilter 330 nm, emission filter 665 nm, and 2^(nd) emission filter 615nm. IC₅₀ values are subsequently calculated. Alternatively, theLanthascreen assay can be used to evaluate Btk activity throughquantification of its phosphorylated peptide product. The FRET(Fluorescence Resonance Energy Transfer) that occurs between thefluorescein on the peptide product and the terbium on the detectionantibody decreases with the addition of inhibitors of Btk that reducethe phosphorylation of the peptide. In a final reaction volume of 25 uL,Btk (h) (0.1 ng/25 ul reaction) is incubated with 50 mM Hepes pH 7.5, 10mM MgCl₂, 2 mM MnCl₂, 2 mM DTT, 0.2 mM NaVO4, 0.01% BSA, and 0.4 uMfluorescein poly-GAT. The reaction is initiated by the addition of ATPto 25 uM (Km of ATP). After incubation for 60 minutes at roomtemperature, the reaction is stopped by the addition of a finalconcentration of 2 nM Tb-PY20 detection antibody in 60 mM EDTA for 30minutes at room temperature. Detection is determined on a Perkin ElmerEnvision with 340 nM excitation and emission at 495 nm and 520 nm.Exemplary Btk inhibition IC50 values are in Tables 1, 2, and 3.

Example 902 Ramos Cell Btk Assay

Another generalized procedure for a standard cellular Btk Kinase Assaythat can be used to test Formula I compounds is as follows. Ramos cellsare incubated at a density of 0.5×10⁷ cells/ml in the presence of testcompound for 1 hr at 37° C. Cells are then stimulated by incubating with10 μg/ml anti-human IgM F(ab)₂ for 5 minutes at 37° C. Cells arepelleted, lysed, and a protein assay is performed on the cleared lysate.Equal protein amounts of each sample are subject to SDS-PAGE and westernblotting with either anti-phosphoBtk (Tyr223) antibody (Cell SignalingTechnology #3531; Epitomics, cat. #2207-1) or phosphoBtk (Tyr551)antibody (BD Transduction Labs #558034) to assess Btkautophosphorylation or an anti-Btk antibody (BD Transduction Labs#611116) to control for total amounts of Btk in each lysate.

Example 903 B-Cell Proliferation Assay

A generalized procedure for a standard cellular B-cell proliferationassay that can be used to test Formula I compounds is as follows.B-cells are purified from spleens of 8-16 week old Balb/c mice using aB-cell isolation kit (Miltenyi Biotech, Cat #130-090-862). Testingcompounds are diluted in 0.25% DMSO and incubated with 2.5×10⁵ purifiedmouse splenic B-cells for 30 min prior to addition of 10 m/ml of ananti-mouse IgM antibody (Southern Biotechnology Associates Cat #1022-01)in a final volume of 100 μl. Following 24 hr incubation, 1μCi³H-thymidine is added and plates are incubated an additional 36 hrprior to harvest using the manufacturer's protocol for SPA[³H] thymidineuptake assay system (Amersham Biosciences # RPNQ 0130). SPA-bead basedfluorescence is counted in a microbeta counter (Wallace Triplex 1450,Perkin Elmer).

Example 904 T Cell Proliferation Assay

A generalized procedure for a standard T cell proliferation assay thatcan be used to test Formula I compounds is as follows. T cells arepurified from spleens of 8-16 week old Balb/c mice using a Pan T cellisolation kit (Miltenyi Biotech, Cat #130-090-861). Testing compoundsare diluted in 0.25% DMSO and incubated with 2.5×10⁵ purified mousesplenic T cells in a final volume of 100 μl in flat clear bottom platesprecoated for 90 min at 37° C. with 10 μg/ml each of anti-CD3 (BD#553057) and anti-CD28 (BD #553294) antibodies. Following 24 hrincubation, 1 μCi³H-thymidine is added and plates incubated anadditional 36 hr prior to harvest using the manufacturer's protocol forSPA[³H] thymidine uptake assay system (Amersham Biosciences # RPNQ0130). SPA-bead based fluorescence was counted in a microbeta counter(Wallace Triplex 1450, Perkin Elmer).

Example 905 CD86 Inhibition Assay

A generalized procedure for a standard assay for the inhibition of Bcell activity that can be used to test Formula I compounds is asfollows. Total mouse splenocytes are purified from spleens of 8-16 weekold Balb/c mice by red blood cell lysis (BD Pharmingen #555899). Testingcompounds are diluted to 0.5% DMSO and incubated with 1.25×10⁶splenocytes in a final volume of 200 μl in flat clear bottom plates(Falcon 353072) for 60 min at 37° C. Cells are then stimulated with theaddition of 15 μg/ml IgM (Jackson ImmunoResearch 115-006-020), andincubated for 24 hr at 37° C., 5% CO₂. Following the 24 hr incubation,cells are transferred to conical bottom clear 96-well plates andpelleted by centrifugation at 1200×g×min. Cells are preblocked byCD16/CD32 (BD Pharmingen #553142), followed by triple staining withCD19-FITC (BD Pharmingen #553785), CD86-PE (BD Pharmingen #553692), and7AAD (BD Pharmingen #51-68981E). Cells are sorted on a BD FACSCaliburand gated on the CD19⁺/7AAD⁻ population. The levels of CD86 surfaceexpression on the gated population is measured versus test compoundconcentration.

Example 906 B-ALL Cell Survival Assay

The following is a procedure for a standard B-ALL (acute lymphoblasticleukemia) cell survival study using an XTT readout to measure the numberof viable cells. This assay can be used to test Formula I compounds fortheir ability to inhibit the survival of B-ALL cells in culture. Onehuman B-cell acute lymphoblastic leukemia line that can be used isSUP-B15, a human Pre-B-cell ALL line that is available from the ATCC.

SUP-B15 pre-B-ALL cells are plated in multiple 9 6-well microtiterplates in 100 μA of Iscove's media+20% FBS at a concentration of 5×10⁵cells/ml. Test compounds are then added with a final conc. of 0.4% DMSO.Cells are incubated at 37° C. with 5% CO₂ for up to 3 days. After 3 dayscells are split 1:3 into fresh 96-well plates containing the testcompound and allowed to grow up to an additional 3 days. After each 24 hperiod, 50 ul of an XTT solution is added to one of the replicate96-well plates and absorbance readings are taken at 2, 4 and 20 hoursfollowing manufacturer's directions. The reading taken with an OD forDMSO only treated cells within the linear range of the assay (0.5-1.5)is then taken and the percentage of viable cells in the compound treatedwells are measured versus the DMSO only treated cells.

Example 907 CD69 Whole Blood Assay

Human blood is obtained from healthy volunteers, with the followingrestrictions: 1 week drug-free, non-smokers. Blood (approximately 20 mlsto test 8 compounds) is collected by venipuncture into Vacutainer®(Becton, Dickinson and Co.) tubes with sodium heparin.

Solutions of Formula I compounds at 10 mM in DMSO are diluted 1:10 in100% DMSO, then are diluted by three-fold serial dilutions in 100% DMSOfor a ten point dose-response curve. The compounds are further diluted1:10 in PBS and then an aliquot of 5.5 μl of each compound is added induplicate to a 2 ml 96-well plate; 5.5 μl of 10% DMSO in PBS is added ascontrol and no-stimulus wells. Human whole blood—HWB (100 μl) is addedto each well. After mixing the plates are incubated at 37° C., 5% CO₂,100% humidity for 30 minutes. Goat F(ab′)₂ anti-human IgM (10 μl of a500 μg/ml solution, 50 μg/ml final) is added to each well (except theno-stimulus wells) with mixing and the plates are incubated for anadditional 20 hours. At the end of the 20 hour incubation, samples areincubated with fluorescent labeled antibodies for 30 minutes, at 37° C.,5% CO₂, 100% humidity. Include induced control, unstained and singlestains for compensation adjustments and initial voltage settings.Samples are then lysed with PharM Lyse™ (BD Biosciences Pharmingen)according to the manufacturer's instructions. Samples are thentransferred to a 96 well plate suitable to be run on the BD BiosciencesHTS 96 well system on the LSR11 machine. Data acquired and MeanFluorescence Intensity values were obtained using BD Biosciences DIVASoftware. Results are initially analyzed by FACS analysis software (FlowJo). The inhibitory concentrations (IC50, IC70, IC90, etc.) for testcompounds is defined as the concentration which decreases by, forexample 50%, the percent positive of CD69 cells that are also CD20positive stimulated by anti-IgM (average of 8 control wells, aftersubtraction of the average of 8 wells for the no-stimulus background).The IC70 values are calculated by Prism version 5, using a nonlinearregression curve fit and are shown in Tables 1 and 2.

Example 908 In Vitro Cell Proliferation Assay

Efficacy of Formula I compounds are measured by a cell proliferationassay employing the following protocol (Mendoza et al (2002) Cancer Res.62:5485-5488). The CellTiter-Glo® Luminescent Cell Viability Assay,including reagents and protocol are commercially available (PromegaCorp., Madison, Wis., Technical Bulletin TB288). The assay assesses theability of compounds to enter cells and inhibit cell proliferation. Theassay principle is based on the determination of the number of viablecells present by quantitating the ATP present in a homogenous assaywhere addition of the Cell-Titer Glo reagent results in cell lysis andgeneration of a luminescent signal through the luciferase reaction. Theluminescent signal is proportional to the amount of ATP present.

A panel of B-cell lymphoma cell lines (BJAB, SUDHL-4, TMD8, OCI-Ly10,OCI-Ly3, WSU-DLCL2) are plated into 384-well plate in normal growthmedium, and serially diluted BTK inhibitors or DMSO alone were added toeach well. Cell viability is assessed after 96 hour incubation byCellTiter-Glo® (Promega). Data may be presented as Relative cellviability in BTK inhibitor-treated cells relative to DMSO-treatedcontrol cells. Data points are the mean of 4 replicates at each doselevel. Error bars represent SD from the mean.

Procedure: Day 1—Seed Cell Plates (384-well black, clear bottom,microclear, TC plates with lid from Falcon #353962), Harvest cells, Seedcells at 1000 cells per 54 μl per well into 384 well Cell Plates for 3days assay. Cell Culture Medium: RPMI or DMEM high glucose, 10% FetalBovine Serum, 2 mM L-Glutamine, P/S. Incubate 0/N at 37° C., 5% CO2.

Day 2—Add Drug to Cells, Compound Dilution, DMSO Plates (serial 1:2 for9 points), Add 20 μl compounds at 10 mM in the 2nd column of 96 wellplate. Perform serial 1:2 across the plate (10 μl+20 μl 100% DMSO) for atotal of 9 points using Precision. Media Plates 96-well conical bottompolypropylene plates from Nunc (cat. #249946) (1:50 dilution) Add 147 μlof Media into all wells. Transfer 3 μl of DMSO+compound from each wellin the DMSO Plate to each corresponding well on Media Plate usingRapidplate.

Drug Addition to Cells, Cell Plate (1:10 dilution), Add 6 μl ofmedia+compound directly to cells (54 μl of media on the cells already).Incubate 3 days at 37° C., 5% CO2 in an incubator that will not beopened often.

Day 5—Develop Plates, Thaw Cell Titer Glo Buffer at room temperature.Remove Cell Plates from 37° C. and equilibrate to room temperature. forabout 30 minutes. Add Cell Titer Glo Buffer to Cell Titer Glo Substrate(bottle to bottle). Add 30 μl Cell Titer Glo Reagent (Promega cat.#G7572) to each well of cells. Place on plate shaker for about 30minutes. Read luminescence on Analyst HT Plate Reader (half second perwell).

Cell viability assays and combination assays: Cells were seeded at1000-2000 cells/well in 384-well plates for 16 h. On day two, nineserial 1:2 compound dilutions are made in DMSO in a 96 well plate. Thecompounds are further diluted into growth media using a Rapidplate robot(Zymark Corp., Hopkinton, Mass.). The diluted compounds are then addedto quadruplicate wells in 384-well cell plates and incubated at 37° C.and 5% CO2. After 4 days, relative numbers of viable cells are measuredby luminescence using Cell-Titer Glo (Promega) according to themanufacturer's instructions and read on a Wallac Multilabel Reader(PerkinElmer, Foster City). EC50 values are calculated using Prism® 4.0software (GraphPad, San Diego). Formula I compounds and chemotherapeuticagents are added simultaneously or separated by 4 hours (one before theother) in all assays.

An additional exemplary in vitro cell proliferation assay includes thefollowing steps:

1. An aliquot of 100 μl of cell culture containing about 10⁴ cells inmedium is deposited in each well of a 384-well, opaque-walled plate.

2. Control wells are prepared containing medium and without cells.

3. The compound is added to the experimental wells and incubated for 3-5days.

4. The plates are equilibrated to room temperature for approximately 30minutes.

5. A volume of CellTiter-Glo Reagent equal to the volume of cell culturemedium present in each well is added.

6. The contents are mixed for 2 minutes on an orbital shaker to inducecell lysis.

7. The plate is incubated at room temperature for 10 minutes tostabilize the luminescence signal.

8. Luminescence is recorded and reported in graphs as RLU=relativeluminescence units.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, the descriptions and examples should not be construed aslimiting the scope of the invention. Accordingly, all suitablemodifications and equivalents may be considered to fall within the scopeof the invention as defined by the claims that follow. The disclosuresof all patent and scientific literature cited herein are expresslyincorporated in their entirety by reference.

We claim:
 1. A method of treating a disease or disorder which comprisesadministering a pharmaceutical composition comprising a therapeuticallyeffective amount of a Formula I compound and a pharmaceuticallyacceptable carrier, glidant, diluent, or excipient to a patient with adisease or disorder selected from immune disorders, cancer,cardiovascular disease, viral infection, inflammation,metabolism/endocrine function disorders and neurological disorders,wherein the Formula I compound has the structure:

or stereoisomers, tautomers, or pharmaceutically acceptable saltsthereof, wherein: X¹ is CR¹ or N; X² is CR² or N; X³ is CR³ or N; whereone or two of X¹, X², and X³ are N; R¹, R² and R³ are independentlyselected from H, F, Cl, —NH₂, —NHCH₃, —N(CH₃)₂, —OH, —OCH₃, —OCH₂CH₃,—OCH₂CH₂OH, and C₁-C₃ alkyl; R⁴ is selected from H, F, Cl, CN, —CH₂OH,—CH(CH₃)OH, —C(CH₃)₂OH, —CH(CF₃)OH, —CH₂F, —CHF₂, —CH₂CHF₂, —CF₃,—C(O)NH₂, —C(O)NHCH₃, —C(O)N(CH₃)₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHC(O)CH₃,—OH, —OCH₃, —OCH₂CH₃, —OCH₂CH₂OH, cyclopropyl, cyclopropylmethyl,1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxy-oxetan-3-yl,oxetan-3-yl, and azetidin-1-yl; R⁵ is optionally substituted C₆-C₂₀aryl, C₃-C₁₂ carbocyclyl, C₂-C₂₀ heterocyclyl, C₁-C₂₀ heteroaryl,—(C₆-C₂₀ aryl)-(C₂-C₂₀ heterocyclyl), —(C₁-C₂₀ heteroaryl)-(C₂-C₂₀heterocyclyl), —(C₁-C₂₀ heteroaryl)-(C₂-C₂₀ heterocyclyl)-(C₂-C₂₀heterocyclyl), —(C₁-C₂₀ heteroaryl)-(C₂-C₂₀ heterocyclyl)-(C₁-C₆ alkyl),—(C₁-C₂₀ heteroaryl)-(C₁-C₆ alkyl), —(C₂-C₂₀ heterocyclyl)-(C₁-C₆alkyl), —(C₂-C₂₀ heterocyclyl)-(C₃-C₁₂ carbocyclyl), —(C₁-C₂₀heteroaryl)-(C₃-C₁₂ carbocyclyl), or —(C₁-C₂₀ heteroaryl)-C(═O)—(C₂-C₂₀heterocyclyl); R⁶ is H, —CH₃, —CH₂CH₃, —CH₂CH₂OH, —CHF₂, —NH₂, or —OH;R⁷ is selected from the structures:

where the wavy line indicates the site of attachment; and Y¹ and Y² areindependently selected from CH and N, where Y¹ and Y² are not each N;where alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl areoptionally substituted with one or more groups independently selectedfrom F, Cl, Br, I, —CN, —CH₃, —CH₂CH₃, —CH(CH₃)₂, —CH₂CH(CH₃)₂, —CH₂OH,—CH₂OCH₃, —CH₂CH₂OH, —C(CH₃)₂OH, —CH(OH)CH(CH₃)₂, —C(CH₃)₂CH₂OH,—CH₂CH₂SO₂CH₃, —CH₂OP(O)(OH)₂, —CH₂F, —CHF₂, —CF₃, —CH₂CF₃, —CH₂CHF₂,—CH(CH₃)CN, —C(CH₃)₂CN, —CH₂CN, —CO₂H, —COCH₃, —CO₂CH₃, —CO₂C(CH₃)₃,—COCH(OH)CH₃, —CONH₂, —CONHCH₃, —CON(CH₃)₂, —C(CH₃)₂CONH₂, —NH₂, —NHCH₃,—N(CH₃)₂, —NHCOCH₃, —N(CH₃)COCH₃, —NHS(O)₂CH₃, —N(CH₃)C(CH₃)₂CONH₂,—N(CH₃)CH₂CH₂S(O)₂CH₃, —NO₂, ═O, —OH, —OCH₃, —OCH₂CH₃, —OCH₂CH₂OCH₃,—OCH₂CH₂OH, —OCH₂CH₂N(CH₃)₂, —OP(O)(OH)₂, —S(O)₂N(CH₃)₂, —SCH₃,—S(O)₂CH₃, —S(O)₃H, cyclopropyl, oxetanyl, azetidinyl,1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino,azetidin-1-ylmethyl, and morpholino.
 2. The method of claim 1 whereinthe disease or disorder is an immune disorder.
 3. The method of claim 2wherein the immune disorder is rheumatoid arthritis.
 4. The method ofclaim 1 wherein the disease or disorder is systemic and localinflammation, arthritis, inflammation related to immune suppression,organ transplant rejection, allergies, ulcerative colitis, Crohn'sdisease, dermatitis, asthma, systemic lupus erythematosus, Sjögren'sSyndrome, multiple sclerosis, scleroderma/systemic sclerosis, idiopathicthrombocytopenic purpura (ITP), anti-neutrophil cytoplasmic antibodies(ANCA) vasculitis, chronic obstructive pulmonary disease (COPD),psoriasis.
 5. The method of claim 1 wherein the disease or disorder iscancer selected from breast, ovary, cervix, prostate, testis,genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma,stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cellcarcinoma, non-small cell lung carcinoma (NSCLC), small cell carcinoma,lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma,thyroid, follicular carcinoma, undifferentiated carcinoma, papillarycarcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, livercarcinoma and biliary passages, kidney carcinoma, pancreatic, myeloiddisorders, lymphoma, hairy cells, buccal cavity, naso-pharyngeal,pharynx, lip, tongue, mouth, small intestine, colon-rectum, largeintestine, rectum, brain and central nervous system, Hodgkin's,leukemia, bronchus, thyroid, liver and intrahepatic bile duct,hepatocellular, gastric, glioma/glioblastoma, endometrial, melanoma,kidney and renal pelvis, urinary bladder, uterine corpus, uterinecervix, multiple myeloma, acute myelogenous leukemia, chronicmyelogenous leukemia, lymphocytic leukemia, chronic lymphoid leukemia(CLL), myeloid leukemia, oral cavity and pharynx, non-Hodgkin lymphoma,melanoma, and villous colon adenoma.
 6. The method of claim 1 furthercomprising administering an additional therapeutic agent selected froman anti-inflammatory agent, an immunomodulatory agent, chemotherapeuticagent, an apoptosis-enhancer, a neurotropic factor, an agent fortreating cardiovascular disease, an agent for treating liver disease, ananti-viral agent, an agent for treating blood disorders, an agent fortreating diabetes, and an agent for treating immunodeficiency disorders.7. The method of claim 1 wherein X¹ is N.
 8. The method of claim 1wherein X² is N.
 9. The method of claim 1 wherein X³ is N.
 10. Themethod of claim 1 wherein X¹ and X³ are N, X¹ and X² are N, or X² and X³are N.
 11. The method of claim 1 wherein R⁵ is optionally substitutedC₁-C₂₀ heteroaryl selected from pyrazolyl, pyridinyl, pyrimidinyl,5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl,5-acetyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl,6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl, and1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-yl.
 12. The method ofclaim 1 wherein R⁵ is —(C₁-C₂₀ heteroaryl)-(C₂-C₂₀ heterocyclyl) whereheteroaryl is optionally substituted pyridinyl and heterocyclyl isoptionally substituted piperazinyl.
 13. The method of claim 1 wherein R⁵is phenyl, optionally substituted with one or more groups selected fromF, Cl, —CH₃, —S(O)₂CH₃, cyclopropyl, azetidinyl, oxetanyl, andmorpholino.
 14. The method of claim 1 wherein R⁵ is selected from thestructures:

where the wavy line indicates the site of attachment.
 15. The method ofclaim 1 wherein R⁵ is:

where R⁸ is selected from H, —CH₃, —CH₂OCH₃, —CH₂CH₃, —CH(CH₃)₂,—CH₂CH₂OH, —CH₂CH₂OCH₃, —CH₂F, —CHF₂, —CF₃, —CH₂CF₃, —CH₂CHF₂,—CH(CH₃)CN, —C(CH₃)₂CN, —CH₂CN, —C(O)CH₃, —C(O)CH₂CH₃, —C(O)CH(CH₃)₂,—NH₂, —NHCH₃, —N(CH₃)₂, —OH, —OCH₃, —OCH₂CH₃, —OCH₂CH₂OH, cyclopropyl,and oxetanyl.
 16. The method of claim 1 wherein R⁶ is CH₃.
 17. Themethod of claim 1 wherein Y¹ is CH and Y² is N.
 18. The method of claim1 wherein Y¹ is N and Y² is CH.
 19. The method of claim 1 wherein Y¹ andY² are each CH.
 20. The method of claim 19 wherein Y¹ and Y² are eachCH, and R⁶ is CH₃.
 21. The method of claim 1 selected from2-{4-Hydroxymethyl-1′-methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6′-oxo-1′,6′-dihydro-[3,3]bipyridinyl-5-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{4-Hydroxymethyl-1′-methyl-5′-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6′-oxo-1′,6′-dihydro-[3,3]bipyridinyl-5-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-(3-(Hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one;2-(3-(Hydroxymethyl)-2-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-4-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one;2-{4-Hydroxymethyl-1′-methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6′-oxo-1′,6′-dihydro-[3,3]bipyridinyl-5-yl}-3,4,5,6,7,8-hexahydro-2H-benzo[4,5]thieno[2,3-c]pyridin-1-one;6-{4-Hydroxymethyl-1′-methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6′-oxo-1′,6′-dihydro-[3,3]bipyridinyl-5-yl}-2,2-dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza-cyclopenta[a]inden-7-one;2-{4-Hydroxymethyl-1′-methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6′-oxo-1′,6′-dihydro-[3,3]bipyridinyl-5-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;6-{3′-Hydroxymethyl-1-methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-2,2-dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza-cyclopenta[α]inden-7-one;2-{3′-Hydroxymethyl-1-methyl-5-[6-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{4-Hydroxymethyl-1′-methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}-2,3,5,6,7,8-hexahydro-4H-2,4-b-diaza-fluoren-1-one;2-[3′-Hydroxymethyl-1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-(4-{6-[4-((R)-1,4-Dimethyl-3-oxo-piperazin-2-yl)-phenylamino]-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl}-3-hydroxymethyl-pyridin-2-yl)-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-[3′-Hydroxymethyl-1-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;3-{4-Hydroxymethyl-1′-methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one;2-[3′-Hydroxymethyl-5-(5-methanesulfonyl-pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-(3′-Hydroxymethyl-5-{5-[4-(2-hydroxy-2-methyl-propyl)-piperazin-1-yl]-pyridin-2-ylamino}-1-methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl)-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one;2-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-(5-{5-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl)-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;3-{3′-Hydroxymethyl-1-methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one;2-[3′-Hydroxymethyl-1-methyl-5-(5-oxetan-3-yl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{4-Hydroxymethyl-1′-methyl-5′-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}-6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one;2-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(5-piperazin-1-yl-pyridin-2-ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-[5-(5-Cyclopropyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-[5-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;2-{5-[5-((S)-2-Ethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{4-[5-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-3-hydroxymethyl-pyridin-2-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{3-Hydroxymethyl-4-[1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-pyridazin-3-yl]-pyridin-2-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;10-Fluoro-2-{3′-hydroxymethyl-1-methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;10-Fluoro-2-[3′-hydroxymethyl-1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;10-Fluoro-2-{3′-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-[4-Hydroxymethyl-1′-methyl-5′-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-2,3,5,6,7,8-hexahydro-4H-2,4-b-diaza-fluoren-1-one;7,7-Difluoro-2-{3′-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-[3′-Hydroxymethyl-1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;2-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;6-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-2,2-dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza-cyclopenta[a]inden-7-one;2-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;6-{3′-Hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-2,2-dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza-cyclopenta[a]inden-7-one;10-Fluoro-2-[3′-hydroxymethyl-1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-[3′-Hydroxymethyl-1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-2,3,5,6,7,8-hexahydro-4H-2,4-b-diaza-fluoren-1-one;2-{3′-(3-Hydroxy-oxetan-3-yl)-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-2,3,5,6,7,8-hexahydro-4H-2,4-b-diaza-fluoren-1-one;2-[4-Hydroxymethyl-1′-methyl-5′-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-((1S,5R)-3-oxetan-3-yl-3,8-diaza-bicyclo[3.2.1]oct-8-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;3-{3′-Hydroxymethyl-1-methyl-5-[5-((R)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one;2-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-2,3,5,6,7,8-hexahydro-4H-2,4-b-diaza-fluoren-1-one;2-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-10-fluoro-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{5′-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-4-hydroxymethyl-1′-methyl-6′-oxo-1′,6′-dihydro-[3,3′]bipyridinyl-5-yl}-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;3-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one;2-{5-[5-((2S,5R)-2,5-Dimethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one;2-{5-[5-((S)-2-Ethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-2,3,5,6,7,8-hexahydro-4H-2,4-b-diaza-fluoren-1-one;2-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrazin-2-ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-[3′-Hydroxymethyl-1-methyl-5-(5-oxetan-3-yl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;2-{5-[5-((S)-2-Ethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;2-{5-[5-((S)-2-Ethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-2H-pyrazino[1,2-a]indol-1-one;10-Fluoro-2-[3′-hydroxymethyl-1-methyl-5-(5-oxetan-3-yl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-3,4,6,7,8,9-hexahydro-2H-pyrazino[1,2-a]indol-1-one;2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydro-6,9-methanopyrazino[1,2-a]indol-1(2H)-one;2-[5-(6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;2-{3′-Hydroxymethyl-1-methyl-5-[5-(4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-3,4,5,6,7,8-hexahydro-2H-benzo[4,5]thieno[2,3-c]pyridin-1-one;2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydro-6,9-methanopyrazino[1,2-a]indol-1(2H)-one;(1S,11R)-6-[3-(Hydroxymethyl)-4-[1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridin-2-yl]-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-7-one;2-(4-(5-(1,2,4-triazin-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one;2-[5-(2,6-Dimethyl-pyrimidin-4-ylamino)-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;(1R,11S)-6-[3-(Hydroxymethyl)-4-[1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo-1,6-dihydropyridin-3-yl]pyridin-2-yl]-3,6-diazatetracyclo[9.2.1.0^(2,10).0^(3,8)]tetradeca-2(10),8-dien-7-one;3-{5-[5-((S)-2-Ethyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-3′-hydroxymethyl-1-methyl-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl}-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one;(S)-2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1(2H)-one;2-(4-(5-(5-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one;3-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyridin-2-ylamino)-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one;2-[3′-Hydroxymethyl-1-methyl-5-(2-methyl-pyrimidin-4-ylamino)-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;2-[3′-Hydroxymethyl-1-methyl-5-(6-methyl-pyrimidin-4-ylamino)-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;3-[3′-Hydroxymethyl-1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one;3-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one;10-fluoro-2-(3-(hydroxymethyl)-4-(1-methyl-6-oxo-5-(pyridin-2-ylamino)-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one;6-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrazin-2-ylamino)-1,6-dihydro-[3,4]bipyridinyl-2′-yl]-2,2-dimethyl-2,3,5,6-tetrahydro-1H,4H-8-thia-6-aza-cyclopenta[α]inden-7-one;2-{3-Hydroxymethyl-4-[6-(imidazo[1,2-a]pyridin-7-ylamino)-4-methyl-5-oxo-4,5-dihydro-pyrazin-2-yl]-pyridin-2-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;10-fluoro-2-(3-(hydroxymethyl)-4-(4-methyl-5-oxo-6-(pyridin-3-ylamino)-4,5-dihydropyrazin-2-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one;2-(4-(5-(5-(2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(hydroxymethyl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one;2-[3′-Hydroxymethyl-1-methyl-6-oxo-5-(pyrazin-2-ylamino)-1,6-dihydro-[3,4′]bipyridinyl-2′-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;and2-(3-(hydroxymethyl)-4-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyrazin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-2-yl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one.22. The method of claim 1 wherein the is selected from2-[4-[5-[[5-[2,2-dimethyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-4-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydropyridazino[4,5-b]indolizin-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(pyrazin-2-ylamino)-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydropyrazino[1,2-a]indol-1-one;3-[4-[5-[(2-cyclopropylpyrimidin-4-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;2-[3-(hydroxymethyl)-4-[4-methyl-6-[[6-[4-(oxetan-3-yl)piperazin-1-yl]-3-pyridyl]amino]-5-oxo-pyrazin-2-yl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-4-one;3-[3-(hydroxymethyl)-4-[5-(imidazo[1,2-a]pyrimidin-7-ylamino)-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[1-(oxetan-3-yl)-3,6-dihydro-2H-pyridin-4-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[6-(imidazo[1,2-a]pyridin-6-ylamino)-4-methyl-5-oxo-pyrazin-2-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,8,9,10-tetrahydropyridazino[4,5-a]indolizin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydropyridazino[4,5-b]indolizin-1-one;2-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methylazetidin-3-yl)oxy-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methylazetidin-3-yl)oxy-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3-b]pyrazin-4-one;2-[4-[5-[(5-ethyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one2-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;2-(7,7-dimethyl-4-oxo-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]pyridine-3-carboxamide;2-(7,7-dimethyl-4-oxo-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-N-methyl-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]pyridine-3-carboxamide;3-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;10-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[4-[5-(6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-ylamino)-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-(hydroxymethyl)-5-[1-methyl-5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-3-pyridyl]-3-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one;2-[3-(hydroxymethyl)-4-[5-(1H-imidazo[4,5-b]pyridin-5-ylamino)-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[4-[5-[(1,5-dimethylpyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[6-(3-aminoanilino)-4-methyl-5-oxo-pyrazin-2-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;5-[2-(3,4,6,7,8,9-hexahydro-1H-pyrazino[1,2-a]indol-2-yl)-3-(hydroxymethyl)-4-pyridyl]-1-methyl-3-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]pyridin-2-one;3-[4-[5-[(6-amino-2-pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-1H-pyridin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;10-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(2-methylpyrimidin-4-yl)amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[4-[5-[(2-ethylpyrimidin-4-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one;10-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methyl-4-piperidyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-ylamino)-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;2-[4-[5-[(5-acetyl-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-10-fluoro-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methyl-4-piperidyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;10-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-5,6,7,8-tetrahydro-1H-pyrrolo[3,4-b]indolizin-3-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methylazetidin-3-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methylazetidin-3-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;10-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one;2-[4-[5-[(1,5-dimethylpyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[[1-[1-(oxetan-3-yl)-4-piperidyl]imidazol-4-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(1-methylazetidin-3-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydropyrido[3,4-b]indolizin-1-one;2-[4-[5-[(1,5-dimethylpyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-6,7,8,9-tetrahydropyrido[3,4-b]indolizin-1-one;3-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(3R)-3-methylmorpholine-4-carbonyl]-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(3R)-3-methylmorpholine-4-carbonyl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;2-[4-[5-[(5,6-dimethyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[4-[5-[(1-ethyl-5-methyl-pyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-1H-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one;2-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-10-fluoro-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(3S)-3-methylmorpholine-4-carbonyl]-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(3S)-3-methylmorpholine-4-carbonyl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-1H-pyrazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;2-[4-[5-[(1,5-dimethylpyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-10-fluoro-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyloxazol-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;10-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(pyrimidin-4-ylamino)pyridazin-3-yl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[5-[[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-4-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-[(5-propanoyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(oxetan-3-yl)-1H-pyrazol-3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(1-methylimidazol-4-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;2-[3-(hydroxymethyl)-4-[1-methyl-5-[(7-methyl-6,8-dihydro-5H-[1,2,4]triazolo[1,S-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-1H-pyridin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[1-(oxetan-3-yl)azetidin-3-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(2-pyridylamino)-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylpyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(5-fluoro-2-pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;6-[[5-[2-(7,7-dimethyl-4-oxo-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-3-(hydroxymethyl)-4-pyridyl]-1-methyl-2-oxo-3-pyridyl]amino]pyridine-3-carbonitrile;3-[3-(hydroxymethyl)-4-[5-[(5-methoxy-2-pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(5-cyclopropyl-2-pyridyl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-[[5-(trifluoromethyl)-2-pyridyl]amino]-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[1-methyl-5-(morpholine-4-carbonyl)pyrazol-3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-2-pyridyl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;10-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-(oxetan-3-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[1-(oxetan-3-yl)imidazol-4-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[5-(isoxazol-3-ylamino)-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;2-[4-[5-[(4,5-dimethyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-(1H-pyrazol-3-ylamino)-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(1-methylpyrazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-6,7,8,9-tetrahydrobenzothiopheno[2,3-d]pyridazin-4-one;3-[4-[5-[(1,5-dimethylpyrazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(1-methyltriazol-4-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(5-tert-butylisoxazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(5-ethylisoxazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;5-[[5-[2-(7,7-dimethyl-4-oxo-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-3-(hydroxymethyl)-4-pyridyl]-1-methyl-2-oxo-3-pyridyl]amino]pyrazine-2-carbonitrile;3-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-[(5-phenylisoxazol-3-yl)amino]-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;(R)-2-(3′-(hydroxymethyl)-5-((5-(1-methoxypropan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;3-[3-(hydroxymethyl)-4-[1-methyl-6-oxo-5-[[6-(trifluoromethyl)pyridazin-3-yl]amino]-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[1-methyl-5-[[methyl(oxetan-3-yl)amino]methyl]pyrazol-3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;(S)-2-(3′-(hydroxymethyl)-5-((5-(1-methoxypropan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-1-methyl-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;3-[3-(hydroxymethyl)-4-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one;3-[3-(hydroxymethyl)-4-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-pyridazin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[5-[(6-methoxypyridazin-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[6-[(1,3-dimethylindazol-5-yl)amino]-4-methyl-5-oxo-pyrazin-2-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one;3-[3-(hydroxymethyl)-4-[5-[[5-(3-methoxypropyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylisothiazol-3-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(5-cyclopropylisoxazol-3-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-methyl-1-(oxetan-3-yl)pyrazol-3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6-oxo-4,7-dihydropyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[[5-(3-hydroxyazetidin-1-yl)-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[[1-methyl-5-(pyrrolidine-1-carbonyl)pyrazol-3-yl]amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[5-[[5-(methoxymethyl)-1-methyl-pyrazol-3-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methyl-6-oxo-4,7-dihydropyrazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one;(R)-2-(5-((4,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-3′-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;(S)-2-(5-((4,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)amino)-3′-(hydroxymethyl)-1-methyl-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one;3-[4-[5-[[5-[(3S,5R)-3,5-dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[[5-[(3S,5R)-3,5-dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1-methyl-6-oxo-pyridazin-3-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;2-[4-[5-[[5-[(3S,5R)-3,5-dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one;3-[3-(hydroxymethyl)-4-[5-[[5-(3-methoxyazetidin-1-yl)-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[[5-[(3S,5S)-3,5-dimethylmorpholine-4-carbonyl]-2-pyridyl]amino]-1-methyl-6-oxo-pyridazin-3-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(1,3-dimethylpyrazolo[3,4-c]pyridin-5-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(2,3-dimethylpyrazolo[3,4-c]pyridin-5-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1,2-dimethyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-(hydroxymethyl)-5-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-3-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-2-[5-[[5-(2-methoxyethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]amino]-1-methyl-6-oxo-3-pyridyl]-4-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(6,6-dimethyl-4,7-dihydropyrazolo[5,1-c][1,4]oxazin-2-yl)amino]-1-methyl-6-oxo-pyridazin-3-yl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one;3-[3-(hydroxymethyl)-4-[4-methyl-6-[(3-methylisothiazol-5-yl)amino]-5-oxo-pyrazin-2-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[3-(hydroxymethyl)-4-[1-methyl-5-[(1-methyltriazol-4-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]thieno[1,3-c]pyridin-4-one;3-[4-[5-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[4-[5-[(6,6-dimethyl-4,7-dihydropyrazolo[5,1-c][1,4]oxazin-2-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-6,8-dihydrocyclopenta[3,4]thieno[1,3-d]pyridazin-4-one;2-[3-(hydroxymethyl)-4-[5-[[5-(methoxymethyl)-1-methyl-pyrazol-3-yl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1-one;3-[4-[5-[(1,2-dimethylimidazol-4-yl)amino]-1-methyl-6-oxo-3-pyridyl]-3-(hydroxymethyl)-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;3-[2-[[5-[2-(7,7-dimethyl-4-oxo-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-3-yl)-3-(hydroxymethyl)-4-pyridyl]-1-methyl-2-oxo-3-pyridyl]amino]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-5-yl]propanenitrile;3-[3-(hydroxymethyl)-4-[5-[[5-[4-(2-methoxyethyl)piperazin-1-yl]-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one;and3-[3-(hydroxymethyl)-4-[5-[[5-[(2S)-4-(2-methoxyethyl)-2-methyl-piperazin-1-yl]-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one.